PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MA, YH; HENDERSON, HE; VENMURTHY, MR; ROEDERER, G; MONSALVE, MV; CLARKE, LA; NORMAND, T; JULIEN, P; GAGNE, C; LAMBERT, M; DAVIGNON, J; LUPIEN, PJ; BRUNZELL, J; HAYDEN, MR				MA, YH; HENDERSON, HE; VENMURTHY, MR; ROEDERER, G; MONSALVE, MV; CLARKE, LA; NORMAND, T; JULIEN, P; GAGNE, C; LAMBERT, M; DAVIGNON, J; LUPIEN, PJ; BRUNZELL, J; HAYDEN, MR			A MUTATION IN THE HUMAN LIPOPROTEIN-LIPASE GENE AS THE MOST COMMON CAUSE OF FAMILIAL CHYLOMICRONEMIA IN FRENCH-CANADIANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MISSENSE MUTATION; DEFICIENCY; HETEROZYGOTE; BINDING; DNA; LPL	Background. Lipoprotein lipase hydrolyzes the triglyceride core of chylomicrons and very-low-density lipoproteins and has a crucial role in regulating plasma lipoprotein levels. Deficiencies of lipoprotein lipase activity lead to aberrations in lipoprotein levels. Worldwide, the frequency of lipoprotein lipase deficiency is highest among French Canadians. We sought to determine the molecular basis of the disorder in this population. Methods. The entire coding sequence of the lipoprotein lipase gene from one French Canadian patient was amplified by the polymerase chain reaction and sequenced. Exon 5 from 36 other French Canadian patients was amplified and analyzed by dot blot hybridization with allele-specific oligonucleotides. Results. Sequence analysis revealed a missense substitution of leucine (CTG) for proline (CCG) at residue 207 in exon 5. This mutation was found on 54 of the 74 mutant alleles (73 percent) in the patients. Studies of site-directed in vitro mutagenesis have confirmed that this mutation generates inactive lipoprotein lipase and is the cause of lipoprotein lipase deficiency. Conclusions. We have identified a missense mutation at residue 207 of the lipoprotein lipase gene that is the most common cause of lipoprotein lipase deficiency in French Canadians. This mutation can be easily detected by dot blot analysis, providing opportunity for definitive DNA diagnosis of the disorder and identification of heterozygous carriers.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1W5,BC,CANADA; UNIV LAVAL,DEPT BIOCHEM,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; CLIN RES INST MONTREAL,MONTREAL H2W 1R7,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV LAVAL,LIPID RES CTR,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of British Columbia; Laval University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Laval University; University of Washington; University of Washington Seattle			Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Clarke, Lorne/0000-0003-0512-7281	NIDDK NIH HHS [DK-02456] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEIS D, 1991, J CLIN INVEST, V87, P1165, DOI 10.1172/JCI115114; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BRUNZELL JD, 1983, J LIPID RES, V24, P12; BRUNZELL JD, 1989, METABOLIC BASIS INHE, V1, P1165; CHARBONNEAU H, 1987, ATLAS HIST CANADA, V1, P118; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CUPP M, 1987, J BIOL CHEM, V262, P6383; DEBRAEKELEER M, IN PRESS HUM HERED; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P6786, DOI 10.1021/bi00442a036; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; EMI M, 1990, J BIOL CHEM, V265, P5910; EMI M, 1990, AM J HUM GENET, V47, P107; FISHER KL, 1987, NUCLEIC ACIDS RES, V15, P7657, DOI 10.1093/nar/15.18.7657; FUNKE H, 1987, NUCLEIC ACIDS RES, V15, P9102, DOI 10.1093/nar/15.21.9102; GAGNE C, 1989, CAN MED ASSOC J, V140, P405; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HATA A, 1990, AM J HUM GENET, V47, P721; HENDERSON HE, 1990, MOL BIOL MED, V7, P511; HENDERSON HE, 1991, J CLIN INVEST, V87, P2005, DOI 10.1172/JCI115229; LANGLOIS S, 1989, P NATL ACAD SCI USA, V86, P948, DOI 10.1073/pnas.86.3.948; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NIKKILA EA, 1983, METABOLIC BASIS INHE, P622; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; WANG XB, 1989, DNA-J MOLEC CELL BIO, V8, P753, DOI 10.1089/dna.1989.8.753; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	30	99	104	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1761	1766		10.1056/NEJM199106203242502	http://dx.doi.org/10.1056/NEJM199106203242502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	2038366	Bronze			2022-12-28	WOS:A1991FR68100002
J	COX, JD				COX, JD			RADIATION ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESIDENTIAL-ADDRESS; RADIOTHERAPY				COX, JD (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77025, USA.							CHAPMAN JD, 1989, PREDICTION TUMOR TRE, P323; COX JD, 1987, INT J RADIAT ONCOL, V13, P1271, DOI 10.1016/0360-3016(87)90215-X; FUKS Z, 1989, International Journal of Radiation Oncology, Biology, Physics, V17, P121; HONG WK, 1989, P AM SOC CLIN CONOL, V8, pA650; Horiot J C, 1988, Front Radiat Ther Oncol, V22, P149; LEIBEL S A, 1990, International Journal of Radiation Oncology, Biology, Physics, V19, P139, DOI 10.1016/0360-3016(90)90681-9; LIEBERMAN HB, 1990, 1990 COL U COLL PHYS, P162; ORDER SE, 1990, INT J RADIAT ONCOL, V18, P981, DOI 10.1016/0360-3016(90)90431-I; ROTMAN M, 1990, INT J RADIAT ONCOL, V19, P513, DOI 10.1016/0360-3016(90)90475-Y; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; TURRISI AT, 1988, INT J RADIAT ONCOL, V15, P183, DOI 10.1016/0360-3016(88)90364-1; WILSON JF, 1988, CURE PRESERVATION FU, P102; 1991, JAMA-J AM MED ASSOC, V265, P391	13	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3165	3167						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041139				2022-12-28	WOS:A1991FQ77000039
J	LACOMBE, MA				LACOMBE, MA			ON BAD DOCTORS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ETHICS, MEDICAL; LITERATURE; PHILOSOPHY		Greed and the desire for power and fame might distract the best of us in medicine. Here, in allegoric form, is a story of such distraction and a remedy.			LACOMBE, MA (corresponding author), OXFORD HILLS INTERNAL MED GRP, 23 WINTER ST, NORWAY, ME 04268 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1054	1056		10.7326/0003-4819-114-12-1054	http://dx.doi.org/10.7326/0003-4819-114-12-1054			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029101				2022-12-28	WOS:A1991FQ55500010
J	BEDELL, SE; DEITZ, DC; LEEMAN, D; DELBANCO, TL				BEDELL, SE; DEITZ, DC; LEEMAN, D; DELBANCO, TL			INCIDENCE AND CHARACTERISTICS OF PREVENTABLE LATROGENIC CARDIAC ARRESTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED VENTRICULAR FLUTTER; DIGITALIS THERAPY; MEDICAL INPATIENTS; INTENSIVE-CARE; DRUG REACTIONS; FIBRILLATION; POINTES; DEATHS; TOXICITY; ILLNESS	We studied the contribution of iatrogenic illness to cardiac arrest among patients hospitalized in 1981 in a university teaching hospital. During this 1-year period, 28 (14%) of 203 arrests in which resuscitation was attempted followed an iatrogenic complication. Seventeen (61%) of the 28 patients died. The demographic characteristics of patients with iatrogenic arrest did not differ strikingly from those of other patients who arrested. However, patients with iatrogenic arrest were less likely to be in cardiogenic shock or to have suffered an acute myocardial infarction prior to arrest. They were more likely to survive to discharge from the hospital and tobe taking digoxin or antiarrhythmic medication prior to arrest. Among the 28 cases of iatrogenic cardiac arrest, 18 (9% of all arrests) might have been prevented by stricter attention to the patient's history, findings on physical examination, and laboratory data. The most common causes of potentially preventable arrest were medication errors and toxic effects (44%) as well as suboptimal response by physicians to clinical signs and symptoms (28%), most frequently dyspnea and tachypnea. Rapid, appropriate response to abnormal drug levels, to electrocardiographic signs of adverse drug effects, and to signs and symptoms of congestive heart failure or toxic effects from digoxin might decrease the incidence of cardiac arrest among hospitalized patients.	HARVARD UNIV, SCH MED, DEPT MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02115 USA; CHARLES A DANA RES INST, BOSTON, MA USA; HARVARD THORNDIKE LAB, BOSTON, MA USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard University; Beth Israel Deaconess Medical Center								ARMITAGE P, 1971, STATISTICAL METHODS; BAZATT HC, 1920, HEART, V7, P353; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BUCHANAN DS, 1978, GERIATRICS, V33, P47; BUCHANAN DS, 1978, GERIATRICS, V33, P59; BURCHELL HB, 1983, J AM COLL CARDIOL, V1, P506, DOI 10.1016/S0735-1097(83)80080-1; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; COUCH NP, 1981, NEW ENGL J MED, V304, P634, DOI 10.1056/NEJM198103123041103; De Mey C, 1979, Acta Tuberc Pneumol Belg, V70, P183; DENES P, 1981, AM J CARDIOL, V48, P9, DOI 10.1016/0002-9149(81)90566-X; DONABEDIAN A, 1978, SCIENCE, V200, P856, DOI 10.1126/science.417400; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FRIEDMAN GD, 1971, J AMER MED ASSOC, V217, P567, DOI 10.1001/jama.217.5.567; FRIEDMAN M, 1982, POSTGRAD MED, V71, P123, DOI 10.1080/00325481.1982.11716096; INGELFINGER JA, 1976, NEW ENGL J MED, V294, P867, DOI 10.1056/NEJM197604152941603; KEREN A, 1981, CIRCULATION, V64, P1167, DOI 10.1161/01.CIR.64.6.1167; KOSSMANN CE, 1978, AM J CARDIOL, V42, P1054, DOI 10.1016/0002-9149(78)90695-1; KOSTER RW, 1976, AM J CARDIOL, V38, P519, DOI 10.1016/0002-9149(76)90471-9; LASAGNA L, 1976, NEW ENGL J MED, V294, P898, DOI 10.1056/NEJM197604152941609; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MCLAMB JT, 1967, SOUTHERN MED J, V60, P469, DOI 10.1097/00007611-196705000-00006; MOORMAN JR, 1985, SOUTHERN MED J, V78, P561, DOI 10.1097/00007611-198505000-00016; MYERS JD, 1981, NEW ENGL J MED, V304, P664, DOI 10.1056/NEJM198103123041109; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; RAVIN CE, 1976, AM J ROENTGENOL, V126, P423, DOI 10.2214/ajr.126.2.423; SCHIMMEL EM, 1964, ANN INTERN MED, V60, P100, DOI 10.7326/0003-4819-60-1-100; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; SHAPIRO S, 1971, J AMER MED ASSOC, V216, P467, DOI 10.1001/jama.216.3.467; SHAPIRO W, 1978, AM J CARDIOL, V41, P852, DOI 10.1016/0002-9149(78)90724-5; SMITH WM, 1980, ANN INTERN MED, V93, P578, DOI 10.7326/0003-4819-93-4-578; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TRUNET P, 1980, JAMA-J AM MED ASSOC, V244, P2617, DOI 10.1001/jama.244.23.2617; VENULET J, 1975, INT J CLIN PHARM BI, V12, P387; WILLIAMSON JW, 1967, J AMER MED ASSOC, V201, P938, DOI 10.1001/jama.201.12.938	37	115	115	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2815	2820		10.1001/jama.265.21.2815	http://dx.doi.org/10.1001/jama.265.21.2815			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033737				2022-12-28	WOS:A1991FN85500029
J	REISER, SJ				REISER, SJ			THE CLINICAL RECORD IN MEDICINE .2. REFORMING CONTENT AND PURPOSE	ANNALS OF INTERNAL MEDICINE			English	Article								Case histories of illness have been important agents of both preserving and changing concepts and practices in medicine. These cases, which constitute the collective medical memory, have been used by innovators to recast diagnosis, therapy, and education. They have done this by both extracting insight from the content of the cases and reshaping the form of the document containing them - the clinical record. How the evidence in this record should be ordered, stored, retrieved, and accessed has been a major source of controversy in medicine. The evolution of the clinical case and its written record is examined. The essay appears in two parts. Part I, published in the 15 May 1991 issue, deals with the several uses of cases in medical practice and learning. Part II focuses mainly on the development of the clinical record.			REISER, SJ (corresponding author), UNIV TEXAS, HLTH SCI CTR, POB 20708, HOUSTON, TX 77225 USA.							AUCHINCLOSS H, 1918, UNIT HIST SYSTEM MED, V10, P30; Cannon WB, 1900, BOSTON MED SURG J, V142, P31, DOI 10.1056/NEJM190001111420202; DONABEDIAN A, 1989, MILBANK Q, V67, P233, DOI 10.2307/3350139; GROSSMAN JH, 1989, PHYSICIANS MANAGERS; HORNSBY J, 1917, B AM COLL SURG, V3, P7; JONES WH, 1923, HIPPOCRATES, V2, P203; JONES WH, 1923, HIPPOCRATES, V1, P279; LAENNEC RT, 1962, TREATISE DISEASES CH, P398; LOUIS PC, 1836, RES EFFECTS BLOODLET, P64; MORGAGNI GB, 1960, SEATS CAUSES DISEASE, V2, P127; NEUHAUSER D, 1990, INT J TECHNOL ASSESS, V6, P315; PAINTER FM, 1918, MOD HOSP, V2, P356; PEARL R, 1923, INTRO MED BIOMETRY S, P91; REISER SJ, IN PRESS LIABILITY M; REISER SJ, 1984, TRANSFORMATION TRADI, P306; RODIN AE, 1984, MED CASEBOOK AC DOYL, P199; SYDENHAM T, 1966, T SYDENHAM 1624 1689, V60, P127; WASHBURN FA, 1939, MASSACHUSETTS GEN HO, P115; WEED LL, 1971, MED RECORDS MED ED P, V25, P98; WHIPPLE AO, 1918, INTERVAL RESULT SYST, V10, P17; 1919, HOSPITAL STANDARDIZA, V4, P5	21	52	52	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					980	985		10.7326/0003-4819-114-11-980	http://dx.doi.org/10.7326/0003-4819-114-11-980			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024867				2022-12-28	WOS:A1991FM97900011
J	BRENNAN, TA				BRENNAN, TA			TRANSMISSION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS IN THE HEALTH-CARE SETTING - TIME FOR ACTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RIGHTS COMMISSION DECISIONS; AIDS LITIGATION PROJECT; UNITED-STATES; HOUSEHOLD CONTACTS; NATIONAL SURVEY; HIV INFECTION; RISK; PHYSICIANS; WORKERS; EMERGENCY				BRENNAN, TA (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.							ABRAHAM K, 1986, DISTRIBUTING RISK, P227; ALTMAN LK, 1991, NY TIMES        0207, P4; ALTMAN LK, 1991, NY TIMES        0223, P9; ALTMAN LK, 1991, NY TIMES        0118, pA3; ANNAS GJ, 1988, HASTINGS CTR REPORT, V18, P26; ARRAS JD, 1988, HASTINGS CENT REP S, V18, P10; BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; BRENNAN TA, 1987, ANN INTERN MED, V107, P581, DOI 10.7326/0003-4819-107-4-581; BRENNAN TA, IN PRESS JUST DOCTOR; BRENNAN TA, 1988, DUKE LAW J, P243; Calabresi Guido, 1970, COSTS ACCIDENTS; CHELIUS JR, 1977, WORKPLACE SAFETY HLT; COOKE M, 1989, NEW ENGL J MED, V321, P1334, DOI 10.1056/NEJM198911093211911; CRISP R, 1990, AIDS MORAL ISSUE, P62; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; EDGAR H, 1990, AM J LAW MED, V16, P155; EMANUEL EJ, 1988, NEW ENGL J MED, V318, P1686, DOI 10.1056/NEJM198806233182511; FIELD MA, 1990, AM J LAW MED, V16, P33; FOY C, 1990, BRIT MED J, V300, P1048, DOI 10.1136/bmj.300.6731.1048; FRIEDLAND G, 1988, JAMA-J AM MED ASSOC, V259, P2898; FRIEDLAND GH, 1986, NEW ENGL J MED, V314, P344, DOI 10.1056/NEJM198602063140604; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GOLDSMITH MF, 1990, JAMA-J AM MED ASSOC, V263, P2413, DOI 10.1001/jama.263.18.2413; GOSTIN L, 1989, HASTINGS CENT REP, V19, P32, DOI 10.2307/3561948; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; GOSTIN LO, 1989, JAMA-J AM MED ASSOC, V261, P1621; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P2086, DOI 10.1001/jama.263.15.2086; HARDY AM, 1986, JAMA-J AM MED ASSOC, V255, P209, DOI 10.1001/jama.255.2.209; HAYWARD RA, 1991, ANN INTERN MED, V114, P23, DOI 10.7326/0003-4819-114-1-23; HENDERSON DK, 1986, ANN INTERN MED, V104, P644, DOI 10.7326/0003-4819-104-5-644; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; JASON JM, 1986, JAMA-J AM MED ASSOC, V255, P212, DOI 10.1001/jama.255.2.212; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1990, J ACQ IMMUN DEF SYND, V3, P987; LEWIS CE, 1990, JAMA-J AM MED ASSOC, V264, P2764, DOI 10.1001/jama.264.21.2764; LIFSON AR, 1986, JAMA-J AM MED ASSOC, V256, P3231, DOI 10.1001/jama.256.23.3231; LO B, 1989, ANN INTERN MED, V110, P727; MANGIONE CM, 1991, AM J MED, V90, P85, DOI 10.1016/0002-9343(91)90510-5; MARSHALL PA, 1990, ARCH INTERN MED, V150, P1501, DOI 10.1001/archinte.150.7.1501; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; Peterson L M, 1989, Law Med Health Care, V17, P139; REED RR, 1987, JAMA-J AM MED ASSOC, V258, P3279, DOI 10.1001/jama.258.22.3279; RHAME FS, 1990, JAMA-J AM MED ASSOC, V264, P507, DOI 10.1001/jama.264.4.507; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; RIZZO JA, 1990, MED CARE, V28, P251, DOI 10.1097/00005650-199003000-00005; ROGERS DE, 1988, JAMA-J AM MED ASSOC, V259, P1368, DOI 10.1001/jama.259.9.1368; SADE RM, 1971, NEW ENGL J MED, V285, P1288, DOI 10.1056/NEJM197112022852304; SMITH TJ, 1990, TENN LAW REV, V57, P539; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; SWARTZ MS, 1988, J HEALTH POLIT POLIC, V13, P607, DOI 10.1215/03616878-13-4-607; Turkington Richard C, 1989, Villanova Law Rev, V34, P871; VOLBERDING P, 1989, JAMA-J AM MED ASSOC, V261, P747, DOI 10.1001/jama.261.5.747; WATERS RC, 1990, FLA STATE U LAW REV, V17, P441; WEIL PA, 1990, MED CARE, V28, P468, DOI 10.1097/00005650-199005000-00006; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924; 1990, NEW ENGL J MED, V322, P1392; 1987, JAMA-J AM MED ASSOC, V258, P2097; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1987, MMWR S2, V36, pS1; 1991, NATIONS HLTH     JAN, pA1; 1990, AAMC WEEKLY REPORT; 1989, PROTECTION DISCRIMIN; 1991, MMWR, V40, P21	65	35	35	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1504	1509		10.1056/NEJM199105233242112	http://dx.doi.org/10.1056/NEJM199105233242112			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FM460	2023611				2022-12-28	WOS:A1991FM46000012
J	BAIN, J				BAIN, J			GENERAL PRACTICES AND THE NEW CONTRACT .1. REACTIONS AND IMPACT	BRITISH MEDICAL JOURNAL			English	Article											BAIN, J (corresponding author), ALDERMOOR HLTH CTR,PRIMARY MED CARE,SOUTHAMPTON SO1 6ST,ENGLAND.							BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; 1990, CM555	2	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1183	1186		10.1136/bmj.302.6786.1183	http://dx.doi.org/10.1136/bmj.302.6786.1183			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043815	Green Published, Bronze			2022-12-28	WOS:A1991FN04500023
J	PEARSON, JW				PEARSON, JW			ENDOCERVICAL BRUSH FOR PAPANICOLAU SMEARS - ADVERSE-EFFECTS OR CONTRAINDICATIONS TO USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											PEARSON, JW (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724, USA.							BOON ME, 1989, ACTA CYTOL, V33, P843; DOTTERS DJ, 1988, AM J OBSTET GYNECOL, V159, P814, DOI 10.1016/S0002-9378(88)80143-1; WEITZMAN GA, 1988, J REPROD MED, V33, P677	3	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2409	2409						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016841				2022-12-28	WOS:A1991FJ95500042
J	COOKE, MP; ABRAHAM, KM; FORBUSH, KA; PERLMUTTER, RM				COOKE, MP; ABRAHAM, KM; FORBUSH, KA; PERLMUTTER, RM			REGULATION OF T-CELL RECEPTOR SIGNALING BY A SRC FAMILY PROTEIN-TYROSINE KINASE (P59FYN)	CELL			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-T; CD4 RECEPTOR; ACTIVATION; EXPRESSION; COMPLEX; PHOSPHORYLATION; POLYPEPTIDE; GENE; IDENTIFICATION	Engagement of the clonotypic antigen receptor (TCR) on T lymphocytes provokes an activation response leading to cell proliferation and lymphokine secretion. To examine the molecular basis of T cell signaling, we generated transgenic animals in which a lymphocyte-specific nonreceptor protein-tyrosine kinase p59fyn(T) is 20-fold overexpressed in developing T lineage cells. Thymocytes from these mice, analyzed using both cellular and biochemical assays, were remarkably hyperstimulable. Moreover, the responsiveness of normal thymocytes to TCR-derived signals correlated well with the extent to which p59fyn was expressed in these cells. Overexpression of a catalytically inactive form of p59fyn substantially inhibited TCR-mediated activation in otherwise normal thymocytes. These effects are unique to p59fyn; overexpression of a closely related T cell-specific tyrosine kinase, p56lck, elicits dramatically different phenotypes. Our results suggest that p59fyn is a critically important component of the TCR signal transduction apparatus.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	COOKE, MP (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195, USA.				NCI NIH HHS [CA09537, CA45682] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009537, R01CA045682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, IN PRESS P NATL ACAD; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JUNE CH, 1990, J IMMUNOL, V144, P1591; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Mishell B.B., 1980, SELECTED METHODS CEL; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Sambrook J, 1989, MOL CLONING LABORATO; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SCHWARTZ RH, 1990, SCIENCE, V248, P1342; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WILLIAMS AF, 1982, SCIENCE, V216, P696, DOI 10.1126/science.6177036; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	53	436	443	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					281	291		10.1016/0092-8674(91)90162-R	http://dx.doi.org/10.1016/0092-8674(91)90162-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015626				2022-12-28	WOS:A1991FH09200011
J	VOS, JC; SASKER, M; STUNNENBERG, HG				VOS, JC; SASKER, M; STUNNENBERG, HG			PROMOTER MELTING BY A STAGE-SPECIFIC VACCINIA VIRUS TRANSCRIPTION FACTOR IS INDEPENDENT OF THE PRESENCE OF RNA-POLYMERASE	CELL			English	Article							ACCURATE TRANSCRIPTION; GENE-TRANSCRIPTION; INITIATION-FACTOR; SOLUBLE EXTRACT; DNA-REPLICATION; PURIFICATION; PROTEIN; INVITRO; REQUIREMENT; MECHANISM	Fractionation of an extract prepared from HeLa cells infected with vaccinia virus resulted in the separation of factors involved in vaccinia virus intermediate transcription. Two activities, VITF-A and VITF-B, in addition to the viral RNA polymerase are necessary and sufficient to direct intermediate transcription in vitro. VITF-B confers intermediate promoter specificity to an early-specific extract prepared from virus particles. A committed complex between VITF-B and the template can sequester VITF-A and RNA polymerase into a preinitiation complex. VITF-B is further able to melt the promoter at the start site of transcription. Open complex formation is stimulated by ATP. In contrast to prokaryotic and eukaryotic pol III transcription, promoter melting is independent of the presence of RNA polymerase.			VOS, JC (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Stunnenberg, Hendrik G./D-6875-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576; Vos, J. Chris/0000-0003-3737-9942				BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BIEKER JJ, 1986, J BIOL CHEM, V261, P9732; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; BROYLES SS, 1986, P NATL ACAD SCI USA, V83, P3141, DOI 10.1073/pnas.83.10.3141; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chamberlin M.J., 1976, RNA POLYMERASE, P159; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIRE A, 1984, J BIOL CHEM, V259, P2509; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HIRSCHMANN P, 1990, J VIROL, V64, P6063, DOI 10.1128/JVI.64.12.6063-6069.1990; HOODADHINGRA U, 1989, J VIROL, V63, P714, DOI 10.1128/JVI.63.2.714-729.1989; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REINBERG D, 1987, J BIOL CHEM, V262, P3310; ROHRMANN G, 1985, J VIROL, V56, P349, DOI 10.1128/JVI.56.2.349-355.1985; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHMITT JFC, 1988, J VIROL, V62, P1889, DOI 10.1128/JVI.62.6.1889-1897.1988; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SCHWER B, 1988, EMBO J, V7, P1183, DOI 10.1002/j.1460-2075.1988.tb02929.x; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VOS JC, 1988, EMBO J, V7, P3487, DOI 10.1002/j.1460-2075.1988.tb03224.x; WRIGHT CF, 1989, J VIROL, V63, P4224, DOI 10.1128/JVI.63.10.4224-4233.1989; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	40	45	45	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					105	113		10.1016/0092-8674(91)90412-R	http://dx.doi.org/10.1016/0092-8674(91)90412-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013091	Bronze			2022-12-28	WOS:A1991FF77300013
J	LINDBLAD, B; STERNBY, NH; BERGQVIST, D				LINDBLAD, B; STERNBY, NH; BERGQVIST, D			INCIDENCE OF VENOUS THROMBOEMBOLISM VERIFIED BY NECROPSY OVER 30 YEARS	BRITISH MEDICAL JOURNAL			English	Article							AUTOPSY	Objective-To determine the incidence of venous thromboembolism in all necropsy reports over 30 years. Design-Study of all necropsies in one hospital in 1987 and longitudinal analysis of results of necropsy in 1957, 1964, 1975, and 1987. Setting-Departments of general surgery, infectious diseases, internal medicine, oncology, and orthopaedics in a Swedish general hospital. Main outcome measure-Number of cases of venous thromboembolism. Results-About a third of all necropsies showed venous thromboembolism. In 1987, 260 of 347 necropsies showing venous thromboembolism found pulmonary embolism, of which 93 were classified as fatal, 90 as contributory, and 77 as incidental. Only 21 contributory or fatal postoperative pulmonary emboli were seen. In only 106 of 260 patients with pulmonary embolism did routine necropsy not show the source of embolism. Calf veins were not routinely examined. Deep venous thrombosis was seen in 239 patients in 1987. The incidence of venous thromboembolism in the four years studied was remarkably stable except in the department of orthopaedics, where the proportion fell from 60.7% in 1975 to 32.2% in 1987 (p < 0.05), although there were only a few patients. Conclusions-The overall incidence of venous thromboembolism has not changed over 30 years. During this period the proportion of the population aged over 65 has doubled, and this may have masked the beneficial effects of prophylaxis and early mobilisation. Prevalences corrected for age are needed.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN PATHOL,S-21401 MALMO,SWEDEN	Lund University	LINDBLAD, B (corresponding author), LUND UNIV,MALMO GEN HOSP,DEPT SURG,S-21401 MALMO,SWEDEN.							BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; Havig O, 1977, Acta Chir Scand Suppl, V478, P1; KAIJ K, 1959, LAKARTIDNINGEN, V56, P1437; RUBINSTEIN I, 1988, ARCH INTERN MED, V148, P1425, DOI 10.1001/archinte.148.6.1425	4	302	334	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					709	711		10.1136/bmj.302.6778.709	http://dx.doi.org/10.1136/bmj.302.6778.709			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	2021744	Bronze, Green Published			2022-12-28	WOS:A1991FE33300029
J	STOELTING, RK				STOELTING, RK			ANESTHESIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY SURGERY; HALOTHANE HEPATITIS; ISOFLURANE; ENFLURANE; CHILDREN				STOELTING, RK (corresponding author), INDIANA UNIV, SCH MED, INDIANAPOLIS, IN 46202 USA.							BUFFINGTON CW, 1988, ANESTHESIOLOGY, V69, P721, DOI 10.1097/00000542-198811000-00014; CHRIST DD, 1988, ANESTHESIOLOGY, V69, P833, DOI 10.1097/00000542-198812000-00006; COTE CJ, 1990, ANESTHESIOLOGY, V72, P589, DOI 10.1097/00000542-199004000-00001; HUBBARD AK, 1988, ANESTHESIOLOGY, V68, P791, DOI 10.1097/00000542-198805000-00021; INOUE K, 1990, ANESTH ANALG, V71, P469; KENNY GNC, 1990, BRIT J ANAESTH, V65, P445, DOI 10.1093/bja/65.4.445; MARTIN JL, 1990, ANESTH ANALG, V70, P154; MCQUAY HJ, 1988, PAIN, V33, P291, DOI 10.1016/0304-3959(88)90287-4; MILLER ED, 1990, ANESTH ANALG, V70, P1; PRIEBE HJ, 1989, ANESTHESIOLOGY, V71, P960, DOI 10.1097/00000542-198912000-00021; SLOGOFF S, 1991, ANESTH ANALG, V72, P22; STOELTING RK, 1987, ANESTH ANALG, V66, P147; TINKER JH, 1989, ANESTHESIOLOGY, V71, P541, DOI 10.1097/00000542-198910000-00010; TIRET L, 1988, BRIT J ANAESTH, V61, P263, DOI 10.1093/bja/61.3.263; 1990, ANESTHESIOLOGY, V73, P770	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3103	3105						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041112				2022-12-28	WOS:A1991FQ77000009
J	ATKIN, SH; DASMAHAPATRA, A; JAKER, MA; CHOROST, MI; REDDY, S				ATKIN, SH; DASMAHAPATRA, A; JAKER, MA; CHOROST, MI; REDDY, S			FINGERSTICK GLUCOSE DETERMINATION IN SHOCK	ANNALS OF INTERNAL MEDICINE			English	Article						GLUCOSE; HYPOTENSION; REAGENT STRIPS, VENOUS; SHOCK; FINGERSTICK GLUCOSE TESTING	BLOOD-GLUCOSE; ACCURACY; SYSTEMS; INSULIN	Objective: To evaluate the accuracy of fingerstick glucose measurements in severely hypotensive patients. Design: Prospective, nonrandomized comparison study. Setting: Emergency department in a university hospital. Patients: Twenty-five severely hypotensive patients (systolic blood pressure less-than-or-equal-to 80 mm Hg) and 39 normotensive patients. Measurements: Simultaneous fingerstick reagent strip glucose, venous reagent strip glucose, and laboratory glucose values were compared. Data were analyzed using error-grid analysis. Results: In hypotensive patients, the mean fingerstick glucose values were significantly lower than the values obtained either by venous reagent strip or laboratory glucose measurements. Fingerstick glucose values in the hypotensive group were 67.5% of laboratory glucose values, and were significantly lower than the values obtained in the normotensive group (91.8%, P < 0.001). Only 36% of the hypotensive patients had fingerstick glucose values within the acceptable range of 20% of the laboratory glucose value. Thirty-two percent of hypotensive patients were incorrectly diagnosed as hypoglycemic (glucose < 3.89 mmol/L [70 mg/dL]); 2 of these patients were actually hyperglycemic (glucose > 11.10 mmol/L [200 mg/dL]). Venous reagent strip measurements accurately reflected laboratory glucose values in both hypotensive and normotensive patients. Conclusions: Fingerstick glucose testing does not accurately represent venous glucose levels in severely hypotensive patients. If fingerstick glucose testing is relied on for these patients, errors in clinical management may be made. Venous reagent strip glucose testing correlates well with laboratory glucose measurements and should be the preferred method for rapid assessment of glucose level in critically ill patients with severe hypotension.			ATKIN, SH (corresponding author), UNIV HOSP NEWARK, DEPT EMERGENCY, C384, 150 BERGEN ST, NEWARK, NJ 07103 USA.							[Anonymous], 1987, DIABETES CARE, V10, P95; BARR B, 1984, DIABETES CARE, V7, P261, DOI 10.2337/diacare.7.3.261; BORST GC, 1987, DIABETES CARE, V10, P256, DOI 10.2337/diacare.10.2.256; BROWNING RG, 1990, ANN EMERG MED, V19, P683, DOI 10.1016/S0196-0644(05)82479-5; CAREY LC, 1970, ANN SURG, V172, P342, DOI 10.1097/00000658-197009000-00004; CHERNOW B, 1982, CRIT CARE MED, V10, P463, DOI 10.1097/00003246-198207000-00012; CLARKE WL, 1987, DIABETES CARE, V10, P622, DOI 10.2337/diacare.10.5.622; CLOWES GHA, 1978, AM J SURG, V135, P577, DOI 10.1016/0002-9610(78)90040-5; COX DJ, 1985, DIABETES CARE, V8, P529, DOI 10.2337/diacare.8.6.529; COX DJ, 1989, DIABETES CARE, V12, P235, DOI 10.2337/diacare.12.3.235; GAZZANIGA AB, 1982, EMERGENCY CARE PRINC, P412; GODINE JE, 1986, AM J MED, V80, P803, DOI 10.1016/0002-9343(86)90619-4; HOLLOWAY R, 1983, ALA J MED SCI, V20, P383; KOSCHINSKY T, 1988, DIABETES CARE, V11, P619, DOI 10.2337/diacare.11.8.619; LIN HC, 1989, J PEDIATR-US, V115, P998, DOI 10.1016/S0022-3476(89)80757-7; MAISELS MJ, 1983, CRIT CARE MED, V11, P293, DOI 10.1097/00003246-198304000-00010; Moghni M R, 1970, J Egypt Med Assoc, V53, P803; PLUM F, 1980, DIAGNOSIS STUPOR COM, P345; POINTER JE, 1986, ANN EMERG MED, V15, P372, DOI 10.1016/S0196-0644(86)80588-1; RASAIAH B, 1985, CAN MED ASSOC J, V132, P1357; SHAPIRO B, 1981, DIABETES CARE, V4, P396, DOI 10.2337/diacare.4.3.396; SHERWOOD MJ, 1983, CLIN CHEM, V29, P438; VITEK V, 1979, CLIN CHIM ACTA, V95, P93, DOI 10.1016/0009-8981(79)90341-3; 1987, ACCU CHEK 2 BLOOD GL	24	116	119	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1020	1024		10.7326/0003-4819-114-12-1020	http://dx.doi.org/10.7326/0003-4819-114-12-1020			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029097				2022-12-28	WOS:A1991FQ55500005
J	BROOKS, PM; DAY, RO				BROOKS, PM; DAY, RO			DRUG-THERAPY - NONSTEROIDAL ANTIINFLAMMATORY DRUGS - DIFFERENCES AND SIMILARITIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ANTI-INFLAMMATORY DRUGS; RARE ADVERSE REACTIONS; ASPIRIN-LIKE DRUGS; RHEUMATOID-ARTHRITIS; OSTEO-ARTHRITIS; IBUPROFEN ENANTIOMERS; ARACHIDONIC-ACID; RENAL-FUNCTION; STEREOSELECTIVE DISPOSITION; RESPONSE RELATIONSHIPS		UNIV NEW S WALES,ST VINCENTS HOSP,KENSINGTON,NSW 2033,AUSTRALIA	University of New South Wales Sydney	BROOKS, PM (corresponding author), UNIV SYDNEY,ROYAL N SHORE HOSP,DEPT RHEUMATOL,ST LEONARDS,NSW 2065,AUSTRALIA.		Day, Richard/D-8699-2011	Day, Richard/0000-0002-6045-6937				ABRAMSON S, 1985, P NATL ACAD SCI USA, V82, P7227, DOI 10.1073/pnas.82.21.7227; ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; BARBER N, 1979, ANN RHEUM DIS, V38, P128; BEARD K, 1987, ARCH INTERN MED, V147, P1621, DOI 10.1001/archinte.147.9.1621; BIEMOND P, 1986, ANN RHEUM DIS, V45, P249, DOI 10.1136/ard.45.3.249; BJARNASON I, 1987, LANCET, V2, P711; BOMALASKI JS, 1986, BIOCHEM BIOPH RES CO, V139, P115, DOI 10.1016/S0006-291X(86)80087-0; BRAY MA, 1986, AGENTS ACTIONS, V19, P87, DOI 10.1007/BF01977263; BROOKS PM, 1988, MED J AUSTRALIA, V148, P248; BRUNE K, 1978, BIOCHEM PHARMACOL, V27, P525, DOI 10.1016/0006-2952(78)90388-X; CAPELL HA, 1979, J RHEUMATOL, V6, P584; CAPELL HA, 1977, BRIT J CLIN PHARMACO, V4, P623, DOI 10.1111/j.1365-2125.1977.tb00797.x; CARSON JL, 1987, ARCH INTERN MED, V147, P1054, DOI 10.1001/archinte.147.6.1054; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; CEUPPENS JL, 1982, LANCET, V1, P528; CHAMPION GD, 1988, MED J AUSTRALIA, V149, P203, DOI 10.5694/j.1326-5377.1988.tb120573.x; CHRISTOPHIDIS N, 1986, CLIN EXP PHARMACOL P, V13, P555, DOI 10.1111/j.1440-1681.1986.tb00938.x; CIABATTONI G, 1987, CLIN PHARMACOL THER, V41, P380, DOI 10.1038/clpt.1987.44; CIABATTONI G, 1984, NEW ENGL J MED, V310, P279, DOI 10.1056/NEJM198402023100502; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; CUMMINGS NA, 1966, ARTHRITIS RHEUM, V9, P47, DOI 10.1002/art.1780090106; CUSH JJ, 1990, ARTHRITIS RHEUM, V33, P19, DOI 10.1002/art.1780330103; DAVIS A, 1986, AUST NZ J MED, V16, P537, DOI 10.1111/j.1445-5994.1986.tb02031.x; Day R O, 1985, Agents Actions Suppl, V17, P15; DAY RO, 1982, CLIN PHARMACOL THER, V31, P733, DOI 10.1038/clpt.1982.103; DAY RO, 1989, BRIT J CLIN PHARMACO, V28, P695, DOI 10.1111/j.1365-2125.1989.tb03562.x; DAY RO, 1988, CLIN PHARMACOL THER, V43, P480, DOI 10.1038/clpt.1988.62; DAY RO, 1988, DRUGS, V36, P643, DOI 10.2165/00003495-198836060-00001; DAY RO, 1987, PHARMACOL THERAPEUT, V33, P384; DAY RO, 1988, BAILLIERES CLIN RHEU, V2, P263; DELFAVERO A, 1987, SIDE EFFECTS DRUGS A, V11, P82; DOHERTY M, 1986, ANN RHEUM DIS, V45, P272, DOI 10.1136/ard.45.4.272; DOYLE DV, 1981, ANN RHEUM DIS, V40, P75, DOI 10.1136/ard.40.1.75; DUKES MNG, 1981, EUR J CLIN PHARMACOL, V19, P3, DOI 10.1007/BF00558371; DUNAGAN FM, 1988, BRIT J RHEUMATOL, V27, P48; DUNN M, 1986, AM J MED S2B, V81, P1; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V264, P41, DOI 10.1001/jama.264.1.41; FAVRE L, 1983, CLIN SCI, V64, P407, DOI 10.1042/cs0640407; FORREST M, 1988, BAILLIERE CLIN RHEUM, V2, P275, DOI 10.1016/S0950-3579(88)80015-3; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; FURST DE, 1988, CLIN PHARMACOL THER, V44, P186, DOI 10.1038/clpt.1988.135; GALL EP, 1982, J RHEUMATOL, V9, P402; GARELLA S, 1984, MEDICINE, V63, P165, DOI 10.1097/00005792-198405000-00003; GHOSH P, 1988, BAILLIERE CLIN RHEUM, V2, P309, DOI 10.1016/S0950-3579(88)80017-7; GOODWIN JS, 1982, ARTHRITIS RHEUM, V25, P1013, DOI 10.1002/art.1780250817; GOTTLIEB NL, 1985, SEMIN ARTHRITIS RHEU, V15, P1, DOI 10.1016/S0049-0172(85)80001-9; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GOTZSCHE PC, 1989, CONTROLLED CLIN TRIA, V10, P356; GRAHAM DY, 1988, LANCET, V2, P1277; GRENNAN DM, 1983, BRIT J CLIN PHARMACO, V15, P311, DOI 10.1111/j.1365-2125.1983.tb01504.x; GUESS HA, 1988, J CLIN EPIDEMIOL, V41, P35, DOI 10.1016/0895-4356(88)90007-8; HALL RC, 1984, ACTA MED SCAND S, V683, P79; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; HELLER CA, 1985, PHARMACOTHERAPY, V5, P30; HENRICH WL, 1981, KIDNEY INT, V19, P822, DOI 10.1038/ki.1981.86; HENRY DA, 1988, BAILLIERE CLIN RHEUM, V2, P425, DOI 10.1016/S0950-3579(88)80021-9; HERMAN J H, 1984, Inflammation, V8, pS125, DOI 10.1007/BF00915721; HIGGS GA, 1980, CLIN RHEUM DIS, V6, P675; HUSKISSON EC, 1976, BRIT MED J, V1, P1048, DOI 10.1136/bmj.1.6017.1048; KITCHEN EA, 1985, ANTIINFLAMMATORY ANT, V1, P21; KOKKO JP, 1981, KIDNEY INT, V19, P791, DOI 10.1038/ki.1981.82; KOWANKO IC, 1981, BRIT J CLIN PHARMACO, V11, P477, DOI 10.1111/j.1365-2125.1981.tb01153.x; KU EC, 1986, AM J MED, V80, P18, DOI 10.1016/0002-9343(86)90074-4; LANDS WEM, 1983, PROSTAGLANDINS RELAT, P203; LANGMAN M J S, 1988, American Journal of Medicine, V84, P15, DOI 10.1016/0002-9343(88)90249-5; LANGMAN MJS, 1989, GASTROENTEROLOGY, V96, P640, DOI 10.1016/S0016-5085(89)80060-5; LANGMAN MJS, 1989, Q J MED, V73, P1089; LEE EJD, 1985, BRIT J CLIN PHARMACO, V19, P669, DOI 10.1111/j.1365-2125.1985.tb02694.x; LEVI F, 1985, CLIN PHARMACOL THER, V37, P77, DOI 10.1038/clpt.1985.15; LIFSCHITZ MD, 1981, KIDNEY INT, V19, P781, DOI 10.1038/ki.1981.80; LUFTSCHEIN S, 1979, J RHEUMATOL, V6, P397; LUGGEN ME, 1989, J RHEUMATOL, V16, P1565; Meffin P J, 1985, Agents Actions Suppl, V17, P85; MINTA JO, 1985, J RHEUMATOL, V12, P751; MURRAY MD, 1990, ANN INTERN MED, V112, P559, DOI 10.7326/0003-4819-112-8-559; NETTER P, 1985, EUR J CLIN PHARMACOL, V29, P319, DOI 10.1007/BF00544088; OBRIEN WM, 1985, J RHEUMATOL, V12, P562; OBRIEN WM, 1985, J RHEUMATOL, V12, P13; OBRIEN WM, 1985, J RHEUMATOL, V12, P347; OBRIEN WM, 1985, J RHEUMATOL, V12, P785; ONEILL LAJ, 1989, BIOCHEM PHARMACOL, V38, P3707, DOI 10.1016/0006-2952(89)90576-5; OREILLY RA, 1980, J CLIN INVEST, V65, P746, DOI 10.1172/JCI109722; ORME M, 1981, SCANDINAVIAN J RHE S, V39, P19; ORME ML, 1988, AGENTS ACTIONS S, V17, P151; PARR G, 1989, BRIT J CLIN PHARMACO, V27, P235, DOI 10.1111/j.1365-2125.1989.tb05356.x; PELLETIER JP, 1989, J RHEUMATOL, V16, P266; PINCUS T, 1989, J RHEUMATOL, V16, P1253; PRESTON SJ, 1989, BRIT J CLIN PHARMACO, V27, P607, DOI 10.1111/j.1365-2125.1989.tb03423.x; PRESTON SJ, 1988, BRIT J CLIN PHARMACO, V26, P759, DOI 10.1111/j.1365-2125.1988.tb05316.x; QUINTERO E, 1986, NEPHRON, V42, P298, DOI 10.1159/000183692; RADACK K, 1987, J GEN INTERN MED, V2, P108, DOI 10.1007/BF02596307; RASHAD S, 1989, LANCET, V2, P519; ROBERTS DG, 1985, CLIN PHARMACOL THER, V38, P258, DOI 10.1038/clpt.1985.168; ROTH S, 1989, ARCH INTERN MED, V149, P775, DOI 10.1001/archinte.149.4.775; ROTH SH, 1988, DRUGS, V36, P1, DOI 10.2165/00003495-198836010-00001; SCHNEIDER HT, 1990, BRIT J CLIN PHARMACO, V29, P127, DOI 10.1111/j.1365-2125.1990.tb03613.x; SCHNERMANN J, 1981, KIDNEY INT, V19, P802, DOI 10.1038/ki.1981.84; SCOTT DL, 1982, BRIT J CLIN PHARMACO, V14, P691, DOI 10.1111/j.1365-2125.1982.tb04958.x; SEIDEMAN P, 1988, BRIT J RHEUMATOL, V27, P117; SEIGEL MI, 1979, P NATL ACAD SCI USA, V76, P3774; SOLL AH, 1990, NEW ENGL J MED, V322, P909; SOMERVILLE K, 1986, LANCET, V1, P462; SWARTZ SL, 1982, AM J CARDIOL, V49, P1405, DOI 10.1016/0002-9149(82)90351-4; TONKIN AL, 1988, BAILLIERE CLIN RHEUM, V2, P455, DOI 10.1016/S0950-3579(88)80022-0; UPTON RA, 1984, BRIT J CLIN PHARMACO, V18, P207, DOI 10.1111/j.1365-2125.1984.tb02454.x; VANDENOUWELAND FA, 1988, CLIN PHARMACOL THER, V43, P79, DOI 10.1038/clpt.1988.14; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WALAN A, 1989, NEW ENGL J MED, V320, P69, DOI 10.1056/NEJM198901123200201; WASNER C, 1981, JAMA-J AM MED ASSOC, V246, P2168, DOI 10.1001/jama.246.19.2168; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568; WILLIAMS K, 1986, BIOCHEM PHARMACOL, V35, P3403, DOI 10.1016/0006-2952(86)90443-0; WILSKE KR, 1989, J RHEUMATOL, V16, P565; 1986, BMJ, V292, P614	113	682	702	0	31	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1716	1725						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	2034249				2022-12-28	WOS:A1991FQ15500007
J	ENG, FJ; WARNER, JR				ENG, FJ; WARNER, JR			STRUCTURAL BASIS FOR THE REGULATION OF SPLICING OF A YEAST MESSENGER-RNA	CELL			English	Article							RIBOSOMAL-PROTEIN GENE; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; BINDING PROTEINS; EXON SEQUENCES; DNA FRAGMENTS; SEX-LETHAL; EXPRESSION; LEVEL; ELEMENTS	In S. cerevisiae, ribosomal protein L32 regulates the splicing of the transcript of its own gene, RPL32. We have identified an RNA structure within the transcript that is responsible for this regulation. Initial deletions limited essential sequences to the 5' exon and the first few nucleotides of the intron. To take advantage of phylogenetic comparison of RNA structures, RPL32 was cloned from the closely related species, Kluyveromyces lactis. The splicing of its transcript is similarly regulated. Sequences conserved between the S. cerevisiae and K. lactis transcripts suggested a structure involving base pairing of a region encompassing the 5' splice site with another near the 5' end of the transcript. Analysis of numerous site-directed mutations supports this structure. We infer that stabilization of this structure by L32 inhibits splicing by precluding the interaction of U1 RNA with the 5' splice site.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	ENG, FJ (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532, T32GM007128] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330] Funding Source: Medline; NIGMS NIH HHS [GM25532, 5T32GM07128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOZZONI I, 1984, J MOL BIOL, V180, P987, DOI 10.1016/0022-2836(84)90267-5; CAFFARELLI E, 1987, EMBO J, V6, P3493, DOI 10.1002/j.1460-2075.1987.tb02674.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; DABEVA MD, 1987, J BIOL CHEM, V262, P16055; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; DRAPER DE, 1989, TRENDS BIOCHEM SCI, V14, P335, DOI 10.1016/0968-0004(89)90167-9; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GUTELL RR, 1986, EMBO J, V5, P1111, DOI 10.1002/j.1460-2075.1986.tb04330.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON SP, 1987, MOL CELL BIOL, V7, P1338, DOI 10.1128/MCB.7.4.1338; KIM CH, 1983, J MOL BIOL, V165, P79, DOI 10.1016/S0022-2836(83)80243-5; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KRETZNER L, 1990, P NATL ACAD SCI USA, V87, P851, DOI 10.1073/pnas.87.2.851; KRUSE C, 1985, P NATL ACAD SCI USA, V82, P7515, DOI 10.1073/pnas.82.22.7515; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LEER RJ, 1985, NUCLEIC ACIDS RES, V13, P5027, DOI 10.1093/nar/13.14.5027; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; McKeown M, 1990, Genet Eng (N Y), V12, P139; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NEWMAN A, 1987, EMBO J, V6, P3833, DOI 10.1002/j.1460-2075.1987.tb02720.x; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PEARSON NJ, 1982, CELL, V29, P347, DOI 10.1016/0092-8674(82)90151-9; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; POTASHKIN JA, 1990, MOL CELL BIOL, V10, P3524, DOI 10.1128/MCB.10.7.3524; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SWIDA U, 1988, YEAST, V4, P209, DOI 10.1002/yea.320040306; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WARNER JR, 1985, MOL CELL BIOL, V5, P1512, DOI 10.1128/MCB.5.6.1512; WITTEKIND M, 1990, MOL CELL BIOL, V10, P2049, DOI 10.1128/MCB.10.5.2049; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WRAY LV, 1987, MOL CELL BIOL, V7, P1111, DOI 10.1128/MCB.7.3.1111; WRNER JR, 1977, J CELL BIOL, V80, P767	54	145	149	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					797	804		10.1016/0092-8674(91)90387-E	http://dx.doi.org/10.1016/0092-8674(91)90387-E			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040015				2022-12-28	WOS:A1991FP51600010
J	MOZZARELLI, A; RIVETTI, C; ROSSI, GL; HENRY, ER; EATON, WA				MOZZARELLI, A; RIVETTI, C; ROSSI, GL; HENRY, ER; EATON, WA			CRYSTALS OF HEMOGLOBIN WITH THE T-QUARTERNARY STRUCTURE BIND OXYGEN NONCOOPERATIVELY WITH NO BOHR EFFECT	NATURE			English	Article							HUMAN-HEMOGLOBIN; SINGLE-CRYSTALS; STEREOCHEMISTRY; MECHANISMS; CONSTANTS; AFFINITY; ENZYME; STATE	THE relationship between the structure and function of haemoglobin has mainly been studied by comparing its X-ray crystal structures with its function in solutions 1-11. To make a direct comparison we have studied the functional properties of haemoglobin in single crystals, an approach that has been an important part of the investigation of several enzyme mechanisms 12, 13. Here we report on the oxygen binding by single crystals of human haemoglobin grown in solutions of polyethylene glycol. Unlike haemoglobin crystals formed in concentrated salt solution, which crack and become disordered on oxygenation 14-16, crystals grown in polyethylene glycol remain intact. X-ray studies have shown that the T (deoxy) quaternary structure of haemoglobin in this crystal at pH 7.0 is maintained at atmospheric oxygen pressure, and that the salt-bridges are not broken 17-19. We find striking differences between oxygen binding by haemoglobin in this crystal and by haemoglobin in solution. Not only is oxygenation of the crystal noncooperative, but the oxygen affinity is independent of pH in the range 6.0-8.5, and is much lower than that of the T state in solution. The lack of cooperativity without a change in quaternary structure is predicted by the two-state allosteric model of Monod, Wyman and Changeux 1, 5. The absence of a Bohr effect without breakage of salt-bridges is predicted by Perutz's stereochemical mechanism 2, 4, 9-11. In contrast to the X-ray result that oxygen binds only to the alpha-haems, our measurements show that the alpha-haems have only a slightly higher affinity than the beta-haems.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	MOZZARELLI, A (corresponding author), UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY.		Henry, Eric R/J-3414-2013; Mozzarelli, Andrea/C-3615-2014	Henry, Eric R/0000-0002-5648-8696; Mozzarelli, Andrea/0000-0003-3762-0062; Rivetti, Claudio/0000-0003-3775-6779				ACKERS GK, 1987, ANNU REV BIOPHYS BIO, V16, P583; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BALDWIN JM, 1975, PROG BIOPHYS MOL BIO, V29, P227; BRZOZOWSKI A, 1984, NATURE, V307, P74, DOI 10.1038/307074a0; BRZOZOWSKI A, 1984, HEMOGLOBIN, P37; CHU AH, 1984, BIOCHEMISTRY-US, V23, P604, DOI 10.1021/bi00299a004; Eaton W A, 1981, Methods Enzymol, V76, P175; EDELSTEIN SJ, 1975, REV BIOCH, V44, P209; Gill S J, 1981, Methods Enzymol, V76, P427; GILL SJ, 1987, BIOCHEMISTRY-US, V26, P3995, DOI 10.1021/bi00387a038; Haurowitz F., 1938, Z PHYSIOL CHEMIE, V254, P266; IMAI K, 1975, J BIOL CHEM, V250, P2227; Imai K., 1982, ALLOSTERIC EFFECTS H; KILMARTIN JV, 1978, J MOL BIOL, V123, P71, DOI 10.1016/0022-2836(78)90377-7; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; LIDDINGTON RC, 1986, THESIS U YORK; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; MAKINEN MW, 1974, NATURE, V247, P62, DOI 10.1038/247062a0; MARDEN MC, 1990, BIOPHYS J, V57, P397, DOI 10.1016/S0006-3495(90)82556-X; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5351; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1953, ACTA CRYSTALLOGR, V6, P859, DOI 10.1107/S0365110X53002507; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1964, NATURE, V203, P687, DOI 10.1038/203687a0; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; ROSSI GL, 1970, J MOL BIOL, V49, P85, DOI 10.1016/0022-2836(70)90377-3; SAWICKI CA, 1977, J BIOL CHEM, V252, P7138; SHIBAYAMA N, 1986, J MOL BIOL, V192, P323, DOI 10.1016/0022-2836(86)90367-0; SHULMAN RG, 1975, Q REV BIOPHYS, V8, P325, DOI 10.1017/S0033583500001840; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0	35	117	117	3	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					416	419		10.1038/351416a0	http://dx.doi.org/10.1038/351416a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034292				2022-12-28	WOS:A1991FN85600062
J	LAI, KN; LI, PKT; LUI, SF; AU, TC; TAM, JSL; TONG, KL; LAI, FM				LAI, KN; LI, PKT; LUI, SF; AU, TC; TAM, JSL; TONG, KL; LAI, FM			MEMBRANOUS NEPHROPATHY RELATED TO HEPATITIS-B VIRUS IN ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC ACTIVE HEPATITIS; SURFACE ANTIGENEMIA; NEPHROTIC SYNDROME; VIRAL-HEPATITIS; GLOMERULONEPHRITIS; INFECTION; ANTIBODY; CHILDREN; ASSOCIATION; INTERFERON	Background. The natural course of adult hepatitis B virus (HBV)-related membranous nephropathy in areas where HBV infection is endemic (characterized by vertical and horizontal transmission of HBV in early childhood) has not been fully defined. Methods. We evaluated the clinical features, pathological findings, serologic profiles, therapeutic responses, and prognoses of 21 patients with adult-onset HBV-related membranous nephropathy. The patients were followed for a mean of 60 months (range, 12 to 108). Only patients with evidence of glomerular capillary deposition of hepatis B e antigen (HBeAg) in a renal-biopsy specimen were included. Results. The clinical features and serologic studies suggested that the patients had acquired chronic HBV infection in early childhood; moreover, other causes of membranous nephropathy had been excluded. All were seropositive for hepatitis B surface antigen and had high titers of antibody to hepatitis B core antigen at first clinical presentation. HBeAg was detected in the serum of 17 patients (81 percent), yet only 3 had even slightly increased plasma alanine aminotransferase levels. The clinical response to therapy with interferon alfa was disappointing; only one of the five patients treated had a complete remission with seroconversion to antibody to HBeAg. Contrary to reports of studies in children, spontaneous remission of the nephrotic syndrome or proteinuria was uncommon in the adults with HBV-related membranous nephropathy whom we studied. Proteinuria and HBV antigenemia persisted in untreated patients. During the follow-up period, 29 percent of the patients had progressive renal failure and 10 percent required maintenance dialysis therapy. Conclusions. The course of HBV-related membranous nephropathy in adults in areas where HBV is endemic is not benign. Regardless of treatment, the disease has a slowly but relentlessly progressive clinical course in approximately one third of patients.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MICROBIOL,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT PATHOL,SHA TIN,HONG KONG; PRINCESS MARGARET HOSP,MED UNIT,HONG KONG,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital			Li, Philip K. T./D-4051-2017					BRZOKO W, 1974, LANCET, V2, P476; COGAN MG, 1977, AM J GASTROENTEROL, V68, P386; COMBES B, 1971, LANCET, V2, P234; FURUSE A, 1982, NEPHRON, V31, P212, DOI 10.1159/000182649; GARCIA G, 1985, HEPATOLOGY, V5, P317, DOI 10.1002/hep.1840050228; GUERRA IL, 1987, AM J KIDNEY DIS, V10, P385, DOI 10.1016/S0272-6386(87)80107-5; HIROSE H, 1984, KIDNEY INT, V26, P338, DOI 10.1038/ki.1984.178; HSU HC, 1983, CLIN NEPHROL, V20, P121; ITO H, 1981, LAB INVEST, V44, P214; KLEINKNECHT C, 1979, J PEDIATR-US, V95, P946, DOI 10.1016/S0022-3476(79)80281-4; KNECHT GL, 1978, GASTROENTEROLOGY, V75, P1152; KNIESER MR, 1974, ARCH PATHOL, V97, P193; KOHLER PF, 1974, ANN INTERN MED, V81, P448, DOI 10.7326/0003-4819-81-4-448; LAI KN, 1989, AM J CLIN PATHOL, V92, P159, DOI 10.1093/ajcp/92.2.159; LAI KN, 1989, ANN TROP PAEDIATR, V9, P45, DOI 10.1080/02724936.1989.11748595; LAI KN, 1990, NEPHRON, V54, P12; LAI KN, 1987, Q J MED, V63, P323; LEVY M, 1982, ADV NEPHROL, V11, P341; LIN CY, 1990, NEPHRON, V55, P37, DOI 10.1159/000185916; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; LOK ASF, 1988, LANCET, V2, P298; MCCOLLUM RW, 1981, J MED VIROL, V8, P1, DOI 10.1002/jmv.1890080102; MIZUSHIMA N, 1987, GASTROENTEROLOGY, V92, P524, DOI 10.1016/0016-5085(87)90152-1; NAGY J, 1979, CLIN NEPHROL, V12, P109; PIGNATELLI M, 1987, J HEPATOL, V4, P15, DOI 10.1016/S0168-8278(87)80004-1; SEGGIE J, 1984, NEPHRON, V38, P115, DOI 10.1159/000183291; Szmuness W, 1978, VIRAL HEPATITIS, P297; TAKEKOSHI Y, 1978, LANCET, V2, P1065; THOMAS HC, 1985, BRIT MED BULL, V41, P374, DOI 10.1093/oxfordjournals.bmb.a072079; WONG VCW, 1984, LANCET, V1, P921	30	193	206	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1457	1463		10.1056/NEJM199105233242103	http://dx.doi.org/10.1056/NEJM199105233242103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM460	2023605				2022-12-28	WOS:A1991FM46000003
J	MOORE, RD; HIDALGO, J; SUGLAND, BW; CHAISSON, RE				MOORE, RD; HIDALGO, J; SUGLAND, BW; CHAISSON, RE			ZIDOVUDINE AND THE NATURAL-HISTORY OF THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; PLACEBO-CONTROLLED TRIAL; SAN-FRANCISCO; DOUBLE-BLIND; AIDS; SURVIVAL; EXPERIENCE; EFFICACY; AZT	Background and Methods. We sought to describe the trends in survival from 1983 to 1989 among persons with the acquired immunodeficiency syndrome (AIDS) and to examine the relative effects on the natural history of AIDS of zidovudine use and demographic and clinical characteristics. This longitudinal, observational, population-based study used data from the Maryland Human Immunodeficiency Virus Information System, a data base that links information from the Maryland AIDS Registry with data on public and private health care claims, vital statistics, and hospital, long-term care, and ambulatory care records. Results. The median survival after diagnosis among persons with AIDS (n = 1028) was 140 days longer for those given their diagnoses between 1987 and 1989 than for those given their diagnoses between 1983 and 1985 (450 vs. 310 days). Among the 714 persons in whom AIDS was diagnosed after April 1987 (when zidovudine became available), two-year survival was greater among men than women (P < 0.03), among persons less than 45 years old than among older persons (P < 0.001), among non-Hispanic whites than among minorities (P < 0.001), and among persons whose category of human immunodeficiency virus transmission was homosexual contact than among those with heterosexual, transfusion-related, or less common modes of transmission (P < 0.02). In all the analyses the groups with the longer survival were more likely to have received zidovudine. The median survival among those who received zidovudine was 770 days, as compared with 190 days among those who never received the drug (P < 0.001). By proportional-hazards analysis, zidovudine therapy was the factor most strongly associated with improved survival. Conclusions. For Maryland residents with AIDS there has been an improvement in survival since 1987. Zidovudine therapy and perhaps other aspects of care associated with it have contributed substantially to the improved survival.	AIDS ADM,DEPT HLTH & MENTAL HYG,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; UNIV MARYLAND,SCH PHARM,CTR DRUG POLICY,BALTIMORE,MD 21201	Maryland Department of Health & Mental Hygiene; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027668] Funding Source: NIH RePORTER; NIAID NIH HHS [5U01AI27668] Funding Source: Medline; PHS HHS [223-89-3603] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; Hidalgo J, 1990, QRB Qual Rev Bull, V16, P355; HIDALGO J, 1990, EVAL PROGRAM PLANN, V13, P39, DOI 10.1016/0149-7189(90)90007-J; HIDALGO J, 1990, 118TH ANN M AM PUBL; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MOORE RD, IN PRESS ARCH INTERN; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SWANSON CE, 1990, AIDS, V4, P749, DOI 10.1097/00002030-199008000-00006; TSAI WY, 1987, BIOMETRIKA, V74, P883	15	299	300	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1412	1416		10.1056/NEJM199105163242006	http://dx.doi.org/10.1056/NEJM199105163242006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020297				2022-12-28	WOS:A1991FL12500006
J	GARCIAPAGAN, JC; FEU, F; BOSCH, J; RODES, J				GARCIAPAGAN, JC; FEU, F; BOSCH, J; RODES, J			PROPRANOLOL COMPARED WITH PROPRANOLOL PLUS ISOSORBIDE-5-MONONITRATE FOR PORTAL-HYPERTENSION IN CIRRHOSIS - A RANDOMIZED CONTROLLED-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							VARICEAL HEMORRHAGE; SYSTEMIC HEMODYNAMICS; ALCOHOLIC CIRRHOSIS; PRESSURE REDUCTION; LIVER-FUNCTION; TRIAL; NITROGLYCERIN; VASOPRESSIN; PREVENTION; ASSOCIATION	Objective: To investigate whether isosorbide-5-mononitrate (Is-5-Mn) given with propranolol reduced hepatic portal pressure more than does propranolol alone in patients with cirrhosis. Design: A randomized controlled trial. Patients: Fifty patients with cirrhosis and esophageal varices entered and 42 completed the study. Intervention: Twenty-one patients received oral propranolol at increasing doses until their resting heart rate was reduced by 25%, and 21 patients received oral propranolol (on the same schedule) plus oral Is-5-Mn, 40 mg twice a day. Measurements: Hepatic vein pressure gradient, liver function, and splanchnic and systemic hemodynamics before and after 3 months of continuous therapy. Main Results: At 3 months, the hepatic venous pressure gradient decreased more (P < 0.01) in patients give propranolol plus Is-5-Mn (19%, from 18.4 +/- 3.9 to 14.9 +/- 3.8 mm Hg; 95% CI, -2.4 to -4.5 mm Hg) than in those given propranolol alone (10%, from 18.2 +/- 3.5 to 16.3 +/- 3.1 mm Hg; CI, -1.1 to -2.7 mm Hg). The hepatic venous pressure gradient decreased by more than 20% of the baseline value in 10% of patients receiving propranolol, but in 50% of patients receiving combined therapy (P < 0.02). There were statistically significant decreases in hepatic blood flow and the intrinsic clearance of indocyanine green after propranolol therapy, but not after combined therapy. The treatments caused similar reductions in azygos blood flow and cardiac output. Conclusions: The long-term combined administration of propranolol plus Is-5-Mn reduces portal pressure more than propranolol alone without adverse effects on hepatic perfusion and liver function. Whether this greater hemodynamic effect translates into better clinical efficacy should be determined in randomized controlled trials.	UNIV BARCELONA, HOSP CLIN & PROVINCIAL,HEPAT HEMODYNAM LAB, LIVER UNIT,C-VILLAROEL 170, E-08036 BARCELONA, SPAIN	University of Barcelona; Hospital Clinic de Barcelona			Garcia-Pagan, Juan-Carlos/P-6291-2015	Garcia-Pagan, Juan-Carlos/0000-0001-9032-4954				ABRAMS J, 1980, AM HEART J, V99, P113, DOI 10.1016/0002-8703(80)90321-X; BOSCH J, 1984, HEPATOLOGY, V4, P1200, DOI 10.1002/hep.1840040617; BOSCH J, 1988, Journal of Hepatology, V7, pS12; BOSCH J, 1989, HEPATOLOGY, V10, P962, DOI 10.1002/hep.1840100612; COLOMBO M, 1989, HEPATOLOGY, V9, P433, DOI 10.1002/hep.1840090315; GARCIAPAGAN JC, 1990, J HEPATOL, V11, P189, DOI 10.1016/0168-8278(90)90112-5; GARCIAPAGAN JC, 1990, HEPATOLOGY, V11, P230, DOI 10.1002/hep.1840110212; GARCIATSAO G, 1986, HEPATOLOGY, V6, P101, DOI 10.1002/hep.1840060119; GIMSON AES, 1986, HEPATOLOGY, V6, P410, DOI 10.1002/hep.1840060314; GROSZMANN RJ, 1982, HEPATOLOGY, V2, P757, DOI 10.1002/hep.1840020602; GROSZMANN RJ, 1990, GASTROENTEROLOGY, V99, P1401, DOI 10.1016/0016-5085(90)91168-6; KROEGER RJ, 1985, HEPATOLOGY, V5, P97, DOI 10.1002/hep.1840050120; LEBREC D, 1980, LANCET, V2, P180; LEBREC D, 1981, NEW ENGL J MED, V305, P1371, DOI 10.1056/NEJM198112033052302; NAVASA M, 1989, GASTROENTEROLOGY, V96, P1110, DOI 10.1016/0016-5085(89)91630-2; NAVASA M, 1988, HEPATOLOGY, V8, P850, DOI 10.1002/hep.1840080425; PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71; PASCAL JP, 1987, NEW ENGL J MED, V317, P856, DOI 10.1056/NEJM198710013171403; PASTA L, 1988, HEPATOLOGY, V8, P1; RIGAU J, 1989, GASTROENTEROLOGY, V96, P873; VINEL JP, 1988, J HEPATOL, V7, P186, DOI 10.1016/S0168-8278(88)80481-1; VOROBIOFF J, 1989, HEPATOLOGY, V9, P88, DOI 10.1002/hep.1840090114	22	197	198	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					869	873		10.7326/0003-4819-114-10-869	http://dx.doi.org/10.7326/0003-4819-114-10-869			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014947				2022-12-28	WOS:A1991FL65000006
J	FITZPATRICK, R				FITZPATRICK, R			AUDIT IN PERSON - SURVEYS OF PATIENT SATISFACTION .2. DESIGNING A QUESTIONNAIRE AND CONDUCTING A SURVEY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE				FITZPATRICK, R (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, ENGLAND.							BAKER R, 1990, BRIT J GEN PRACT, V40, P487; DAVIES AR, 1986, HEALTH SERV RES, V21, P429; DIXON P, 1989, NHS ITS CUSTOMERS, V2; Eardley A, 1990, Health Serv J, V100, P1773; Fallowfield L, 1990, QUALITY LIFE MISSING; FITZPATRICK R, 1991, BRIT MED J, V302, P887, DOI 10.1136/bmj.302.6781.887; Fitzpatrick R., 1984, EXPERIENCE ILLNESS, P154; Green J, 1988, Health Serv J, V98, P880; HALL JA, 1988, SOC SCI MED, V27, P637, DOI 10.1016/0277-9536(88)90012-3; HALL JA, 1990, MED CARE, V28, P261, DOI 10.1097/00005650-199003000-00006; LINN LS, 1982, MED CARE, V20, P425, DOI 10.1097/00005650-198204000-00007; MARSH C, 1982, SURVEY METHOD; Nunnally J.C., 1978, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; Pascoe G C, 1983, Eval Program Plann, V6, P335, DOI 10.1016/0149-7189(83)90013-7; SNIDER EL, 1980, SOC SCI MED-MED SOC, V14, P527, DOI 10.1016/0160-7979(80)90054-5	16	188	196	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 11	1991	302	6785					1129	1132		10.1136/bmj.302.6785.1129	http://dx.doi.org/10.1136/bmj.302.6785.1129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	2043786	Green Published, Bronze			2022-12-28	WOS:A1991FL43900022
J	BENFIELD, DG; FLAKSMAN, RJ; LIN, TH; KANTAK, AD; KOKOMOOR, FW; VOLLMAN, JH				BENFIELD, DG; FLAKSMAN, RJ; LIN, TH; KANTAK, AD; KOKOMOOR, FW; VOLLMAN, JH			TEACHING INTUBATION SKILLS USING NEWLY DECEASED INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This prospective study was designed to (1) test the hypothesis that the majority of families of newly dead infants in a tertiary neonatal intensive care unit would consent to their infants' being intubated for teaching purposes, (2) determine factors related to family consent, and (3) determine the effects of participation on resident physicians and respiratory therapists. Family consent for intubation was requested following 44 (80%) of the 55 deaths that occurred during the 10-month study period. Of these requests, 32 (73%) were granted. Proportionately more white than black families consented and consent was positively related to autopsy permission. Fifty-three (75%) of 71 trainees completed a mailed questionnaire after their first intubation experience. Although each respondent found the experience helpful, many reported mixed feelings categorized as doubt about participating, apprehension and discomfort, respect for the body, appreciation for the opportunity, a sense of achievement, and feelings of comfort knowing that consent had been obtained. These findings confirm our initial hypothesis and suggest that (1) newly dead infants can be a valuable resource for teaching intubation skills, and (2) others considering a similar approach need to be aware of and sensitive to trainees' feelings.	CHILDRENS HOSP MED CTR,NEONATOL INTENS CARE UNIT,AKRON,OH 44308; AKRON REG PERINATAL CTR,AKRON,OH; NORTHEASTERN OHIO UNIV,COLL MED,DEPT PEDIAT,ROOTSTOWN,OH 44272	Northeast Ohio Medical University (NEOMED)	BENFIELD, DG (corresponding author), CHILDRENS HOSP MED CTR,DEPT PEDIAT,DIV NEONATOL,281 LOCUST ST,AKRON,OH 44308, USA.							BRANDT AM, 1978, HASTINGS CTR REP, V8, P28; Crawford T, 1987, Physician Exec, V13, P25; FELDMAN DS, 1986, STATVIEW 512 PLUS PR; Fox Renee, 1979, ESSAYS MED SOCIOLOGY, P51; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; ORLOWSKI JP, 1989, NEW ENGL J MED, V320, P396; TOCHEN ML, 1979, J PEDIATR-US, V95, P1050, DOI 10.1016/S0022-3476(79)80309-1	8	48	48	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2360	2363		10.1001/jama.265.18.2360	http://dx.doi.org/10.1001/jama.265.18.2360			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016832				2022-12-28	WOS:A1991FJ95500030
J	CLUTTONBROCK, TH; VINCENT, ACJ				CLUTTONBROCK, TH; VINCENT, ACJ			SEXUAL SELECTION AND THE POTENTIAL REPRODUCTIVE RATES OF MALES AND FEMALES	NATURE			English	Article							BREEDING-BEHAVIOR; PARENTAL INVESTMENT; PIMEPHALES-PROMELAS; SPRING EMERGENCE; MATING SYSTEMS; FATHEAD MINNOW; MATE CHOICE; SUCCESS; PISCES; CARE	PRONOUNCED sex differences in mating competition are a prominent feature of many animal breeding systems. These differences are widely attributed to sex differences in parental investment 1,2 which bias the ratio of sexually receptive females to males 3 (the operational sex ratio), generating more intense competition between members of one sex, usually males 3-5. Unfortunately, relative parental investment 1 is usually impossible to measure in species where both sexes invest in their offspring 6,7 and there is currently no empirical basis for predicting the pattern of mating competition in these species. In contrast, the potential rate of reproduction by males and females (measured as the maximum number of independent offspring that parents can produce per unit time) is both more directly related to the operational sex ratio and more easily estimated in natural populations 7. Here we show that among species where males care for the young, the sex with the higher potential reproductive rate competes more intensely for mates than the sex with the lower potential rate of reproduction.			CLUTTONBROCK, TH (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, LARGE ANIM RES GRP, CAMBRIDGE CB3 0DT, ENGLAND.							Barlow GW, 1964, Z TIERPSYCHOL, V21, P99, DOI [10.1111/j.1439-0310.1964.tb01188.x, DOI 10.1111/J.1439-0310.1964.TB01188.X]; BARLOW GW, 1962, COPEIA, P346; BAYLIS JR, 1981, ENVIRON BIOL FISH, V6, P223, DOI 10.1007/BF00002788; BAYLIS JR, 1978, NATURE, V276, P738, DOI 10.1038/276738a0; BERGLUND A, 1986, MAR ECOL PROG SER, V29, P209, DOI 10.3354/meps029209; BERGLUND A, 1989, AM NAT, V133, P506, DOI 10.1086/284932; BERGLUND A, IN PRESS EVOLUTION; BREDER CM, 1966, MODES REPRODUCTION F; Breitwisch R., 1989, Current Ornithology, V6, P1; BRUNING D F, 1974, Living Bird, V13, P251; BRUNING DF, 1973, NAT HIST, V82, P68; BRUNING DF, 1974, THESIS U COLORADO; BURLEY N, 1986, AM NAT, V127, P415, DOI 10.1086/284493; BURLEY N, 1977, P NATL ACAD SCI USA, V74, P3476, DOI 10.1073/pnas.74.8.3476; CLUTTONBROCK TH, EVOLUTION PARENTAL C; Cramp S., 1980, BIRDS W PALEARCTIC, V2; CRESPO J, 1979, THESIS U LISBON; DEMARTINI EE, 1987, ANIM BEHAV, V35, P1145, DOI 10.1016/S0003-3472(87)80171-9; DEMARTINI EE, 1985, COPEIA, P966; Duellman W. E., 1986, BIOL AMPHIBIANS; EMLEN ST, 1977, SCIENCE, V197, P215, DOI 10.1126/science.327542; GALE WF, 1985, T AM FISH SOC, V114, P220, DOI 10.1577/1548-8659(1985)114<220:FASFOC>2.0.CO;2; GOTO A, 1987, COPEIA, P32; GREGORY PT, 1974, CAN J ZOOL, V52, P1063, DOI 10.1139/z74-141; GRONELL AM, 1989, ETHOLOGY, V81, P89; GWYNNE DT, 1991, TRENDS ECOL EVOL, V6, P118, DOI 10.1016/0169-5347(91)90089-G; GWYNNE DT, 1990, NATURE, V346, P172, DOI 10.1038/346172a0; GWYNNE DT, 1985, BEHAV ECOL SOCIOBIOL, V16, P355, DOI 10.1007/BF00295549; HANDFORD P, 1985, BIOL J LINN SOC, V25, P77, DOI 10.1111/j.1095-8312.1985.tb00387.x; HOFFMANN ALFRED, 1950, ORNITHOL BER, V2, P119; HOFFMANN. ALFRED., 1949, ZOOL JAHRB ABT SYST OKOL U GEOGR TIERE, V78, P367; IWASA Y, 1983, THEOR POPUL BIOL, V23, P363, DOI 10.1016/0040-5809(83)90024-2; JENNI DA, 1972, AUK, V89, P743, DOI 10.2307/4084107; Kluge A.G., 1981, MISC PUBL MUS ZOOL, V160, P1; KNAPTON RW, 1984, CAN J ZOOL, V62, P2673, DOI 10.1139/z84-388; KREBS JR, 1987, INTRO ANIMAL ECOLOGY; KUWAMURA T, 1985, ENVIRON BIOL FISH, V13, P17, DOI 10.1007/BF00004852; KYNARD BE, 1978, BEHAVIOUR, V67, P178, DOI 10.1163/156853978X00323; MARCONATO A, 1988, J FISH BIOL, V33, P905, DOI 10.1111/j.1095-8649.1988.tb05539.x; MATTHEW DN, 1964, J BOMBAY NAT HIST SO, V61, P295; McDiarmid R.W., 1978, P127; MICHENER GR, 1983, BEHAV ECOL SOCIOBIOL, V14, P29, DOI 10.1007/BF00366653; MYERS JP, 1981, CAN J ZOOL, V59, P1527, DOI 10.1139/z81-207; NUSSBAUM R A, 1985, Miscellaneous Publications Museum of Zoology University of Michigan, P1; OCHI H, 1986, ENVIRON BIOL FISH, V17, P117, DOI 10.1007/BF00001741; ORING L W, 1972, Living Bird, V11, P59; ORING LW, 1983, AUK, V100, P272, DOI 10.1093/auk/100.2.272; OSBORNE D R, 1982, Wilson Bulletin, V94, P206; OSBORNE DR, 1977, CONDOR, V79, P98, DOI 10.2307/1367536; REYNOLDS JD, 1986, BEHAV ECOL SOCIOBIOL, V18, P303, DOI 10.1007/BF00300008; RIDLEY MW, 1980, IBIS, V122, P210, DOI 10.1111/j.1474-919X.1980.tb02660.x; ROSENQVIST G, 1990, ANIM BEHAV, V39, P1110, DOI 10.1016/S0003-3472(05)80783-3; SARGENT RC, 1989, BEHAV ECOL SOCIOBIOL, V25, P379, DOI 10.1007/BF00300183; Smith BG, 1907, BIOL BULL-US, V13, P5, DOI 10.2307/1535594; SUTHERLAND WJ, 1985, ANIM BEHAV, V33, P1349, DOI 10.1016/S0003-3472(85)80197-4; THOMPSON S, 1986, ANIM BEHAV, V34, P580, DOI 10.1016/S0003-3472(86)80127-0; THORNHILL R, 1986, AM SCI, V74, P382; Thornhill R., 1983, pi; Thornhill R., 1986, P113; THRESHER RE, 1984, REPRODUCTION REEF FI; TOWNSEND DS, 1989, AM NAT, V133, P266, DOI 10.1086/284915; Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; Trivers R. L., 1985, SOCIAL EVOLUTION; UNGER LM, 1983, BEHAV ECOL SOCIOBIOL, V13, P125, DOI 10.1007/BF00293802; Urban E.K., 1986, BIRDS AFRICA, V2; VERNON C J, 1973, Ostrich, V44, P85; Vincent ACJ, 1990, THESIS U CAMBRIDGE; Wells K.D., 1981, P184; Wilson E.O., 1971, INSECT SOC; Wintle C.C., 1975, Honeyguide, VNo. 82, P27; [No title captured]	71	560	569	3	218	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	1991	351	6321					58	60						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027382				2022-12-28	WOS:A1991FK19300058
J	DULCEY, CS; GEORGER, JH; KRAUTHAMER, V; STENGER, DA; FARE, TL; CALVERT, JM				DULCEY, CS; GEORGER, JH; KRAUTHAMER, V; STENGER, DA; FARE, TL; CALVERT, JM			DEEP UV PHOTOCHEMISTRY OF CHEMISORBED MONOLAYERS - PATTERNED COPLANAR MOLECULAR ASSEMBLIES	SCIENCE			English	Article							GOLD	Deep ultraviolet (UV) irradiation is shown to modify organosilane self-assembled monolayer (SAM) films by a photocleavage mechanism, which renders the surface amenable to further SAM modification. Patterned UV exposure creates alternating regions of intact SAM film and hydrophilic, reactive sites. The exposed regions can undergo a second chemisorption reaction to produce an assembly of SAMs in the same molecular plane with similar substrate attachment chemistry. The UV-patterned films are used as a template for selective buildup of fluorophores, metals, and biological cells.	USN,RES LAB,CTR BIOMOLEC SCI & ENGN,CODE 6090,WASHINGTON,DC 20375; GEOCENTERS INC,FT WASHINGTON,MD 20744; US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857	United States Department of Defense; United States Navy; Naval Research Laboratory; US Food & Drug Administration (FDA)								Benson S.W, 1976, THERMOCHEMICAL KINET; BIEDLER JL, 1973, CANCER RES, V33, P2643; DOUB DL, 1947, J AM CHEM SOC, V69, P2714; KALLURY KMR, 1988, ANAL CHEM, V60, P169, DOI 10.1021/ac00153a014; KLEINFELD D, 1988, J NEUROSCI, V8, P4098; LAIBINIS PE, 1989, SCIENCE, V245, P845, DOI 10.1126/science.245.4920.845; LAND DP, 1990, REV SCI INSTRUM, V61, P1674, DOI 10.1063/1.1141131; POLYMEROPOULOS EE, 1978, J CHEM PHYS, V69, P1836, DOI 10.1063/1.436844; ROBERTS G, 1990, LANGMUIR BLODGETT FI, pCH7; SCHNUR JM, Patent No. 7182123; SRINIVASAN R, 1989, CHEM REV, V89, P1303, DOI 10.1021/cr00096a003; STENGER DA, Patent No. 7598194; SWALEN JD, 1987, LANGMUIR, V3, P932, DOI 10.1021/la00078a011; WALSH R, 1981, ACCOUNTS CHEM RES, V14, P246, DOI 10.1021/ar00068a004; WASSERMAN SR, 1989, J MATER RES, V4, P886, DOI 10.1557/JMR.1989.0886; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013; Zisman WA., 1964, ADV CHEM SER	17	489	538	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					551	554		10.1126/science.2020853	http://dx.doi.org/10.1126/science.2020853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	2020853				2022-12-28	WOS:A1991FJ12700042
J	RIVIERE, Y; BLANK, V; KOURILSKY, P; ISRAEL, A				RIVIERE, Y; BLANK, V; KOURILSKY, P; ISRAEL, A			PROCESSING OF THE PRECURSOR OF NF-KAPPA-B BY THE HIV-1 PROTEASE DURING ACUTE INFECTION	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTOR; BINDING; EXPRESSION	TRANSCRIPTION of the human immunodeficiency virus type-1 (HIV-1) genome is regulated in part by cellular factors and is stimulated by activation of latently infected T cells. T-cell activation also correlates with the induction of the factor NF-kappa-B which binds to two adjacent sites in the HIV-1 long terminal repeat 1. This factor consists of two DNA-binding subunits of relative molecular mass 50,000 (50K) associated with two 65K subunits. It is located in the nucleus in mature B cells, but is present in other cell types as an inactive cytoplasmic complex 2, 3. External stimuli, including those that activate T cells, result in nuclear translocation of active NF-kappa-B. The cloning of the complementary DNA for the 50K subunit 4,5 helped to identify an exclusively cytoplasmic 105K precursor (p105) (V.B., P.K. and A.I., manuscript submitted). The expression of active NF-kappa-B might therefore also be regulated by the extent of processing of p105. Because HIV-1 requires active NF-kappa-B for efficient transcription 1, we tested the effect of HIV-1 infection on the processing of the human 105K precursor. We show here that the HIV-1 protease can process p105 and increases levels of active nuclear NF-kappa-B complex.	INST PASTEUR,UNITE BIOL MOLEC GENE,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE VIROL & IMMUNOL CELLULAIRE,CNRS,URA 1157,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, GENE DEV, V3, P1689; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Hirel PH, 1990, ANTIVIR CHEM CHEMOTH, V1, P9, DOI 10.1177/095632029000100103; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; LAURENT AG, 1989, J VIROL, V63, P4074, DOI 10.1128/JVI.63.9.4074-4078.1989; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	13	165	167	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					625	626		10.1038/350625a0	http://dx.doi.org/10.1038/350625a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017258				2022-12-28	WOS:A1991FH11200064
J	BRENNAN, TA; HEBERT, LE; LAIRD, NM; LAWTHERS, A; THORPE, KE; LEAPE, LL; LOCALIO, AR; LIPSITZ, SR; NEWHOUSE, JP; WEILER, PC; HIATT, HH				BRENNAN, TA; HEBERT, LE; LAIRD, NM; LAWTHERS, A; THORPE, KE; LEAPE, LL; LOCALIO, AR; LIPSITZ, SR; NEWHOUSE, JP; WEILER, PC; HIATT, HH			HOSPITAL CHARACTERISTICS ASSOCIATED WITH ADVERSE EVENTS AND SUBSTANDARD CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY DATA; DEATH RATES; QUALITY; ILLNESS; DISEASE; COST; SEVERITY	To explore the epidemiology of adverse events (AEs), which were defined as injuries due to medical treatment, and that subset of AEs caused by negligence, we studied interhospital variation in these outcomes in a sample of 31 000 medical records drawn from a random selection of 51 hospitals in New York in 1984. We found a substantial variation in both AE rates (0.2% to 7.9%; mean, 3.2%) and the percentage of AEs due to negligence (1% to 60%; mean, 24.9%) among hospitals. Univariate analyses of AEs revealed that primary teaching institutions had significantly higher rates (4.1%) and rural hospitals had significantly lower ones (1.0%). The percentage of AEs due to negligence was lower in primary teaching (10.7%) and for-profit (9.5%) hospitals and was significantly higher in hospitals with predominantly (> 80%) minority patients who had been discharged (37%). These findings were corroborated by multivariate analysis. Our results suggest that AEs and negligence are not randomly distributed and that certain types of hospitals have significantly higher rates of injuries due to substandard care. These observations may represent an important improvement on existing measures of quality because they take into account the fact that some hospitals' populations may be at risk of suffering a poor outcome.	HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	BRENNAN, TA (corresponding author), BRIGHAM & WOMENS HOSP,DIV GEN MED,BOSTON,MA 02115, USA.		Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022					ABRAMSON NS, 1980, JAMA-J AM MED ASSOC, V244, P582; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BIGBY J, 1986, AM J MED, V83, P1031; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1989, MED CARE, V29, P505; BURSTIN H R, 1991, Clinical Research, V39, p189A; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; COUCH NP, 1981, NEW ENGL J MED, V304, P634, DOI 10.1056/NEJM198103123041103; DONABEDIAN A, 1985, INQUIRY-J HEALTH CAR, V22, P282; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FEIGENSON JS, 1978, JAMA-J AM MED ASSOC, V240, P1878; FINK A, 1989, MED CARE, V27, P315, DOI 10.1097/00005650-198904000-00001; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JOST TS, 1989, OHIO ST LJ, V50, P1; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1953, DOI 10.1001/jama.264.15.1953; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; LAKSHMANAN MC, 1986, ARCH INTERN MED, V146, P1931, DOI 10.1001/archinte.146.10.1931; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MASON WB, 1980, MED CARE, V18, P147, DOI 10.1097/00005650-198002000-00002; MOREHEAD MA, 1964, STUDY HOSPITAL CARE; PALMER RH, 1983, AMBULATORY HLTH CARE; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; SAFRAN C, 1989, MED CARE, V27, P204, DOI 10.1097/00005650-198902000-00010; SHAH BV, 1981, SESUDAAN STANDARD ER; SHAH BV, 1984, RTI LOGIT PROCEDURE; SHORTELL SM, 1981, MED CARE, V19, P1041, DOI 10.1097/00005650-198110000-00006; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1985, 1984 NEW YORK STAT D; 1975, MED INSURANCE FEASIB	36	194	196	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3265	3269		10.1001/jama.265.24.3265	http://dx.doi.org/10.1001/jama.265.24.3265			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR835	2046108				2022-12-28	WOS:A1991FR83500032
J	REIDENBERG, MM				REIDENBERG, MM			CLINICAL-PHARMACOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EOSINOPHILIA-MYALGIA-SYNDROME; CONSUMMATORY BEHAVIORS; ALCOHOL INTAKE; METABOLIZERS; DEBRISOQUINE; POOR				REIDENBERG, MM (corresponding author), CORNELL UNIV, NEW YORK, NY 10021 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; BROSEN K, 1990, CLIN PHARMACOKINET, V18, P220, DOI 10.2165/00003088-199018030-00004; CRAIG WA, 1987, ANN INTERN MED, V106, P900, DOI 10.7326/0003-4819-106-6-900; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; HEIM M, 1990, LANCET, V336, P529, DOI 10.1016/0140-6736(90)92086-W; LEE JT, 1990, NEW ENGL J MED, V322, P1764, DOI 10.1056/NEJM199006213222502; LENNARD L, 1989, CLIN PHARMACOL THER, V46, P149, DOI 10.1038/clpt.1989.119; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; MORTIMER O, 1990, CLIN PHARMACOL THER, V47, P27, DOI 10.1038/clpt.1990.4; NARANJO CA, 1989, CLIN PHARMACOL THER, V46, P301, DOI 10.1038/clpt.1989.142; NARANJO CA, 1990, CLIN PHARMACOL THER, V47, P490, DOI 10.1038/clpt.1990.62; SINDRUP SH, 1990, CLIN PHARMACOL THER, V48, P686, DOI 10.1038/clpt.1990.212; SLUTSKER L, 1990, JAMA-J AM MED ASSOC, V264, P213, DOI 10.1001/jama.264.2.213; VERPOOTEN GA, 1989, CLIN PHARMACOL THER, V45, P22, DOI 10.1038/clpt.1989.4; WOOSLEY RL, 1990, CLIN PHARMACOL THER, V47, P553, DOI 10.1038/clpt.1990.75	15	1	1	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3107	3109						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041114				2022-12-28	WOS:A1991FQ77000011
J	HERMAN, J				HERMAN, J			AVI STORY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1061	1061		10.7326/0003-4819-114-12-1061	http://dx.doi.org/10.7326/0003-4819-114-12-1061			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029104				2022-12-28	WOS:A1991FQ55500013
J	HIRSH, J				HIRSH, J			HEPARIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; TISSUE PLASMINOGEN-ACTIVATOR; DEEP-VEIN THROMBOSIS; LOW-DOSE HEPARIN; MOLECULAR WEIGHT HEPARIN; CONTINUOUS INTRAVENOUS HEPARIN; PARTIAL THROMBOPLASTIN TIME; VENOUS THROMBOSIS; ANTITHROMBIN-III; SUBCUTANEOUS HEPARIN		MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University	HIRSH, J (corresponding author), HAMILTON CIV HOSP, RES CTR, 711 CONCESS ST, HAMILTON L8V 1C3, ONTARIO, CANADA.							ABILDGAARD U, 1968, SCAND J CLIN LAB INV, V21, P89, DOI 10.3109/00365516809076981; AGNELLI G, 1990, BLOOD, V76, P2030; AGNELLI G, 1990, THROMB HAEMOSTASIS, V63, P204; AGNELLI G, 1988, THROMB HAEMOSTASIS, V60, P311; ANDERSSON G, 1982, THROMB RES, V27, P631, DOI 10.1016/0049-3848(82)90001-9; ANDERSSON LO, 1976, THROMB RES, V9, P575, DOI 10.1016/0049-3848(76)90105-5; ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; [Anonymous], 1987, Eur Heart J, V8, P634; BARRITT DW, 1960, LANCET, V1, P1309; BARSHAVIT R, 1989, J CLIN INVEST, V84, P1096, DOI 10.1172/JCI114272; BASU D, 1972, NEW ENGL J MED, V287, P324, DOI 10.1056/NEJM197208172870703; BECKER RC, 1990, AM HEART J, V119, P1254, DOI 10.1016/S0002-8703(05)80172-3; BEGUIN S, 1988, THROMB HAEMOSTASIS, V60, P457; BENTLEY PG, 1980, THROMB RES, V18, P177, DOI 10.1016/0049-3848(80)90182-6; BJORNSSON TD, 1982, CLIN PHARMACOL THER, V31, P104, DOI 10.1038/clpt.1982.16; BLAJCHMAN MA, 1989, ANN NY ACAD SCI, V556, P245; BLEICH SD, 1989, CIRCULATION S2, V80, P113; BODE V, 1990, ARCH INTERN MED, V150, P2117, DOI 10.1001/archinte.150.10.2117; Brinkhous KM, 1939, AM J PHYSIOL, V125, P683, DOI 10.1152/ajplegacy.1939.125.4.683; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CAMILLERI JF, 1988, ARCH MAL COEUR VAISS, V81, P1037; CASTELLOT JJ, 1982, J BIOL CHEM, V257, P1256; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CERCEK B, 1986, CIRCULATION, V74, P583, DOI 10.1161/01.CIR.74.3.583; CHESEBRO JH, 1986, CIRCULATION, V74, P1; CHIU HM, 1977, BLOOD, V49, P171; CHIU HM, 1977, J LAB CLIN MED, V90, P204; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Choay J, 1981, Ann N Y Acad Sci, V370, P644, DOI 10.1111/j.1749-6632.1981.tb29770.x; CHONG BH, 1989, BLOOD, V73, P1592; CLAGETT GP, 1988, ANN SURG, V208, P227, DOI 10.1097/00000658-198808000-00016; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; COLBURN WA, 1976, DRUG METAB REV, V5, P281, DOI 10.3109/03602537609029980; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; CURRY N, 1973, ARCH INTERN MED, V132, P744, DOI 10.1001/archinte.132.5.744; DAWES J, 1978, THROMB RES, V12, P851, DOI 10.1016/0049-3848(78)90279-7; DAWES J, 1979, THROMB RES, V14, P845, DOI 10.1016/0049-3848(79)90004-5; DEBONO DP, IN PRESS BR HEART J; DESWART CAM, 1982, BLOOD, V60, P1251; DOYLE DJ, 1987, ANN INTERN MED, V107, P441, DOI 10.7326/0003-4819-107-4-441; EDELBERG JM, 1990, BIOCHEMISTRY-US, V29, P5906, DOI 10.1021/bi00477a004; EIKA C, 1971, SCAND J HAEMATOL, V8, P216; EISENBERG PR, 1986, J AM COLL CARDIOL, V7, P1255, DOI 10.1016/S0735-1097(86)80144-9; FAGHER B, 1981, ACTA MED SCAND, V210, P357; FENNERTY AG, 1985, BRIT MED J, V290, P27, DOI 10.1136/bmj.290.6461.27-a; FERNANDEZ F, 1986, THROMB RES, V43, P491, DOI 10.1016/0049-3848(86)90094-0; FOLKMAN J, 1985, BIOCHEM PHARMACOL, V34, P905, DOI 10.1016/0006-2952(85)90588-X; FRANCIS CW, 1983, JAMA-J AM MED ASSOC, V249, P374, DOI 10.1001/jama.249.3.374; FRIEDMAN Y, 1974, BIOCHEM J, V139, P699, DOI 10.1042/bj1390699; FRY ETA, 1988, BLOOD, V71, P1347; GALLUS A, 1986, LANCET, V2, P1293; GALLUS AS, 1989, SEMIN THROMB HEMOST, V15, P99, DOI 10.1055/s-2007-1002692; GINSBERG JS, 1989, CHEST, V95, pS156, DOI 10.1378/chest.95.2.156S; GINSBERG JS, 1990, THROMB HAEMOSTASIS, V64, P286; GLAZIER RL, 1976, JAMA-J AM MED ASSOC, V236, P1365, DOI 10.1001/jama.236.12.1365; GLIMELIUS B, 1978, THROMB RES, V12, P773, DOI 10.1016/0049-3848(78)90271-2; HABBAB MA, 1986, CIRCULATION, V74, P321; HALKIN H, 1982, ANN INTERN MED, V96, P561, DOI 10.7326/0003-4819-96-5-561; HEIDEN D, 1977, BRIT J HAEMATOL, V36, P427, DOI 10.1111/j.1365-2141.1977.tb00666.x; HERAS M, 1989, CIRCULATION, V79, P657, DOI 10.1161/01.CIR.79.3.657; HIGHSMITH RF, 1974, J BIOL CHEM, V249, P4335; HIRSH J, 1976, CIRCULATION, V53, P691, DOI 10.1161/01.CIR.53.4.691; HIRSH J, 1990, ACTA CHIR SCAND, P42; HODBY ED, 1972, CAN MED ASSOC J, V106, P562; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOLT JC, 1985, SEMIN HEMATOL, V22, P151; HOOK M, 1976, FEBS LETT, V66, P90, DOI 10.1016/0014-5793(76)80592-3; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; JAQUES LB, 1979, PHARMACOL REV, V31, P99; JICK H, 1968, NEW ENGL J MED, V279, P284, DOI 10.1056/NEJM196808082790603; KAKKAR VV, 1975, LANCET, V2, P674; KANIS JA, 1974, THROMB DIATH HAEMOST, V32, P519, DOI 10.1055/s-0038-1647720; KAPLAN K, 1987, AM J CARDIOL, V59, P241, DOI 10.1016/0002-9149(87)90792-2; KELTON JG, 1980, SEMIN HEMATOL, V17, P259; KING DJ, 1984, ANN INTERN MED, V100, P535, DOI 10.7326/0003-4819-100-4-535; LAGERSTEDT CI, 1985, LANCET, V2, P515; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LEROY J, 1985, SEMIN THROMB HEMOST, V11, P326, DOI 10.1055/s-2007-1004387; Levine M, 1989, HEPARIN CHEM BIOL PR, P517; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEVINE MN, 1986, SEMIN THROMB HEMOST, V12, P39, DOI 10.1055/s-2007-1003533; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LEYVRAZ PF, 1983, NEW ENGL J MED, V309, P954, DOI 10.1056/NEJM198310203091605; LIJNEN HR, 1983, J BIOL CHEM, V258, P3803; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MACMAHON S, 1988, CIRCULATION S2, V78, P98; MAHADOO J, 1978, THROMB RES, V12, P79, DOI 10.1016/0049-3848(78)90087-7; MANT MJ, 1977, LANCET, V1, P1133; MARCINIAK E, 1973, BRIT J HAEMATOL, V24, P391, DOI 10.1111/j.1365-2141.1973.tb01662.x; MCALLISTER BM, 1966, NATURE, V212, P293, DOI 10.1038/212293a0; McLean J, 1916, AM J PHYSIOL, V41, P250, DOI 10.1152/ajplegacy.1916.41.2.250; MORABIA A, 1986, LANCET, V1, P1278; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; OCKELFORD PA, 1982, THROMB RES, V27, P679, DOI 10.1016/0049-3848(82)90006-8; OFOSU FA, 1989, BIOCHEM J, V257, P143, DOI 10.1042/bj2570143; OFOSU FA, 1987, BIOCHEM J, V243, P579, DOI 10.1042/bj2430579; OFOSU FA, 1986, ANN NY ACAD SCI, V485, P41, DOI 10.1111/j.1749-6632.1986.tb34566.x; OKELLY R, 1983, J CLIN ENDOCR METAB, V56, P108, DOI 10.1210/jcem-56-1-108; OLSSON P, 1963, ACTA MED SCAND, V173, P619; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; OWEN J, 1988, BLOOD, V72, P616; PAQUES EP, 1986, THROMB RES, V42, P797, DOI 10.1016/0049-3848(86)90116-7; PINI M, 1990, THROMB HAEMOSTASIS, V64, P222; PIZZULLI L, 1988, DEUT MED WOCHENSCHR, V113, P1837, DOI 10.1055/s-2008-1067897; POWERS PJ, 1989, ARCH INTERN MED, V149, P771, DOI 10.1001/archinte.149.4.771; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; RAPOLD HJ, 1989, CIRCULATION, V79, P980, DOI 10.1161/01.CIR.79.5.980; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1987, HEMOSTASIS THROMBOSI, P1373; SALZMAN EW, 1980, J CLIN INVEST, V65, P64, DOI 10.1172/JCI109661; SALZMAN EW, 1975, NEW ENGL J MED, V292, P1046, DOI 10.1056/NEJM197505152922002; SERNERI GGN, 1987, LANCET, V1, P937; SERNERI GGN, 1990, LANCET, V335, P615; SETHI GK, 1990, J AM COLL CARDIOL, V15, P15, DOI 10.1016/0735-1097(90)90168-O; SHOJANIA AM, 1988, AM J CLIN PATHOL, V89, P19, DOI 10.1093/ajcp/89.1.19; SY MS, 1983, CELL IMMUNOL, V82, P23, DOI 10.1016/0008-8749(83)90137-5; TAVAZZI L, 1989, LANCET, V2, P182; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VANDEWERF F, 1990, LANCET, V336, P71; WALKER AM, 1980, JAMA-J AM MED ASSOC, V244, P1209, DOI 10.1001/jama.244.11.1209; WALKER FJ, 1979, BIOCHEM BIOPH RES CO, V90, P641, DOI 10.1016/0006-291X(79)91283-X; WALKER MG, 1987, BRIT MED J, V294, P1189, DOI 10.1136/bmj.294.6581.1189; WALLENTIN L, 1990, LANCET, V336, P827; WARKENTIN TE, 1989, ANNU REV MED, V40, P31; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WHEELER AP, 1988, ARCH INTERN MED, V148, P1321, DOI 10.1001/archinte.148.6.1321; WHITE PW, 1979, ANN SURG, V190, P595, DOI 10.1097/00000658-197911000-00007; WILSON JE, 1981, AM J MED, V70, P808, DOI 10.1016/0002-9343(81)90537-4; WILSON JR, 1979, AM HEART J, V97, P155, DOI 10.1016/0002-8703(79)90349-1; YETT HS, 1978, NEW ENGL J MED, V298, P1092; 1989, CIRCULATION S3, V80, P14	141	933	956	0	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1991	324	22					1565	1574						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN051	2027360				2022-12-28	WOS:A1991FN05100006
J	GULLIFORD, MC; PETRUCKEVITCH, A; BURNEY, PGJ				GULLIFORD, MC; PETRUCKEVITCH, A; BURNEY, PGJ			HOSPITAL CASE NOTES AND MEDICAL AUDIT - EVALUATION OF NONRESPONSE	BRITISH MEDICAL JOURNAL			English	Article											GULLIFORD, MC (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT PUBL HLTH MED,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.		Gulliford, Martin C/I-8606-2018	Gulliford, Martin C/0000-0003-1898-9075; Burney, Peter/0000-0001-8635-5678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER RJ, 1985, GLIM SYSTEM; Buck N, 1987, REPORT CONFIDENTIAL; HEATH DA, 1990, BRIT MED J, V300, P651, DOI 10.1136/bmj.300.6725.651; HOPKINS A, 1990, MEASURING QUALITY ME, P24; WILLIAMS JG, 1990, BRIT MED J, V300, P991, DOI 10.1136/bmj.300.6730.991	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1128	1129		10.1136/bmj.302.6785.1128	http://dx.doi.org/10.1136/bmj.302.6785.1128			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	2043785	Green Published, Bronze			2022-12-28	WOS:A1991FL43900021
J	ERSLEV, AJ				ERSLEV, AJ			DRUG-THERAPY - ERYTHROPOIETIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RECOMBINANT HUMAN ERYTHROPOIETIN; STAGE RENAL-DISEASE; IMMUNOREACTIVE ERYTHROPOIETIN; RHEUMATOID-ARTHRITIS; CLINICAL-TRIAL; ANEMIA; RADIOIMMUNOASSAY; FAILURE; OXYGEN; BLOOD				ERSLEV, AJ (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MED, CARDEZA FDN HEMATOL RES, 1015 WALNUT ST, PHILADELPHIA, PA 19107 USA.							ABRAHAM PA, 1990, AM J KIDNEY DIS, V16, P438, DOI 10.1016/S0272-6386(12)80056-4; ANDERSON KE, 1990, NEW ENGL J MED, V322, P315, DOI 10.1056/NEJM199002013220507; BAER AN, 1987, BRIT J HAEMATOL, V66, P559, DOI 10.1111/j.1365-2141.1987.tb01344.x; Besarab A, 1990, ASAIO Trans, V36, pM749; BESARAB A, IN PRESS J AM SOC NE; BIRGEGARD G, 1989, BRIT J HAEMATOL, V72, P462, DOI 10.1111/j.1365-2141.1989.tb07733.x; BLUMBERG N, 1989, ARCH PATHOL LAB MED, V113, P246; BOWEN D, 1991, BRIT J HAEMATOL, V77, P419, DOI 10.1111/j.1365-2141.1991.tb08594.x; BROWN MS, 1984, J PEDIATR-US, V105, P793, DOI 10.1016/S0022-3476(84)80309-1; COHEN RA, 1985, P SOC EXP BIOL MED, V179, P296; DACOSTA NA, 1991, AM J HEMATOL, V36, P71, DOI 10.1002/ajh.2830360118; EGRIE JC, 1987, J IMMUNOL METHODS, V99, P235, DOI 10.1016/0022-1759(87)90133-5; ERSLEV AJ, 1984, BLOOD CELLS, V10, P177; ERSLEV AJ, 1980, ANN CLIN LAB SCI, V10, P250; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; FISCHL M, 1990, NEW ENGL J MED, V322, P1488, DOI 10.1056/NEJM199005243222103; FISHER JW, 1989, AM J KIDNEY DIS, V14, P163; FLAHARTY KK, 1990, CLIN PHARMACOL THER, V47, P557, DOI 10.1038/clpt.1990.76; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; HALEY NR, 1989, AM J HYPERTENS, V2, pA56; Hallberg L, 1984, Acta Med Scand, V216, P147; HALPERIN DS, 1990, J PEDIATR-US, V116, P779, DOI 10.1016/S0022-3476(05)82671-X; HEYLL A, 1991, BLOOD, V77, P906; HOCHBERG MC, 1988, ARTHRITIS RHEUM, V31, P1318, DOI 10.1002/art.1780311016; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JELKMANN W, 1990, CONTRIB NEPHROL, V87, P68; KINDLER J, 1989, NEPHROL DIAL TRANSPL, V4, P345, DOI 10.1093/oxfordjournals.ndt.a091888; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LUDWIG H, 1990, NEW ENGL J MED, V322, P1693, DOI 10.1056/NEJM199006143222402; MCMAHON FG, 1990, BLOOD, V76, P1718; MILLER CB, 1990, NEW ENGL J MED, V322, P1689, DOI 10.1056/NEJM199006143222401; MILLER ME, 1981, BRIT J HAEMATOL, V49, P189, DOI 10.1111/j.1365-2141.1981.tb07215.x; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; MUIRHEAD N, 1990, NEPHROL DIAL TRANSPL, V5, P232, DOI 10.1093/ndt/5.3.232; NONNASTDANIEL B, 1990, NEPHROL DIAL TRANSPL, V5, P444, DOI 10.1093/ndt/5.6.444; OSTER W, 1990, J CLIN ONCOL, V8, P956, DOI 10.1200/JCO.1990.8.6.956; PINCUS T, 1990, AM J MED, V89, P161, DOI 10.1016/0002-9343(90)90294-N; SAWYER ST, 1989, BLOOD, V74, P103; SCHAPIRA L, 1990, BLOOD, V76, P2354; SCHUSTER S J, 1987, Hematologic Pathology, V1, P193; SHERWOOD JB, 1986, BLOOD, V67, P46; SHERWOOD JB, 1979, BLOOD, V54, P885; STEBLER C, 1990, EXP HEMATOL, V18, P1204; VANWYCK DB, 1989, KIDNEY INT, V35, P712, DOI 10.1038/ki.1989.43; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6; WU HS, 1988, J CLIN ONCOL, V6, P1348, DOI 10.1200/JCO.1988.6.8.1348; ZANJANI ED, 1981, J CLIN INVEST, V67, P1183, DOI 10.1172/JCI110133	54	375	380	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1339	1344		10.1056/NEJM199105093241907	http://dx.doi.org/10.1056/NEJM199105093241907			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017231				2022-12-28	WOS:A1991FK18600007
J	FRANK, LG; GLICKMAN, SE; LICHT, P				FRANK, LG; GLICKMAN, SE; LICHT, P			FATAL SIBLING AGGRESSION, PRECOCIAL DEVELOPMENT, AND ANDROGENS IN NEONATAL SPOTTED HYENAS	SCIENCE			English	Article							CROCUTA-CROCUTA; SOCIAL-ORGANIZATION	Fatal neonatal sibling aggression is common in predatory birds but has not been previously reported in wild mammals. Spotted hyena females are strongly masculinized, both anatomically and behaviorally, apparently by high levels of androgens during ontogeny. Neonates display elevated androgen levels, precocial motor development, and fully erupted front teeth. Litters are usually twins, and siblings fight violently at birth, apparently leading to the death of one sibling in same-sex litters, whereas in mixed-sex litters both siblings usually survive.	UNIV CALIF BERKELEY, DEPT INTEGRAT BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	FRANK, LG (corresponding author), UNIV CALIF BERKELEY, DEPT PSYCHOL, BERKELEY, CA 94720 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039917] Funding Source: NIH RePORTER; NIMH NIH HHS [MH39917] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BEKOFF M, 1981, AGGRESSIVE BEHAV, V7, P225, DOI 10.1002/1098-2337(1981)7:3<225::AID-AB2480070306>3.0.CO;2-I; FRANK LG, 1986, ANIM BEHAV, V34, P1510, DOI 10.1016/S0003-3472(86)80221-4; FRANK LG, 1990, J ZOOL, V221, P308, DOI 10.1111/j.1469-7998.1990.tb04001.x; FRANK LG, 1986, ANIM BEHAV, V34, P1500, DOI 10.1016/S0003-3472(86)80220-2; FRANK LG, UNPUB; Fraser D, 1990, J Reprod Fertil Suppl, V40, P355; GLICKMAN SE, 1987, P NATL ACAD SCI USA, V84, P3444, DOI 10.1073/pnas.84.10.3444; GOULD SJ, 1982, PALEOBIOLOGY, V8, P4, DOI 10.1017/S0094837300004310; GOULD SJ, 1981, NAT HIST, V90, P16; HOFER H, 1989, 5TH INT THER C ROM; Kranendonk H.J., 1983, Zoologische Garten, V53, P339; KRUUK H, 1972, SPOTTED HYENA; LICHT P, 1982, BIOL REPROD, V27, P411, DOI 10.1095/biolreprod27.2.411; LINDEQUE M, 1982, J REPROD FERTIL, V65, P405; LINDEQUE M, 1986, J REPROD FERTIL, V78, P211; MACPHERSON AH, 1969, CAN WILDL REP SER, V8; MATTHEWS L. HARRISON, 1939, PHIL TRANS ROY SOC LONDON SER B BIOL SCI, V230, P1; MILLS MGL, 1990, KALAHARI HYAENAS, P138; MOCK DW, 1990, AM SCI, V78, P438; PARKER GA, 1989, AM NAT, V133, P846, DOI 10.1086/284956; Pournelle G. H., 1965, Journal of Mammalogy, V46, P503, DOI 10.2307/1377649; Rieger I., 1981, MAMMALIAN SPECIES, V150, P1; SMALE L, 1989, 5TH INT THER C ROM; TILSON RL, 1984, ANIM BEHAV, V32, P715, DOI 10.1016/S0003-3472(84)80147-5	24	134	139	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					702	704		10.1126/science.2024122	http://dx.doi.org/10.1126/science.2024122			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024122				2022-12-28	WOS:A1991FK18500047
J	ARANA, GW				ARANA, GW			DEXAMETHASONE SUPPRESSION TEST IN THE DIAGNOSIS OF DEPRESSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PSYCHIATRY; UTILITY				ARANA, GW (corresponding author), MED UNIV S CAROLINA,CHARLESTON,SC 29425, USA.							ARANA GW, 1985, ARCH GEN PSYCHIAT, V42, P1193; ARANA GW, 1988, AM J PSYCHIAT, V145, P707; CARROLL BJ, 1981, ARCH GEN PSYCHIAT, V38, P15; GLASSMAN AH, 1987, AM J PSYCHIAT, V144, P1253	4	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2253	2254						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH877	2013959				2022-12-28	WOS:A1991FH87700042
J	CHARLTON, B				CHARLTON, B			ANATOMY PAST AND PRESENT	BRITISH MEDICAL JOURNAL			English	Editorial Material											CHARLTON, B (corresponding author), UNIV GLASGOW,DEPT ANAT,GLASGOW G12 8QQ,SCOTLAND.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					1001	1002		10.1136/bmj.302.6783.1001	http://dx.doi.org/10.1136/bmj.302.6783.1001			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039877	Bronze, Green Published			2022-12-28	WOS:A1991FJ50800021
J	BOMAN, HG				BOMAN, HG			ANTIBACTERIAL PEPTIDES - KEY COMPONENTS NEEDED IN IMMUNITY	CELL			English	Review							CECROPIN; PRECURSOR; FORMS				BOMAN, HG (corresponding author), UNIV STOCKHOLM,DEPT MICROBIOL,S-10691 STOCKHOLM,SWEDEN.							BANGALORE N, 1990, J BIOL CHEM, V265, P13584; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BOMAN HG, 1989, J BIOL CHEM, V264, P5852; DIAMOND G, 1991, IN PRESS P NATL ACAD, V88; FRANK RW, 1990, J BIOL CHEM, V265, P18871; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P7620, DOI 10.1021/bi00420a008; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KANIA A, 1989, FEBS LETT, V258, P199; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SAMAKOVLIS C, 1991, EMBO J, V10, P163, DOI 10.1002/j.1460-2075.1991.tb07932.x; SIMMACO M, 1991, IN PRESS EUR J BIOCH; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; XANTHOPOULOS KG, 1988, EUR J BIOCHEM, V172, P371, DOI 10.1111/j.1432-1033.1988.tb13896.x; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	18	533	585	2	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					205	207		10.1016/0092-8674(91)90154-Q	http://dx.doi.org/10.1016/0092-8674(91)90154-Q			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015623				2022-12-28	WOS:A1991FH09200003
J	DELAMOTHE, T				DELAMOTHE, T			THE NEW NHS - EAST-BIRMINGHAM - THE GREAT BUREAUCRATIC SQUARE DANCE BEGINS	BRITISH MEDICAL JOURNAL			English	Editorial Material																		BLAIRFISH D, 1990, BRIT MED J, V301, P7; MCCONVILLE A, 1990, BETTER HLTH E BIRMIN	2	4	4	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					714	718		10.1136/bmj.302.6778.714	http://dx.doi.org/10.1136/bmj.302.6778.714			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	2021746	Green Published, Bronze			2022-12-28	WOS:A1991FE33300031
J	ELLIS, BW; SENSKY, T				ELLIS, BW; SENSKY, T			AUDIT IN PERSON - A CLINICIAN GUIDE TO SETTING UP AUDIT	BRITISH MEDICAL JOURNAL			English	Article									HOUNSLOW & SPELTHORNE HEALTH AUTHOR,DIST AUDIT ADVISORY COMM,HOUNSLOW,ENGLAND									ANDERSON J, 1989, BRIT MED J, V299, P1477, DOI 10.1136/bmj.299.6714.1477; BATSTONE GF, 1990, BRIT MED J, V301, P326, DOI 10.1136/bmj.301.6747.326; BENNETT J, 1990, BRIT MED J, V300, P1248, DOI 10.1136/bmj.300.6734.1248; ELLIS BW, 1989, BRIT MED J, V298, P1635, DOI 10.1136/bmj.298.6688.1635; ELLIS BW, 1990, BRIT MED J, V301, P159, DOI 10.1136/bmj.301.6744.159; ELLIS BW, 1988, BRIT J HOSP MED, V39, P187; GRUER R, 1986, LANCET, V1, P23; GUMPERT R, 1990, BRIT MED J, V301, P162, DOI 10.1136/bmj.301.6744.162; LYONS C, 1990, BRIT MED J, V300, P1563, DOI 10.1136/bmj.300.6739.1563; MCCONNACHIE RW, 1990, BRIT MED J, V300, P1566, DOI 10.1136/bmj.300.6739.1566; NIXON SJ, 1990, BRIT MED J, V300, P380, DOI 10.1136/bmj.300.6721.380; SHAW CD, 1989, BRIT MED J, V299, P498, DOI 10.1136/bmj.299.6697.498; SMITH T, 1990, BRIT MED J, V300, P65, DOI 10.1136/bmj.300.6717.65; 1989, MED AUDIT ED IMPLICA; 1989, 6 SECR STAT HLTH WOR	15	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					704	707		10.1136/bmj.302.6778.704	http://dx.doi.org/10.1136/bmj.302.6778.704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	2021743	Green Published, Bronze			2022-12-28	WOS:A1991FE33300028
J	KOOPMAN, WJ				KOOPMAN, WJ			RHEUMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROCOLLAGEN GENE COL2A1; MILD CHONDRODYSPLASIA; METHOTREXATE; ARTHRITIS				KOOPMAN, WJ (corresponding author), UNIV ALABAMA,SCH MED,BIRMINGHAM,AL 35233, USA.							ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; ALARCON GS, 1990, ARTHRITIS RHEUM, V33, P1156; EYRE DR, 1991, J CLIN INVEST, V87, P357, DOI 10.1172/JCI114994; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; KNOWLTON RG, 1990, NEW ENGL J MED, V322, P526, DOI 10.1056/NEJM199002223220807; KUJALA GA, 1990, ARTHRITIS RHEUM-US, V33, P1037, DOI 10.1002/art.1780330717; MORGAN SL, 1990, ARTHRITIS RHEUM-US, V33, P9, DOI 10.1002/art.1780330102; SPERLING RI, 1990, ARTHRITIS RHEUM, V33, P1149; VIITANEN AM, 1991, ARTHRITIS RHEUM, V34, P84	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3169	3170						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041141				2022-12-28	WOS:A1991FQ77000041
J	LEADBETTER, GW; GILLENWATER, JY				LEADBETTER, GW; GILLENWATER, JY			UROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY CYSTINE EXCRETION; CAPTOPRIL		UNIV VIRGINIA,HLTH SCI CTR,CHARLOTTESVILLE,VA 22903	University of Virginia	LEADBETTER, GW (corresponding author), UNIV VERMONT,COLL MED,BURLINGTON,VT, USA.							CHAUSSY C, 1982, J UROLOGY, V127, P417, DOI 10.1016/S0022-5347(17)53841-0; CLAYMAN R V, 1990, Journal of Endourology, V4, P247, DOI 10.1089/end.1990.4.247; Coptcoat M. J., 1988, J ENDOUROL, V2, P321; CORTESI N, 1976, ENDOSCOPY, V8, P33, DOI 10.1055/s-0028-1098372; GILLENWATER JY, 1991, ADULT PEDIATRIC UROL, pCH20; GRIFFITH DP, 1990, J UROLOGY, V143, pA270; Jenkins AD, 1991, ADULT PEDIAT UROLOGY, P403; LINGEMAN JE, 1990, JAMA-J AM MED ASSOC, V264, P2869, DOI 10.1001/jama.1990.03450220030014; LINGEMAN JE, 1990, JAMA-J AM MED ASSOC, V263, P1789, DOI 10.1001/jama.263.13.1789; MANSON AL, 1985, J UROLOGY, V134, P919, DOI 10.1016/S0022-5347(17)47528-8; SLOAND JA, 1987, ARCH INTERN MED, V147, P1409, DOI 10.1001/archinte.147.8.1409; STREEM SB, 1989, J UROLOGY, V142, P1522, DOI 10.1016/S0022-5347(17)39146-2; Weinberg J. J., 1988, J ENDOUROL, V2, P355; WINFIELD H N, 1990, Journal of Endourology, V4, P37, DOI 10.1089/end.1990.4.37; Yendt ER, 1990, J LITHOTRIPSY STONE, V2, P164	15	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3175	3176		10.1001/jama.265.23.3175	http://dx.doi.org/10.1001/jama.265.23.3175			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041143				2022-12-28	WOS:A1991FQ77000044
J	MORREY, BF				MORREY, BF			ORTHOPEDICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISCECTOMY				MORREY, BF (corresponding author), MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905, USA.							ANDREWS DW, 1990, SPINE, V15, P329, DOI 10.1097/00007632-199004000-00015; BODIN SD, 1990, J BONE JOINT SURG AM, V72, P403; Hale D, 1990, J BONE JOINT SURG BR, V72, P1090; HASHIMOTO K, 1990, SPINE, V15, P1166, DOI 10.1097/00007632-199011010-00015; JASTY M, 1990, J BONE JOINT SURG AM, V72A, P1220, DOI 10.2106/00004623-199072080-00015; JOYCE ME, 1990, ANN NY ACAD SCI, V593, P107, DOI 10.1111/j.1749-6632.1990.tb16104.x; KAHANOVITZ N, 1990, SPINE, V15, P713, DOI 10.1097/00007632-199007000-00017; KAVANAGH BF, 1989, J BONE JOINT SURG AM, V71A, P1496, DOI 10.2106/00004623-198971100-00007; LIVERMORE J, 1990, J BONE JOINT SURG AM, V72A, P518, DOI 10.2106/00004623-199072040-00008; MALONEY WJ, 1990, J BONE JOINT SURG BR, V72, P966, DOI 10.1302/0301-620X.72B6.2246299; NEIRICH SD, 1990, SPINE, V15, P630; OLSEWSKI JM, 1990, J BONE JOINT SURG AM, V72A, P541, DOI 10.2106/00004623-199072040-00011; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SANTAVIRTA S, 1990, J BONE JOINT SURG AM, V72A, P252, DOI 10.2106/00004623-199072020-00014; SPENGLER DM, 1990, J BONE JOINT SURG AM, V72A, P230, DOI 10.2106/00004623-199072020-00010; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; YONEZAWA T, 1990, SPINE, V15, P1175, DOI 10.1097/00007632-199011010-00017	17	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3151	3152						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041132				2022-12-28	WOS:A1991FQ77000031
J	BLANC, P; WONG, H; BERNSTEIN, MS; BOUSHEY, HA				BLANC, P; WONG, H; BERNSTEIN, MS; BOUSHEY, HA			AN EXPERIMENTAL HUMAN-MODEL OF METAL FUME FEVER	ANNALS OF INTERNAL MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; BRONCHOALVEOLAR WASHINGS; FACTOR-ALPHA; ZINC; INTERLEUKIN-1; INFLAMMATION; MEDIATOR; CYTOKINE; LAVAGE; CELLS	Objective: To examine the pathogenesis of metal fume fever in humans by studying functional, cellular, and biochemical responses after exposure to zinc welding fume. Design: Clinical experimental study. Participants: We studied 14 welders recruited through public advertisements. Interventions: Participants welded galvanized steel. Measurements: We measured lung volumes, airflow, diffusing capacity for carbon monoxide, and airway reactivity at baseline as well as either 6 or 20 hours after welding. We carried out bronchoalveolar lavage either 8 hours (early follow-up, 5 participants) or 22 hours (late follow-up, 9 participants) after welding, assaying the fluid for total and differential cell counts and bronchoalveolar lavage supernatant concentrations of interleukin-1 and tumor necrosis factor (TNF). Main Results: Changes in pulmonary function and airway reactivity were minimal. Cumulative zinc exposure and polymorphonuclear leukocyte count in bronchoalveolar lavage fluid at late (r = 0.87; P < 0.01) and early (r = 0.93; P < 0.05)follow-up were positively correlated. Among the late follow-up group, the mean proportion of polymorphonuclear leukocytes was 37% (range, 19% to 63%), a statistically greater proportion than the 9% (range, 2% to 21%) seen among the early follow-up group (P < 0.05). We did not detect TNF or more than a trace amount of interleukin-1 in the bronchoalveolar lavage supernatant. Conclusions: Zinc oxide welding fume was associated with a marked dose-dependent increase in the number of polymorphonuclear leukocytes recovered in bronchoalveolar lavage fluid 22 hours after exposure but was not associated with a clinically significant change in pulmonary function or airway reactivity. Although we did not identify increases in either interleukin-1 or TNF levels in bronchoalveolar lavage fluid, cytokines or a cytokine-like mechanism may mediate the syndrome of metal fume fever.	UNIV CALIF SAN FRANCISCO, DIV OCCUPAT & ENVIRONM MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV PULM MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24136] Funding Source: Medline; PHS HHS [K010H00079] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BEECKMANS JM, 1963, ARCH ENVIRON HEALTH, V7, P346, DOI 10.1080/00039896.1963.10663544; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BIBBY DC, 1989, J PHYSIOL-LONDON, V410, P367, DOI 10.1113/jphysiol.1989.sp017538; BROCKS A, 1977, BRIT MED J, V1, P1390, DOI 10.1136/bmj.1.6073.1390; CALLENDER G. R., 1937, Military Surgeon, V80, P67; CONNER MW, 1988, J TOXICOL ENV HEALTH, V25, P57, DOI 10.1080/15287398809531188; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DINARELLO CA, 1988, REV INFECT DIS, V10, P168; DRINKER PHILIP, 1927, JOUR INDUST HYG, V9, P98; GELB AF, 1973, AM REV RESPIR DIS, V107, P50; KUNKEL SL, 1990, PROG CLIN BIOL RES, V349, P433; LAM HF, 1985, TOXICOL APPL PHARM, V78, P29, DOI 10.1016/0041-008X(85)90301-1; LARSEN C, 1990, PROG CLIN BIOL RES, V349, P419; LECOURS R, 1986, THORAX, V41, P924, DOI 10.1136/thx.41.12.924; LEHMANN KB, 1910, ARCH HYG, V72, P358; LITOVITZ TL, 1989, AM J EMERG MED, V7, P495, DOI 10.1016/0735-6757(89)90252-0; MALO JL, 1990, EUR RESPIR J, V3, P111; MALO JL, 1987, CHEST, V92, P375, DOI 10.1378/chest.92.2.375; MARCHAT-AMORUSO B, 1990, American Review of Respiratory Disease, V141, pA423; MITCHELL MM, 1968, AM REV RESPIR DIS, V97, P571; MORI T, 1975, INT ARCH OCC ENV HEA, V36, P29, DOI 10.1007/BF01267849; MORIMOTO A, 1988, AM J PHYSIOL, V254, pR633, DOI 10.1152/ajpregu.1988.254.4.R633; MORIMOTO A, 1989, AM J PHYSIOL, V256, pR35, DOI 10.1152/ajpregu.1989.256.1.R35; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; MUELLER E J, 1985, Journal of Emergency Medicine, V2, P271, DOI 10.1016/0736-4679(85)90106-4; MURPHY JV, 1970, J AMER MED ASSOC, V212, P2119, DOI 10.1001/jama.212.12.2119; NELSON S, 1989, J INFECT DIS, V159, P189, DOI 10.1093/infdis/159.2.189; NETA R, 1988, ANN INTERN MED, V109, P1, DOI 10.7326/0003-4819-109-1-1; OLGILVIE CM, 1957, J CLIN INVEST, V36, P1; PERNIS B, 1960, CLIN LAVORO, V51, P579; RYAN L K, 1990, American Review of Respiratory Disease, V141, pA678; SCHMIDTKEHL L, 1928, ZENTRALBLATT GEWERBE, V5, P272; SCUDERI P, 1990, CELL IMMUNOL, V126, P391, DOI 10.1016/0008-8749(90)90330-T; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SILER TM, 1989, EXP LUNG RES, V15, P881, DOI 10.3109/01902148909069633; STURGIS CYRUS C., 1927, JOUR INDUST HYG, V9, P88; TANAKA Y, 1990, SCAND J IMMUNOL, V31, P547, DOI 10.1111/j.1365-3083.1990.tb02805.x; TAYLOR G, 1986, OCCUPATIONAL RESPIRA, P607; VACHERON F, 1990, J GEN VIROL, V71, P477, DOI 10.1099/0022-1317-71-2-477; VOLGELMEIER C, 1987, CHEST, V92, P946; WANKOWICZ Z, 1988, J LEUKOCYTE BIOL, V43, P349, DOI 10.1002/jlb.43.4.349; WILMOTT RW, 1990, AM REV RESPIR DIS, V142, P365, DOI 10.1164/ajrccm/142.2.365; WINCHURCH RA, 1987, EUR J IMMUNOL, V17, P127, DOI 10.1002/eji.1830170121; 1990, AM REV RESPIR DIS, V141, pS165; 1975, OCCUPATIONAL EXPOSUR; 1988, CRITERIA RECOMMENDED; 1989, OSHA3112 US DEP LAB	48	69	72	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					930	936		10.7326/0003-4819-114-11-930	http://dx.doi.org/10.7326/0003-4819-114-11-930			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024859				2022-12-28	WOS:A1991FM97900003
J	EARNEST, DL; ADWERS, JR; CAREY, WD; CASARELLA, WJ; KATZ, S; LOEB, PM; NAHRWOLD, DL; SABESIN, SM; THOMPSON, JC; VENNES, JA				EARNEST, DL; ADWERS, JR; CAREY, WD; CASARELLA, WJ; KATZ, S; LOEB, PM; NAHRWOLD, DL; SABESIN, SM; THOMPSON, JC; VENNES, JA			GUIDELINES FOR TRAINING IN GALLSTONE LITHOTRIPSY	ANNALS OF INTERNAL MEDICINE			English	Article								Representatives of eight professional societies present recommendations for the training of health care professionals in extracorporeal shock-wave gallstone lithotripsy,on the basis of data obtained from a questionnaire completed by 85 physicians who were selected because of their experience with gallstone lithotripsy. This training should be done in a medical facility that permits a multispecialty approach to patient care by physicians who are trained in gastroenterology, radiology, and general surgery and who are experienced and competent in the diagnosis and management of biliary tract disease. Candidates for training should be gastroenterologists, radiologists, or general surgeons who are licensed to practice medicine and who have had specific training and clinical experience in treating gallstone disease and in ultrasound imaging of the biliary tract. The guidelines specify requirements for the training site and the lithotripsy device, the qualifications of the training site director, and the components of the educational program. The experience must include not only didactic course work and clinical observation, but also practical "hands-on" experience at the training site. Subsequent additional practical experience under supervision at the trainee's own lithotripsy treatment facility is recommended. Credentialing of the trainee in this procedure should be the responsibility of an appropriate board or committee of the trainee's own institution or lithotripsy center.	EMORY UNIV HOSP, DEPT RADIOL, ATLANTA, GA 30322 USA; PRESBYTERIAN MED CTR, GASTROENTEROL UNIT, DALLAS, TX 75230 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL 60612 USA; UNIV TEXAS, MED BRANCH, DEPT SURG, GALVESTON, TX 77550 USA; UNIV MINNESOTA HOSP & CLIN, DIV GASTROENTEROL, MINNEAPOLIS, MN 55455 USA	Emory University; Rush University; University of Texas System; University of Texas Medical Branch Galveston; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital	EARNEST, DL (corresponding author), UNIV ARIZONA, HLTH SCI CTR, GASTROENTEROL SECT, 1501 N CAMPBELL AVE, TUCSON, AZ 85724 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					977	979		10.7326/0003-4819-114-11-977	http://dx.doi.org/10.7326/0003-4819-114-11-977			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024866				2022-12-28	WOS:A1991FM97900010
J	MILLER, C				MILLER, C			1990 - ANNUS-MIRABILIS OF POTASSIUM CHANNELS	SCIENCE			English	Article							CA-2+-ACTIVATED K+ CHANNEL; SENSITIVE ION CHANNELS; SODIUM-CHANNEL; HIGH-CONDUCTANCE; ELECTROPHORUS-ELECTRICUS; CHARYBDOTOXIN BLOCK; MEMBRANE-PROTEINS; MOLECULAR-MODEL; XENOPUS-OOCYTES; VOLTAGE	Voltage-gated potassium channels make up a large molecular family of integral membrane proteins that are fundamentally involved in the generation of bioelectric signals such as nerve impulses. These proteins span the cell membrane, forming potassium-selective pores that are rapidly switched open or closed by changes in membrane voltage. After the cloning of the first potassium channel over 3 years ago, recombinant DNA manipulation of potassium channel genes is now leading to a molecular understanding of potassium channel behavior. During the past year, functional domains responsible for channel gating and potassium selectivity have been identified, and detailed structural pictures underlying these functions are beginning to emerge.			MILLER, C (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,GRAD DEPT BIOCHEM,WALTHAM,MA 02254, USA.							ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; ARMSTRONG CM, 1990, P NATL ACAD SCI USA, V87, P7579, DOI 10.1073/pnas.87.19.7579; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1975, QUART REV BIOPH, V7, P179; BEGENISICH T, 1980, J GEN PHYSIOL, V76, P83, DOI 10.1085/jgp.76.1.83; BENHAM CD, 1985, PFLUG ARCH EUR J PHY, V403, P120, DOI 10.1007/BF00584088; BONTEMS F, 1991, EUR J BIOCHEM, V196, P19, DOI 10.1111/j.1432-1033.1991.tb15780.x; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHOI KL, IN PRESS P NATL ACAD; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1989, MONOVALENT CATIONS B; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hille B, 1984, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; KOSOWER EM, 1985, FEBS LETT, V182, P234, DOI 10.1016/0014-5793(85)80306-9; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LEONARD RJ, 1989, P NATL ACAD SCI USA, V86, P7629, DOI 10.1073/pnas.86.19.7629; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1989, BIOCHEMISTRY-US, V28, P8087, DOI 10.1021/bi00446a019; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1988, NEURON, V1, P1003, DOI 10.1016/0896-6273(88)90157-2; MILLER C, 1987, J GEN PHYSIOL, V90, P427, DOI 10.1085/jgp.90.3.427; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; NEYTON J, 1988, J GEN PHYSIOL, V92, P549, DOI 10.1085/jgp.92.5.549; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SPALDING BC, 1981, AM J PHYSIOL, V241, pC68, DOI 10.1152/ajpcell.1981.241.1.C68; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; THOMPSON SH, 1980, CELL SURFACE NEURONA, P49; VERGARA C, 1983, J GEN PHYSIOL, V82, P543, DOI 10.1085/jgp.82.4.543; VESTERGAARDBOGIND B, 1985, J MEMBRANE BIOL, V88, P67, DOI 10.1007/BF01871214; VILLARROEL A, 1988, PFLUG ARCH EUR J PHY, V413, P118, DOI 10.1007/BF00582521; WHITE SH, 1990, J MEMBRANE BIOL, V115, P145, DOI 10.1007/BF01869453; YELLEN G, 1987, ANNU REV BIOPHYS BIO, V16, P227; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	54	235	241	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1092	1096		10.1126/science.252.5009.1092	http://dx.doi.org/10.1126/science.252.5009.1092			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031183				2022-12-28	WOS:A1991FN05600034
J	YU, S; PRITCHARD, M; KREMER, E; LYNCH, M; NANCARROW, J; BAKER, E; HOLMAN, K; MULLEY, JC; WARREN, ST; SCHLESSINGER, D; SUTHERLAND, GR; RICHARDS, RI				YU, S; PRITCHARD, M; KREMER, E; LYNCH, M; NANCARROW, J; BAKER, E; HOLMAN, K; MULLEY, JC; WARREN, ST; SCHLESSINGER, D; SUTHERLAND, GR; RICHARDS, RI			FRAGILE-X GENOTYPE CHARACTERIZED BY AN UNSTABLE REGION OF DNA	SCIENCE			English	Article								DNA sequences have been located at the fragile X site by in situ hybridization and by the mapping of breakpoints in two somatic cell hybrids that were constructed to break at the fragile site. These hybrids were found to have breakpoints in a common 5-kilobase Eco RI restriction fragment. When this fragment was used as a probe on the chromosomal DNA of normal and fragile X genotype individuals, alterations in the mobility of the sequences detected by the probe were found only in fragile X genotype DNA. These sequences were of an increased size in all fragile X individuals and varied within families, indicating that the region was unstable. This probe provides a means with which to analyze fragile X pedigrees and is a diagnostic reagent for the fragile X genotype.	ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; WASHINGTON UNIV,CTR GENET MED,ST LOUIS,MO 63110	Emory University; Washington University (WUSTL)			Warren, Stephen T/A-2498-2012; Sutherland, Grant Robert/D-2606-2012; Richards, Robert/ABE-6423-2020; Kremer, Eric J/D-3734-2013; Kremer, EJ/P-9838-2019	Kremer, EJ/0000-0001-6114-7530; Richards, Robert Ian/0000-0002-5978-6453				CALLEN DF, 1986, ANN GENET-PARIS, V29, P235; KREMER E, UNPUB ANN GENET; KREMER EJ, IN PRESS AM J HUM GE; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; RICHARDS RI, IN PRESS AM J HUM GE; Sutherland G, 1985, FRAGILE SITES HUMAN; SUTHERLAND GR, 1990, CLIN GENET, V37, P2; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856	9	723	742	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1179	1181		10.1126/science.252.5009.1179	http://dx.doi.org/10.1126/science.252.5009.1179			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031189				2022-12-28	WOS:A1991FN05600053
J	BORSANI, G; TONLORENZI, R; SIMMLER, MC; DANDOLO, L; ARNAUD, D; CAPRA, V; GROMPE, M; PIZZUTI, A; MUZNY, D; LAWRENCE, C; WILLARD, HF; AVNER, P; BALLABIO, A				BORSANI, G; TONLORENZI, R; SIMMLER, MC; DANDOLO, L; ARNAUD, D; CAPRA, V; GROMPE, M; PIZZUTI, A; MUZNY, D; LAWRENCE, C; WILLARD, HF; AVNER, P; BALLABIO, A			CHARACTERIZATION OF A MURINE GENE EXPRESSED FROM THE INACTIVE X-CHROMOSOME	NATURE			English	Article							MOUSE; DNA; MECHANISMS; SEQUENCES; ALIGNMENT; REGION; FAMILY; CDNA	IN mammals, equal dosage of gene products encoded by the X chromosome in male and female cells is achieved by X inactivation. Although X-chromosome inactivation represents the most extensive example known of long range cis gene regulation, the mechanism by which thousands of gene on only one of a pair of identical chromosomes are turned off is poorly understood. We have recently identified a human gene (XIST) exclusively expressed from the inactive X chromosome 1. Here we report the isolation and characterization of its murine homologue (Xist) which localizes to the mouse X inactivation centre region and is the first murine gene found to be expressed from the inactive X chromosome. Nucleotide sequence analysis indicates that Xist may be associated with a protein product. The similar map positions and expression patterns for Xist in mouse and man suggest that this gene may have a role in X inactivation.	BAYLOR UNIV,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030; INST PASTEUR,UNITE GENET MOLEC MARINE,F-75724 PARIS 15,FRANCE; STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305	Baylor College of Medicine; Baylor University; Baylor University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Stanford University			BALLABIO, Andrea/AAL-2672-2020; Tonlorenzi, Rossana/AAN-2241-2020; Borsani, Giuseppe/B-1709-2010; Valeria, Capra/AAB-1501-2019; capra, valeria/N-4367-2013	BALLABIO, Andrea/0000-0003-1381-4604; Borsani, Giuseppe/0000-0003-0110-1148; Grompe, Markus/0000-0002-6616-4345; capra, valeria/0000-0002-3097-0388; PIZZUTI, Antonio/0000-0003-3245-1925; Tonlorenzi, Rossana/0000-0002-6060-8208				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMAR L C, 1988, Genomics, V2, P220, DOI 10.1016/0888-7543(88)90006-7; AVNER P, 1987, P NATL ACAD SCI USA, V84, P5330, DOI 10.1073/pnas.84.15.5330; BALLABIO A, 1987, P NATL ACAD SCI USA, V84, P4519, DOI 10.1073/pnas.84.13.4519; BENDER PK, 1989, P NATL ACAD SCI USA, V86, P9996, DOI 10.1073/pnas.86.24.9996; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CATTANACH BM, 1975, ANNU REV GENET, V9, P1, DOI 10.1146/annurev.ge.09.120175.000245; CATTANACH BM, IN PRESS CYTOGENET C; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; EHRICH E, 1987, GENE, V57, P229, DOI 10.1016/0378-1119(87)90126-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; JONES J, 1989, GENET RES, V53, P193, DOI 10.1017/S0016672300028160; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; KEER JT, 1990, GENOMICS, V7, P566, DOI 10.1016/0888-7543(90)90200-E; LYON MF, 1971, NATURE-NEW BIOL, V232, P229, DOI 10.1038/newbio232229a0; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MITCHELL M, 1989, GENETICS, V121, P803; MOHANDAS T, 1987, P NATL ACAD SCI USA, V84, P4954, DOI 10.1073/pnas.84.14.4954; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHERER SE, 1988, NUCLEIC ACIDS RES, V16, P1593, DOI 10.1093/nar/16.4.1593; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SEFTON L, IN PRESS MAMMALIAN G	29	460	470	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					325	329		10.1038/351325a0	http://dx.doi.org/10.1038/351325a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034278				2022-12-28	WOS:A1991FM97600064
J	GRUMBACH, K; BODENHEIMER, T; HIMMELSTEIN, DU; WOOLHANDLER, S				GRUMBACH, K; BODENHEIMER, T; HIMMELSTEIN, DU; WOOLHANDLER, S			LIBERAL BENEFITS, CONSERVATIVE SPENDING - THE PHYSICIANS FOR A NATIONAL-HEALTH PROGRAM PROPOSAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; CONTROLLED TRIAL; PROMOTE QUALITY; CARE; INSURANCE; CHOICE; COST; SERVICES; CANADA; EXPENDITURES	The Physicians for a National Health Program proposes to cover all Americans under a single, comprehensive public insurance program without copayments or deductibles and with free choice of provider. Such a national health program could reap tens of billions of dollars in administrative savings in the initial years, enough to fund generous increases in health care services not only for the uninsured, but for the underinsured as well. We delineate a transitional national health program budget that would hold overall health spending at current levels while accommodating increases in hospital and physician utilization. Future national health program spending would be indexed to the growth in gross national product adjusted for demographic, epidemiologic, and technologic shifts. Financing for the national health program would transfer funds into the public program without disrupting the general pattern of current revenue sources. We suggest a funding package that would augment existing government health spending with earmarked health care taxes. Because these new taxes would replace employer-employee insurance premiums and substantial portions of current out-of-pocket expenditures, they would not increase health costs for the average American.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; CAMBRIDGE HOSP,DEPT MED,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,BOSTON,MA 02115; PUBLIC CITIZEN HLTH RES GRP,WASHINGTON,DC	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University; Harvard Medical School	GRUMBACH, K (corresponding author), PHYSICIANS NATL HLTH PROGRAM,1493 CAMBRIDGE ST,CAMBRIDGE,MA 02139, USA.		Grumbach, Kevin/L-9222-2016					AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; [Anonymous], 1987, Health Care Financ Rev, V8, P1; BEAUCHAMP DE, 1990, NEW ENGL J MED, V323, P640, DOI 10.1056/NEJM199009063231005; BERGTHOLD L, 1990, PURCHASING POWER HLT; BLENDON RJ, 1990, NEW ENGL J MED, V323, P208, DOI 10.1056/NEJM199007193230329; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; DiCarlo Steven, 1989, Health Care Financ Rev, V10, P77; EISENBERG J, 1986, DOCTORS DECISIONS CO; ENTERLINE PE, 1973, NEW ENGL J MED, V289, P1174, DOI 10.1056/NEJM197311292892206; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; EVANS RG, 1988, HEALTH AFFAIR, V7, P17, DOI 10.1377/hlthaff.7.5.17; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; EVANS RG, 1990, 1990 R H ROS LECT WA, P7; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GONZALEZ ML, 1988, SOCIOECONOMIC CHARAC; GRUMBACH K, 1989, WESTERN J MED, V151, P210; GRUMBACH K, 1990, HEALTH AFFAIR, V9, P120, DOI 10.1377/hlthaff.9.4.120; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; IGLEHART JK, 1990, NEW ENGL J MED, V322, P562, DOI 10.1056/NEJM199002223220827; JONES SB, 1989, HEALTH AFFAIR, V8, P51, DOI 10.1377/hlthaff.8.3.51; Last J M, 1985, Am J Prev Med, V1, P1; Levit K R, 1989, Health Care Financ Rev, V10, P1; LEVIT KR, 1990, HEALTH AFFAIR, V9, P171, DOI 10.1377/hlthaff.9.2.171; MCDONALD AD, 1974, NEW ENGL J MED, V291, P649, DOI 10.1056/NEJM197409262911304; NEEDLEMAN J, 1990, HLTH CARE FINANCING; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; Pechman JA, 1987, FEDERAL TAX POLICY; PFAFF M, 1990, J HEALTH POLIT POLIC, V15, P1, DOI 10.1215/03616878-15-1-1; REINER O, 1987, DNA-J MOLEC CELL BIO, V6, P101, DOI 10.1089/dna.1987.6.101; Wagstaff, 1989, OXFORD REV ECON POL, V5, P89, DOI [DOI 10.1093/0XREP/5.1.89, DOI 10.1093/OXREP/51.89]; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WOOLHANDLER S, 1989, JAMA-J AM MED ASSOC, V262, P2136; WOOLHANDLER S, 1989, J GEN INTERN MED, V4, P54, DOI 10.1007/BF02596493; 1990, CALL ACTION; 1990, REDUCING DEFICIT SPE; 1989, HLTH NATION; 1989, AGGREGATE HOSPITAL F; 1989, HLTH CARE FINANCIN S, V10, P1; 1990, NATIONAL HLTH EXPEND; 1989, SOCIOECONOMIC MONITO, V3, P2; 1989, VA89 AM MED ASS REP; 1990, Q SUMMARY FEDERAL ST; 1990, HLTH ACCESS AM; 1990, STATISTICAL ABSTRACT	47	53	53	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2549	2554		10.1001/jama.265.19.2549	http://dx.doi.org/10.1001/jama.265.19.2549			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK903	2020074				2022-12-28	WOS:A1991FK90300031
J	HARMON, RG				HARMON, RG			A PRIMARY CARE SYSTEM FOR THE UNDERSERVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HARMON, RG (corresponding author), US HLTH RESOURCES & SERV ADM,ROCKVILLE,MD, USA.							[Anonymous], 1988, FUTURE PUBLIC HLTH; 1990, HLTH PEOPLE 2000 NAT	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2464	2464						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK903	2020061				2022-12-28	WOS:A1991FK90300005
J	PHILIPSON, L				PHILIPSON, L			TURMOIL IN EUROPEAN BIOLOGY	NATURE			English	Editorial Material											PHILIPSON, L (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.								0	5	5	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					91	92		10.1038/351091a0	http://dx.doi.org/10.1038/351091a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	2030737				2022-12-28	WOS:A1991FL03500012
J	GARDNER, JF				GARDNER, JF			LEEK SOUP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2324	2324						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016825				2022-12-28	WOS:A1991FJ95500011
J	WEATHERALL, DJ				WEATHERALL, DJ			THE PHYSICIAN SCIENTIST - AN ENDANGERED BUT FAR FROM EXTINCT SPECIES	BRITISH MEDICAL JOURNAL			English	Editorial Material							SCIENCE				WEATHERALL, DJ (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND.							COMROE JH, 1976, SCIENCE, V192, P105, DOI 10.1126/science.769161; EISENBERG L, 1988, AM J MED, V84, P483; GILL GN, 1984, AM SCHOLAR, V53, pF353; GOLDSTEIN JL, 1986, J CLIN INVEST, V78, P848, DOI 10.1172/JCI112652; HARVEY AM, 1990, OSLERS LEGACY DEPART; Weatherall David J., 1991, NEW GENETICS CLIN PR; 1988, PRIORITIES MED RES; 1987, HOSPITAL MED STAFFIN; 1989, CMND555	9	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					1002	1005		10.1136/bmj.302.6783.1002	http://dx.doi.org/10.1136/bmj.302.6783.1002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039878	Bronze, Green Published			2022-12-28	WOS:A1991FJ50800022
J	LISKOWSKY, DR				LISKOWSKY, DR			NEURAL GRAFTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LISKOWSKY, DR (corresponding author), US CONGRESS,OFF TECHNOL ASSESSMENT,BIOL APPLICAT PROGRAM,WASHINGTON,DC 20510, USA.							1990, NEURAL GRAFTING REPA	1	9	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3225	3225						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	2046098				2022-12-28	WOS:A1991FR83500008
J	DOVER, JS; ARNDT, KA				DOVER, JS; ARNDT, KA			DERMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; EPIDEMIC KAPOSIS-SARCOMA; HERPES-ZOSTER; AIDS; INFECTION; VIRUS; ANGIOMATOSIS; RISK		BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	DOVER, JS (corresponding author), NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215, USA.							BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CHACHOUA A, 1989, J CLIN ONCOL, V7, P774, DOI 10.1200/JCO.1989.7.6.774; COCKERELL CJ, 1987, LANCET, V2, P654; DUVIC M, 1987, ARCH DERMATOL, V123, P1622, DOI 10.1001/archderm.123.12.1622; FRIEDMANKIEN AE, 1986, J AM ACAD DERMATOL, V14, P1023, DOI 10.1016/S0190-9622(86)70127-8; GREENSPAN D, 1987, J INFECT DIS, V155, P475, DOI 10.1093/infdis/155.3.475; HOPPENJANS WB, 1990, ARCH DERMATOL, V126, P1048, DOI 10.1001/archderm.126.8.1048; HORN TD, 1989, J AM ACAD DERMATOL, V21, P781, DOI 10.1016/S0190-9622(89)70254-1; KAYE BR, 1989, ANN INTERN MED, V111, P158, DOI 10.7326/0003-4819-111-2-158; KOVACS JA, 1989, ANN INTERN MED, V111, P280, DOI 10.7326/0003-4819-111-4-280; KRIGEL RL, 1990, SEMIN ONCOL, V17, P350; MARTE C, 1990, 6TH P INT C AIDS SAN, V1, P211; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; ROSENTHAL D, 1991, ARCH DERMATOL, V127, P206, DOI 10.1001/archderm.127.2.206; RUTHERFORD G W, 1990, Journal of Acquired Immune Deficiency Syndromes, V3, pS1	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3111	3113						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041116				2022-12-28	WOS:A1991FQ77000013
J	FISHER, LL; DOUGLAS, RG				FISHER, LL; DOUGLAS, RG			INFECTIOUS-DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; CONTROLLED TRIAL; CORTICOSTEROIDS; EHRLICHIOSIS		MERCK SHARP & DOHME INT,RAHWAY,NJ		FISHER, LL (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021, USA.							BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HIRSCH MS, 1990, J INFECT DIS, V161, P845, DOI 10.1093/infdis/161.5.845; MCDADE JE, 1990, J INFECT DIS, V161, P609, DOI 10.1093/infdis/161.4.609; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, MMWR, V39, P630; 1990, ANN INTERN MED, V113, P604; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1	13	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3130	3132						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041125				2022-12-28	WOS:A1991FQ77000023
J	FOEGE, WH				FOEGE, WH			PREVENTIVE MEDICINE AND PUBLIC-HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FOEGE, WH (corresponding author), EMORY UNIV,CARTER CTR,ATLANTA,GA 30322, USA.							HINMAN AR, 1987, B WORLD HEALTH ORGAN, V65, P835; RICE DP, 1991, W J MED, V154, P349; 1990, SUMMARY REV STATUS P; 1990, PROTECTING WORLDS CH; 1990, HLTH PEOPLE 2000 NAT; 1985, PROTECTING WORLDS CH; 1980, PROMOTING HLTH PREVE; 1988, PROTECTING WORLDS CH	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3162	3163						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ770	2041137				2022-12-28	WOS:A1991FQ77000037
J	SAYEGH, MH; FINE, NA; SMITH, JL; RENNKE, HG; MILFORD, EL; TILNEY, NL				SAYEGH, MH; FINE, NA; SMITH, JL; RENNKE, HG; MILFORD, EL; TILNEY, NL			IMMUNOLOGICAL-TOLERANCE TO RENAL-ALLOGRAFTS AFTER BONE-MARROW TRANSPLANTS FROM THE SAME DONORS	ANNALS OF INTERNAL MEDICINE			English	Note							VERSUS-HOST DISEASE; GRAFT; IRRADIATION; TRANSFUSION; BLOOD	A severe potential complication of clinical bone marrow transplantation is the eventual development of end-stage renal failure, probably as a direct consequence of chemotherapy and radiation, by as many as half of the long-term survivors. There have been no clinical descriptions of the use of renal allografts in recipients of successful bone marrow grafts who went on to develop subsequent kidney failure. This report describes two patients receiving bone marrow transplants from HLA-identical siblings who, 3 and 6 years later, accepted kidneys from the same donors. Although we did not use any immunosuppressive therapy, we did not observe any rejection episodes, and both renal allografts continue to function normally more than 1 and 2 years later. One of the patients developed a transient episode of mild graft-versus-host-disease. These are the first reported cases of specific acquired immunologic tolerance to vascularized whole-organ allografts in humans.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV IOWA HOSP & CLIN, IOWA CITY, IA 52242 USA	Harvard University; Harvard Medical School; University of Iowa	SAYEGH, MH (corresponding author), BRIGHAM & WOMENS HOSP, 75 FRANCIS ST, BOSTON, MA 02115 USA.							ANTIGNAC C, 1989, KIDNEY INT, V35, P1336, DOI 10.1038/ki.1989.132; BERGSTEIN J, 1986, TRANSPLANTATION, V41, P63, DOI 10.1097/00007890-198601000-00013; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; MAIN JM, 1955, J NATL CANCER I, V15, P1023; MITCHISON NA, 1956, BRIT J EXP PATHOL, V37, P239; STROBER S, 1989, NEW ENGL J MED, V321, P28, DOI 10.1056/NEJM198907063210106; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; THALER M, 1989, NEW ENGL J MED, V321, P25, DOI 10.1056/NEJM198907063210105; VONFLIEDNER V, 1982, AM J MED, V72, P951	10	212	224	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					954	955		10.7326/0003-4819-114-11-954	http://dx.doi.org/10.7326/0003-4819-114-11-954			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024863				2022-12-28	WOS:A1991FM97900007
J	BALTIMORE, D				BALTIMORE, D			THE IMANISHI-KARI AFFAIR - BALTIMORE DECLARES OTOOLE MISTAKEN	NATURE			English	Editorial Material																		IMANISHIKARL T, 1991, NATURE, V350, P263; OTOOLE M, 1991, NATURE, V351, P180, DOI 10.1038/351180a0; WEAVER D, 1986, CELL; 1991, NATURE, V351, P94	4	1	1	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					341	343		10.1038/351341a0	http://dx.doi.org/10.1038/351341a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034280	Green Accepted			2022-12-28	WOS:A1991FN85600017
J	DILEO, AJ; ALLEGREZZA, AE				DILEO, AJ; ALLEGREZZA, AE			VALIDATABLE VIRUS REMOVAL FROM PROTEIN SOLUTIONS	NATURE			English	Article											DILEO, AJ (corresponding author), MILLIPORE CORP,80 ASHBY RD,BEDFORD,MA, USA.							BECHTEL MK, 1988, BIOMATER ARTIF CELL, V16, P123, DOI 10.3109/10731198809132562; DILEO AJ, MEMBRANE PROCESS SYS; DILEO AJ, UNPUB BIOTECHNOLOGY	3	7	8	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					420	421		10.1038/351420a0	http://dx.doi.org/10.1038/351420a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034293				2022-12-28	WOS:A1991FN85600065
J	SIXMA, TK; PRONK, SE; KALK, KH; WARTNA, ES; VANZANTEN, BAM; WITHOLT, B; HOL, WGJ				SIXMA, TK; PRONK, SE; KALK, KH; WARTNA, ES; VANZANTEN, BAM; WITHOLT, B; HOL, WGJ			CRYSTAL-STRUCTURE OF A CHOLERA TOXIN-RELATED HEAT-LABILE ENTEROTOXIN FROM ESCHERICHIA-COLI	NATURE			English	Article							AERUGINOSA EXOTOXIN-A; ADP-RIBOSYLTRANSFERASE ACTIVITY; AMINO-ACID-SEQUENCE; X-RAY-DIFFRACTION; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; NUCLEOTIDE-SEQUENCE; B-SUBUNIT; DIPHTHERIA-TOXIN; 3-DIMENSIONAL STRUCTURE	Examination of the structure of Escherichia coli heat-labile enterotoxin in the AB5 complex at a resolution of 2.3 angstrom reveals that the doughnut-shaped B pentamer binds the enzymatic A subunit using a hairpin of the A2 fragment, through a highly charged central pore. Putative ganglioside G(M1-) binding sites on the B subunits are more than 20 angstrom removed from the membrane-crossing A1 subunit. This ADP-ribosylating (A1) fragment of the toxin has structural homology with the catalytic region of exotoxin A and hence also to diphtheria toxin.	STATE UNIV GRONINGEN, DEPT CHEM, BIOCHEM LAB, 9747 AG GRONINGEN, NETHERLANDS	University of Groningen	SIXMA, TK (corresponding author), STATE UNIV GRONINGEN, BIOSON RES INST, NIJENBORGH 16, 9747 AG GRONINGEN, NETHERLANDS.		Witholt, Bernard/A-7340-2012	Sixma, Titia K/0000-0001-6180-0632				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BRANDHUBER BJ, 1988, PROTEINS, V3, P146, DOI 10.1002/prot.340030303; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CLEMENS JD, 1986, LANCET, V2, P124; CZERKINSKY C, 1989, INFECT IMMUN, V57, P1072, DOI 10.1128/IAI.57.4.1072-1077.1989; DALLAS WS, 1980, NATURE, V288, P499, DOI 10.1038/288499a0; DERTZBAUGH MT, 1990, INFECT IMMUN, V58, P70, DOI 10.1128/IAI.58.1.70-79.1990; DEWOLF MJS, 1981, J BIOL CHEM, V256, P5489; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; FINKELSTEIN RA, 1988, IMMUNOCHEMICAL MOL G, P85; FOSTER JW, 1985, CRC CR REV MICROBIOL, V11, P273; FUJINAGA M, 1989, J APPL CRYSTALLOGR, V22, P1, DOI 10.1107/S0021889888009550; GALLOWAY TS, 1987, BIOCHEM J, V244, P225, DOI 10.1042/bj2440225; GEARY SJ, 1982, INFECT IMMUN, V36, P215, DOI 10.1128/IAI.36.1.215-220.1982; GILL DM, 1987, BIOCHEMISTRY-US, V26, P6364, DOI 10.1021/bi00394a009; GILL DM, 1980, J INFECT DIS, V141, P64, DOI 10.1093/infdis/141.1.64; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; GOINS B, 1988, BIOCHEMISTRY-US, V27, P2046, DOI 10.1021/bi00406a035; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HARFORD S, 1989, EUR J BIOCHEM, V183, P311, DOI 10.1111/j.1432-1033.1989.tb14930.x; HIRST TR, 1984, P NATL ACAD SCI-BIOL, V81, P7752, DOI 10.1073/pnas.81.24.7752; HOFSTRA H, 1984, J BIOL CHEM, V259, P5182; IIDA T, 1989, J BIOL CHEM, V264, P14065; JACOB CO, 1985, EMBO J, V4, P3339, DOI 10.1002/j.1460-2075.1985.tb04086.x; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LAI CY, 1983, BIOCHEM BIOPH RES CO, V116, P341, DOI 10.1016/0006-291X(83)90420-5; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LUDWIG DS, 1985, J BIOL CHEM, V260, P2528; LUKAC M, 1988, BIOCHEMISTRY-US, V27, P7629, DOI 10.1021/bi00420a009; MCDANIEL RV, 1986, BIOPHYS J, V49, P94, DOI 10.1016/S0006-3495(86)83606-2; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MOSS J, 1977, J BIOL CHEM, V252, P2455; MOSS J, 1981, J BIOL CHEM, V256, P2861; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; OKAMOTO K, 1988, J BACTERIOL, V170, P2208, DOI 10.1128/jb.170.5.2208-2211.1988; PETERSON JW, 1989, SCIENCE, V245, P857, DOI 10.1126/science.2549637; PICKETT CL, 1989, J BACTERIOL, V171, P4945, DOI 10.1128/jb.171.9.4945-4952.1989; PRONK SE, 1985, J BIOL CHEM, V260, P3580; RATTI G, 1983, NUCLEIC ACIDS RES, V11, P6589, DOI 10.1093/nar/11.19.6589; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; SANCHEZ J, 1988, FEBS LETT, V241, P110, DOI 10.1016/0014-5793(88)81041-X; SANDKVIST M, 1987, J BACTERIOL, V169, P4570, DOI 10.1128/jb.169.10.4570-4576.1987; SCHODEL F, 1989, INFECT IMMUN, V57, P1347; SPICER EK, 1982, J BIOL CHEM, V257, P5716; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSUJI T, 1985, J BIOL CHEM, V260, P8552; TSUJI T, 1990, J BIOL CHEM, V265, P22520; VANHEYNINGEN S, 1983, CURR TOP MEMBR TRANS, V18, P445; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0; YAMAMOTO T, 1987, J BACTERIOL, V169, P1352, DOI 10.1128/jb.169.3.1352-1357.1987	65	487	508	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 30	1991	351	6325					371	377		10.1038/351371a0	http://dx.doi.org/10.1038/351371a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034287				2022-12-28	WOS:A1991FN85600047
J	LUPAS, A; VANDYKE, M; STOCK, J				LUPAS, A; VANDYKE, M; STOCK, J			PREDICTING COILED COILS FROM PROTEIN SEQUENCES	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; TRANSFER-RNA-SYNTHETASE; LEUCINE ZIPPER MOTIF; DNA-BINDING PROTEIN; ESCHERICHIA-COLI; INTERMEDIATE FILAMENTS; MYOSIN ROD; EXPRESSION; SUBUNIT; GENE	The probability that a residue in a protein is part of a coiled-coil structure was assessed by comparison of its flanking sequences with sequences of known coiled-coil proteins. This method was used to delineate coiled-coil domains in otherwise globular proteins, such as the leucine zipper domains in transcriptional regulators, and to predict regions of discontinuity within coiled-coil structures, such as the hinge region in myosin. More than 200 proteins that probably have coiled-coil domains were identified in GenBank, including alpha- and beta-tubulins, flagellins, G protein beta-subunits, some bacterial transfer RNA synthetases, and members of the heat shock protein (Hsp70) family.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20980] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYER PD, 1987, NUCLEIC ACIDS RES, V15, P2309, DOI 10.1093/nar/15.5.2309; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; FEDOROV OV, 1988, FEBS LETT, V241, P145, DOI 10.1016/0014-5793(88)81048-2; FREYMANN D, 1990, FASEB J, V4, pA2166; FREYMANN DM, 1984, NATURE, V311, P167, DOI 10.1038/311167a0; FU JH, 1989, MOL CELL BIOL, V9, P1120; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HARTINGS H, 1989, EMBO J, V8, P2795, DOI 10.1002/j.1460-2075.1989.tb08425.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; JASIN M, 1984, CELL, V36, P1089, DOI 10.1016/0092-8674(84)90059-X; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; KUWAJIMA G, 1988, J BACTERIOL, V170, P3305, DOI 10.1128/jb.170.7.3305-3309.1988; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; STEINERT PM, 1985, ANNU REV CELL BIOL, V1, P41; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; YANEVA M, 1989, J BIOL CHEM, V264, P13407	31	3495	3594	6	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1162	1164		10.1126/science.252.5009.1162	http://dx.doi.org/10.1126/science.252.5009.1162			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031185				2022-12-28	WOS:A1991FN05600047
J	BENDEFY, IM				BENDEFY, IM			HOME NEBULIZERS IN CHILDHOOD ASTHMA - SURVEY OF HOSPITAL SUPERVISED USE	BRITISH MEDICAL JOURNAL			English	Article							NEBULIZERS	Objective - To review the management of and outcome in asthmatic children using home nebulisers under hospital supervision. Design - Postal questionnaires sent to parents. Setting - Paediatric departments of a children's hospital and a district general hospital. Subjects - Parents of 93 asthmatic children who had been loaned home nebulisers for administration of bronchodilators with verbal instructions on their use. Main outcome measures - Drugs administered with nebuliser, side effects, frequency of hospital admission, and theoretical management of a severe attack. Results - 84 children took salbutamol and 37 received more than 10 mg a day during attacks; side effects were reported in 54 children. Parents of 16 children said that they would give another dose of bronchodilator rather than seek medical help if their child failed to respond to the first dose. Since being loaned nebulisers 65 children were admitted to hospital less frequently and 16 were not readmitted; over two thirds of parents thought that there had been a marked improvement in their child's asthma. Conclusions - Home nebulisers are valuable in childhood asthma. Excessive doses of bronchodilators may be given, however, and a weight related dose may be more appropriate. Parents should be given written as well as verbal instructions, especially regarding the management of severe attacks.	DEPT COMMUNITY CHILD HLTH,COMMUNITY HOUSE,MORDEN,SURREY,ENGLAND									FORFAR JO, 1984, TXB PAEDIATRICS, P554; LAROCHE CM, 1985, BRIT MED J, V290, P1611, DOI 10.1136/bmj.290.6482.1611; LENNEY W, 1978, LANCET, V1, P440; MILNER AD, 1981, ARCH DIS CHILD, V56, P84, DOI 10.1136/adc.56.2.84; MILNER AD, 1987, UPDATE          0215, P398; REISER J, 1986, ARCH DIS CHILD, V61, P88, DOI 10.1136/adc.61.1.88; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; STORR J, 1988, ARCH DIS CHILD, V63, P774, DOI 10.1136/adc.63.7.774; 1982, BMJ, V285, P1251	9	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1180	1181		10.1136/bmj.302.6786.1180	http://dx.doi.org/10.1136/bmj.302.6786.1180			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043813	Bronze, Green Published			2022-12-28	WOS:A1991FN04500020
J	PARISI, MA; CLAYTON, DA				PARISI, MA; CLAYTON, DA			SIMILARITY OF HUMAN MITOCHONDRIAL TRANSCRIPTION FACTOR-I TO HIGH MOBILITY GROUP PROTEINS	SCIENCE			English	Article							RNA POLYMERASE-I; SEX-DETERMINING REGION; DNA-BINDING MOTIF; REGULATORY ELEMENTS; MESSENGER-RNAS; SEQUENCE; PROMOTERS; GENES; IDENTIFICATION; INITIATION	Human mitochondrial transcription factor 1 (mtTF1) has been sequenced and is a nucleus-encoded DNA binding protein of 204 amino acids (24,400 daltons). Expression of human mtTF1 in bacteria yields a protein with correct physical properties and the ability to activate mitochondrial DNA promoters. Analysis of the protein's sequence reveals no similarities to any other DNA binding proteins except for the existence of two domains that are characteristic of high mobility group (HMG) proteins. Human mrTF1 is most closely related to a DNA binding HMG-box regions in hUBF, a human protein known to be important for transcription by RNA polymerase I.			PARISI, MA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033088, R01GM033088, T32GM007365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07365-15, GM33088-20] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AUSUBEL FM, 1987, CURRENT PROTOCOL S11; BAIROCH A, 1990, THESIS U GENEVA; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BRUTLAG DL, 1990, COMPUT APPL BIOSCI, V6, P237; CARBALLO M, 1983, EMBO J, V2, P1759, DOI 10.1002/j.1460-2075.1983.tb01654.x; CARON F, 1979, P NATL ACAD SCI USA, V76, P4265, DOI 10.1073/pnas.76.9.4265; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; DEFRANCESCO L, 1981, NUCLEIC ACIDS RES, V9, P6017, DOI 10.1093/nar/9.22.6017; DIFFEY JFX, COMMUNICATION; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FISHER RA, UNPUB; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FISHER RP, 1989, GENE DEV, V3, P2202, DOI 10.1101/gad.3.12b.2202; FISHER RP, IN PRESS J BIOL CHEM; GOODWIN GH, 1982, HMG CHROMOSOMAL PROT, P193; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HIXSON JE, 1985, P NATL ACAD SCI USA, V82, P2660, DOI 10.1073/pnas.82.9.2660; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; Johns E.W., 1982, HMG CHROMOSOMAL PROT, P1; KELLY M, 1988, EMBO J, V7, P1536; KOLODRUBETZ D, 1990, NUCLEIC ACIDS RES, V18, P5565, DOI 10.1093/nar/18.18.5565; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; PARISI M, UNPUB; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENTECOST BT, 1985, NUCLEIC ACIDS RES, V13, P4871, DOI 10.1093/nar/13.13.4871; REECK GR, 1982, NATURE, V300, P76, DOI 10.1038/300076a0; ROTH SY, 1987, NUCLEIC ACIDS RES, V15, P8112, DOI 10.1093/nar/15.19.8112; Sambrook J, 1989, MOL CLONING LABORATO; SCHULMAN IG, 1987, J CELL BIOL, V104, P1485, DOI 10.1083/jcb.104.6.1485; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOPPER JN, 1989, MOL CELL BIOL, V9, P1200, DOI 10.1128/MCB.9.3.1200; WALBERG MW, 1983, J BIOL CHEM, V258, P1268; WALKER JM, 1982, HMG CHROMOSOMAL PROT, P69; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197	53	453	476	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					965	969		10.1126/science.2035027	http://dx.doi.org/10.1126/science.2035027			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	2035027				2022-12-28	WOS:A1991FM04000036
J	LOGAN, GM; WEIMER, MK; ELLEFSON, M; PIERACH, CA; BLOOMER, JR				LOGAN, GM; WEIMER, MK; ELLEFSON, M; PIERACH, CA; BLOOMER, JR			BILE PORPHYRIN ANALYSIS IN THE EVALUATION OF VARIEGATE PORPHYRIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTOPORPHYRINOGEN OXIDASE; ENZYMATIC DEFECT; HEMOGLOBIN; FECES; HEME	Background. Variegate porphyria is a genetic disorder of porphyrin metabolism in which patients may have both neurologic dysfunction and photocutaneous lesions. Biochemical confirmation of the diagnosis can be difficult, particularly in patients without neurologic dysfunction at the time of testing. The demonstration of increased fecal excretion of porphyrin is frequently used for this purpose, but levels may be normal. Since elevated fecal porphyrin levels in variegate porphyria are presumably a consequence of increased biliary excretion, we evaluated whether analysis of porphyrins in bile distinguishes better between patients with variegate porphyria and controls. Methods. Bile samples were collected by duodenal aspiration from 10 patients with proved variegate porphyria who had no neurologic symptoms when they were studied and 17 control subjects. Bile and fecal porphyrin levels were measured fluorometrically. Results. The mean total porphyrin concentration in bile in the patients with variegate porphyria was significantly higher than that in the controls (67.8 vs. 0.71-mu-mol per liter; P < 0.00002). There was more than a ninefold difference between the highest level in any control subject and the lowest level in any patient with variegate porphyria. The mean fecal porphyrin level in the patients with variegate porphyria also differed significantly from that in the controls (0.79 vs. 0.14-mu-mol per gram of dry weight; P < 0.007), but four patients had levels within the control range. Conclusions. The concentration of porphyrin in bile is higher in patients with variegate porphyria than in controls, and the difference is greater than that for fecal porphyrin. Bile porphyrin measurements may be helpful in the evaluation of asymptomatic patients suspected of having variegate porphyria.	UNIV MINNESOTA,DEPT MED,DIV GASTROENTEROL HEPATOL & NUTR,BOX 36 UMHC,HARVARD ST & RIVER RD,MINNEAPOLIS,MN 55455; MINNEAPOLIS MED RES FDN INC,DEPT MED,MINNEAPOLIS,MN; ABBOTT NW HOSP,DEPT MED,MINNEAPOLIS,MN; ST PAUL RAMSEY MED CTR,GASTROENTEROL SECT,ST PAUL,MN 55101	University of Minnesota System; University of Minnesota Twin Cities; Minneapolis Medical Research Foundation; Saint Paul Ramsey Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034931, R01DK026466, R37DK026466] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34931, DK 26466] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZIZ MA, 1969, CLIN CHIM ACTA, V26, P525, DOI 10.1016/0009-8981(69)90083-7; BELCHER RV, 1969, CLIN CHIM ACTA, V25, P45, DOI 10.1016/0009-8981(69)90225-3; BEUKEVELD GJJ, 1987, CLIN CHEM, V33, P2164; BRENNER DA, 1980, NEW ENGL J MED, V302, P765, DOI 10.1056/NEJM198004033021401; COREY TJ, 1980, J AM ACAD DERMATOL, V2, P36, DOI 10.1016/S0190-9622(80)80290-8; DEYBACH JC, 1981, HUM GENET, V58, P425, DOI 10.1007/BF00282829; DUANE WC, 1976, J LIPID RES, V17, P211; Eales L, 1966, S Afr Med J, V40, P380; EALES L, 1990, INT J BIOCHEM, V12, P837; ELDER GH, 1975, J CLIN PATHOL, V28, P601, DOI 10.1136/jcp.28.8.601; FORD RE, 1981, CLIN CHEM, V27, P397; FROMKE VL, 1978, AM J MED, V65, P80, DOI 10.1016/0002-9343(78)90696-4; GROSSER Y, 1973, S AFR MED J, V47, P2162; JENDRASSIK A, 1938, BIOCHEM Z, V296, P71; MORTON KO, 1988, GASTROENTEROLOGY, V94, P1488, DOI 10.1016/0016-5085(88)90690-7; MUSTAJOKI P, 1978, ANN INTERN MED, V89, P238, DOI 10.7326/0003-4819-89-2-238; MUSTAJOKI P, 1976, ACTA MED SCAND, V200, P171; POHFITZPATRICK MB, 1980, ARCH DERMATOL, V116, P543, DOI 10.1001/archderm.116.5.543; RIMINGTON C, 1968, CLIN SCI, V35, P211; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061; SCHWARTZ S, 1985, GASTROENTEROLOGY, V89, P19, DOI 10.1016/0016-5085(85)90740-1; SIEPKER L, 1986, S AFR MED J, V70, P819; VILJOEN DJ, 1983, EUR J CLIN INVEST, V13, P283, DOI 10.1111/j.1365-2362.1983.tb00102.x; WATSON CJ, 1960, NEW ENGL J MED, V263, P1205, DOI 10.1056/NEJM196012152632401; 1989, SAS STAT GUIDE PERSO, P261	25	34	34	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1408	1411		10.1056/NEJM199105163242005	http://dx.doi.org/10.1056/NEJM199105163242005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020296				2022-12-28	WOS:A1991FL12500005
J	FRICKHOFEN, N; KALTWASSER, JP; SCHREZENMEIER, H; RAGHAVACHAR, A; VOGT, HG; HERRMANN, F; FREUND, M; MEUSERS, P; SALAMA, A; HEIMPEL, H				FRICKHOFEN, N; KALTWASSER, JP; SCHREZENMEIER, H; RAGHAVACHAR, A; VOGT, HG; HERRMANN, F; FREUND, M; MEUSERS, P; SALAMA, A; HEIMPEL, H			TREATMENT OF APLASTIC-ANEMIA WITH ANTILYMPHOCYTE GLOBULIN AND METHYLPREDNISOLONE WITH OR WITHOUT CYCLOSPORINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; RED-CELL APLASIA; ANTITHYMOCYTE GLOBULIN; THERAPY; IMMUNOSUPPRESSION; ANDROGENS; DISEASE; ADULTS; TRIAL	Background and Methods. Immunosuppression is the most effective treatment for patients with aplastic anemia, except for bone marrow transplantation. The best results are achieved with antilymphocyte globulin or cyclosporine. Patients have been treated successfully with a combination of both agents, but there has been no controlled evaluation of its efficacy. We conducted a randomized, multicenter trial in 84 patients not eligible for bone marrow transplantation, comparing treatment with antilymphocyte globulin and methylprednisolone (41 patients - the control group) with antilymphocyte globulin, methylprednisolone, and cyclosporine (43 patients - the cyclosporine group). Results. At three months significantly more patients in the cyclosporine group had a complete or partial remission in response to treatment than did patients in the control group (65 percent vs. 39 percent, P < 0.03); this difference was confirmed at six months (70 percent vs. 46 percent, P < 0.05). The superior results of the regimen including cyclosporine were most evident in the patients with severe or very severe aplastic anemia, whose response rate at six months was 65 percent, as compared with 31 percent of such patients in the control group (P < 0.02). Granulocyte and hemoglobin levels became normal in most patients who responded, but platelet counts continued to be subnormal in 61 percent of the patients. Ten of 52 patients with responses (3 in the cyclosporine group and 7 in the control group) relapsed 4 to 37 months after treatment. The actuarial survival of all patients at 41 months is 64 percent in the cyclosporine group and 58 percent in the control group (P = 0.16); among the patients with severe or very severe disease, survival is 80 percent and 44 percent, respectively (P = 0.077). Cyclosporine had substantial but reversible side effects. Conclusions. Immunosuppressive treatment of aplastic anemia with antilymphocyte globulin, methylprednisolone, and cyclosporine appears to be more effective than a regimen of antilymphocyte globulin and methylprednisolone without cyclosporine and may thus represent a treatment of choice for patients who are not eligible for bone marrow transplantation.			FRICKHOFEN, N (corresponding author), UNIV ULM,DEPT MED 3,POB 3880,W-7900 ULM,GERMANY.							APPELBAUM FR, 1987, EXP HEMATOL, V15, P1134; BACIGALUPO A, 1981, BRIT J HAEMATOL, V47, P423, DOI 10.1111/j.1365-2141.1981.tb02810.x; BACIGALUPO A, 1988, BRIT J HAEMATOL, V70, P177, DOI 10.1111/j.1365-2141.1988.tb02460.x; CAMITTA B, 1983, BLOOD, V62, P883; CAMITTA BM, 1979, BLOOD, V53, P504; CHAMPLIN R, 1983, NEW ENGL J MED, V308, P113, DOI 10.1056/NEJM198301203080301; DEPLANQUE MM, 1988, BRIT J HAEMATOL, V70, P55; DEPLANQUE MM, 1989, BRIT J HAEMATOL, V73, P121; DONEY K, 1987, EXP HEMATOL, V15, P239; ESPEROU H, 1989, NOUV REV FR HEMATOL, V31, P65; FRICKHOFEN N, 1986, KLIN WOCHENSCHR, V64, P1165, DOI 10.1007/BF01728454; GLUCKMAN E, 1987, TRANSPLANT P, V19, P2597; HINTERBERGERFISCHER M, 1986, ACTA HAEMATOL-BASEL, V76, P196, DOI 10.1159/000206055; HINTERBERGERFISCHER M, 1989, EUR J HAEMATOL, V43, P136; HOWS JM, 1991, BRIT J HAEMATOL, V77, P1, DOI 10.1111/j.1365-2141.1991.tb07940.x; HOWS JM, 1989, BONE MARROW TRANSPL, V4, P126; HUNTER RF, 1985, P NATL ACAD SCI USA, V82, P4823, DOI 10.1073/pnas.82.14.4823; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAWANO Y, 1988, BRIT J HAEMATOL, V68, P115, DOI 10.1111/j.1365-2141.1988.tb04188.x; KLINGEMANN HG, 1986, BLOOD, V67, P770; LEONARD EM, 1989, BRIT J HAEMATOL, V72, P278, DOI 10.1111/j.1365-2141.1989.tb07695.x; LOCASCIULLI A, 1990, BONE MARROW TRANSPL, V6, P211; MARSH JCW, 1987, BLOOD, V70, P1046; MATHE G, 1970, BMJ-BRIT MED J, V2, P131, DOI 10.1136/bmj.2.5702.131; MCGLAVE PB, 1987, BLOOD, V70, P1325; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; PENN I, 1987, TRANSPLANTATION, V43, P32, DOI 10.1097/00007890-198701000-00008; PORWIT A, 1987, BLUT, V54, P73, DOI 10.1007/BF00321033; RAEFSKY EL, 1986, BLOOD, V68, P712; ROGERSON ME, 1986, TRANSPLANTATION, V41, P276; SALAMA A, 1988, BRIT J HAEMATOL, V68, P41, DOI 10.1111/j.1365-2141.1988.tb04177.x; SPECK B, 1986, EXP HEMATOL, V14, P126; SPECK B, 1989, APLASTIC ANEMIA OTHE, P96; STORB R, 1986, BLOOD, V68, P119; STRYCKMANS PA, 1984, NEW ENGL J MED, V310, P655; TANIGUCHI Y, 1990, EUR J HAEMATOL, V44, P244; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; TOTTERMAN TH, 1989, EUR J HAEMATOL, V42, P126; WISLOFF F, 1985, NEW ENGL J MED, V312, P1193; YOUNG N, 1988, BLOOD, V72, P1861; ZOUMBOS NC, 1985, NEW ENGL J MED, V312, P257, DOI 10.1056/NEJM198501313120501; [No title captured]	42	387	400	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1297	1304		10.1056/NEJM199105093241901	http://dx.doi.org/10.1056/NEJM199105093241901			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017225	Bronze			2022-12-28	WOS:A1991FK18600001
J	SALIH, MAM; HARVEY, I; FRANKEL, S; COUPE, DJ; WEBB, M; CRIPPS, HA				SALIH, MAM; HARVEY, I; FRANKEL, S; COUPE, DJ; WEBB, M; CRIPPS, HA			POTENTIAL AVAILABILITY OF CADAVER ORGANS FOR TRANSPLANTATION	BRITISH MEDICAL JOURNAL			English	Article							BRAIN-STEM DEATH; DONATION	Objective - To determine the potential number of cadaver kidney donors by applying defined donor criteria to people dying in hospital. Design - Prospective study of all deaths occurring in 21 hospitals from 1 September 1988 to 31 August 1989. Questionnaires were administered to medical and nursing staff and families of potential donors aged 1-69. Setting - Acute care hospitals in Gwent, South Glamorgan, Mid Glamorgan, West Glamorgan, Pembrokeshire, and East Dyfed health authorities, serving a population of 2.2 million. Main outcome measures - Cause of death, age, ventilation at time of death, diagnosis of brain death, and consideration of consent. Results - Adequate data were available for 9840 of 10 095 hospital deaths (97.5% coverage). 188 patients aged 0-69 were identified as potential organ donors (widest definition), and of these 108 died without being ventilated at the time of death. Test of brain stem death were formally completed in 57 cases, and organ donation was considered by the families of 47 of these potential donors. 26 patients became organ donors. Patients aged 50-69 with stroke were less likely to be ventilated than those aged less-than-or-equal-to 49 (21/96 v 24/34). Families of potential donors aged 20-39 were least likely to give permission. Conclusions - The supply of donor organs (specifically kidneys) could be increased by altering the management of patients aged 50-69 dying of severe cerebrovascular disease in general medical wards, in particular by increasing the proportion ventilated. The ethics of elective ventilation for the purposes of organ donation require discussion.	TEMPLE PEACE & HLTH,DEPT PUBL HLTH MED,CARDIFF CF1 3NW,WALES; DEPT EPIDEMIOL & PUBL HLTH MED,HLTH CARE EVALUAT UNIT,BRISTOL BS8 2PR,ENGLAND; CARDIFF ROYAL INFIRM,CONTINUOUS AMBULATORY PERITONEAL DIALYSIS UNIT,CARDIFF CF2 1SZ,S GLAM,WALES; MID GLAMORGAN HLTH AUTHOR,DEPT PUBL HLTH MED,PONTYPRIDD CF37 1LA,M GLAM,WALES	Cardiff Royal Infirmary								BODENHAM A, 1989, BRIT MED J, V299, P1009, DOI 10.1136/bmj.299.6706.1009; COLLINS C, 1989, BRIT MED J, V299, P1463, DOI 10.1136/bmj.299.6713.1463-b; DENNIS MJS, 1989, BRIT MED J, V299, P1218; FEEST TG, 1990, LANCET, V335, P1133, DOI 10.1016/0140-6736(90)91134-V; GORE SM, 1989, BRIT MED J, V299, P1193, DOI 10.1136/bmj.299.6709.1193; NIVET H, 1989, INTENS CARE MED, V15, pS64, DOI 10.1007/BF00260891; 1987, REPORT WORKING PARTY; 1990, LANCET, V335, P80; 1989, INTENSIVE CARE NURSI, V5, P76; 1989, 1989 UKTS UNINTED KI	10	38	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1053	1055		10.1136/bmj.302.6784.1053	http://dx.doi.org/10.1136/bmj.302.6784.1053			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	2036502	Green Published, Bronze			2022-12-28	WOS:A1991FK56300022
J	FERGUSON, BM; BREWER, BJ; REYNOLDS, AE; FANGMAN, WL				FERGUSON, BM; BREWER, BJ; REYNOLDS, AE; FANGMAN, WL			A YEAST ORIGIN OF REPLICATION IS ACTIVATED LATE IN S-PHASE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOME-REPLICATION; DNA; SEQUENCES; GENES; ORGANIZATION; PLASMIDS; TIME	The mechanism that causes large regions of eukaryotic chromosomes to remain unreplicated until late in S phase is not understood. We have found that 67 kb of telomere-adjacent DNA at the right end of chromosome V in S. cerevisiae is replicated late in S phase. An ARS element in this region, ARS501, was shown by two-dimensional gel analysis to be an active origin of replication. Kinetic analyses indicate that the rate of replication fork movement within this late region is similar to that in early replicating regions. Therefore, the delayed replication of the region is a consequence of late origin activation. The results also support the idea that the pattern of interspersed early and late replication along the chromosomes of higher eukaryotes is a consequence of the temporal regulation of origin activation.	UNIV WASHINGTON,DEPT GENET SK-50,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Reynolds, Ann/B-7324-2013	Reynolds, Ann/0000-0002-2881-6955	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018926, R37GM018926] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18926] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BREWER BJ, 1988, CANCER CELL, V6, P229; CALDERON IL, 1983, CURR GENET, V7, P93, DOI 10.1007/BF00365632; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703; EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLEER R, 1987, MOL CELL BIOL, V7, P1180, DOI 10.1128/MCB.7.3.1180; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HAUSWIRTH WW, 1987, MITOCHONDRIA, P171; HINNEBUSCH AG, 1983, J BIOL CHEM, V258, P5238; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HOLLINGSWORTH NM, 1988, THESIS U WASHINGTON; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACKSON DA, 1984, EMBO J, V3, P1837; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; MAINE GT, 1984, MOL CELL BIOL, V4, P86, DOI 10.1128/MCB.4.1.86; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MANIATIS T, 1908, MOL CLONING; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; RIVIN CJ, 1980, J CELL BIOL, V85, P108, DOI 10.1083/jcb.85.1.108; SITNEY K, 1987, THESIS U CALIFORNIA; STINCHCOMB DT, 1982, J MOL BIOL, V158, P157, DOI 10.1016/0022-2836(82)90427-2; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; THRASHBINGHAM C, 1989, MOL CELL BIOL, V9, P809, DOI 10.1128/MCB.9.2.809; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; ZAKIAN VA, 1988, MOL CELL BIOL, V8, P2257, DOI 10.1128/MCB.8.5.2257	38	184	188	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					507	515		10.1016/0092-8674(91)90468-E	http://dx.doi.org/10.1016/0092-8674(91)90468-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018976				2022-12-28	WOS:A1991FK18200017
J	FENELON, G; MAHIEUX, F; ROULLET, E; GUILLARD, A				FENELON, G; MAHIEUX, F; ROULLET, E; GUILLARD, A			MUNCHAUSENS-SYNDROME AND ABNORMALITIES ON MAGNETIC-RESONANCE-IMAGING OF THE BRAIN	BMJ-BRITISH MEDICAL JOURNAL			English	Article									HOP ST ANTOINE, SERV NEUROL, F-75571 PARIS 12, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	FENELON, G (corresponding author), HOP TENON, SERV MALAD SYST NERVEUX, F-75970 PARIS 20, FRANCE.		Fenelon, Gilles/R-3361-2018					ASHER R, 1951, LANCET, V260, P339; BARKER JC, 1962, J MENT SCI, V108, P167, DOI 10.1192/bjp.108.453.167; BRECKER SJD, 1990, LANCET, V335, P231, DOI 10.1016/0140-6736(90)90330-8; HOLLAND BA, 1987, MAGNETIC RESONANCE I, P259; LIDZ T, 1949, ARCH NEURO PSYCHIATR, V62, P304, DOI 10.1001/archneurpsyc.1949.02310150051006	5	18	19	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 27	1991	302	6783					996	997		10.1136/bmj.302.6783.996	http://dx.doi.org/10.1136/bmj.302.6783.996			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039898	Bronze, Green Published			2022-12-28	WOS:A1991FJ50800019
J	REDDY, P; HAHN, S				REDDY, P; HAHN, S			DOMINANT NEGATIVE MUTATIONS IN YEAST TFIID DEFINE A BIPARTITE DNA-BINDING REGION	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTION INITIATION-FACTOR; UPSTREAM ACTIVATION SITE; TATA-BOX; SACCHAROMYCES-CEREVISIAE; CYC1 GENE; HAP1 ACTIVATOR; S-CEREVISIAE; PROTEIN; SEQUENCES	Genetic analysis showed that the conserved C-terminal 180 amino acids of yeast TFIID contain all the essential functions for growth of yeast and response to acidic transcriptional activation signals. A genetic screen was used to identify functionally important residues within this C-terminal region. Five dominant TFIID mutations were isolated that had lost the ability to bind DNA. Four of these mutations were single amino acid substitutions in the most N-terminal of two 66-67 amino acid repeats in TFIID. Analogous mutations made in the most C-terminal repeat all failed to bind DNA and inhibited growth of cells, suggesting that the DNA-binding function of TFIID is partitioned between the two repeated regions. Overproduction of wild-type TFIID rescued the dominance of the TFIID mutants, suggesting that the mutant proteins are dominant because they compete with wild-type TFIID for binding to one or more essential transcription factors.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	REDDY, P (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.			Hahn, Steven/0000-0001-7240-2533				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HOEIJMAKERS JHJ, 1990, NATURE, V343, P417, DOI 10.1038/343417b0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAIO X, 1990, GENE, V88, P107; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; NAWGA F, 1985, P NATL ACAD SCI USA, V82, P8557; OGDEN JE, 1986, MOL CELL BIOL, V6, P4335, DOI 10.1128/MCB.6.12.4335; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIKORSKI RS, 1989, GENETICS, V122, P19; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	45	120	121	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					349	357		10.1016/0092-8674(91)90168-X	http://dx.doi.org/10.1016/0092-8674(91)90168-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015629				2022-12-28	WOS:A1991FH09200017
J	ORMEROD, W				ORMEROD, W			SCIENCE AND SECRECY	NATURE			English	Editorial Material											ORMEROD, W (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							MOLLOY JO, 1971, J PROTOZOOL, V18, P157, DOI 10.1111/j.1550-7408.1971.tb03298.x	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					551	552		10.1038/350551a0	http://dx.doi.org/10.1038/350551a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017252				2022-12-28	WOS:A1991FH11200024
J	GARCIA, JV; MILLER, AD				GARCIA, JV; MILLER, AD			SERINE PHOSPHORYLATION-INDEPENDENT DOWN-REGULATION OF CELL-SURFACE CD4 BY NEF	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HTLV-III; T-CELLS; PROTEIN; PATHOGENESIS; MODULATION; TYPE-1	A DECLINE in the T-cell population usually marks the onset of progressive immunological disease in individuals infected with the human immunodeficiency virus (HIV). Because CD4+ cells help to coordinate efficient immune responses, some of the defects in the immune function in advanced cases of AIDS may be explained by the disappearance of these cells. Therefore, an understanding of the mechanisms used by HIV to induce the reduction of CD4+ cells is important. Here we use a Moloney murine leukaemia virus-based retroviral vector in order to express the nef gene of HIV-1 in three lymphocytic cell lines expressing CD4. In all cases we find that cell-surface CD4 expression is inversely related to nef expression. However, nef does not alter steady-state levels of CD4 RNA or CD4 protein. Also, nef can downregulate a CD4 triple mutant (Ser --> Ala) that is neither phosphorylated nor down-regulated by phorbol esters, indicating that nef is acting by a different mechanism.			GARCIA, JV (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM MOLEC MED,SEATTLE,WA 98104, USA.			Miller, Dusty/0000-0002-3736-3660				ACRES RB, 1986, J BIOL CHEM, V261, P6210; AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; GALLO RC, 1990, J ACQ IMMUN DEF SYND, V3, P380; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HASELTINE WA, 1990, RETROVIRUS BIOL HUMA; HOXIE JA, 1986, J IMMUNOL, V137, P1194; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PAVLAKIS G N, 1990, New Biologist, V2, P20; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; TEMIN HM, 1980, COLD SPRING HARB SYM, V44, P773, DOI 10.1101/SQB.1980.044.01.083; WELLER SK, 1980, J VIROL, V33, P494, DOI 10.1128/JVI.33.1.494-506.1980	18	704	717	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					508	511		10.1038/350508a0	http://dx.doi.org/10.1038/350508a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	2014052				2022-12-28	WOS:A1991FG14300054
J	ROMANOWSKI, B; SUTHERLAND, R; FICK, GH; MOONEY, D; LOVE, EJ				ROMANOWSKI, B; SUTHERLAND, R; FICK, GH; MOONEY, D; LOVE, EJ			SEROLOGIC RESPONSE TO TREATMENT OF INFECTIOUS SYPHILIS	ANNALS OF INTERNAL MEDICINE			English	Article							SECONDARY SYPHILIS; TESTS	Objective: To evaluate the serologic response to treatment of patients with infectious syphilis. Design: Historical cohort study of all cases of infectious syphilis in Alberta from 1981 to 1987. Patients: A total of 1090 patients were entered; 857 with primary syphilis, 183 with secondary syphilis, and 50 with early latent disease. Two hundred and eight patients were excluded who either were pregnant, had negative serologic results before treatment, had clinical relapse, were treatment failures, or were lost to follow-up. Interventions: All 882 evaluable patients were treated with a recommended antibiotic regimen for infectious syphilis and returned for re-assessment including repeat serologic testing. Measurements and Main Results: Seventy-two percent (95% CI, 66% to 77%) and 56% (CI, 43% to 70%) of patients with initial episodes of primary or secondary syphilis had seroreverted according to rapid plasma reagin (RPR) test results by 36 months. A 2- and 3-tube decline was seen by 6 and 12 months in primary and secondary syphilis. Early latent syphilis resulted in only a 2-tube decrease at 12 months. Serologic response was not affected by sex, age, race, or sexual orientation. Patients with their first infection were more likely to experience RPR seroreversal than those with repeat infections. The RPR reversal rates also depended on the pretreatment titer and stage of disease. At 36 months, 24% (CI, 20% to 28%) of patients had nonreactive fluorescent treponemal antibody absorption tests (FTA-Abs), and 13% (CI, 11% to 15%) had nonreactive microhemoglutination tests for Treponema pallidum (MHA-TP). Conclusions: Adequate therapeutic response for syphilis must be based on illness episode and the pretreatment RPR titer. Treponemal tests can demonstrate seroreversion after 36 months, and a negative treponemal test does not rule out a past history of syphilis.	UNIV CALGARY, FAC MED DEPT COMMUNITY HLTH SERV, CALGARY T2N 4N1, ALBERTA, CANADA	University of Calgary	ROMANOWSKI, B (corresponding author), ALBERTA HLTH, STD CONTROL, 4TH FLOOR, EXECUT BLDG, 10105 109TH ST, EDMONTON T5J 1M8, ALBERTA, CANADA.							ARMITAGE P, 1987, STATISTICAL METHODS, P424; BROWN ST, 1985, JAMA-J AM MED ASSOC, V253, P1296, DOI 10.1001/jama.253.9.1296; FIUMARA NJ, 1977, SEX TRANSM DIS, V4, P92, DOI 10.1097/00007435-197707000-00004; FIUMARA NJ, 1977, SEX TRANSM DIS, V4, P96, DOI 10.1097/00007435-197707000-00005; FIUMARA NJ, 1986, J AM ACAD DERMATOL, V15, P1059, DOI 10.1016/S0190-9622(86)80319-X; FIUMARA NJ, 1980, JAMA-J AM MED ASSOC, V243, P2500, DOI 10.1001/jama.243.24.2500; FIUMARA NJ, 1980, SEX TRANSM DIS, V7, P111, DOI 10.1097/00007435-198007000-00003; HAAS JS, 1990, J INFECT DIS, V162, P862, DOI 10.1093/infdis/162.4.862; PERRYMAN MW, 1982, J CLIN MICROBIOL, V16, P286, DOI 10.1128/JCM.16.2.286-290.1982; PETERSEN CS, 1984, DAN MED BULL, V31, P70; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; WILLCOX RR, 1981, B WORLD HEALTH ORGAN, V59, P655; 1982, TECHNICAL REPORT SER, V674; 1951, J VENER DIS, V32, P355	14	177	186	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1005	1009		10.7326/0003-4819-114-12-1005	http://dx.doi.org/10.7326/0003-4819-114-12-1005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029095				2022-12-28	WOS:A1991FQ55500002
J	LANGLOIS, JA; WALLEN, BAR; TERET, SP; BAILEY, LA; HERSHEY, JH; PEELER, MO				LANGLOIS, JA; WALLEN, BAR; TERET, SP; BAILEY, LA; HERSHEY, JH; PEELER, MO			THE IMPACT OF SPECIFIC TOY WARNING LABELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							FOREIGN-BODY; CHOKING; AIRWAY	According to the 1980 Consumer Product Safety Commission's small parts standard, toys with small parts that pose a choking hazard cannot be marketed for children under the age of 3 years. To comply with the standard, toy manufacturers place age labels on packaging to indicate the ages for which toys with small parts are recommended. We conducted a survey of 199 toy buyers to determine the degree to which they understood such labels as warnings and whether more explicit warning labels would affect toy buyers' willingness to purchase toys with small parts for children between 2 and 3 years of age. Forty-four percent of respondents said they would buy for a child between 2 and 3 years of age a toy with the label "Recommended for 3 and up"; only 5% said they would buy for a young child a toy with the label "Not recommended for below 3 - small parts." These findings indicate that a change in the small parts standard to require more specific labeling might substantially reduce potentially hazardous toy purchases.	JOHNS HOPKINS UNIV,CTR INJURY PREVENT,DEPT HLTH POLICY & MANAGEMENT,HAMPTON HOUSE,BALTIMORE,MD 21205; COMMONWEALTH VIRGINIA DEPT CORRECT,DILLWYN,VA; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University								BAKER M D, 1989, Pediatric Emergency Care, V5, P34, DOI 10.1097/00006565-198903000-00011; BAKER SP, 1980, JAMA-J AM MED ASSOC, V244, P1343; BLAZER S, 1980, AM J DIS CHILD, V134, P68, DOI 10.1001/archpedi.1980.02130130050015; KARNES EW, 1986, TRENDS ERGONOMICS, V3; KIM IG, 1973, LARYNGOSCOPE, V83, P347, DOI 10.1288/00005537-197303000-00004; KRAMER J, 1989, DATA UPDATE TOY RELA; MITTLEMAN RE, 1984, AM J FOREN MED PATH, V5, P201, DOI 10.1097/00000433-198409000-00003; TINSWORTH DK, 1985, AE LABELING CHILDREN	8	10	11	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2848	2850		10.1001/jama.265.21.2848	http://dx.doi.org/10.1001/jama.265.21.2848			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033742				2022-12-28	WOS:A1991FN85500035
J	ASHWORTH, A; RASTAN, S; LOVELLBADGE, R; KAY, G				ASHWORTH, A; RASTAN, S; LOVELLBADGE, R; KAY, G			X-CHROMOSOME INACTIVATION MAY EXPLAIN THE DIFFERENCE IN VIABILITY OF XO HUMANS AND MICE	NATURE			English	Article							SEX-DETERMINING REGION; CONTROLLING ELEMENTS; Y-CHROMOSOME; MOUSE; GENE; MUTATION; ZFX; EXPRESSION; PROTEIN; FINGER	ONLY about 1% of human XO conceptuses survive to birth and these usually have the characteristics of Turner's syndrome, with a complex and variable phenotype including short stature, gonadal dysgenesis and anatomical defects 1. Both the embryonic lethality and Turner's syndrome are thought to be due to monosomy for a gene or genes common to the X and Y chromosomes 2. These genes would be expected to be expressed in females from both active and inactive X chromosomes to ensure correct dosage of gene product. Two genes with these properties are ZFX and RPS4X, both of which have been proposed to play a role in Turner's syndrome 3, 4. In contrast to humans, mice that are XO are viable with no prenatal lethality (P. Burgoyne, personal communication) and are anatomically normal and fertile. We have devised a system to analyse whether specific genes on the mouse X chromosome are inactivated, and demonstrate that both Zfx and Rps4X undergo normal X-inactivation in mice. Thus the relative viability of XO mice compared to XO humans may be explained by differences between the two species in the way that dosage compensation of specific genes is achieved.	MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; NATL INST MED RES,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND	Medical Research Council Clinical Trials Unit; MRC National Institute for Medical Research	ASHWORTH, A (corresponding author), INST CANC RES,CHESTER BEATTY LABS,FULHAM RD,LONDON SW3 6JB,ENGLAND.		Kay, Graham F/A-4130-2011	Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; BONHOMME F, 1989, GENETIC VARIANTS STR, P649; BROWN CJ, 1989, AM J HUM GENET, V45, P592; BURGOYNE PS, 1989, NATURE, V342, P860, DOI 10.1038/342860a0; CATTANACH BM, 1981, HEREDITAS, V94, P5; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMARS R, 1976, P NATL ACAD SCI USA, V73, P1693, DOI 10.1073/pnas.73.5.1693; DEVI KRG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P258; FERGUSON-SMITH M A, 1965, J Med Genet, V2, P142, DOI 10.1136/jmg.2.2.142; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1990, DEVELOPMENT, V109, P647; JOHNSTON PG, 1981, GENET RES, V37, P151, DOI 10.1017/S0016672300020127; KOOPMAN P, 1991, TRENDS GENET, V7, P132, DOI 10.1016/0168-9525(91)90458-3; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; LYON MF, 1964, CYTOGENETICS, V3, P306, DOI 10.1159/000129820; MARDON G, 1990, MOL CELL BIOL, V10, P681, DOI 10.1128/MCB.10.2.681; MCMAHON A, 1982, GENET RES, V41, P69; MITCHELL M, 1989, GENETICS, V121, P803; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PALMER MS, 1989, NATURE, V342, P830; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; TETTENBORN U, 1971, NATURE-NEW BIOL, V234, P37, DOI 10.1038/newbio234037a0; Turner HH, 1938, ENDOCRINOLOGY, V23, P566, DOI 10.1210/endo-23-5-566; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027	29	116	117	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					406	408		10.1038/351406a0	http://dx.doi.org/10.1038/351406a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034290				2022-12-28	WOS:A1991FN85600058
J	BAIN, J				BAIN, J			GENERAL PRACTICES AND THE NEW CONTRACT .2. FUTURE-DIRECTIONS	BRITISH MEDICAL JOURNAL			English	Article											BAIN, J (corresponding author), ALDERMOOR HLTH CTR,PRIMARY MED CARE,SOUTHAMPTON SO1 6ST,ENGLAND.							BAIN J, 1991, BRIT MED J, V302, P1183, DOI 10.1136/bmj.302.6786.1183; BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; ROBERTS J, 1991, BRIT MED J, V302, P97, DOI 10.1136/bmj.302.6768.97	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1247	1249		10.1136/bmj.302.6787.1247	http://dx.doi.org/10.1136/bmj.302.6787.1247			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043850	Green Published, Bronze			2022-12-28	WOS:A1991FP27200026
J	OBERLE, I; ROUSSEAU, F; HEITZ, D; KRETZ, C; DEVYS, D; HANAUER, A; BOUE, J; BERTHEAS, MF; MANDEL, JL				OBERLE, I; ROUSSEAU, F; HEITZ, D; KRETZ, C; DEVYS, D; HANAUER, A; BOUE, J; BERTHEAS, MF; MANDEL, JL			INSTABILITY OF A 550 BASE PAIR DNA SEGMENT AND ABNORMAL METHYLATION IN FRAGILE X-SYNDROME	SCIENCE			English	Article								The fragile X syndrome, a common cause of inherited mental retardation, is characterized by an unusual mode of inheritance. Phenotypic expression has been linked to abnormal cytosine methylation of a single CpG island, at or very near the fragile site. Probes adjacent to this island detected very localized DNA rearrangements that constituted the fragile X mutations, and whose target was a 550-base pair GC-rich fragment. Normal transmitting males had a 150- to 400-base pair insertion that was inherited by their daughters either unchanged, or with small differences in size. Fragile X-positive individuals in the next generation had much larger fragments that differed among siblings and showed a generally heterogeneous pattern indicating somatic mutation. The mutated allele appeared unmethylated in normal transmitting males, methylated only on the inactive X chromosome in their daughters, and totally methylated in most fragile X males. However, some males had a mosaic pattern. Expression of the fragile X syndrome thus appears to result from a two-step mutation as well as a highly localized methylation. Carriers of the fragile X mutation can easily be detected regardless of sex or phenotypic expression, and rare apparent false negatives may result from genetic heterogeneity or misdiagnosis.	FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM,U184, F-67085 STRASBOURG, FRANCE; INSERM, U73, F-75016 PARIS, FRANCE; HOP NORD ST PRIEST JAREZ, F-42277 St Priest En Jarez, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm)				Devys, Didier/0000-0001-9655-3512				BAKER E, 1985, AM J MED GENET, V22, P433; BEHE M, 1981, P NATL ACAD SCI-BIOL, V78, P1619, DOI 10.1073/pnas.78.3.1619; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; CAMERINO G, 1983, NATURE, V306, P701, DOI 10.1038/306701a0; DRISCOLL DJ, 1990, SOMAT CELL MOLEC GEN, V16, P267, DOI 10.1007/BF01233363; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; JACKY PB, 1991, AM J MED GENET, V38, P400, DOI 10.1002/ajmg.1320380249; JENKINS EC, 1991, AM J MED GENET, V38, P447, DOI 10.1002/ajmg.1320380262; KENNERKNECHT I, 1991, AM J MED GENET, V38, P467, DOI 10.1002/ajmg.1320380266; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1991, AM J MED GENET, V38, P391, DOI 10.1002/ajmg.1320380247; LAIRD CD, 1987, GENETICS, V117, P587; MIGEON BR, 1986, P NATL ACAD SCI USA, V83, P2182, DOI 10.1073/pnas.83.7.2182; NUSSBAUM RL, 1986, AM J MED GENET, V23, P457, DOI 10.1002/ajmg.1320230137; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; OBERLE I, 1986, HUM GENET, V72, P43, DOI 10.1007/BF00278816; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; RHOADS FA, 1982, AM J MED GENET, V12, P205, DOI 10.1002/ajmg.1320120211; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; ROUSSEAU F, UNPUB; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; SUTHERS GK, 1991, AM J HUM GENET, V48, P460; SVED JA, 1990, AM J HUM GENET, V46, P443; TOMMERUP N, 1989, HUM GENET, V81, P377, DOI 10.1007/BF00283696; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; VOELCKEL MA, 1989, HUM GENET, V81, P353, DOI 10.1007/BF00283690; VOGEL F, 1990, HUM GENET, V86, P25; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WEBB T, 1989, FRAGILE X SYNDROME, P40; WENGER SL, 1987, AM J MED GENET, V26, P909, DOI 10.1002/ajmg.1320260419; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]	37	1317	1345	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1097	1102		10.1126/science.252.5009.1097	http://dx.doi.org/10.1126/science.252.5009.1097			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031184				2022-12-28	WOS:A1991FN05600035
J	GRIEM, P; WALLNY, HJ; FALK, K; ROTZSCHKE, O; ARNOLD, B; SCHONRICH, G; HAMMERLING, G; RAMMENSEE, HG				GRIEM, P; WALLNY, HJ; FALK, K; ROTZSCHKE, O; ARNOLD, B; SCHONRICH, G; HAMMERLING, G; RAMMENSEE, HG			UNEVEN TISSUE DISTRIBUTION OF MINOR HISTOCOMPATIBILITY PROTEINS VERSUS PEPTIDES IS CAUSED BY MHC EXPRESSION	CELL			English	Article							CLASS-I MOLECULES; TOXIC LYMPHOCYTES-T; INFLUENZA NUCLEOPROTEIN; CYTOTOXIC RESPONSE; VIRAL PEPTIDES; Y-ANTIGEN; H-Y; CELLS; COMPLEX; GRAFT	Naturally processed minor histocompatibility (H) peptides corresponding to H-4b, H-Y, and an unmapped BALB.B minor H gene were quantified in a relative way in 15 different tissues of male BALB.B mice. For one of these minor H antigens, we could also determine the relative content of the respective protein. For each minor H peptide, an individual tissue distribution was found. Tissues expressing little or no MHC (major histocompatibility complex), like brain, contained only small amounts of minor H peptides or none at all, although the same tissues contained minor H protein in substantial quantities. By contrast, K(b)-expressing brains from mice transgenic for K(b) under control of the glial acidic protein promoter contained both minor H peptide and protein in high amounts. Thus, the expression of minor H peptides in a given tissue is dependent on coexpression of the restricting MHC class I molecules.	DEUTSCH KLIN DIAGNOST,INST GENET,W-6200 WIESBADEN,GERMANY		GRIEM, P (corresponding author), MAX PLANCK INST BIOL,IMMUNGENET ABT,CORRENSSTR 42,W-7400 TUBINGEN,GERMANY.		Roetzschke, Olaf/GXH-0012-2022	Schonrich, Gunther/0000-0002-5346-5704				BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; BEVAN MJ, 1975, NATURE, V256, P419, DOI 10.1038/256419a0; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; COUNCE S, 1956, ANN SURG, V144, P198, DOI 10.1097/00000658-195608000-00009; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FLAJNIK MF, 1985, EUR J IMMUNOL, V15, P540, DOI 10.1002/eji.1830150603; FORMAN J, 1984, J EXP MED, V159, P1724, DOI 10.1084/jem.159.6.1724; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; GRAFF RJ, 1979, BIOL HDB, V3, P118; KLEIN J, 1986, NATURAL HIST MAJOR H; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOVELAND B, 1986, IMMUNOL TODAY, V7, P223, DOI 10.1016/0167-5699(86)90109-X; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; OHLEN C, 1990, J IMMUNOL, V145, P52; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; STEINMULLER D, 1981, J IMMUNOL, V126, P1754; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; TOWNSEND A, 1989, COLD SH Q B, V54, P299; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VANBLEEK GM, 1990, NATURE, V348, P213; VONBOEHMER H, 1979, J EXP MED, V150, P1134, DOI 10.1084/jem.150.5.1134; VOOGT PJ, 1990, LANCET, V335, P131, DOI 10.1016/0140-6736(90)90003-N; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; WETTSTEIN PJ, 1989, HUMAN IMMUNOGENETICS, P339; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	32	73	75	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					633	640		10.1016/0092-8674(91)90095-G	http://dx.doi.org/10.1016/0092-8674(91)90095-G			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032287				2022-12-28	WOS:A1991FM03700013
J	ROCKEFELLER, JD				ROCKEFELLER, JD			A CALL FOR ACTION - THE PEPPER-COMMISSIONS BLUEPRINT FOR HEALTH-CARE REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								After a year of deliberation and investigation, the Pepper Commission recommended action to ensure that all Americans would have health insurance protection in an efficient, effective health care system. Because it believes that action is urgent, the commission would build universal coverage by securing, improving, and extending the combination of job-based and public coverage we now have. Reform would entail the following elements: a combination of incentives and requirements that would guarantee all workers (with their nonworking dependents) insurance coverage through their jobs; replacement of Medicaid with a new federal program that would cover all those not covered through the workplace and workers whose employers find public coverage more affordable; guaranteed affordable coverage for employers-through reform of private insurance, tax credits for small employers, and the opportunity to purchase public coverage; a minimum benefit standard for private and public plans that would cover preventive and primary services as well as catastrophic care and would include cost sharing, subject to ability to pay; and a combination of public and private sector initiatives to promote quality and contain costs.			ROCKEFELLER, JD (corresponding author), US SENATE,109 HART SENATE OFF BLDG,WASHINGTON,DC 20510, USA.							BLENDON RJ, 1990, NEW ENGL J MED, V323, P200; Levit K R, 1989, Health Care Financ Rev, V10, P1; ROCKEFELLER JD, 1990, NEW ENGL J MED, V323, P5; 1990, CALL ACTION FINAL RE	4	30	30	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2507	2510		10.1001/jama.265.19.2507	http://dx.doi.org/10.1001/jama.265.19.2507			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK903	2020066				2022-12-28	WOS:A1991FK90300022
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - VAGINAL BLEEDING IN EARLY-PREGNANCY .1.	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1141	1143		10.1136/bmj.302.6785.1141	http://dx.doi.org/10.1136/bmj.302.6785.1141			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	2043788	Bronze, Green Published			2022-12-28	WOS:A1991FL43900025
J	PLUM, F				PLUM, F			VULNERABILITY OF THE BRAIN AND HEART AFTER CARDIAC-ARREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											PLUM, F (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021, USA.							BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; HIRSCH H, 1957, PFLUG ARCH GES PHYS, V265, P281, DOI 10.1007/BF00364180; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; PLUM F, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P541; PLUM F, IN PRESS DISEASES NE; PULSINELLI WA, 1985, MOL MECH ISCHEMIC BR, P29; 1991, NEW ENGL J MED, V324, P1225; 1986, NEW ENGL J MED, V314, P397	8	10	11	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1278	1280		10.1056/NEJM199105023241809	http://dx.doi.org/10.1056/NEJM199105023241809			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	2014039				2022-12-28	WOS:A1991FJ82300009
J	HUGHES, PH; CONARD, SE; BALDWIN, DC; STORR, CL; SHEEHAN, DV				HUGHES, PH; CONARD, SE; BALDWIN, DC; STORR, CL; SHEEHAN, DV			RESIDENT PHYSICIAN SUBSTANCE USE IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STUDENTS	A national survey was conducted to determine patterns of drug use among 3000 American resident physicians. Sixty percent (1785) of the residents surveyed responded. This report evaluates the prevalence of drug use among the respondents, when they initiated drug use, and their reasons for current use. Substance use rates are compared with other studies of resident physicians and with a sample of their nonphysician age peers surveyed the same year. Heavy substance use patterns were not observed among resident physicians. They had significantly lower rates of use for most psychoactive substances than their peers in the general population but did report higher rates of past-month use of alcohol and benzodiazepines. A sizable minority began using benzodiazepines and prescription opiates during their residency years - the stage in physicians' training when they first receive prescribing privileges. Current users of benzodiazepines and opiates used these drugs primarily for self-treatment rather than recreation. These two substances are often associated with impairment at later stages in the physician's career.	JAMES A HALEY VET ADM MED CTR, TAMPA, FL 33612 USA; UNIV TEXAS, HLTH SCI CTR, DEPT FAMILY & COMMUNITY MED, DALLAS, TX 75235 USA; AMER MED ASSOC, DIV MED EDUC RES, CHICAGO, IL 60610 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; University of Texas System; University of Texas Dallas; American Medical Association	HUGHES, PH (corresponding author), UNIV S FLORIDA, DEPT PSYCHIAT & BEHAV MED, CTR STUDY IMPAIRED PROFESS, 3515 E FLETCHER AVE, TAMPA, FL 33613 USA.		Sheehan, David V/L-6879-2013	Sheehan, David V/0000-0002-5118-7050	NIDA NIH HHS [1 R01 DA04877] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004877] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CLARK AW, 1988, J MED EDUC, V63, P44; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; CONARD S, 1989, AM J PSYCHIAT, V146, P382; CROWLEY AE, 1988, JAMA-J AM MED ASSOC, V260, P1049, DOI 10.1001/jama.1988.03410080019002; JOHNSTON L, 1989, ADM891638 DEP HLTH H; KORAN LM, 1988, WESTERN J MED, V148, P97; MADDUX JF, 1987, J MED EDUC, V62, P852; MCAULIFFE WE, 1984, J HEALTH SOC BEHAV, V25, P34, DOI 10.2307/2136703; REUBEN DB, 1990, JAMA-J AM MED ASSOC, V263, P958, DOI 10.1001/jama.263.7.958; SETHI BB, 1980, ACTA PSYCHIAT SCAND, V62, P447, DOI 10.1111/j.1600-0447.1980.tb00633.x; SINGH G, 1981, INDIAN J MED RES, V73, P594; TALBOTT GD, 1987, JAMA-J AM MED ASSOC, V257, P2927, DOI 10.1001/jama.257.21.2927; 1985, RES MONOGRAPH, V57	13	89	90	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2069	2073		10.1001/jama.265.16.2069	http://dx.doi.org/10.1001/jama.265.16.2069			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013925				2022-12-28	WOS:A1991FG90700022
J	MCFARLANE, MJ				MCFARLANE, MJ			THE EPIDEMIOLOGIC NECROPSY FOR ABDOMINAL AORTIC-ANEURYSM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVALENCE; SELECTION; CANCER; BIAS	The epidemiologic necropsy measures the occurrence of unsuspected disease through the examination of necropsy records. The estimates of unsuspected disease should approximate what occurs in the living population. The necropsy records of the University of Kansas Medical Center (Kansas City) from 1950 to 1984 were examined for the occurrence rate of abdominal aortic aneurysms. Each adult patient was categorized as (1) without abdominal aortic aneurysm, (2) abdominal aortic aneurysm discovered as a necropsy surprise, or (3) abdominal aortic aneurysm diagnosed or suspected during life. Necropsy detection rates of unsuspected abdominal aortic aneurysms were compared with those found in five published screening surveys. The necropsy detection rate in men was 81 (0.019) of 4155 and was 28 (0.009) of 3142 in women, a difference that was statistically significant. When the necropsy series was adjusted to reflect the same demographic composition as the screening surveys, the results from necropsy and screening were statistically similar. In particular two surveys from the United Kingdom showed screening detection rates among white men of 0.072 compared with a necropsy detection rate of 0.058. These results further support the use of the epidemiologic necropsy as a research tool for estimating the reservoir of disease in the population.	UNIV KANSAS,MED CTR,DIV GEN & GERIATR MED,KANSAS CITY,KS 66103	University of Kansas; University of Kansas Medical Center	MCFARLANE, MJ (corresponding author), CASE WESTERN RESERVE UNIV,CLEVELAND METROHEALTH MED CTR,DIV GEN INTERNAL MED,3395 SCRANTON RD,CLEVELAND,OH 44109, USA.							CHAN CK, 1988, J CLIN EPIDEMIOL, V41, P1125, DOI 10.1016/0895-4356(88)90082-0; COLLIN J, 1988, LANCET, V2, P613; COLLIN J, 1990, ANGIOLOGY, V41, P53, DOI 10.1177/000331979004100108; FEINSTEIN AR, 1987, AM J MED, V82, P113, DOI 10.1016/0002-9343(87)90386-X; KIRCHER T, 1985, ARCH PATHOL LAB MED, V109, P904; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; LINDHOLM L, 1985, ACTA MED SCAND, V218, P305; MCFARLANE MJ, 1990, J GEN INTERN MED, V5, P495, DOI 10.1007/BF02600878; MCFARLANE MJ, 1989, ARCH PATHOL LAB MED, V113, P64; MCFARLANE MJ, 1987, JAMA-J AM MED ASSOC, V258, P331, DOI 10.1001/jama.258.3.331; MCFARLANE MJ, 1987, ARCH PATHOL LAB MED, V111, P67; MCMAHAN C. A., 1960, HUMAN BIOL, V32, P185; MEINERT CL, 1986, CLIN TRIALS DESIGN C, P198; OHMAN EM, 1985, IRISH MED J, V78, P127; OKELLY TJ, 1989, BRIT J SURG, V76, P479, DOI 10.1002/bjs.1800760517; Pearl R, 1926, ARCH PATHOL LAB MED, V1, P329; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9	17	70	70	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2085	2088		10.1001/jama.265.16.2085	http://dx.doi.org/10.1001/jama.265.16.2085			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013928				2022-12-28	WOS:A1991FG90700025
J	REGNIER, FE				REGNIER, FE			PERFUSION CHROMATOGRAPHY	NATURE			English	Article							LIQUID-CHROMATOGRAPHY; PROTEINS	Perfusion chromatography is a technique based on fluid dynamics for reducing stagnant mobile phase mass transfer in liquid chromatography. This is achieved by using supports with large pores that allow mobile phase to flow through particles.			REGNIER, FE (corresponding author), PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907, USA.							AFEYAN N, 1991, IN PRESS J CHROMATOG; AFEYAN N, 1989, 595661 US PAT APPL; AFEYAN NB, 1990, J CHROMATOGR, V519, P1, DOI 10.1016/0021-9673(90)85132-F; DONE JN, 1972, J CHROMATOGR SCI, V10, P606, DOI 10.1093/chromsci/10.10.606; Giddings J.C., 1965, DYNAMICS CHROMATOGRA; HORVATH C, 1976, J CHROMATOGR, V126, P401, DOI 10.1016/S0021-9673(01)84088-7; PEARSON JD, 1984, HIGH PERFORMANCE LIQ; REGNIER FE, 1987, CHROMATOGRAPHIA, V24, P241, DOI 10.1007/BF02688486; REGNIER FE, 1991, CHROMATOGRAPHY, pCH14; SNYDER LR, 1969, J CHROMATOGR SCI, V7, P352, DOI 10.1093/chromsci/7.6.352; THEVENON G, 1989, J CHROMATOGR, V476, P499, DOI 10.1016/S0021-9673(01)93894-4; TWEETEN KA, 1986, J CHROMATOGR, V359, P111, DOI 10.1016/0021-9673(86)80066-8; YANG Y, 1990, 469956 US PAT APPL	13	137	141	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					634	635		10.1038/350634a0	http://dx.doi.org/10.1038/350634a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017260				2022-12-28	WOS:A1991FH11200068
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - CHECKING FOR FETAL WELLBEING .2.	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					900	902		10.1136/bmj.302.6781.900	http://dx.doi.org/10.1136/bmj.302.6781.900			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025732	Bronze, Green Published			2022-12-28	WOS:A1991FG42100030
J	MADEN, A; SWINTON, M; GUNN, J				MADEN, A; SWINTON, M; GUNN, J			DRUG-DEPENDENCE IN PRISONERS	BRITISH MEDICAL JOURNAL			English	Article											MADEN, A (corresponding author), INST PSYCHIAT,DEPT FORENS PSYCHIAT,LONDON SE5 8AF,ENGLAND.							CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; Home Office, 1988, PUNISHMENT CUSTODY C; MADEN A, 1990, BRIT MED J, V301, P1133, DOI 10.1136/bmj.301.6761.1133; 1988, POLICY STATEMENT THR	4	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					880	880		10.1136/bmj.302.6781.880	http://dx.doi.org/10.1136/bmj.302.6781.880			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG421	2025727	Green Published, Bronze			2022-12-28	WOS:A1991FG42100022
J	PRINGLE, M; HASLER, J; DEMARCO, P				PRINGLE, M; HASLER, J; DEMARCO, P			TRAINING FOR MINOR SURGERY IN GENERAL-PRACTICE DURING PREREGISTRATION SURGICAL POSTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study the teaching of minor surgery to preregistration house officers in surgery and their confidence in their skills. Design-Questionnaire survey of consultants and vocational trainees. Setting-Trent, Oxford, and East Anglian Regional Health Authorities. Subjects-All consultant surgeons (n = 148) with preregistration house officers on their firm and all first year vocational trainees in general practice (n = 165). Main outcome measures-Time spent teaching minor surgery to preregistration house officers; source of teaching; trainees' confidence in their skills in 15 minor surgical procedures and degree of confidence that consultants expected their junior house officers to achieve. Results-137 (93%) consultants and 139 (84%) vocational trainees replied; 131 of the consultants' replies and all the trainees' replies were analysable. Only 14 consultants had a curriculum for teaching junior house officers, and 90 offered less than four hours' teaching a week. Only 11 trainees thought that their firm had had a curriculum, and 102 reported having received under two hours' teaching a week. The consultants indicated that they did most of the teaching, but the trainees reported having received most of their teaching from junior registrars. Seventy nine consultants attempted to teach minor surgery. They expected their junior house officers to acquire greater confidence in their skills in minor surgery than did the other consultants, but overall the confidence expected was low. The trainees were more confident than the consultants expected them to be, but overall confidence was still low. Those who had received more teaching were significantly more confident. Conclusions-The educational potential of the post of preregistration house officer in surgery seems underexploited, particularly with regard to teaching skills in minor surgery.	UNIV OXFORD,SCH MED,OXFORD,ENGLAND	University of Oxford	PRINGLE, M (corresponding author), QUEENS MED CTR,SCH MED,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							BROWN JS, 1979, BRIT MED J, V1, P1609, DOI 10.1136/bmj.1.6178.1609; KEALEY K, 1990, BR J GEN PRACT, V40, P409; MILNE R, 1990, BRIT J GEN PRACT, V40, P175; SHARMAN J, 1986, PRACTITIONER, V230, P27; STYLES WM, 1989, J ROY COLL GEN PRACT, V39, P96; STYLES WM, 1990, BRIT J GEN PRACT, V40, P401; Wall D W, 1982, J R Coll Gen Pract, V32, P480; WALL DW, 1987, FAM PRACT, V4, P322, DOI 10.1093/fampra/4.4.322; WHITFIELD M, 1989, FAM PRACT, V6, P274, DOI 10.1093/fampra/6.4.274; WHITFIELD M, 1988, BRIT MED J, V297, P398, DOI 10.1136/bmj.297.6645.398; 1990, STATEMENT FEES ALLOW; 1989, GENERAL PRACTICE NAT	12	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					830	832		10.1136/bmj.302.6780.830	http://dx.doi.org/10.1136/bmj.302.6780.830			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025708	Bronze, Green Published			2022-12-28	WOS:A1991FF37700028
J	GU, H; KITAMURA, D; RAJEWSKY, K				GU, H; KITAMURA, D; RAJEWSKY, K			B-CELL DEVELOPMENT REGULATED BY GENE REARRANGEMENT - ARREST OF MATURATION BY MEMBRANE-BOUND D-MU PROTEIN AND SELECTION OF DH ELEMENT READING FRAMES	CELL			English	Article							IMMUNOGLOBULIN HEAVY-CHAINS; PRE-B; LIGHT-CHAIN; TRANSGENIC MICE; STEM-CELLS; VH-GENE; SEGMENTS; REGION; LOCUS; MOUSE	In productively rearranged murine V(H)-D(H)-J(H) genes (encoding immunoglobulin heavy chain variable regions), the D(H) elements are preferentially used in one particular reading frame (RF1), although the recombination breakpoints at the D(H)-J(H) border vary. Despite this variability, the bias of RF usage is not due to cellular selection by antigen but is quantitatively established at the stage of D(H)-J(H) rearrangement: RF3 is counterselected on the basis of stop codons. RF2 allows the expression of a truncated-mu-chain (D-mu-protein) from most D(H)-J(H) joints. Using B cells in which the membrane exon of the mu-chain is disrupted by homologous recombination on one of the two homologous chromosomes, we obtain evidence that membrane-bound D-mu-signals arrest of differentiation, presumably by preventing V(H)-D(H)J(H) joining. In addition to RF3 and RF2 counterselection, promotion of D(H)-J(H) joining in areas of sequence homology further enforces RF1 usage.			GU, H (corresponding author), UNIV COLOGNE, INST GENET, W-5000 COLOGNE 41, GERMANY.							ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BRADLEY A, 1987, TERATOCARCINOMAS EMB; CAMBIER JC, 1987, IMMUNOL REV, V95, P37, DOI 10.1111/j.1600-065X.1987.tb00499.x; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; EILAT D, 1988, J IMMUNOL, V141, P1745; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; KAARTINEN M, 1985, IMMUNOL TODAY, V6, P324, DOI 10.1016/0167-5699(85)90127-6; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; KUROSAWA Y, 1981, NATURE, V290, P565, DOI 10.1038/290565a0; LANGMAN RE, 1987, MOL IMMUNOL, V24, P675, DOI 10.1016/0161-5890(87)90050-2; MARION TN, 1990, J IMMUNOL, V145, P2322; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER AM, 1990, SCIENCE, V250, P820; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; RATHBUN G, 1989, IMMUNOGLOBULIN GENES; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SMITH RG, 1990, MOL IMMUNOL, V27, P463, DOI 10.1016/0161-5890(90)90171-U; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSUKADA S, 1990, J IMMUNOL, V144, P4053; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	35	213	215	2	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					47	54		10.1016/0092-8674(91)90406-O	http://dx.doi.org/10.1016/0092-8674(91)90406-O			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013094				2022-12-28	WOS:A1991FF77300007
J	COWAN, BD; MORRISON, JC				COWAN, BD; MORRISON, JC			CURRENT CONCEPTS - MANAGEMENT OF ABNORMAL GENITAL BLEEDING IN GIRLS AND WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MENSTRUAL BLOOD-LOSS; ECTOPIC PREGNANCY; CHORIONIC-GONADOTROPIN; UTERINE; MENORRHAGIA; CHILDREN; ADOLESCENTS; INHIBITORS; DIAGNOSIS; ETIOLOGY		UNIV MISSISSIPPI, MED CTR,DEPT OBSTET & GYNECOL, DIV REPROD ENDOCRINOL,2500 N STATE ST, JACKSON, MS 39216 USA; UNIV MISSISSIPPI, MED CTR, DEPT OBSTET & GYNECOL, DIV MATERNAL FETAL MED, JACKSON, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center								AKSEL S, 1974, OBSTET GYNECOL, V44, P1; ANDERSON ABM, 1976, LANCET, V1, P774; Barber HRK, 1973, OBSTET GYNECOL SURV, V28, P357; BREEN J L, 1977, Clinical Obstetrics and Gynecology, V20, P607, DOI 10.1097/00003081-197709000-00010; BUTTRAM VC, 1981, FERTIL STERIL, V36, P433; CACCIATORE B, 1989, OBSTET GYNECOL, V73, P770; CAMERON IT, 1989, BAILLIERE CLIN OB GY, V3, P315, DOI 10.1016/S0950-3552(89)80024-0; CAPRARO VJ, 1970, AM J OBSTET GYNECOL, V108, P572, DOI 10.1016/0002-9378(70)90233-4; CARTWRIGHT PS, 1984, OBSTET GYNECOL, V63, P76; CHOO YC, 1985, OBSTET GYNECOL, V66, P225; CLAESSENS EA, 1981, AM J OBSTET GYNECOL, V139, P277, DOI 10.1016/0002-9378(81)90009-0; COWELL CA, 1981, PEDIATR CLIN N AM, V28, P247; CREASMAN WT, 1990, DANDORTHS OBSTETRICS, P1040; DAYA DA, 1988, GYNECOL ONCOL, V29, P290, DOI 10.1016/0090-8258(88)90228-4; DEVORE GR, 1982, OBSTET GYNECOL, V59, P285; DISAIA PJ, 1990, DANFORTHS OBSTETRICS, P995; EBERLEIN WR, 1960, J PEDIATR-US, V57, P484, DOI 10.1016/S0022-3476(60)80257-0; EMANS SJ, 1987, PEDIATRICS, V79, P778; FRASER IS, 1986, OBSTET GYNECOL, V68, P630; FREIDMAN AJ, 1988, CURR PROB OBST GYN F, V11, P207; FUNK A, 1989, ARCH GYNECOL OBSTET, V244, P163, DOI 10.1007/BF00931294; GOLDSTEIN SR, 1990, AM J OBSTET GYNECOL, V163, P119, DOI 10.1016/S0002-9378(11)90683-8; GRAINGER DA, 1989, BAILLIERE CLIN OB GY, V3, P403, DOI 10.1016/S0950-3552(89)80030-6; HALL P, 1987, BRIT J OBSTET GYNAEC, V94, P554, DOI 10.1111/j.1471-0528.1987.tb03150.x; HELLER ME, 1978, BRIT J OBSTET GYNAEC, V85, P721, DOI 10.1111/j.1471-0528.1978.tb15590.x; HILL NCW, 1989, BRIT J OBSTET GYNAEC, V96, P467, DOI 10.1111/j.1471-0528.1989.tb02424.x; KADAR N, 1981, OBSTET GYNECOL, V58, P162; LOFFER FD, 1989, OBSTET GYNECOL, V73, P16; MAHONY BS, 1985, J ULTRAS MED, V4, P221; MCLACHLAN RI, 1986, BRIT J OBSTET GYNAEC, V93, P431; MENDENHALL HW, 1984, SEMIN REPROD ENDOCR, V2, P369, DOI 10.1055/s-2007-1023853; MERCER LJ, 1988, ADOLESCENT PEDIAT G, V1, P181, DOI 10.1016/S0932-8610(88)80058-6; MILWIDSKY A, 1977, OBSTET GYNECOL, V50, P145; MURAM D, 1986, PEDIATR ANN, V15, P616, DOI 10.3928/0090-4481-19860801-09; MURAM D, 1990, OBSTET GYN CLIN N AM, V17, P389; NORRIS HJ, 1972, CANCER, V30, P713, DOI 10.1002/1097-0142(197209)30:3<713::AID-CNCR2820300319>3.0.CO;2-G; OVERSTREET EW, 1962, SURG CLIN N AM, V42, P1013; PADWICK ML, 1986, NEW ENGL J MED, V315, P930, DOI 10.1056/NEJM198610093151504; River M S, 1981, Pediatr Ann, V10, P46; ROMERO R, 1985, OBSTET GYNECOL, V66, P357; SHEPPARD BL, 1984, CLIN OBSTET GYNAECOL, V11, P227; SPEROFF L, 1989, CLIN GYNECOLOGIC END, P265; WHITEHEAD MI, 1990, OBSTET GYNECOL, V75, pS59; WILANSKY DL, 1989, AM J OBSTET GYNECOL, V160, P673, DOI 10.1016/S0002-9378(89)80056-0	44	28	30	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1710	1715						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	2034248				2022-12-28	WOS:A1991FQ15500006
J	ELLERBROCK, TV; BUSH, TJ; CHAMBERLAND, ME; OXTOBY, MJ				ELLERBROCK, TV; BUSH, TJ; CHAMBERLAND, ME; OXTOBY, MJ			EPIDEMIOLOGY OF WOMEN WITH AIDS IN THE UNITED-STATES, 1981 THROUGH 1990 - A COMPARISON WITH HETEROSEXUAL MEN WITH AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS DRUG-USERS; TO-FEMALE TRANSMISSION; HIV; MORTALITY; INFECTION; SEROPREVALENCE; PREVALENCE; NEWBORNS; IMPACT	In the United States, women account for an increasing number and percentage of adults with the acquired immunodeficiency syndrome (AIDS). Overall, 51% of women with AIDS were infected through intravenous drug use and 29% through heterosexual contact; the proportion of intravenous drug users decreased, while the proportion attributed to heterosexual contact increased, between 1986 and 1990. Most women with AIDS were black or Hispanic (72%); residents of large metropolitan areas (73%), especially cities along the Atlantic coast; and of reproductive age (15 to 44 years) (85%). However, the proportion of women with AIDS reported by smaller cities and rural areas has increased from 22% in 1986 to 28% in 1990. The male-to-female ratio of heterosexuals with AIDS has remained about 2.4:1 since 1987. A comparison of women with AIDS to heterosexual men with AIDS showed that these two groups were similar by age, race, and geographic distribution. Also, survival times from AIDS diagnosis to death for women and heterosexual men with AIDS were not significantly different.			ELLERBROCK, TV (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,1600 CLIFTON RD NE,MAILSTOP E-45,ATLANTA,GA 30333, USA.							ALLEN DM, 1990, 6TH INT C AIDS SAN F; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; BUEHLER JW, 1989, JAMA-J AM MED ASSOC, V262, P2896; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; CHU SY, 1990, AM J PUBLIC HEALTH, V80, P1380, DOI 10.2105/AJPH.80.11.1380; DEVINE O, 1989, 5TH INT C AIDS MONTR; GINZBURG HM, 1984, PUBLIC HEALTH REP, V99, P206; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; MARMOR M, 1986, ANN INTERN MED, V105, P969, DOI 10.7326/0003-4819-105-6-969_1; MONZON OT, 1987, LANCET, V2, P40; NOVICK LF, 1989, JAMA-J AM MED ASSOC, V261, P1745, DOI 10.1001/jama.261.12.1745; PADIAN N, 1990, 6TH INT C AIDS SAN F; PADIAN NS, 1987, REV INFECT DIS, V9, P947; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SELIK RM, 1990, J ACQ IMMUN DEF SYND, V3, P73; SHAPIRO CN, 1989, OBSTET GYNECOL, V74, P800; THOMAS PA, 1989, 5TH INT C AIDS MONTR; 1987, MMWR S1S, V36, pS1; 1988, LANCET, V2, P1043; 1988, LANCET, V2, P1039; 1981, MMWR, V30, P409; [No title captured]; 1990, PREVALENCE HIV 1 ANT; 1987, MMWR S6, V36, P1; 1990, MMWR, V39, P1; 1985, MMWR, V34, P373	30	143	143	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2971	2975		10.1001/jama.265.22.2971	http://dx.doi.org/10.1001/jama.265.22.2971			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP635	2033768				2022-12-28	WOS:A1991FP63500034
J	ZWERDLING, RG; BROWN, J				ZWERDLING, RG; BROWN, J			PULMONARY-EMBOLISM IN CHILDREN - RISKS AND PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ZWERDLING, RG (corresponding author), UNIV MASSACHUSETTS,MED CTR,WORCESTER,MA 01605, USA.							BERNSTEIN D, 1986, AM J DIS CHILD, V140, P667, DOI 10.1001/archpedi.1986.02140210065028; BUCK JR, 1981, J PEDIATR SURG, V16, P385, DOI 10.1016/S0022-3468(81)80700-2; BYARD RW, 1990, ARCH PATHOL LAB MED, V114, P142; GRACEY DR, 1982, MAYO CLIN PROC, V57, P742; RAMAN K, 1971, CHEST, V60, P555; 1986, JAMA-J AM MED ASSOC, V256, P744	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2888	2888						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033750				2022-12-28	WOS:A1991FN85500042
J	GOLDING, J; ROWLAND, A; GREENWOOD, R; LUNT, P				GOLDING, J; ROWLAND, A; GREENWOOD, R; LUNT, P			ALUMINUM SULFATE IN WATER IN NORTH CORNWALL AND OUTCOME OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine whether the excess aluminium sulphate accidentally added to the local water supply in north Cornwall in July 1988 had an adverse effect on the outcome of pregnancies. Design - Outcomes of all singleton pregnancies in the affected area at the time of the incident (n = 92) were compared with those in two control groups: pregnancies in this area completed before the incident (n = 68) and pregnancies in a neighbouring area (n = 193). Subjects - Mothers in the three groups, among whom there were 13 miscarriages, five terminations of pregnancy, and 336 live births. Main outcome measures - Fetal and perinatal loss, birth weight, gestation, obstetric complications, neonatal condition, and congenital defects. Results - Among 88 pregnancies in women exposed to excess aluminium sulphate there was no excess of perinatal deaths (n = 0), low birthweight (n = 3), preterm delivery (n = 4), or severe congenital malformations (n = 0). There was, however, an increased rate of talipes in exposed fetuses (four cases, one control; p = 0.01). Conclusions - Because of small numbers it is not possible to say that high doses of aluminium sulphate are safe in pregnancy, but there is no evidence from this study of major problems apparent at birth.	CORNWALL & ISLES SCILLY HLTH AUTHOR,TRURO TR1 1NR,ENGLAND		GOLDING, J (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND.		Lunt, Peter/AAF-8265-2020	Golding, Jean/0000-0003-2826-3307				Akar N, 1989, Paediatr Perinat Epidemiol, V3, P102; BERNUZZI V, 1989, TERATOLOGY, V40, P21, DOI 10.1002/tera.1420400104; GOLDING J, 1984, CHILD HLTH, V3, P31; LAPPE M, 1988, TRACE ELEMENTS HLTH; MARLOWE M, 1985, ARCH ENVIRON HEALTH, V40, P221, DOI 10.1080/00039896.1985.10545922; MATSUMOTO H, 1965, J NEUROPATH EXP NEUR, V24, P563, DOI 10.1097/00005072-196510000-00002; MORTON MS, 1976, BRIT J PREV SOC MED, V30, P36; OLIVER JMT, 1983, LANCET, V1, P181	8	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1175	1177		10.1136/bmj.302.6786.1175	http://dx.doi.org/10.1136/bmj.302.6786.1175			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043811	Green Published, Bronze			2022-12-28	WOS:A1991FN04500018
J	NYLENNA, M; RIIS, P				NYLENNA, M; RIIS, P			IDENTIFICATION OF PATIENTS IN MEDICAL PUBLICATIONS - NEED FOR INFORMED CONSENT	BRITISH MEDICAL JOURNAL			English	Article									HERLEV UNIV HOSP,DEPT GASTROENTEROL,DK-2730 HERLEV,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	NYLENNA, M (corresponding author), JOURNAL NORWEGIAN MED ASSOC,N-1324 LYSAKER,NORWAY.							MILES SH, 1988, JAMA-J AM MED ASSOC, V259, P2582; MORGAN C, 1985, LANCET, V1, P644; RIESENBERG DE, 1990, CBE VIEWS, V13, P8; SLUE WE, 1989, NEW ENGL J MED, V321, P550, DOI 10.1056/NEJM198908243210823; SQUIRES BP, 1989, CAN MED ASSOC J, V141, P379	5	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1182	1182		10.1136/bmj.302.6786.1182	http://dx.doi.org/10.1136/bmj.302.6786.1182			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043814	Bronze, Green Published			2022-12-28	WOS:A1991FN04500021
J	FRANK, D; KESHET, I; SHANI, M; LEVINE, A; RAZIN, A; CEDAR, H				FRANK, D; KESHET, I; SHANI, M; LEVINE, A; RAZIN, A; CEDAR, H			DEMETHYLATION OF CPG ISLANDS IN EMBRYONIC-CELLS	NATURE			English	Article							X-CHROMOSOME INACTIVATION; DENOVO METHYLATION; DNA METHYLATION; CHROMATIN STRUCTURE; TRANSGENIC MICE; 2 GENES; MOUSE; EXPRESSION; EMBRYOGENESIS; LINES	DNA in differentiated somatic cells has a fixed pattern of methylation, which is faithfully copied after replication. By contrast, the methylation patterns of many tissue-specific and some housekeeping genes are altered during normal development 1. This modification of DNA methylation in the embryo has also been observed in transgenic mice and in transfection experiments 2. Here we report the fate in mice of an in vitro-methylated adenine phosphoribosyltransferase transgene. The entire 5' CpG island region became demethylated, whereas the 3' end of the gene remained modified and was even methylated de novo at additional sites. Transfection experiments in vitro show that the demethylation is rapid, is specific for embryonic cell-types and affects a variety of different CpG island sequences. This suggests that gene sequences can be recognized in the early embryo and imprinted with the correct methylation pattern through a combination of demethylation and de novo methylation.	AGR RES ORG, VOLCANI CTR, INST ANIM SCI, IL-50250 BET DAGAN, ISRAEL	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	FRANK, D (corresponding author), HEBREW UNIV JERUSALEM, SCH MED, DEPT CELLULAR BIOCHEM, POB 1172, JERUSALEM, ISRAEL.		Levine, Alex/A-6867-2008					ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; CEDAR H, 1982, COLD SPRING HARB SYM, V47, P605, DOI 10.1101/SQB.1983.047.01.071; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; CORDELL B, 1979, CELL, V18, P533, DOI 10.1016/0092-8674(79)90070-9; DRISCOLL DJ, 1990, SOMAT CELL MOLEC GEN, V16, P267, DOI 10.1007/BF01233363; EINAT P, 1987, GENE DEV, V1, P1075, DOI 10.1101/gad.1.10.1075; GARTLER SM, 1975, EXP CELL RES, V91, P454, DOI 10.1016/0014-4827(75)90127-5; GAUTSCH JW, 1983, NATURE, V301, P32, DOI 10.1038/301032a0; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jahner D., 1984, DNA METHYLATION BIOC, P189; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; KOLSTO AB, 1986, NUCLEIC ACIDS RES, V14, P9667; KRATZER PG, 1981, P NATL ACAD SCI-BIOL, V78, P3093, DOI 10.1073/pnas.78.5.3093; KRATZER PG, 1983, CELL, V33, P37, DOI 10.1016/0092-8674(83)90332-X; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; LOWRY I, 1980, CELL, V22, P817; MONK M, 1987, DEVELOPMENT, V99, P371; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PONZETTOZIMMERMAN C, 1984, NUCLEIC ACIDS RES, V12, P2807, DOI 10.1093/nar/12.6.2807; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SHEMER R, 1990, J BIOL CHEM, V265, P1010; SHIMADA T, 1987, MOL CELL BIOL, V7, P2830, DOI 10.1128/MCB.7.8.2830; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; STEIN R, 1983, P NATL ACAD SCI-BIOL, V80, P2422, DOI 10.1073/pnas.80.9.2422	27	133	135	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					239	241		10.1038/351239a0	http://dx.doi.org/10.1038/351239a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041571				2022-12-28	WOS:A1991FL99000059
J	MOORE, JM; PEATTIE, DA; FITZGIBBON, MJ; THOMSON, JA				MOORE, JM; PEATTIE, DA; FITZGIBBON, MJ; THOMSON, JA			SOLUTION STRUCTURE OF THE MAJOR BINDING-PROTEIN FOR THE IMMUNOSUPPRESSANT FK506	NATURE			English	Article							CIS-TRANS ISOMERASE; PEPTIDYL-PROLYL ISOMERASE; FK506-BINDING PROTEIN; H-1-NMR SPECTRA; CYCLOSPORIN-A; CYCLOPHILIN; DISTINCT; PATHWAYS; CELL	THE major FK506 binding protein (FKBP, relative molecular mass approximately 11,800; M(r) 11.8K) and cyclophilin (M(r) approximately 17K) belong to a class of proteins termed immunophilins 1. Although unrelated at the amino-acid sequence level, they both possess peptidyl-prolyl cis-trans isomerase activities which are inhibited by immunosuppressants that block signal transduction pathways leading to T-lymphocyte activation. FK506 and rapamycin strongly inhibit the peptidyl-prolyl cis-trans isomerase activity of FKBP, whereas cyclosporin A inhibits that of cyclophilin 2-12. The significance of this enzyme activity and the role of the immunophilins in immunoregulation is unknown 1,13. To understand better the function of the immunophilins and their interaction with inhibitors, we are investigating the solution structures of FKBP and FKBP-inhibitor complexes by multidimensional NMR methods. Here we report the solution conformation of FKBP, as generated by NMR, distance geometry and molecular dynamics methods. The regular secondary structure of FKBP is composed mainly of beta-sheet (approximately 35%) with little helical structure (< 10%). The hydrophobic core of the molecule, containing the buried side chains of six of the protein's nine aromatic amino acids, is enclosed by a five-stranded antiparallel beta-sheet on one side, a loop and a short helix at residues 51-56 and 57-65, and an aperiodic loop at residues 81-95. Examination of the structure suggests a possible site of interaction with FK506.			MOORE, JM (corresponding author), VERTEX PHARMACEUT INC,40 ALLSTON ST,CAMBRIDGE,MA 02139, USA.			Moore, Jonathan/0000-0001-8633-3313				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; ECCLES C, 1989, 10TH M INT SOC MAGN; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; GUENTERT P, IN PRESS J MOL BIOL; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; WANDLESS TJ, 1991, J AM CHEM SOC, V113, P2339, DOI 10.1021/ja00006a083; Wuthrich K., 1986, NMR PROTEINS NUCL AC	27	150	154	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1991	351	6323					248	250		10.1038/351248a0	http://dx.doi.org/10.1038/351248a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041572				2022-12-28	WOS:A1991FL99000062
J	SELBY, JV; NEWMAN, B; QUIROGA, J; CHRISTIAN, JC; AUSTIN, MA; FABSITZ, RR				SELBY, JV; NEWMAN, B; QUIROGA, J; CHRISTIAN, JC; AUSTIN, MA; FABSITZ, RR			CONCORDANCE FOR DYSLIPIDEMIC HYPERTENSION IN MALE TWINS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; RISK-FACTORS; INSULIN; PREVALENCE	Sixty cases of dyslipidemic hypertension were identified in the 1028 middle-aged, white, male twin participants in the first examination of the National Heart, Lung, and Blood Institute Twin Study (1969 to 1973). The prevalence of dyslipidemic hypertension was similar by zygosity but proband concordance was three times greater in monozygotic than dizygotic twins (0.44 [seven concordant and 18 discordant pairs] vs 0.14 [two concordant and 24 discordant pairs]), suggesting a genetic effect on the condition. Low high-density lipoprotein cholesterol level was the most common lipid abnormality in concordant pairs. Mortality from ischemic heart disease was significantly higher in individuals with dyslipidemic hypertension. Obesity and glucose intolerance were closely associated with the syndrome. Moreover, within the 18 discordant monozygotic twin pairs, the twins with dyslipidemic hypertension had gained significantly more weight as adults and were significantly heavier than their unaffected cotwins. Thus, although genetic factors may influence development of dyslipidemic hypertension, nongenetic, potentially modifiable aspects of obesity are also closely related to expression of this clinically important syndrome.	VET AFFAIRS MED CTR,DEPT MED,LONG BEACH,CA; UNIV CALIF BERKELEY,SCH PUBL HLTH,DEPT EPIDEMIOL,BERKELEY,CA 94720; INDIANA UNIV,SCH MED,DEPT MED GENET,INDIANAPOLIS,IN 46202; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; NHLBI,CLIN GENET & EPIDEMIOL BRANCH,BETHESDA,MD 20892	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Berkeley; Indiana University System; Indiana University-Purdue University Indianapolis; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	SELBY, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM,DIV RES,NO CALIF REG,3451 PIEDMONT AVE,OAKLAND,CA 94611, USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055026] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC55026] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; COX NJ, 1989, DIABETES, V38, P653, DOI 10.2337/diabetes.38.5.653; CRIQUI MH, 1986, CIRCULATION, V73, P40; CRIQUI MH, 1980, PREV MED, V9, P525, DOI 10.1016/0091-7435(80)90047-X; FABSITZ RR, 1978, BEHAV GENET, V8, P15, DOI 10.1007/BF01067701; FEINLEIB M, 1970, ACTA GENET MED GEMEL, V19, P243, DOI 10.1017/S1120962300025592; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; FUH MMT, 1987, ARCH INTERN MED, V147, P1035, DOI 10.1001/archinte.147.6.1035; HUNT SC, 1989, ARTERIOSCLEROSIS, V9, P335, DOI 10.1161/01.ATV.9.3.335; JABLON S, 1967, AM J HUM GENET, V19, P133; KING MC, 1984, ANNU REV PUBL HEALTH, V5, P1; LEE ET, 1980, STATISTICAL METHODS; MACMAHON SW, 1985, ARTERIOSCLEROSIS, V5, P391, DOI 10.1161/01.ATV.5.4.391; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; NEUFELD HN, 1983, CIRCULATION, V67, P943, DOI 10.1161/01.CIR.67.5.943; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; NEWMAN B, 1990, AM J PUBLIC HEALTH, V80, P675, DOI 10.2105/AJPH.80.6.675; PERMUTT MA, 1990, DIABETES CARE, V13, P364, DOI 10.2337/diacare.13.3.364; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REED T, IN PRESS J CLIN EPID; ROHLFING JJ, 1986, WESTERN J MED, V145, P210; SHIEH SM, 1987, ATHEROSCLEROSIS, V67, P49, DOI 10.1016/0021-9150(87)90264-4; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	25	87	88	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2079	2084		10.1001/jama.265.16.2079	http://dx.doi.org/10.1001/jama.265.16.2079			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013927				2022-12-28	WOS:A1991FG90700024
J	SMITH, R				SMITH, R			MEDICAL-RESEARCH IN AUSTRALIA - THE NITTY-GRITTY - FUNDING, REVIEWING, TRAINING, AND COMMUNICATING	BRITISH MEDICAL JOURNAL			English	Article																		EWING T, 1990, TODAYS LIFE SCI  NOV, P44; 1990, REV NHMRC POSTGRADUA; 1989, PROFILE AUSTR SCI; 1990, MED RES 1989; 1991, PEER REV; 1990, FUNDING BIOMEDICAL R	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					946	948		10.1136/bmj.302.6782.946	http://dx.doi.org/10.1136/bmj.302.6782.946			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032038	Bronze, Green Published			2022-12-28	WOS:A1991FH48700023
J	GREENBLATT, DJ; HARMATZ, JS; SHAPIRO, L; ENGELHARDT, N; GOUTHRO, TA; SHADER, RI				GREENBLATT, DJ; HARMATZ, JS; SHAPIRO, L; ENGELHARDT, N; GOUTHRO, TA; SHADER, RI			SENSITIVITY TO TRIAZOLAM IN THE ELDERLY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BENZODIAZEPINE HYPNOTICS; TRIAZOLOBENZODIAZEPINES ALPRAZOLAM; REBOUND INSOMNIA; HIP FRACTURE; DRUG-THERAPY; HALF-LIFE; OLD-AGE; DIAZEPAM; FLURAZEPAM; EFFICACY	Background. Elderly persons frequently appear to be sensitive to the effects of many drugs that depress the central nervous system. We studied the effect of age on the pharmacokinetics and pharmacodynamics of the benzodiazepine hypnotic agent triazolam, now the most frequently prescribed hypnotic drug in the United States. Methods. Twenty-six healthy young subjects (mean age, 30 years) and 21 healthy elderly subjects (mean age, 69 years) participated in a four-way crossover study. After a single-blind adaptation trial with placebo, each subject received, in random order and in double-blind fashion, single doses of placebo, 0.125 mg of triazolam, and 0.25 mg of triazolam. For 24 hours after the administration of each of the three study medications, plasma triazolam levels were determined and psychomotor performance, memory, and degree of sedation were assessed. Results. Plasma triazolam concentrations increased in proportion to the dose, but the elderly subjects had higher plasma concentrations due to reduced clearance of the drug. The degree of sedation as rated by an observer and the reduction in the subjects' performance on the digit-symbol substitution test were both greater in the elderly than in the young subjects after they were given the same doses. The relation of the plasma triazolam concentration to the degree of impairment was similar for the two groups. As part of the study, information was presented 1 1/2 hours after the administration of the drugs; the subjects' ability to recall the information 24 hours later was impaired by both doses of triazolam, and the percent decrease was similar in the young and elderly groups. Conclusions. Triazolam caused a greater degree of sedation and greeater impairment of psychomotor performance in healthy elderly persons than in young persons who received the same dose. These effects resulted from reduced clearance and higher plasma concentrations of triazolam rather than from an increased intrinsic sensitivity to the drug. On the basis of these results, the dosage of triazolam for elderly persons should be reduced on average by 50 percent.	NEW ENGLAND MED CTR HOSP,BOSTON,MA; TUFTS UNIV,SCH MED,DIV CLIN PHARMACOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT PHARMACOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University; Tufts University; Tufts University				Shader, Richard/0000-0002-1888-7565	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH034223, R01MH034223] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-34223] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABERNETHY DR, 1983, PSYCHOPHARMACOLOGY, V80, P275, DOI 10.1007/BF00436169; ADAM K, 1989, PHARMACOPSYCHIATRY, V22, P115, DOI 10.1055/s-2007-1014592; BARNHILL JG, 1990, J PHARMACOL EXP THER, V253, P1153; BIXLER EO, 1987, PHARMACOLOGY, V35, P286, DOI 10.1159/000138322; BLIWISE D, 1983, SLEEP, V6, P156, DOI 10.1093/sleep/6.2.156; BLIWISE DL, 1988, J CLIN PSYCHIAT, V49, P349; CARSKADON MA, 1982, SLEEP, V5, P361, DOI 10.1093/sleep/5.4.361; CASTLEDEN CM, 1977, BRIT MED J, V1, P10, DOI 10.1136/bmj.1.6052.10; COHN JB, 1984, J CLIN PSYCHIAT, V45, P104; FRIEDMAN H, 1988, J CLIN PHARMACOL, V28, P228, DOI 10.1002/j.1552-4604.1988.tb03137.x; GHONEIM MM, 1990, ANESTHESIOLOGY, V72, P926; GILES HG, 1978, CAN MED ASSOC J, V118, P513; GILLIN JC, 1989, J CLIN PSYCHOPHARM, V9, P161; GREENBLATT DJ, 1988, CLIN PHARMACOL THER, V44, P326, DOI 10.1038/clpt.1988.158; GREENBLATT DJ, 1983, NEW ENGL J MED, V309, P354; GREENBLATT DJ, 1983, NEW ENGL J MED, V309, P410; GREENBLATT DJ, 1983, BRIT J CLIN PHARMACO, V15, P303, DOI 10.1111/j.1365-2125.1983.tb01503.x; GREENBLATT DJ, 1989, J CLIN PHARMACOL, V29, P866, DOI 10.1002/j.1552-4604.1989.tb03246.x; GREENBLATT DJ, 1981, J CHROMATOGR, V225, P202, DOI 10.1016/S0378-4347(00)80261-3; GREENBLATT DJ, 1989, ARCH GEN PSYCHIAT, V46, P326; GREENBLATT DJ, 1977, CLIN PHARMACOL THER, V21, P355; GREENBLATT DJ, 1987, NEW ENGL J MED, V317, P722, DOI 10.1056/NEJM198709173171202; GREENBLATT DJ, 1981, CLIN PHARMACOL THER, V30, P475, DOI 10.1038/clpt.1981.191; GREENBLATT DJ, 1989, ARCH GEN PSYCHIAT, V46, P793; GREENBLATT DJ, 1982, METHODOLOGY ANAL TOX, V2, P19; GRIFFITHS RR, 1985, NEUROSCI BIOBEHAV R, V9, P133, DOI 10.1016/0149-7634(85)90039-9; GUTHRIE S, 1987, PHARMACOL TOXICOL, V61, P308, DOI 10.1111/j.1600-0773.1987.tb01825.x; HINRICHS JV, 1987, PSYCHOPHARMACOLOGY, V92, P100, DOI 10.1007/BF00215487; KALES A, 1990, HOSP PRACT, V25, P7; KALES A, 1986, CLIN PHARMACOL THER, V40, P378, DOI 10.1038/clpt.1986.194; KALES A, 1983, J CLIN PSYCHOPHARM, V3, P140, DOI 10.1097/00004714-198304000-00038; KALES A, 1983, PHARMACOLOGY, V26, P121, DOI 10.1159/000137794; KOMISKEY HL, 1988, PHARMACOL BIOCHEM BE, V31, P611, DOI 10.1016/0091-3057(88)90238-9; LAPIERRE KA, 1990, J CLIN PHARMACOL, V30, P454, DOI 10.1002/j.1552-4604.1990.tb03485.x; LISTER RG, 1985, NEUROSCI BIOBEHAV R, V9, P87, DOI 10.1016/0149-7634(85)90034-X; MILLER LG, 1987, J NEUROCHEM, V49, P1595, DOI 10.1111/j.1471-4159.1987.tb01032.x; MORGAN K, 1990, DRUGS, V40, P688, DOI 10.2165/00003495-199040050-00004; MORGAN K, 1982, BRIT MED J, V284, P942, DOI 10.1136/bmj.284.6320.942; MORRIS HH, 1987, JAMA-J AM MED ASSOC, V258, P945, DOI 10.1001/jama.258.7.945; MOSCHITTO LJ, 1983, J PHARM PHARMACOL, V35, P179, DOI 10.1111/j.2042-7158.1983.tb04302.x; NIKAIDO AM, 1990, PSYCHOPHARMACOLOGY, V100, P90, DOI 10.1007/BF02245796; OCHS HR, 1987, BRIT J CLIN PHARMACO, V23, P759, DOI 10.1111/j.1365-2125.1987.tb03112.x; OGURA C, 1980, PSYCHOPHARMACOLOGY, V68, P61, DOI 10.1007/BF00426651; PAKES GE, 1981, DRUGS, V22, P81, DOI 10.2165/00003495-198122020-00001; PATTERSON JF, 1987, SOUTHERN MED J, V80, P1425, DOI 10.1097/00007611-198711000-00020; POMARA N, 1985, J CLIN PSYCHIAT, V46, P185; POMARA N, 1989, PSYCHOPHARMACOL BULL, V25, P144; PRINZ PN, 1990, NEW ENGL J MED, V323, P520; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; REIDENBERG MM, 1978, CLIN PHARMACOL THER, V23, P371; ROEHRS T, 1985, NEUROBIOL AGING, V6, P293, DOI 10.1016/0197-4580(85)90006-5; ROMNEY DM, 1984, PSYCHOPHARMACOL BULL, V20, P313; ROTH T, 1983, PHARMACOTHERAPY, V3, P137; SCAVONE JM, 1987, ARZNEIMITTEL-FORSCH, V37-1, P2; SCAVONE JM, 1986, J CLIN PHARMACOL, V26, P208, DOI 10.1002/j.1552-4604.1986.tb02935.x; SHADER RI, 1986, CLIN PHARMACOL THER, V39, P526, DOI 10.1038/clpt.1986.90; SHORR RI, 1990, AM J MED, V89, P725, DOI 10.1016/0002-9343(90)90213-W; SMITH RB, 1983, J CLIN PSYCHOPHARM, V3, P172; SOLOMON F, 1979, NEW ENGL J MED, V300, P803, DOI 10.1056/NEJM197904053001423; SWIFT CG, 1985, BRIT J CLIN PHARMACO, V20, P111, DOI 10.1111/j.1365-2125.1985.tb05040.x; WEINER H, 1991, PSYCHOL BULL, V109, P147; WILKINSON GR, 1987, PHARMACOL REV, V39, P1; WOO E, 1991, J CLIN PHARMACOL, V31, P168, DOI 10.1002/j.1552-4604.1991.tb03702.x	64	223	224	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1691	1698		10.1056/NEJM199106133242403	http://dx.doi.org/10.1056/NEJM199106133242403			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ155	2034245	Bronze			2022-12-28	WOS:A1991FQ15500003
J	LIANG, TJ; HASEGAWA, K; RIMON, N; WANDS, JR; BENPORATH, E				LIANG, TJ; HASEGAWA, K; RIMON, N; WANDS, JR; BENPORATH, E			A HEPATITIS-B VIRUS MUTANT ASSOCIATED WITH AN EPIDEMIC OF FULMINANT-HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							E-ANTIGEN; PRECORE REGION; CORE ANTIGEN; NON-A; GENOME; LIVER; HBE; DNA; IDENTIFICATION; REPLICATION	Background. A nosocomial outbreak of fulminant hepatitis B occurred in five patients in Haifa, Israel. Previous investigations identified the suspected source as a carrier of hepatitis B surface antigen who was positive for antibodies to hepatitis B e antigen and had chronic liver disease. We examined the strain of hepatitis B virus (HBV) that caused this epidemic, in order to identify specific mutations in the precore or core region. Methods. The presence of HBV was identified by polymerase-chain-reaction amplification of viral DNA in serum from the source patient, the five patients with fulminant hepatitis B, and five controls with acute, self-limited hepatitis B. The amplified viral HBV DNA samples were then cloned and sequenced. Results. Sequence analysis of viral DNA established that the same HBV mutant with two mutations in the precore region was present in the source patient and the five patients with fulminant hepatic failure. This HBV mutant had significant sequence divergence from other known HBV subtypes in the X, precore, and core regions. Cloned HBV DNA derived from a hospitalized patient who had subclinical hepatitis B at the same time as the outbreak and from four other control subjects with acute, self-limited hepatitis B all contained the wild-type sequence in the precore region. Conclusions. In the outbreak we studied, a mutant hepatitis B viral strain was transmitted from a common source to five patients who subsequently died of fulminant hepatitis B infection. Naturally occurring viral mutations in the HBV genome may predispose the infected host to more severe liver injury.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114; TECHNION ISRAEL INST TECHNOL,RAMBAM MED CTR,FAC MED,VIROL LAB,HAIFA,ISRAEL	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	LIANG, TJ (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,149 13TH ST,7TH FL,BOSTON,MA 02114, USA.				NCI NIH HHS [CA-35711] Funding Source: Medline; NIAAA NIH HHS [AA-08169, AA-02666] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA035711, R01CA035711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008169, R37AA002666, R01AA002666] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BARKER LF, 1972, AM J MED SCI, V263, P27, DOI 10.1097/00000441-197201000-00005; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; BLUM HE, 1990, IN PRESS VIRAL HEPAT; BRECHOT C, 1984, BRIT MED J, V288, P270, DOI 10.1136/bmj.288.6413.270; BRUNETTO MR, 1990, J HEPATOL, V10, P258, DOI 10.1016/0168-8278(90)90062-V; BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151; BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213; CARMAN WF, 1989, LANCET, V2, P588; CARMAN WF, 1990, 1990 INT S VIR HEP L; CHANG C, 1987, J VIROL, V61, P3322, DOI 10.1128/JVI.61.10.3322-3325.1987; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DECOCK KM, 1986, ANN INTERN MED, V105, P546, DOI 10.7326/0003-4819-105-4-546; DELAPLANE D, 1983, PEDIATRICS, V72, P176; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GIRONES R, 1989, VIROLOGY, V170, P595, DOI 10.1016/0042-6822(89)90455-8; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; LIANG TJ, 1989, J CLIN INVEST, V84, P1367, DOI 10.1172/JCI114308; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MIYAZAKI K, 1990, 1990 M JAP ASS STUD; MONDELLI M, 1984, SEMIN LIVER DIS, V4, P47, DOI 10.1055/s-2008-1040645; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; SARACCO G, 1988, ANN INTERN MED, V108, P380, DOI 10.7326/0003-4819-108-3-380; SHAW FE, 1986, JAMA-J AM MED ASSOC, V255, P3260, DOI 10.1001/jama.255.23.3260; SUMMERS J, 1990, J VIROL, V64, P2819, DOI 10.1128/JVI.64.6.2819-2824.1990; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOKITA M, 1990, 1990 M JAP ASS STUD; TONG SP, 1990, VIROLOGY, V176, P596, DOI 10.1016/0042-6822(90)90030-U; YOAKUM GH, 1983, SCIENCE, V222, P385, DOI 10.1126/science.6194563; 1984, MMWR, V33, P70; 1984, MMWR, V33, P76; 1979, MMWR, V28, P373	38	429	441	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1705	1709		10.1056/NEJM199106133242405	http://dx.doi.org/10.1056/NEJM199106133242405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	2034247				2022-12-28	WOS:A1991FQ15500005
J	OMATA, M; EHATA, T; YOKOSUKA, O; HOSODA, K; OHTO, M				OMATA, M; EHATA, T; YOKOSUKA, O; HOSODA, K; OHTO, M			MUTATIONS IN THE PRECORE REGION OF HEPATITIS-B VIRUS-DNA IN PATIENTS WITH FULMINANT AND SEVERE HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; POLYMERASE CHAIN-REACTION; CHRONIC LIVER-DISEASE; PRE-C REGION; E-ANTIGEN; SUBTYPE-ADR; ESCHERICHIA-COLI; CORE PROTEIN; SERUM; ANTIBODY	Background. The presence of the hepatitis B e antigen (HBeAg) in serum is known to be a marker of a high degree of viral infectivity. However, fulminant hepatitis may occur in persons who are negative for HBeAg. A single point mutation has been reported to produce a stop codon in the precore region of hepatitis B virus DNA and prevent the formation of the precore protein required to make HBeAg. To determine whether a precore-mutant virus is causally related to severe liver injury, we analyzed the entire precore region in viral strains isolated from patients with fatal cases and uncomplicated cases of hepatitis B. Methods. Serum was obtained from 9 patients with fatal hepatitis B(5 with fulminant and 4 with severe exacerbations of chronic hepatitis) and 10 patients with acute, self-limited hepatitis B. Serum samples from a sex partner implicated as the source of the virus in one case of fulminant hepatitis were also studied. The 87 nucleotides in the precore region of the hepatitis B virus were amplified by the polymerase chain reaction and then directly sequenced. Results. Of the nine patients with fatal hepatitis, seven had retrievable hepatitis B DNA. In all seven there was a point mutation from G to A at nucleotide 1896 of the precore region, converting tryptophan (TGG) to a stop codon (TAG). In contrast, this mutation was not found in the 10 patients with acute, self-limited hepatitis B. The hepatitis B DNA from the implicated source contained a sequence with the stop-codon mutation that was identical to the sequence in her partner, who had fulminant hepatitis. Conclusions. The presence of a mutant viral strain is associated with and may be involved in the pathogenesis of fulminant hepatitis B and severe exacerbations of chronic hepatitis.			OMATA, M (corresponding author), CHIBA UNIV,SCH MED,DEPT MED 1,1-8-1 INOHANA,CHIBA 280,JAPAN.							BICHKO V, 1985, FEBS LETT, V185, P208, DOI 10.1016/0014-5793(85)80771-7; BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151; CARMAN WF, 1989, LANCET, V2, P588; CHANG MH, 1987, J PEDIATR-US, V111, P34, DOI 10.1016/S0022-3476(87)80338-4; DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; HADZIYANNIS SJ, 1983, HEPATOLOGY, V3, P656; HOOFNAGLE JH, 1983, GASTROENTEROLOGY, V84, P422; IMAZEKI F, 1985, HEPATOLOGY, V5, P783, DOI 10.1002/hep.1840050513; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KOBAYASHI M, 1984, GENE, V30, P227; KROGSGAARD K, 1986, J INFECT DIS, V153, P298, DOI 10.1093/infdis/153.2.298; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; MATSUYAMA Y, 1985, GASTROENTEROLOGY, V89, P1104, DOI 10.1016/0016-5085(85)90216-1; OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OKAMOTO H, 1986, J GEN VIROL, V67, P2305, DOI 10.1099/0022-1317-67-11-2305; OKUDA K, 1987, HEPATOLOGY, V7, P974; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; RHO HM, 1989, NUCLEIC ACIDS RES, V17, P2124, DOI 10.1093/nar/17.5.2124; ROOSSINCK MJ, 1986, MOL CELL BIOL, V6, P1393, DOI 10.1128/MCB.6.5.1393; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLICHT HJ, 1989, J VIROL, V63, P5399, DOI 10.1128/JVI.63.12.5399-5404.1989; SCHLICHT HJ, 1987, J VIROL, V61, P3701, DOI 10.1128/JVI.61.12.3701-3709.1987; SHIRAKI K, 1980, J PEDIATR-US, V97, P768, DOI 10.1016/S0022-3476(80)80261-7; TADA M, 1990, CANCER RES, V50, P1121; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TONG SP, 1990, VIROLOGY, V176, P596, DOI 10.1016/0042-6822(90)90030-U; TREPO CG, 1976, GUT, V17, P10, DOI 10.1136/gut.17.1.10; UY A, 1986, VIROLOGY, V155, P89, DOI 10.1016/0042-6822(86)90170-4; VALENZUELA P, 1980, ICN UCLA S MOL CELLU, V18, P57; VAUDIN M, 1988, J GEN VIROL, V69, P1383, DOI 10.1099/0022-1317-69-6-1383; VENTO S, 1985, HEPATOLOGY, V5, P192, DOI 10.1002/hep.1840050206; YOKOSUKA O, 1986, NEW ENGL J MED, V315, P1187, DOI 10.1056/NEJM198611063151903	40	482	494	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1699	1704		10.1056/NEJM199106133242404	http://dx.doi.org/10.1056/NEJM199106133242404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	2034246				2022-12-28	WOS:A1991FQ15500004
J	ELLIOTT, T; CERUNDOLO, V; ELVIN, J; TOWNSEND, A				ELLIOTT, T; CERUNDOLO, V; ELVIN, J; TOWNSEND, A			PEPTIDE-INDUCED CONFORMATIONAL CHANGE OF THE CLASS-I HEAVY-CHAIN	NATURE			English	Article							TOXIC LYMPHOCYTES-T; INFLUENZA-A VIRUS; HLA-B ANTIGENS; SURFACE EXPRESSION; SYNTHETIC PEPTIDES; VIRAL PEPTIDES; NUCLEOPROTEIN; MOLECULES; BETA-2-MICROGLOBULIN; INVITRO	THERE is evidence that peptide ligands take part in the assembly of class I molecules 1-8. In particular, addition of peptides to extracts of the mutant cells RMA-S and .174/T2, in which stable assembly of class I does not occur 9-11, results in a conformational change in the class I heavy chain and stable association of the heavy chain with beta-2-microglobulin (beta-2m) (refs 1-3). Thus specific peptides may stabilize or induce a conformational change in the class I heavy chain that results in a rise in the binding affinity of the heavy chain for beta-2m (Fig. 1a). Here we show that peptides have two cooperative roles in class I assembly. Specific short peptides (9-10 amino acids) can induce folding of the heavy chain in the absence of beta-2m. Both short (nine amino acids) and longer sequences (15 amino acids) can stabilize performed low-affinity complexes of heavy chain and beta-2m. To alter the conformation of free heavy chains, the peptides must be exactly the correct size, and they are found to correspond to the sequences isolated from infected cells 12. This property may therefore be the basis for selection of epitopes presented in vivo.			ELLIOTT, T (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.			Cerundolo, Vincenzo/0000-0003-0040-3793; Townsend, Alain/0000-0002-3702-0107	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, IN PRESS EUR J IMMUN; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; HUDDLESTON JA, 1982, NUCLEIC ACIDS RES, V10, P1029, DOI 10.1093/nar/10.3.1029; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; OZATO K, 1981, J IMMUNOL, V126, P317; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796	19	246	252	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					402	406		10.1038/351402a0	http://dx.doi.org/10.1038/351402a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034289				2022-12-28	WOS:A1991FN85600057
J	SOKOL, S; MELTON, DA				SOKOL, S; MELTON, DA			PREEXISTENT PATTERN IN XENOPUS ANIMAL POLE CELLS REVEALED BY INDUCTION WITH ACTIVIN	NATURE			English	Article							NEURAL INDUCTION; LAEVIS; MESODERM; EMBRYOS; AXIS; DIFFERENTIATION; GASTRULATION; HOMOLOG; SIGNALS; MARKER	ACTIVIN, a peptide growth factor related to tumour growth factor-beta, has been implicated in early inductive interactions in vertebrates 1-4 and can induce Xenopus blastula ectodermal explants to develop a rudimentary axial pattern with anteroposterior and dorsoventral polarity 4, 5. Here we demonstrate that prospective dorsal and ventral regions of the ectoderm respond differently to the same concentration of activin. Thus, activin does not seem to endow ectodermal cells with polarity but rather reveals a pre-existent pattern. Our results suggest that patterning of mesoderm is determined not only by a localized inducer, but also by the differential competence of cells in the responding tissue.			SOKOL, S (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Sokol, Sergei/0000-0002-3963-9202				ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; DALE L, 1987, DEVELOPMENT, V100, P279; DIXON JE, 1989, DEVELOPMENT, V106, P749; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; NAKAMURA O, 1978, ORG MILESTONE HALF C, P179; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V163, P298, DOI 10.1007/BF00577017; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; Spemann H., 1938, EMBRYONIC DEV INDUCT; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0	20	189	192	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					409	411		10.1038/351409a0	http://dx.doi.org/10.1038/351409a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034291				2022-12-28	WOS:A1991FN85600059
J	BLUM, RW				BLUM, RW			GLOBAL TRENDS IN ADOLESCENT HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MATERNAL MORTALITY; DRUG-USE; RURAL BANGLADESH; INDUCED-ABORTION; PERSPECTIVE; FERTILITY; SUICIDE; YOUTH; CARE	Increasingly, morbidity and mortality trends for young people in developing nations are paralleling those in the industrialized world. As infectious causes of mortality diminish, unintentional injuries, suicide, homicide, war, and maternal mortality represent the primary causes of death in the second decade of life for most nations where data are maintained. As developing nations increasingly place priority on the education of their youth, early marriage and precocious child rearing are discouraged, and other problems, such as out-of-wedlock childbirth and illicit abortions, emerge. Problems such as substance abuse and suicide arise with the urban migration, increased unemployment, and disruption of traditional social structures that are experienced as developing countries industrialize.			BLUM, RW (corresponding author), UNIV MINNESOTA HOSP & CLIN,DIV GEN PEDIAT & ADOLESCENT HLTH,ADOLESCENT HLTH PROGRAM,BOX 721,MINNEAPOLIS,MN 55455, USA.							ADLER I, 1981, J STUD ALCOHOL, V42, P701, DOI 10.15288/jsa.1981.42.701; AKINGBA J, 1969, J NIGERIAN MED ASSOC, V6, P16; BERTRAND JT, 1991, AM J PUBLIC HEALTH, V81, P53, DOI 10.2105/AJPH.81.1.53; BLUM R, 1987, JAMA-J AM MED ASSOC, V257, P3390, DOI 10.1001/jama.257.24.3390; BLUM RW, 1990, J ADOLESCENT HEALTH, V11, P289, DOI 10.1016/0197-0070(90)90037-3; BLUM RW, 1989, STATE ADOLESCENT HLT; BRUNSWICK A, 1972, AM J PUBLIC HEALTH, V1, P1; Cates Jr, 1990, Adolesc Med, V1, P409; CHEN LC, 1974, STUD FAMILY PLANN, V5, P334, DOI 10.2307/1965185; CHERLIN A, 1986, 8623 WORLD BANK TECH; CURTIS H, 1908, ARCH DIS CHILD, V64, P1240; DEWEISS SP, 1990, AM J PUBLIC HEALTH, V80, P715, DOI 10.2105/AJPH.80.6.715; DIEKSTRA R, 1989, CRISIS, V10, P15; FINGERHUT LA, 1990, JAMA-J AM MED ASSOC, V263, P3292, DOI 10.1001/jama.263.24.3292; FORTNEY JA, 1988, INT J GYNECOL OBSTET, V26, P21, DOI 10.1016/0020-7292(88)90192-0; FRANK O, 1987, STUD FAMILY PLANN, V18, P181, DOI 10.2307/1966870; FRIEDMAN HL, 1987, 4TH INT S AD HLTH SY; GEIZEROVA H, 1988, SMOKING HLTH 1987, P123; GYPIGARBRADH B, 1985, ADOLESCENT FERTILITY; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P76, DOI 10.2307/2135512; HENSHAW SK, 1986, FAM PLANN PERSPECT, V18, P250, DOI 10.2307/2134947; HOLDEN C, 1986, SCIENCE, V233, P839, DOI 10.1126/science.3738513; IGA M, 1981, SUICIDE LIFE-THREAT, V11, P17; JOHNSTON L, 1990, BKD42 NAT I DRUG AB; JONES EF, 1986, TEENAGE PREGNANCY IN; KANDEL D, 1984, PUBLIC HEALTH REP, V99, P277; KANDEL D, 1975, SCIENCE, V190, P912, DOI 10.1126/science.1188374; KANDEL DB, 1984, AM J PUBLIC HEALTH, V74, P660, DOI 10.2105/AJPH.74.7.660; KHAN AR, 1986, STUD FAMILY PLANN, V17, P7, DOI 10.2307/1966950; KOKKEVI A, 1991, AM J PUBLIC HEALTH, V81, P48, DOI 10.2105/AJPH.81.1.48; KWAST BE, 1986, STUD FAMILY PLANN, V17, P288, DOI 10.2307/1966906; LAMPTEY P, 1981, J BIOSOC SCI, V17, P195; LEVENSON PM, 1987, J ADOLESCENT HEALTH, V8, P171, DOI 10.1016/0197-0070(87)90261-0; MACKENZIE RG, 1985, PSYCHOSOCIAL ASPECTS, P195; MARKS A, 1983, J PEDIATR-US, V102, P456, DOI 10.1016/S0022-3476(83)80677-5; MASIRONI R, IN PRESS CIGARETTE S; Michaud P A, 1983, REV SUISSE MED, V49, P1545; MORRIS L, 1983, NOV REG AD REPR HLTH; MUNAN L, 1972, PEDIATRICS, V49, P177; MURUNGU D, 1986, 8623 WORLD BANK TECH; NATH UR, 1986, SMOKING 3RD WORLD AL; OMU A E, 1981, International Journal of Gynecology and Obstetrics, V19, P495, DOI 10.1016/0020-7292(81)90011-4; OWUAMANAM DO, 1982, ADOLESCENCE, V17, P81; PARCEL GS, 1977, PEDIATRICS, V60, P157; PERRY CL, IN PRESS INT J ADDIC; PRADA E, 1988, ADOLESCENTS HOY PADR; Schorr LB, 1988, OUR REACH BREAKING C; SENDEROWITZ J, 1985, POPUL BULL, V40, P1; SINGH S, 1991, TODAYS TEENAGERS TOM; SUAREZ E, 1985, SCI PUBLICATION, V489, P3; Taket A, 1986, World Health Stat Q, V39, P232; TIETZE C, 1979, INDUCED ABORTION 197; Tursz A, 1986, World Health Stat Q, V39, P257; WESTON N, CITED INDIRECTLY; 1986, WHO731 TECHN REP, P41; 1986, MATERNAL MORTALITY R; 1989, ACCIDENT FACTS; 1986, WORLD POPULATION PRO; 1989, HLTH YOUTH; 1989, HLTH YOUTH FACTS ACT; 1986, WHO731 TECHN REP; 1989, DEMOGRAPHIC YB 1987; 1990, WKLY EPIDEMIOL REC, V31, P239; 1988, 109 UN POP STUD; 1989, PHS89123 US DEP HLTH	65	42	43	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2711	2719		10.1001/jama.265.20.2711	http://dx.doi.org/10.1001/jama.265.20.2711			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL989	2023354				2022-12-28	WOS:A1991FL98900038
J	WALT, AJ				WALT, AJ			A SURGICAL CURTAIN CALL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2677	2677						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023347				2022-12-28	WOS:A1991FL98900030
J	PAIRAUDEAU, PW; WILSON, RG; HALL, MA; MILNE, M				PAIRAUDEAU, PW; WILSON, RG; HALL, MA; MILNE, M			INHALATION OF BABY POWDER - AN UNAPPRECIATED HAZARD	BRITISH MEDICAL JOURNAL			English	Article									ODSTOCK HOSP,PAEDIAT,SALISBURY SP2 8BJ,WILTS,ENGLAND	Salisbury District Hospital	PAIRAUDEAU, PW (corresponding author), SOUTHAMPTON GEN HOSP,CHILD HLTH,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							BROUILLETTE F, 1978, CAN MED ASSOC J, V119, P354; COTTON WH, 1985, NEW ENGL J MED, V313, P1662; CRUTHIRDS TP, 1977, SOUTHERN MED J, V70, P626, DOI 10.1097/00007611-197705000-00041; DELAROCHA SR, 1989, PEDIATR EMERG CARE, V5, P43; FEIGIN DS, 1986, AM J ROENTGENOL, V146, P295, DOI 10.2214/ajr.146.2.295; Gould S R, 1972, Br J Dis Chest, V66, P230, DOI 10.1016/S0007-0971(72)80021-4; HAYDEN GF, 1984, CLIN PEDIATR, V23, P163, DOI 10.1177/000992288402300306; JOLLY H, 1985, BOOK CHILD CARE; LITOVITZ TL, 1987, AM J EMERG MED, V5, P405, DOI 10.1016/0735-6757(87)90393-7; MCCORMICK MA, 1982, JAMA-J AM MED ASSOC, V248, P2159; MOFENSON HC, 1981, PEDIATRICS, V68, P265; MOSS MH, 1969, PEDIATRICS, V43, P1058; MOTOMATSU K, 1979, CHEST, V75, P448, DOI 10.1378/chest.75.4.448; NASH B, 1980, COMPLETE BOOK BABY C; PFENNINGER J, 1977, ARCH DIS CHILD, V52, P157, DOI 10.1136/adc.52.2.157; Rook A, 1986, TXB DERMATOLOGY, V4th; STANWAY A, 1987, BABY CHILD BOOK	17	14	15	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1200	1201		10.1136/bmj.302.6786.1200	http://dx.doi.org/10.1136/bmj.302.6786.1200			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043820	Green Published, Bronze			2022-12-28	WOS:A1991FN04500031
J	GOODMAN, LJ; BRUESCHKE, EE; BONE, RC; ROSE, WH; WILLIAMS, EJ; PAUL, HA				GOODMAN, LJ; BRUESCHKE, EE; BONE, RC; ROSE, WH; WILLIAMS, EJ; PAUL, HA			AN EXPERIMENT IN MEDICAL-EDUCATION - A CRITICAL ANALYSIS USING TRADITIONAL CRITERIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								In 1984, in addition to its standard traditional curriculum, Rush Medical College (Chicago, III) developed a Socratic problem-based method of teaching basic science material called the alternative curriculum. As part of an evaluation of this new curriculum, students in the two curricula were compared using three traditional measurments: (1) test scores from the National Board of Medical Examiners, Part I; (2) test scores from the National Board of Medical Examiners, Part II; and (3) performance on an oral examination. Alternative curriculum students did not differ significantly from their traditional curriculum classmates on National Board of Medical Examiners, Part I and Part II total scores, although their subset scores on Part I did tend to be lower, reaching significance in one subset area. Differences in performance favoring the traditional curriculum were primarily seen in the early years of the program. Alternative curriculum students in the class matriculated in 1987 scored significantly higher in three of five categories on the oral examination.	COLUMBUS PUBL SCH DIST,PROGRAM EVALUAT,COLUMBUS,OH		GOODMAN, LJ (corresponding author), RUSH MED COLL,MED STUDENT PROGRAMS,600 S PAULINA ST,CHICAGO,IL 60612, USA.							ARNDT CB, 1986, MED EDUC, V20, P274, DOI 10.1111/j.1365-2923.1986.tb01366.x; BOK D, 1984, HARV MAG         JUN, V86, P32; BOK D, 1984, HARVARD MAG, V86, P70; FRIEDMAN CP, 1990, ACAD MED, V65, P8, DOI 10.1097/00001888-199001000-00002; GOTTERER G, 1987, ALTERNATIVE PRECLINI, V101, P179; JAYAWICKRAMARAJAH PT, 1985, MED EDUC, V19, P290, DOI 10.1111/j.1365-2923.1985.tb01323.x; OLDER J, 1984, CAN J PSYCHIAT, V29, P42, DOI 10.1177/070674378402900110; STILLMAN PL, 1990, ACAD MED, V65, P320, DOI 10.1097/00001888-199005000-00013; STILLMAN PL, 1987, ARCH INTERN MED, V147, P1981, DOI 10.1001/archinte.147.11.1981; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405; 1984, PHYSICIANS 21ST CENT, P5	12	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2373	2376						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016834				2022-12-28	WOS:A1991FJ95500033
J	PHILLIPS, DR; CHARO, IF; SCARBOROUGH, RM				PHILLIPS, DR; CHARO, IF; SCARBOROUGH, RM			GPIIB-IIIA - THE RESPONSIVE INTEGRIN	CELL			English	Review							FIBRINOGEN GAMMA-CHAIN; IIB-GLYCOPROTEIN-IIIA; SITE; RECEPTOR; PEPTIDE; LOCALIZATION; CONFORMATION; ADHESION; BINDING				PHILLIPS, DR (corresponding author), COR THERAPEUT INC, 256 E GRAND AVE, SAN FRANCISCO, CA 94080 USA.							CADROY Y, 1989, J CLIN INVEST, V84, P939, DOI 10.1172/JCI114256; CHARO IF, 1991, J BIOL CHEM, V266, P1415; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU X, 1991, CELL, V65; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KIEFFER N, 1991, IN PRESS J CELL BIOL; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LAM SCT, 1987, J BIOL CHEM, V262, P947; LINDON JN, 1986, BLOOD, V68, P355; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; SCARBOROUGH RM, 1991, IN PRESS J BIOL CHEM; SHEBUSKI RJ, 1989, J BIOL CHEM, V264, P21550; SMITH JW, 1990, J BIOL CHEM, V265, P12267; STEINER B, 1989, J BIOL CHEM, V264, P13102	21	507	529	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					359	362		10.1016/0092-8674(91)90451-4	http://dx.doi.org/10.1016/0092-8674(91)90451-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018971				2022-12-28	WOS:A1991FK18200001
J	GILL, G; TJIAN, R				GILL, G; TJIAN, R			A HIGHLY CONSERVED DOMAIN OF TFIID DISPLAYS SPECIES SPECIFICITY INVIVO	CELL			English	Article							RNA POLYMERASE-II; TATA-BOX; TRANSCRIPTION INITIATION; FUNCTIONAL-ANALYSIS; BINDING PROTEIN; GENE-EXPRESSION; YEAST; PROMOTER; IDENTIFICATION; PURIFICATION	Recombinant TFIID proteins from yeast, Drosophila, and human function interchangeably in vitro to restore basal level transcription to a human HeLa extract depleted for TFIID. Here we report that the recently cloned human and Drosophila TFIID genes fail to substitute in vivo for the S. cerevisiae TFIID gene, SPT15, which is essential for viability. Analysis of yeast-human hybrid TFIID proteins reveals that the failure of human TFIID to functionally replace yeast TFIID maps to the highly conserved C-terminal domain. Thus, the C-terminal conserved domain of TFIID, as well as the N-terminal divergent domain, appears to be involved in species-specific interactions.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	GILL, G (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HOEIJMAKERS JHJ, 1990, NATURE, V343, P417, DOI 10.1038/343417b0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	48	87	88	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					333	340		10.1016/0092-8674(91)90166-V	http://dx.doi.org/10.1016/0092-8674(91)90166-V			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015627				2022-12-28	WOS:A1991FH09200015
J	LAW, MR; FROST, CD; WALD, NJ				LAW, MR; FROST, CD; WALD, NJ			BY HOW MUCH DOES DIETARY SALT REDUCTION LOWER BLOOD-PRESSURE .1. ANALYSIS OF OBSERVATIONAL DATA AMONG POPULATIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SODIUM-INTAKE; 24-HOUR EXCRETION; RISK-FACTORS; HYPERTENSION; POTASSIUM; CULTURE; DISEASE; BELGIUM; CATIONS; MILTON	Objective-To estimate the quantitative relation between blood pressure and sodium intake. Design-Data were analysed from published reports of blood pressure and sodium intake for 24 different communities (47 000 people) throughout the world. Main outcome measure-Difference in blood pressure for a 100 mmol/24 h difference in sodium intake. Allowance was made for differences in blood pressure between economically developed and undeveloped communities to minimise overestimation of the association through confounding with other determinants of blood pressure. Results-Blood pressure was higher on average in the developed communities, but the association with sodium intake was similar in both types of community. A difference in sodium intake of 100 mmol/24 h was associated with an average difference in systolic blood pressure that ranged from 5 mm Hg at age 15-19 years to 10 mm Hg at age 60-69. The differences in diastolic blood pressure were about half as great. The standard deviation of blood pressure increased with sodium intake implying that the association of blood pressure with sodium intake in individuals was related to the initial blood pressure-the higher the blood pressure the greater the expected reduction in blood pressure for the same reduction in sodium intake. For example, at age 60-69 the estimated systolic blood pressure reduction in response to a 100 mmol/24 h reduction in sodium intake was on average 10 mm Hg but varied from 6 mm Hg for those on the fifth blood pressure centile to 15 mm Hg for those on the 95th centile. Conclusions-The association of blood pressure with sodium intake is substantially larger than is generally appreciated and increases with age and initial blood pressure.			LAW, MR (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					BAILEY K V, 1961, Trop Geogr Med, V13, P216; BAILEY KV, 1963, BRIT MED J, P775, DOI 10.1136/bmj.2.5360.775; BARNES R, 1965, Med J Aust, V1, P611; DAHL LK, 1972, AM J CLIN NUTR, V25, P231; DAWBER THOMAS R., 1967, P255; ELLIOTT P, 1988, BRIT MED J, V297, P319; FODOR JG, 1980, EPIDEMIOLOGY ARTERIA, P353; FROMENT A, 1979, REV EPIDEMIOL SANTE, V27, P437; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GILLUM RF, 1982, AM HEART J, V104, P852, DOI 10.1016/0002-8703(82)90022-9; GILLUM RF, 1979, HYPERTENSION, V1, P468, DOI 10.1161/01.HYP.1.5.468; GLEIBERMANN L., 1973, Ecology of Food and Nutrition, V2, P143, DOI 10.1080/03670244.1973.9990329; GRIM CE, 1980, J CHRON DIS, V33, P87, DOI 10.1016/0021-9681(80)90032-6; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; KESTELOOT H, 1980, EUR J CARDIOL, V11, P169; KESTELOOT H, 1987, HYPERTENSION, V9, P654, DOI 10.1161/01.HYP.9.6.654; KESTELOOT H, 1984, ANN CLIN RES, V16, P72; KOMACHI Y, 1971, JPN CIRCULATION J, V35, P189, DOI 10.1253/jcj.35.189; KURTZ TW, 1987, NEW ENGL J MED, V317, P1043, DOI 10.1056/NEJM198710223171702; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LEE MR, 1986, BMJ-BRIT MED J, V293, P266, DOI 10.1136/bmj.293.6541.266-b; LOWENSTEIN F, 1961, LANCET, V1, P389; LUFT FC, 1988, J CARDIOVASC PHARM, V12, pS49; MADDOCKS I., 1965, Papua and New Guinea Medical Journal, V8, P17; MCDONOUGH JR, 1964, ANN INTERN MED, V61, P208, DOI 10.7326/0003-4819-61-2-208; MORSE WR, 1937, LANCET, V1, P966; MOSER M, 1959, AM J CARDIOL, V4, P727, DOI 10.1016/0002-9149(59)90122-5; OLIVER WJ, 1975, CIRCULATION, V52, P146, DOI 10.1161/01.CIR.52.1.146; PAGE LB, 1974, CIRCULATION, V49, P1132, DOI 10.1161/01.CIR.49.6.1132; PAGE LB, 1981, AM J CLIN NUTR, V34, P527, DOI 10.1093/ajcn/34.4.527; PRIOR IAM, 1968, NEW ENGL J MED, V279, P515, DOI 10.1056/NEJM196809052791004; SASAKI N, 1962, JPN HEART J, V3, P313; SCHNECKLOTH RE, 1962, AM HEART J, V63, P607, DOI 10.1016/0002-8703(62)90005-4; SIMMONS D, 1986, J EPIDEMIOL COMMUN H, V40, P188, DOI 10.1136/jech.40.2.188; SIMPSON FO, 1978, NEW ZEAL MED J, V87, P379; SIMPSON FO, 1982, NEW ZEAL MED J, V95, P873; STAESSEN J, 1981, J EPIDEMIOL COMMUN H, V35, P256, DOI 10.1136/jech.35.4.256; STAMLER J, 1976, JAMA-J AM MED ASSOC, V235, P2299, DOI 10.1001/jama.235.21.2299; TSENG WP, 1967, AM J EPIDEMIOL, V86, P513, DOI 10.1093/oxfordjournals.aje.a120762; TUOMILEHTO J, 1981, ACTA CARDIOL, V36, P83; 1989, J HUMAN HYPERTENSION, V3, P279	41	339	345	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	1991	302	6780					811	815		10.1136/bmj.302.6780.811	http://dx.doi.org/10.1136/bmj.302.6780.811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025703	Bronze, Green Published			2022-12-28	WOS:A1991FF37700020
J	JOHNSON, N; MANT, D; JONES, L; RANDALL, T				JOHNSON, N; MANT, D; JONES, L; RANDALL, T			USE OF COMPUTERIZED GENERAL-PRACTICE DATA FOR POPULATION SURVEILLANCE - COMPARATIVE-STUDY OF INFLUENZA DATA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the potential for using routine computerised general practice data for surveillance of illness. Design-Comparison of the incidence of influenza during the 1989 epidemic derived from a computerised database with that derived from the Royal College of General Practitioner's weekly returns service-a well established predominantly manual surveillance system. Setting-433 general practices throughout the United Kingdom that used a commercial computer system linked to a central databank. Main outcome measure-Incidence of influenza. Results-The slope of the influenza epidemic curve was essentially the same whether derived from the routine computerised data or royal college's weekly returns service data, and the computerised data were geographically consistent. Throughout the study period, however, the computer derived incidence was between one third and one quarter of that derived from the royal college's system (which is served by practitioners trained in surveillance methods). The peak weekly rates were 164 cases per 100 000 for the computerised system and 583 cases per 100 000 for the royal college's surveillance system. Conclusions-The apparent underreporting in the routine computerised data probably reflects lack of motivation and experience in disease surveillance and haphazard computer entry (particularly of consultations that took place outside of the surgery and consultations that did not result in a prescription), along with overestimation of the population under surveillance. Nevertheless, routine computerised surveillance allows rapid data collection from a large number of practices over a wide geographical area and would greatly augment existing methods.			JOHNSON, N (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.		Mant, David CA/C-7763-2009					ALLEN ME, 1990, THESIS U READING REA; CAMPBELL DM, 1988, J ROY COLL GEN PRACT, V38, P418; Fleming D M, 1985, Health Trends, V17, P13; FLEMING DM, 1988, J ROY COLL GEN PRACT, V38, P461; HUEL G, 1986, STAT MED, V5, P171, DOI 10.1002/sim.4780050207; MCCORMICK A, 1987, BRIT MED J, V294, P74, DOI 10.1136/bmj.294.6564.74-a; Read J, 1986, BRIT J HEALTHC COMP, V3, P22; 1977, J R COLL GEN PRACT, V27, P544; 1989, OPCS MONITOR, V89, P43; 1990, COMPUTING SURVEY 199	10	44	44	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					763	765		10.1136/bmj.302.6779.763	http://dx.doi.org/10.1136/bmj.302.6779.763			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021767	Bronze, Green Published			2022-12-28	WOS:A1991FF22900026
J	HERZENBERG, H				HERZENBERG, H			INTERFERON-ALFA-2B FOR CHRONIC HEPATITIS-B	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											HERZENBERG, H (corresponding author), KAISER PERMANENTE MED CTR,SANTA CLARA,CA 95051, USA.							PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503	1	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 14	1991	324	7					493	494						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX363	2025320				2022-12-28	WOS:A1991EX36300019
J	GEISLER, FH; DORSEY, FC; COLEMAN, WP				GEISLER, FH; DORSEY, FC; COLEMAN, WP			RECOVERY OF MOTOR FUNCTION AFTER SPINAL-CORD INJURY - A RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH GM-1 GANGLIOSIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CENTRAL NERVOUS-SYSTEM; GM1 GANGLIOSIDE; RETROGRADE DEGENERATION; DOPAMINERGIC-NEURONS; RAT; METHYLPREDNISOLONE; LESIONS; REGENERATION; SURVIVAL; NALOXONE	Background. Spinal-cord injury is devastating; until recently, there was no medical treatment to improve recovery of the initial neurologic deficit. Studies in animals have shown that monosialotetrahexosylganglioside (GM-1) ganglioside enhances the functional recovery of damaged neurons. Methods. A prospective, randomized, placebo-controlled, double-blind trial of GM-1 ganglioside was conducted in patients with spinal-cord injuries. Of 37 patients entered into the study, 34 (23 with cervical injuries and 11 with thoracic injuries) completed the test-drug protocol (100 mg of GM-1 sodium salt or placebo intravenously per day for 18 to 32 doses, with the first dose taken within 72 hours of the injury) and a one-year follow-up period. Neurologic recovery was assessed with the Frankel scale (comprising five categories) and the American Spinal Injury Association (ASIA) motor score (a scale of scores from 0 to 100, derived from strength tests of 20 specific muscles, each scored from 0 to 5). Results. There was a significant difference between groups in the distribution of improvement of Frankel grades from base line to the one-year follow-up (improvement of 0, 1, 2, and 3 grades in 13, 4, 1, and 0 patients, respectively, in the placebo group and 8, 1, 6, and 1 patients, respectively, in the GM-1 group; P = 0.034 by the Cochran-Mantel-Haenszel chi-square test). The GM-1-treated patients also had a significantly greater mean improvement in ASIA motor score from base line to the one-year follow-up than the placebo-treated patients (36.9 vs. 21.6 points; P = 0.047 by analysis of covariance with the base-line ASIA motor score as the covariate). An analysis of individual muscle recoveries revealed that the increased recovery in the GM-1 group was attributable to initially paralyzed muscles that regained useful motor strength rather than to strengthening of paretic muscles. Conclusions. This small study provides evidence that GM-1 enhances the recovery of neurologic function after one year. A larger study must be conducted, however, before GM-1 is considered efficacious and safe in treating spinal-cord injury.	UNIV MARYLAND,DEPT SURG,DIV NEUROSURG,BALTIMORE,MD 21201; MARYLAND INST EMERGENCY MED SERV SYST,CTR SHOCK TRAUMA,BALTIMORE,MD; FIDIA PHARMACEUT CORP,DEPT BIOMETR,WASHINGTON,DC; UNIV MARYLAND,DEPT MATH & STAT,BALTIMORE,MD 21201; PATUXENT MED GRP,DEPT NEUROSURG,COLUMBIA,MD	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore								ANDO S, 1983, NEUROCHEM INT, V5, P507, DOI 10.1016/0197-0186(83)90043-8; ARGENTINO C, 1989, STROKE, V20, P1143, DOI 10.1161/01.STR.20.9.1143; BATTISTIN L, 1985, EUR NEUROL, V24, P343, DOI 10.1159/000115823; BEATTIE MS, 1988, PHARM APPROACHES TRE, P43; BENZEL EC, 1987, NEUROSURGERY, V20, P742, DOI 10.1227/00006123-198705000-00012; BLIGHT AR, 1989, J NEUROL SCI, V91, P15, DOI 10.1016/0022-510X(89)90073-7; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; BRACKEN MB, 1981, AM J EPIDEMIOL, V113, P615, DOI 10.1093/oxfordjournals.aje.a113140; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Ceccarelli B, 1976, Adv Exp Med Biol, V71, P275; COMMISSIONG JW, 1986, BRAIN RES, V380, P205, DOI 10.1016/0006-8993(86)90215-5; CUELLO AC, 1986, BRAIN RES, V376, P373, DOI 10.1016/0006-8993(86)90202-7; DIGREGORIO F, 1984, NEUROPEDIATRICS, V15, P93, DOI 10.1055/s-2008-1052388; DUCKER TB, 1978, SURG NEUROL, V10, P71; Faden A I, 1988, Adv Neurol, V47, P531; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P217; FADEN AI, 1987, CLIN NEUROPHARMACOL, V10, P193, DOI 10.1097/00002826-198706000-00001; FEHLINGS MG, 1989, J NEUROTRAUMA, V66, P49; FLAMM ES, 1985, J NEUROSURG, V63, P390, DOI 10.3171/jns.1985.63.3.0390; Frankel H L, 1969, Paraplegia, V7, P179; Geisler F H, 1988, Md Med J, V37, P525; GEISLER FH, 1990, NEUROSURGERY, V26, P957; GEISLER FH, 1986, SHOCK TRAUMA CRITICA, P313; GEISLER WO, 1983, PARAPLEGIA, V21, P364, DOI 10.1038/sc.1983.60; Gorio A, 1984, Adv Exp Med Biol, V174, P549; Gorio A, 1984, Cent Nerv Syst Trauma, V1, P29; GORIO A, 1986, CRC CR REV CL NEUROB, V2, P241; Gorio A, 1988, Adv Neurol, V47, P523; GORIO A, 1986, FIDIA RES SERIES, V3, P227; Guttmann L, 1973, SPINAL CORD INJURIES; HADJICONSTANTINOU M, 1989, BRAIN RES, V484, P297, DOI 10.1016/0006-8993(89)90373-9; HADJICONSTANTINOU M, 1988, J NEUROCHEM, V51, P1190, DOI 10.1111/j.1471-4159.1988.tb03086.x; HADJICONSTANTINOU M, 1986, BRAIN RES, V366, P343, DOI 10.1016/0006-8993(86)91315-6; HEINEMANN AW, 1989, ARCH NEUROL-CHICAGO, V46, P1098, DOI 10.1001/archneur.1989.00520460084017; HOLTZ A, 1990, NEUROSURGERY, V26, P952, DOI 10.1227/00006123-199006000-00005; JANSSEN L, 1989, SPINE, V14, P23, DOI 10.1097/00007632-198901000-00005; JONSSON G, 1986, PROCESSES RECOVERY N, P291; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; LE CT, 1982, J CHRON DIS, V35, P487, DOI 10.1016/0021-9681(82)90063-7; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; LEDEEN RW, 1984, J NEUROSCI RES, V12, P147, DOI 10.1002/jnr.490120204; MARSHALL LF, 1987, J NEUROSURG, V66, P400, DOI 10.3171/jns.1987.66.3.0400; MERRIAM WF, 1986, J BONE JOINT SURG BR, V68, P708, DOI 10.1302/0301-620X.68B5.3782229; SABEL BA, 1988, EXP BRAIN RES, V71, P365; SABEL BA, 1988, BRAIN RES, V459, P373, DOI 10.1016/0006-8993(88)90655-5; SABEL BA, 1984, J NEUROSCI RES, V12, P429, DOI 10.1002/jnr.490120227; SABEL BA, 1986, NATURE, V323, P493, DOI 10.1038/323493a0; SABEL BA, 1987, NEUROSCI LETT, V77, P360, DOI 10.1016/0304-3940(87)90528-3; SABEL BA, 1984, SCIENCE, V225, P340, DOI 10.1126/science.6740316; SABEL BA, 1988, PHARM APPROACHES TRE, P167; SABEL BA, 1985, ADV BEHAV BIOL, V28, P481; SAUL TG, 1982, PATHOPHYSIOLOGY SHOC, P624; SIEGEL JH, 1987, TRAUMA EMERGENCY SUR, P1; SIMPSON RK, 1989, J TRAUMA, V29, P42; SOFRONIEW MV, 1986, BRAIN RES, V398, P393, DOI 10.1016/0006-8993(86)91503-9; STOVER SL, 1986, SPINAL CORD INJURY F; THOMAS JP, 1982, SPINAL CORD INJURY S, P1; TOFFANO G, 1984, BRAIN RES, V296, P233, DOI 10.1016/0006-8993(84)90061-1; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; TOMINAGA S, 1989, PARAPLEGIA, V29, P227; URBANICS R, 1989, STROKE, V20, P795, DOI 10.1161/01.STR.20.6.795; WAGNER FC, 1982, J NEUROSURG, V56, P699, DOI 10.3171/jns.1982.56.5.0699; WOJCIK M, 1982, NEUROSCIENCE, V7, P495, DOI 10.1016/0306-4522(82)90282-2; YOUNG HF, 1982, PATHOPHYSIOLOGY SHOC, P613; YOUNG JS, 1978, PARAPLEGIA, V16, P39, DOI 10.1038/sc.1978.6; Young W, 1986, Cent Nerv Syst Trauma, V3, P235; YOUNG W, 1990, PREVENTING INTRAOPER; YOUNG W, 1989, NEURAL REGENERATION, V6, P157; YOUNG W, 1987, CRITICAL CARE STATE, V8, P71; 1991, NEUROSURGERY, V28, P628; 1984, STANDARDS NEUROLOGIC	73	401	428	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1829	1838		10.1056/NEJM199106273242601	http://dx.doi.org/10.1056/NEJM199106273242601			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	2041549				2022-12-28	WOS:A1991FT58000001
J	EISENBERG, JM				EISENBERG, JM			ECONOMICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE PAYMENT SYSTEM; FINANCIAL INCENTIVES; PHYSICIANS; CARE; IMPLEMENTATION				EISENBERG, JM (corresponding author), UNIV PENN,PHILADELPHIA,PA 19104, USA.							CHRISTENSEN S, 1990, NOV WORKSH BEH RESP; ESCARCE JJ, 1990, NOV WORKSH BEH RESP; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; GARRISON LP, 1990, NOV AMA CTR HLTH POL; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; HOLAHAN J, 1990, JAMA-J AM MED ASSOC, V263, P1658, DOI 10.1001/jama.263.12.1658; Hurley J, 1990, Adv Health Econ Health Serv Res, V11, P49; Kay T L, 1990, Health Care Financ Rev, V11, P133; MITCHELL JB, 1989, HEALTH AFFAIR, V8, P21, DOI 10.1377/hlthaff.8.1.21; PALMER RM, 1989, ARCH INTERN MED, V149, P2237, DOI 10.1001/archinte.149.10.2237; REYNOLDS RA, 1990, NOV WORKSH BEH RESP; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; WEDIG G, 1989, J HEALTH POLIT POLIC, V14, P601, DOI 10.1215/03616878-14-3-601	15	4	4	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3113	3115						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ770	2041117				2022-12-28	WOS:A1991FQ77000014
J	DUNHAM, NC; KINDIG, DA; LASTIRIQUIROS, S; BARHAM, MT; RAMSAY, P				DUNHAM, NC; KINDIG, DA; LASTIRIQUIROS, S; BARHAM, MT; RAMSAY, P			UNCOMPENSATED AND DISCOUNTED MEDICAID CARE PROVIDED BY PHYSICIAN GROUP PRACTICES IN WISCONSIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								A survey of a sample of physician group practices in Wisconsin was undertaken to determine the amounts of charity care, bad debt, and discounted Medicaid care that were provided in 1988. Overall, the physician group practices in the sample reported dollar amounts of uncompensated care and discounted Medicaid care that averaged approximately 7.6% of their total billings for the year (1.6% of charity care, 3.0% of bad debt, and 3.0% of discounted Medicaid care). From the dollar totals reported, it was calculated that the individual physicians represented by this sample of group practices were responsible for, on average, $4300 of charity care, $9100 of bad debt, and $7500 of Medicaid discounted services, for a yearly per-physician total of $20 900 of uncompensated care and discounted care provided to uninsured and indigent patients. The results indicate that a majority of the group practices provided more charity care in 1988 than they had 5 years earlier and suggest that the burden of providing uncompensated care tends to fall disproportionately on those group practices that are also providing relatively high levels of service to Medicaid recipients.	UNIV WISCONSIN,PROGRAMS HLTH MANAGEMENT,MADISON,WI 53706; STATE MED SOC WISCONSIN,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison	DUNHAM, NC (corresponding author), ST MARYS HOSP,MED CTR,707 S MILLS ST,MADISON,WI 53715, USA.							CARRANZA S, 1989, WIS MED J, V4, P23; FARLEY PJ, 1985, MILBANK FUND Q, V63, P476, DOI 10.2307/3349844; LEWIN ME, 1984, BUSINESS HLTH    SEP, P9; MULSTEIN S, 1984, INQUIRY-J HEALTH CAR, V21, P214; 1988, PHYSICIAN CHARACTERI	5	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2982	2986		10.1001/jama.265.22.2982	http://dx.doi.org/10.1001/jama.265.22.2982			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP635	2033770				2022-12-28	WOS:A1991FP63500036
J	SUSSMAN, GL; TARLO, S; DOLOVICH, J				SUSSMAN, GL; TARLO, S; DOLOVICH, J			THE SPECTRUM OF IGE-MEDIATED RESPONSES TO LATEX	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTACT URTICARIA; RUBBER GLOVES; SURGICAL GLOVES; NATURAL LATEX; ANAPHYLAXIS; ALLERGY; ASTHMA; SHOCK	A spectrum of IgE-mediated allergic responses to latex is presented in this report of 14 patients, including health care workers, sensitized by exposure to latex gloves. Symptoms often occurred immediately after exposure to latex, and manifestations varied according to the route of latex antigen presentation. Skin exposure usually caused contact urticaria. Exposure to latex in the air elicited allergic rhinitis, conjuctivitis, and asthma. Systemic effects from latex occurred intraoperatively due to the surgeon's latex gloves. Anaphylactic shock included the above symptoms with the addition of tachycardia and hypotension. All patients had positive latex skin tests. Serum IgE antibody to latex was found with a latex radioallergosorbent test in all but one tested patient. Physicians should be aware that latex allergy can present as anaphylaxis during surgery, barium enema, or dental work. Latex skin tests are a satisfactory method of diagnosis. Nonlatex gloves are available and are tolerated by affected people.	UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA	University of Toronto; McMaster University				Tarlo, Susan/0000-0002-4746-5310				AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BYARS NE, 1976, CLIN EXP IMMUNOL, V24, P352; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; Cronin E., 1980, RUBBER CONTACT DERMA, P714; ESTLANDER T, 1986, CONTACT DERMATITIS, V14, P20, DOI 10.1111/j.1600-0536.1986.tb01147.x; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P33, DOI 10.1111/j.1600-0536.1980.tb03887.x; FROSCH PJ, 1986, CONTACT DERMATITIS, V14, P241, DOI 10.1111/j.1600-0536.1986.tb01233.x; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; JANCELOWICZ Z, 1989, J ALLERGY CLIN IMMUN, V83, P267; KLEINHANS D, 1984, CONTACT DERMATITIS, V10, P124, DOI 10.1111/j.1600-0536.1984.tb00363.x; Kopman A, 1983, Duodecim, V99, P221; LEYNADIER F, 1988, PRESSE MED, V17, P390; MEDING B, 1984, CONTACT DERMATITIS, V10, P52, DOI 10.1111/j.1600-0536.1984.tb00071.x; MONERETVAUTRIN DA, 1990, ANESTHESIOLOGY, V73, P556, DOI 10.1097/00000542-199009000-00032; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MOSCICKI RA, 1990, J ALLERGY CLIN IMMUN, V86, P325, DOI 10.1016/S0091-6749(05)80095-8; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSSMAN GL, 1989, SEMIN DERMATOL, V8, P158; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TAYLOR JS, 1986, CONTACT DERMATITIS, P603; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; WRANGSJO K, 1986, CONTACT DERMATITIS, V15, P79, DOI 10.1111/j.1600-0536.1986.tb01281.x; 1983, N ENGL REG ALLERGY P, V4, P224; 1983, BLUE BOOK 1983 MATER, P576	29	223	229	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2844	2847		10.1001/jama.265.21.2844	http://dx.doi.org/10.1001/jama.265.21.2844			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033741				2022-12-28	WOS:A1991FN85500034
J	BLACK, PM				BLACK, PM			BRAIN-TUMORS .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CENTRAL NERVOUS-SYSTEM; PRIMITIVE NEUROECTODERMAL TUMORS; THERAPY-ONCOLOGY-GROUP; RADIATION-THERAPY; PITUITARY-ADENOMAS; ACOUSTIC NEUROMAS; MALIGNANT GLIOMAS; POSTOPERATIVE RADIOTHERAPY; MENINGEAL CARCINOMATOSIS; PETROCLIVAL MENINGIOMAS		BRIGHAM & WOMENS HOSP,BRAIN TUMOR GRP,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	BLACK, PM (corresponding author), BRIGHAM & WOMENS HOSP,NEUROSURG SERV,75 FRANCIS ST,BOSTON,MA 02115, USA.							ALMEFTY O, 1988, NEUROSURGERY, V22, P510, DOI 10.1227/00006123-198803000-00010; AMMIRATI M, 1987, NEUROSURGERY, V21, P201, DOI 10.1227/00006123-198708000-00012; AMMIRATI M, 1987, NEUROSURGERY, V21, P607, DOI 10.1227/00006123-198711000-00001; Bailey P, 1926, CLASSIFICATION TUMOR; BARBA D, 1989, J NEUROSURG, V70, P175, DOI 10.3171/jns.1989.70.2.0175; BARBARO NM, 1987, NEUROSURGERY, V20, P525, DOI 10.1227/00006123-198704000-00003; BARKAN AL, 1988, J CLIN ENDOCR METAB, V67, P1040, DOI 10.1210/jcem-67-5-1040; BASKIN DS, 1986, J NEUROSURG, V65, P22, DOI 10.3171/jns.1986.65.1.0022; BERGER MS, 1985, J NEUROSURG, V62, P214, DOI 10.3171/jns.1985.62.2.0214; BLACK PM, 1987, J NEUROSURG, V66, P244, DOI 10.3171/jns.1987.66.2.0244; BLACK PM, 1987, NEUROSURGERY, V20, P920, DOI 10.1227/00006123-198706000-00017; BOGGAN JE, 1983, J NEUROSURG, V59, P159; BRUNER JM, 1987, SEMIN DIAGN PATHOL, V4, P251; BULLARD DE, 1985, J NEUROSURG, V63, P2, DOI 10.3171/jns.1985.63.1.0002; BULLARD DE, 1987, CANCER-AM CANCER SOC, V60, P2179, DOI 10.1002/1097-0142(19871101)60:9<2179::AID-CNCR2820600912>3.0.CO;2-G; BULLARD DE, 1986, SEMIN ONCOL, V13, P94; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CAIRNCROSS JG, 1988, ANN NEUROL, V23, P360, DOI 10.1002/ana.410230408; CARMEL PW, 1985, ACTA NEUROCHIR, V75, P136, DOI 10.1007/BF01406334; CASTILLO M, 1990, AM J ROENTGENOL, V154, P607, DOI 10.2214/ajr.154.3.2106228; CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2; CHOUCAIR AK, 1986, J NEUROSURG, V65, P654, DOI 10.3171/jns.1986.65.5.0654; CHUN M, 1988, INT J RADIAT ONCOL, V15, P305, DOI 10.1016/S0360-3016(98)90009-8; COFFEY RJ, 1985, NEUROSURGERY, V17, P12, DOI 10.1227/00006123-198507000-00003; Collins VP, 1990, BRAIN PATHOL, V1, P19, DOI 10.1111/j.1750-3639.1990.tb00634.x; Cushing H, 1932, INTRACRANIAL TUMORS; DEANGELIS LM, 1990, NEUROLOGY, V40, P80, DOI 10.1212/WNL.40.1.80; DELAMONTE SM, 1986, AM J SURG PATHOL, V10, P836, DOI 10.1097/00000478-198612000-00002; DELATTRE JY, 1988, ARCH NEUROL-CHICAGO, V45, P741, DOI 10.1001/archneur.1988.00520310047016; EDWARDS MSB, 1989, J NEUROSURG, V70, P691, DOI 10.3171/jns.1989.70.5.0691; EPSTEIN F, 1986, J NEUROSURG, V64, P11, DOI 10.3171/jns.1986.64.1.0011; FAHLBUSCH R, 1985, ACTA NEUROCHIR, V75, P125, DOI 10.1007/BF01406333; FARIA MA, 1982, J NEUROSURG, V56, P33, DOI 10.3171/jns.1982.56.1.0033; FINLAY F, 1989, J NEUROONCOL S, V7, pS11; FISCHER EG, 1985, J NEUROSURG, V62, P496, DOI 10.3171/jns.1985.62.4.0496; FORBES AR, 1984, J CLIN ONCOL, V2, P1139, DOI 10.1200/JCO.1984.2.10.1139; GAFFNEY CC, 1985, J NEURO-ONCOL, V3, P23; GREEN SB, 1984, P AN M AM SOC CLIN, V3, P260; GROSSMAN A, 1985, CLIN ENDOCRINOL, V22, P679, DOI 10.1111/j.1365-2265.1985.tb03004.x; HALL WA, 1987, J NEUROSURG, V66, P186, DOI 10.3171/jns.1987.66.2.0186; HARDY J, 1982, CAN J NEUROL SCI, V9, P375, DOI 10.1017/S0317167100044279; HARSH GR, 1987, NEUROSURGERY, V21, P615, DOI 10.1227/00006123-198711000-00002; HART MN, 1973, CANCER, V32, P890, DOI 10.1002/1097-0142(197310)32:4<890::AID-CNCR2820320421>3.0.CO;2-O; HEALY EA, IN PRESS NEUROSURGER; HEROS DO, 1988, NEUROSURGERY, V22, P474, DOI 10.1227/00006123-198803000-00004; HOCHBERG FH, 1981, J NEUROSURG, V54, P455, DOI 10.3171/jns.1981.54.4.0455; HOCHBERG FH, 1988, J NEUROSURG, V68, P835, DOI 10.3171/jns.1988.68.6.0835; HOFFMAN HJ, 1985, CAN J NEUROL SCI, V12, P348, DOI 10.1017/S0317167100035514; HOFFMAN HJ, 1980, NEUROSURGERY, V7, P243, DOI 10.1227/00006123-198009000-00007; HOSHINO T, 1986, CANCER, V58, P1466, DOI 10.1002/1097-0142(19861001)58:7<1466::AID-CNCR2820580715>3.0.CO;2-W; HUBBARD JL, 1987, J NEUROSURG, V67, P816, DOI 10.3171/jns.1987.67.6.0816; HUGHES EN, 1988, CANCER, V61, P1992, DOI 10.1002/1097-0142(19880515)61:10<1992::AID-CNCR2820611011>3.0.CO;2-J; HUMPHREY PA, 1988, CANCER RES, V48, P2231; JAASKELAINEN J, 1986, SURG NEUROL, V26, P461, DOI 10.1016/0090-3019(86)90259-4; JACOBS SK, 1986, CANCER RES, V46, P2101; KALYANRAMAN UP, 1987, NEUROSURGERY, V20, P428, DOI 10.1227/00006123-198703000-00012; KEPES J, 1982, MENINGIOMAS BIOL PAT; KERNOHAN JW, 1949, P STAFF M MAYO CLIN, V24, P71; KLIBANSKI A, 1991, NEW ENGL J MED, V324, P822; KOVAKS K, 1984, PROGR ENDOCRINE RES, V1, P365; LASHFORD LS, 1988, CANCER, V61, P857, DOI 10.1002/1097-0142(19880301)61:5<857::AID-CNCR2820610502>3.0.CO;2-S; LAWS ER, 1984, J NEUROSURG, V61, P665, DOI 10.3171/jns.1984.61.4.0665; LAWS ER, 1987, ENDOCRIN METAB CLIN, V16, P647, DOI 10.1016/S0889-8529(18)30467-5; LESCH KP, 1987, J NEUROL, V234, P328, DOI 10.1007/BF00314289; LEVIN VA, 1988, J NEUROSURG, V68, P383, DOI 10.3171/jns.1988.68.3.0383; LEVIN VA, 1985, J NEUROSURG, V63, P218, DOI 10.3171/jns.1985.63.2.0218; LINSKEY ME, 1990, NEUROSURGERY, V226, P336; Loeffler J S, 1990, Oncology (Williston Park), V4, P21; LOEFFLER JS, 1990, J CLIN ONCOL, V8, P576, DOI 10.1200/JCO.1990.8.4.576; LOEFFLER JS, 1987, TXB UNCOMMON CANCER, P693; MAHALEY MS, 1985, J NEUROSURG, V63, P719, DOI 10.3171/jns.1985.63.5.0719; MANAKA S, 1985, J NEUROSURG, V62, P648, DOI 10.3171/jns.1985.62.5.0648; MAXWELL RE, 1988, OPERATIVE NEUROSURGI, V1, P547; MCCULLOUGH DC, 1985, CANCER, V56, P1789, DOI 10.1002/1097-0142(19851001)56:7+<1789::AID-CNCR2820561312>3.0.CO;2-Y; MERCHANT RE, 1989, J NEUROONCOL S, V7, pS19; MIESCHER S, 1988, J NEUROSURG, V68, P438, DOI 10.3171/jns.1988.68.3.0438; MIRIMANOFF RO, 1985, J NEUROSURG, V62, P18, DOI 10.3171/jns.1985.62.1.0018; MOLLER AR, 1984, J NEUROSURG, V61, P757, DOI 10.3171/jns.1984.61.4.0757; MULVIHILL JJ, 1990, ANN INTERN MED, V113, P39, DOI 10.7326/0003-4819-113-1-39; NADOL JB, 1987, LARYNGOSCOPE, V97, P1287, DOI 10.1288/00005537-198711000-00007; NELSON DF, 1983, INT J RADIAT ONCOL, V9, P1143, DOI 10.1016/0360-3016(83)90172-4; NEUMANN HPH, 1989, J NEUROSURG, V70, P24, DOI 10.3171/jns.1989.70.1.0024; Ojemann R G, 1989, Clin Neurosurg, V35, P254; OJEMANN RG, 1985, NEUROSURGERY, V1, P635; Oldfield E H, 1985, N Engl J Med, V312, P100, DOI 10.1056/NEJM198501103120207; ONEILL BP, 1989, MAYO CLIN PROC, V64, P1005, DOI 10.1016/S0025-6196(12)61228-2; PALMA L, 1985, J NEUROSURG, V61, P811; PANAGOPOULOS KP, 1990, ARCH NEUROL-CHICAGO, V47, P813, DOI 10.1001/archneur.1990.00530070111020; PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802; PIERCE SM, 1990, CANCER, V65, P45, DOI 10.1002/1097-0142(19900101)65:1<45::AID-CNCR2820650111>3.0.CO;2-Z; QUEST DO, 1978, NEUROSURGERY, V3, P219, DOI 10.1227/00006123-197809000-00016; ROSENBLUM ML, 1988, ANN NEUROL, V23, pS13, DOI 10.1002/ana.410230707; RUBINSTEIN AB, 1989, SURG GYNECOL OBSTET, V169, P334; SAMII M, 1989, NEUROSURGERY, V24, P12, DOI 10.1227/00006123-198901000-00003; SCHRAMM J, 1988, NEUROSURGERY, V22, P694, DOI 10.1227/00006123-198804000-00013; SCHRELL UMH, 1991, HORMONAL MANIPULATIO, P273; SERRI O, 1983, NEW ENGL J MED, V309, P280, DOI 10.1056/NEJM198308043090505; SUNDARESAN N, 1985, CANCER, V55, P1382, DOI 10.1002/1097-0142(19850315)55:6<1382::AID-CNCR2820550637>3.0.CO;2-Z; SUTTON LN, 1987, PEDIATR NEUROSCI, V13, P98, DOI 10.1159/000120311; SZE G, 1989, AM J NEURORADIOL, V10, P965; TAKAKURA K, 1986, J NEUROSURG, V64, P53, DOI 10.3171/jns.1986.64.1.0053; TANAKA R, 1989, J NEUROONCOL S, V7, pS27; TATOR CH, 1985, J NEUROSURG, V63, P168, DOI 10.3171/jns.1985.63.2.0168; TAYLOR BW, 1988, INT J RADIAT ONCOL, V15, P299, DOI 10.1016/S0360-3016(98)90008-6; THOMAS DGT, 1985, BRIT J CANCER, V51, P525, DOI 10.1038/bjc.1985.75; TOMITA T, 1986, J NEUROSURG, V64, P238, DOI 10.3171/jns.1986.64.2.0238; TROJANOWSKI T, 1988, J NEURO-ONCOL, V6, P285, DOI 10.1007/BF00163714; WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALLNER KE, 1986, INT J RADIAT ONCOL, V12, P1937, DOI 10.1016/0360-3016(86)90128-8; WASSERMAN TH, 1981, CANCER, V47, P2382, DOI 10.1002/1097-0142(19810515)47:10<2382::AID-CNCR2820471010>3.0.CO;2-F; WASSERSTROM WR, 1982, CANCER, V49, P759, DOI 10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7; Weir B, 1976, Can J Neurol Sci, V3, P47; WEIR B, 1973, J NEUROSURG, V38, P448, DOI 10.3171/jns.1973.38.4.0448; Weiss M H, 1986, Clin Neurosurg, V33, P547; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; YAP HY, 1982, CANCER, V50, P219; YUNG WKA, 1989, J NEUROONCOL S, V7, pS32	118	176	179	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1991	324	22					1555	1564		10.1056/NEJM199105303242205	http://dx.doi.org/10.1056/NEJM199105303242205			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN051	2027359				2022-12-28	WOS:A1991FN05100005
J	HELLMAN, S; HELLMAN, DS				HELLMAN, S; HELLMAN, DS			OF MICE BUT NOT MEN - PROBLEMS OF THE RANDOMIZED CLINICAL-TRIAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AIDS TRIALS; EQUIPOISE; ETHICS		HARVARD UNIV,CAMBRIDGE,MA 02138	Harvard University	HELLMAN, S (corresponding author), UNIV CHICAGO,CHICAGO,IL 60637, USA.			Hellman, Deborah/0000-0003-2447-8351				ANGELL M, 1984, NEW ENGL J MED, V310, P1385, DOI 10.1056/NEJM198405243102111; BYAR DP, 1990, NEW ENGL J MED, V323, P1343, DOI 10.1056/NEJM199011083231912; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Hellman S., 1979, CANCER CLIN TRIALS, V2, P189; KASS LR, 1985, MORE NATURAL SCI BIO, P196; Longcope WT, 1932, B JOHNS HOPKINS HOSP, V50, P4; MERIGAN TC, 1990, NEW ENGL J MED, V323, P1341, DOI 10.1056/NEJM199011083231911; PALCA J, 1989, SCIENCE, V246, P19, DOI 10.1126/science.2506644; POPPER K, 1985, POPPER SELECTIONS, P101; RAWLS J, 1971, THEORY JUSTICE, P183; Royall Richard M, 1991, Stat Sci, V6, P52, DOI 10.1214/ss/1177011934; SINGER PA, 1988, CLIN RES, V36, P539; 1949, WORLD MED ASS B, V1, P109; 1984, 4TH P NAT C HUM VAL, P144	14	246	247	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1991	324	22					1585	1589		10.1056/NEJM199105303242208	http://dx.doi.org/10.1056/NEJM199105303242208			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN051	2027362				2022-12-28	WOS:A1991FN05100008
J	BARTON, NW; BRADY, RO; DAMBROSIA, JM; DIBISCEGLIE, AM; DOPPELT, SH; HILL, SC; MANKIN, HJ; MURRAY, GJ; PARKER, RI; ARGOFF, CE; GREWAL, RP; YU, KT				BARTON, NW; BRADY, RO; DAMBROSIA, JM; DIBISCEGLIE, AM; DOPPELT, SH; HILL, SC; MANKIN, HJ; MURRAY, GJ; PARKER, RI; ARGOFF, CE; GREWAL, RP; YU, KT			REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELLS; GENE	Background and Methods. Gaucher's disease, the most prevalent of the sphingolipid storage disorders, is caused by a deficiency of the enzyme glucocerebrosidase (glucosylceramidase). Enzyme replacement was proposed as a therapeutic strategy for this disorder in 1966. To assess the clinical effectiveness of this approach, we infused macrophage-targeted human placental glucocerebrosidase (60 IU per kilogram of body weight every 2 weeks for 9 to 12 months) into 12 patients with type 1 Gaucher's disease who had intact spleens. The frequency of infusions was increased to once a week in two patients (children) during part of the trial because they had clinically aggressive disease. Results. The hemoglobin concentration increased in all 12 patients, and the platelet count in 7. Serum acid phosphatase activity decreased in 10 patients during the trial, and the plasma glucocerebroside level in 9. Splenic volume decreased in all patients after six months of treatment, and hepatic volume in five. Early signs of skeletal improvements were seen in three patients. The enzyme infusions were well tolerated, and no antibody to the exogenous enzyme developed. Conclusions. Intravenous administration of macrophage-targeted glucocerebrosidase produces objective clinical improvement in patients with type 1 Gaucher's disease. The hematologic and visceral responses to enzyme replacement develop more rapidly than the skeletal response.	NINCDS,BIOMETRY & FIELD STUDIES BRANCH,BETHESDA,MD 20892; NIDDKD,LIVER DIS SECT,BETHESDA,MD; NIH,CTR CLIN,DEPT DIAGNOST RADIOL,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT CLIN PATHOL,BETHESDA,MD 20892; MASSACHUSETTS GEN HOSP,DEPT ORTHOPED SURG,BOSTON,MA 02114	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Harvard University; Massachusetts General Hospital	BARTON, NW (corresponding author), NINCDS,DEV & METAB NEUROL BRANCH,BLDG 10,RM 3D04,BETHESDA,MD 20892, USA.			Kaneski, Christine/0000-0003-1453-2502				BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; BEUTLER E, 1988, BLOOD REV, V2, P59, DOI 10.1016/0268-960X(88)90009-4; Brady R. O., 1983, METABOLIC BASIS INHE, P842; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; BRADY RO, 1974, NEW ENGL J MED, V291, P989, DOI 10.1056/NEJM197411072911901; BRADY RO, 1966, J CLIN INVEST, V45, P1112, DOI 10.1172/JCI105417; BRADY RO, 1966, NEW ENGL J MED, V275, P312, DOI 10.1056/NEJM196608112750606; BRADY RO, 1984, MOL BASIS LYSOSOMAL, P461; Brady RO, 1982, MEMBRANES TRANSPORT, V2, P587; DOEBBER TW, 1982, J BIOL CHEM, V257, P2193; DRAPER NR, 1981, APPLIED REGRESSION A, P8; EYAL N, 1990, GENE, V96, P277, DOI 10.1016/0378-1119(90)90264-R; FIRON N, 1990, AM J HUM GENET, V46, P527; FURBISH FS, 1978, BIOCHEM BIOPH RES CO, V81, P1047, DOI 10.1016/0006-291X(78)91456-0; FURBISH FS, 1981, BIOCHIM BIOPHYS ACTA, V673, P425, DOI 10.1016/0304-4165(81)90474-8; FURBISH FS, 1977, P NATL ACAD SCI USA, V74, P3560, DOI 10.1073/pnas.74.8.3560; FURBISH FS, 1984, MOL BASIS LYSOSOMAL, P219; Kolodny EH, 1982, GAUCHER DISEASE CENT, P33; LEHMANN EL, 1975, NONPARAMETRICS STATI, P156; Ludwig J, 1979, CURRENT METHODS AUTO, P676; MURRAY GJ, 1987, METHOD ENZYMOL, V149, P25; MURRAY GJ, 1991, IMMUNOL METHODS, V137, P113; Pentchev P G, 1978, Adv Exp Med Biol, V101, P745; PETERS SP, 1977, MEDICINE, V56, P425, DOI 10.1097/00005792-197709000-00004; Seber GAF, 1989, NONLINEAR REGRESSION, DOI [10.1002/0471725315, DOI 10.1002/0471725315]; STAHL PD, 1978, P NATL ACAD SCI USA, V75, P1399, DOI 10.1073/pnas.75.3.1399; THEOPHILUS B, 1989, AM J HUM GENET, V45, P212; TOKORO T, 1987, J LIPID RES, V28, P968; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; ULLMAN MD, 1977, J LIPID RES, V18, P371	30	1019	1089	0	56	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1464	1470		10.1056/NEJM199105233242104	http://dx.doi.org/10.1056/NEJM199105233242104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM460	2023606				2022-12-28	WOS:A1991FM46000004
J	FISCHER, A; BLANCHE, S; LEBIDOIS, J; BORDIGONI, P; GARNIER, JL; NIAUDET, P; MORINET, F; LEDEIST, F; FISCHER, AM; GRISCELLI, C; HIRN, M				FISCHER, A; BLANCHE, S; LEBIDOIS, J; BORDIGONI, P; GARNIER, JL; NIAUDET, P; MORINET, F; LEDEIST, F; FISCHER, AM; GRISCELLI, C; HIRN, M			ANTI-B-CELL MONOCLONAL-ANTIBODIES IN THE TREATMENT OF SEVERE B-CELL LYMPHOPROLIFERATIVE SYNDROME FOLLOWING BONE-MARROW AND ORGAN-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; INFECTION; DISORDERS; CHILDREN; RECIPIENTS; LYMPHOMAS; ACYCLOVIR; DISEASE; LESIONS; THERAPY	Background. The B-cell lymphoproliferative syndrome is an infrequent life-threatening complication of marrow or organ transplantation that is the consequence of profound immunosuppression. The results of treatment have been disappointing, although a small number of patients have been cured by chemoradiotherapy or antiviral agents after a reduction in the dosage of immunosuppressive therapy. We report here the results of treating this disorder with anti-B-cell antibodies. Methods. Twenty-six patients in whom aggressive B-cell lymphoproliferative syndrome developed after bone marrow (n = 14) or organ (n = 12) transplantation received 0.2 mg of CD21-specific and of CD24-specific antibodies per kilogram of body weight for 10 consecutive days in an open, prospective, multicenter trial. Results. The treatment was well tolerated. All patients had transient neutropenia, apparently because the CD24 molecule is also expressed on granulocytes. The treatment was ineffective in seven patients with monoclonal B-cell proliferation. In contrast, 16 patients with oligoclonal B-cell proliferation had complete remission. Systemic remission also occurred in two other patients with oligoclonal proliferation who had central nervous system involvement, although they subsequently died because of progression of the central nervous system disease. In one patient who died early, clonality was not determined. Of the 16 patients who had complete remission, 2 with persistent immunodeficiency due to graft (marrow) rejection or acute graft-versus-host disease had a relapse, and the 1 with graft-versus-host disease subsequently died. Eleven patients were alive and disease-free after a median follow-up of 35 months (5 of 14 marrow recipients and 6 of 12 organ recipients). Four other patients in complete remission died of unrelated causes 4 to 12 months after treatment. Conclusions. Intravenous administration of anti-B-cell antibodies may be effective in controlling diffuse, severe, oligoclonal B-cell proliferation not involving the central nervous system.	HOP NECKER ENFANTS MALAD,UNITE CARDIOL,F-75743 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,UNITE NEPHROL,F-75743 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,DEPT HEMATOL,F-75743 PARIS 15,FRANCE; CHR NANCY,DEPT PEDIAT,F-54037 NANCY,FRANCE; HOP EDOUARD HERRIOT,UNITE NEPHROL,F-69374 LYONS 08,FRANCE; HOP ST LOUIS,MICROBIOL LAB,F-75010 PARIS,FRANCE; IMMUNOTECH SA,MARSEILLE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Nancy; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	FISCHER, A (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,U132,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.							ASH RC, 1990, NEW ENGL J MED, V322, P485, DOI 10.1056/NEJM199002223220801; BLANCHE S, 1988, ANN INTERN MED, V108, P199, DOI 10.7326/0003-4819-108-2-199; BOUCHEIX C, 1985, LEUKEMIA RES, V9, P597, DOI 10.1016/0145-2126(85)90139-0; BROCHIER J, 1983, J IMMUNOL METHODS, V58, pM4; CRAWFORD DH, 1986, TRANSPLANTATION, V42, P50, DOI 10.1097/00007890-198607000-00010; DEEG HJ, 1984, BRIT J HAEMATOL, V57, P185, DOI 10.1111/j.1365-2141.1984.tb08521.x; FERMAND JP, 1990, ANN INTERN MED, V112, P511, DOI 10.7326/0003-4819-112-7-511; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FISCHER A, 1986, LANCET, V2, P1080; FISCHER AM, 1990, TRANSPLANTATION, V49, P731, DOI 10.1097/00007890-199004000-00015; FRIZZERA G, 1981, CANCER RES, V41, P4262; HANTO DW, 1989, TRANSPLANTATION, V47, P458, DOI 10.1097/00007890-198903000-00012; HANTO DW, 1985, TRANSPLANT P, V17, P89; HANTO DW, 1985, TRANSPLANTATION, V39, P461, DOI 10.1097/00007890-198505000-00001; HO M, 1988, TRANSPLANTATION, V45, P719, DOI 10.1097/00007890-198804000-00011; JARRY A, 1988, GUT, V29, P1632, DOI 10.1136/gut.29.12.1632; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; PEREZ N, 1989, BONE MARROW TRANSPL, V4, P379; PIRSCH JD, 1989, AM J MED, V86, P241, DOI 10.1016/0002-9343(89)90279-9; SCHUBACH WH, 1985, BLOOD, V65, P535; SHAPIRO RS, 1988, NEW ENGL J MED, V318, P1334; STARZL TE, 1984, LANCET, V1, P583; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; ZUTTER MM, 1988, BLOOD, V72, P520	26	291	295	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1451	1456		10.1056/NEJM199105233242102	http://dx.doi.org/10.1056/NEJM199105233242102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM460	2023604				2022-12-28	WOS:A1991FM46000002
J	MEISTER, M; WONG, ROL; BAYLOR, DA; SHATZ, CJ				MEISTER, M; WONG, ROL; BAYLOR, DA; SHATZ, CJ			SYNCHRONOUS BURSTS OF ACTION-POTENTIALS IN GANGLION-CELLS OF THE DEVELOPING MAMMALIAN RETINA	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; OCULAR DOMINANCE COLUMNS; CATS RETINOGENICULATE PATHWAY; RECEPTIVE-FIELD CHARACTERISTICS; PRENATAL DEVELOPMENT; FUNCTIONAL CONNECTIONS; VISUAL-CORTEX; RABBIT; TETRODOTOXIN; SEGREGATION	The development of orderly connections in the mammalian visual system depends on action potentials in the optic nerve fibers, even before the retina receives visual input. In particular, it has been suggested that correlated firing of retinal ganglion cells in the same eye directs the segregation of their synaptic terminals into eye-specific layers within the lateral geniculate nucleus. Such correlations in electrical activity were found by simultaneous recording of the extracellular action potentials of up to 100 ganglion cells in the isolated retina of the newborn ferret and the fetal cat. These neurons fired spikes in nearly synchronous bursts lasting a few seconds and separated by 1 to 2 minutes of silence. Individual bursts consisted of a wave of excitation, several hundred micrometers wide, sweeping across the retina at about 100 micrometers per second. These concerted firing patterns have the appropriate spatial and temporal properties to guide the refinement of connections between the retina and the lateral geniculate nucleus.			MEISTER, M (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT NEUROBIOL, STANFORD, CA 94305 USA.			Meister, Markus/0000-0003-2136-6506	NATIONAL EYE INSTITUTE [R01EY005750] Funding Source: NIH RePORTER; NEI NIH HHS [EY 05750] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], [No title captured]; CUCCHIARO J, 1984, PROC R SOC SER B-BIO, V223, P141, DOI 10.1098/rspb.1984.0087; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GREINER JV, 1981, EXP EYE RES, V33, P315, DOI 10.1016/S0014-4835(81)80055-3; GUILLERY RW, 1972, J COMP NEUROL, V144, P117, DOI 10.1002/cne.901440106; HARRIS WA, 1981, ANNU REV PHYSIOL, V43, P689, DOI 10.1146/annurev.ph.43.030181.003353; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; JEFFERY G, 1989, DEV BRAIN RES, V46, P187, DOI 10.1016/0165-3806(89)90282-4; KALIL RE, 1986, NATURE, V323, P156, DOI 10.1038/323156a0; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LEVICK WR, 1973, HDB SENSORY PHYSL, V7, P575; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MASLAND RH, 1977, J COMP NEUROL, V175, P275, DOI 10.1002/cne.901750303; MASLIM J, 1986, BRAIN RES, V373, P35, DOI 10.1016/0006-8993(86)90313-6; Miller K.D., 1990, CONNECTIONIST MODELI, P255; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; PAYNE B, 1988, CEREB CORTEX, V7, P309; Pine J., 1982, SOC NEUR ABST, V8, P670; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; RAPISARDI SC, 1975, EXP BRAIN RES, V22, P295; REGEHR WG, 1989, J NEUROSCI METH, V30, P91, DOI 10.1016/0165-0270(89)90055-1; SCHWARTZ EA, 1982, J PHYSIOL-LONDON, V323, P211, DOI 10.1113/jphysiol.1982.sp014069; SCHWARTZ EA, 1986, J PHYSIOL-LONDON, V376, P411, DOI 10.1113/jphysiol.1986.sp016160; SHATZ CJ, 1984, J NEUROSCI, V4, P1378; SHATZ CJ, 1983, J NEUROSCI, V3, P482; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHATZ CJ, 1990, J NEUROBIOL, V21, P197, DOI 10.1002/neu.480210113; SPEAR PD, 1972, BRAIN RES, V45, P67, DOI 10.1016/0006-8993(72)90216-8; SRETAVAN DW, 1986, J NEUROSCI, V6, P234; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; STRYKER MP, 1986, BIOL CHANGE OTOLARYN, P211; WILLSHAW DJ, 1976, PROC R SOC SER B-BIO, V194, P431, DOI 10.1098/rspb.1976.0087; WINFREE AT, 1990, ANN NY ACAD SCI, V591, P190	38	844	857	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	1991	252	5008					939	943		10.1126/science.2035024	http://dx.doi.org/10.1126/science.2035024			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	2035024				2022-12-28	WOS:A1991FM04000028
J	CHARNAS, LR; BERNARDINI, I; RADER, D; HOEG, JM; GAHL, WA				CHARNAS, LR; BERNARDINI, I; RADER, D; HOEG, JM; GAHL, WA			CLINICAL AND LABORATORY FINDINGS IN THE OCULOCEREBRORENAL SYNDROME OF LOWE, WITH SPECIAL REFERENCE TO GROWTH AND RENAL-FUNCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM CREATININE CONCENTRATION; HIGH-DENSITY-LIPOPROTEIN; FANCONI SYNDROME; LENS EXAMINATION; CARNITINE; DISEASE; CYSTINOSIS; CHILDREN; PROGRESSION; DEFICIENCY	Background. The oculocerebrorenal syndrome of Lowe is an X-linked disorder whose clinical manifestations include congenital cataracts, mental retardation, and renal tubular dysfunction. We investigated growth, renal function, and serum chemistry values in patients with the oculocerebrorenal syndrome to determine the natural history of the disorder and its heterogeneity with respect to these characteristics. Methods. Twenty-three patients with the oculocerebrorenal syndrome, ranging in age from 4 months to 31 years, were examined. Height was compared with bone age. Renal function was assessed by measurements of proteinuria, urinary volume, and fractional excretions of potassium, phosphate, carnitine, and amino acids. Creatinine clearance was determined as a measure of glomerular function. Results. In the oculocerebrorenal syndrome, linear growth decreases after one year of age; bone age lies between chronologic age and height age. Renal dysfunction occurs in the first year of life, characterized by proteinuria (mean [+/- SD], 1.38 +/- 0.77 g of urinary protein per square meter of body-surface area per day; normal, less-than-or-equal-to 0.10), generalized aminoaciduria (mean, 686 +/- 505-mu-mol of urinary amino acid per kilogram of body weight per day; normal, 94 +/- 45), carnitine wasting (mean fractional excretion, 0.10 +/- 0.05; normal, 0.03 +/- 0.01), and phosphaturia progressing into the third decade. Urinary wasting of individual amino acids is milder than in cystinosis, and branched-chain amino acids are relatively spared. Reciprocal serum creatinine levels fall linearly with age, predicting renal failure in the fourth decade. Concentrations of the muscle enzymes creatine kinase, aspartate aminotransferase, and lactate dehydrogenase, as well as of total serum protein, serum alpha-2-globulin, and high-density lipoprotein cholesterol, are elevated. Conclusions. Renal glomerular deterioration is slowly progressive in the oculocerebrorenal syndrome. Renal tubular dysfunction begins early and persists; most patients require alkalinization therapy, and many benefit from supplemental potassium, phosphate, calcium, or carnitine. Serum enzyme elevations suggest muscle involvement in the oculocerebrorenal syndrome.	NICHHD,HUMAN GENET BRANCH,HUMAN BIOCHEM GENET SECT,BLDG 10,RM 9S242,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; NICHHD,HUMAN GENET BRANCH,NEUROGENET UNIT,BETHESDA,MD 20892; NHLBI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ABBASSI VALIOLLAH, 1968, AMER J DIS CHILD, V115, P145; ABITBOL C, 1990, J PEDIATR-US, V116, P243, DOI 10.1016/S0022-3476(05)82881-1; ADAMSON MD, 1989, SEMIN NEPHROL, V9, P147; ARBUS GS, 1981, PEDIATRICS, V67, P871; ATHREYA BH, 1983, ARTHRITIS RHEUM, V26, P728, DOI 10.1002/art.1780260605; ATTREE O, 1990, AM J HUM GENET SA244, V47; BANERJEE AK, 1982, IRISH J MED SCI, V15, P42; BERNARDINI I, 1985, J CLIN INVEST, V75, P1124, DOI 10.1172/JCI111806; BREMER HJ, 1981, DISTURBANCES AMINO A; CHARNAS L, 1988, NEUROPEDIATRICS, V19, P7, DOI 10.1055/s-2008-1052393; CHUTORIAN A, 1966, NEUROLOGY, V16, P115, DOI 10.1212/WNL.16.2_Part_1.115; CIBIS GW, 1986, OPHTHALMOLOGY, V93, P1041; DELLEMAN JW, 1977, J PEDIATR OPHTHALMOL, V14, P205; ELLIMAN D, 1983, J PEDIATR-US, V103, P1011, DOI 10.1016/S0022-3476(83)80759-8; FISHER DA, 1977, J CLIN ENDOCR METAB, V45, P191, DOI 10.1210/jcem-45-2-191; Gahl W A, 1986, Adv Pediatr, V33, P95; GAHL WA, 1990, PEDIATR NEPHROL, V4, P129, DOI 10.1007/BF00858823; GAHL WA, 1988, ANN INTERN MED, V109, P557, DOI 10.7326/0003-4819-109-7-557; GAHL WA, 1988, J CLIN INVEST, V81, P549, DOI 10.1172/JCI113353; GAHL WA, 1989, METABOLIC BASIS INHE, V2, P2619; GARDNER RJM, 1976, J MED GENET, V13, P449, DOI 10.1136/jmg.13.6.449; GARZULY F, 1973, NEUROPADIATRIE, V4, P304, DOI 10.1055/s-0028-1091747; Gellis S S, 1972, Am J Dis Child, V124, P891; GINSBERG J, 1981, J PEDIAT OPHTH STRAB, V18, P16; GOBERNADO JM, 1984, ARCH NEUROL-CHICAGO, V41, P208, DOI 10.1001/archneur.1984.04050140106037; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GORMAN LS, 1985, CLIN CHEM PRINCIPLES, P354; Haldane JBS, 1935, J GENET, V31, P317, DOI 10.1007/BF02982403; HARPER GS, 1987, J BIOL CHEM, V262, P5637; HOEG JM, 1984, CLIN PHARMACOL THER, V36, P555, DOI 10.1038/clpt.1984.219; HOLTGREWE JL, 1986, J PEDIATR ORTHOPED, V6, P165, DOI 10.1097/01241398-198603000-00009; KIERAS FJ, 1984, BIOCHEM MED METAB B, V31, P201, DOI 10.1016/0006-2944(84)90024-3; KOHYAMA J, 1989, PEDIATR NEUROL, V5, P373, DOI 10.1016/0887-8994(89)90052-0; KORNFELD M, 1975, ARCH NEUROL-CHICAGO, V32, P103, DOI 10.1001/archneur.1975.00490440053008; LACHAUX A, 1986, ARCH FR PEDIATR, V43, P68; LEUMANN EP, 1978, HELV PAEDIATR ACTA, V33, P25; LOWE CU, 1952, AMA AM J DIS CHILD, V83, P164, DOI 10.1001/archpedi.1952.02040060030004; MATIN MA, 1980, J MENT DEFIC RES, V24, P1; MCGARRY JD, 1976, J LIPID RES, V17, P277; PAPADOPOULOS NM, 1989, CLIN CHEM, V35, P2231; REBOUCHE CJ, 1983, MAYO CLIN PROC, V58, P533; REIMOLD EW, 1981, AM J DIS CHILD, V135, P1039, DOI 10.1001/archpedi.1981.02130350039013; ROSE SR, 1989, J CLIN ENDOCR METAB, V68, P1086, DOI 10.1210/jcem-68-6-1086; ROSENBLATT D, 1974, J PEDIATR-US, V84, P924, DOI 10.1016/S0022-3476(74)80819-X; RUTHERFORD WE, 1977, KIDNEY INT, V11, P62, DOI 10.1038/ki.1977.8; SEPPALA R, 1990, LAB INVEST, V63, P197; SILVER DN, 1987, J CLIN INVEST, V79, P282, DOI 10.1172/JCI112795; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; TRIPATHI RC, 1986, OPHTHALMOLOGY, V93, P1046; WADELIUS C, 1989, AM J HUM GENET, V44, P241; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WITZLEBEN CL, 1968, AM J MED, V44, P319, DOI 10.1016/0002-9343(68)90163-0; YAMASHINA I, 1983, MOL CELL BIOCHEM, V52, P107; YOSHIDA R, 1982, BIOCHEM BIOPH RES CO, V107, P1144; 1980, NIH81527 NAT HEART L	55	84	88	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1318	1325		10.1056/NEJM199105093241904	http://dx.doi.org/10.1056/NEJM199105093241904			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017228				2022-12-28	WOS:A1991FK18600004
J	HANDFORD, PA; MAYHEW, M; BARON, M; WINSHIP, PR; CAMPBELL, ID; BROWNLEE, GG				HANDFORD, PA; MAYHEW, M; BARON, M; WINSHIP, PR; CAMPBELL, ID; BROWNLEE, GG			KEY RESIDUES INVOLVED IN CALCIUM-BINDING MOTIFS IN EGF-LIKE DOMAINS	NATURE			English	Article							BETA-HYDROXYASPARTIC ACID; EPIDERMAL GROWTH-FACTOR; HUMAN FACTOR-IX; NUCLEOTIDE-SEQUENCE; PROTEIN; GENE; HOMOLOGY; REPEATS; SITE	MANY extracellular proteins with diverse functions contain domains similar to epidermal growth factor (EGF), a number of which have a consensus Asp/Asn, Asp/Asn, Asp*/Asn*, Tyr/Phe (where the asterisk denotes a beta-hydroxylated residue) 1. These include the coagulation factors IX and X, proteins with two EGF-like domains, the first of which contains the consensus residues 2. The first EGF-like domain of human factor IX contains a calcium-binding site, which is believed to be responsible for one of the high-affinity sites detected in this protein 3. Similar results have been obtained for bovine factor X 4. We have now used protein engineering and H-1-NMR techniques to investigate the importance of individual consensus residues for ligand binding. Measurement of a calcium-dependent Tyr 69 shift 3 in the isolated first EGF-like domain from human factor IX demonstrates that Asp 47, Asp 49, and Asp 64 are directly involved in this binding. Gln 50, whose importance has previously been overlooked, is also involved in this binding. Two mutations 5 in this domain, Asp 47 --> Glu, and Asp 64 --> Asn, present in patients with haemophilia B, reduce calcium binding to the domain > 4-fold and > 1,000-fold, respectively. Furthermore, the defective calcium binding of Asn 64 can be partially rescued by the compensatory mutation Gln 50 --> Glu. This latter mutation, when introduced singly more than doubles the affinity of the domain for calcium. This study thus defines residues involved in a new type of calcium-binding site and provides strong circumstantial evidence for calcium-binding motifs in many extracellular proteins, including the developmentally important proteins of Drosophila, notch, delta and crumbs 1,6-8.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3RE,ENGLAND; UNIV OXFORD,OXFORD CTR MOLEC SCI,OXFORD OX1 3RE,ENGLAND	University of Oxford; University of Oxford	HANDFORD, PA (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.							BARON M, 1990, THESIS U OXFORD; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; JAENICKE R, 1989, PROTEIN STRUCTURE PR, P208; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NISHIMURA H, 1989, THROMB HAEMOSTASIS, V62, P17; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PERSSON E, 1989, J BIOL CHEM, V264, P16897; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VILLIERS CL, 1985, P NATL ACAD SCI USA, V82, P4477, DOI 10.1073/pnas.82.13.4477; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	22	274	277	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					164	167		10.1038/351164a0	http://dx.doi.org/10.1038/351164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	2030732				2022-12-28	WOS:A1991FL03500057
J	MCCABE, M; SIBERT, JR; ROUTLEDGE, PA				MCCABE, M; SIBERT, JR; ROUTLEDGE, PA			PHOSPHATE ENEMAS IN CHILDHOOD - CAUSE FOR CONCERN	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									UNIV WALES, LLANDOUGH HOSP, COLL MED, DEPT CHILD HLTH, PENARTH CF6 1XX, S GLAM, WALES; UNIV WALES, LLANDOUGH HOSP, COLL MED, WELSH NATL POISONS UNIT, PENARTH CF6 1XX, S GLAM, WALES									ASHTON MR, 1990, BMJ-BRIT MED J, V300, P541, DOI 10.1136/bmj.300.6723.541-a; DAVIS RF, 1977, J PEDIATR-US, V90, P484, DOI 10.1016/S0022-3476(77)80723-3; FORMAN J, 1979, J PEDIATR-US, V94, P149, DOI 10.1016/S0022-3476(79)80383-2; MARTIN RR, 1987, JAMA-J AM MED ASSOC, V257, P2190, DOI 10.1001/jama.257.16.2190; PHARMAX UK, 1990, DATA SHEET FLETCHERS; SOTOS JF, 1977, PEDIATRICS, V60, P305; 1990, BRIT NATIJONAL FORMU, P70	7	26	26	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 4	1991	302	6784					1074	1074		10.1136/bmj.302.6784.1074	http://dx.doi.org/10.1136/bmj.302.6784.1074			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	2036507	Green Published, Bronze			2022-12-28	WOS:A1991FK56300030
J	KENNEDY, A; SCHON, F				KENNEDY, A; SCHON, F			EPILEPSY - DISAPPEARING LESIONS APPEARING IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							CT LESIONS; COMPUTED-TOMOGRAPHY; CYSTICERCOSIS; SEIZURES; INDIA; SCAN	Objective-Investigation of spontaneously resolving lesions associated with epilepsy. Design-Observational study during one year. Setting-One neurology department. Patients-4 cases in patients (one of Indian parents, one African, one white English, and one Afro-Caribbean) resident in the United Kingdom, who presented with transient epilepsy. Main outcome measures-Findings on computed tomography and on screening for infections. Results-In all four cases a small mass lesion in one cerebral hemisphere was observed on computed tomography, which resolved after 9, 4, 3 and 1.5 months respectively without surgery. Conclusions-The number of cases seen in one year suggests that the lesions may be more common in the United Kingdom than previously recognised and that research into their cause is warranted.	ATKINSON MORLEYS HOSP,DEPT NEUROL,LONDON SW20 0NE,ENGLAND									AHUJA GK, 1989, J NEUROL NEUROSUR PS, V52, P915, DOI 10.1136/jnnp.52.7.915; BANSAL BC, 1989, J NEUROL NEUROSUR PS, V52, P1185, DOI 10.1136/jnnp.52.10.1185; CHANDY MJ, 1989, LANCET, V1, P390, DOI 10.1016/S0140-6736(89)91771-6; DEBEYL DZ, 1985, J NEUROL NEUROSUR PS, V48, P187, DOI 10.1136/jnnp.48.2.187; FEINSTEIN A, 1990, J NEUROL NEUROSUR PS, V53, P244, DOI 10.1136/jnnp.53.3.244; GOULATIA RK, 1987, EPILEPSIA, V28, P523, DOI 10.1111/j.1528-1157.1987.tb03682.x; MINGUETTI G, 1983, J NEUROL NEUROSUR PS, V46, P936, DOI 10.1136/jnnp.46.10.936; RAJSHEKHAR V, 1990, J NEUROL NEUROSUR PS, V53, P818, DOI 10.1136/jnnp.53.9.818-a; WADIA RS, 1987, J NEUROL NEUROSUR PS, V50, P1298, DOI 10.1136/jnnp.50.10.1298	9	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					933	935		10.1136/bmj.302.6782.933	http://dx.doi.org/10.1136/bmj.302.6782.933			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032034	Bronze, Green Published			2022-12-28	WOS:A1991FH48700016
J	MALIM, MH; CULLEN, BR				MALIM, MH; CULLEN, BR			HIV-1 STRUCTURAL GENE-EXPRESSION REQUIRES THE BINDING OF MULTIPLE REV MONOMERS TO THE VIRAL RRE - IMPLICATIONS FOR HIV-1 LATENCY	CELL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ESCHERICHIA-COLI; TRANS-ACTIVATOR; MESSENGER-RNA; PROTEIN; SEQUENCE; INVITRO; PURIFICATION; RECOGNITION; POLYMERASE	Expression of the structural proteins of HIV-1 requires the direct interaction of the viral Rev trans-activator with its cis-acting RNA target sequence, the Rev response element or RRE. Here, we demonstrate that this specific RNA-binding event is, as expected, mediated by the conserved arginine-rich motif of Rev. However, we also show that amino acid residues located proximal to this basic domain that are critical for in vivo Rev function are dispensable for sequence-specific binding to the RRE. Instead, these sequences are required for the multimerization of Rev on the viral RRE target sequence. The observation that Rev function requires the sequential binding of multiple Rev molecules to the RRE provides a biochemical explanation for the observed threshold effect for Rev function in vivo and suggests a molecular model for the high incidence of latent infection by HIV-1.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University; Duke University	MALIM, MH (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.			Malim, Michael/0000-0002-7699-2064				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; GENDELMAN HE, 1986, J VIROL, V58, P67, DOI 10.1128/JVI.58.1.67-74.1986; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; JONES K A, 1989, New Biologist, V1, P127; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NALIN CM, 1990, P NATL ACAD SCI USA, V87, P7593, DOI 10.1073/pnas.87.19.7593; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; PERKINS A, 1989, J ACQ IMMUN DEF SYND, V2, P256; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TILEY LS, 1990, P NATL ACAD SCI USA, V87, P7497, DOI 10.1073/pnas.87.19.7497; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	37	356	363	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					241	248		10.1016/0092-8674(91)90158-U	http://dx.doi.org/10.1016/0092-8674(91)90158-U			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015625				2022-12-28	WOS:A1991FH09200007
J	ROWLAND, D				ROWLAND, D			GOVERNMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											ROWLAND, D (corresponding author), JOHNS HOPKINS UNIV,BALTIMORE,MD 21218, USA.							ROWLAND D, 1990, B NEW YORK ACAD MED, V66, P29; ROWLAND D, 1990, JAMA-J AM MED ASSOC, V263, P2646; 1991, WASHINGTON REP, V1, P1; 1991, EC BUDGET OUTLOOK FI; 1990, CALL ACTION FINAL RE; 1991, TRENDS HLTH EXPENDIT; 1991, BUDGET US GOVT FISCA; 1990, MEDICARE OMNIBUS REC	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3127	3128						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041123				2022-12-28	WOS:A1991FQ77000021
J	PARVING, HH				PARVING, HH			PROTEIN RESTRICTION AND RENAL-FAILURE IN DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							AGGRESSIVE ANTIHYPERTENSIVE TREATMENT; KIDNEY-FUNCTION; NEPHROPATHY; PROGRESSION; ALBUMINURIA		HVIDOVRE UNIV HOSP,DK-2930 KLAMPENBORG,DENMARK		PARVING, HH (corresponding author), STENO MEM HOSP,DK-2930 KLAMPENBORG,DENMARK.							BJORCK S, 1986, BMJ-BRIT MED J, V293, P471, DOI 10.1136/bmj.293.6545.471; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; NYBERG G, 1987, DIABETOLOGIA, V30, P82; PARVING HH, 1983, LANCET, V1, P1175; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; PARVING HH, 1981, DIABETES CARE, V4, P459, DOI 10.2337/diacare.4.4.459; PARVING HH, 1986, DIABETIC RENAL RETIN, V3, P183; ROSMAN JB, 1990, NEW ENGL J MED, V322, P1610; VIBERTI GC, 1983, AM J MED, V74, P256, DOI 10.1016/0002-9343(83)90624-1; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	10	10	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1743	1744						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	2034255				2022-12-28	WOS:A1991FQ15500026
J	FRANKEL, AD; KIM, PS				FRANKEL, AD; KIM, PS			MODULAR STRUCTURE OF TRANSCRIPTION FACTORS - IMPLICATIONS FOR GENE-REGULATION	CELL			English	Review							DNA-BINDING DOMAIN; GLUCOCORTICOID RECEPTOR; C-JUN; PROTEIN; ACTIVATION; ONCOPROTEIN; COMPLEX; DIMER; CELLS; FOS		MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	FRANKEL, AD (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.							BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BROWN AM, 1989, P NATL ACAD SCI USA, V86, P7387, DOI 10.1073/pnas.86.19.7387; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JONAT G, 1990, CELL, V62, P1189; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PAVLETICH NP, 1991, IN PRESS SCIENCE; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; Sauer R T, 1990, Adv Protein Chem, V40, P1, DOI 10.1016/S0065-3233(08)60286-7; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	33	236	240	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					717	719		10.1016/0092-8674(91)90378-C	http://dx.doi.org/10.1016/0092-8674(91)90378-C			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040012				2022-12-28	WOS:A1991FP51600002
J	BAYER, R				BAYER, R			PUBLIC-HEALTH POLICY AND THE AIDS EPIDEMIC - AN END TO HIV EXCEPTIONALISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											BAYER, R (corresponding author), COLUMBIA UNIV,NEW YORK,NY 10027, USA.							ABRAHAM L, 1988, AM MED NEWS     0708, P4; ALBAEK E, IN PRESS PASSIONS PO; [Anonymous], 1988, REPORT PRESIDENTIAL, P130; Bayer R., 1991, PRIVATE ACTS SOCIAL; FRANKENBERG G, IN PRESS PASSIONS PO; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; HENRIKSSON B, IN PRESS PASSION POL; JONES L, 1990, HIV INFECTION LABELE, P3; KRAUTHAMMER C, 1990, TIME            0625, P80; WINKENWERDER W, 1989, NEW ENGL J MED, V320, P1598, DOI 10.1056/NEJM198906153202406; 1989, 43RD AMA P HOUS DEL, P76; 1989, REPORT HOUSE DELEGAT, P23; 1990, MMWR, V39, P861; 1988, FED REGISTER, V53, P3554; 1990, MMWR, V39, P110; 1988, C LOCAL HLTH OFFICES; 1990, HAS FEDERAL RES AIDS; 1988, CONFRONTING AIDS UPD, P82; 1990, 1989 INT AIDS REP, P3	19	174	175	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1500	1504		10.1056/NEJM199105233242111	http://dx.doi.org/10.1056/NEJM199105233242111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FM460	2023610				2022-12-28	WOS:A1991FM46000011
J	PERROT, V; RICHERD, S; VALERO, M				PERROT, V; RICHERD, S; VALERO, M			TRANSITION FROM HAPLOIDY TO DIPLOIDY	NATURE			English	Article							DOMINANCE	AS a direct consequence of sex, organisms undergo a haploid and a diploid stage during their life cycle. Although the relative duration of haploid and diploid phases varies greatly among taxa, the diploid phase is more conspicuous in all higher organisms. Therefore it is widely believed that diploidy offers more evolutionary possibilities 1-3 and is thus nearly always selected for. We have now performed computer simulations to investigate one possible advantage of diploidy, that is, protection against the expression of deleterious mutations. Instead of comparing isolated haploid and diploid populations, we considered interbreeding haploids and diploids. Diploids invaded the population only when the dominance degree of a single deleterious mutation was smaller than about 1/2, and the condition allowing diploidy to invade depended on how harmful the mutation was.	UNIV SCI & TECHNOL LILLE FLANDRES ARTOIS, GENET & EVOLUT POPULAT VEGETALES LAB, CNRS, URA 1185, F-59655 VILLENEUVE DASCQ, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	PERROT, V (corresponding author), UNIV BASEL, INST ZOOL, RHEINSPRUNG 9, CH-4051 BASEL, SWITZERLAND.		Valero, Myriam/C-7550-2011; Valero, Myriam/M-6052-2019	Valero, Myriam/0000-0002-9000-1423; Valero, Myriam/0000-0002-9000-1423				BERNSTEIN H, 1981, AM NAT, V117, P537, DOI 10.1086/283734; CHARLESWORTH B, 1979, NATURE, V278, P848, DOI 10.1038/278848a0; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; CROW JAMES F., 1965, AMER NATUR, V99, P439, DOI 10.1086/282389; Fisher RA, 1928, AM NAT, V62, P115, DOI 10.1086/280193; Haldane JBS, 1937, AM NAT, V71, P337, DOI 10.1086/280722; KACSER H, 1981, GENETICS, V97, P639; KIMURA M, 1961, JAPAN J GENET      S, V36, P179; KONDRASHOV AS, 1991, NATURE, V351, P314, DOI 10.1038/351314a0; LEWIS J, 1979, J THEOR BIOL, V78, P425, DOI 10.1016/0022-5193(79)90341-2; MAYNARD SMITH J., 1978, EVOLUTION SEX; PAQUIN C, 1983, NATURE, V302, P495, DOI 10.1038/302495a0; STEBBINS GL, 1950, VARIATION EVOLUTION; Wright S, 1934, AM NAT, V68, P24, DOI 10.1086/280521	14	109	110	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	1991	351	6324					315	317		10.1038/351315a0	http://dx.doi.org/10.1038/351315a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034274				2022-12-28	WOS:A1991FM97600060
J	RIDKER, PM; MANSON, JE; GAZIANO, JM; BURING, JE; HENNEKENS, CH				RIDKER, PM; MANSON, JE; GAZIANO, JM; BURING, JE; HENNEKENS, CH			LOW-DOSE ASPIRIN THERAPY FOR CHRONIC STABLE ANGINA - A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL-TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; UNSTABLE ANGINA; PROGNOSIS; INHIBITION; PHYSICIANS; MORTALITY; DISEASE; AGENTS; ACID	Objective: To evaluate the efficacy of low-dose aspirin in the primary prevention of myocardial infarction among patients with chronic stable angina. Design: A randomized, double-blind, trial. Patients: The study included 333 men with baseline chronic stable angina but with no previous history of myocardial infarction, stroke, or transient ischemic attack who were enrolled in the Physician's Health Study, a trial of aspirin among 22 071 male physicians. Intervention: Patients were randomly assigned to receive alternate-day aspirin therapy (325 mg) or placebo and were followed for an average of 60.2 months for the occurrence of myocardial infarction, stroke, or cardiovascular death. Results: During follow-up, 27 patients had confirmed myocardial infarction; 7 were among the 178 patients with chronic stable angina who received aspirin therapy and 20 were among the 155 patients who received placebo (relative risk, 0.30; 95% CI, 0.14 to 0.63; P = 0.003). While simultaneously controlling for other cardiovascular risk factors in a proportional hazards model, an overall 87% risk reduction was calculated (relative risk, 0.13; CI, 0.04 to 0.42; P < 0.001). For the subgroup of patients with chronic stable angina but no previous coronary bypass surgery or coronary angioplasty, an almost identical reduction in the risk for myocardial infarction was found (relative risk, 0.14; CI, 0.04 to 0.56; P = 0.006). Of 13 strokes, 11 occurred in the aspirin group and 2 in the placebo group (relative risk, 5.4; CI, 1.3 to 22.1; P = 0.02). No stroke was fatal, but 4 produced some long-term impairment of function. One stroke, in the aspirin group, was hemorrhagic. Conclusion: Our data indicated that alternate-day aspirin therapy greatly reduced the risk for first myocardial infarction among patients with chronic stable angina, a group of patients at high risk for cardiovascular death (P < 0.001). Although our results for stroke were based on small numbers, they suggested an apparent increase in frequency of stroke with aspirin therapy; this finding requires confirmation in randomized trials of adequate sample size.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-26490, HL-34595] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1982, Lancet, V1, P237; [Anonymous], 1980, CIRCULATION, V62, P449; [Anonymous], 1988, NEW ENGL J MED; BRAUNWALD E, 1978, INT S BETA ADRENERGI; BREDDIN K, 1979, THROMB HAEMOSTASIS, V41, P225; BURCH JW, 1978, J CLIN INVEST, V61, P314, DOI 10.1172/JCI108941; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; CHESEBRO JH, 1989, CIRCULATION S2, V80, P266; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; ELWOOD PC, 1979, LANCET, V2, P1313; Fiddler G.I., 1990, CIRCULATION S1, V81, P69; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FRISHMAN WH, 1985, AM J CARDIOL, V56, P81; HARPER RW, 1979, AM HEART J, V97, P178, DOI 10.1016/0002-8703(79)90353-3; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HENNEKENS CH, 1988, NEW ENGL J MED, V318, P923; Hopf R., 1983, CALCIUM CHANNEL BLOC, P241; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KENT KM, 1982, AM J CARDIOL, V49, P1823, DOI 10.1016/0002-9149(82)90198-9; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; KRIKLER DM, 1987, AM J CARDIOL, V59, pB95, DOI 10.1016/0002-9149(87)90088-9; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; PRICHARD B, 1978, CARDIOVASCULAR DRUGS, V2, P85; RIDKER PM, 1990, CLIN RES, V38, pA291; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; ROSENBERG HM, 1978, DHEW NIH791610 PUBL, P11; ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073; SCHOENBERGER JA, 1980, JAMA-J AM MED ASSOC, V243, P661; SHERRY S, 1980, NEW ENGL J MED, V302, P250; STONE PH, 1980, ANN INTERN MED, V93, P886, DOI 10.7326/0003-4819-93-6-886; THADANI U, 1980, CIRCULATION, V62, P491, DOI 10.1161/01.CIR.62.3.491; THANAVARO S, 1980, CIRCULATION, V61, P29, DOI 10.1161/01.CIR.61.1.29; VOGEL G, 1981, PROPHYLAXIS VENOUS P, P123; 1988, BR MED J CLIN RES, V296, P320; 1978, NEW ENGL J MED, V298, P289; 1971, ISCHAEMIC HEART DISE; 1976, J CHRON DIS, V29, P625; 1988, BR MED J CLIN RES, V296, P316	43	169	174	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					835	839		10.7326/0003-4819-114-10-835	http://dx.doi.org/10.7326/0003-4819-114-10-835			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014943				2022-12-28	WOS:A1991FL65000001
J	FOWKES, FGR; FULTON, PM				FOWKES, FGR; FULTON, PM			CRITICAL-APPRAISAL OF PUBLISHED RESEARCH - INTRODUCTORY GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article							DISEASE				FOWKES, FGR (corresponding author), UNIV EDINBURGH,SCH MED,DEPT COMMUNITY MED,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							ALTMAN DG, 1980, BRIT MED J, V281, P1336, DOI 10.1136/bmj.281.6251.1336; ALTMAN DG, 1983, BRIT MED J, V286, P1489, DOI 10.1136/bmj.286.6376.1489; COLLIN J, 1988, LANCET, V2, P613; DALY LE, 1991, BRIT MED J, V302, P333, DOI 10.1136/bmj.302.6772.333; GARDNER MJ, 1986, BRIT MED J, V292, P810, DOI 10.1136/bmj.292.6523.810; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HUTH EJ, 1987, ANN INTERN MED, V106, P626, DOI 10.7326/0003-4819-106-4-626; JELNES R, 1986, BRIT MED J, V293, P1137, DOI 10.1136/bmj.293.6555.1137; KEIGHLEY MRB, 1979, BRIT MED J, V2, P967, DOI 10.1136/bmj.2.6196.967; KERNAHAN J, 1987, BRIT MED J, V295, P15, DOI 10.1136/bmj.295.6589.15; LOCK S, 1988, BRIT MED J, V297, P156, DOI 10.1136/bmj.297.6642.156; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; SCOTT J, 1990, BRIT MED J, V301, P1015, DOI 10.1136/bmj.301.6759.1015; SCRAGG RKR, 1984, BRIT MED J, V288, P1113, DOI 10.1136/bmj.288.6424.1113; SIMMONS D, 1989, BRIT MED J, V298, P18, DOI 10.1136/bmj.298.6665.18; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; 1985, NEW ENGL J MED, V313, P1191	17	244	244	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1136	1140		10.1136/bmj.302.6785.1136	http://dx.doi.org/10.1136/bmj.302.6785.1136			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	2043787	Green Published, Bronze			2022-12-28	WOS:A1991FL43900024
J	SOKAL, RR; ODEN, NL; WILSON, C				SOKAL, RR; ODEN, NL; WILSON, C			GENETIC-EVIDENCE FOR THE SPREAD OF AGRICULTURE IN EUROPE BY DEMIC DIFFUSION	NATURE			English	Article							FREQUENCIES; POPULATIONS; TRANSITION; DISTANCES; PATTERNS	EUROPEAN agriculture originated in the Near East about 9,000 years ago 1-3. The Neolithic reached almost all areas suitable for agriculture by 5,000 yr BP (before present) 2,4. The routes and times of the spread of agriculture through Europe are relatively well established 2,3,5, but not its manner of spreading 6-8. This could have been by cultural diffusion with few genetic consequences. By contrast, Ammerman and Cavalli-Sforza 2 proposed that the spread of farming increased local population densities, causing demic expansion into new territory and diffusive gene flow between the neolithic farmers and mesolithic groups. We have now tested observed genetic patterns against expectations derived from the demic expansion hypothesis. We found significant partial correlations of genetic distances with a distance matrix especially designed to represent the spread of agriculture on that continent, when geographic distances are held constant. These findings support the hypothesis of Ammerman and Cavalli-Sforza and invite further investigation into Renfrew's hypothesis on the origin of the Indo-European languages.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PREVENT MED, DIV MICROBIOL & PUBL HLTH, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	SOKAL, RR (corresponding author), SUNY STONY BROOK, DEPT ECOL & EVOLUT, STONY BROOK, NY 11794 USA.							AMMERMAN AJ, 1989, ANTIQUITY, V63, P162, DOI 10.1017/S0003598X00075694; AMMERMAN AJ, 1984, NEOLITHIC TRANSITION; Barker G., 1985, PREHISTORIC FARMING; Barraclough G., 1979, TIMES ATLAS WORLD HI; CHAMPION T, 1984, PREHISTORIC EUROPE; CLARK JGD, 1965, P PREHIST SOC, V31, P58, DOI 10.1017/S0079497X00014717; DERISH PA, 1988, HUM BIOL, V60, P801; Fisher RA, 1937, ANN EUGENIC, V7, P355, DOI 10.1111/j.1469-1809.1937.tb02153.x; KIMURA M, 1964, GENETICS, V49, P561; MANTEL N, 1967, CANCER RES, V27, P209; MEIKLEJOHN C, IN PRESS BIOCULTURAL; MENOZZI P, 1978, SCIENCE, V201, P786, DOI 10.1126/science.356262; Mourant AE., 1976, DISTRIBUTION HUMAN B; MOURANT AE, 1983, BLOOD RELATIONS; PREVOSTI A, 1975, THEOR APPL GENET, V45, P231, DOI 10.1007/BF00831894; RENFREW C, 1987, ARCHAEOLOGY LANGUAGE; ROYCHOUDHOURY AK, 1988, HUMAN POLYMORPHIC GE; SMOUSE PE, 1986, SYST ZOOL, V35, P627, DOI 10.2307/2413122; Sokal R. R., 1981, BIOMETRY; SOKAL RR, 1989, HUM BIOL, V61, P691; SOKAL RR, 1988, AM J PHYS ANTHROPOL, V76, P337, DOI 10.1002/ajpa.1330760308; SOKAL RR, 1982, AM NAT, V119, P1, DOI 10.1086/283886; SOKAL RR, 1989, AM J PHYS ANTHROPOL, V80, P267, DOI 10.1002/ajpa.1330800302; SOKAL RR, 1988, P NATL ACAD SCI USA, V85, P1722, DOI 10.1073/pnas.85.5.1722; SOKAL RR, 1979, SYST ZOOL, V28, P227, DOI 10.2307/2412528; SOKAL RR, 1989, GENETICS, V121, P845; ZVELEBIL M, 1988, ANTIQUITY, V62, P574, DOI 10.1017/S0003598X00074743; [No title captured]	28	235	238	1	24	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 9	1991	351	6322					143	145		10.1038/351143a0	http://dx.doi.org/10.1038/351143a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	2030731				2022-12-28	WOS:A1991FL03500049
J	MURPHY, E				MURPHY, E			COMMUNITY MENTAL-HEALTH-SERVICES - A VISION FOR THE FUTURE	BRITISH MEDICAL JOURNAL			English	Article											MURPHY, E (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,LONDON SE1 9RT,ENGLAND.							CLIFFORD P, 1988, CASE MANAGEMENT SYST; MURPHY E, 1987, HOME AWAY; RICH M, 1989, PSYCHIATRIC B, V13, P290; RICHARDSON K, 1989, PSYCHIATRIC B, V13, P287; TURNER TH, 1990, PSYCHIATRIC B, V14, P661; 1989, CARING PEOPLE COMMUN	6	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1064	1065		10.1136/bmj.302.6784.1064	http://dx.doi.org/10.1136/bmj.302.6784.1064			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK563	2036504	Green Published, Bronze			2022-12-28	WOS:A1991FK56300027
J	DU, XP; PLOW, EF; FRELINGER, AL; OTOOLE, TE; LOFTUS, JC; GINSBERG, MH				DU, XP; PLOW, EF; FRELINGER, AL; OTOOLE, TE; LOFTUS, JC; GINSBERG, MH			LIGANDS ACTIVATE INTEGRIN ALPHA-IIB-BETA-3 (PLATELET GPIIB-IIIA)	CELL			English	Article							ARG-GLY-ASP; FUNCTION-ASSOCIATED ANTIGEN-1; IIB-GLYCOPROTEIN-IIIA; AMINO-ACID SEQUENCES; CELL-BINDING DOMAIN; SYNTHETIC PEPTIDES; GLANZMANNS THROMBASTHENIA; FIBRONECTIN RECEPTOR; RECOGNITION SIGNAL; ADHESIVE PROTEINS	Integrin alpha-IIb-beta-3 (platelet GPIIb-IIIa) binds fibrinogen via recognition sequences such as Arg-Gly-Asp (RGD). Fibrinogen binding requires agonist activation of platelets, whereas the binding of short synthetic RGD peptides does not. We now find that RGD peptide binding leads to changes in alpha-IIb-beta-3 that are associated with acquisition of high affinity fibrinogen-binding function (activation) and subsequent platelet aggregation. The structural specificities for peptide activation and for inhibition of ligand binding are similar, indicating that both are consequences of occupancy of the same site(s) on alpha-IIb-beta-3. Thus, the RGD sequence is a trigger of high affinity ligand binding to alpha-IIb-beta-3, and certain RGD-mimetics are partial agonists as well as competitive antagonists of integrin function.			DU, XP (corresponding author), Scripps Res Inst, RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA.		O'Toole, Timothy/I-4172-2013	Frelinger, Andrew/0000-0002-6871-7441	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039150, P01HL016411, R01HL028235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28235, HL-39150, HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COHEN I, 1989, BLOOD, V73, P1880; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; COLLER BS, 1980, BLOOD, V55, P169; DANA N, 1984, J CLIN INVEST, V73, P153, DOI 10.1172/JCI111186; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1987, J BIOL CHEM, V262, P5437; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GINSBERG MH, 1980, BLOOD, V55, P661; GINSBERG MH, 1983, METHODS HEMATOLOGY, P158; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LAM SCT, 1987, J BIOL CHEM, V262, P947; LASH JW, 1987, DEV BIOL, V123, P411, DOI 10.1016/0012-1606(87)90399-X; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MARGUERIE GA, 1982, J BIOL CHEM, V257, P1872; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCEVER RP, 1980, J CLIN INVEST, V66, P1311, DOI 10.1172/JCI109983; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PEERSCHKE EI, 1981, BLOOD, V57, P663; PHILLIPS DR, 1988, BLOOD, V71, P831; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1990, IN PRESS J BIOL CHEM; STEINER B, 1989, J BIOL CHEM, V264, P13102; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; TAKADA Y, 1987, P NATL ACAD SCI USA, V84, P3239, DOI 10.1073/pnas.84.10.3239; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOODS VL, 1986, J BIOL CHEM, V261, P5242; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; ZAMARRON C, 1990, THROMB HAEMOSTASIS, V64, P41	66	472	479	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					409	416		10.1016/0092-8674(91)90458-B	http://dx.doi.org/10.1016/0092-8674(91)90458-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018974				2022-12-28	WOS:A1991FK18200007
J	MITTNACHT, S; WEINBERG, RA				MITTNACHT, S; WEINBERG, RA			G1/S PHOSPHORYLATION OF THE RETINOBLASTOMA PROTEIN IS ASSOCIATED WITH AN ALTERED AFFINITY FOR THE NUCLEAR COMPARTMENT	CELL			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; SUSCEPTIBILITY GENE; CELL-CYCLE; ENCODED PROTEIN; RB GENE; PRODUCT; EXPRESSION; CHROMOSOME-13	Hyperphosphorylation of the retinoblastoma protein (pRB) is assumed to be a regulatory event leading to the inactivation of its growth-repressing functions. We demonstrate a functional alteration linked to the phosphorylation status of the protein. The un- or under-phosphorylated species are tightly associated with the nuclear structure. The association is resistant to digestion with nucleases, and release requires elevated salt concentrations. In contrast, the hyperphosphorylated species are eluted under hypotonic buffer conditions. The conversion from low salt-resistant to low salt-extractable pRB occurs with transition through the G1/S boundary of the cell cycle and thus parallels the reported onset of pRB phosphorylation. The ability to form a tight nuclear association is impaired in several naturally occuring pRB mutants, all of which show alterations within the binding region for viral oncoproteins. We suggest that the tight nuclear interaction is essential for the growth-regulating functions of pRB and may be preempted by viral oncoproteins.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	MITTNACHT, S (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [CA39826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COMMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRANKE WW, 1984, CELL, V36, P813, DOI 10.1016/0092-8674(84)90031-X; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GODBOUT R, 1983, NATURE, V304, P451, DOI 10.1038/304451a0; GRAND RJA, 1989, ONCOGENE, V4, P1291; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUBERMAN JA, 1987, CELL, V48, P7, DOI 10.1016/0092-8674(87)90347-3; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOPS AD, 1988, CELL, V55, P857, DOI 10.1016/0092-8674(88)90141-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REISSMANN PT, 1989, ONCOGENE, V4, P839; RYGAARD K, 1990, CANCER RES, V50, P5312; SCHROTER H, 1985, EMBO J, V4, P3867, DOI 10.1002/j.1460-2075.1985.tb04159.x; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHEW JY, 1989, ONCOGENE RES, V4, P205; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARLEY JM, 1989, ONCOGENE, V4, P725; VAUGHN JP, 1990, NUCLEIC ACIDS RES, V18, P1965, DOI 10.1093/nar/18.8.1965; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YOKOTA J, 1988, ONCOGENE, V3, P471	71	325	328	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					381	393		10.1016/0092-8674(91)90456-9	http://dx.doi.org/10.1016/0092-8674(91)90456-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018973				2022-12-28	WOS:A1991FK18200005
J	OKANO, Y; EISENSMITH, RC; GUTTLER, F; LICHTERKONECKI, U; KONECKI, DS; TREFZ, FK; DASOVICH, M; WANG, T; HENRIKSEN, K; LOU, H; WOO, SLC				OKANO, Y; EISENSMITH, RC; GUTTLER, F; LICHTERKONECKI, U; KONECKI, DS; TREFZ, FK; DASOVICH, M; WANG, T; HENRIKSEN, K; LOU, H; WOO, SLC			MOLECULAR-BASIS OF PHENOTYPIC HETEROGENEITY IN PHENYLKETONURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN PHENYLALANINE-HYDROXYLASE; PRENATAL-DIAGNOSIS; LINKAGE DISEQUILIBRIUM; MAMMALIAN-CELLS; DNA; GENE; MUTATION; LOCUS; HYPERPHENYLALANINEMIA; SUBSTITUTION	Background. Phenylketonuria is a metabolic disorder that results from a deficiency of the hepatic enzyme phenylalanine hydroxylase. Its clinical phenotype varies widely, and to date more than 10 mutations in the phenylalanine hydroxylase gene have been identified in persons with the disorder. We attempted to relate the clinical phenotype of patients to their genotype. Methods. We studied 258 patients with phenylketonuria from Denmark and Germany for the presence of eight mutations previously found in patients from these countries. The in vitro activity of the enzymes associated with these mutations was determined by expression analysis in heterologous mammalian cells. The level of activity was then used to predict the in vivo level of phenylalanine hydroxylase activity in patients with various combinations of mutant phenylalanine hydroxylase alleles. Results. The eight mutations involved 64 percent of all mutant phenylalanine hydroxylase alleles in the patients. Expression analysis showed that these mutant enzymes produced from 0 to 50 percent of normal enzyme activity. The predicted level of phenylalanine hydroxylase activity correlated strongly with the pretreatment serum level of phenylalanine (r = 0.91, P < 0.001 in the Danish patients and r = 0.74, P < 0.001 in the German patients), phenylalanine tolerance in the Danish patients (r = 0.84, P < 0.001), and the serum phenylalanine level measured after standardized oral protein loading in the German patients (r = 0.84, P < 0.001). Conclusions. Our results strongly support the hypothesis that there is a molecular basis for phenotypic heterogeneity in phenylketonuria. The establishment of genotype will therefore aid in the prediction of biochemical and clinical phenotypes in patients with this disease.	BAYLOR UNIV, HOWARD HUGHES MED INST, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA; BAYLOR UNIV, INST MOLEC GENET, HOUSTON, TX 77030 USA; JOHN F KENNEDY INST, GLOSTRUP, DENMARK; UNIV HEIDELBERG, KINDERKLIN, W-6900 HEIDELBERG, GERMANY	Baylor College of Medicine; Baylor University; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor University; Ruprecht Karls University Heidelberg					NICHD NIH HHS [HD-17711] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017711, R01HD017711] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABADIE V, 1989, GENOMICS, V5, P936, DOI 10.1016/0888-7543(89)90137-7; BARTHOLOME K, 1975, PEDIATR RES, V9, P899, DOI 10.1203/00006450-197509120-00006; BLASKOVICS ME, 1974, ARCH DIS CHILD, V49, P835, DOI 10.1136/adc.49.11.835; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DILELLA AG, 1987, METHOD ENZYMOL, V152, P447; DILELLA AG, 1988, LANCET, V1, P497; DILELLA AG, 1987, NATURE, V327, P333, DOI 10.1038/327333a0; DILELLA AG, 1986, NATURE, V322, P799, DOI 10.1038/322799a0; DWORNICZAK B, 1989, HUM GENET, V84, P95, DOI 10.1007/BF00210683; GUTTLER F, 1987, J PEDIATR-US, V110, P68, DOI 10.1016/S0022-3476(87)80290-1; GUTTLER F, 1980, ACTA PAEDIATR SCAND, P1; JERVIS GA, 1947, J BIOL CHEM, V169, P651; JOHN SWM, 1990, AM J HUM GENET, V46, P970; JOHN SWM, 1989, AM J HUM GENET, V45, P905; KANG ES, 1970, PEDIATRICS, V45, P83; KAUFMAN S, 1975, PEDIATR RES, V9, P632, DOI 10.1203/00006450-197508000-00004; Kaufman S., 1976, ADV NEUROCHEM, P1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEDLEY FD, 1986, NEW ENGL J MED, V314, P1276, DOI 10.1056/NEJM198605153142002; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; LEDLEY FD, 1985, SCIENCE, V228, P77, DOI 10.1126/science.3856322; LICHTERKONECKI U, 1988, HUM GENET, V78, P347, DOI 10.1007/BF00291733; LICHTERKONECKI U, 1988, BIOCHEMISTRY-US, V27, P2881, DOI 10.1021/bi00408a032; LIDSKY AS, 1985, LANCET, V1, P549; LIDSKY AS, 1985, AM J HUM GENET, V37, P619; LYONNET S, 1989, AM J HUM GENET, V44, P511; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MCCAMAN MW, 1962, J LAB CLIN MED, V59, P885; MOORE S, 1958, ANAL CHEM, V30, P1185, DOI 10.1021/ac60139a005; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; OKANO Y, 1991, GENOMICS, V9, P96, DOI 10.1016/0888-7543(91)90225-4; OKANO Y, 1990, AM J HUM GENET, V46, P919; OKANO Y, 1990, AM J HUM GENET, V46, P18; OKANO Y, IN PRESS EUR J PEDIA; THOMPSON GN, 1990, J CLIN INVEST, V86, P317, DOI 10.1172/JCI114701; TREFZ FK, 1981, J INHERIT METAB DIS, V4, P101, DOI 10.1007/BF02263611; TREFZ FK, 1979, CLIN CHIM ACTA, V99, P211, DOI 10.1016/0009-8981(79)90264-X; WOO SLC, 1988, AM J HUM GENET, V43, P781; WOO SLC, 1983, NATURE, V306, P151, DOI 10.1038/306151a0; [No title captured]; 1990, SOMAT CELL MOLEC GEN, V16, P885	41	223	226	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1232	1238		10.1056/NEJM199105023241802	http://dx.doi.org/10.1056/NEJM199105023241802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	2014036				2022-12-28	WOS:A1991FJ82300002
J	RAMACHANDRAN, VS; GREGORY, RL				RAMACHANDRAN, VS; GREGORY, RL			PERCEPTUAL FILLING IN OF ARTIFICIALLY INDUCED SCOTOMAS IN HUMAN VISION	NATURE			English	Article							APPARENT MOTION; VISUAL AREAS; COLOR; CONTOURS; FORM	PATIENTS with scotomas or blind-spots in their visual field 1-5 resulting from damage to the visual pathways often report that the pattern from the rest of the visual field 'fills in' to occupy the scotoma. Here we describe a novel technique for generating an artificial perceptual scotoma which enabled us to study the spatial and temporal characteristics of this filling-in process. A homogeneous grey square subtending 1.5-degrees was displayed against a background of twinkling two-dimensional noise of equal mean luminance (Fig. 1). On steady eccentric fixation for 10 s the square vanished and was filled in by the twinkling noise from the surround. Using this display we found that 'filling in' is an active visual process that probably involves creating an actual neural representation of the surround rather than merely ignoring the absence of information from the scotoma; filling in can occur separately for colour and texture, suggesting separate mechanisms; the filling-in process does not completely suppress information from the scotoma, even after an image has faded completely from consciousness it can nevertheless contribute to motion perception; and the process can be strongly influenced by illusory contours.	UNIV BRISTOL,DEPT PSYCHOL,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol	RAMACHANDRAN, VS (corresponding author), UNIV CALIF SAN DIEGO,DEPT PSYCHOL 0109,LA JOLLA,CA 92092, USA.							ALLMAN J, 1985, PERCEPTION, V14, P105, DOI 10.1068/p140105; BENDER MB, 1946, ARCH NEURO PSYCHIATR, V55, P627, DOI 10.1001/archneurpsyc.1946.02300170075008; Brewster D., 1832, LETT NATURAL MAGIC; CRANE HD, 1983, SCIENCE, P1078; FINKEL LH, 1989, J NEUROSCI, V9, P3188; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GROSSBERG S, 1985, PSYCHOL REV, V92, P173, DOI 10.1037/0033-295X.92.2.173; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; Kaniza G., 1979, ORG VISION; KRAUSKOPF J, 1961, AM J PSYCHOL, V80, P632; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; POGGIO T, 1985, NATURE, V138, P645; POPPEL E, 1986, NATURE, V320, P523, DOI 10.1038/320523a0; RAMACHANDRAN VS, 1990, PERCEPTION, V19, P273; RAMACHANDRAN VS, 1990, AI AND THE EYE, P21; RAMACHANDRAN VS, 1986, PERCEPT PSYCHOPHYS, V39, P361, DOI 10.3758/BF03203005; RAMACHANDRAN VS, 1985, PERCEPTION, V14, P127, DOI 10.1068/p140127; RAMACHANDRAN VS, 1987, NATURE, V328, P645, DOI 10.1038/328645a0; RAMACHANDRAN VS, IN PRESS ARTFUL BRAI; RAMACHANDRAN VS, 1987, 11TH EUR C VIS PERC; RAMACHANDRAN VS, SOC NEUR ABSTR, V15, P624; Rock I., 1983, LOGIC PERCEPTION; SERGENT J, 1988, BRAIN, V3, P347; Shepard R. N., 1981, PERCEPTUAL ORG, P279; Teuber H.L., 1966, BRAIN CONSCIOUS EXPE, P182; TROXLER D, 1804, OPHTHALMOLOGISCHE 2, V1, P1; VANESSEN DC, 1979, ANNU REV NEUROSCI, V2, P227, DOI 10.1146/annurev.ne.02.030179.001303; VONDERHEYDT RE, 1978, SCIENCE, V224, P1260; WEISZCRANTZ IL, 1961, CURRENTPROBLEMS ANIM, P30; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	31	330	335	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					699	702		10.1038/350699a0	http://dx.doi.org/10.1038/350699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FJ130	2023631				2022-12-28	WOS:A1991FJ13000058
J	ROSENFELD, MA; SIEGFRIED, W; YOSHIMURA, K; YONEYAMA, K; FUKAYAMA, M; STIER, LE; PAAKKO, PK; GILARDI, P; STRATFORDPERRICAUDET, LD; PERRICAUDET, M; JALLAT, S; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG				ROSENFELD, MA; SIEGFRIED, W; YOSHIMURA, K; YONEYAMA, K; FUKAYAMA, M; STIER, LE; PAAKKO, PK; GILARDI, P; STRATFORDPERRICAUDET, LD; PERRICAUDET, M; JALLAT, S; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG			ADENOVIRUS-MEDIATED TRANSFER OF A RECOMBINANT ALPHA-L-ANTITRYPSIN GENE TO THE LUNG EPITHELIUM INVIVO	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; INSITU HYBRIDIZATION; DNA; ALPHA-1-ANTITRYPSIN; IDENTIFICATION; EXPRESSION; CELLS; INDIVIDUALS; TYPE-5; ASSAY	The respiratory epithelium is a potential site for somatic gene therapy for the common hereditary disorders alpha-1-antitrypsin (alpha-1AT) deficiency and cystic fibrosis. A replication-deficient adenoviral vector (Ad-alpha-1AT) containing an adenovirus major late promoter and a recombinant human alpha-1AT gene was used to infect epithelial cells of the cotton rat respiratory tract in vitro and in vivo. Freshly isolated tracheobronchial epithelial cells infected with Ad-alpha-1AT contained human alpha-1AT messenger RNA transcripts and synthesized and secreted human alpha-1AT. After in vivo intratracheal administration of Ad-alpha-1AT to these rats, human alpha-1AT messenger RNA was observed in the respiratory epithelium, human alpha-1AT was synthesized and secreted by lung tissue, and human alpha-1AT was detected in the epithelial lining fluid for at least 1 week.	NHLBI,PULM BRANCH,BETHESDA,MD 20892; INST GUSTAVE ROUSSY,CNRS,UA 1301,F-94805 VILLEJUIF,FRANCE; TRANSGENE SA,F-67082 STRASBOURG,FRANCE	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Transgene SA								BALLAY A, 1985, EMBO J, V4, P3861, DOI 10.1002/j.1460-2075.1985.tb04158.x; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BERNAUDIN JF, 1988, J IMMUNOL, V140, P3822; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705; CHANOCK RM, 1966, JAMA-J AM MED ASSOC, V195, P151; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COURTNEY M, 1984, P NATL ACAD SCI-BIOL, V81, P669, DOI 10.1073/pnas.81.3.669; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CRYSTAL RG, 1989, TRENDS GENET, V5, P411, DOI 10.1016/0168-9525(89)90200-X; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Evans MJ, 1989, LUNG CELL BIOL, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILARDI P, 1990, FEBS LETT, V267, P60, DOI 10.1016/0014-5793(90)80287-S; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAJAHMAD Y, 1986, J VIROL, V57, P267, DOI 10.1128/JVI.57.1.267-274.1986; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORWITZ MS, 1990, VIROLOGY, P01679; HUBBARD RC, 1990, LUNG, V168, P565, DOI 10.1007/BF02718179; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; MASSARO GD, 1989, LUNG CELL BIOL, P81; MICHALSKI JP, 1985, J IMMUNOL METHODS, V83, P101, DOI 10.1016/0022-1759(85)90063-8; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MORNEX JF, 1986, J CLIN INVEST, V77, P1952, DOI 10.1172/JCI112524; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; Strauss SE, 1984, ADENOVIRUSES, P451; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	40	696	1198	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					431	434		10.1126/science.2017680	http://dx.doi.org/10.1126/science.2017680			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017680				2022-12-28	WOS:A1991FH10300040
J	HALLIGAN, PW; MARSHALL, JC				HALLIGAN, PW; MARSHALL, JC			LEFT NEGLECT FOR NEAR BUT NOT FAR SPACE IN MAN	NATURE			English	Article								IT has been suggested that, among the many visual areas of the human brain, there might be one set of spatial maps specialized for 'near' (peripersonal) and another for 'far' (extrapersonal) space. A distinction between 'grasping distance' and 'walking distance' 1, or between a 'reaching field' and a pointing or throwing field 2 has commonly been made. Evidence for such a division has been found in monkeys. Unilateral ablation of the frontal eye field (area 8) produces a more prominent inattention (or 'neglect') for objects in contralesional far space than in near space; by contrast, unilateral ablation of frontal area 6, which receives direct projections from area 7b (the rostral part of the inferior parietal lobules) results in inattention to visual stimuli limited to contralesional near space 3. Despite predictions that comparable dissociations should be found in man 4, there has been no convincing evidence. We report here such evidence in a patient with a unilateral right hemisphere stroke. Within peripersonal space, he showed severe left visuo-spatial neglect on conventional tests, including the highly sensitive task of line bisection. When line bisection was performed in extrapersonal space, neglect was abolished or attenuated.	RIVERMEAD REHABIL CTR,OXFORD OX1 4XD,ENGLAND		HALLIGAN, PW (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN NEUROL,NEUROPSYCHOL UNIT,OXFORD OX2 6HE,ENGLAND.		Halligan, Peter W/A-1669-2010	Halligan, Peter W/0000-0003-2784-6690				BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P759, DOI 10.1016/0028-3932(86)90075-8; Brain WR, 1941, BRAIN, V64, P244, DOI 10.1093/brain/64.4.244; BROUCHON M, 1986, BIOL FDN GESTURES MO, P95; HALLIGAN PW, 1990, NEUROPSYCHOLOGIA, V28, P1043, DOI 10.1016/0028-3932(90)90139-F; HEILMAN KM, 1990, BEHAV BRAIN SCI, V13, P552, DOI 10.1017/S0140525X00080134; Kennard MA, 1939, ARCH NEURO PSYCHIATR, V41, P1153, DOI 10.1001/archneurpsyc.1939.02270180081008; LATTO R, 1982, ANAL VISUAL BEHAVIOR, P671; PIZZAMIGLIO L, 1989, CORTEX, V25, P471, DOI 10.1016/S0010-9452(89)80060-7; PREVIC FH, 1990, BEHAV BRAIN SCI, V13, P519, DOI 10.1017/S0140525X00080018; RIZZOLATTI G, 1983, BRAIN, V106, P655, DOI 10.1093/brain/106.3.655; Rizzolatti G, 1988, HDB NEUROPSYCHOLOGY, V1, P223; Wilson B.A., 1987, BEHAVIOURAL INATTENT	12	405	407	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					498	500		10.1038/350498a0	http://dx.doi.org/10.1038/350498a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	2014049				2022-12-28	WOS:A1991FG14300050
J	CALHOUN, KH				CALHOUN, KH			OTOLARYNGOLOGY - HEAD AND NECK-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDOSCOPIC SINUS SURGERY; ARGON-LASER; THYROPLASTY; CHILDREN				CALHOUN, KH (corresponding author), UNIV TEXAS,MED BRANCH,JOHN SEALY HOSP,MED BRANCH,GALVESTON,TX 77550, USA.							BECKER S, 1991, JAN MIDDL SECT TRIOL; CASTRO DJ, 1990, LARYNGOSCOPE, V100, P1208; GHERINI SG, 1990, LARYNGOSCOPE, V100, P1276; HOPP M, 1991, JAN W SECT TRIOL SOC; KAMEL R, 1990, ARCH OTOLARYNGOL, V116, P841; KENNEDY DW, 1990, ARCH OTOLARYNGOL, V116, P275; KRAUSE K, 1991, JAN MIDDL SECT TRIOL; KURILOFF DB, 1990, LARYNGOSCOPE, V100, P615; LEVINE HL, 1990, LARYNGOSCOPE, V100, P79; LUSK RP, 1990, LARYNGOSCOPE, V100, P654; MATTOX DE, 1990, LARYNGOSCOPE, V100, P857; MCKENNAN KX, 1990, LARYNGOSCOPE, V100, P1143; RICE DH, 1990, ARCH OTOLARYNGOL, V116, P1061; SASAKI CT, 1990, LARYNGOSCOPE, V100, P849; SIMMONS FB, 1990, OTOLARYNG HEAD NECK, V103, P625, DOI 10.1177/019459989010300417; SLAVIT DH, 1990, LARYNGOSCOPE, V100, P844; STANKIEWICZ JA, 1990, OTOLARYNG HEAD NECK, V103, P931, DOI 10.1177/019459989010300608; STEEN KH, 1990, LARYNGOSCOPE, V100, P525; STEVENSON EW, 1990, LARYNGOSCOPE, V100, P820; TAKAHASHI H, 1990, ARCH OTOLARYNGOL, V116, P1186	20	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3152	3154						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041133				2022-12-28	WOS:A1991FQ77000032
J	DELLON, AL				DELLON, AL			PLASTIC-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BURN WOUNDS; FRACTURES; COVERAGE				DELLON, AL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.							ACHAUER BM, 1986, LANCET, V1, P14; BAIN JR, IN PRESS PLAST RECON; BURKE JF, 1974, NEW ENGL J MED, V290, P269, DOI 10.1056/NEJM197401312900509; COMPTON CC, 1989, LAB INVEST, V60, P600; DELLON A L, 1985, Journal of Reconstructive Microsurgery, V2, P7, DOI 10.1055/s-2007-1007040; DELLON AL, 1988, ANN PLAS SURG, V20, P117, DOI 10.1097/00000637-198802000-00004; DELLON AL, 1988, ANN PLAS SURG, V20, P103, DOI 10.1097/00000637-198802000-00001; DELLON AL, 1988, DIABETES, V37, pA139; DELLON AL, 1990, SEP AM SOC SURG HAND; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; GRUSS JS, 1986, PLAST RECONSTR SURG, V78, P9; Kelly K J, 1990, J Craniofac Surg, V1, P168, DOI 10.1097/00001665-199001040-00003; LEE WPA, IN PRESS PLAST RECON; MACKINNON SE, 1988, SURGERY PERIPHERAL N, pCH15; MANSON PN, 1990, PLAST RECONSTR SURG, V85, P202, DOI 10.1097/00006534-199002000-00006; MANSON PN, 1985, PLAST RECONSTR SURG, V76, P1; MASSEM M, 1990, PLAST RECONSTR SURG, V85, P773; MATHES SJ, 1982, PLAST RECONSTR SURG, V69, P815, DOI 10.1097/00006534-198205000-00018; MAY JW, 1982, NEW ENGL J MED, V306, P253, DOI 10.1056/NEJM198202043060501; MUNSTER AM, 1990, ANN SURG, V211, P676, DOI 10.1097/00000658-199006000-00005; TERZIS JK, 1990, 6TH P INT S FAC NERV, P525; 1990, AM COLL SURGEONS DEC, P51	23	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3160	3162		10.1001/jama.265.23.3160	http://dx.doi.org/10.1001/jama.265.23.3160			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041136				2022-12-28	WOS:A1991FQ77000036
J	ABRAMSON, SB; DOBRO, J; EBERLE, MA; BENTON, M; REIBMAN, J; EPSTEIN, H; RAPOPORT, DM; BELMONT, HM; GOLDRING, RM				ABRAMSON, SB; DOBRO, J; EBERLE, MA; BENTON, M; REIBMAN, J; EPSTEIN, H; RAPOPORT, DM; BELMONT, HM; GOLDRING, RM			ACUTE REVERSIBLE HYPOXEMIA IN SYSTEMIC LUPUS-ERYTHEMATOSUS	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLEMENT ACTIVATION; NEUTROPHIL AGGREGATION; INCREASED EXPRESSION; C5A ANAPHYLATOXINS; RECEPTOR CR3; DISEASE; C3A; HEMODIALYSIS; GLYCOPROTEIN; LEUKOSTASIS	Objective: To determine the frequency of unexplained reversible hypoxemia in patients with systemic lupus erythematosus and to assess the relation between hypoxemia and elevated plasma levels of complement split products. Design: Cohort study. Setting: Inpatient and outpatient facilities of the New York University Medical Center/Bellevue Hospital and the Hospital for Joint Diseases. Patients: Case patients were 22 patients hospitalized with disease exacerbation and no evidence of parenchymal lung disease on chest roentgenogram. Four patients with stable disease were followed in the outpatient clinic, and five healthy normal volunteers served as controls. Measurements: Plasma levels of complement split products (C3a, factor Bb fragment), alveolar-arterial (A-a) Po2 gradients, and pulmonary function were measured. Main Results: Nine episodes of hypoxemia or hypocapnia (mean A-a gradient, 30.4 +/- 4.8 mm Hg) or both (despite normal chest roentgenogram results) were noted in six hospitalized patients (group 1). Gas exchange improved within 72 hours of steroid therapy (mean A-a gradient, 11.6 +/- 4.3 mm Hg; P < 0.01). These patients had an elevated initial mean C3a level (938.4 +/- 246.8 ng/mL) that decreased within 72 hours (407.8 +/- 80.9 ng/mL; P < 0.01), concomitant with improved oxygenation. Ventilation-perfusion scans, obtained for four of six group 1 patients, excluded pulmonary emboli. Four hospitalized patients (group 2) had a normal A-a gradient (mean, 7.5 +/- 2.7 mm Hg). The mean C3a level of this group (358.3 +/- 39.2 ng/mL) was lower than that of group 1 (P < 0.05). Four patients with stable disease (group 3) had a mean A-a gradient and a mean C3a level of 3.3 +/- 2.7 mm Hg and 237.8 +/- 105.7 ng/mL, respectively, similar to values found in five normal volunteers, in whom the mean A-a gradient was 3.7 +/- 1.7 mm Hg and the mean C3a level was 124.8 +/- 9.2 ng/mL. Conclusion: A syndrome of reversible hypoxemia, unassociated with parenchymal lung disease, is unexpectedly common in acutely ill, hospitalized patients with systemic lupus erythematosus. The pathogenesis of this syndrome is unclear, although the data are compatible with the hypothesis that hypoxemia may be related to pulmonary leukoaggregation.	NYU MED CTR, DEPT MED, DIV RHEUMATOL, NEW YORK, NY 10016 USA; NYU MED CTR, DEPT MED, DIV PULM CRIT CARE, NEW YORK, NY 10016 USA	New York University; New York University	ABRAMSON, SB (corresponding author), HOSP JOINT DIS & MED CTR, INST ORTHOPAED, DEPT RHEUMAT DIS, 301 E 17TH ST, NEW YORK, NY 10003 USA.		Benton, Michael J/A-5639-2008	Benton, Michael J/0000-0002-4323-1824; Abramson, Steven/0000-0002-0668-6344; Belmont, Howard/0000-0003-3389-2976; Reibman, Joan/0000-0001-7878-1511; goldring, roberta/0000-0003-3319-4932; Rapoport, David/0000-0002-4855-2600				ABRAMSON SB, 1983, ARTHRITIS RHEUM-US, V26, P630, DOI 10.1002/art.1780260509; ALARCONSEGOVIA D, 1961, DIS CHEST, V39, P7; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1985, NEW ENGL J MED, V312, P457, DOI 10.1056/NEJM198502213120801; BELMONT HM, 1986, ARTHRITIS RHEUM, V29, P1085, DOI 10.1002/art.1780290905; BURGESS JH, 1974, CIRCULATION, V49, P541, DOI 10.1161/01.CIR.49.3.541; BUYON J, 1988, CLIN RES, V36, pA531; BUYON JP, 1988, CLIN IMMUNOL IMMUNOP, V46, P141, DOI 10.1016/0090-1229(88)90014-1; BUYON JP, 1987, LEUKOCYTE TYPING, V3, P844; CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901; CHENOWETH DE, 1980, MOL IMMUNOL, V17, P151, DOI 10.1016/0161-5890(80)90067-X; CRADDOCK PR, 1977, NEW ENGL J MED, V296, P769, DOI 10.1056/NEJM197704072961401; CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710; GIVEN WP, 1984, ARTHRITIS RHEUM, V27, P631, DOI 10.1002/art.1780270605; GOLDSTEIN I, 1973, P NATL ACAD SCI USA, V70, P2916, DOI 10.1073/pnas.70.10.2916; HAMMERSCHMIDT DE, 1980, LANCET, V1, P947; HAMMERSCHMIDT DE, 1978, BLOOD, V51, P721; HARVEY AM, 1954, MEDICINE, V33, P291, DOI 10.1097/00005792-195412000-00001; HOFFBRAND BI, 1965, BMJ-BRIT MED J, V1, P1273, DOI 10.1136/bmj.1.5445.1273; HOPKINS P, 1988, ARTHRITIS RHEUM, V31, P632, DOI 10.1002/art.1780310508; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; JACOB HS, 1980, NEW ENGL J MED, V302, P789; JESSAR RA, 1953, ANN INTERN MED, V38, P717, DOI 10.7326/0003-4819-38-4-717; MOORE FD, 1986, NEW ENGL J MED, V314, P948, DOI 10.1056/NEJM198604103141503; MYERS JL, 1986, AM J CLIN PATHOL, V85, P552, DOI 10.1093/ajcp/85.5.552; MYHRE JR, 1959, ACTA MED SCAND, V165, P55; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; POLLEY MJ, 1983, J EXP MED, V158, P603, DOI 10.1084/jem.158.2.603; RATNOFF WD, 1985, COMPLEMENT, P215; SEGAL AM, 1985, SEMIN ARTHRITIS RHEU, V14, P202, DOI 10.1016/0049-0172(85)90040-X; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WEBSTER RO, 1980, IMMUNOPHARMACOLOGY, V2, P201, DOI 10.1016/0162-3109(80)90050-8	32	57	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					941	947		10.7326/0003-4819-114-11-941	http://dx.doi.org/10.7326/0003-4819-114-11-941			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024861				2022-12-28	WOS:A1991FM97900005
J	DINHXUAN, AT; HIGENBOTTAM, TW; CLELLAND, CA; PEPKEZABA, J; CREMONA, G; BUTT, AY; LARGE, SR; WELLS, FC; WALLWORK, J				DINHXUAN, AT; HIGENBOTTAM, TW; CLELLAND, CA; PEPKEZABA, J; CREMONA, G; BUTT, AY; LARGE, SR; WELLS, FC; WALLWORK, J			IMPAIRMENT OF ENDOTHELIUM-DEPENDENT PULMONARY-ARTERY RELAXATION IN CHRONIC OBSTRUCTIVE LUNG-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NITRIC-OXIDE; RELAXING FACTOR; SMOOTH-MUSCLE; GUANOSINE-MONOPHOSPHATE; RAT; VASOCONSTRICTION; CIRCULATION; CELLS; TRANSPLANTATION; INHIBITION	Background. Endothelial cells release endothelium-derived relaxing factor (EDRF) in a variety of vascular beds, including the pulmonary circulation. However, the role of EDRF-mediated pulmonary-artery relaxation in chronic hypoxic lung disease is unknown. Methods. We studied endothelium-dependent relaxation mediated by EDRF in vitro in pulmonary arteries that had been obtained from 22 patients undergoing heart-lung transplantation for end-stage chronic obstructive lung disease. Control pulmonary arteries were obtained from 15 patients undergoing lobectomy for lung carcinoma who did not have evidence of other chronic lung disease. The responses of all vascular rings (external diameter, 1.2 to 3.4 mm) to the endothelium-dependent vasodilators acetylcholine and adenosine diphosphate were studied immediately after lung excision. Results. Pulmonary arterial rings from the patients with chronic lung disease developed a greater tension (2.19 +/- 0.16 g) in response to phenylephrine (10(-6) M) than the rings from control patients (1.28 +/- 0.18 g, P < 0.05). Inhibition of EDRF synthesis by treatment with N(G)-monomethyl-L-arginine (10(-4) M) eliminated this difference, increasing the tension in the rings from the controls (P < 0.01) but not in those from the patients with chronic lung disease. Rings from control patients relaxed in response to cumulative doses (10(-10) to 10(-5) M) of acetylcholine (maximal relaxation, 81.3 +/- 3.9 percent) and adenosine diphosphate (maximal relaxation, 85.3 +/- 2.6 percent). By contrast, rings from patients with chronic obstructive lung disease achieved only 41.3 +/- 4.8 percent of maximal relaxation in response to acetylcholine (n = 32) and 49.4 +/- 5.5 percent in response to adenosine diphosphate (n = 24) (P < 0.001, as compared with control rings). Rings from both the controls and the patients with chronic lung disease relaxed similarly in response to the endothelium-independent vasodilator sodium nitroprusside (10(-4) M). There was an inverse correlation between the degree of intimal thickening and the level of maximal relaxation of the rings from the patients with chronic lung disease (r = -0.60, P < 0.001). Maximal relaxation was also related directly to the partial pressure of arterial oxygen before transplantation (r = 0.68, P < 0.01) and inversely to the partial pressure of arterial carbon dioxide before transplantation (r = -0.55, P < 0.01), but not to the forced expiratory volume in one second (r = 0.19, P not significant). Conclusions. Endothelium-dependent pulmonary-artery relaxation in vitro is impaired in arteries from patients with end-stage chronic obstructive lung disease. Such impairment may contribute to the development of pulmonary hypertension in chronic hypoxic lung disease.	PAPWORTH HOSP, DEPT RESP PHYSIOL, CAMBRIDGE CB3 8RE, ENGLAND; PAPWORTH HOSP, DEPT CARDIOTHORAC SURG, CAMBRIDGE CB3 8RE, ENGLAND; PAPWORTH HOSP, DEPT HISTOPATHOL, CAMBRIDGE CB3 8RE, ENGLAND	Papworth Hospital; Papworth Hospital; Papworth Hospital			Pepke-Zaba, Joanna/AGW-3073-2022; DINH-XUAN, Anh Tuan/A-9691-2008	DINH-XUAN, Anh Tuan/0000-0001-8651-5176				ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; [Anonymous], 1963, CIRCULATION, V27, P594, DOI DOI 10.1161/01.CIR.27.4.594; ARCHER SL, 1989, BIOCHEM BIOPH RES CO, V164, P1198, DOI 10.1016/0006-291X(89)91796-8; ARMITAGE P, 1987, STAT METHODS; BORLAND CDR, 1989, EUR RESPIR J, V2, P56; BRASHERS VL, 1988, J CLIN INVEST, V82, P1495, DOI 10.1172/JCI113757; BURROWS B, 1972, NEW ENGL J MED, V286, P912, DOI 10.1056/NEJM197204272861703; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; CRAWLEY DE, 1990, BRIT J PHARMACOL, V101, P166; Dinh Xuan AT, 1989, EUR J PHARMACOL, V163, P401, DOI 10.1016/0014-2999(89)90217-3; Dinh Xuan AT, 1990, BRIT J PHARMACOL, V99, P9, DOI 10.1111/j.1476-5381.1990.tb14643.x; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; KON V, 1990, J CLIN INVEST, V85, P1728, DOI 10.1172/JCI114628; LIU SF, 1991, AM REV RESPIR DIS, V143, P32, DOI 10.1164/ajrccm/143.1.32; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MAGEE F, 1988, THORAX, V43, P183, DOI 10.1136/thx.43.3.183; MAZMANIAN GM, 1989, J APPL PHYSIOL, V66, P1040, DOI 10.1152/jappl.1989.66.3.1040; MEYRICK B, 1978, LAB INVEST, V38, P188; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; MONCADA S, 1987, THROMB DIATH HAEMO, P597; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; OGAWA S, 1990, BRIT J HAEMATOL, V75, P517, DOI 10.1111/j.1365-2141.1990.tb07792.x; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANG JA, 1982, AM REV RESPIR DIS, V125, P194; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PENKETH A, 1987, BRIT MED J, V295, P311, DOI 10.1136/bmj.295.6593.311; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; REEVES JT, 1989, PULMONARY CIRCULATIO, P27; ROBERTSON BE, 1990, EXP PHYSIOL, V75, P255, DOI 10.1113/expphysiol.1990.sp003399; SCOTT J, 1988, LANCET, V2, P192; VANHOUTTE PM, 1988, NEW ENGL J MED, V319, P512, DOI 10.1056/NEJM198808253190809; WARREN JB, 1989, CLIN SCI, V77, P671, DOI 10.1042/cs0770671; WILKINSON M, 1988, Q J MED, V66, P65; XUAN ATD, 1989, J INT MED RES, V17, P305, DOI 10.1177/030006058901700401; YAMAGUCHI T, 1989, EUR J PHARMACOL, V161, P259, DOI 10.1016/0014-2999(89)90856-X	40	454	470	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1991	324	22					1539	1547		10.1056/NEJM199105303242203	http://dx.doi.org/10.1056/NEJM199105303242203			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN051	2027358				2022-12-28	WOS:A1991FN05100003
J	PRETTYMAN, RJ; FRIEDMAN, T				PRETTYMAN, RJ; FRIEDMAN, T			CARE OF WOMEN WITH PUERPERAL PSYCHIATRIC-DISORDERS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									LEICESTER GEN HOSP,LEICESTER LE5 4PW,ENGLAND	University Hospitals of Leicester NHS Trust; Leicester General Hospital								KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; Marce LV, 1858, TRAITE FOLIE FEMMES; OATES M, 1988, MOTHERHOOD MENTAL IL, V2, P138	3	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1245	1246		10.1136/bmj.302.6787.1245	http://dx.doi.org/10.1136/bmj.302.6787.1245			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP272	2043849	Green Published, Bronze			2022-12-28	WOS:A1991FP27200025
J	SEIDMAN, DS; LAOR, A; GALE, R; STEVENSON, DK; MASHIACH, S; DANON, YL				SEIDMAN, DS; LAOR, A; GALE, R; STEVENSON, DK; MASHIACH, S; DANON, YL			BIRTH-WEIGHT, CURRENT BODY-WEIGHT, AND BLOOD-PRESSURE IN LATE ADOLESCENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; ADULT LIFE; PREGNANCY; CHILDHOOD; CHILDREN; SIZE	Objective - To study the effect of birth weight and body weight on blood pressure in late adolescence. Design - Analysis of data on weight, height, and blood pressure at age 17 of subjects from the Jerusalem perinatal study, according to their birth weight. Data for men and women were analysed separately. Setting - Jerusalem, Israel. Subjects - 32 580 subjects (19 734 men and 12 846 women) born in the three major hospitals in Jerusalem during 1964-71 and subsequently drafted in to the army. Main outcome measures - Correlations between birth weight and blood pressure at age 17 and weight and height at age 17 and blood pressure. Results - Diastolic and systolic blood pressures were associated with birth weight in both young men and young women, but the correlation coefficients were low. A high body weight at age 17 (> 66 kg for women, > 75 kg for men) rather than a low birth weight (< 2500 g) was linked with higher systolic and diastolic blood pressures in both men and women (p < 0.01). Conclusions - Intrauterine environment, as reflected by birth weight, has little effect on blood pressure in young men and women. Modification of factors which lead to excess weight during adolescence may have a major role in preventing hypertension in adults.	ISRAELI DEF FORCES, MED CORPS, MED STAT BRANCH, JERUSALEM, ISRAEL; BIKUR CHOLIM HOSP, DEPT NEONATOL, JERUSALEM, ISRAEL; STANFORD UNIV, MED CTR, SCH MED, DEPT PAEDIAT, STANFORD, CA 94305 USA; TEL AVIV UNIV, SACKLER SCH MED, BEILINSON MED CTR, DIV PAEDIAT IMMUNOL, TEL AVIV, ISRAEL	Stanford University; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	SEIDMAN, DS (corresponding author), CHAIM SHEBA MED CTR, DEPT OBSTET & GYNAECOL, IL-52621 TEL HASHOMER, ISRAEL.							BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Cater J, 1984, LOW BIRTH WEIGHT MED, P191; DAVIES AM, 1969, ISRAEL J MED SCI, V5, P1095; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HACK M, 1990, PEDIATR RES, V27, pA93; HARLAP S, 1977, ISRAEL J MED SCI, V13, P1073; HIGGINS M, 1980, AM J EPIDEMIOL, V111, P142, DOI 10.1093/oxfordjournals.aje.a112882; KARK JD, 1986, ISRAEL J MED SCI, V22, P318; LAUER RM, 1989, PEDIATRICS, V84, P633; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; SIMPSON A, 1981, HYPERTENSION YOUNG O, P154; WILSON SL, 1985, HYPERTENSION, V7, P417, DOI 10.1161/01.HYP.7.3_Pt_1.417; 1985, SAS USERS GUIDE	17	128	129	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1991	302	6787					1235	1237		10.1136/bmj.302.6787.1235	http://dx.doi.org/10.1136/bmj.302.6787.1235			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043845	Bronze, Green Published			2022-12-28	WOS:A1991FP27200020
J	KONDRASHOV, AS; CROW, JF				KONDRASHOV, AS; CROW, JF			HAPLOIDY OR DIPLOIDY - WHICH IS BETTER	NATURE			English	Article							SELECTION	ALTHOUGH the evolutionary advantages of sexual reproduction have been extensively discussed 1-3, much less attention has been paid to haploid and diploid phases of the sexual life cycle. The relative lengths of these phases differ greatly in various taxa, including as extremes those with one or the other phase reduced to a single cell. Here we consider the efficiency of elimination of deleterious mutations as an evolutionary force and compare the mutation loads under haploid and diploid selection, L(n) and L2n. With truncation-like selection, partial dominance, and heterozygous effect of a mutation less than about 1/4 its hemizygous effect, L2n < L(n); otherwise L2n > L(n). The difference becomes important when the genomic deleterious mutation rate exceeds about 1 per genome. This suggests that the mutation rate, degree of dominance and mode of selection can be important in life-cycle evolution.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; ACAD SCI USSR,CTR RES COMP,PUSHCHINO 142292,USSR	University of Wisconsin System; University of Wisconsin Madison; Russian Academy of Sciences								CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; CROW JAMES F., 1965, AMER NATUR, V99, P439, DOI 10.1086/282389; CROW JF, 1979, P NATL ACAD SCI USA, V76, P396, DOI 10.1073/pnas.76.1.396; EFROIMSON V, 1932, J BIOL, V1, P87; Haldane JBS, 1937, AM NAT, V71, P337, DOI 10.1086/280722; KARLIN S, 1974, THEOR POPUL BIOL, V5, P59, DOI 10.1016/0040-5809(74)90052-5; KIMURA M, 1961, JAPAN J GENET      S, V36, P179; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Michod R. E., 1988, THE EVOLUTION OF SEX; MILKMAN R, 1978, GENETICS, V88, P391	13	147	151	0	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					314	315		10.1038/351314a0	http://dx.doi.org/10.1038/351314a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034273				2022-12-28	WOS:A1991FM97600059
J	THELEN, M; ROSEN, A; NAIRN, AC; ADEREM, A				THELEN, M; ROSEN, A; NAIRN, AC; ADEREM, A			REGULATION BY PHOSPHORYLATION OF REVERSIBLE ASSOCIATION OF A MYRISTOYLATED PROTEIN-KINASE-C SUBSTRATE WITH THE PLASMA-MEMBRANE	NATURE			English	Article							PHORBOL ESTERS; GROWTH-FACTORS; OKADAIC ACID; ACTIVATION; RECEPTOR; BINDING; BRAIN	PROTEIN kinase C (PKC) transduces receptor-mediated signals by phosphorylating membrane-bound substrates which then act as effectors of specific cellular responses 1. The myristoylated alanine-rich C kinase substrate (MARCKS) is a specific PKC substrate which has been implicated in macrophage activation, neurosecretion and growth factor-dependent mitogenesis 2-5. Myristoylation of MARCKS is required for effective binding to the plasma membrane 6 where it colocalizes with PKC 7. Here we report that PKC-dependent phosphorylation displaces MARCKS from the membrane and that its subsequent dephosphorylation is accompanied by its reassociation with the membrane. This cycle of phosphorylation-dependent membrane attachment and detachment of a myristoylated protein represents a novel mechanism of reversible membrane targeting. As MARCKS is a calmodulin- and actin-binding protein (ref. 8, and J. Hartwig et al., manuscript submitted), the cycle of membrane attachment/detachment represents a mechanism through which PKC might reversibly regulate actin-membrane interaction.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University				Nairn, Angus/0000-0002-7075-0195				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; DEWALD B, 1988, J BIOL CHEM, V263, P16179; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	17	355	365	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					320	322		10.1038/351320a0	http://dx.doi.org/10.1038/351320a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034276				2022-12-28	WOS:A1991FM97600062
J	WILLEY, J; SANTAMARIA, R; GUIJARRO, J; GEISTLICH, M; LOSICK, R				WILLEY, J; SANTAMARIA, R; GUIJARRO, J; GEISTLICH, M; LOSICK, R			EXTRACELLULAR COMPLEMENTATION OF A DEVELOPMENTAL MUTATION IMPLICATES A SMALL SPORULATION PROTEIN IN AERIAL MYCELIUM FORMATION BY S-COELICOLOR	CELL			English	Article							STREPTOMYCES-COELICOLOR; COLONY MUTANTS; A-FACTOR; GRISEUS; DIFFERENTIATION; QUANTITIES; SEQUENCE; CLONING; A3(2)	The filamentous bacterium S. coelicolor differentiates by forming aerial hyphae, which protrude into the air and metamorphose into chains of spores. Aerial hyphae formation is associated with the production of a small, abundant protein, SapB, which is present in a zone around colonies of differentiating bacteria. Production of SapB is impaired in bld mutants, which are blocked in aerial hyphae formation, but not in whi mutants in which spore formation is prevented. We report that aerial hyphae formation by a newly identified bld mutant is restored by juxtaposition of the mutant near colonies of SapB-producing bacteria or by the application of the purified protein near mutant colonies. These observations implicate SapB in aerial mycelium formation and suggest that SapB is a morphogenetic protein that enables hyphae on the surface of colonies to grow into the air.			WILLEY, J (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,BIOL LABS,CAMBRIDGE,MA 02138, USA.		Moya GUIJARRO, Arsenio Jesús/GXH-0909-2022; Santamaria, Ramon I/M-9069-2019; Santamaria, Ramon I/K-2870-2014	Santamaria, Ramon I/0000-0002-2181-6776; Santamaria, Ramon I/0000-0002-2181-6776; Willey, Joanne/0000-0003-4544-4417				ADAMIDIS T, 1990, J BACTERIOL, V172, P2962, DOI 10.1128/jb.172.6.2962-2969.1990; BIRO S, 1980, EUR J BIOCHEM, V103, P359, DOI 10.1111/j.1432-1033.1980.tb04322.x; CHAMPNESS WC, 1988, J BACTERIOL, V170, P1168, DOI 10.1128/jb.170.3.1168-1174.1988; Chater K. F., 1982, CURR TOP MICROBIOL I, V96, P69; Chater K. F., 1984, MICROBIAL DEV, P89; CHATER KF, 1972, J GEN MICROBIOL, V72, P9, DOI 10.1099/00221287-72-1-9; CHATER KF, 1989, REGULATION PROCARYOT, V1, P277; GUIJARRO J, 1988, J BACTERIOL, V170, P1895, DOI 10.1128/jb.170.4.1895-1901.1988; HARA O, 1982, J ANTIBIOT, V35, P349, DOI 10.7164/antibiotics.35.349; Hopwood D.A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1988, PROC R SOC SER B-BIO, V235, P121, DOI 10.1098/rspb.1988.0067; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KHOKHLOV AS, 1973, Z ALLG MIKROBIOL, V13, P647, DOI 10.1002/jobm.3630130803; KHOKHLOV AS, 1985, 6TH P INT S ACT BIOL, P791; KIM SK, 1990, CELL, V61, P19, DOI 10.1016/0092-8674(90)90211-V; LAWLOR EJ, 1987, GENE DEV, V1, P1305, DOI 10.1101/gad.1.10.1305; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCANN PA, 1979, J ANTIBIOT, V32, P673, DOI 10.7164/antibiotics.32.673; MENDEZ C, 1987, J BACTERIOL, V169, P5715, DOI 10.1128/jb.169.12.5715-5720.1987; MERRICK MJ, 1976, J GEN MICROBIOL, V96, P299, DOI 10.1099/00221287-96-2-299; PIRET JM, 1985, J BACTERIOL, V163, P965, DOI 10.1128/JB.163.3.965-972.1985; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; Thomas J O, 1978, Methods Cell Biol, V18, P429	23	152	155	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					641	650		10.1016/0092-8674(91)90096-H	http://dx.doi.org/10.1016/0092-8674(91)90096-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032288				2022-12-28	WOS:A1991FM03700014
J	ENTHOVEN, AC; KRONICK, R				ENTHOVEN, AC; KRONICK, R			UNIVERSAL HEALTH-INSURANCE THROUGH INCENTIVES REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROMOTE QUALITY; CARE; CHOICE; ECONOMY; 1990S; TRIAL; COST; PLAN	Roughly 35 million Americans have no health care coverage. Health care expenditures are out of control. The problems of access and cost are inextricably related. Important correctable causes include cost-unconscious demand, a system not organized for quality and economy, market failure, and public funds not distributed equitably or effectively to motivate widespread coverage. We propose Public Sponsor agencies to offer subsidized coverage to those otherwise uninsured, mandated employer-provided health insurance, premium contributions from all employers and employees, a limit on tax-free employer contributions to employee health insurance, and "managed competition." Our proposed new government revenues equal proposed new outlays. We believe our proposal will work because efficient managed care does exist and can provide satisfactory care for a cost far below that of the traditional fee-for-service third-party payment system. Presented with an opportunity to make an economically responsible choice, people choose value for money; the dynamic created by these individual choices will give providers strong incentives to render high-quality, economical care. We believe that providers will respond to these incentives.	UNIV CALIF SAN DIEGO,DEPT COMMUNITY & FAMILY MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego	ENTHOVEN, AC (corresponding author), STANFORD UNIV,GRAD SCH BUSINESS,STANFORD,CA 94305, USA.							DAVIES AR, 1986, HEALTH SERV RES, V21, P429; ELDMAN R, 1989, PHS89343 US DEP HLTH; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; ENTHOEN A, 1988, THEORY PRACTICE MANA; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; FELDMAN R, 1989, J HUM RESOUR, V24, P115, DOI 10.2307/145935; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; JENSEN GA, 1987, MILBANK Q, V65, P521, DOI 10.2307/3349979; KRONICK R, 1990, THESIS U ROCHESTER R; LONG S, 1988, ENTHOVENKRONICK PLAN; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; REIS P, 1987, PHS871250 US DEP HLT; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SCHIEBER GJ, 1987, HEALTH AFFAIR, V6, P105, DOI 10.1377/hlthaff.6.3.105; SLOSS EM, 1987, ANN INTERN MED, V106, P130, DOI 10.7326/0003-4819-106-1-130; WELLER CD, 1984, IOWA LAW REV, V69, P1351; WILENSKY GR, 1988, HEALTH AFFAIR, V7, P133, DOI 10.1377/hlthaff.7.3.133; 1988, HLTH INSURANCE UNINS; 1991, 1991 US IND OUTLOOK; 1989, MANAGED CARE PLANS; 1987, HLTH CARE FINANC REV, V8, P1	23	53	57	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2532	2536		10.1001/jama.265.19.2532	http://dx.doi.org/10.1001/jama.265.19.2532			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK903	2020071				2022-12-28	WOS:A1991FK90300027
J	LITAM, P; SWAN, F; CABANILLAS, F; TUCKER, SL; MCLAUGHLIN, P; HAGEMEISTER, FB; RODRIGUEZ, MA; VELASQUEZ, WS				LITAM, P; SWAN, F; CABANILLAS, F; TUCKER, SL; MCLAUGHLIN, P; HAGEMEISTER, FB; RODRIGUEZ, MA; VELASQUEZ, WS			PROGNOSTIC VALUE OF SERUM BETA-2 MICROGLOBULIN IN LOW-GRADE LYMPHOMA	ANNALS OF INTERNAL MEDICINE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LACTATE-DEHYDROGENASE LEVELS; HL-A ANTIGENS; MALIGNANT-LYMPHOMA; MULTIPLE-MYELOMA; HODGKINS-DISEASE; CELL LYMPHOMAS; SMALL SUBUNIT; BETA-2-MICROGLOBULIN; BETA2-MICROGLOBULIN	Objective: To evaluate serum beta-2 microglobulin (beta-2M) and other prognostic indicators in previously untreated low-grade lymphoma. Design: Cohort study of 80 patients with uniformly treated low-grade lymphoma, followed for a median of 21 months. These 80 patients, all of whom had serum beta-2M drawn within 2 weeks before starting therapy, were derived from a cohort of 119 previously untreated patients entered into one of three clinical trials. Setting: Tertiary referral cancer center. Patients: Eight previously untreated stage I to IV patients (mean age, 55 years). Intervention: Treatment was given according to Ann Arbor stage: Patients in stage IV were treated with CHOP-blemycin and maintained on interferon therapy; those in stage III received CHOP-bleomycin and radiotherapy; and those in stage I and II received COP-bleomycin and radiotherapy. Measurements: Outcome was determined by assessing complete remission rate and time to treatment failure. Univariate and multivariate analyses were used. Results: The complete remission rate for patients with a beta-2M level of 3.0 mg/L or greater was 36% compared with 71% for those with a level of less than 3.0 mg/L. Using multivariate analysis that tested beta-2M as a continuous variable, it was selected as the most significant factor for complete response. The adjusted odds ratio was 0.285 (95% CI, 0.101 to 0.809). The Ann Arbor stage had marginal significance (adjusted odds ratio, 0.435; CI, 0.150 to 1.263). For time to treatment failure, beta-2M was the only variable retained in the multivariate model. At 42 months, no patient with a beta-2M level of 3.0 mg/L or greater was projected to be in remission as compared with 85% of patients with a beta-2M level of less than 3.0 mg/L. Conclusions: The serum beta-2M level is a good predictor of complete response and time to treatment failure. A large number of patients should be studied to clarify the role of other potentially independent variables such as stage and age.	UNIV TEXAS, MD ANDERSON CANCER CTR, 1515 HOLCOMBE BLVD, BOX 68, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center				Cabanillas, Fernando/0000-0001-9234-7893				ALEXANIAN R, 1985, AM J HEMATOL, V20, P345, DOI 10.1002/ajh.2830200405; AMLOT PL, 1979, EUR J CANCER, V15, P791, DOI 10.1016/0014-2964(79)90155-5; ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BACH FH, 1976, NEW ENGL J MED, V295, P872, DOI 10.1056/NEJM197610142951606; BACH FH, 1976, NEW ENGL J MED, V295, P927, DOI 10.1056/NEJM197610212951705; BATAILLE R, 1983, BRIT J HAEMATOL, V55, P439, DOI 10.1111/j.1365-2141.1983.tb02158.x; BERGGARD I, 1968, J BIOL CHEM, V243, P4095; BODMER WF, 1981, TISSUE ANTIGENS, V17, P9; CARBONE PP, 1971, CANCER RES, V31, P1860; CHILD JA, 1980, CANCER-AM CANCER SOC, V45, P318, DOI 10.1002/1097-0142(19800115)45:2<318::AID-CNCR2820450220>3.0.CO;2-C; COX DR, 1972, J R STAT SOC B, V34, P187; CRESSWEL.P, 1974, P NATL ACAD SCI USA, V71, P2123, DOI 10.1073/pnas.71.5.2123; DIXON DO, 1987, J CLIN ONCOL, V5, P1670, DOI 10.1200/JCO.1987.5.10.1670; EVRIN PE, 1973, CLIN CHIM ACTA, V43, P183, DOI 10.1016/0009-8981(73)90449-X; FERRARIS AM, 1979, BLOOD, V54, P928; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GOSPODAROWICZ MK, 1984, INT J RADIAT ONCOL, V10, P489, DOI 10.1016/0360-3016(84)90028-2; GREY HM, 1973, J EXP MED, V138, P1608, DOI 10.1084/jem.138.6.1608; HAGBERG H, 1983, CANCER, V51, P2220, DOI 10.1002/1097-0142(19830615)51:12<2220::AID-CNCR2820511212>3.0.CO;2-A; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; JAGANNATH S, 1986, J CLIN ONCOL, V4, P859, DOI 10.1200/JCO.1986.4.6.859; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEGROS M, 1987, P AN M AM SOC CLIN, V6, P748; MALE DK, 1986, IMMUNOLOGY, P57; MCLAUGHLIN P, 1987, J CLIN ONCOL, V5, P867, DOI 10.1200/JCO.1987.5.6.867; MCLAUGHLIN P, 1990, 4TH P INT C MAL LYMP; MOLLER P, 1987, INT J CANCER, V40, P32, DOI 10.1002/ijc.2910400107; MOLLER P, 1986, IMMUNOLOGY, V59, P411; NILSSON K, 1974, TRANSPLANT REV, V21, P53; PARHAM P, 1979, J IMMUNOL, V123, P342; PETERSON PA, 1972, P NATL ACAD SCI USA, V69, P1697, DOI 10.1073/pnas.69.7.1697; ROSENBERG SA, 1982, CANCER, V49, P2112; RUDDERS RA, 1979, CANCER, V43, P1643, DOI 10.1002/1097-0142(197905)43:5<1643::AID-CNCR2820430513>3.0.CO;2-J; SCHNEIDER RJ, 1980, CANCER, V46, P139, DOI 10.1002/1097-0142(19800701)46:1<139::AID-CNCR2820460122>3.0.CO;2-8; SHUSTER J, 1976, CLIN CHIM ACTA, V67, P307, DOI 10.1016/0009-8981(76)90339-9; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; SWAN F, 1988, BLOOD, V72, pA258; TROWSDALE J, 1980, J EXP MED, V152, pS11; VEZZONI MA, 1983, TUMORI, V69, P279, DOI 10.1177/030089168306900401; ZINKERNAGEL RM, 1979, ADV IMMUNOL, V27, P151	40	86	87	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					855	860		10.7326/0003-4819-114-10-855	http://dx.doi.org/10.7326/0003-4819-114-10-855			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014946				2022-12-28	WOS:A1991FL65000004
J	BODENSTEIN, H				BODENSTEIN, H			SUCCESSFUL TREATMENT OF APLASTIC-ANEMIA WITH HIGH-DOSE IMMUNOGLOBULIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							RED-CELL APLASIA; GLOBULIN				BODENSTEIN, H (corresponding author), KLINIKUM MINDEN,W-4950 MINDEN,GERMANY.							BERKMAN SA, 1988, SEMIN HEMATOL, V25, P140; BODENSTEIN H, 1990, BLUT, V61, P168; CHAMPLIN R, 1983, NEW ENGL J MED, V308, P113, DOI 10.1056/NEJM198301203080301; KURTZMAN G, 1989, NEW ENGL J MED, V321, P519, DOI 10.1056/NEJM198908243210807; MCGUIRE WA, 1987, NEW ENGL J MED, V317, P1004, DOI 10.1056/NEJM198710153171606; NEWLAND AC, 1989, BRIT J HAEMATOL, V72, P301, DOI 10.1111/j.1365-2141.1989.tb07708.x	6	6	6	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1368	1369						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017237				2022-12-28	WOS:A1991FK18600018
J	LERNER, RA; BENKOVIC, SJ; SCHULTZ, PG				LERNER, RA; BENKOVIC, SJ; SCHULTZ, PG			AT THE CROSSROADS OF CHEMISTRY AND IMMUNOLOGY - CATALYTIC ANTIBODIES	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; CLAISEN REARRANGEMENT; ENZYMIC CATALYSIS; COMBINING SITES; BINDING-ENERGY; NOBEL LECTURE; SPECIFICITY; GENERATION; AMIDE; HYDROLYSIS	Immunochemistry has historically focused on the nature of antigenicity and antibody-antigen recognition. However, in the last 5 years, the field of immunochemistry has taken a new direction. With the aid of mechanistic and synthetic chemistry, the vast network of molecules and cells of the immune system has been tapped to produce antibodies with a new function - catalytic antibodies. Because antibodies can be generated that selectively bind almost any molecule of interest, this new technology offers the potential to tailor-make highly selective catalysts for applications in biology, chemistry, and medicine. In addition, catalytic antibodies provide fundamental insight into important aspects of biological catalysis, including the importance of transition-state stabilization, proximity effects, general acid and base catalysts, electrophilic and nucleophilic catalysis, and strain.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; PENN STATE UNIV, DEPT CHEM, UNIVERSITY PK, PA 16802 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA	Scripps Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California Berkeley	LERNER, RA (corresponding author), Scripps Res Inst, RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA.							ARATA Y, 1990, J SYNTH ORG CHEM JPN, V6, P482; ARMSTRONG RW, 1989, J AM CHEM SOC, V111, P7530, DOI 10.1021/ja00201a038; BALAN A, 1988, J CHEM SOC CHEM COMM, P106, DOI 10.1039/c39880000106; BALDWIN E, 1989, SCIENCE, V245, P1104, DOI 10.1126/science.2672338; BARTLETT P, 1983, BIOCHEMISTRY-US, V22, P4168; BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BENKOVIC SJ, 1988, P NATL ACAD SCI USA, V85, P5355, DOI 10.1073/pnas.85.15.5355; BLACKBURN GF, IN PRESS ANAL CHEM; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P7246, DOI 10.1021/bi00397a008; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; CARTER EA, 1987, J CHEM PHYS, V86, P862, DOI 10.1063/1.452287; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; COCHRAN AG, 1990, J AM CHEM SOC, V112, P9414, DOI 10.1021/ja00181a065; COCHRAN AG, 1988, J AM CHEM SOC, V110, P7888, DOI 10.1021/ja00231a056; COCHRAN AG, UNPUB; CRAM DJ, 1988, ANGEW CHEM INT EDIT, V27, P1009, DOI 10.1002/anie.198810093; CRAM DJ, 1987, PRIX NOBEL, P129; CRAM DJ, 1987, PRIX NOBEL, P105; DAFFRON A, 1971, BIOCHEM BIOPH RES CO, V52, P779; DANISHEVSKY S, UNPUB; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DURFOR CN, 1988, J AM CHEM SOC, V110, P8713, DOI 10.1021/ja00234a032; ESCHENMOSER A, 1989, 25TH EUCHEM C STER B; GOODMAN JW, 1985, ANTIGEN, V3; HERMES JD, 1987, COLD SPRING HARB SYM, V52, P597, DOI 10.1101/SQB.1987.052.01.068; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1988, J AM CHEM SOC, V110, P5593, DOI 10.1021/ja00224a066; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HILVERT D, UNPUB; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; INAGAMI T, 1969, J BIOCHEM, V65, P809, DOI 10.1093/oxfordjournals.jbchem.a129081; IVERSON BL, 1990, SCIENCE, V249, P659, DOI 10.1126/science.2116666; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; IVERSON BL, 1990, J AM CHEM SOC, V112, P5320, DOI 10.1021/ja00169a044; JACKSON DY, 1988, J AM CHEM SOC, V110, P4841, DOI 10.1021/ja00222a060; JACKSON DY, IN PRESS J AM CHEM S; JACKSON DY, IN PRESS P NATL ACAD; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JACOBS JW, 1989, THESIS U CALIFORNIA; JACOBSEN JL, UNPUB; JANDA K, UNPUB; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1990, J AM CHEM SOC, V112, P8886, DOI 10.1021/ja00180a035; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JANDA KD, 1988, SCIENCE, V241, P1188, DOI 10.1126/science.3413482; JANDA KD, 1988, J AM CHEM SOC, V110, P4835, DOI 10.1021/ja00222a056; JANJIC N, 1989, J AM CHEM SOC, V111, P6374, DOI 10.1021/ja00198a058; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KAISER ET, 1984, SCIENCE, V226, P505, DOI 10.1126/science.6238407; KEINAN E, 1990, PURE APPL CHEM, V62, P2013, DOI 10.1351/pac199062102013; KHORANA HG, 1968, P INT C BIOCH, V7, P17; KITAZUME T, IN PRESS J AM CHEM S; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOSHLAND DE, 1973, SCI AM, V229, P52, DOI 10.1038/scientificamerican1073-52; KRAFT GA, 1989, ANNU REP MED CHEM, V25, P299; LANDSTEINER K, 1944, SPECIFICITY SEROLOGI; Lavallee D. K., 1988, MOL STRUCT ENERG, V9, P279; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; LERNER RA, 1984, ADV IMMUNOL, V36, P1, DOI 10.1016/S0065-2776(08)60898-6; LERNER RA, UNPUB; LUEBKE KJ, 1989, J AM CHEM SOC, V111, P8733, DOI 10.1021/ja00205a033; MARTIN JT, IN PRESS CIBA F S; MERRIFIELD RB, 1985, ANGEW CHEM INT EDIT, V24, P799, DOI 10.1002/anie.198507993; NAKAYAMA GR, IN PRESS CIBA F S; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; Nisonoff A, 1975, ANTIBODY MOL; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PAULING L, 1948, Am Sci, V36, P51; Pauling L, 1944, J AM CHEM SOC, V66, P784, DOI 10.1021/ja01233a039; POCKER Y, 1977, J AM CHEM SOC, V99, P2276, DOI 10.1021/ja00449a042; POLLACK SJ, 1987, COLD SPRING HARB SYM, V52, P97, DOI 10.1101/SQB.1987.052.01.014; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; POLLACK SJ, 1988, SCIENCE, V242, P1038, DOI 10.1126/science.3194752; POLLACK SJ, 1989, J AM CHEM SOC, V111, P1929, DOI 10.1021/ja00187a085; POLLACK SJ, 1988, METHOD ENZYMOL, V178, P551; PRESSMAN D, 1968, STRUCTURAL BASES ANT; RASO W, 1975, BIOCHEMISTRY-US, V14, P584; ROSTER MJ, 1988, SCIENCE, V241, P1200; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SEEBACH D, 1990, ANGEW CHEM INT EDIT, V29, P1320, DOI 10.1002/anie.199013201; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; SHOKAT KM, 1990, ANGEW CHEM INT EDIT, V29, P1296, DOI 10.1002/anie.199012961; SHOKAT KM, 1988, ANGEW CHEM INT EDIT, V27, P1172, DOI 10.1002/anie.198811721; SHOKAT R, IN PRESS CIBA F S; SUDHIR P, 1989, SCIENCE, V244, P1158; TAWFIK DS, 1990, BIOCHEMISTRY-US, V29, P9916, DOI 10.1021/bi00494a023; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; TRAMONTANO A, 1986, P NATL ACAD SCI USA, V83, P6736, DOI 10.1073/pnas.83.18.6736; WESTHEIMER FH, 1962, ADV ENZYMOL, V24, P456; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415; Woolley D., 1952, STUDY ANTIMETABOLITE; ZERNER B, 1964, J AM CHEM SOC, V86, P3674, DOI 10.1021/ja01072a016	102	653	698	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					659	667		10.1126/science.2024118	http://dx.doi.org/10.1126/science.2024118			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024118				2022-12-28	WOS:A1991FK18500037
J	BELL, LR; HORABIN, JI; SCHEDL, P; CLINE, TW				BELL, LR; HORABIN, JI; SCHEDL, P; CLINE, TW			POSITIVE AUTOREGULATION OF SEX-LETHAL BY ALTERNATIVE SPLICING MAINTAINS THE FEMALE DETERMINED STATE IN DROSOPHILA	CELL			English	Article								Sex-lethal is a binary switch gene that controls all aspects of Drosophila sexual dimorphism. It must be active in females and inactive in males. The on/off regulation reflects alternative RNA splicing in which full-length proteins are produced only in females. Here we investigate the role of Sxl in maintaining sexual pathway commitments. By ectopic expression of a female Sxl cDNA in transgenic male flies, we show that Sxl protein induces a rapid switch from male- to female-specific splicing. The ectopically expressed Sxl protein will trans-activate an endogenous wild-type Sxl gene. This establishes a feedback loop in which Sxl proteins induce their own synthesis by directing the female-specific splicing of Sxl transcripts. We conclude that the female determined state is maintained by Sxl through positive autoregulation, while the male determined state is maintained by default.	PRINCETON UNIV, DEPT BIOL, PRINCETON, NJ 08544 USA	Princeton University								BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOPP D, 1991, IN PRESS GENES DEV; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1979, DEV BIOL, V72, P266, DOI 10.1016/0012-1606(79)90117-9; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; ERICKSON JW, 1991, IN PRESS SCIENCE; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEHRING WJ, 1973, DEV SYSTEMS INSECTS, V2; GERGEN JP, 1987, GENETICS, V117, P477; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LINDALEY D, 1985, DROS INFORM SERV, V62, P1; Lindsley D.L., 1990, Drosophila Information Service, V68, P1; LINDSLEY DL, 1986, DROS INF SERV, V64, P1; LINDSLEY DL, 1987, DROS INFORM SERV, V65, P1; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; MAINE EM, 1985, COLD SPRING HARB SYM, V50, P595, DOI 10.1101/SQB.1985.050.01.072; MASON PJ, 1982, J MOL BIOL, V156, P21, DOI 10.1016/0022-2836(82)90456-9; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MULLER H. J., 1932, Proceedings. 6th Int. Congr. Genet., V1, P213; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; OLIVER B, 1990, GENETICS, V125, P535; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROBERTSON HM, 1988, GENETICS, V118, P461; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SANCHEZ L, 1982, ROUX ARCH DEV BIOL, V191, P211, DOI 10.1007/BF00848339; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SCHUPBACH T, 1985, GENETICS, V109, P529; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STEINMANNZWICKY M, 1989, CELL, V57, P157, DOI 10.1016/0092-8674(89)90181-5; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; ZUSMAN SB, 1987, GENETICS, V115, P725	49	282	289	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					229	239		10.1016/0092-8674(91)90157-T	http://dx.doi.org/10.1016/0092-8674(91)90157-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015624				2022-12-28	WOS:A1991FH09200006
J	CORMACK, BP; STRUBIN, M; PONTICELLI, AS; STRUHL, K				CORMACK, BP; STRUBIN, M; PONTICELLI, AS; STRUHL, K			FUNCTIONAL DIFFERENCES BETWEEN YEAST AND HUMAN TFIID ARE LOCALIZED TO THE HIGHLY CONSERVED REGION	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTION INITIATION SITES; TATA-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; FACTOR ATF; GENE; BOX; SEQUENCES	TFIID, the general transcription factor that binds TATA promoter elements, is highly conserved throughout the eukaryotic kingdom. TFIIDs from different organisms contain C-terminal core domains that are at least 80% identical and display similar biochemical properties. Despite these similarities, yeast cells containing human TFIID instead of the endogenous yeast protein grow extremely poorly. Surprisingly, this functional distinction reflects differences in the core domains, not the divergent N-terminal regions. The N-terminal region is unimportant for the essential function(s) of yeast TFIID because expression of the core domain permits efficient cell growth. Analysis of yeast-human hybrid TFIIDs indicates that several regions within the conserved core account for the phenotypic difference, with some regions being more important than others. This species specificity might reflect differences in DNA-binding properties and/or interactions with activator proteins or other components of the RNA polymerase II transcription machinery.	HARVARD UNIV,SCH MED,DEPT MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	CORMACK, BP (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R37GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HOMA FL, 1988, GENE DEV, V2, P40, DOI 10.1101/gad.2.1.40; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAMBADUR R, 1990, P NATL ACAD SCI USA, V87, P9168, DOI 10.1073/pnas.87.23.9168; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; MCNEIL JB, 1986, J MOL BIOL, V187, P363, DOI 10.1016/0022-2836(86)90439-0; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	53	109	111	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					341	348		10.1016/0092-8674(91)90167-W	http://dx.doi.org/10.1016/0092-8674(91)90167-W			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015628				2022-12-28	WOS:A1991FH09200016
J	PROST, J; RONDELEZ, F				PROST, J; RONDELEZ, F			STRUCTURES IN COLLOIDAL PHYSICAL-CHEMISTRY	NATURE			English	Review							ANGLE NEUTRON-SCATTERING; TEMPERATURE-DEPENDENCE; HYDRODYNAMIC RADIUS; FLEXIBLE COILS; PHASE-TRANSITIONS; LIQUID-CRYSTALS; FLUID MEMBRANES; BLUE PHASES; POLYMERS; INTERFACES	The vast range of technological and industrial applications of colloidal systems is largely a direct result of their diversity of structure on microscopic and mesoscopic scales. Recent progress in understanding these structures allows for greater control of the macroscopic properties, as well as providing new avenues of fundamental research in physics, chemistry and materials science.	UNIV PARIS 06,STRUCT & REACT INTERFACES LAB,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; Sorbonne Universite	PROST, J (corresponding author), ECOLE SUPER PHYS & CHIM IND,PHYS CHIM THEOR LAB,10 RUE VAUGUELIN,F-75231 PARIS 05,FRANCE.							ADAMSON AW, 1990, PHYSICAL CHEM SURFAC; AJDARI A, IN PRESS PHYS REV LE; ALDER BJ, 1968, J CHEM PHYS, V49, P3679; ANDELMAN D, 1987, J CHEM PHYS, V86, P3673, DOI 10.1063/1.451970; ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347; AUVRAY L, 1984, J PHYS-PARIS, V45, P913, DOI 10.1051/jphys:01984004505091300; BASTIDE J, 1984, MACROMOLECULES, V17, P83, DOI 10.1021/ma00131a015; BASTIDE J, 1988, MACROMOLECULES, V21, P2647, DOI 10.1021/ma00186a058; BATES FS, 1990, ANNU REV PHYS CHEM, V41, P525, DOI 10.1146/annurev.pc.41.100190.002521; BEENAKKER CWJ, 1988, PHYS REV A, V37, P1697, DOI 10.1103/PhysRevA.37.1697; BELORGEY O, 1991, PHYS REV LETT, V66, P313, DOI 10.1103/PhysRevLett.66.313; BELYAKOV VA, 1985, USP FIZ NAUK, V148, P369; BENOIT H, 1984, PHYSICS FINELY DIVID, P2; BERGE B, 1990, PHYS REV A, V41, P6893, DOI 10.1103/PhysRevA.41.6893; BIBETTE J, 1990, PHYS REV LETT, V66, P2470; Bikerman J, 1973, FOAMS, P1; BIVAS I, 1987, J PHYS-PARIS, V48, P855, DOI 10.1051/jphys:01987004805085500; Boothby W. M., 1986, INTRO DIFFERENTIAL M; BOULIGAND Y, 1972, TISSUE CELL, V4, P189, DOI 10.1016/S0040-8166(72)80042-9; Brule B., 1987, B LIAISON LAB PONTS, V148, P69; CABANE B, 1985, COLLOID SURFACE, V13, P19, DOI 10.1016/0166-6622(85)80003-2; CANDAU S, 1982, ADV POLYM SCI, V44, P27; CHARVOLIN J, 1987, J PHYS-PARIS, V48, P1559, DOI 10.1051/jphys:019870048090155900; DAILLANT J, 1990, EUROPHYS LETT, V12, P715, DOI 10.1209/0295-5075/12/8/008; De Gennes P.-G., 1979, SCALING CONCEPTS POL; DEGENNES PG, 1987, ADV COLLOID INTERFAC, V27, P189, DOI 10.1016/0001-8686(87)85003-0; DEGENNES PG, 1982, J PHYS CHEM-US, V86, P2294, DOI 10.1021/j100210a011; DEGENNES PG, 1972, SOLID STATE COMMUN, V10, P753, DOI 10.1016/0038-1098(72)90186-X; DEGENNES PG, 1972, PHYSICS LIQUID CRYST; DEULING HJ, 1976, BIOPHYS J, V16, P861, DOI 10.1016/S0006-3495(76)85736-0; DJABOUROV M, 1988, CONTEMP PHYS, V29, P273, DOI 10.1080/00107518808224377; Einstein A, 1906, ANN PHYS-BERLIN, V19, P289, DOI 10.1002/andp.19063240204; Flory P.J., 1971, PRINCIPLES POLYM CHE; Friedel G., 1922, ANN PHYS, V9, P273, DOI [DOI 10.1051/ANPHYS/192209180273, 10.1051/anphys/192209180273]; GAE F, 1990, J PHYS, V7, P169; GARLAND C, 1989, P NATO ADV WORKSHOP; GEORGER JH, 1987, J AM CHEM SOC, V109, P6169, DOI 10.1021/ja00254a042; GOLUBOVIC L, 1989, PHYS REV B, V39, P12110, DOI 10.1103/PhysRevB.39.12110; GOODBY JW, 1989, NATURE, V337, P449, DOI 10.1038/337449a0; Graham T., 1861, PHILOS T ROYAL SOC L, V151, P183, DOI DOI 10.1098/RSTL.1861.0011; GUO XH, 1990, PHYS REV LETT, V64, P2579, DOI 10.1103/PhysRevLett.64.2579; HEKL WM, 1986, BERL BUNSEN GES PHYS, V90, P1159; HELFAND E, 1976, MACROMOLECULES, V9, P879, DOI 10.1021/ma60054a001; HELFRICH W, 1985, J PHYS-PARIS, V46, P1263, DOI 10.1051/jphys:019850046070126300; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HELM CA, 1987, EUROPHYS LETT, V4, P697, DOI 10.1209/0295-5075/4/6/010; HORNREICH RM, 1987, Z PHYS B CON MAT, V68, P369, DOI 10.1007/BF01304254; HUSE DA, 1991, PHYS REV LETT, V66, P437, DOI 10.1103/PhysRevLett.66.437; Israelachvili JN, 1985, INTERMOLECULAR SURFA; KAHLWEIT M, 1975, ADV COLLOID INTERFAC, V5, P1, DOI 10.1016/0001-8686(75)85001-9; KJAER K, 1987, PHYS REV LETT, V58, P2224, DOI 10.1103/PhysRevLett.58.2224; KOSE A, 1973, J COLLOID INTERF SCI, V44, P330, DOI 10.1016/0021-9797(73)90224-5; LANDAU LD, 1937, PHYS Z SOWJETUNION, V2, P26; LANGEVIN D, 1978, POLYMER, V19, P875, DOI 10.1016/0032-3861(78)90191-X; LARCHE FC, 1986, PHYS REV LETT, V56, P1700, DOI 10.1103/PhysRevLett.56.1700; LEIBLER L, 1980, MACROMOLECULES, V13, P1602, DOI 10.1021/ma60078a047; LEIBLER S, 1989, STATISTICAL MECHANIC, P46; LEIBLER S, 1990, P NATN ACAD SCI, P6433; LEVELUT AM, 1981, PHYS REV A, V24, P2180, DOI 10.1103/PhysRevA.24.2180; LIN B, 1990, PHYS REV LETT, V65, P191, DOI 10.1103/PhysRevLett.65.191; LIPOWSKY R, 1986, PHYS REV LETT, V56, P2541, DOI 10.1103/PhysRevLett.56.2541; LIPOWSKY R, 1991, NATURE, V349, P475, DOI 10.1038/349475a0; LOSCHE M, 1983, BER BUNSEN PHYS CHEM, V87, P848, DOI 10.1002/bbpc.19830871004; LUCASSEN J, IN PRESS J COLLOID I; LUZZATI V, 1987, PHYSICS AMPHIPHILIC, P131; MARDER M, 1987, PHYS REV A, V36, P438, DOI 10.1103/PhysRevA.36.438; MCCONNELL HM, 1984, P NATL ACAD SCI USA, V81, P3249, DOI 10.1073/pnas.81.10.3249; MCCONNELL HM, 1988, J PHYS CHEM-US, V92, P4520, DOI 10.1021/j100326a053; MILLER A, 1986, PHYS REV LETT, V56, P2633, DOI 10.1103/PhysRevLett.56.2633; MILNER ST, 1988, EUROPHYS LETT, V5, P413, DOI 10.1209/0295-5075/5/5/006; MILNER ST, 1988, J PHYS-PARIS, V49, P1951, DOI 10.1051/jphys:0198800490110195100; MILNER ST, 1988, EUROPHYS LETT, V7, P695, DOI 10.1209/0295-5075/7/8/005; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; MOORE BG, J CHEM SOC F2, V82, P1753; MULLINS WW, 1963, J APPL PHYS, V34, P323, DOI 10.1063/1.1702607; MURRAY CA, 1987, PHYS REV LETT, V58, P1200, DOI 10.1103/PhysRevLett.58.1200; Mysels K. J., 1959, SOAP FILMS STUDIES T; Nelson D.R., 1989, SUPERCONDUCTIVITY QU, P1, DOI [10.1016/S0081-1947(08)60079-X, DOI 10.1016/S0081-1947(08)60079-X]; OTT A, 1990, J PHYS C SOLID STATE, V2, P6862; PAPPAS NA, 1987, HYDROGELS MED PHARM, V1; PAPPAS NA, 1987, HYDROGELS MED PHARM, V2; PARK Y, 1988, PHYS REV A, V37, P2197, DOI 10.1103/PhysRevA.37.2197; Peierls R. E., 1935, ANN I H POINCARE, V5, P177; PELITI L, 1985, PHYS REV LETT, V54, P1690, DOI 10.1103/PhysRevLett.54.1690; PETERS R, 1983, P NATL ACAD SCI-BIOL, V80, P7183, DOI 10.1073/pnas.80.23.7183; PIERANSKI P, 1980, PHYS REV LETT, V45, P569, DOI 10.1103/PhysRevLett.45.569; Plateau J., 1873, STATIQUE EXPT THEORI; POMMIER J, 1990, SOLITONS LIQUID CRYS; PORTE G, 1980, J PHYS CHEM-US, V84, P3105, DOI 10.1021/j100460a027; PROST J, 1984, ADV PHYS, V33, P1, DOI 10.1080/00018738400101631; PROST J, 1980, P C LIQUID CRYSTALS, P125; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; PUSEY PN, 1987, J PHYS-PARIS, V48, P709, DOI 10.1051/jphys:01987004805070900; Ramachandran G.N., 1967, TREATISE COLLAGEN, V1; RATNA BR, 1984, PHYS REV LETT, V53, P2141; RENN SR, 1988, PHYS REV A, V38, P2132, DOI 10.1103/PhysRevA.38.2132; ROUX D, 1990, EUROPHYS LETT, V11, P229, DOI 10.1209/0295-5075/11/3/008; ROUX D, 1987, J PHYS-PARIS, V49, P673; ROUX D, 1990, DYNAMICS PATERNS COM, P19; SACKMANN E, 1987, PHYSICS AMPHIPHILIC, P25; SCHLOSSMAN ML, 1989, MATERIALS RES SOC P, P351; SCHMUR JM, 1987, THIN SOLID FILMS, V152, P181; Schwarz H, 1890, GESAMMELTE MATH ABHA, V1; SEMENOV AN, 1985, ZH EKSP TEOR FIZ, V0061, P00733; SKOULIOS A, 1967, ADV COLLOID INTERFAC, V1, P79; SOOD AK, 1991, SOLID STATE PHYS, V45, P1; STAVANS J, 1989, PHYS REV LETT, V62, P1318, DOI 10.1103/PhysRevLett.62.1318; STEGEMEYER H, 1985, LIQ CRYST, V1, P3; STINE KJ, 1990, PHYS REV A, V41, P6884, DOI 10.1103/PhysRevA.41.6884; SZWARC M, 1956, J AM CHEM SOC, V78, P2656, DOI 10.1021/ja01592a101; TACHIBANA T, 1980, B CHEM SOC JPN, V53, P1714, DOI 10.1246/bcsj.53.1714; TANAKA T, 1981, SCI AM, V244, P110; TANFORD C, 1980, HYDROPHOBIC EFFECT; TERECH P, 1985, J PHYS-PARIS, V46, P895, DOI 10.1051/jphys:01985004606089500; THOMAS EL, 1988, NATURE, V334, P598, DOI 10.1038/334598a0; VANDERHOFF JW, 1973, J MACROMOLEC SCI C A, V7, P679; VANWINKLE DH, 1986, PHYS REV A, V34, P562, DOI 10.1103/PhysRevA.34.562; VIDAKOVIC P, 1985, MACROMOLECULES, V18, P700, DOI 10.1021/ma00146a022; VIDAKOVIC P, 1984, MACROMOLECULES, V17, P418, DOI 10.1021/ma00133a028; VIDAKOVIC P, 1983, MACROMOLECULES, V16, P253, DOI 10.1021/ma00236a019; VONTSCHARNER V, 1981, BIOPHYS J, V36, P409, DOI 10.1016/S0006-3495(81)84740-6; WAUGH R, 1979, BIOPHYS J, V26, P115, DOI 10.1016/S0006-3495(79)85239-X; WILSON AJ, 1990, FOAMS PHYSICS CHEM S; WITTEN TA, 1988, J PHYS-PARIS, V49, P1055, DOI 10.1051/jphys:019880049060105500; WITTEN TA, 1990, J PHYS-CONDENS MAT, V2, pSA1, DOI 10.1088/0953-8984/2/S/001; WRIGHT DC, 1989, REV MOD PHYS, V61, P385, DOI 10.1103/RevModPhys.61.385; YEN TF, 1981, 178TH P M AM CHEM SO	127	54	54	2	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319		S			11	23						13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH681	2017261				2022-12-28	WOS:A1991FH68100007
J	MCKINNEY, PA; ALEXANDER, FE; CARTWRIGHT, RA; PARKER, L				MCKINNEY, PA; ALEXANDER, FE; CARTWRIGHT, RA; PARKER, L			PARENTAL OCCUPATIONS OF CHILDREN WITH LEUKEMIA IN WEST CUMBRIA, NORTH-HUMBERSIDE, AND GATESHEAD	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD-CANCER; LEUKEMIA; BIRTH; ASSOCIATION; EXPOSURES; AGE	Objective-To determine whether parental occupations and chemical and other specific exposures are risk factors for childhood leukaemia. Design-Case-control study. Information on parents was obtained by home interview. Setting-Three areas in north England: Copeland and South Lakeland (west Cumbria); Kingston upon Hull, Beverley, East Yorkshire, and Holderness (north Humberside), and Gateshead. Subjects-109 children aged 0-14 born and diagnosed as having leukaemia or non-Hodgkin's lymphoma in study areas during 1974-88. Two controls matched for sex and date and district of birth were obtained for each child. Main outcome measures-Occupations of parents and specific exposure of parents before the children's conception, during gestation, and after birth. Other adults living with the children were included in the postnatal analysis. Results-Few risk factors were identified for mothers, although preconceptional association with the food industry was significantly increased in case mothers (odds ratio 2.56; 95% confidence interval 1.32 to 5.00). Significant associations were found between childhood leukaemia and reported preconceptional exposure of fathers to wood dust (2.73, 1.44 to 5.16), radiation (3.23, 1.36 to 7.72), and benzene (5.81, 1.67 to 26.44); ionising radiation alone gave an odds ratio of 2.35 (0.92 to 6.22). Raised odds ratios were found for paternal exposure during gestation, but no independent postnatal effect was evident. Conclusion-These results should be interpreted cautiously because of the small numbers, overlap with another study, and multiple exposure of some parents. It is important to distinguish periods of parental exposures; identified risk factors were almost exclusively restricted to the time before the child's birth.	UNIV LEEDS,CTR CLIN EPIDEMIOL,LEUKAEMIA RES FUND,LEEDS LS2 9NG,W YORKSHIRE,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,CHILDRENS CANC UNIT,NEWCASTLE TYNE NE2 4HH,ENGLAND	University of Leeds; Newcastle University - UK				PARKER, LOUISE/0000-0002-5188-8113				ALEXANDER F, 1990, J EPIDEMIOL COMMUN H, V44, P39, DOI 10.1136/jech.44.1.39; ALEXANDER FE, IN PRESS PATTERN CHI; [Anonymous], 1980, CLASSIFICATION OCCUP; ARUNDEL SE, 1986, J EPIDEMIOL COMMUN H, V40, P30, DOI 10.1136/jech.40.1.30; BAXTER MS, 1990, REV RADIOACTIVITY CA; BLACK D, 1984, INVESTIGATION POSSIB; BRESLOW NE, 1975, J CHRON DIS, V28, P289, DOI 10.1016/0021-9681(75)90010-7; BUCKLEY JD, 1989, CANCER RES, V49, P4030; CARTWRIGHT RA, 1990, LEUKAEMIA LYMPHOMA A; CRAFT AW, 1983, LANCET, V2, P1299; CRONKITE EP, 1985, AM J IND MED, V7, P447, DOI 10.1002/ajim.4700070509; EVANS HJ, 1990, NATURE, V345, P16, DOI 10.1038/345016a0; FABIA J, 1974, BRIT J PREV SOC MED, V28, P98; GARDNER MJ, 1990, BRIT MED J, V300, P429, DOI 10.1136/bmj.300.6722.429; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; GOLD EB, 1982, J OCCUP ENVIRON MED, V24, P578, DOI 10.1097/00043764-198208000-00011; GRAHAM S, 1966, J NCI, V19, P347; HEMMINKI K, 1981, J EPIDEMIOL COMMUN H, V35, P11, DOI 10.1136/jech.35.1.11; HICKS N, 1984, CANCER, V53, P1637, DOI 10.1002/1097-0142(19840415)53:8<1637::AID-CNCR2820530802>3.0.CO;2-Y; INFANTE PF, 1990, LANCET, V336, P814, DOI 10.1016/0140-6736(90)93282-T; KWA SL, 1980, J OCCUP ENVIRON MED, V22, P792, DOI 10.1097/00043764-198012000-00012; LOWENGART RA, 1987, J NATL CANCER I, V79, P39; MACFARLANE GJ, 1988, SEARCH COMPUTER PACK; MCKINNEY PA, 1989, LEUKEMIA, V3, P880; MCKINNEY PA, 1987, ARCH DIS CHILD, V62, P279, DOI 10.1136/adc.62.3.279; MELITA CR, 1990, STAT XACT; MELITA CR, 1985, J AM STATISTICS ASS, V80, P969; OPENSHAW S, 1988, LANCET, V1, P272; PETO J, 1990, NATURE, V345, P389, DOI 10.1038/345389a0; REEVES JD, 1981, LANCET, V2, P300; SANDERS BM, 1981, J EPIDEMIOL COMMUN H, V35, P245, DOI 10.1136/jech.35.4.245; SAVITZ DA, 1990, ENVIRON HEALTH PERSP, V88, P325, DOI 10.2307/3431095; SHAW G, 1984, AM J EPIDEMIOL, V119, P788, DOI 10.1093/oxfordjournals.aje.a113799; SHU XO, 1988, CANCER-AM CANCER SOC, V62, P635, DOI 10.1002/1097-0142(19880801)62:3<635::AID-CNCR2820620332>3.0.CO;2-3; STEWART A, 1958, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.5086.1495; VANSTEENSELMOLL HA, 1985, AM J EPIDEMIOL, V121, P214; VIANNA NJ, 1984, J OCCUP ENVIRON MED, V26, P679; [No title captured]; 1987, IARC MONOGRAPH S7, V1	40	72	75	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					681	687		10.1136/bmj.302.6778.681	http://dx.doi.org/10.1136/bmj.302.6778.681			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FE333	2021741	Bronze, Green Published			2022-12-28	WOS:A1991FE33300020
J	GORE, JM; DALEN, JE				GORE, JM; DALEN, JE			CARDIOVASCULAR-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; ACUTE MYOCARDIAL-INFARCTION; THROMBOLYSIS; EMERGENCY; HEPARIN; ASPIRIN; TRIAL		UNIV ARIZONA, COLL MED, TUCSON, AZ 85721 USA	University of Arizona	GORE, JM (corresponding author), UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA.							ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1989, NEW ENGL J MED, V320, P618; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; LEE TH, 1989, ANN INTERN MED, V110, P957, DOI 10.7326/0003-4819-110-12-957; MANOLIS AS, 1989, AM HEART J, V118, P445, DOI 10.1016/0002-8703(89)90256-1; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; PETERSEN P, 1989, LANCET, V1, P175; VANDEWERF F, 1990, LANCET, V336, P71; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0	14	4	8	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3105	3107						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041113				2022-12-28	WOS:A1991FQ77000010
J	TAITZ, LS				TAITZ, LS			CHILD-ABUSE AND METABOLIC BONE-DISEASE - ARE THEY OFTEN CONFUSED	BRITISH MEDICAL JOURNAL			English	Article							OSTEOGENESIS IMPERFECTA				TAITZ, LS (corresponding author), CHILDRENS HOSP,PAEDIAT,SHEFFIELD S10 2TH,S YORKSHIRE,ENGLAND.							PATERSON CR, 1989, BMJ-BRIT MED J, V299, P1451, DOI 10.1136/bmj.299.6713.1451; PATTERSON CR, 1989, BMJ, V295, P213; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; TAITZ LS, 1988, BRIT MED J, V296, P292, DOI 10.1136/bmj.296.6617.292-a; TAITZ LS, 1987, CHILD ABUSE REV, V1, P6	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1244	1244		10.1136/bmj.302.6787.1244	http://dx.doi.org/10.1136/bmj.302.6787.1244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP272	2043847	Green Published			2022-12-28	WOS:A1991FP27200023
J	SPIES, T; DEMARS, R				SPIES, T; DEMARS, R			RESTORED EXPRESSION OF MAJOR HISTOCOMPATIBILITY CLASS-I MOLECULES BY GENE-TRANSFER OF A PUTATIVE PEPTIDE TRANSPORTER	NATURE			English	Article							HLA-B ANTIGENS; LYMPHOBLASTOID CELLS; T-CELLS; MHC; COMPLEX; REGION; DETERMINANT; BINDING; PROTEIN; PATHWAY	CYTOTOXIC T lymphocytes recognize antigen-derived peptides bound to major histocompatibility complex (MHC) class I molecules with which they assemble in the endoplasmic reticulum or in an undefined subcompartment 1-10. There is genetic evidence that the peptides that are products of cytosolic protein degradation are transported into this compartment by a peptide supply factor (PSF), encoded in the MHC class II region 11. Like the corresponding genes RING4, HAM1 and mtp1 (refs 12-14), PSF is related to the multidrug-resistance family of transporters 11 and may be a peptide pump, as translocation of peptides across membranes must occur independently of the secretory pathway 15. There is, however, no functional evidence for this role so far. Here we report gene transfer experiment showing that expression of PSF complementary DNA in the human lymphoblastoid cell line mutant 721.134 (refs 11, 16, 17) restores normal levels of surface HLA-A2 and -B5. No similar effect was observed in 721.174 mutant cells, in which a homozygous deletion includes PSF among several other closely linked genes 11. At least one of these genes may therefore also be required for PSF function.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	SPIES, T (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115, USA.							BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; LONG EO, IN PRESS HUM IMMUN; MANN DL, 1983, NATURE, V305, P58, DOI 10.1038/305058a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHIMIZU Y, 1986, MOL CELL BIOL, V6, P1074, DOI 10.1128/MCB.6.4.1074; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SPIES T, 1989, SCIENCE, V243, P214, DOI 10.1126/science.2911734; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; WAYS JP, 1986, J IMMUNOL, V137, P217	25	417	432	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					323	324		10.1038/351323a0	http://dx.doi.org/10.1038/351323a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034277				2022-12-28	WOS:A1991FM97600063
J	SANDEMAN, DD; PYM, CA; GREEN, EM; SEAMARK, C; SHORE, AC; TOOKE, JE				SANDEMAN, DD; PYM, CA; GREEN, EM; SEAMARK, C; SHORE, AC; TOOKE, JE			MICROVASCULAR VASODILATATION IN FEET OF NEWLY DIAGNOSED NON-INSULIN-DEPENDENT DIABETIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article											SANDEMAN, DD (corresponding author), UNIV EXETER,SCH POSTGRAD MED,DIABET RES LABS,EXETER EX2 5DW,ENGLAND.			Shore, Angela/0000-0003-3039-308X				OHARE JA, 1988, AM J MED, V84, P505, DOI 10.1016/0002-9343(88)90273-2; RAYMAN G, 1986, BRIT MED J, V292, P1295, DOI 10.1136/bmj.292.6531.1295; REAVEN GM, 1989, AM J MED S6A, V87, P6; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P353; WIEDEMAN MP, 1976, MICROVASC RES, V12, P71, DOI 10.1016/0026-2862(76)90008-X	5	63	63	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1122	1123		10.1136/bmj.302.6785.1122	http://dx.doi.org/10.1136/bmj.302.6785.1122			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	2043783	Bronze, Green Published			2022-12-28	WOS:A1991FL43900019
J	RAUB, WF				RAUB, WF			COMBINATION THERAPY MOST BENEFICIAL AGAINST RECTAL-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, WF (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, NEW ENGL J MED, V324, P709	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2173	2173		10.1001/jama.265.17.2173	http://dx.doi.org/10.1001/jama.265.17.2173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013940				2022-12-28	WOS:A1991FH87700008
J	HOFFMAN, SL; NUSSENZWEIG, V; SADOFF, JC; NUSSENZWEIG, RS				HOFFMAN, SL; NUSSENZWEIG, V; SADOFF, JC; NUSSENZWEIG, RS			PROGRESS TOWARD MALARIA PREERYTHROCYTIC VACCINES	SCIENCE			English	Editorial Material							CIRCUMSPOROZOITE PROTEIN; EPITOPE		NYU MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; WALTER REED ARMY MED CTR, DIV COMMUNICABLE DIS & IMMUNOL, WASHINGTON, DC 20307 USA; NYU, SCH MED, DEPT MED & MOLEC PARASITOL, NEW YORK, NY 10010 USA	New York University; New York University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; New York University	HOFFMAN, SL (corresponding author), USN, MED RES INST, BETHESDA, MD 20889 USA.							AGGARWAL A, 1990, J EXP MED, V172, P1083, DOI 10.1084/jem.172.4.1083; ALVING CR, UNPUB; CHAROENVIT Y, 1991, SCIENCE, V251, P668, DOI 10.1126/science.1704150; DELGIUDICE G, 1990, IMMUNOL LETT, V25, P59, DOI 10.1016/0165-2478(90)90092-5; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; ETLINGER HM, 1990, SCIENCE, V249, P423, DOI 10.1126/science.1696030; GOOD MF, 1988, ANNU REV IMMUNOL, V6, P663, DOI 10.1146/annurev.iy.06.040188.003311; GORDON DM, 1990, AM J TROP MED HYG, V42, P527, DOI 10.4269/ajtmh.1990.42.527; HERRINGTON DA, 1990, B WORLD HEALTH ORGAN, V68, P33; HERRINGTON DA, UNPUB; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HOFFMAN SL, 1989, J IMMUNOL, V142, P1299; HOLLINGDALE MR, 1990, IMMUNOL LETT, V25, P71, DOI 10.1016/0165-2478(90)90094-7; KHUSMITH S, IN PRESS SCIENCE; LUSSOW AR, 1990, P NATL ACAD SCI USA, V87, P2960, DOI 10.1073/pnas.87.8.2960; MALIK A, IN PRESS P NATL ACAD; NARDIN EH, 1989, SCIENCE, V246, P1603, DOI 10.1126/science.2480642; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0; RICKMAN L, IN PRESS LANCET; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROSENBERG R, 1989, SCIENCE, V245, P973, DOI 10.1126/science.2672336; SADOFF JC, UNPUB; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; TSUJI M, 1990, J EXP MED, V172, P1353, DOI 10.1084/jem.172.5.1353; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; WIRTZ RA, 1990, LANCET, V336, P593, DOI 10.1016/0140-6736(90)93393-4; 1990, TROP DIS RES NEWS, V31, P3	29	40	41	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1991	252	5005					520	521		10.1126/science.2020852	http://dx.doi.org/10.1126/science.2020852			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	2020852				2022-12-28	WOS:A1991FJ12700034
J	BREO, DL				BREO, DL			CARING FOR THE POOR - A DAY WITH DESHAZER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2117	&		10.1001/jama.265.16.2117	http://dx.doi.org/10.1001/jama.265.16.2117			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013933				2022-12-28	WOS:A1991FG90700033
J	NEIL, HAW				NEIL, HAW			CHOLESTEROL SCREENING AND LIFE ASSURANCE	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BLOOD LIPID CONCENTRATIONS; DEATH; RISK	Objectives-To examine how insurance companies assess proposals for life assurance from applicants with raised cholesterol concentrations and to determine the excess mortality rating applied. Design-Survey of 49 companies underwriting term life assurance. Setting-United Kingdom. Subjects-Four fictional men aged 30 seeking 20 year term policies paying benefit only on death. Two had total cholesterol concentrations of 6.4 and 8.1 mmol/l but no other cardiovascular risk factors; one was overweight, hypertensive, smoked 20 cigarettes daily, and had a total cholesterol concentration of 8.1 mmol/l; and one had possible familial hypercholesterolaemia and a total cholesterol concentration of 10.7 mmol/l after treatment. Main outcome measure-Percentage excess mortality rating. Results-All companies used explicit criteria to assess the mortality risk associated with hyperlipidaemias, and 47 companies applied the same criteria to men and women. No excess mortality rating was imposed on an applicant with a total cholesterol concentration of 6.4 mmol/l, but a small excess was applied to an applicant with a concentration of 8.1 mmol/l (median excess 50%, range 0-75%). When multiple cardiovascular risk factors were present the same concentration of 8.1 mmol/l resulted in a substantial excess (median 135%, range 50-200%). A smaller but more variable excess was applied to an applicant with possible familial hypercholesterolaemia (median 75%, range 0-200%). Conclusions-Despite considerable differences among companies in the excess mortality ratings applied, increases in term life assurance premiums are likely to be restricted to patients with severe hypercholesterolaemia, in particular those with familial hypercholesterolaemia. In the absence of other cardiovascular risk factors milder hypercholesterolaemia is unlikely to result in higher premiums.			NEIL, HAW (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.							Brackenridge R. D. C., 1985, MED SELECTION LIFE R; DURRINGTON PN, 1989, HYPERLIPIDAEMIA DIAG, P103; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; MARTEAU TM, 1990, BRIT MED J, V301, P26, DOI 10.1136/bmj.301.6742.26; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SHEPHERD J, 1987, BRIT MED J, V295, P1245, DOI 10.1136/bmj.295.6608.1245; SLACK J, 1969, LANCET, V2, P1380; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STONE NJ, 1974, CIRCULATION, V49, P476, DOI 10.1161/01.CIR.49.3.476; 1988, EUR HEART J, V9, P571	11	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					891	893		10.1136/bmj.302.6781.891	http://dx.doi.org/10.1136/bmj.302.6781.891			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025730	Green Published, Bronze			2022-12-28	WOS:A1991FG42100027
J	JICK, H; JICK, SS; DERBY, LE				JICK, H; JICK, SS; DERBY, LE			VALIDATION OF INFORMATION RECORDED ON GENERAL-PRACTITIONER BASED COMPUTERIZED DATA RESOURCE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the extent of agreement between clinical information recorded on surgery computers of selected general practitioners and similar information in manual records of letters received from hospital consultants and kept in the general practitioners' files. Design-Hospital consultants' letters in the manual records of selected general practitioners were photocopied and the consultants' clinical diagnoses were compared with diagnoses recorded on computer. Setting-General practices in the United Kingdom using computers provided by VAMP Health for recording clinical information. Subjects-2491 patients who received one of three non-steroidal anti-inflammatory drugs and who attended 58 practices whose computer recorded data were considered after a preliminary review to be of satisfactory quality. Results-Among 1191 patients for whom consultants' letters were forwarded a clinical diagnosis reflecting the diagnosis noted on a consultant letter was present on the computer record for 1038 (87%). Conclusion-Clinical information available on the computer records of the general practitioners who participated in this study is satisfactory for many clinical studies.			JICK, H (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067	FDA HHS [FD-U-000071-09] Funding Source: Medline	FDA HHS		FINDLAY GH, 1982, LANCET, V2, P95; JICK H, 1984, PHARMACOTHERAPY, V4, P99; JICK H, 1990, PHARMACOTHERAPY, V10, P395; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; SKEGG DCG, 1977, LANCET, V2, P475; TILSON H H, 1989, Journal of Clinical Research and Drug Development, V3, P39; WEST R, 1988, AM J PREVENTIVE ME S, P25	7	723	724	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					766	768		10.1136/bmj.302.6779.766	http://dx.doi.org/10.1136/bmj.302.6779.766			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021768	Bronze, Green Published			2022-12-28	WOS:A1991FF22900027
J	JACKMAN, WM; WANG, XZ; FRIDAY, KJ; ROMAN, CA; MOULTON, KP; BECKMAN, KJ; MCCLELLAND, JH; TWIDALE, N; HAZLITT, HA; PRIOR, MI; MARGOLIS, PD; CALAME, JD; OVERHOLT, ED; LAZZARA, R				JACKMAN, WM; WANG, XZ; FRIDAY, KJ; ROMAN, CA; MOULTON, KP; BECKMAN, KJ; MCCLELLAND, JH; TWIDALE, N; HAZLITT, HA; PRIOR, MI; MARGOLIS, PD; CALAME, JD; OVERHOLT, ED; LAZZARA, R			CATHETER ABLATION OF ACCESSORY ATRIOVENTRICULAR PATHWAYS (WOLFF-PARKINSON-WHITE SYNDROME) BY RADIOFREQUENCY CURRENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLOSED-CHEST ABLATION; LEFT FREE-WALL; ELECTRICAL ABLATION; TRANSCATHETER ABLATION; ELECTRODE CONFIGURATION; CORONARY SINUS; TACHYCARDIA; JUNCTION; PATIENT; ENERGY	Background. Surgical or catheter ablation of accessory pathways by means of high-energy shocks serves as definitive therapy for patients with Wolff-Parkinson-White syndrome but has substantial associated morbidity and mortality. Radiofrequency current, an alternative energy source for ablation, produces smaller lesions without adverse effects remote from the site where current is delivered. We conducted this study to develop catheter techniques for delivering radiofrequency current to reduce morbidity and mortality associated with accessory-pathway ablation. Methods. Radiofrequency current (mean power, 30.9 +/- 5.3 W) was applied through a catheter electrode positioned against the mitral or tricuspid annulus or a branch of the coronary sinus; when possible, delivery was guided by catheter recordings of accessory-pathway activation. Ablation was attempted in 166 patients with 177 accessory pathways (106 pathways in the left free wall, 13 in the anteroseptal region, 43 in the posteroseptal region, and 15 in the right free wall). Results. Accessory-pathway conduction was eliminated in 164 of 166 patients (99 percent) by a median of three applications of radiofrequency current. During a mean follow-up (+/- SD) of 8.0 +/- 5.4 months, preexcitation or atrioventricular reentrant tachycardia returned in 15 patients (9 percent). All underwent a second, successful ablation. Electrophysiologic study 3.1 +/- 1.9 months after ablation in 75 patients verified the absence of accessory-pathway conduction in all. Complications of radiofrequency-current application occurred in three patients (1.8 percent): atrioventricular block (one patient), pericarditis (one), and cardiac tamponade (one) after radiofrequency current was applied in a small branch of the coronary sinus. Conclusions. Radiofrequency current is highly effective in ablating accessory pathways, with low morbidity and no mortality.	DEPT VET AFFAIRS MED CTR,OKLAHOMA CITY,OK	University of Oklahoma System; University of Oklahoma Health Sciences Center	JACKMAN, WM (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,CARDIOVASC SECT,POB 26901,RM 5SP300,OKLAHOMA CITY,OK 73190, USA.				NHLBI NIH HHS [R01-HL-39670] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039670] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARDY GH, 1984, AM J CARDIOL, V54, P1366, DOI 10.1016/S0002-9149(84)80102-2; BARDY GH, 1988, AM J CARDIOL, V61, P309, DOI 10.1016/0002-9149(88)90936-8; BORGGREFE M, 1987, J AM COLL CARDIOL, V10, P576, DOI 10.1016/S0735-1097(87)80200-0; COX JL, 1985, J THORAC CARDIOV SUR, V90, P490; FELD M, 1987, J ELECTROPHYSIOL, V1, P257; FISHER JD, 1984, J AM COLL CARDIOL, V4, P685, DOI 10.1016/S0735-1097(84)80394-0; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; GANG ES, 1985, J AM COLL CARDIOL, V6, P1167, DOI 10.1016/S0735-1097(85)80327-2; GANG ES, 1986, J AM COLL CARDIOL, V7, P450; Guiraudon GM, 1990, CARDIAC ELECTROPHYSI, P907; HARTZLER GO, 1985, J AM COLL CARDIOL, V6, P250, DOI 10.1016/S0735-1097(85)80285-0; HUANG SKS, 1989, AM HEART J, V118, P1317; HUANG SKS, 1988, CIRCULATION, V78, P416, DOI 10.1161/01.CIR.78.2.416; JACKMAN WM, 1987, J AM COLL CARDIOL, V9, pA99; JACKMAN WM, 1989, PACE, V12, P204, DOI 10.1111/j.1540-8159.1989.tb02648.x; JACKMAN WM, 1983, CIRCULATION, V68, P906, DOI 10.1161/01.CIR.68.5.906; JACKMAN WM, 1988, CIRCULATION, V78, P598, DOI 10.1161/01.CIR.78.3.598; JACKMAN WM, 1988, CIRCULATION, V78, P1288, DOI 10.1161/01.CIR.78.5.1288; JACKMAN WM, IN PRESS CIRCULATION; KUCK KH, 1989, PACE, V12, P1681, DOI 10.1111/j.1540-8159.1989.tb01847.x; KUCK KH, 1988, EUR HEART J, V9, P927, DOI 10.1093/oxfordjournals.eurheartj.a062589; KUNZE KP, 1984, CIRCULATION, V70, P412; LANGBERG J, 1987, J AM COLL CARDIOL, V9, pA99; LANGBERG JJ, 1989, CIRCULATION, V80, P1527, DOI 10.1161/01.CIR.80.6.1527; LAVERGNE T, 1987, J AM COLL CARDIOL, V9, pA99; LEVY S, 1988, PACE, V11, P1149, DOI 10.1111/j.1540-8159.1988.tb03966.x; MAHOMED Y, 1988, ANN THORAC SURG, V45, P495, DOI 10.1016/S0003-4975(10)64521-3; MORADY F, 1984, NEW ENGL J MED, V310, P705, DOI 10.1056/NEJM198403153101108; MORADY F, 1989, CIRCULATION, V79, P1160, DOI 10.1161/01.CIR.79.6.1160; MORADY F, 1985, CIRCULATION, V72, P170, DOI 10.1161/01.CIR.72.1.170; RING ME, 1989, PACE, V12, P1502, DOI 10.1111/j.1540-8159.1989.tb06155.x; RUDER MA, 1988, J AM COLL CARDIOL, V11, P1245, DOI 10.1016/0735-1097(88)90288-4; SCHEINMAN MM, 1984, CIRCULATION, V70, P1024, DOI 10.1161/01.CIR.70.6.1024; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; Sealy W C, 1969, Ann Thorac Surg, V8, P1; SEBAG C, 1989, AM J CARDIOL, V63, P890, DOI 10.1016/0002-9149(89)90070-2; WARD DE, 1985, BRIT HEART J, V53, P64; WARIN JF, 1988, CIRCULATION, V78, P800, DOI 10.1161/01.CIR.78.4.800; WARIN JF, 1990, PACE, V13, P1609, DOI 10.1111/j.1540-8159.1990.tb06862.x; WEBER H, 1983, NEW ENGL J MED, V308, P653; [No title captured]	41	1166	1197	2	32	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1605	1611		10.1056/NEJM199106063242301	http://dx.doi.org/10.1056/NEJM199106063242301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	2030716	Bronze			2022-12-28	WOS:A1991FP30700001
J	MARBER, M; MACRAE, C; JOY, M				MARBER, M; MACRAE, C; JOY, M			DELAY TO INVASIVE INVESTIGATION AND REVASCULARIZATION FOR CORONARY HEART-DISEASE IN SOUTH WEST THAMES REGION - A 2 TIER SYSTEM	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To assess the accessibility of invasive investigation and revascularisation procedures in the management of coronary heart disease in a defined population in the South West Thames region over 10 years, and to audit the performance of both the NHS and the private sector. Design - Analysis of all patient referrals to the regional cardiothoracic centres for coronary heart disease during 1979-88. Setting - North West Surrey District Health Authority, which had a mean catchment population of 205 000 during the study period. The health district is one of the 13 in the South West Thames region. Patients - 823 patients aged 34-80 years with suspected coronary heart disease, 204 of whom were referred for private investigation and 619 were referred within the NHS. The NHS referrals were mainly to St Thomas's Hospital during 1979-83 and to St George's Hospital during 1984-8. Main outcome measures - Difference in time to investigation and intervention between the NHS and the private patients. Results - After some variation in earlier years the mean (SD, range) waiting times from referral to cardiac catheterisation and then revascularisation increased progressively in NHS patients, to 115.8 (126.5, 22-482) days and 305.9 (164.4, 22-620) days respectively in 1988. There was no significant change over the 10 years in waiting times within the private sector, with a mean of 17.2 (18.2, 1-62) days to angiography and 22.8 (14.5, 2-152) days to surgery. Fifteen people on the NHS waiting list died of probable cardiac causes. No people on the private waiting list died. Conclusions - The performance of the NHS system in South West Thames region in response to emergency referral is adequate. The waiting time to routine investigation and revascularisation is prolonged and seems to be worsening despite increased investigative and surgical activity by the regional centre. The delays may subject NHS patients to unnecessary risk, which is not shared by private patients.	ST PETERS HOSP,GEN MED,CHERTSEY KT16 0PZ,SURREY,ENGLAND				marber, michael/AAW-7916-2021					ARMITAGE P, 1987, STATISTICAL METHODS; CAINE N, 1991, BMJ-BRIT MED J, V302, P511, DOI 10.1136/bmj.302.6775.511; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V97, P78; CRIPPS T, 1986, BRIT HEART J, V55, P488; GARDNER MJ, 1990, STATISTICS CONFIDENC; MACRAE CM, IN PRESS BR HEART J; MYERS WO, 1987, ANN THORAC SURG, V44, P471, DOI 10.1016/S0003-4975(10)62104-2; VAMAURKAS E, 1985, CIRCULATION, V72, P90; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; 1984, BMJ, V289, P1527; 1987, 1986 MORTALITY S DH5, V12; 1989, CORONARY HEART DISEA; 1989, CMND555	13	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1189	1191		10.1136/bmj.302.6786.1189	http://dx.doi.org/10.1136/bmj.302.6786.1189			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043817	Bronze, Green Published			2022-12-28	WOS:A1991FN04500025
J	SIDDIQUE, T; FIGLEWICZ, DA; PERICAKVANCE, MA; HAINES, JL; ROULEAU, G; JEFFERS, AJ; SAPP, P; HUNG, WY; BEBOUT, J; MCKENNAYASEK, D; DENG, G; HORVITZ, HR; GUSELLA, JF; BROWN, RH; ROSES, AD				SIDDIQUE, T; FIGLEWICZ, DA; PERICAKVANCE, MA; HAINES, JL; ROULEAU, G; JEFFERS, AJ; SAPP, P; HUNG, WY; BEBOUT, J; MCKENNAYASEK, D; DENG, G; HORVITZ, HR; GUSELLA, JF; BROWN, RH; ROSES, AD			LINKAGE OF A GENE CAUSING FAMILIAL AMYOTROPHIC-LATERAL-SCLEROSIS TO CHROMOSOME-21 AND EVIDENCE OF GENETIC-LOCUS HETEROGENEITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOTOR NEURON DISEASE; COMMITTEE; MAPS	Background. Amyotrophic lateral sclerosis is a progressive neurologic disorder that commonly results in paralysis and death. Despite more than a century of research, no cause of, cure for, or means of preventing this disorder has been found. In a minority of cases, it is familial and inherited as an autosomal dominant trait with age-dependent penetrance. In contrast to the sporadic form of amyotrophic lateral sclerosis, the familial form provides the opportunity to use molecular genetic techniques to localize an inherited defect. Furthermore, such studies have the potential to discover the basic molecular defect causing motor-neuron degeneration. Methods and Results. We evaluated 23 families with familial amyotrophic lateral sclerosis for linkage of the gene causing this disease to four DNA markers on the long arm of chromosome 21. Multipoint linkage analyses demonstrated linkage between the gene and these markers. The maximum lod score - 5.03 - was obtained 10 centimorgans distal (telomeric) to the DNA marker D21S58. There was a significant probability (P < 0.0001) of genetic-locus heterogeneity in the families. Conclusions. The localization of a gene causing familial amyotrophic lateral sclerosis provides a means of isolating this gene and studying its function. Insight gained from understanding the function of this gene may be applicable to the design of rational therapy for both the familial and sporadic forms of the disease.	MCGILL UNIV, CTR RES NEUROSCI, MONTREAL H3A 2T5, QUEBEC, CANADA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; MIT, CAMBRIDGE, MA 02139 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA	McGill University; Duke University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	SIDDIQUE, T (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT NEUROL, SEARLE 11-543, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		halperin, john/X-6433-2019; Haines, Jonathan/C-3374-2012; Siddique, Teepu/AAT-8166-2021	halperin, john/0000-0003-1170-1710; Haines, Jonathan/0000-0002-4351-4728; mathews, katherine/0000-0003-4160-0435; Siddique, Teepu/0000-0001-7293-9146	NINDS NIH HHS [P0-NS-26630, P0-NS-21442, NS-20012] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS021442, P01NS026630, P01NS021442, R01NS020012] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Emery A E, 1982, Adv Neurol, V36, P139; ENGEL WK, 1959, BRAIN, V82, P203, DOI 10.1093/brain/82.2.203; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; HORTON WA, 1976, NEUROLOGY, V26, P460, DOI 10.1212/WNL.26.5.460; Hughes J T, 1982, Adv Neurol, V36, P61; KEATS B, 1989, CYTOGENET CELL GENET, V51, P459, DOI 10.1159/000132805; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KURLAND LT, 1955, NEUROLOGY, V5, P182, DOI 10.1212/WNL.5.3.182; KURLAND LT, 1955, NEUROLOGY, V5, P249, DOI 10.1212/WNL.5.4.249; Kurtzke J, 1989, CLIN NEUROLOGY, P1; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Mulder D W, 1982, Adv Neurol, V36, P15; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; MYRIANTHOPOULOS NC, 1954, AM J HUM GENET, V6, P387; OSLER W, 1880, ARCH MED, V4, P316; OTT J, 1985, ANAL HUMAN GENETIC L, P111; SIDDIQUE T, 1990, ANN NEUROL, V28, P269; SIDDIQUE T, 1989, NEUROLOGY, V39, P919, DOI 10.1212/WNL.39.7.919; SIDDIQUE T, 1990, Neurology, V40, P315; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; TANZI R E, 1988, Genomics, V3, P129, DOI 10.1016/0888-7543(88)90143-7; WILLIAMS DB, 1988, J NEUROL SCI, V86, P215, DOI 10.1016/0022-510X(88)90100-1	22	379	383	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1381	1384		10.1056/NEJM199105163242001	http://dx.doi.org/10.1056/NEJM199105163242001			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020294				2022-12-28	WOS:A1991FL12500001
J	BRONOW, RS; BELTRAN, RA; COHEN, SC; ELLIOTT, PT; GOLDMAN, GM; SPOTNITZ, SG				BRONOW, RS; BELTRAN, RA; COHEN, SC; ELLIOTT, PT; GOLDMAN, GM; SPOTNITZ, SG			THE PHYSICIANS WHO CARE PLAN - PRESERVING QUALITY AND EQUITABILITY IN AMERICAN MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-HEALTH PROGRAM; CANADIAN REALITY; PROMOTE QUALITY; EXPENDITURES; INSURANCE; ECONOMY; TUNNEL; 1990S; END				BRONOW, RS (corresponding author), NATL ORG PHYSCIANS WHO CARE,215 E QUINCY,SUITE 305,SAN ANTONIO,TX 78215, USA.							BERK ML, 1988, HEALTH AFFAIR, V7, P46, DOI 10.1377/hlthaff.7.4.46; BRONOW R, 1990, JAMA-J AM MED ASSOC, V263, P2488; BURDA D, 1990, MODERN HLTH CARE, V20, P20; CURTIS R, 1990, INSURANCE SMALL EMPL; DICKMAN RL, 1987, NEW ENGL J MED, V317, P106; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FLETCHER RD, 1990, ONTARIO MED REV, V57, P1; FLETCHER RD, 1990, ONTARIO MED REV, V57, P12; GABEL JR, 1989, INQUIRY-J HEALTH CAR, V26, P419; GOODMAN JC, 1990, AGENDA SOLVING AM HL; HAISLMAIER ES, 1990, BACKGROUNDER, P755; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; IGLEHART J, 1989, HLTH AFF, V19, P71; JOHNSTON B, 1990, ONTARIO MED REV, V57, P8; KENDEL P, 1990, MOD HEALTHCARE, V20, P3; LOAMS J, 1990, HPRU9021D U BRIT COL; MCMENAMIN P, 1990, HEALTH AFFAIR, V9, P112, DOI 10.1377/hlthaff.9.4.112; MONHEIT AC, 1989, HEALTH AFFAIR, V8, P22, DOI 10.1377/hlthaff.8.4.22; MORAN D, 1990, REP MED GUIDELINES O, V1, P10; NADEL M, 1989, THRD9002 PUBL; REINHARDT UE, 1989, HLTH AFF, V8, P10; SELMON C, 1989, HLTH ARE ONTARIO ONT; SULLIVAN LW, 1990, OCT FOR LTH CAR COST; TUPPER CJ, 1990, JAMA-J AM MED ASSOC, V264, P1150; WAGNER L, 1991, MOD HEALTHCARE, V21, P8; WAITZKIN H, 1989, WESTERN J MED, V150, P101; WOOLHANDLER S, 1989, JAMA-J AM MED ASSOC, V262, P2136; 1987, NEW ENGL J MED, V317, P1729; 1990, MANAGED CARE MEDICAR; 1987, NEW ENGL J MED, V317, P1743; 1988, INSURING UNINSURED O; 1989, HLTH NATION SHARED R	34	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2511	2515		10.1001/jama.265.19.2511	http://dx.doi.org/10.1001/jama.265.19.2511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK903	2020067				2022-12-28	WOS:A1991FK90300023
J	TOPOL, EJ; HOLMES, DR; ROGERS, WJ				TOPOL, EJ; HOLMES, DR; ROGERS, WJ			CORONARY ANGIOGRAPHY AFTER THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Review							TISSUE PLASMINOGEN-ACTIVATOR; INTRAVENOUS STREPTOKINASE THERAPY; RANDOMIZED CONTROLLED TRIAL; FINANCIAL INCENTIVES; PROGNOSTIC VALUE; FOLLOW-UP; ANGIOPLASTY; REPERFUSION; ARTERY; COMBINATION	Purpose: To review the status of emergency, urgent, routine, and selective angiography after intravenous thrombolytic therapy. Data Sources: Relevant English-language articles published from January 1985 to July 1990 were identified through MEDLINE. Study Selection: For emergency angiography, four major randomized studies were reviewed and data from nine studies that incorporated rescue coronary angioplasty were pooled for meta-analysis. For urgent angiography, two controlled trials were reviewed. Comparisons of routine and selective angiography were done using data from two dedicated, large-scale, controlled trials and the ancillary findings of four other studies of reperfusion that incorporated angiography. Data Extraction: The review emphasizes the findings from multicenter, randomized, controlled trials. Data Synthesis: Emergency coronary angiography is done primarily in preparation for primary or rescue angioplasty; the value of rescue angioplasty has yet to be assessed in a randomized trial, but technical success and reocclusion improve significantly after therapy with nonspecific plasminogen activators compared with relatively specific agents (success rate, 86% compared with 75%, respectively; P = 0.03; reocclusion rate, 10.9% compared with 26.8%, respectively; P < 0.001). Urgent coronary angiography has value for treating recurrent ischemia, but patients who develop this complication after thrombolysis are likely to have a suboptimal outcome despite aggressive care. Studies support the use of either selective or routine angiography in uncomplicated patients after thrombolytic therapy; either approach is acceptable, but the former is more practical and may prove to be cost effective. Conclusions: Optimal follow-up for patients with evolving myocardial infarction who receive thrombolysis may incorporate coronary angiography at various stages. Although our ability to noninvasively detect reperfusion, reocclusion, or viable but ischemic myocardium is limited at present, available data may assist in selecting a catheterization strategy.	MAYO CLIN & MAYO FDN, SCH MED, ROCHESTER, MN 55905 USA; UNIV ALABAMA, BIRMINGHAM, AL 35294 USA	Mayo Clinic; University of Alabama System; University of Alabama Birmingham	TOPOL, EJ (corresponding author), UNIV MICHIGAN, MED CTR,SCH MED,DIV CARDIOL,B1-F245, 1500 E MED CTR DR, ANN ARBOR, MI 48109 USA.				NHLBI NIH HHS [HL38529-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL038529] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTTSMITH CW, 1990, J AM COLL CARDIOL, V16, P770, DOI 10.1016/S0735-1097(10)80320-1; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1990, CIRCULATION, V82, P664; BAIM DS, 1988, CIRCULATION S2, V78, P112; BETRIU A, 1982, CIRCULATION, V65, P1099, DOI 10.1161/01.CIR.65.6.1099; BRAUNWALD E, 1989, CIRCULATION, V79, P441, DOI 10.1161/01.CIR.79.2.441; BURNS R J, 1989, Journal of the American College of Cardiology, V13, p125A; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; CALIFF RM, 1989, J AM COLL CARDIOL, V14, P1382, DOI 10.1016/0735-1097(89)90445-2; CALIFF RM, 1991, IN PRESS CIRCULATION, V83; CHAITMAN B R, 1990, Journal of the American College of Cardiology, V15, p251A; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHARLES ED, 1989, J AM COLL CARDIOL, V13, pA152; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CHEITLIN MD, 1988, JAMA-J AM MED ASSOC, V260, P2894, DOI 10.1001/jama.260.19.2894; CLEEMPOEL H, 1988, BRIT HEART J, V60, P98; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; DELLBORG M, 1989, CIRCULATION S2, V80, P355; ELLIS SG, 1989, CIRCULATION, V80, P1159, DOI 10.1161/01.CIR.80.5.1159; ELLIS SG, 1989, J AM COLL CARDIOL, V13, P1122, DOI 10.1016/0735-1097(89)90272-6; ERBEL R, 1986, J AM COLL CARDIOL, V8, P485, DOI 10.1016/S0735-1097(86)80172-3; FUNG AY, 1986, AM J CARDIOL, V58, P686, DOI 10.1016/0002-9149(86)90338-3; GACIOCH GM, 1989, J AM COLL CARDIOL, V14, P1202, DOI 10.1016/0735-1097(89)90418-X; GACIOCH GM, 1989, CIRCULATION, V80, P625; GERSH BJ, 1989, TXB INTERVENTIONAL C, P240; GOA KL, 1990, DRUGS, V39, P693, DOI 10.2165/00003495-199039050-00006; GRINES C L, 1990, Journal of the American College of Cardiology, V15, p4A; GRINES CL, 1989, J AM COLL CARDIOL, V14, P573, DOI 10.1016/0735-1097(89)90095-8; GRINES CL, 1989, CIRCULATION, V80, P245, DOI 10.1161/01.CIR.80.2.245; GRUNDFEST WS, 1989, TXB INTERVENTIONAL C, P799; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HALE SL, 1988, AM HEART J, V116, P1508, DOI 10.1016/0002-8703(88)90736-3; HAMM LF, 1989, AM J CARDIOL, V63, P1193, DOI 10.1016/0002-9149(89)90177-X; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HOCHMAN JS, 1987, CIRCULATION, V75, P299, DOI 10.1161/01.CIR.75.1.299; HOLMES D R JR, 1989, Journal of the American College of Cardiology, V13, p193A; HOLMES DR, 1985, MAYO CLIN PROC, V60, P449, DOI 10.1016/S0025-6196(12)60868-4; HOLMES DR, 1989, J AM COLL CARDIOL, V14, P1572, DOI 10.1016/0735-1097(89)90401-4; JEREMY RW, 1989, J AM COLL CARDIOL, V13, P304, DOI 10.1016/0735-1097(89)90503-2; KEREIAKES DJ, 1991, J AM COLL CARDIOL, V17, P304, DOI 10.1016/S0735-1097(10)80091-9; KERSSCHOT IE, 1986, J AM COLL CARDIOL, V7, P1234, DOI 10.1016/S0735-1097(86)80141-3; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LEE KL, 1988, CIRCULATION, V78, P500; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MILLER PF, 1987, ARCH INTERN MED, V147, P1565, DOI 10.1001/archinte.147.9.1565; MULLER D W M, 1990, Journal of the American College of Cardiology, V15, p63A; OCONNOR CM, 1989, J INV CARDIOL, V1, P85; OKEEFE JH, 1989, AM J CARDIOL, V64, P1221, DOI 10.1016/0002-9149(89)90558-4; PASSAMANI E, 1987, J AM COLL CARDIOL, V10, pB51, DOI 10.1016/S0735-1097(87)80429-1; PRIDA XE, 1986, AM J CARDIOL, V57, P1069, DOI 10.1016/0002-9149(86)90676-4; ROGERS W J, 1990, Journal of the American College of Cardiology, V15, p64A; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; ROTHBAUM DA, 1987, J AM COLL CARDIOL, V10, P264, DOI 10.1016/S0735-1097(87)80006-2; SCHMIDT WG, 1987, EUR HEART J, V8, P1182, DOI 10.1093/oxfordjournals.eurheartj.a062190; SCHULMAN SP, 1988, J AM COLL CARDIOL, V11, P1164, DOI 10.1016/0735-1097(88)90277-X; SEACORD L M, 1988, Fibrinolysis, V2, P151, DOI 10.1016/0268-9499(88)90028-8; SIMOONS ML, 1988, LANCET, V1, P199; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; SLEIGHT P, 1990, CIRCULATION, V81, P1706; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; TOPEL EJ, 1989, TXB INTERVENTIONAL C, P269; TOPOL E J, 1989, Journal of the American College of Cardiology, V13, p92A; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1988, CIRCULATION, V77, P1100, DOI 10.1161/01.CIR.77.5.1100; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; TOPOL EJ, 1988, ANN INTERN MED, V109, P970, DOI 10.7326/0003-4819-109-12-970; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; TOPOL EJ, 1987, J AM COLL CARDIOL, V10, P1173, DOI 10.1016/S0735-1097(87)80114-6; TOPOL EJ, 1988, J AM COLL CARDIOL, V12, pA24, DOI 10.1016/0735-1097(88)92638-1; TOPOL EJ, 1989, TXB INTERVENTIONAL C, P76; TOUCHSTONE DA, 1988, AM HEART J, V116, P1500, DOI 10.1016/0002-8703(88)90735-1; TURNER JD, 1980, CHEST, V77, P58, DOI 10.1378/chest.77.1.58; VANDEWERF F, 1990, LANCET, V336, P71; WEISS AT, 1989, AM HEART J, V118, P9, DOI 10.1016/0002-8703(89)90065-3; WHITE LJ, 1989, ANN INTERN MED, V110, P485; WILCOX RG, 1988, LANCET, V2, P525; YOCK PG, 1989, TXB INTERVENTIONAL C, P816; 1989, LANCET, V2, P863	82	58	58	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					877	885		10.7326/0003-4819-114-10-877	http://dx.doi.org/10.7326/0003-4819-114-10-877			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014950				2022-12-28	WOS:A1991FL65000009
J	VANHOOFT, IMS; GROBBEE, DE; DERKX, FHM; DELEEUW, PW; SCHALEKAMP, MADH; HOFMAN, A				VANHOOFT, IMS; GROBBEE, DE; DERKX, FHM; DELEEUW, PW; SCHALEKAMP, MADH; HOFMAN, A			RENAL HEMODYNAMICS AND THE RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM IN NORMOTENSIVE SUBJECTS WITH HYPERTENSIVE AND NORMOTENSIVE PARENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CALCIUM ENTRY BLOCKADE; BLOOD-PRESSURE; RESPONSES; PLASMA; RADIOIMMUNOASSAY; TRANSPLANTATION; PREDICTION; PRORENIN; FAILURE	Background and Methods. The kidney is important in blood-pressure regulation, but its role in the development of essential hypertension is still subject to debate. We compared renal hemodynamics, measured in terms of the clearance of para-aminohippuric acid and inulin, and the characteristics of the renin-angiotensin-aldosterone system in three groups of normotensive subjects at different degrees of risk for hypertension: 41 subjects with two normotensive parents, 52 with one normotensive and one hypertensive parent, and 61 with two hypertensive parents. The subjects ranged in age from 7 to 32 years. Results. The mean renal blood flow was lower in the subjects with two hypertensive parents than in those with two normotensive parents (mean difference [+/- SE], 198 +/- 61 ml per minute per 1.73 m2 of body-surface area; P = 0.002). Moreover, both the filtration fraction and renal vascular resistance were higher in the subjects with two hypertensive parents (filtration fraction: mean difference, 3.0 +/- 1.1 percentage points; P = 0.006; renal vascular resistance: mean difference, 2.7 +/- 0.8 mm Hg per deciliter per minute per 1.73 m2; P = 0.006). The subjects with two hypertensive parents had lower plasma concentrations of renin (mean difference, 3.3 +/- 1.6 mU per liter; P = 0.03) and aldosterone (mean difference, 111 +/- 36 pmol per liter; P = 0.003) than those with two normotensive parents. The differences could not be explained by the small differences in blood pressure between the groups. The values in the subjects with one hypertensive and one normotensive parent fell between those for the other two groups. Conclusions. Renal vasoconstriction is increased and renin and aldosterone secretion is decreased in young persons at risk for hypertension. These findings support the hypothesis that alterations in renal hemodynamics occur at an early stage in the development of familial hypertension.	ERASMUS UNIV, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS; ZUIDERZIEKENHUIS, DEPT INTERNAL MED, ROTTERDAM, NETHERLANDS; ERASMUS UNIV, HOSP DIJKZIGT, DEPT INTERNAL MED 1, ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC			Grobbee, Diederick/C-7651-2014; de Leeuw, Peter W./J-4552-2016	Grobbee, Diederick/0000-0003-4472-4468; de Leeuw, Peter W./0000-0002-4949-5812				BELLO CT, 1965, AM J MED SCI, V250, P24, DOI 10.1097/00000441-196507000-00005; BERGER EY, 1948, J CLIN INVEST, V27, P710, DOI 10.1172/JCI102020; BIANCHI G, 1983, KIDNEY INT, V23, P870, DOI 10.1038/ki.1983.109; BIANCHI G, 1974, CLIN SCI MOL MED, V47, P435, DOI 10.1042/cs0470435; BIANCHI G, 1979, LANCET, V1, P173, DOI 10.1016/S0140-6736(79)90577-4; BLACKSHEAR JL, 1987, HYPERTENSION, V9, P384, DOI 10.1161/01.HYP.9.4.384; BROWN JJ, 1976, LANCET, V1, P1217; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; CURTIS JJ, 1983, NEW ENGL J MED, V309, P1009, DOI 10.1056/NEJM198310273091702; De Leeuw P. W., 1981, HYPERTENSION YOUNG O, P57; DELEEUW PW, 1987, ACTA MED SCAND S, V622, P5; DERKX FHM, 1983, HYPERTENSION, V5, P244, DOI 10.1161/01.HYP.5.2.244; DERKX FHM, 1987, J CLIN ENDOCR METAB, V65, P349, DOI 10.1210/jcem-65-2-349; DLUHY RG, 1988, J CARDIOVASC PHARM, V12, pS149; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; GUIDI E, 1985, NEPHRON, V41, P14, DOI 10.1159/000183539; GUYTON AC, 1972, AM J MED, V52, P584, DOI 10.1016/0002-9343(72)90050-2; GUYTON AC, 1984, NETH J MED, V27, P117; HARRAP SB, 1986, J HYPERTENS, V4, pS249; HOFMAN A, 1980, EPIDEMIOLOGY ARTERIA, V8, P99; Hollenberg N K, 1970, Trans Assoc Am Physicians, V83, P93; HOLLENBERG NK, 1978, MEDICINE, V57, P167, DOI 10.1097/00005792-197803000-00004; HOLLENBERG NK, 1986, AM J MED, V81, P412, DOI 10.1016/0002-9343(86)90291-3; HOLLENBERG NK, 1981, HYPERTENSION, V3, P11, DOI 10.1161/01.HYP.3.1.11; LIJNEN PJ, 1978, CLIN CHIM ACTA, V88, P403, DOI 10.1016/0009-8981(78)90447-3; LONDON GM, 1988, AM J HYPERTENS, V1, pS127, DOI 10.1093/ajh/1.3.127S; LOWENSTEIN J, 1967, CIRCULATION, V35, P250, DOI 10.1161/01.CIR.35.2.250; MALVANO R, 1976, J NUCL BIOL MED, V20, P37; MESSERLI FH, 1978, CIRCULATION, V58, P441, DOI 10.1161/01.CIR.58.3.441; MONTANARI A, 1988, HYPERTENSION, V12, P498, DOI 10.1161/01.HYP.12.5.498; REUBI FC, 1978, AM J MED, V64, P556, DOI 10.1016/0002-9343(78)90573-9; SCHALEKAMP MA, 1970, CLIN SCI, V38, P101, DOI 10.1042/cs0380101; SHOBACK DM, 1983, J CLIN INVEST, V72, P2115, DOI 10.1172/JCI111176; SMITH HW, 1945, J CLIN INVEST, V24, P388, DOI 10.1172/JCI101618; UNEDA S, 1984, J HYPERTENS       S3, V2, P437; VANHOOFT IM, 1988, J HYPERTENS, V6, pS594, DOI 10.1097/00004872-198812040-00186; VANHOOFT IMS, 1988, INT J EPIDEMIOL, V17, P228, DOI 10.1093/ije/17.1.228; WATT G, 1986, J HYPERTENS, V4, P1, DOI 10.1097/00004872-198602000-00001	38	135	136	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1305	1311		10.1056/NEJM199105093241902	http://dx.doi.org/10.1056/NEJM199105093241902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017226				2022-12-28	WOS:A1991FK18600002
J	BINDER, PS				BINDER, PS			OPHTHALMOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADIAL KERATOTOMY; CORNEAL; GLAUCOMA		SHARP CABRILLO HOSP,SAN DIEGO,CA		BINDER, PS (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SAN DIEGO,CA 92103, USA.		Binder, Perry S/M-2263-2018	Binder, Perry S/0000-0002-2588-8080				ATEBARA NH, 1990, AM J OPHTHALMOL, V110, P172, DOI 10.1016/S0002-9394(14)76987-9; BARR JT, 1991, CONTACT LENS SPECTRU, V6, P32; BEEBE WE, 1990, OPHTHALMOLOGY, V97, P1414; BINDER PS, 1990, JAMA-J AM MED ASSOC, V263, P1127; BINDER PS, 1990, ARCH OPHTHALMOL-CHIC, V108, P1541, DOI 10.1001/archopht.1990.01070130043026; KURIYAMA S, 1990, ARCH OPHTHALMOL-CHIC, V108, P1559, DOI 10.1001/archopht.1990.01070130061031; Lass J H, 1990, Refract Corneal Surg, V6, P92; RABOWSKY JH, 1989, OPHTHALMIC SURG LAS, V20, P347; RYDER MI, 1990, INVEST OPHTH VIS SCI, V31, P2230; SCHWARTZ SD, 1990, AM J OPHTHALMOL, V109, P701, DOI 10.1016/S0002-9394(14)72439-0; WILSON LA, 1990, AM J OPHTHALMOL, V110, P193, DOI 10.1016/S0002-9394(14)76991-0; WILSON SE, 1990, OPHTHALMOLOGY, V97, P734	12	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3143	3144						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041131				2022-12-28	WOS:A1991FQ77000030
J	EVENS, RG				EVENS, RG			RADIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADIOGRAPHY; LITHOTRIPSY				EVENS, RG (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							AISEN AM, 1989, RADIOLOGY, V173, P593, DOI 10.1148/radiology.173.3.2682768; BARKLEY GL, 1990, HEADACHE, V30, P428, DOI 10.1111/j.1526-4610.1990.hed3007428.x; BURHENNE HJ, 1990, INVEST RADIOL, V25, P1149, DOI 10.1097/00004424-199010000-00015; EDELMAN RR, 1990, AM J ROENTGENOL, V154, P937, DOI 10.2214/ajr.154.5.2108568; HELVIE MA, 1990, RADIOLOGY, V174, P657, DOI 10.1148/radiology.174.3.2305045; HILSENRATH PE, 1991, AM J ROENTGENOL, V156, P177, DOI 10.2214/ajr.156.1.1898556; KALENDER WA, 1990, RADIOLOGY, V176, P181, DOI 10.1148/radiology.176.1.2353088; KNEELAND JB, 1989, RADIOLOGY, V171, P1; MURPHY WA, 1990, RADIOLOGY, V175, P319, DOI 10.1148/radiology.175.2.2326453; REIMAN EM, 1989, SCIENCE, V243, P1071, DOI 10.1126/science.2784226; SAGEL SS, 1990, J THORAC IMAG, V5, P36, DOI 10.1097/00005382-199001000-00007; SCHOENFIELD LJ, 1990, NEW ENGL J MED, V323, P1239, DOI 10.1056/NEJM199011013231804; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SKOLNICK A, 1990, JAMA-J AM MED ASSOC, V263, P623, DOI 10.1001/jama.263.5.623; THURMOND AS, 1990, RADIOLOGY, V174, P371, DOI 10.1148/radiology.174.2.2296648; WEGRYN SA, 1990, RADIOLOGY, V175, P225, DOI 10.1148/radiology.175.1.2315485	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3167	3168						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041140				2022-12-28	WOS:A1991FQ77000040
J	HAUKEBO, N				HAUKEBO, N			MEDICINE MAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2788	2788						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033731				2022-12-28	WOS:A1991FN85500007
J	GURWITZ, JH; AVORN, J				GURWITZ, JH; AVORN, J			THE AMBIGUOUS RELATION BETWEEN AGING AND ADVERSE DRUG-REACTIONS	ANNALS OF INTERNAL MEDICINE			English	Review							ANTI-INFLAMMATORY DRUGS; ELDERLY PATIENTS; PEPTIC-ULCER; BLOOD-PRESSURE; BREAST-CANCER; RISK-FACTORS; PSYCHOACTIVE MEDICATION; ANTICOAGULANT-THERAPY; PLASMA-CONCENTRATIONS; ANTIARRHYTHMIC DRUG	Purpose: To examine the evidence for a relation between advancing patient age and the risk for adverse drug reactions. Data Sources: A computer-assisted search of the English-language literature (MEDLINE, 1966 to 1990) followed by selective review of all pertinent articles. Study Selection: Studies that stratified data on adverse drug reactions by patient age were screened for review. Article selection was not limited by study design; the relation between age and the occurrence of adverse drug reactions did not have to be a primary focus of the study. Data Extraction: Pertinent data were abstracted from the results of case-control and cohort studies and from clinical trials. The methodologic strengths and weaknesses of these studies are discussed with particular reference to gerontologic issues. Results of Data Synthesis: Most studies have neglected the issue of whether the increased frequency of adverse drug reactions in the elderly is attributable to age alone or to the fact that older patients are more likely to have coexisting illnesses and to be taking several medications. Studies that combine all drug exposures for each patient and report the risk for any adverse effect provide little useful information about the risks associated with specific drug therapies in the elderly. The association between age and the risk for adverse drug reactions is best examined for individual pharmacologic agents. However, the exclusion of elderly subjects from clinical trials makes the determination of age effects impossible in many studies. Where subjects do represent an adequate age range, most studies fail to control for important clinical differences among subjects of different ages to distinguish the independent effects of chronologic age. Conclusion: Conventional clinical wisdom suggests that the risk for adverse drug reactions increases with advancing age, but available data do not confirm this "truism" of geriatric medicine. The inter-individual variability of the aging process, including the non-uniform nature of the pharmacokinetic and pharmacodynamic changes that occur with aging, indicates that clinical reality is far more complex. Patient-specific physiologic and functional characteristics are probably more important than any chronologic measure in predicting both adverse and beneficial outcomes associated with specific drug therapies.	HARVARD UNIV, SCH MED, HEBREW REHABIL CTR AGED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CTR GERIATR RES & TRAINING, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	GURWITZ, JH (corresponding author), BETH ISRAEL HOSP, PROGRAM ANAL CLIN STRATEGIES, 333 LONGWOOD AVE, BOSTON, MA 02215 USA.				NIA NIH HHS [AG-08812] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG008812, P30AG008812] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AAGAARD GN, 1989, J FAM PRACTICE, V28, P665; ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALLEN C, 1986, J AM GERIATR SOC, V34, P637, DOI 10.1111/j.1532-5415.1986.tb04904.x; AMERY A, 1986, LANCET, V2, P589; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1972, CIRCULATION, V45, P991; APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; AVORN J, 1989, NEW ENGL J MED, V320, P227, DOI 10.1056/NEJM198901263200406; AVORN J, 1990, JAMA-J AM MED ASSOC, V263, P1823, DOI 10.1001/jama.263.13.1823; BAUM C, 1983, DRUG UTILIZATION US; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BEGG CB, 1983, CANCER, V52, P1986, DOI 10.1002/1097-0142(19831201)52:11<1986::AID-CNCR2820521103>3.0.CO;2-7; BEGG CB, 1989, CANCER ELDERLY APPRO; BERGMAN HD, 1971, AM J HOSP PHARM, V28, P343, DOI 10.1093/ajhp/28.5.343; BERLINGER WG, 1982, CLIN PHARMACOL THER, V32, P387, DOI 10.1038/clpt.1982.176; BERRY GL, 1988, AM J PUBLIC HEALTH, V78, P157, DOI 10.2105/AJPH.78.2.157; BLAZER DG, 1983, J GERONTOL, V38, P31, DOI 10.1093/geronj/38.1.31; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; COLLIER DS, 1985, GUT, V26, P359, DOI 10.1136/gut.26.4.359; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; CURB JD, 1985, JAMA-J AM MED ASSOC, V253, P3263, DOI 10.1001/jama.253.22.3263; DARNELL JC, 1986, J AM GERIATR SOC, V34, P1; DASH LA, 1980, AM REV RESPIR DIS, V121, P1039; FLETCHER RH, 1989, HLTH CARE ELDERLY IN, P451; GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081; GREENBLATT DJ, 1989, J CLIN PHARMACOL, V29, P866, DOI 10.1002/j.1552-4604.1989.tb03246.x; GREENBLATT DJ, 1977, CLIN PHARMACOL THER, V21, P355; GREENBLATT DJ, 1981, CLIN PHARMACOL THER, V30, P475, DOI 10.1038/clpt.1981.191; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRYMONPRE RE, 1988, J AM GERIATR SOC, V36, P1092, DOI 10.1111/j.1532-5415.1988.tb04395.x; GUESS HA, 1988, J CLIN EPIDEMIOL, V41, P35, DOI 10.1016/0895-4356(88)90007-8; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; GURWITZ JH, 1988, ARCH INTERN MED, V148, P1733, DOI 10.1001/archinte.148.8.1733; HURWITZ N, 1969, BRIT MED J, V1, P536, DOI 10.1136/bmj.1.5643.536; HUTCHINSON TA, 1986, J CHRON DIS, V39, P533, DOI 10.1016/0021-9681(86)90198-0; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; IRVIN TT, 1989, BRIT J SURG, V76, P215, DOI 10.1002/bjs.1800760304; ISEMAN MD, 1989, AM REV RESPIR DIS, V140, P575, DOI 10.1164/ajrccm/140.3.575; JAFFE ME, 1987, CLIN PHARMACOL THER, V42, P686, DOI 10.1038/clpt.1987.223; JICK H, 1968, NEW ENGL J MED, V279, P284, DOI 10.1056/NEJM196808082790603; JICK H, 1985, PHARMACOTHERAPY, V5, P280; JOHNSON SL, 1985, CLIN PHARMACOL THER, V38, P331, DOI 10.1038/clpt.1985.181; KAISER L, 1989, STAT MED, V8, P1183, DOI 10.1002/sim.4780081002; KANNRY JL, 1989, CONTROLLED CLIN TRIA, V10, P348; KELLAWAY GS, 1973, NEW ZEAL MED J, V78, P525; KLEIN U, 1976, INT J CLIN PHARM BI, V13, P187; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, J CLIN EPIDEMIOL, V42, P711, DOI 10.1016/0895-4356(89)90066-8; LEVIN ML, 1974, MARYLAND STATE MED J, V23, P64; LEVY M, 1977, ISRAEL J MED SCI, V13, P1065; LINDEMAN RD, 1985, J AM GERIATR SOC, V33, P278, DOI 10.1111/j.1532-5415.1985.tb07117.x; LIPSCHITZ DA, 1990, PRINCIPLES GERIATRIC; MONTAMAT SC, 1989, NEW ENGL J MED, V321, P303; MORGANROTH J, 1986, J AM COLL CARDIOL, V8, P607, DOI 10.1016/S0735-1097(86)80190-5; MOULDING TS, 1989, AM REV RESPIR DIS, V140, P700, DOI 10.1164/ajrccm/140.3.700; NATTEL S, 1990, AM J CARDIOL, V66, P96, DOI 10.1016/0002-9149(90)90743-K; NERENZ DR, 1986, HEALTH SERV RES, V20, P961; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NOLAN L, 1988, J AM GERIATR SOC, V36, P142, DOI 10.1111/j.1532-5415.1988.tb01785.x; OAKES M, 1986, STATISTICAL INFERENC, P13; OLGILVIE RI, 1967, CAN MED ASSOC J, V97, P1450; PETITTI DB, 1986, AM J MED, V81, P255, DOI 10.1016/0002-9343(86)90260-3; PFEIFER HJ, 1976, AM HEART J, V92, P168, DOI 10.1016/S0002-8703(76)80252-9; PODRID PJ, 1989, AM J CARDIOL, V63, P735, DOI 10.1016/0002-9149(89)90261-0; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; POMARA N, 1985, J CLIN PSYCHIAT, V46, P185; POMARA N, 1984, PSYCHOPHARMACOLOGY, V84, P342, DOI 10.1007/BF00555210; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; REIDENBERG MM, 1978, CLIN PHARMACOL THER, V23, P371; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; SAMET J, 1986, JAMA-J AM MED ASSOC, V255, P3385, DOI 10.1001/jama.255.24.3385; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; SHEPHERD AMM, 1977, BRIT J CLIN PHARMACO, V4, P315, DOI 10.1111/j.1365-2125.1977.tb00719.x; SILLIMAN RA, 1989, J GERONTOL, V44, pM46, DOI 10.1093/geronj/44.2.M46; SMIDT NA, 1972, NEW ZEAL MED J, V76, P397; SMITH JW, 1966, ANN INTERN MED, V65, P629, DOI 10.7326/0003-4819-65-4-629; SOMERVILLE K, 1986, LANCET, V1, P462; SOROCK GS, 1988, ARCH INTERN MED, V148, P2441, DOI 10.1001/archinte.148.11.2441; SPAGNOLI A, 1989, J AM GERIATR SOC, V37, P619, DOI 10.1111/j.1532-5415.1989.tb01252.x; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; STULTS BM, 1989, WESTERN J MED, V151, P414; SVANES C, 1989, ANN SURG, V209, P418, DOI 10.1097/00000658-198904000-00005; SWIFT CG, 1985, BRIT J CLIN PHARMACO, V20, P111, DOI 10.1111/j.1365-2125.1985.tb05040.x; TEMPLE R, 1983, FDA DISCUSSION PAPER; THIESSEN BQ, 1990, ARCH INTERN MED, V150, P2286, DOI 10.1001/archinte.150.11.2286; TIBALDI JM, 1986, AM J MED, V81, P619, DOI 10.1016/0002-9343(86)90547-4; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; VESTAL RE, 1975, CLIN PHARMACOL THER, V18, P425; VESTAL RE, 1979, CLIN PHARMACOL THER, V26, P181; VIEWEG WVR, 1970, J AMER MED ASSOC, V213, P1303, DOI 10.1001/jama.213.8.1303; WALKER AM, 1980, JAMA-J AM MED ASSOC, V244, P1209, DOI 10.1001/jama.244.11.1209; WILLIAMSON J, 1980, AGE AGEING, V9, P73, DOI 10.1093/ageing/9.2.73; 1983, MMWR, V32, P121; 1980, MMWR, V32, P465	104	222	226	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					956	966		10.7326/0003-4819-114-11-956	http://dx.doi.org/10.7326/0003-4819-114-11-956			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024864				2022-12-28	WOS:A1991FM97900008
J	KNILL, DC; KERSTEN, D				KNILL, DC; KERSTEN, D			APPARENT SURFACE CURVATURE AFFECTS LIGHTNESS PERCEPTION	NATURE			English	Article							ILLUMINATION; INFORMATION	THE human visual system has the remarkable capacity to perceive accurately the lightness, or relative reflectance, of surfaces, even though much of the variation in image luminance may be caused by other scene attributes, such as shape and illumination. Most physiological 1,2, and computational models 3-6 of lightness perception invoke early sensory mechanisms that act independently of, or before, the estimation of other scene attributes. In contrast to the modularity of lightness perception assumed in these models are experiments that show that supposedly 'higher-order' percepts of planar surface attributes, such as orientation, depth and transparency 7-10, can influence perceived lightness. Here we show that perceived surface curvature can also affect perceived lightness. The results of the earlier experiments indicate that perceiving luminance edges as changes in surface attributes other than reflectance can influence lightness. These results suggest that the interpretation of smooth variations in luminance can also affect lightness percepts.			KNILL, DC (corresponding author), UNIV MINNESOTA,DEPT PSYCHOL,MINNEAPOLIS,MN 55455, USA.							ADELSON A, 1990, S INVEST OPHTHALMOL, V31, P265; [Anonymous], 1974, COMPUT VISION GRAPH, DOI DOI 10.1016/0146-664X(74)90022-7; AREND LE, 1971, PERCEPT PSYCHOPHYS, V9, P367, DOI 10.3758/BF03212669; BARROW HG, 1981, ARTIF INTELL, V17, P75, DOI 10.1016/0004-3702(81)90021-7; BERGSTROM SS, 1977, SCAND J PSYCHOL, V18, P180, DOI 10.1111/j.1467-9450.1977.tb00275.x; BLAKE A, 1985, COMPUT VISION GRAPH, V32, P314, DOI 10.1016/0734-189X(85)90054-4; Cornsweet T., 1970, VISUAL PERCEPTION; Craik W. A., 1965, J AUSTEN 6 NOVELS; GILCHRIST A, 1983, PERCEPT PSYCHOPHYS, V33, P425, DOI 10.3758/BF03202893; GILCHRIST AL, 1977, SCIENCE, V195, P185, DOI 10.1126/science.831266; GROSSBERG S, 1988, NEURAL NETWORKS NATU, P127; LAND EH, 1971, J OPT SOC AM, V61, P1, DOI 10.1364/JOSA.61.000001; Mach E, 1897, CONTRIBUTIONS ANAL S, P63; OBRIEN V, 1958, J OPT SOC AM, V48, P112, DOI 10.1364/JOSA.48.000112; RAMACHANDRAN VS, 1988, SCI AM, V259, P76, DOI 10.1038/scientificamerican0888-76; SHAPLEY R, 1986, VISION RES, V26, P45, DOI 10.1016/0042-6989(86)90070-2	16	165	166	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1991	351	6323					228	230		10.1038/351228a0	http://dx.doi.org/10.1038/351228a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FL990	2041568				2022-12-28	WOS:A1991FL99000055
J	DELORON, P; LEPERS, JP; RAHARIMALALA, L; DUBOIS, B; COULANGES, P; POCIDALO, JJ				DELORON, P; LEPERS, JP; RAHARIMALALA, L; DUBOIS, B; COULANGES, P; POCIDALO, JJ			PEFLOXACIN FOR FALCIPARUM-MALARIA - ONLY MODEST SUCCESS	ANNALS OF INTERNAL MEDICINE			English	Note							NORFLOXACIN; INVITRO; MICE; DRUG	To assess the efficacy of pefloxacin in treating Plasmodium falciparum malaria in Madagascar, an area of chloroquine resistance, we conducted a case series intervention study in a rural population. Twenty-two adults with pure P. falciparum parasitemia, and no glucose-6-phosphate dehydrogenase deficiency, pregnancy, or other illness, were given an oral dose of 400 mg of pefloxacin every 12 hours for 3 days. Pefloxacin and chloroquine susceptibilities of 10 isolates were measured by an in-vitro microtest. The overall success rate of treatment was 9 of 22 (41%; 95% CI, 20% to 61%). Sixteen patients cleared parasitemia, but late recrudescence occurred in 7. Early therapeutic failure occurred in the 6 other patients. Efficacy of pefloxacin treatment was not related to the in-vitro activity of chloroquine or pefloxacin against the corresponding strain. These data contrast with those from a preliminary report from India of successful malaria therapy with a similar regimen of norfloxacin, the main metabolite of pefloxacin in humans.	INST PASTEUR MADAGASCAR, ANTANANARIVO, MADAGASCAR	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Madagascar	DELORON, P (corresponding author), HOP CLAUDE BERNARD, INSERM, UB, 10 AVE PORT DAUBERVILLIERS, F-75019 PARIS, FRANCE.		Deloron, Philippe/G-6305-2010	Deloron, Philippe/0000-0003-4705-2484				[Anonymous], 1986, CHEMOTHERAPY MALARIA; ASTAGNEAU P, 1991, AM J EPIDEMIOL, V133, P177, DOI 10.1093/oxfordjournals.aje.a115856; DIVO AA, 1988, ANTIMICROB AGENTS CH, V32, P1182, DOI 10.1128/AAC.32.8.1182; LEPERS JP, 1989, T ROY SOC TROP MED H, V83, P491, DOI 10.1016/0035-9203(89)90263-0; MONTAY G, 1984, ANTIMICROB AGENTS CH, V25, P463, DOI 10.1128/AAC.25.4.463; RIOU JF, 1986, BIOCHEMISTRY-US, V25, P1471, DOI 10.1021/bi00355a001; SALMON D, 1990, ANTIMICROB AGENTS CH, V34, P2327, DOI 10.1128/AAC.34.12.2327; SARMA PS, 1989, ANN INTERN MED, V111, P336, DOI 10.7326/0003-4819-111-4-336; WISE R, 1984, J ANTIMICROB CHEMOTH, V13, P59, DOI 10.1093/jac/13.suppl_B.59; WOLFSON JS, 1985, ANTIMICROB AGENTS CH, V28, P581, DOI 10.1128/AAC.28.4.581	10	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					874	875		10.7326/0003-4819-114-10-874	http://dx.doi.org/10.7326/0003-4819-114-10-874			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014948				2022-12-28	WOS:A1991FL65000007
J	FRIEDMAN, E				FRIEDMAN, E			THE UNINSURED - FROM DILEMMA TO CRISIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTEMS											Aday L A, 1990, Health Manage Q, V12, P18; Blendon R J, 1989, Health Manage Q, V11, P2; BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; BLOOM B, 1990, ADV DATA VITAL HLTH, V188; CERNE F, 1990, AM HOSP ASS NEWS, V26, P8; CHOLLET DJ, 1990, UNINSURED US NONELDE; FARLEY PJ, 1985, MILBANK FUND Q, V63, P476, DOI 10.2307/3349844; FOSSETT JW, 1990, 118TH ANN M AM PUBL; FRIEDMAN E, 1990, HOSPITALS, V64, P38; FRIEDMAN E, 1990, JAMA-J AM MED ASSOC, V264, P310, DOI 10.1001/jama.264.3.310; FRIEDMAN E, 1989, JAMA-J AM MED ASSOC, V262, P2975, DOI 10.1001/jama.262.21.2975; FRIEDMAN E, 1977, PROBLEMS PROMISES ME; FRIEDMAN E, 1991, HLTH BUSINESS, V6, pT1; GORNICK M, 1985, HLTH CARE FINANC R S, V7, P13; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; KASPER JA, 1980, WHO ARE UNINSURED; NELSON C, 1990, CURENT POPULATIO P70, V17; OHSFELDT RL, 1985, MED CARE, V23, P1338, DOI 10.1097/00005650-198512000-00003; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; SHORT PF, 1989, NATIONAL MED EXPENDI, V1; SHORT PF, 1990, NATIONAL MED EXPENDI, V2; SWARTZ K, 1989, STRATEGIES ASSISTING; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; YUDKOWSKY BK, 1990, PEDIATRICS, V85, P567; 1991, MED HLTH, V45, P2; 1990, HLTH INSURANCE AVAIL; 1989, SMS REP, V3, P3; 1991, MEDICAID UNDERPAYMEN; 1989, SMS REP, V3, P1	29	75	75	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2491	2495		10.1001/jama.265.19.2491	http://dx.doi.org/10.1001/jama.265.19.2491			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK903	2020064				2022-12-28	WOS:A1991FK90300019
J	HOLAHAN, J; MOON, M; WELCH, WP; ZUCKERMAN, S				HOLAHAN, J; MOON, M; WELCH, WP; ZUCKERMAN, S			AN AMERICAN APPROACH TO HEALTH SYSTEM REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROMOTE QUALITY; UNITED-STATES; INSURANCE; ECONOMY; 1990S; PLAN				HOLAHAN, J (corresponding author), URBAN INST,CTR HLTH POLICY,2100 M ST NW,WASHINGTON,DC 20037, USA.							ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; MONHEIT AC, 1989, HEALTH AFFAIR, V8, P22, DOI 10.1377/hlthaff.8.4.22; MOYER ME, 1989, HEALTH AFFAIR, V8, P102, DOI 10.1377/hlthaff.8.2.102; NELSON C, 1990, CURRENT POPULATI P70, V17; POULIER JP, 1990, HLTH CARE FINANC REV, V11, P159; SCHIEBER GJ, 1989, HLTH CARE FINANCIN S, P1; ZEDLWESKI SR, IN PRESS EXPANDING E; 1990, CALL ACTION FINAL RE; 916 URB I REP; [No title captured]	14	14	14	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2537	2540		10.1001/jama.265.19.2537	http://dx.doi.org/10.1001/jama.265.19.2537			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK903	2020072				2022-12-28	WOS:A1991FK90300028
J	MCINTIRE, WS; WEMMER, DE; CHISTOSERDOV, A; LIDSTROM, ME				MCINTIRE, WS; WEMMER, DE; CHISTOSERDOV, A; LIDSTROM, ME			A NEW COFACTOR IN A PROKARYOTIC ENZYME - TRYPTOPHAN TRYPTOPHYLQUINONE AS THE REDOX PROSTHETIC GROUP IN METHYLAMINE DEHYDROGENASE	SCIENCE			English	Article							COVALENTLY BOUND PQQ; AMINO-ACID-SEQUENCE; PSEUDOMONAS SP-J; PYRROLOQUINOLINE QUINONE; PARACOCCUS-DENITRIFICANS; PYRIDOXO-QUINOPROTEIN; DIAMINE OXIDASE; BIOSYNTHESIS; PURIFICATION; TYROSINE	Methylamine dehydrogenase (MADH), an alpha-2-beta-2 enzyme from numerous methylotrophic soil bacteria, contains a novel quinonoid redox prosthetic group that is covalently bound to its small beta-subunit through two amino acyl residues. A comparison of the amino acid sequence deduced from the gene sequence of the small subunit for the enzyme from Methylobacterium extorquens AM1 with the published amino acid sequence obtained by the Edman degradation method, allowed the identification of the amino acyl constituents of the cofactor as two tryptophyl residues. This information was crucial for interpreting H-1 and C-13 nuclear magnetic resonance, and mass spectral data collected for the semicarbazide- and carboxymethyl-derivatized bis(tripeptidyl)-cofactor of MADH from bacterium W3A1. The cofactor is composed of two cross-linked tryptophyl residues. Although there are many possible isomers, only one is consistent with all the data: The first tryptophyl residue in the peptide sequence exists as an indole-6,7-dione, and is attached at its 4 position to the 2 position of the second, otherwise unmodified, indole side group. Contrary to earlier reports, the cofactor of MADH is not 2,7,9-tricarboxypyrroloquinoline quinone (PQQ), a derivative thereof, or pro-PQQ. This appears to be the only example of two cross-linked, modified amino acyl residues having a functional role in the active site of an enzyme, in the absence of other cofactors or metal ions.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIA, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; CALTECH, WM KECK LABS, PASADENA, CA 91125 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; California Institute of Technology	MCINTIRE, WS (corresponding author), DEPT VET AFFAIRS MED CTR, DIV MOLEC BIOL, SAN FRANCISCO, CA 94121 USA.				NHLBI NIH HHS [HL 16251] Funding Source: Medline; NIGMS NIH HHS [GM 36296] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036296] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI O, 1989, PQQ AND QUINOPROTEINS, P145; AMEYAMA M, 1984, AGR BIOL CHEM TOKYO, V48, P561, DOI 10.1080/00021369.1984.10866184; ANTHONY C, 1989, PQQ AND QUINOPROTEINS, P1; BACKES G, UNPUB; CHISTOSERDOV AY, 1990, BIOCHEM BIOPH RES CO, V172, P211, DOI 10.1016/S0006-291X(05)80195-0; CLARK K, 1990, J AM CHEM SOC, V112, P6433, DOI 10.1021/ja00173a061; DAVIDSON VL, 1987, FEMS MICROBIOL LETT, V44, P121, DOI 10.1111/j.1574-6968.1987.tb02254.x; DEBEER R, 1980, BIOCHIM BIOPHYS ACTA, V622, P370, DOI 10.1016/0005-2795(80)90050-1; DOOLEY DM, 1990, J AM CHEM SOC, V112, P2782, DOI 10.1021/ja00163a047; DRYHURST G, 1990, CHEM REV, V90, P795, DOI 10.1021/cr00103a007; DUINE J A, 1989, Biofactors, V2, P87; GALLOP PM, 1989, TRENDS BIOCHEM SCI, V14, P343, DOI 10.1016/0968-0004(89)90169-2; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GLATZ Z, 1987, BIOCHEM J, V242, P603, DOI 10.1042/bj2420603; GROEN BW, 1988, FEBS LETT, V237, P98, DOI 10.1016/0014-5793(88)80179-0; HARTMANN C, 1988, Biofactors, V1, P41; HARTMANN C, 1990, FEBS LETT, V261, P441, DOI 10.1016/0014-5793(90)80611-L; HARTMANN C, 1987, J BIOL CHEM, V262, P962; HAYWOOD GW, 1982, FEMS MICROBIOL LETT, V15, P79, DOI 10.1111/j.1574-6968.1982.tb00042.x; HOUCK DR, 1989, PQQ AND QUINOPROTEINS, P177; HOUCK DR, 1988, J AM CHEM SOC, V110, P6920, DOI 10.1021/ja00228a070; HUSAIN M, 1987, BIOCHEMISTRY-US, V26, P4139, DOI 10.1021/bi00387a059; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; HUSAIN M, 1987, J BACTERIOL, V169, P1712, DOI 10.1128/jb.169.4.1712-1717.1987; ISHII Y, 1983, J BIOCHEM, V93, P107, DOI 10.1093/oxfordjournals.jbchem.a134144; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JENKINS O, 1987, J GEN MICROBIOL, V133, P453; KARHUNEN E, 1990, FEBS LETT, V267, P6, DOI 10.1016/0014-5793(90)80273-L; KASPRZAK AA, 1983, J BACTERIOL, V156, P348, DOI 10.1128/JB.156.1.348-353.1983; KENNEY WC, 1983, BIOCHEMISTRY-US, V22, P3858, DOI 10.1021/bi00285a022; KENNEY WC, 1984, MICROBIAL GROWTH C1, P165; KILLGORE J, 1989, SCIENCE, V245, P850, DOI 10.1126/science.2549636; LARGE PJ, 1988, METHYLOTROPHY BIOTEC, P18; Lee E, UNPUB; LERCH K, 1982, J BIOL CHEM, V257, P6414; LOBENSTEINVERBEEK CL, 1984, FEBS LETT, V170, P305, DOI 10.1016/0014-5793(84)81333-2; Martin G. E., 1988, 2 DIMENSIONAL NMR ME; MATHEWS FS, COMMUNICATION; MATSUMOTO T, 1978, J BIOCHEM-TOKYO, V83, P1591, DOI 10.1093/oxfordjournals.jbchem.a132070; MATSUMOTO T, 1978, BIOCHIM BIOPHYS ACTA, V522, P303, DOI 10.1016/0005-2744(78)90064-5; MATSUMOTO T, 1978, BIOCHIM BIOPHYS ACTA, V522, P291, DOI 10.1016/0005-2744(78)90063-3; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; MCINTIRE WS, 1991, BIOCHEMISTRY-US, V30, P125, DOI 10.1021/bi00215a019; MCINTIRE WS, 1986, BIOCHEM BIOPH RES CO, V141, P562, DOI 10.1016/S0006-291X(86)80210-8; MCINTIRE WS, 1987, APPL ENVIRON MICROB, V53, P2183, DOI 10.1128/AEM.53.9.2183-2188.1987; MICHAUDSORET I, 1990, BIOCHEM BIOPH RES CO, V172, P1122, DOI 10.1016/0006-291X(90)91563-8; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; PENNINGS EJM, 1989, FEBS LETT, V255, P97, DOI 10.1016/0014-5793(89)81068-3; PRINCE RC, 1990, TRENDS BIOCHEM SCI, V15, P170, DOI 10.1016/0968-0004(90)90152-2; PRINCE RC, 1988, TRENDS BIOCHEM SCI, V13, P286, DOI 10.1016/0968-0004(88)90119-3; RAPHALS P, 1990, SCIENCE, V249, P619, DOI 10.1126/science.2166338; ROBERTSON JG, 1989, J BIOL CHEM, V264, P19916; RODRIGUEZ EJ, 1989, J AM CHEM SOC, V111, P7947, DOI 10.1021/ja00202a041; RUCKER R, 1989, PQQ AND QUINOPROTEINS, P159; RUCKER RB, 1988, FASEB J, V2, P2252, DOI 10.1096/fasebj.2.7.3127264; SALISBURY SA, 1979, NATURE, V280, P843, DOI 10.1038/280843a0; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; VANDERMEER RA, 1986, FEBS LETT, V206, P111, DOI 10.1016/0014-5793(86)81350-3; VANDERMEER RA, 1989, FEBS LETT, V254, P99, DOI 10.1016/0014-5793(89)81017-8; VANDERMEER RA, 1989, FEBS LETT, V246, P109, DOI 10.1016/0014-5793(89)80263-7; VANDERMEER RA, 1987, FEBS LETT, V221, P299, DOI 10.1016/0014-5793(87)80944-4; VANKLEEF MAG, 1988, FEBS LETT, V237, P91, DOI 10.1016/0014-5793(88)80178-9; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; VANSPANNING RJM, 1990, FEBS LETT, V275, P217, DOI 10.1016/0014-5793(90)81475-4; VELDINK GA, 1990, FEBS LETT, V270, P135, DOI 10.1016/0014-5793(90)81252-J; VELLIEUX FMD, 1989, FEBS LETT, V255, P460, DOI 10.1016/0014-5793(89)81145-7; VELLIEUX FMD, 1986, EUR J BIOCHEM, V154, P383, DOI 10.1111/j.1432-1033.1986.tb09409.x; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104; Wuthrich K., 1986, NMR PROTEINS NUCL AC; 1990, MORB MORTAL WKLY REP, V39, P589; 1990, MORB MORTAL WKLY REP, V39, P789	74	341	345	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1991	252	5007					817	824		10.1126/science.2028257	http://dx.doi.org/10.1126/science.2028257			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	2028257				2022-12-28	WOS:A1991FL12300039
J	SORGER, PK				SORGER, PK			HEAT-SHOCK FACTOR AND THE HEAT-SHOCK RESPONSE	CELL			English	Review							HSP70 GENE; TRANSCRIPTION FACTOR; REGULATORY ELEMENTS; DNA-BINDING; ACTIVATION; EXPRESSION; PROMOTER; CELLS				SORGER, PK (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.			Sorger, Peter/0000-0002-3364-1838				AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; DIDOMENICO BJ, 1982, P NATL ACAD SCI-BIOL, V79, P6181, DOI 10.1073/pnas.79.20.6181; FUJITA A, 1989, GENE, V85, P321; GALLO GJ, 1991, MOL CELL BIOL, V11, P281, DOI 10.1128/MCB.11.1.281; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; LARSON JS, 1988, NATURE, V336, P184, DOI 10.1038/336184a0; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; MCDANIEL D, 1989, MOL CELL BIOL, V9, P4789, DOI 10.1128/MCB.9.11.4789; MEZGER V, 1989, MOL CELL BIOL, V9, P3888, DOI 10.1128/MCB.9.9.3888; Morimoto RI, 1990, STRESS PROTEINS BIOL; PARK HO, 1989, MOL CELL BIOL, V9, P2025, DOI 10.1128/MCB.9.5.2025; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SHUEY DJ, 1986, J BIOL CHEM, V261, P7934; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124	29	537	559	2	58	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					363	366		10.1016/0092-8674(91)90452-5	http://dx.doi.org/10.1016/0092-8674(91)90452-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018972				2022-12-28	WOS:A1991FK18200002
J	MCCORMICK, MC; BROOKSGUNN, J; SHAPIRO, S; BENASICH, AA; BLACK, G; GROSS, RT				MCCORMICK, MC; BROOKSGUNN, J; SHAPIRO, S; BENASICH, AA; BLACK, G; GROSS, RT			HEALTH-CARE USE AMONG YOUNG-CHILDREN IN DAY-CARE - RESULTS IN A RANDOMIZED TRIAL OF EARLY INTERVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; MEDICAL-CARE; INFECTIOUS-DISEASES; RE-HOSPITALIZATION; MORBIDITY; INFANT; ILLNESS; CHILDHOOD; SERVICES; COSTS	Exposure of young children to group day-care settings increases the risk of illness and may result in higher use of medical care. These observations raise concerns that the use of such settings for early intervention programs for low-birth-weight infants may increase the already high burden of medical care costs incurred by these children and their families. To address the question of medical care use associated with center-based care, we examined the hospital-based and ambulatory care reported for participants of the Infant Health and Development Program. This project is a multisite randomized trial of an early intervention program for preterm low-birth-weight infants with an intervention including 2 years of center-based care. The Intervention group did not differ in hospital-based care and averaged only two more physicians' visits over the 3-year observation period than the comparison group. We conclude that early intervention programs involving high-quality group care are not accompanied by substantial increases in health care use.	INFANT HLTH & DEV PROGRAM,STANFORD,CA; HARVARD UNIV,SCH MED,DEPT PEDIAT,DIV NEONATOL,BOSTON,MA 02115; EDUC TESTING SERV,PRINCETON,NJ 08541; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR HLTH SERV RES & DEV,BALTIMORE,MD 21218; RUTGERS STATE UNIV,CTR MOLEC & BEHAV NEUROSCI,NEWARK,NJ 07102	Harvard University; Harvard Medical School; Educational Testing Service (ETS); Johns Hopkins University; Rutgers State University Newark; Rutgers State University New Brunswick				McCormmick, Marie/0000-0002-3938-1707; Benasich, April A/0000-0002-5137-776X	PHS HHS [MCJ-060515] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ANDERSON LJ, 1988, PEDIATRICS, V82, P300; Baker P. C., 1989, NLSY CHILD HDB 1989; BAYDAR N, IN PRESS DEV PSYCHOL; BELL DM, 1989, AM J PUBLIC HEALTH, V79, P479, DOI 10.2105/AJPH.79.4.479; BERG AT, 1991, AM J EPIDEMIOL, V133, P154, DOI 10.1093/oxfordjournals.aje.a115854; Berkelman R L, 1989, Public Health Rep, V104, P101; BOWMAN E, 1989, EARLY HUM DEV, V18, P165; BROOKSGUNN J, 1990, IMPROVING THE LIFE CHANCES OF CHILDREN AT RISK, P125; BROOKSGUNN J, 1990, APR INT C INF STUD M; CAFFERATA GL, 1985, MED CARE, V23, P250; DARLINGTON RB, 1980, SCIENCE, V208, P202, DOI 10.1126/science.208.4440.202; DEGRAW C, 1988, J PEDIATR-US, V113, P971, DOI 10.1016/S0022-3476(88)80565-1; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; ELANDER G, 1986, AM J ORTHOPSYCHIAT, V56, P612, DOI 10.1111/j.1939-0025.1986.tb03494.x; FLEISS JL, 1986, CONTROL CLIN TRIALS, V7, P267, DOI 10.1016/0197-2456(86)90034-6; HACK M, 1983, J DEV BEHAV PEDIATR, V4, P243; HACK M, 1981, AM J DIS CHILD, V135, P263, DOI 10.1001/archpedi.1981.02130270055018; HASKINS R, 1986, PEDIATRICS, V77, P951; Hayes C, 1990, WHO CARES AM CHILDRE; HORWITZ SM, 1985, MED CARE, V23, P946, DOI 10.1097/00005650-198508000-00002; HURWITZ ES, 1991, PEDIATRICS, V87, P62; KRAEMER HS, IN PRESS J CLIN EPID; KRAMER MS, 1984, MED CARE, V22, P223, DOI 10.1097/00005650-198403000-00005; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCCORMICK MC, 1980, PEDIATRICS, V66, P991; MCCORMICK MC, IN PRESS PEDIATRICS; NEWACHECK PW, 1986, PEDIATRICS, V78, P813; OLDS DL, 1990, IMPROVING LIFE CHANC, P79; OSTERHOLM MT, 1986, REV INFECT DIS, V8, P513; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; RAMEY CT, IN PRESS PEDIATRICS; SCOTT DT, 1989, PEDIATR RES, V25, P263; SHANKARAN S, 1988, PEDIATRICS, V81, P372; SHAPIRO S, 1980, AM J OBSTET GYNECOL, V136, P363, DOI 10.1016/0002-9378(80)90863-7; SPARLING J, 1984, IN PRESS PARTNERS LE; SPARLING J, EARLY PARTNERS; STARFIELD B, 1979, PEDIATRICS, V63, P633; WASIK BH, COPING PARENTING EFF; WOLFE BL, 1980, MED CARE, V18, P1196, DOI 10.1097/00005650-198012000-00005; ZIGLER E, 1986, REV INFECT DIS, V8, P514; 1985, SAS USERS GUIDE STAT; 1990, JAMA-J AM MED ASSOC, V263, P3035; 1982, VITAL HLTH STATIS 10, V141	44	24	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2212	2217		10.1001/jama.265.17.2212	http://dx.doi.org/10.1001/jama.265.17.2212			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH877	2013954				2022-12-28	WOS:A1991FH87700033
J	AAMODT, EJ; CHUNG, MA; MCGHEE, JD				AAMODT, EJ; CHUNG, MA; MCGHEE, JD			SPATIAL CONTROL OF GUT-SPECIFIC GENE-EXPRESSION DURING CAENORHABDITIS-ELEGANS DEVELOPMENT	SCIENCE			English	Article							TRANSGENIC NEMATODES; CELL; TRANSFORMATION; LINEAGE; FUSION; EMBRYO	The nematode Caenorhabditis elegans was transformed with constructs containing upstream deletions of the gut-specific ges-1 carboxylesterase gene. With particular deletions, ges-1 was expressed, not as normally in the gut, but rather in muscle cells of the pharynx (which belong to a sister lineage of the gut) or in body wall muscle and hypodermal cells (which belong to a cousin lineage of the gut). These observations suggest that gut-specific gene expression in C. elegans involves not only gut-specific activators but also multiple repressors that are present in particular nongut lineages.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary				McGhee, James/0000-0001-7266-7275				AAMODT EJ, UNPUB; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; DEAROLF CR, 1989, GENE DEV, V3, P384, DOI 10.1101/gad.3.3.384; DEPPE U, 1978, P NATL ACAD SCI USA, V75, P376, DOI 10.1073/pnas.75.1.376; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRANKS RR, 1988, GENE DEV, V2, P1, DOI 10.1101/gad.2.1.1; GOODBOURN S, 1990, BIOCHIM BIOPHYS ACTA, V1032, P53, DOI 10.1016/0304-419X(90)90012-P; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOUGHEVANS BR, 1990, DEVELOPMENT, V110, P41; JEFFERSON RA, 1987, J MOL BIOL, V193, P41, DOI 10.1016/0022-2836(87)90624-3; MCGHEE JD, 1990, GENETICS, V125, P505; MELLO CC, COMMUNICATION; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SPIETH J, 1988, DEV BIOL, V130, P285, DOI 10.1016/0012-1606(88)90434-4; STINCHCOMB DT, 1985, MOL CELL BIOL, V5, P3484, DOI 10.1128/MCB.5.12.3484; STROEHER VL, UNPUB; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x	23	84	90	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					579	582		10.1126/science.2020855	http://dx.doi.org/10.1126/science.2020855			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	2020855				2022-12-28	WOS:A1991FJ12700052
J	THORPE, K; GOLDING, J; MACGILLIVRAY, I; GREENWOOD, R				THORPE, K; GOLDING, J; MACGILLIVRAY, I; GREENWOOD, R			COMPARISON OF PREVALENCE OF DEPRESSION IN MOTHERS OF TWINS AND MOTHERS OF SINGLETONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INCREASED CHILD-ABUSE; COMMUNITY; WOMEN	Objective-To determine whether the apparent additional and exceptional stresses associated with bearing and parenting twins affect the emotional wellbeing of mothers. Setting-Great Britain, 1970-5. Design-Cohort study of 13 135 children born between 4 April and 11 April 1970. Mothers of all children, both singletons and twins, were interviewed by health visitors (providing demographic data) and completed a self report measure of emotional well-being (the Rutter malaise inventory) when the child was 5 years of age. The malaise scores of mothers of twins were compared with those of all mothers of singletons and then with those of mothers categorised by the age spacing of their children (only one child, widely spaced, or closely spaced), taking account of maternal age, social class, and whether the study child had a disability, by using logistic regression. Subjects-139 mothers of twins-122 pairs of twins and 17 twins whose cotwin had died-and 12 573 controls, who were mothers of singletons. Results-A significantly higher proportion of mothers of twins at 5 years had malaise scores indicative of depression than mothers of singletons at the same age. Mothers who had borne twins, one of whom had subsequently died, had the highest malaise scores and were three times more likely than mothers of singletons to experience depression. Both mothers of twin pairs and mothers of singletons closely spaced in age were at significantly higher risk of experiencing depression than mothers of children widely spaced in age or mothers of only one child (p < 0.0001). Odds ratios indicated that the risk of depression in mothers of twins was higher than that in mothers of closely spaced singletons. Conclusion-Mothers of twins are more likely to experience depression. This suggests a relation between the additional and exceptional stresses that twins present and the mother's emotional wellbeing.	UNIV ABERDEEN, OBSTET & GYNAECOL, ABERDEEN AB9 1FX, SCOTLAND	University of Aberdeen	THORPE, K (corresponding author), UNIV BRISTOL, INST CHILD HLTH, BRISTOL BS2 8BJ, ENGLAND.		Thorpe, Karen/N-1159-2017	Thorpe, Karen/0000-0001-8927-4064; Golding, Jean/0000-0003-2826-3307				BEBBINGTON PE, 1984, PSYCHOL MED, V14, P347, DOI 10.1017/S0033291700003603; BRODMAN K, 1949, JAMA-J AM MED ASSOC, V140, P530, DOI 10.1001/jama.1949.02900410026007; Brown G., 1978, SOCIAL ORIGINS DEPRE; BRYAN EM, 1983, MATERNAL CHILD H MAY, P201; Butler NR, 1986, BIRTH 5 STUDY HLTH B; COSTELLO CG, 1982, PSYCHOL MED, V12, P329, DOI 10.1017/S0033291700046663; DELLAVVOCATO L, 1988, HLTH VISITOR, V61, P37; FREIDRICH L, 1983, TWINS HDB; GOTTSTEIN ERG, 1980, PSYCHIATRY, V43, P189; GREEN J, 1990, OCCASIONAL PAPERS GA, V2; GROOTHUIS JR, 1982, PEDIATRICS, V70, P769; GROSSMAN F, 1980, PREGNANCY BIRTH PARE; Haigh J, 1989, Health Visit, V62, P43; HAMMEN C, 1988, COGNITIVE PROCESSES; HENDERSON S, 1979, ACTA PSYCHIAT SCAND, V60, P355, DOI 10.1111/j.1600-0447.1979.tb00285.x; KUMAR R, 1984, BRIT J PSYCHIAT, V144, P35, DOI 10.1192/bjp.144.1.35; LEWIS E, 1988, BRIT MED J, V297, P1321, DOI 10.1136/bmj.297.6659.1321; LINNEY J, 1983, MULTIPLE BIRTHS; MacGillivray I, 1988, TWINNING TWINS; MAGNUS P, 1990, EARLY HUM DEV, V22, P89, DOI 10.1016/0378-3782(90)90083-U; NELSON HB, 1985, CHILD ABUSE NEGLECT, V9, P501; OHARA MW, 1986, ARCH GEN PSYCHIAT, V43, P569; PAYKEL ES, 1969, ARCH GEN PSYCHIAT, V21, P753; PAYKEL ES, 1979, PSYCHOBIOLOGY DEPRES, P245; POWELL TJ, 1981, THESIS SURREY U; RICHMAN N, 1978, J ROY SOC MED, V71, P489, DOI 10.1177/014107687807100706; ROBIN M, 1988, ACTA GENET MED GEMEL, V37, P151, DOI 10.1017/S0001566000004074; RUTTER M, 1976, PSYCHOL MED, V6, P313, DOI 10.1017/S003329170001388X; RUTTER M, 1980, ED HLTH BEHAVIOR; SANDBANK AC, 1988, ACTA GENET MED GEMEL, V37, P161, DOI 10.1017/S0001566000004086; SCHEINFIELD A, 1973, TWINS SUPERTWINS; SNAITH RP, 1976, BRIT J PSYCHIAT, V128, P156, DOI 10.1192/bjp.128.2.156; Spillman J R, 1987, Midwife Health Visit Community Nurse, V23, P54; SPILLMAN JR, 1984, MIDWIFE HLTH VISITOR, V20, P92; TANIMURA M, 1990, LANCET, V336, P1298, DOI 10.1016/0140-6736(90)92975-N; TROWELL J, 1982, EARLY HUM DEV, V7, P41, DOI 10.1016/0378-3782(82)90006-8; Zajicek E, 1981, PREGNANCY PSYCHOL SO	37	149	150	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	1991	302	6781					875	878		10.1136/bmj.302.6781.875	http://dx.doi.org/10.1136/bmj.302.6781.875			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025725	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1991FG42100020
J	RENWICK, IGH; BUTT, WP; STEELE, B				RENWICK, IGH; BUTT, WP; STEELE, B			HOW WELL CAN RADIOGRAPHERS TRIAGE X-RAY-FILMS IN ACCIDENT AND EMERGENCY DEPARTMENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the ability of radiographers to identify abnormal radiographs of patients attending accident and emergency departments. Design - Prospective study over six weeks. Setting - Teaching hospital casualty x ray department. Patients - 3994 consecutive patients referred for radiography. Interventions - Radiographs were assessed by radiographers who were offered a four point triage scheme: normal, abnormal, insignificantly abnormal, or further advice required. Main outcome measures - Comparison of radiographers' assessments with an assessment made independently by the reporting radiologists. Results - Overall disagreement between the radiographers and radiologists was 9.4%. There were 7% false positives and 14% false negatives. Most errors occurred in assessing radiographs of the skull, facial bones, chest, abdomen, and soft tissues. Conclusion - Unselected radiographers can offer useful advice on radiographs to casualty officers, but their high rate of false positive diagnoses indicates that they cannot triage casualty radiographs sufficiently accurately to allow them to extend their current reporting role.	ST JAMES UNIV HOSP,DEPT DIAGNOST RADIOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Saint James's University Hospital								ABERDOUR KR, 1976, BRIT J RADIOL, V49, P573, DOI 10.1259/0007-1285-49-582-573; BERIMAN L, 1985, BMJ, V290, P421; CLARKE JA, 1990, CLIN RADIOL, V41, P152, DOI 10.1016/S0009-9260(05)80957-2; CRAIG TOM, 1983, ROYAL COLLEGE RADIOL, V15, P8; DELACEY G, 1980, BRIT J RADIOL, V53, P304, DOI 10.1259/0007-1285-53-628-304; FIELDING JA, 1990, CLIN RADIOL, V41, P149, DOI 10.1016/S0009-9260(05)80956-0; GLEADHILL DNS, 1987, BRIT MED J, V294, P943, DOI 10.1136/bmj.294.6577.943; MUCCI B, 1983, INJURY, V14, P343, DOI 10.1016/0020-1383(83)90252-8; SWINBURNE K, 1971, LANCET, V1, P589; VINCENT CA, 1988, ARCH EMERG MED, V5, P101; WARDROPE J, 1985, BMJ, V290, P1639; 1988, 1988 MED DEF UN ANN, P21	12	40	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					568	569		10.1136/bmj.302.6776.568	http://dx.doi.org/10.1136/bmj.302.6776.568			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021720	Green Published, Bronze			2022-12-28	WOS:A1991FB93600019
J	STARK, RP; MCGINN, AL; WILSON, RF				STARK, RP; MCGINN, AL; WILSON, RF			CHEST PAIN IN CARDIAC-TRANSPLANT RECIPIENTS - EVIDENCE OF SENSORY REINNERVATION AFTER CARDIAC TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DISEASE; HEART		UNIV MINNESOTA,MINNESOTA HEART & LUNG INST,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	STARK, RP (corresponding author), UNIV MINNESOTA,DEPT MED,BOX 508 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.							BROWN AM, 1967, J PHYSIOL-LONDON, V190, P35, DOI 10.1113/jphysiol.1967.sp008191; FORMAN MB, 1984, AM J CARDIOL, V53, P476, DOI 10.1016/0002-9149(84)90015-8; GAO SZ, 1988, J AM COLL CARDIOL, V12, P334, DOI 10.1016/0735-1097(88)90402-0; KAYE MP, 1977, AM J PHYSIOL, V233, pH431, DOI 10.1152/ajpheart.1977.233.4.H431; KLEIN RL, 1982, NEUROTRANSMITTER VES, P16; KONTOS HA, 1970, J THORAC CARDIOV SUR, V59, P382, DOI 10.1016/S0022-5223(19)42475-6; Leriche R, 1928, AM HEART J, V3, P649, DOI 10.1016/S0002-8703(28)90349-X; LINDGREN I, 1947, J NEUROSURG, V4, P19, DOI 10.3171/jns.1947.4.1.0019; LOMBARDI F, 1981, CIRC RES, V48, P69, DOI 10.1161/01.RES.48.1.69; MALLIANI A, 1982, AM HEART J, V103, P575, DOI 10.1016/0002-8703(82)90352-0; NORVELL JE, 1973, TRANSPLANTATION, V15, P337, DOI 10.1097/00007890-197303000-00015; PASSON PG, 1973, ANAL BIOCHEM, V51, P618, DOI 10.1016/0003-2697(73)90517-4; PEISS CN, 1966, CIRC RES, V19, P153, DOI 10.1161/01.RES.19.1.153; POPE SE, 1980, AM J CARDIOL, V46, P213, DOI 10.1016/0002-9149(80)90060-0; ROWAN RA, 1988, J HEART TRANSPLANT, V7, P448; SCHWAIGER M, 1990, Journal of the American College of Cardiology, V15, p224A; STINSON EB, 1972, CIRCULATION, V45, P1183, DOI 10.1161/01.CIR.45.6.1183; Sutton DC, 1930, ARCH INTERN MED, V45, P827, DOI 10.1001/archinte.1930.00140120002001; THURESONKLEIN A, 1982, NEUROTRANSMITTER VES, P131; URETSKY BF, 1987, CIRCULATION, V76, P827, DOI 10.1161/01.CIR.76.4.827; WHITE JC, 1957, CIRCULATION, V16, P644, DOI 10.1161/01.CIR.16.4.644; WILLMAN VL, 1963, CIRCULATION, V27, P713, DOI 10.1161/01.CIR.27.4.713; WILSON RF, 1991, CIRCULATION, V83, P1210, DOI 10.1161/01.CIR.83.4.1210	23	178	179	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1791	1794		10.1056/NEJM199106203242507	http://dx.doi.org/10.1056/NEJM199106203242507			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	2038368				2022-12-28	WOS:A1991FR68100007
J	RAKEL, RE				RAKEL, RE			FAMILY-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRYPTOSPORIDIUM				RAKEL, RE (corresponding author), BAYLOR UNIV,HOUSTON,TX 77030, USA.							ARROWOOD MJ, 1989, J CLIN MICROBIOL, V27, P1490, DOI 10.1128/JCM.27.7.1490-1495.1989; Bell M M, 1990, J Am Board Fam Pract, V3, P259; Culpepper L, 1991, Fam Med, V23, P10; KASS EH, 1960, ARCH INTERN MED, V105, P194, DOI 10.1001/archinte.1960.00270140016003; RUSNAK J, 1989, J CLIN MICROBIOL, V27, P1135, DOI 10.1128/JCM.27.5.1135-1136.1989; SCHIEVEN BC, 1990, SERODIAG IMMUN INF D, V4, P109, DOI 10.1016/0888-0786(90)90034-L; WADLAND WC, 1989, J FAM PRACTICE, V29, P372; 1990, J AM BOARD FAM PRACT, V3, P143	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3120	3121						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041120				2022-12-28	WOS:A1991FQ77000017
J	STOECKLE, JD; GOODSON, JD				STOECKLE, JD; GOODSON, JD			GENERAL INTERNAL-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FRACTURE RATE; OUTCOMES; OSTEOPOROSIS; WOMEN				STOECKLE, JD (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							American College of Physicians, 1990, ANN INTERN MED, V112, P641; BARKER LR, 1990, PRINCIPLES AMBULATOR; BARSKY AJ, 1990, JAMA-J AM MED ASSOC, V264, P1132, DOI 10.1001/jama.264.9.1132; BILLINGS JA, 1989, CLIN ENCOUNTER GUIDE; BRANCH WT, 1987, OFFICE PRACTICE MED; CHARON R, 1989, SOUNDINGS, V72, P1101; COHENCOLE S, 1990, MED INTERVIEW 3 FUNC; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; GOROLL AH, 1987, PRIMARY CARE MED OFF; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; Mulley AJ., 1990, EFFECTIVENESS OUTCOM; NOBLE J, 1987, TXB GENERAL MED PRIM; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; ROTER DL, 1989, ANNU REV PUBL HEALTH, V10, P163, DOI 10.1146/annurev.pu.10.050189.001115; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; 1990, DIRECTORY PRIMARY CA; 1990, NEW ENGL J MED, V323, P1505	24	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3123	3125						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041121				2022-12-28	WOS:A1991FQ77000019
J	CAPON, SM; DEPOND, WD; TYAN, DB; PEPKOWITZ, SH; TOYODA, H; CINMAN, AC; AZER, PC; GOLDFINGER, D				CAPON, SM; DEPOND, WD; TYAN, DB; PEPKOWITZ, SH; TOYODA, H; CINMAN, AC; AZER, PC; GOLDFINGER, D			TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE IN AN IMMUNOCOMPETENT PATIENT	ANNALS OF INTERNAL MEDICINE			English	Note						GRAFT VS HOST DISEASE; BLOOD TRANSFUSION; HLA ANTIGENS; DONORS, BLOOD; IRRADIATION	BLOOD	Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but increasingly recognized transfusion hazard, described primarily in severely immunocompromised blood recipients. We report a case of fatal TA-GVHD in an immunocompetent patient after resection of a renal adenocarcinoma. Two of the patient's blood donors were children from a consanguineous marriage. HLA studies suggested that one of the patient's children was homozygous for an HLA haplotype shared by the patient and her husband. The transfusion of blood from an HLA-homozygous donor to a haplo-identical HLA-heterozygous recipient can result in TA-GVHD, regardless of the recipient's immune status. Although the probability of this donor-recipient relationship occurring is increased with related donor-recipient pairings, recent data suggest that it may also be significant among unrelated individuals. Although no effective treatment exists, TA-GVHD can be prevented by the irradiation of blood before transfusion. Consideration should be given to wider preventive measures to eliminate this transfusion complication.	CEDARS SINAI MED CTR, DEPT PATHOL & LAB MED, DIV TRANSFUS MED, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DIV MED GENET, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ITO K, 1988, LANCET, V1, P413; KRUSKALL MS, 1990, NEW ENGL J MED, V322, P1005; LIZAK GE, 1980, HUM IMMUNOL, V1, P87, DOI 10.1016/0198-8859(80)90012-9; THALER M, 1989, NEW ENGL J MED, V321, P25, DOI 10.1056/NEJM198907063210105; TOYODA H, 1989, DIS MARKERS, V7, P215; VARTDAL F, 1986, TISSUE ANTIGENS, V28, P301; VONFLIEDNER V, 1982, AM J MED, V72, P951	7	26	26	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1025	1026		10.7326/0003-4819-114-12-1025	http://dx.doi.org/10.7326/0003-4819-114-12-1025			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029098				2022-12-28	WOS:A1991FQ55500006
J	JEURISSEN, MEC; BOERBOOMS, AMT; VANDEPUTTE, LBA; DOESBURG, WH; LEMMENS, AM				JEURISSEN, MEC; BOERBOOMS, AMT; VANDEPUTTE, LBA; DOESBURG, WH; LEMMENS, AM			INFLUENCE OF METHOTREXATE AND AZATHIOPRINE ON RADIOLOGIC PROGRESSION IN RHEUMATOID-ARTHRITIS - A RANDOMIZED, DOUBLE-BLIND-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ARTHRITIS; RHEUMATOID ARTHRITIS; AZATHIOPRINE; METHOTREXATE; ANTIINFLAMMATORY AGENTS, NONSTEROIDAL	LOW-DOSE METHOTREXATE; CONTROLLED CLINICAL-TRIAL; PULSE METHOTREXATE; EFFICACY; PLACEBO; THERAPY; DISEASE; DAMAGE; GOLD	Objective: To compare the effects of azathioprine and methotrexate on progression of radiologic damage in patients with rheumatoid arthritis. Design: Double-blind, randomized 48-week trial. Patients: Sixty-four patients with active rheumatoid arthritis who either have not responded to or who have reacted with side effects to at least parenteral gold and D-penicillamine. Interventions: Either azathioprine, 100 mg daily, or methotrexate, 7.5 mg weekly, was administered orally. Depending on the clinical effect after 8 weeks, the dosage was increased to either azathioprine, 150 mg, or methotrexate, 15 mg. The dosages for nonsteroidal anti-inflammatory drugs and prednisone were held stable. Measurements: Clinical and laboratory assessments were done by the same physician every 4 weeks for the first 24 weeks and every 8 weeks thereafter. Radiographs of hands, wrists, and feet obtained at baseline and after 24 and 48 weeks were scored by one rheumatologist blinded to medication and clinical findings. Main Results: Initial radiologic scores were comparable in both groups and correlated with disease duration (r = 0.38). An intention-to-treat analysis after 24 and 48 weeks showed significantly fewer new erosions in the methotrexate group compared with the azathioprine group (difference, 2.0 [95% CI, 0.2 to 3.9] and 3.5 [CI, 1.3 to 5.8], respectively). The change in total joint score was also significantly less pronounced in the methotrexate group compared with the azathioprine group after 24 weeks (difference, 2.8 [CI, 0.2 to 5.2]) and after 48 weeks (difference, 3.9 [CI, 0.3 to 7.4]). Radiologic stabilization after 48 weeks was present in 10% of the azathioprine group compared with 29% of the methotrexate group. Conclusions: Patients with rheumatoid arthritis treated with low-dose methotrexate showed significantly less radiologic progression than patients treated with azathioprine. This result suggests that methotrexate therapy is clinically superior in these patients.			JEURISSEN, MEC (corresponding author), UNIV HOSP NIJMEGEN, DEPT RHEUMATOL, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.							American Rheumatism Association, 1973, ARTHRITIS RHEUM, V16, P353; AMOS RS, 1977, BRIT MED J, V1, P195, DOI 10.1136/bmj.1.6055.195; BERRY H, 1976, BRIT MED J, V1, P1052, DOI 10.1136/bmj.1.6017.1052; BORG G, 1988, J RHEUMATOL, V15, P1747; BROOK A, 1977, ANN RHEUM DIS, V36, P274, DOI 10.1136/ard.36.3.274; CALIN A, 1989, ARTHRITIS RHEUM, V32, P1221, DOI 10.1002/anr.1780321006; DWOSH IL, 1977, ARTHRITIS RHEUM, V20, P685, DOI 10.1002/art.1780200208; Fleiss JL., 1986, DESIGN ANAL CLIN EXP, DOI [10.1002/9781118032923.ch1, DOI 10.1002/9781118032923.CH1, DOI 10.1002/9781118032923]; FUCHS HA, 1989, J RHEUMATOL, V16, P585; HAMDY H, 1987, ARTHRITIS RHEUM, V30, P361, DOI 10.1002/art.1780300401; HANRAHAN PS, 1989, BRIT J RHEUMATOL, V28, P147; JEURISSEN M E C, 1990, Arthritis and Rheumatism, V33, pS39; KREMER JM, 1988, ARTHRITIS RHEUM-US, V31, P577, DOI 10.1002/art.1780310501; NORDSTROM DM, 1987, ANN INTERN MED, V107, P797, DOI 10.7326/0003-4819-107-6-797; REYKDAL S, 1989, SCAND J RHEUMATOL, V18, P221, DOI 10.3109/03009748909099932; SHARP JT, 1985, ARTHRITIS RHEUM, V28, P1326, DOI 10.1002/art.1780281203; SHARP JT, 1989, ARTHRITIS RHEUM-US, V32, P221, DOI 10.1002/anr.1780320218; SIGLER JW, 1974, ANN INTERN MED, V80, P21, DOI 10.7326/0003-4819-80-1-21; SJOBLOM KG, 1984, SCAND J RHEUMATOL, V13, P21; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; THOMPSON PW, 1987, ARTHRITIS RHEUM, V30, P618, DOI 10.1002/art.1780300603; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; WEINBLATT ME, 1988, ARTHRITIS RHEUM, V31, P167, DOI 10.1002/art.1780310203; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; WESTGEEST AAA, 1987, J RHEUMATOL, V14, P893; WILLIAMS HJ, 1985, ARTHRITIS RHEUM-US, V28, P721, DOI 10.1002/art.1780280702; 1970, NEW ENGL J MED, V283, P883	27	122	124	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					999	1004		10.7326/0003-4819-114-12-999	http://dx.doi.org/10.7326/0003-4819-114-12-999			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029111				2022-12-28	WOS:A1991FQ55500001
J	ROSE, MD; VALLEN, EA				ROSE, MD; VALLEN, EA			ACID LOOPS FAIL THE ACID TEST	CELL			English	Review							YEAST CALMODULIN; PROTEIN; GENE				ROSE, MD (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.			Rose, Mark/0000-0003-1112-4765	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037739] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM037739] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; COHEN P, 1988, MOL ASPECTS CELLULAR, V5, P145; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; CYERT MS, 1991, IN PRESS P NATL ACAD, V88; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GREENLEE DV, 1982, BIOCHEMISTRY-US, V21, P2759, DOI 10.1021/bi00540a028; IIDA H, 1990, J BIOL CHEM, V265, P13391; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; KLEE CB, 1988, CALMODULIN MOL ASPEC, V5, P35; OHYA Y, 1989, BIOCHEM BIOPH RES CO, V158, P541, DOI 10.1016/S0006-291X(89)80083-X; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; STULL JT, 1988, CALMODULIN, V5, P91	17	2	2	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					919	920		10.1016/0092-8674(91)90541-6	http://dx.doi.org/10.1016/0092-8674(91)90541-6			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044151				2022-12-28	WOS:A1991FR04700002
J	WOLF, GT				WOLF, GT			INDUCTION CHEMOTHERAPY PLUS RADIATION COMPARED WITH SURGERY PLUS RADIATION IN PATIENTS WITH ADVANCED LARYNGEAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; ADVANCED RESECTABLE HEAD; NECK-CANCER; ADJUVANT CHEMOTHERAPY; GLOTTIC CANCER; COMBINATION CHEMOTHERAPY; EPIDERMOID CARCINOMA; SUPRAGLOTTIC LARYNX; ONCOLOGY-GROUP; RADIOTHERAPY	Background. We performed a prospective, randomized study in patients with previously untreated advanced (Stage III or IV) laryngeal squamous carcinoma to compare the results of induction chemotherapy followed by definitive radiation therapy with those of conventional laryngectomy and postoperative radiation. Methods. Three hundred thirty-two patients were randomly assigned to receive either three cycles of chemotherapy (cisplatin and fluorouracil) and radiation therapy or surgery and radiation therapy. The clinical tumor response was assessed after two cycles of chemotherapy, and patients with a response received a third cycle followed by definitive radiation therapy (6600 to 7600 cGy). Patients in whom there was no tumor response or who had locally recurrent cancers after chemotherapy and radiation therapy underwent salvage laryngectomy. Results. After two cycles of chemotherapy, the clinical tumor response was complete in 31 percent of the patients and partial in 54 percent. After a median follow-up of 33 months, the estimated 2-year survival was 68 percent (95 percent confidence interval, 60 to 76 percent) for both treatment groups (P = 0.9846). Patterns of recurrence differed significantly between the two groups, with more local recurrences (P = 0.0005) and fewer distant metastases (P = 0.016) in the chemotherapy group than in the surgery group. A total of 59 patients in the chemotherapy group (36 percent) required total laryngectomy. The larynx was preserved in 64 percent of the patients overall and 64 percent of the patients who were alive and free of disease. Conclusions. These preliminary results suggest a new role for chemotherapy in patients with advanced laryngeal cancer and indicate that a treatment strategy involving induction chemotherapy and definitive radiation therapy can be effective in preserving the larynx in a high percentage of patients, without compromising overall survival.			WOLF, GT (corresponding author), VET AFFAIRS MED CTR, OTOLARYNGOL SERV, 112D, ANN ARBOR, MI 48105 USA.							[Anonymous], 1987, CANCER-AM CANCER SOC, V60, P301; CROLL GA, 1989, EUR J SURG ONCOL, V15, P350; DEMARD F, 1990, HEAD NECK-J SCI SPEC, V12, P225, DOI 10.1002/hed.2880120306; DESANTO LW, 1984, LARYNGOSCOPE, V94, P1311; EIBAND JD, 1989, AM J SURG, V158, P314, DOI 10.1016/0002-9610(89)90123-2; ENSLEY JF, 1984, CANCER, V54, P811, DOI 10.1002/1097-0142(19840901)54:5<811::AID-CNCR2820540508>3.0.CO;2-E; ERVIN TJ, 1987, J CLIN ONCOL, V5, P10, DOI 10.1200/JCO.1987.5.1.10; FLETCHER GH, 1975, LARYNGOSCOPE, V85, P987, DOI 10.1288/00005537-197506000-00008; GOEPFERT H, 1975, LARYNGOSCOPE, V85, P14, DOI 10.1288/00005537-197501000-00002; HARRIS HS, 1969, AM J SURG, V118, P676, DOI 10.1016/0002-9610(69)90212-8; HARWOOD AR, 1983, INT J RADIAT ONCOL, V9, P311, DOI 10.1016/0360-3016(83)90289-4; HARWOOD AR, 1982, INT J RADIAT ONCOL, V8, P1121, DOI 10.1016/0360-3016(82)90058-X; HARWOOD AR, 1983, INT J RADIAT ONCOL, V9, P335, DOI 10.1016/0360-3016(83)90292-4; HARWOOD AR, 1979, INT J RADIAT ONCOL, V5, P899, DOI 10.1016/0360-3016(79)90075-0; HARWOOD AR, 1980, ARCH OTOLARYNGOL, V106, P697; HAWKINS NV, 1975, LARYNGOSCOPE, V85, P1485, DOI 10.1288/00005537-197509000-00009; HOLOYE PY, 1985, OTOLARYNG HEAD NECK, V93, P712, DOI 10.1177/019459988509300604; Hong W K, 1985, Prog Clin Biol Res, V201, P191; JACOBS C, 1987, CANCER, V60, P1178, DOI 10.1002/1097-0142(19870915)60:6<1178::AID-CNCR2820600604>3.0.CO;2-S; JESSE RH, 1975, LARYNGOSCOPE, V85, P1424, DOI 10.1288/00005537-197509000-00002; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; Karp D, 1988, P AN M AM SOC CLIN, V7, P152; KAZEM I, 1984, LARYNGOSCOPE, V94, P1355; KIES MS, 1985, OTOLARYNG HEAD NECK, V93, P199, DOI 10.1177/019459988509300213; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; MEREDITH APD, 1987, J LARYNGOL OTOL, V101, P1046, DOI 10.1017/S0022215100103202; NORRIS CM, 1986, LARYNGOSCOPE, V96, P292; OGURA JH, 1975, LARYNGOSCOPE, V85, P1801, DOI 10.1288/00005537-197511000-00001; Price L A, 1985, Prog Clin Biol Res, V201, P159; PRICE LA, 1983, CANCER TREAT REP, V67, P535; RAZACK MS, 1989, AM J SURG, V158, P318, DOI 10.1016/0002-9610(89)90124-4; SCHULLER DE, 1988, LARYNGOSCOPE, V98, P1205; SCHULLER DE, 1983, CANCER-AM CANCER SOC, V51, P15, DOI 10.1002/1097-0142(19830101)51:1<15::AID-CNCR2820510105>3.0.CO;2-2; SHAH JP, 1974, AM J SURG, V128, P494, DOI 10.1016/0002-9610(74)90262-1; Silverberg E., 1988, CA-CANCER J CLIN, V38, P5; SOM ML, 1975, LARYNGOSCOPE, V85, P1298, DOI 10.1288/00005537-197508000-00005; STELL PM, 1983, CLIN RADIOL, V34, P463, DOI 10.1016/S0009-9260(83)80247-5; TAYLOR SG, 1985, J CLIN ONCOL, V3, P672, DOI 10.1200/JCO.1985.3.5.672; THYSS A, 1986, BRIT J CANCER, V54, P755, DOI 10.1038/bjc.1986.237; URBA S, 1989, P AN M AM SOC CLIN, V8, P172	40	1793	1813	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1685	1690		10.1056/nejm199106133242402	http://dx.doi.org/10.1056/nejm199106133242402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	2034244				2022-12-28	WOS:A1991FQ15500002
J	TAYLOR, WC				TAYLOR, WC			INDIRECT LARYNGOSCOPY AS A SCREENING-TEST FOR LARYNGEAL-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ADULT HEALTH MAINTENANCE; PREVENTION; DISEASES				TAYLOR, WC (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, BOSTON, MA 02215 USA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; DEWEESE DD, 1982, TXB OTOLARYNGOLOGY, P111; DRIPPS RD, 1988, INTRO ANESTHESIA PRI, P403; Frame P S, 1975, J Fam Pract, V2, P189; Frame P S, 1975, J Fam Pract, V2, P283; Frame P S, 1975, J Fam Pract, V2, P29; FRAME PS, 1986, J FAM PRACTICE, V22, P341; FRAME PS, 1986, J FAM PRACTICE, V22, P511; FRAME PS, 1986, J FAM PRACTICE, V22, P417; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; LEMORE T, 1987, PHS871250 DEP HLTH H; OBOLER SK, 1989, ANN INTERN MED, V110, P214, DOI 10.7326/0003-4819-110-3-214; SACKETT DL, 1987, J FAM PRACTICE, V24, P233; TAYLOR WC, 1980, ANN INTERN MED, V93, P773, DOI 10.7326/0003-4819-93-5-773; Wilson JMG, 1968, PRINCIPLES PRACTICE; 1979, CAN MED ASS J, V121, P1193; 1991, JAMA-J AM MED ASSOC, V265, P412; 1988, 8820M AM CANC SOC PR; 1989, 89450M AM CAN SOC PU, P8	19	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					3011	+		10.1001/jama.265.22.3011	http://dx.doi.org/10.1001/jama.265.22.3011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033776				2022-12-28	WOS:A1991FP63500043
J	JENNETT, B; DYER, C				JENNETT, B; DYER, C			PERSISTENT VEGETATIVE STATE AND THE RIGHT-TO-DIE - THE UNITED-STATES AND BRITAIN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FATE WORSE; DEATH				JENNETT, B (corresponding author), INST NEUROL SCI, NEUROSURG, GLASGOW G51 4TF, SCOTLAND.							ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; ANNAS GJ, 1990, NEW ENGL J MED, V323, P686, DOI 10.1056/NEJM199009063231020; BOYD K, 1991, LANCET, V337, P96; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRAHAMS D, 1988, LANCET, V1, P779; FEINBERG WM, 1984, AM J DIS CHILD, V138, P128, DOI 10.1001/archpedi.1984.02140400014003; GILLON R, 1988, J MED ETHICS, V14, P59, DOI 10.1136/jme.14.2.59; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1976, ARCH NEUROL-CHICAGO, V33, P595, DOI 10.1001/archneur.1976.00500090001001; JENNETT B, 1988, ANAESTHESIA, V43, P921, DOI 10.1111/j.1365-2044.1988.tb05650.x; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; LO B, 1990, NEW ENGL J MED, V322, P1228, DOI 10.1056/NEJM199004263221711; Minderhoud J M, 1985, Ned Tijdschr Geneeskd, V129, P2385; 1991, PROPOSALS ESTABLISHM; 1991, MENTALLY INCAPACITAT; 1986, JAMA-J AM MED ASSOC, V236, P471; 1990, JAMA-J AM MED ASSOC, V263, P426	18	19	19	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1991	302	6787					1256	1258		10.1136/bmj.302.6787.1256	http://dx.doi.org/10.1136/bmj.302.6787.1256			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043853	Bronze, Green Published			2022-12-28	WOS:A1991FP27200029
J	PRIME, KL; WHITESIDES, GM				PRIME, KL; WHITESIDES, GM			SELF-ASSEMBLED ORGANIC MONOLAYERS - MODEL SYSTEMS FOR STUDYING ADSORPTION OF PROTEINS AT SURFACES	SCIENCE			English	Article							HYDROPHOBIC CHROMATOGRAPHY; GOLD; THIOLS; CHAIN; FILMS; COADSORPTION; ELLIPSOMETRY; INTERFACES; POLYMERS; SERIES	Self-assembled monolayers (SAMs) of omega-functionalized long-chain alkanethiolates on gold films are excellent model systems with which to study the interactions of proteins with organic surfaces. Monolayers containing mixtures of hydrophobic (methyl-terminated) and hydrophilic [hydroxyl-, maltose-, and hexa(ethylene glycol)-terminated] alkanethiols can be tailored to select specific degrees of adsorption: the amount of protein adsorbed varies monotonically with the composition of the monolayer. The hexa(ethylene glycol)-terminated SAMs are the most effective in resisting protein adsorption. The ability to create interfaces with similar structures and well-defined compositions should make it possible to test hypotheses concerning protein adsorption.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University								ALLMER K, 1990, J POLYM SCI POL CHEM, V28, P173, DOI 10.1002/pola.1990.080280112; ANDRADE JD, 1986, ADV POLYM SCI, V79, P1; [Anonymous], [No title captured]; ARNEBRANT T, 1985, PROG COLL POL SCI S, V70, P62; BAIN CD, 1989, J AM CHEM SOC, V111, P7155, DOI 10.1021/ja00200a039; BAIN CD, 1989, J PHYS CHEM-US, V93, P1670, DOI 10.1021/j100341a095; BAIN CD, 1989, J AM CHEM SOC, V111, P7164, DOI 10.1021/ja00200a040; BAIN CD, 1988, SCIENCE, V240, P62, DOI 10.1126/science.240.4848.62; BJORLING M, 1990, J PHYS CHEM-US, V94, P471, DOI 10.1021/j100364a082; BOHNERT JL, 1988, INVEST OPHTHALMOL VI, V29, P363; BORETOS JW, 1980, SYNTHETIC BIOMEDICAL, P187; BRASH JL, 1985, MAKROMOL CHEM S, V9, P69; CHIDSEY CED, 1989, J CHEM PHYS, V91, P4421, DOI 10.1063/1.456776; CUYPERS PA, 1983, J BIOL CHEM, V258, P2426; CUYPERS PA, 1978, ANAL BIOCHEM, V84, P56, DOI 10.1016/0003-2697(78)90483-9; DETTRE RH, 1965, J PHYS CHEM-US, V69, P1507, DOI 10.1021/j100889a012; EVERETT DH, 1988, BASIC PRINCIPLES COL, P45; FLEMINGER G, 1990, J CHROMATOGR, V510, P271, DOI 10.1016/S0021-9673(01)93761-6; GRAINGER DW, 1989, J COLLOID INTERF SCI, V132, P161, DOI 10.1016/0021-9797(89)90226-9; HALPERIN G, 1984, J CHROMATOGR, V317, P103, DOI 10.1016/S0021-9673(01)91651-6; Horbett T. A., 1986, HYDROGELS MED PHARM, V1, P127; IVERSSON B, 1986, CRIT REV BIOCOMPUT, V2, P1; JENNISSEN HP, 1989, BER BUNSEN PHYS CHEM, V93, P948, DOI 10.1002/bbpc.19890930905; Jeon I, 1991, J COLLOID INTERF SCI, V142, P149; JEON SI, 1991, J COLLOID INTERF SCI, V142, P159, DOI 10.1016/0021-9797(91)90044-9; KARLSTROM G, 1985, J PHYS CHEM-US, V89, P4962, DOI 10.1021/j100269a015; Macritchie F, 1978, Adv Protein Chem, V32, P283, DOI 10.1016/S0065-3233(08)60577-X; MATSUURA H, 1985, J MOL STRUCT, V126, P251, DOI 10.1016/0022-2860(85)80118-6; MATSUURA H, 1991, J AM CHEM SOC, V113, P1193, DOI 10.1021/ja00004a020; MIZUTANI T, 1985, J LIQ CHROMATOGR, V8, P925, DOI 10.1080/01483918508067122; MUIRHEAD H, 1987, BIOL MACROMOL, V3, P143; NUZZO RG, 1990, J AM CHEM SOC, V112, P558, DOI 10.1021/ja00158a012; NUZZO RG, 1990, J CHEM PHYS, V93, P767, DOI 10.1063/1.459528; PALEGROSDEMANGE C, 1991, J AM CHEM SOC, V113, P12, DOI 10.1021/ja00001a002; PORATH J, 1987, BIOTECHNOL PROGR, V3, P14, DOI 10.1002/btpr.5420030104; ROSEVEAR P, 1980, BIOCHEMISTRY-US, V19, P4108, DOI 10.1021/bi00558a032; SADA E, 1985, BIOTECHNOL BIOENG, V27, P514, DOI 10.1002/bit.260270418; SCHAKENRAAD JM, 1989, COLLOID SURFACE, V42, P331; SEVASTIANOV VI, 1988, CRIT REV BIOCOMPAT, V4, P109; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; WEST TP, 1985, BIOCHIM BIOPHYS ACTA, V839, P32, DOI 10.1016/0304-4165(85)90178-3; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010	43	2056	2141	15	556	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1164	1167		10.1126/science.252.5009.1164	http://dx.doi.org/10.1126/science.252.5009.1164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031186				2022-12-28	WOS:A1991FN05600048
J	JAFFE, D; WESSON, D				JAFFE, D; WESSON, D			CURRENT CONCEPTS - EMERGENCY MANAGEMENT OF BLUNT TRAUMA IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CERVICAL-SPINE INJURIES; SEVERE HEAD-INJURY; PEDIATRIC TRAUMA; NONOPERATIVE MANAGEMENT; MAJOR TRAUMA; CORD INJURY; EXPERIENCE; CHILDHOOD; FRACTURES; SCORE		HOSP SICK CHILDREN,DEPT SURG,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	JAFFE, D (corresponding author), HOSP SICK CHILDREN,DEPT EMERGENCY,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.							[Anonymous], 1990, ABBREVIATED INJURY S; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEAVER BL, 1990, J PEDIATR SURG, V25, P97, DOI 10.1016/S0022-3468(05)80171-X; BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; BOHN D, 1990, J TRAUMA, V30, P463, DOI 10.1097/00005373-199030040-00017; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BREAUX CW, 1990, J TRAUMA, V30, P37, DOI 10.1097/00005373-199001000-00006; Bushore M, 1988, Pediatr Rev, V10, P49, DOI 10.1542/pir.10-2-49; CHAN BSH, 1989, J TRAUMA, V291, P1540; COOPER A, 1987, J PEDIATR SURG, V22, P24, DOI 10.1016/S0022-3468(87)80008-8; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; DRISCOLL P, 1990, BRIT MED J, V300, P1329, DOI 10.1136/bmj.300.6735.1329; Duncan C C, 1984, Conn Med, V48, P282; DYKES EH, 1989, J TRAUMA, V29, P724, DOI 10.1097/00005373-198906000-00004; EDDY A C, 1989, Pediatric Emergency Care, V5, P228, DOI 10.1097/00006565-198912000-00007; EIN SH, 1978, J PEDIATR SURG, V13, P117, DOI 10.1016/S0022-3468(78)80001-3; FERRY PC, 1982, PEDIATRICS, V69, P237; FISER DH, 1990, NEW ENGL J MED, V322, P1579; Greensher J, 1988, Pediatr Rev, V10, P171, DOI 10.1542/pir.10-6-171; HAFTEL AJ, 1990, PEDIATR EMERG CARE, V6, P226; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HARRIS BH, 1989, J PEDIATR SURG, V24, P419, DOI 10.1016/S0022-3468(89)80392-6; HOELZER DJ, 1986, J TRAUMA, V26, P57, DOI 10.1097/00005373-198601000-00011; HUBBARD DD, 1974, CLIN ORTHOP RELAT R, V100, P56; JAFFE DM, 1987, ANN EMERG MED, V16, P270, DOI 10.1016/S0196-0644(87)80171-3; KANE NM, 1988, PEDIATRICS, V82, P11; KEWALRAMANI LS, 1980, PARAPLEGIA, V18, P206, DOI 10.1038/sc.1980.36; KING DR, 1985, PEDIATR CLIN N AM, V32, P1299; KISSOON N, 1990, CAN MED ASSOC J, V142, P27; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; LANGER JC, 1989, J PEDIATR SURG, V24, P1091, DOI 10.1016/S0022-3468(89)80225-8; LEONIDAS JC, 1982, PEDIATRICS, V69, P139; LILLEHEI KO, 1985, ANN EMERG MED, V14, P789, DOI 10.1016/S0196-0644(85)80059-7; MATTOX KL, 1989, J TRAUMA, V29, P1104, DOI 10.1097/00005373-198908000-00007; MCSWAIN NE, 1988, ANN EMERG MED, V17, P506, DOI 10.1016/S0196-0644(88)80248-8; MINER W F, 1989, Pediatric Emergency Care, V5, P5, DOI 10.1097/00006565-198903000-00002; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; NAKAYAMA DK, 1990, ANN SURG, V211, P218, DOI 10.1097/00000658-199002000-00015; NAKAYAMA DK, 1989, ANN SURG, V210, P770, DOI 10.1097/00000658-198912000-00013; PANG D, 1989, J TRAUMA, V29, P654, DOI 10.1097/00005373-198905000-00021; PASCUCCI RC, 1988, INTENS CARE MED, V14, P185, DOI 10.1007/BF00717985; REID AB, 1990, J TRAUMA, V30, P384, DOI 10.1097/00005373-199030040-00003; ROSHKOW JE, 1990, RADIOLOGY, V175, P359, DOI 10.1148/radiology.175.2.2326461; ROTHENBERG SS, 1989, J TRAUMA, V29, P1322, DOI 10.1097/00005373-198910000-00004; SHAFFER MA, 1981, ANN EMERG MED, V10, P508, DOI 10.1016/S0196-0644(81)80004-2; STREITWIESER DR, 1983, ANN EMERG MED, V12, P538, DOI 10.1016/S0196-0644(83)80293-5; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; WALKER ML, 1985, EMERGENCY MANAGEMENT, P272; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; 1986, HOSPITAL PREHOSPITAL; 1985, TXB PEDIATRIC ADV LI, V5, P28; 1989, ADV TRAUMA LIFE SUPP, P267; 1990, AM J DIS CHILD, V144, P627	56	47	50	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1477	1482						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM460	2023607				2022-12-28	WOS:A1991FM46000006
J	SASAKI, K; YAMANO, Y; BARDHAN, S; IWAI, N; MURRAY, JJ; HASEGAWA, M; MATSUDA, Y; INAGAMI, T				SASAKI, K; YAMANO, Y; BARDHAN, S; IWAI, N; MURRAY, JJ; HASEGAWA, M; MATSUDA, Y; INAGAMI, T			CLONING AND EXPRESSION OF A COMPLEMENTARY-DNA ENCODING A BOVINE ADRENAL ANGIOTENSIN-II TYPE-1 RECEPTOR	NATURE			English	Article							BINDING-SITES; SOLUBILIZATION; MEMBRANES; SEQUENCE; SUBTYPES; CORTEX	ANGIOTENSIN II elicits different responses which affect cardiovascular, neuronal and electrolyte transport regulation 1. To understand the mechanisms responsible for its various actions, the receptor for angiotensin II has long been sought, but numerous attempts to purify the receptor have been unsuccessful owing to its instability and low concentration 2-6. We report here the expression cloning of a complementary DNA encoding a bovine angiotensin II receptor to overcome these difficulties. The receptor cDNA encodes a protein of 359 amino-acid residues with a transmembrane topology similar to that of other G protein-coupled receptors. COS-7 cells transfected with cDNA expressed specific and high-affinity binding sites for angiotensin II, angiotensin II antagonist and a non-peptide specific antagonist for type-1 receptor. Dithiothreitol inhibited ligand binding. The concentration of intracellular Ca2+ and of inositol-1,4,5-trisphospate increased in the transfected COS-7 cells in response to angiotensin II or angiotensin III, indicating that this receptor is the type-1 receptor for angiotensin II. Northern blot analysis revealed that the messenger RNA for this receptor is expressed in bovine adrenal medulla, cortex and kidney.	VANDERBILT UNIV, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA; KYOWA HAKKO KOGYO CO LTD, TOKYO RES LABS, TOKYO 194, JAPAN	Vanderbilt University; Vanderbilt University; Kyowa Kirin Ltd								AKIYAMA F, 1984, BIOMED RES-TOKYO, V5, P9, DOI 10.2220/biomedres.5.9; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; CAPPONI AM, 1980, J BIOL CHEM, V255, P2081; CARSON MC, 1987, MOL ENDOCRINOL, V1, P147, DOI 10.1210/mend-1-2-147; CHANG RSL, 1982, BIOCHEM PHARMACOL, V31, P1903, DOI 10.1016/0006-2952(82)90495-6; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; GLOSSMANN H, 1974, J BIOL CHEM, V249, P825; GUILLEMETTE G, 1983, BIOCHEMISTRY-US, V22, P5591, DOI 10.1021/bi00293a021; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAGLIN S, 1982, P NATL ACAD SCI-BIOL, V79, P3739, DOI 10.1073/pnas.79.12.3739; PEACH MJ, 1990, J CARDIOVASC PHARM, V16, pS25, DOI 10.1097/00005344-199016004-00007; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; ROGERS TB, 1984, J BIOL CHEM, V259, P8106; RONDEAU JJ, 1990, BIOCHEM J, V268, P443, DOI 10.1042/bj2680443; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SKORECKI KL, 1983, FED PROC, V42, P3064; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	26	807	825	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					230	233		10.1038/351230a0	http://dx.doi.org/10.1038/351230a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041569				2022-12-28	WOS:A1991FL99000056
J	ULLMANN, D; PHILLIPS, RL; BEESON, WL; DEWEY, HG; BRIN, BN; KUZMA, JW; MATHEWS, CP; HIRST, AE				ULLMANN, D; PHILLIPS, RL; BEESON, WL; DEWEY, HG; BRIN, BN; KUZMA, JW; MATHEWS, CP; HIRST, AE			CAUSE-SPECIFIC MORTALITY AMONG PHYSICIANS WITH DIFFERING LIFE-STYLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; UNITED-STATES RAILROAD; 7TH-DAY ADVENTISTS; CARDIOVASCULAR-DISEASE; HEALTH; CANCER; CHOLESTEROL; MEDICINE; SCHOOL; HABITS	We compare the mortality experience of medical school graduates from Loma Linda University (LLU [n = 4342]) and the University of Southern California (USC [n = 2832]) with each other and with that of contemporaneous, white, American men. When compared with US white men from the general population, both USC and LLU graduates had below expected deaths for all causes (USC, standardized mortality ratio [SMR] = 76; LLU, SMR = 56), although deaths due to cerebrovascular disease, airplane accidents, and suicides were elevated for USC (SMRs = 132, 360, and 218, respectively). The LLU graduates had a risk similar to that of the USC graduates for fatal cancer, with a mortality ratio (MR) of 0.92 (95% confidence interval, 0.67 to 1.26); but half the risk of fatal atherosclerotic disease, with MRs of 0.58 (0.46 to 0.73) and 0.66 (0.43 to 0.99) for coronary and cerebrovascular disease, respectively; and three times the risk of fatal airplane accidents. The overall mortality rate of LLU physicians was only 75% as high as that of the USC physicians and only 56% as high as that of the US male population at large. We attribute this reduced mortality mainly to the low cardiovascular mortality rates, which may be accounted for by the life-style of the substantial proportion of Seventh-day Adventists among LLU graduates.	OREGON HLTH SCI UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & CLIN NUTR,PORTLAND,OR 97201; LOMA LINDA UNIV,SCH MED,DEPT PREVENT MED,LOMA LINDA,CA 92354; LOMA LINDA UNIV,SCH MED,DEPT PATHOL,LOMA LINDA,CA 92354; LOMA LINDA UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,LOMA LINDA,CA 92350; LOMA LINDA UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,LOMA LINDA,CA 92350; UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033; US DEPT DEF,ARMED FORCES MED INTELLIGENCE CTR,DEPT EPIDEMIOL,FT DETRICK,MD; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT OBSTET & GYNECOL,NEW BRUNSWICK,NJ 08903	Oregon Health & Science University; Loma Linda University; Loma Linda University; Loma Linda University; Loma Linda University; University of Southern California; University of Southern California; United States Department of Defense; Rutgers State University New Brunswick; Rutgers State University Medical Center	ULLMANN, D (corresponding author), OREGON HLTH SCI UNIV,SCH MED,DEPT PREVENT MED,DIV EPIDEMIOL & BIOSTAT,L-352,PORTLAND,OR 97201, USA.				NATIONAL CANCER INSTITUTE [R01CA014703] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005352] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1-CA14703] Funding Source: Medline; NCRR NIH HHS [2S07RR05352-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1983, STAT B, V64, P2; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BLACKBURN H, 1988, NEW ENGL J MED, V319, P1217, DOI 10.1056/NEJM198811033191808; BLOCK G, 1985, AM J EPIDEMIOL, V122, P27, DOI 10.1093/oxfordjournals.aje.a114084; BOOZE CF, 1977, AVIAT SPACE ENVIR MD, V48, P1081; BOUCHARD C, 1983, AM J CLIN NUTR, V37, P461, DOI 10.1093/ajcn/37.3.461; BRESLOW L, 1980, PREV MED, V9, P469, DOI 10.1016/0091-7435(80)90042-0; CLEVER LH, 1984, WESTERN J MED, V141, P846; COX DR, 1972, J R STAT SOC B, V34, P187; CRAIG A, 1968, DIS NERV SYST, V219, P763; DEHART C, 1974, J MAINE MED ASSOC, V65, P32; DICKINSON FG, 1956, JAMA-J AM MED ASSOC, V162, P1462, DOI 10.1001/jama.1956.72970330004008; DOLL R, 1977, BMJ-BRIT MED J, V1, P1433, DOI 10.1136/bmj.1.6074.1433; ENSTROM JE, 1983, BRIT MED J, V286, P1101, DOI 10.1136/bmj.286.6371.1101; GLANZ K, 1982, J MED EDUC, V57, P637; GOODMAN LJ, 1975, MILBANK FUND Q, V53, P353, DOI 10.2307/3349496; GOODNIGHT SH, 1982, ARTERIOSCLEROSIS, V2, P87, DOI 10.1161/01.ATV.2.2.87; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; HADLEY GG, 1983, WESTERN J MED, V138, P742; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KING H, 1970, J CHRON DIS, V23, P257, DOI 10.1016/0021-9681(70)90005-6; KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011; MANTEL N, 1959, J NATL CANCER I, V22, P719; MATANOSKI GM, 1975, AM J EPIDEMIOL, V101, P199, DOI 10.1093/oxfordjournals.aje.a112087; MATHIES AW, 1983, WESTERN J MED, V138, P441; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; PARKERSON GR, 1989, J CLIN EPIDEMIOL, V42, P217, DOI 10.1016/0895-4356(89)90058-9; PHILLIPS RL, 1980, JNCI-J NATL CANCER I, V65, P1097; PHILLIPS RL, 1985, JNCI-J NATL CANCER I, V74, P307; PHILLIPS RL, 1978, AM J CLIN NUTR, V31, pS191, DOI 10.1093/ajcn/31.10.S191; PHILLIPS RL, 1980, AM J EPIDEMIOL, V112, P296, DOI 10.1093/oxfordjournals.aje.a112996; PHILLIPS RL, 1986, PLANT PROTEINS APPLI, P162; Preston SH, 1972, CAUSES DEATH LIFE TA; ROSE KD, 1973, ARCH GEN PSYCHIAT, V29, P800; ROTHMAN KJ, 1979, DHEW NIH791649 PHS P; SCHNEIDERMAN N, 1989, HDB RES METHODS CARD; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; SERVIN MP, 1969, SO CALIFORNIA ITS U, P106; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; SNOWDON DA, 1985, AM J PUBLIC HEALTH, V75, P507, DOI 10.2105/AJPH.75.5.507; SNOWDON DA, 1984, PREV MED, V13, P490, DOI 10.1016/0091-7435(84)90017-3; STEPPACHER RC, 1974, JAMA-J AM MED ASSOC, V228, P323, DOI 10.1001/jama.228.3.323; ULLMANN D, IN PRESS EXERCISE ME; ULLMANN D, 1988, CIRCULATION, V78, P73; WAGNER ME, 1964, NEW YORK STATE J MED, V64, P1849; WEIDNER G, 1985, CORONARY HEART DISEA, P157; WILLIAMS SV, 1971, J CHRON DIS, V24, P393, DOI 10.1016/0021-9681(71)90139-1; WYSHAK G, 1980, NEW ENGL J MED, V303, P104, DOI 10.1056/NEJM198007103030210; 1985, AM MED DIRECTORY; 1983, PHS8450204 PUBL; 1988, CIRCULATION, V77, pA721; 1988, DHHS PHS8850210 US D	54	31	34	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2352	2359		10.1001/jama.265.18.2352	http://dx.doi.org/10.1001/jama.265.18.2352			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ955	2016831				2022-12-28	WOS:A1991FJ95500029
J	MASSEFSKI, W				MASSEFSKI, W			CORRECTION	SCIENCE			English	Correction, Addition														Massefski, Walter/0000-0003-4728-4218				BONTEMS F, 1991, EUR J BIOCHEM, V196, P19, DOI 10.1111/j.1432-1033.1991.tb15780.x; BONTEMS F, 1990, 14TH INT C MAGN RES; LAMBERT P, 1990, BIOCHEM BIOPH RES CO, V170, P684, DOI 10.1016/0006-291X(90)92145-P; 1990, SCIENCE, V249, P521	4	7	7	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					631	631		10.1126/science.252.5006.631-a	http://dx.doi.org/10.1126/science.252.5006.631-a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024115				2022-12-28	WOS:A1991FK18500006
J	BENJAMIN, RJ; MADRIGAL, JA; PARHAM, P				BENJAMIN, RJ; MADRIGAL, JA; PARHAM, P			PEPTIDE BINDING TO EMPTY HLA-B27 MOLECULES OF VIABLE HUMAN-CELLS	NATURE			English	Article							TOXIC LYMPHOCYTES-T; ANKYLOSING-SPONDYLITIS; MONOCLONAL-ANTIBODIES; ANTIGEN; HLA; ASSOCIATION; RECOGNITION; MUTAGENESIS; CHAINS; VIRUS	INTRACELLULAR binding of antigenic peptides by polymorphic class I major histocompatibility complex molecules creates the ligands recognized by receptors of CD8+ T cells 1. Previously described in vitro assays of peptide binding to class I molecules have been limited by either the low proportion of accessible binding sites or the lack of allelic specificity 2-6. Here we describe a system in which the human class I molecule HLA-B27 binds considerable amounts of an influenza peptide with precise allelic discrimination. Binding requires viable cells, is stimulated by gamma-interferon and is inhibited by brefeldin A. Our results are consistent with the presence of fairly stable 'empty' HLA-B27 molecules at the cell surface. By contrast, analysis of the binding of a second influenza peptide indicates that empty HLA-Aw68 molecules are relatively short-lived. We speculate that HLA-B27 might bind extracellular peptides in vivo and that this property could underlie its association with autoimmune disease.	STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University	BENJAMIN, RJ (corresponding author), STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305, USA.							BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BREWERTON DA, 1973, LANCET, V1, P904; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MCMICHAEL AJ, 1980, HUM IMMUNOL, V1, P121, DOI 10.1016/0198-8859(80)90099-3; MCMICHAEL AJ, 1986, J EXP MED, V164, P1397, DOI 10.1084/jem.164.5.1397; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1987, J EXP MED, V166, P283, DOI 10.1084/jem.166.1.283; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; WAYS JP, 1983, BIOCHEM J, V216, P423, DOI 10.1042/bj2160423; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	35	149	150	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					74	77		10.1038/351074a0	http://dx.doi.org/10.1038/351074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027387				2022-12-28	WOS:A1991FK19300064
J	LOMAS, J; ENKIN, M; ANDERSON, GM; HANNAH, WJ; VAYDA, E; SINGER, J				LOMAS, J; ENKIN, M; ANDERSON, GM; HANNAH, WJ; VAYDA, E; SINGER, J			OPINION LEADERS VS AUDIT AND FEEDBACK TO IMPLEMENT PRACTICE GUIDELINES - DELIVERY AFTER PREVIOUS CESAREAN-SECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTINUING-EDUCATION; RHEUMATOID-ARTHRITIS; CONSENSUS PROCESS; CARE; DISSEMINATION; PHYSICIAN; QUALITY; PROGRAM; ONTARIO	A randomized controlled trial with 76 physicians in 16 community hospitals evaluated audit and feedback and local opinion leader education as methods of encouraging compliance with a guideline for the management of women with a previous cesarean section. The guideline recommended clinical actions to increase trial of labor and vaginal birth rates. Charts for all 3552 cases in the study groups were audited. After 24 months the trial of labor and vaginal birth rates in the audit and feedback group were no different from those in the control group, but rates were 46% and 85% higher, respectively, among physicians educated by an opinion leader. Duration of hospital stay was lower in the opinion leader education group than in the other two groups. The overall cesarean section rate was reduced only in the opinion leader education group. There were no adverse clinical outcomes attributable to the interventions. The use of opinion leaders improved the quality of care.	UNIV TORONTO,DEPT OBSTET & GYNAECOL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT HLTH ADM,DIV COMMUNITY HLTH,TORONTO M5S 1A1,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT OBSTET & GYNAECOL,HAMILTON L8N 3Z5,ONTARIO,CANADA; UNIV BRITISH COLUMBIA,DIV HLTH SERV RES & DEV,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA	University of Toronto; University of Toronto; McMaster University; McMaster University; University of British Columbia; University of British Columbia	LOMAS, J (corresponding author), MCMASTER UNIV,HLTH SCI CTR,CTR HLTH ECON & POLICY ANAL,HAMILTON L8N 3Z5,ONTARIO,CANADA.							ANDERSON GM, 1984, NEW ENGL J MED, V311, P887, DOI 10.1056/NEJM198410043111405; ANDERSON GM, 1989, CAN MED ASSOC J, V141, P1049; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; EDDY DM, 1988, HEALTH AFFAIR, V7, P19, DOI 10.1377/hlthaff.7.1.19; EISENBERG J, 1986, DOCTORS DECISIONS CO; ENKIN M, 1989, EFFECTIVE CARE PREGN, P1196; FOWLER G, 1989, LANCET, V1, P1253; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; HARVILLE DA, 1977, J AM STAT ASSOC, V72, P320, DOI 10.2307/2286796; HAYNES RB, 1987, ARCH INTERN MED, V147, P1297, DOI 10.1001/archinte.147.7.1297; HISS RG, 1978, RES MED ED, V17, P283; JENRICH RI, 1983, BMDP STATISTICAL SOF, P413; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LOMAS J, 1986, CAN MED ASSOC J, V134, P1340; LOMAS J, 1988, JAMA-J AM MED ASSOC, V259, P3001, DOI 10.1001/jama.259.20.3001; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; LOMAS J, 1988, BRIT MED J, V297, P569, DOI 10.1136/bmj.297.6648.569; LOMAS J, 1988, American Journal of Preventive Medicine, V4, P77; LOMAS J, 1990, CHALLENGE MED PRACTI, P174; MYERS SA, 1988, NEW ENGL J MED, V319, P151; Phelan J, 1988, CESAREAN DELIVERY; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; Schroeder S A, 1987, Int J Technol Assess Health Care, V3, P39; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; STROSS JK, 1980, ARTHRITIS RHEUM, V23, P846, DOI 10.1002/art.1780230711; STROSS JK, 1979, ARTHRITIS RHEUM, V22, P787, DOI 10.1002/art.1780220717; WHITINGOKEEFE QE, 1984, MED CARE, V22, P1101, DOI 10.1097/00005650-198412000-00005; WINER BJ, 1962, STATISTICAL PRINCIPL, P244; 1986, CAN MED ASSOC J, V134, P1384; 1989, ANN REPORT C PHYSICI, P219	31	510	513	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2202	2207		10.1001/jama.265.17.2202	http://dx.doi.org/10.1001/jama.265.17.2202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013952				2022-12-28	WOS:A1991FH87700031
J	TUCK, MW; CRICK, RP				TUCK, MW; CRICK, RP			EFFICIENCY OF REFERRAL FOR SUSPECTED GLAUCOMA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the efficiency of referral for suspected glaucoma to general practitioners and consultants by optometrists. Design-A prospective survey covering 5% of all sight tests performed by optometrists in England and Wales over six months, with analysis of referred patients. Setting-241 optometrists' practices in areas representative of England and Wales in socio-economic terms. Subjects-Of 275 600 people attending for a sight test, 1505 were referred with suspected glaucoma (0.9% of those aged over 40). Outcomes were recorded for 1228 patients, 1103 (90%) of whom attended for examination by a consultant ophthalmologist (8% on a private basis). The analysis was confined to the 704 cases in which the information on diagnosis was received directly from a consultant or general practitioner. Main outcome measures-Diagnoses reported by consultant ophthalmologists. Waiting times before an appointment for examination by a consultant ophthalmologist. Results-Glaucoma was confirmed in 283 of the 704 referred patients, and another 222 patients were considered to require further monitoring. In all, 112 (41%) of 275 confirmed cases of glaucoma were in patients with intraocular pressures greater-than-or-equal-to 30 mm Hg. At all levels of intraocular pressure the accuracy of referral was greater when the optometrist also recorded the presence of suspicious optic discs or loss of visual field, or both; but only 331 (47%) out of the 704 referred patients had been tested with a field screener. The median waiting time for an NHS clinic appointment was nine weeks. Almost a 10th of confirmed cases of glaucoma were in people in a high risk category for glaucoma who had to wait at least 14 weeks for an appointment. Conclusions-Closer cooperation, especially at the local level, among consultants, general practitioners, and optometrists is needed to improve testing and referral for suspected glaucoma. Optometrists should be encouraged to perform all the three main tests-ophthalmoscopy, tonometry, and perimetry-in patients before referral and to report precisely on reasons for referral to help prioritisation. The optometrist's referral letter to the general practitioner should always be passed on to the consultant. Similarly, the diagnosis should always be reported back to the optometrist.	UNIV LONDON KINGS COLL HOSP,INT GLAUCOMA ASSOC,LONDON SE5 9RS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London								Brittain G P, 1988, Health Trends, V20, P43; CLEARKIN L, 1983, T OPHTHAL SOC UK, V103, P284; CRICK RP, 1982, DISPENSING OPTICIAN, V34, P192; GILLIE RF, 1982, OPHTHALMIC OPT, V22, P586; GRANT WM, 1982, OPHTHALMOLOGY, V89, P991; HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162; HOWIE JGR, 1982, BRIT MED J, V285, P1009, DOI 10.1136/bmj.285.6347.1009-a; KLJAKOVIC M, 1985, BRIT MED J, V290, P1043, DOI 10.1136/bmj.290.6474.1043; MACKEAN M, 1982, BRIT MED J, V285, P1093; PORT MJA, 1988, OPHTHAL PHYSL OPT, V8, P323, DOI 10.1016/0275-5408(88)90182-2; PORT MJA, 1989, OPHTHAL PHYSL OPT, V9, P31, DOI 10.1111/j.1475-1313.1989.tb00801.x; PORT MJA, 1989, BCO SURVEY MED REFER; STEINMANN WC, 1982, BMJ-BRIT MED J, V285, P1091, DOI 10.1136/bmj.285.6348.1091; TUCK M, 1990, OPTICIAN, V191, P16; TUCK M, 1989, HLTH TRENDS, V21, P131; TUCK M, 1990, OPTICIAN, V199, P24; TUCK MW, 1991, OPHTHAL PHYSL OPT, V11, P22, DOI 10.1111/j.1475-1313.1991.tb00190.x; VOGEL R, 1990, BRIT J OPHTHALMOL, V74, P3, DOI 10.1136/bjo.74.1.3; WILSON R, 1982, ARCH OPHTHALMOL-CHIC, V100, P737, DOI 10.1001/archopht.1982.01030030741002	19	44	44	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					998	1000		10.1136/bmj.302.6783.998	http://dx.doi.org/10.1136/bmj.302.6783.998			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039899	Bronze, Green Published			2022-12-28	WOS:A1991FJ50800020
J	ELLIS, BW				ELLIS, BW			MANAGEMENT IMPORTANCE OF COMMON TREATMENTS - CONTRIBUTION OF TOP 20 PROCEDURES TO SURGICAL WORKLOAD AND COST	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the contribution of the most frequently performed procedures to surgical workload and to evaluate the financial implications. Design-Analysis of data held on the department's computerised clinical information system. Setting-Department of surgery in a district general hospital. Patients-4845 patients were treated by surgeons in three consultant firms over an 18 month period and 5346 patients by surgeons in a single firm over a five year period. Main outcome measures-Percentage and cumulative percentage contribution to workload in order of frequency by procedure. Costs of the commonest and costliest treatments. Results-Half of the workload of the department was encompassed by eight procedures. Twenty procedures accounted for 70% of the work. For a single firm 20 procedures represented over 80% of all the surgical work. Transurethral prostatectomy was the treatment that consumed most resources (Laplace operational symbol 240 900 for 198 patients in 18 months). The costliest patients were those who had undergone complicated large bowel surgery, vascular reconstructions, or amputation. Conclusions-Clinicians and managers need to appreciate the importance of the most common surgical procedures. It is vital that performance and costing of these procedures are optimum as they contribute disproportionately to overall results and finance.			ELLIS, BW (corresponding author), ASHFORD HOSP,ASHFORD TW15 3AA,MIDDX,ENGLAND.							DUDLEY H, 1974, BRIT MED J, V1, P275, DOI 10.1136/bmj.1.5902.275; ELLIS BW, 1990, BRIT MED J, V301, P159, DOI 10.1136/bmj.301.6744.159; ELLIS BW, 1986, J R SOC MED, V80, P157; LYONS C, 1990, BRIT MED J, V300, P1563, DOI 10.1136/bmj.300.6739.1563; SMITH T, 1990, BRIT MED J, V300, P65, DOI 10.1136/bmj.300.6717.65; 1989, WORKING PATIENTS; 1989, BUPA SCHEDULE PROCED; 1986, CLASSIFICATION SURGI	8	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					882	884		10.1136/bmj.302.6781.882	http://dx.doi.org/10.1136/bmj.302.6781.882			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025729	Bronze, Green Published			2022-12-28	WOS:A1991FG42100024
J	RAMANATHAN, C; SMELT, GJC				RAMANATHAN, C; SMELT, GJC			DESENSITIZATION	BRITISH MEDICAL JOURNAL			English	Letter											RAMANATHAN, C (corresponding author), ROYAL HALIFAX INFIRM,HALIFAX HX1 2YP,ENGLAND.							[Anonymous], 1986, BMJ-BRIT MED J, V293, P948; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					726	727		10.1136/bmj.302.6778.726-c	http://dx.doi.org/10.1136/bmj.302.6778.726-c			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	2021753	Green Published			2022-12-28	WOS:A1991FE33300042
J	MAYGARDEN, SJ; MCLENDON, WW				MAYGARDEN, SJ; MCLENDON, WW			PATHOLOGY AND LABORATORY MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; DNA; CARCINOMA; CYTOMETRY; TUMORS				MAYGARDEN, SJ (corresponding author), UNIV N CAROLINA, SCH MED, CHAPEL HILL, NC 27514 USA.							CHECK WA, 1990, CAP TODAY, V4, P1; CORKELL ME, 1990, MODERN PATHOL, V3, pA23; CORWIN DJ, 1989, ARCH PATHOL LAB MED, V113, P645; DAWSON AE, 1990, AM J PATHOL, V136, P1115; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; KOSS LG, 1989, HUM PATHOL, V20, P528, DOI 10.1016/0046-8177(89)90244-X; KOSS LG, 1990, NOV M AM SOC CYT WAS; MASOOD S, 1990, MODERN PATHOL, V3, P724; ROSS DW, 1990, ARCH PATHOL LAB MED, V114, P734; SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TADA M, 1991, GASTROENTEROLOGY, V100, P233, DOI 10.1016/0016-5085(91)90606-L; VISSCHER DW, 1990, PATHOL ANNU, V25, P171; WICK MR, 1989, PATHOLOGY URINARY BL, P285	14	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3154	3156						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041134				2022-12-28	WOS:A1991FQ77000033
J	DURRIN, LK; MANN, RK; KAYNE, PS; GRUNSTEIN, M				DURRIN, LK; MANN, RK; KAYNE, PS; GRUNSTEIN, M			YEAST HISTONE H4 N-TERMINAL SEQUENCE IS REQUIRED FOR PROMOTER ACTIVATION INVIVO	CELL			English	Article								To search for histone domains that may regulate transcription in vivo, we made deletions and amino acid substitutions in the histone N-termini of S. cerevisiae. Histone H4 N-terminal residues 4-23, which include the extremely conserved, reversibly acetylated lysines (at positions 5, 8, 12, and 16), were found to encompass a region required for the activation of the GAL1 promoter. Deletions in the H4 N-terminus reduce GAL1 activation 20-fold. This effect is specific to histone H4 in that large deletions in the N-termini of H2A, H2B, and H3 do not similarly decrease induction. Activation of the PH05 promoter is reduced approximately 4- to 5-fold by these H4 deletions. Mutations in histone H4 acetylation sites and surrounding residues can cause comparable and, in some cases, even greater effects on induction of these two promoters. We postulate that the H4 N-terminus may interact with a component of the transcription initiation complex, allowing nucleosome unfolding and subsequent initiation.	UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	DURRIN, LK (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.				NIGMS NIH HHS [GM23674] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023674, R37GM023674] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; Allfrey V. G, 1977, CHROMATIN CHROMOSOME, P167; ALLFREY VG, 1983, AFFINITY PROBES PROT; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HEREFORD L, 1979, CELL, V18, P1261, DOI 10.1016/0092-8674(79)90237-X; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAUGHON A, 1982, P NATL ACAD SCI-BIOL, V79, P6827, DOI 10.1073/pnas.79.22.6827; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; Maniatis T., 1982, MOL CLONING; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NELSON DA, 1982, J BIOL CHEM, V257, P1565; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; NORTON VG, 1990, J BIOL CHEM, V265, P19848; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RAINBOW M, 1989, BIOCHEMISTRY-US, V28, P7486, DOI 10.1021/bi00444a048; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROTH GP, 1990, FEBS LETT, V268, P117, DOI 10.1016/0014-5793(90)80987-T; SCHUSTER T, 1986, CELL, V45, P445, DOI 10.1016/0092-8674(86)90330-2; Sherman F., 1986, METHODS YEAST GENETI; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; STRAKA C, 1991, IN PRESS EMBO J, V10; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; van Holde K.E., 1988, CHROMATIN; WALLIS JW, 1983, CELL, V35, P711, DOI 10.1016/0092-8674(83)90104-6; WATERBORG JH, 1984, EUR J BIOCHEM, V142, P329, DOI 10.1111/j.1432-1033.1984.tb08290.x; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WHITLOCK JP, 1978, J BIOL CHEM, V253, P3857; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; XU HX, 1990, MOL CELL BIOL, V10, P2687, DOI 10.1128/MCB.10.6.2687	58	282	284	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					1023	1031		10.1016/0092-8674(91)90554-C	http://dx.doi.org/10.1016/0092-8674(91)90554-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044150				2022-12-28	WOS:A1991FR04700013
J	PARDES, H; WEST, A; PINCUS, HA				PARDES, H; WEST, A; PINCUS, HA			PHYSICIANS AND THE ANIMAL-RIGHTS MOVEMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY 10032 USA; AMER PSYCHIAT ASSOC, RES OFF, WASHINGTON, DC 20009 USA	New York State Psychiatry Institute	PARDES, H (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, 630 W 168TH ST, NEW YORK, NY 10032 USA.							BEHAR R, 1989, FORBES MAGAZINE 0320, P43; COHEN C, 1986, NEW ENGL J MED, V315, P865, DOI 10.1056/NEJM198610023151405; COHEN C, 1987, NEW ENGL J MED, V316, P553; COWLEY G, 1988, NEWSWEEK        1226, P50; DeBakey M E, 1988, J Invest Surg, V1, P81, DOI 10.3109/08941938809141078; DEBAKEY ME, 1989, PHYSICIANS MANAGE, V29, P17; FEENEY DM, 1987, AM PSYCHOL, V42, P593, DOI 10.1037/0003-066X.42.6.593; HORTON L, 1989, J NATL CANCER I, V81, P736, DOI 10.1093/jnci/81.10.736; HORTON L, 1988, SRA-J SOC RES ADMIN, V19, P5; KOOP CE, 1990, COMMUNICATION; NASSAR R, 1988, AM HUMANE ASS ANIMAL; Regan Tom, 1983, CASE ANIMAL RIGHTS; SHARPE R, CRUEL DECEPTION USE; Singer Peter, 1977, ANIMAL LIBERATION; SMITH SJ, 1988, JAMA-J AM MED ASSOC, V259, P2007, DOI 10.1001/jama.259.13.2007; THOMAS JA, 1988, NEW ENGL J MED, V318, P1630, DOI 10.1056/NEJM198806163182429; WOOLSEY TA, 1988, CIRCULATION, V77, P1197, DOI 10.1161/01.CIR.77.6.1197; 1990, 1990 P HOUS DEL RES, P392; 1986, OTABA273 PUBL; 1990, PAMPHLET AM ASS ACCR	20	18	18	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1640	1643		10.1056/NEJM199106063242306	http://dx.doi.org/10.1056/NEJM199106063242306			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	2030720				2022-12-28	WOS:A1991FP30700006
J	AUKERMAN, GF				AUKERMAN, GF			ACCESS TO HEALTH-CARE FOR THE UNINSURED - THE PERSPECTIVE OF THE AMERICAN-ACADEMY-OF-FAMILY-PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											AUKERMAN, GF (corresponding author), AMER ACAD FAMILY PHYSICIANS,600 MARYLAND AVE SW,SUITE 770,WASHINGTON,DC 20024, USA.							CHOLLET DJ, 1990, PUBLICATION EMPLOYEE, V104, P4; HORKITZ K, 1990, PUBLICATION EMPLOYEE, V106, P2; 1990, AAFP POSITION STATEM; 1990, ANAL AM ACADEMY FAMI	4	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2856	2858						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN855	2033744				2022-12-28	WOS:A1991FN85500037
J	BOVBJERG, RR; TANCREDI, LR; GAYLIN, DS				BOVBJERG, RR; TANCREDI, LR; GAYLIN, DS			OBSTETRICS AND MALPRACTICE - EVIDENCE ON THE PERFORMANCE OF A SELECTIVE NO-FAULT SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL PROFESSIONAL LIABILITY; TORT; INSURANCE; COMPENSATION; CRISIS; CARE	Most malpractice litigation in obstetrics could be replaced with an alternative insurance system based on "accelerated-compensation events," which are classes of medical injuries determined in advance by medical experts to be readily identifiable, normally preventable with good care, and nondistorting of medical decision making. This professionally derived system would help prevent injury and improve the resolution of injuries. Prior work on accelerated-compensation events was largely conceptual, so to study the likely effects of accelerated-compensation events, we applied the events to a large database of obstetrical malpractice claims. Results refute prior criticisms. Accelerated-compensation events (1) are definitely feasible to develop and apply, (2) would probably cover two thirds of currently paid claims and three quarters of indemnity dollars, (3) would likely involve substantial savings in time and expense per case, and (4) would probably not introduce an unmanageable number of large new claims.	UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225	University of Texas System; University of Texas Health Science Center Houston	BOVBJERG, RR (corresponding author), URBAN INST,2100 M ST NW,WASHINGTON,DC 20037, USA.							BOVBJERG RR, 1989, NORTHWEST U LAW REV, V83, P908; BOVBJERG RR, 1986, LAW CONTEMP PROBL, V49, P321, DOI 10.2307/1191431; BOVBJERG RR, 1990, COURTS HLTH SCI, V1, P19; BOVBJERG RR, IN PRESS LAW CONT PR; BOYDEN JR, 1979, DESIGNATED COMPENSAB, P11; CALABRESI G, 1978, EC MED MALPRACTICE, P233; DANZON PM, 1985, MED MALPRACTICE THEO; EPSTEIN RA, 1978, EC MED MALPRACTICE, P245; FREEMAN AD, 1989, J HEALTH POLIT POLIC, V14, P707, DOI 10.1215/03616878-14-4-707; GALLUP CL, 1989, J HEALTH POLIT POLIC, V14, P691, DOI 10.1215/03616878-14-4-691; HAVIGHURST CC, 1973, MILBANK FUND Q, V51, P125, DOI 10.2307/3349578; HENDERSON JA, 1989, MED PROFESSIONAL LIA, V2, P194; HUBER PW, 1988, LIABILITY LEGAL REVO; HUGHES D, 1989, MED PROFESSIONAL LIA, V2, P58; JACOBSON PD, 1989, JAMA-J AM MED ASSOC, V262, P3320, DOI 10.1001/jama.262.23.3320; JOHNSON KB, 1989, VANDERBILT LAW REV, V42, P1365; JOHNSON KB, 1987, JAMA-J AM MED ASSOC, V257, P827; KEETON RE, 1973, U PENN LAW REV, V121, P590, DOI 10.2307/3311302; KEETON W, 1984, PROSSER KEETON TORTS; LATZ RS, 1989, J LEGAL MED, V10, P479, DOI 10.1080/01947648909513582; LEWISIDEMA D, 1989, MED PROFESSIONAL LIA, V2, P78; MCCOID, 1959, VANDERBILT LAW REV, V12, P549; MILLS D, 1977, MED INSURANCE FEASIB; MILLS DH, 1978, WESTERN J MED, V128, P360; OCONNELL J, 1986, LAW CONTEMP PROBL, V49, P125, DOI 10.2307/1191419; OCONNELL J, 1987, BLAME GAME INJURIES; PHILLIPS CG, 1989, MED PROFESSIONAL LIA, V2, P136; PRIEST GL, 1987, YALE LAW J, V96, P1521, DOI 10.2307/796494; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; ROSTOW VP, 1989, NEW ENGL J MED, V321, P1057, DOI 10.1056/NEJM198910123211526; SACHS BP, 1989, MED PROFESSIONAL LIA, V2, P27; SCHWARTZ WB, 1978, NEW ENGL J MED, V298, P1282, DOI 10.1056/NEJM197806082982304; SLOAN FA, IN PRESS INSURING ME; SLOAN FA, 1990, LAW SOC REV, V24, P601; Tancredi L R, 1977, Inquiry, V14, P341; TANCREDI LR, 1986, LAW CONTEMP PROBL, V49, P277, DOI 10.2307/1191428; TANCREDI LR, 1974, MED CARE, V12, P935, DOI 10.1097/00005650-197411000-00005; THACKER SB, 1989, MED PROFESSIONAL LIA, V2, P26; 1989, MED PROFESSIONAL LIA, P1; 1987, GAOHRD8755 GEN ACC O; 1973, DHEW OS7388 PUBL, V1, P5; 1988, PROPOSED ALTERNATIVE, P3; 1990, PATIENTS DOCTORS LAW	43	26	27	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2836	2843		10.1001/jama.265.21.2836	http://dx.doi.org/10.1001/jama.265.21.2836			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN855	2033740				2022-12-28	WOS:A1991FN85500033
J	ROSS, PD; DAVIS, JW; EPSTEIN, RS; WASNICH, RD				ROSS, PD; DAVIS, JW; EPSTEIN, RS; WASNICH, RD			PREEXISTING FRACTURES AND BONE MASS PREDICT VERTEBRAL FRACTURE INCIDENCE IN WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article							MINERAL MEASUREMENTS; OSTEOPOROSIS; ABSORPTIOMETRY; RISK	Objective: To determine the independent contributions of bone mass and existing fractures as predictors of the risk for new vertebral fractures. Subjects: Postmenopausal Japanese-American women. Measurements: Baseline measurements of the distal radius, the proximal radius, and the calcaneus were obtained in 1981 using single-photon absorptiometry. Measurements of the lumbar spine were obtained in 1984 using dual-photon absorptiometry. Prevalent vertebral fractures were identified using dimensions measured on lateral radiographs; vertebral height values more than 3 SD below vertebra-specific means were considered to indicate fracture. Statistical models were used to evaluate the utility of bone mass and existing (prevalent) fractures to predict the risk for new fractures during an average follow-up of 4.7 years. Main Results: Differences of 2 SD in bone mass were associated with fourfold to sixfold increases in the risk for new vertebral fractures. A single fracture at the baseline examination increased the risk for new vertebral fractures fivefold. Presence of two or more fractures at baseline increased the risk 12-fold. A combination of low bone mass (below the 33d percentile) and the presence of two or more prevalent fractures increased the risk 75-fold, relative to women with the highest bone mass (above the 67th percentile) and no prevalent fractures. Stature, body mass index, arm span, and spinal conditions such as scoliosis, osteoarthritis, and sacroiliitis did not predict fracture incidence (P > 0.05). Weight was marginally predictive (P = 0.04) of fracture incidence but became nonpredictive after adjusting for bone mass (P greater-than-or-equal-to 0.05). Conclusions: Both bone mass and prevalent vertebral fractures are powerful predictors of the risk for new vertebral fractures. Combining information about bone mass and prevalent fracture appears to be better for predicting new fractures than either variable alone. Physicians can use these risk factors to identify patients at greatest risk for new fractures.	MERCK SHARP & DOHME LTD, W POINT, PA 19486 USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA	Merck & Company; University System of Maryland; University of Maryland Baltimore	ROSS, PD (corresponding author), HAWAII OSTEOPOROSIS CTR, 932 WARD AVE, SUITE 400, HONOLULU, HI 96814 USA.							BENGNER U, 1988, CALCIFIED TISSUE INT, V42, P293, DOI 10.1007/BF02556362; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; Heilbrun L K, 1985, Hawaii Med J, V44, P294; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P111; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; ROSS PD, 1988, J BONE MINER RES, V3, P1; ROSS PD, 1991, BONE, V12, P107, DOI 10.1016/8756-3282(91)90008-7; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; WASNICH RD, 1989, J NUCL MED, V30, P1166; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WASNICH RD, 1987, OSTEOPOROSIS 1987, P394; WASNICH RD, 1989, OSTEOPOROSIS CRITIQU; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; YANO K, 1984, AM J EPIDEMIOL, V119, P751, DOI 10.1093/oxfordjournals.aje.a113796	16	882	917	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					919	923		10.7326/0003-4819-114-11-919	http://dx.doi.org/10.7326/0003-4819-114-11-919			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024857				2022-12-28	WOS:A1991FM97900001
J	SZAREWSKI, A; GUILLEBAUD, J				SZAREWSKI, A; GUILLEBAUD, J			CONTRACEPTION	BRITISH MEDICAL JOURNAL			English	Review							PELVIC INFLAMMATORY DISEASE; PRACTITIONERS ORAL CONTRACEPTION; INTRAUTERINE-DEVICE; CARBOHYDRATE-METABOLISM; MYOCARDIAL-INFARCTION; TUBAL INFERTILITY; LEVONORGESTREL; WOMEN; RISK; INACTIVATION				SZAREWSKI, A (corresponding author), MARGARET PYKE CTR STUDY & TRAINING FAMILY PLANNING,FAMILY PLANNING,LONDON W1V 5TW,ENGLAND.							ANDERSSON JK, 1990, BRIT J OBSTET GYNAEC, V97, P690, DOI 10.1111/j.1471-0528.1990.tb16240.x; [Anonymous], 1990, LANCET, V336, P955; Bisset AM, 1990, BRIT J FAM PLAN, V16, P84; Bounds W., 1988, British Journal of Family Planning, V14, P83; BOUNDS WC, 1989, CONTRACEPTION SCI PR, P172; BOWENSIMPKINS P, 1989, CONTRACEPTION SCI PR, P224; BUCHAN H, 1990, BRIT J OBSTET GYNAEC, V97, P780, DOI 10.1111/j.1471-0528.1990.tb02571.x; CHRISTIAN CD, 1974, AM J OBSTET GYNECOL, V119, P441, DOI 10.1016/0002-9378(74)90198-7; CRAIG S, 1982, CONTRACEPTION, V26, P347, DOI 10.1016/0010-7824(82)90102-0; CRAMER DW, 1985, NEW ENGL J MED, V312, P941, DOI 10.1056/NEJM198504113121502; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; DALING JR, 1985, NEW ENGL J MED, V312, P937, DOI 10.1056/NEJM198504113121501; DICFALUSY E, 1982, ACTA OBSTET GYNECO S, V105, P7; DRIFE J, 1989, BRIT J OBSTET GYNAEC, V96, P1255, DOI 10.1111/j.1471-0528.1989.tb03220.x; ELGAR W, 1986, ADV CONTRACEPTIVE DE, V2, P182; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; FORTNEY JA, 1990, IPPF MED B, V24, P3; FOTHERBY K, 1987, CONTRACEPTION, V35, P323, DOI 10.1016/0010-7824(87)90069-2; FRASER IS, 1989, CONTRACEPTION SCI PR, P109; FRASER IS, 1985, CLIN REPRODUCTIVE EN, P634; GILLMER MDG, 1989, CONTRACEPTION SCI PR, P11; GODSLAND IF, 1990, NEW ENGL J MED, V323, P1375, DOI 10.1056/NEJM199011153232003; GUILLEBAUD J, 1990, AM J OBSTET GYNECOL, V163, P443, DOI 10.1016/0002-9378(90)90598-2; Guillebaud J., 1987, BRIT J FAM PLAN, V12, P35; GUILLEBAUD J, 1989, CONTRACEPTION SCI PR, P69; HAMMOND GL, 1984, FERTIL STERIL, V42, P44; HICKS DR, 1985, LANCET, V2, P1422; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JONES WR, 1988, LANCET, V1, P1295; JORDAN WM, 1961, LANCET, V2, P1146, DOI DOI 10.1016/S0140-6736(61)91061-3; KAY C, 1984, J OBSTET GYNECOL, V4, P98; KAY CR, 1984, CLIN OBSTET GYNAECOL, V11, P759; KLOOSTERBOER HJ, 1988, CONTRACEPTION, V38, P325, DOI 10.1016/0010-7824(88)90104-7; LAYDE PM, 1982, INT FAMILY PLANNING, V2, P79; LEE NC, 1988, OBSTET GYNECOL, V72, P1; LEE NC, 1983, OBSTET GYNECOL, V62, P1; Lepot M R, 1987, Int J Fertil, V32 Suppl, P15; MACKENZIE IZ, 1987, BRIT J OBSTET GYNAEC, V94, P449, DOI 10.1111/j.1471-0528.1987.tb03124.x; MALKOVSKY M, 1988, LANCET, V1, P645; MAMMEN EF, 1982, AM J OBSTET GYNECOL, V142, P781; MANN JI, 1975, BRIT MED J, V2, P245, DOI 10.1136/bmj.2.5965.245; MANN RD, 1990, ORAL CONTRACEPTIVES; NEWTON J, 1990, LANCET, V335, P1322, DOI 10.1016/0140-6736(90)91198-J; NIRAPATHPONGPORN A, 1990, LANCET, V335, P894, DOI 10.1016/0140-6736(90)90487-P; NIRUTHISARD S, IN PRESS SEXUALLY TR; ODLIND V, 1991, BR J FAM PLANN S, V16, P8; PARDTHAISONG T, 1980, LANCET, V1, P509; Rabe T, 1987, Int J Fertil, V32 Suppl, P29; REKERS H, 1988, CONTRACEPTION NEXT D, P13; RIETMEIJER CAM, 1988, JAMA-J AM MED ASSOC, V259, P1851, DOI 10.1001/jama.259.12.1851; RINEHART W, 1975, POPULATION REP, V3, pA53; RIOUX JE, 1989, CONTRACEPTION SCI PR, P275; ROTHERBY K, 1989, CONTRACEPTION SCI PR, P94; SACHS BP, 1985, NEW ENGL J MED, V311, P667; SAPIRE EK, 1990, CONTRACEPTION SEXUAL, P179; SIVIN I, 1987, CONTRACEPTION, V35, P245, DOI 10.1016/0010-7824(87)90026-6; SMITH GL, 1986, LANCET, V2, P1392; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; TACCHI D, 1990, LANCET, V335, P182; TIKKANEN MJ, 1986, J REPROD MED, V31, P898; Trap R, 1990, Int J STD AIDS, V1, P346; VANDERVANGE N, 1987, AM J OBSTET GYNECOL, V156, P918, DOI 10.1016/0002-9378(87)90355-3; Vessey M, 1985, BR J FAMILY PLANNING, V10, P117; Vessey M. P., 1988, British Journal of Family Planning, V14, P40; VESSEY M P, 1980, British Journal of Family Planning, V6, P1; VESSEY MP, 1989, BMJ-BRIT MED J, V299, P1487, DOI 10.1136/bmj.299.6714.1487; VESSEY MP, 1989, CONTRACEPTION SCI PR, P52; VESSEY MP, 1982, LANCET, V2, P841; 1990, CONTRACEPTION, V41, P105; 1990, OPCS MONITOR, V3, P13; 1986, J HOPKINS U POPULA J, V33; 1986, NEW ENGL J MED, V315, P415; 1987, OPCS GHS17 OFF POP C, P50; 1987, WHO TECHNICAL REPORT, V753; 1987, J HOPKINS U POPULA K, V3	75	9	15	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1224	1226		10.1136/bmj.302.6787.1224	http://dx.doi.org/10.1136/bmj.302.6787.1224			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043843	Green Published, Bronze			2022-12-28	WOS:A1991FP27200005
J	ENGEL, AK; KONIG, P; KREITER, AK; SINGER, W				ENGEL, AK; KONIG, P; KREITER, AK; SINGER, W			INTERHEMISPHERIC SYNCHRONIZATION OF OSCILLATORY NEURONAL RESPONSES IN CAT VISUAL-CORTEX	SCIENCE			English	Article								Neurons in area 17 of cat visual cortex display oscillatory responses that can synchronize across spatially separate columns in a stimulus-specific way. Response synchronization has now been shown to occur also between neurons in area 17 of the right and left cerebral hemispheres. This synchronization was abolished by section of the corpus callosum. Thus, the response synchronization is mediated by corticocortical connections. These data are compatible with the hypothesis that temporal synchrony of neuronal discharges serves to bind features within and between the visual hemifields.			ENGEL, AK (corresponding author), MAX PLANCK INST HIRNFORSCH, DEUTSCHORDENSTR 46, W-6000 FRANKFURT 71, GERMANY.		Engel, Andreas K./AAH-6384-2019; Engel, Andreas K/C-7781-2012; König, Peter/ABB-2380-2020; Singer, Wolf/D-6874-2012	Engel, Andreas K./0000-0003-4899-8466; Engel, Andreas K/0000-0003-4899-8466; König, Peter/0000-0003-3654-5267; 				ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1990, PARALLEL PROCESSING IN NEURAL SYSTEMS AND COMPUTERS, P105; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; ENGEL AK, 1990, SOC NEUR ABSTR, V16, P5231; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1967, J NEUROPHYSIOL, V30, P1561, DOI 10.1152/jn.1967.30.6.1561; INNOCENTI GM, 1980, ARCH ITAL BIOL, V118, P124; Innocenti GM., 1986, CEREBRAL CORTEX VOL, P291, DOI [10.1007/978-1-4613-2149-1_9, DOI 10.1007/978-1-4613-2149-1_9]; Konig P, 1991, NEURAL COMPUT, V3, P155, DOI 10.1162/neco.1991.3.2.155; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; TOYAMA K, 1988, NEUROBIOLOGY NEOCORT, P203; TUSA RJ, 1978, J COMP NEUROL, V177, P213, DOI 10.1002/cne.901770204; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; Woelcke M, 1942, J PSYCHOL NEUROL, V51, P199	17	681	686	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1177	1179		10.1126/science.252.5009.1177	http://dx.doi.org/10.1126/science.252.5009.1177			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031188				2022-12-28	WOS:A1991FN05600052
J	BREO, DL				BREO, DL			BUILDING MEDICAL BRIDGES - CARDIOLOGY FROM AMA TO ZAGREB	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2740	2740		10.1001/jama.265.20.2740	http://dx.doi.org/10.1001/jama.265.20.2740			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023357				2022-12-28	WOS:A1991FL98900041
J	PUGIN, J; AUCKENTHALER, R; LEW, DP; SUTER, PM				PUGIN, J; AUCKENTHALER, R; LEW, DP; SUTER, PM			OROPHARYNGEAL DECONTAMINATION DECREASES INCIDENCE OF VENTILATOR-ASSOCIATED PNEUMONIA - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL-TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY ILL PATIENTS; INTENSIVE-CARE UNIT; NOSOCOMIAL BACTERIAL PNEUMONIA; PROTECTED SPECIMEN BRUSH; MULTIPLE TRAUMA PATIENTS; GRAM-NEGATIVE BACILLI; SELECTIVE DECONTAMINATION; DIGESTIVE-TRACT; MECHANICAL VENTILATION; RESPIRATORY-TRACT	Secondary pneumonia in patients requiring mechanical ventilation has a high morbidity and mortality. Diagnosis is difficult and treatment failure common; therefore, preventive measures are important. In a double-blind, placebo-controlled trial, we evaluated selective decontamination of the oropharynx with polymyxin B sulfate, neomycin sulfate, and vancomycin hydrochloride (PNV) in 52 patients requiring mechanical ventilation during a 3- to 34-day period (mean, 10 days). Either PNV or placebo was administered six times daily in the oropharynx. During the first 12 days of intubation, tracheobronchial colonization by gram-negative bacteria and Staphylococcus aureus, as well as pneumonia, occurred less frequently in the PNV than in the placebo group (16% vs 78%; P < .0001). Hospital mortality was not different, but systemic antibiotics were prescribed less often in the PNV group and no resistant microorganism emerged. In these critically ill patients, topical oropharyngeal antibiotic application lowered the rate of ventilator-associated pneumonia by a factor of 5, probably by interrupting the stomach-to-trachea route of infection, and decreased the requirement for intravenous antibiotics.	UNIV GENEVA,HOP CANTONAL,DEPT ANESTHESIOL,DIV SURG INTENS CARE,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,HOP CANTONAL,DEPT MED,DIV INFECT DIS,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva								ALCOCK SR, 1989, INFECTION CONTROL SE, P102; ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; ATHERTON ST, 1978, LANCET, V2, P968; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; CHASTRE J, 1988, AM J MED, V85, P499; DALNOGARE AR, 1987, AM REV RESPIR DIS, V135, P671; DASCHNER FD, 1982, INTENS CARE MED, V8, P5; DRICKS MR, 1987, NEW ENGL J MED, V317, P1376; DUMOULIN GC, 1982, LANCET, V1, P242; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FEELEY TW, 1975, NEW ENGL J MED, V293, P471, DOI 10.1056/NEJM197509042931003; GARVEY BM, 1989, CRIT CARE MED, V17, P211, DOI 10.1097/00003246-198903000-00002; GASTINNE H, 1990, 1ST P INT C PREV INF, P136; HALEY RW, 1981, AM J MED, V70, P51, DOI 10.1016/0002-9343(81)90411-3; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; JOHANSON WG, 1988, AM REV RESPIR DIS, V137, P259, DOI 10.1164/ajrccm/137.2.259; KAISER AB, 1986, NEW ENGL J MED, V315, P1129; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KLASTERSKY J, 1974, CHEST, V65, P650, DOI 10.1378/chest.65.6.650; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; LANGER M, 1987, INTENS CARE MED, V13, P342; LEDINGHAM IM, 1988, LANCET, V1, P785; MAKI DG, 1989, ARCH INTERN MED, V149, P30, DOI 10.1001/archinte.149.1.30; MISSET B, 1990, 1ST P INT C PREV INF, P135; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; REUSSER P, 1989, J INFECT DIS, V160, P414, DOI 10.1093/infdis/160.3.414; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; SANDERSON PJ, 1989, BRIT MED J, V299, P1413, DOI 10.1136/bmj.299.6713.1413; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1986, INTENS CARE MED, V12, P419, DOI 10.1007/BF00254674; STOUTENBEEK CP, 1984, J ANTIMICROB CHEMOTH, V14, P203, DOI 10.1093/jac/14.suppl_B.203; TETTEROO GWM, 1990, LANCET, V335, P704, DOI 10.1016/0140-6736(90)90813-K; TRYBA M, 1987, AM J MED, V83, P117, DOI 10.1016/0002-9343(87)90840-0; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; UNERTL K, 1984, CURRENT ASPECTS BACT, P127	37	226	233	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2704	2710		10.1001/jama.265.20.2704	http://dx.doi.org/10.1001/jama.265.20.2704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023353				2022-12-28	WOS:A1991FL98900037
J	SULLIVAN, LW				SULLIVAN, LW			CHILD SURVIVAL AND AIDS IN AFRICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		1991, PUBLIC HLTH REP, V106, P105	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2652	2652						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023337				2022-12-28	WOS:A1991FL98900005
J	DAVIS, K				DAVIS, K			EXPANDING MEDICARE AND EMPLOYER PLANS TO ACHIEVE UNIVERSAL HEALTH-INSURANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This article presents a proposal for expanding Medicare and employer-based health insurance plans to achieve universal health insurance. Under this proposed health care financing system, employers would provide basic health insurance coverage to workers and dependents, or pay a payroll tax contribution toward the cost of their coverage under Medicare. States would have the option of buying all Medicaid beneficiaries and other poor individuals into Medicare by paying the Medicare premiums and cost sharing. Other uninsured individuals would be automatically covered by Medicare. Employer plans would incorporate Medicare's provider payment methods. This proposal would result in incremental federal governmental outlays on the order of $25 billion annually. These new federal budgetary costs would be met through a combination of premiums, employer payroll tax, income tax, and general tax revenues. The principal advantage of this plan is that it draws on the strengths of the current system while simplifying the benefit and provider payment structure and instituting innovations to promote efficiency.			DAVIS, K (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21218, USA.							BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V260, P3176; DAVIS K, 1989, AM ECON REV, V79, P349; DAVIS K, 1990, HLTH INSURANCE OPTIO; DAVIS K, 1975, NATIONAL HLTH INSURA; DAVIS K, 1990, DOCTORING AM; DAVIS K, 1986, MEDICARE POLICY NEW; DAVIS K, 1990, HLTH CARE COST CONTA; DAVIS K, 1991, HLTH SERVICES RES, P93; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; GINSBURG PB, 1990, HEALTH AFFAIR, V9, P178, DOI 10.1377/hlthaff.9.1.178; ROGERS DE, 1982, NEW ENGL J MED, V307, P13, DOI 10.1056/NEJM198207013070103; 1990, CALL ACTION; 1990, OVERVIEW ENTITLEMENT	13	13	13	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2525	2528		10.1001/jama.265.19.2525	http://dx.doi.org/10.1001/jama.265.19.2525			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK903	2020069				2022-12-28	WOS:A1991FK90300025
J	KADUNCE, DP; BURR, R; GRESS, R; KANNER, R; LYON, JL; ZONE, JJ				KADUNCE, DP; BURR, R; GRESS, R; KANNER, R; LYON, JL; ZONE, JJ			CIGARETTE-SMOKING - RISK FACTOR FOR PREMATURE FACIAL WRINKLING	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-FLOW; SKIN; SMOKERS; FACE	Objective: To determine if cigarette smoking is a risk factor for the development of premature facial wrinkling. Design: Cross-sectional study. Setting: Smoking cessation clinic and community. Patients: Convenience sample of 132 adult smokers and nonsmokers in 1988. Measurements: A questionnaire was administered to quantify cigarette smoking and to obtain information about possibly confounding factors such as skin pigmentation, sun exposure, age, and sex. Wrinkling was assessed using photographs of the temple region, and a severity score based on predetermined criteria was assigned. A logistic regression model, which controlled for confounding variables, was developed to assess the risk for premature wrinkling in response to pack-years of smoking. Main Results: The prevalence of premature wrinkling was independently associated with sun exposure and pack-years of smoking. After controlling for age, sex, and sun exposure, premature wrinkling increased with increased pack-years of smoking. Heavy cigarette smokers (> 50 pack-years) were 4.7 times more likely to be wrinkled than nonsmokers (95% CI, 1.0 to 22.6; P value for trend = 0.05). Sun exposure of more than 50 000 lifetime hours also increased the risk of being excessively wrinkled 3.1-fold (CI, 1.2 to 7.1). When excessive sun exposure and cigarette smoking occurred together, the risk for developing excessive wrinkling was multiplicative (prevalence ratio of 12.0; CI, 1.5 to 530). Conclusion: Cigarette smoking is an independent risk factor for the development of premature wrinkling.			KADUNCE, DP (corresponding author), UNIV UTAH, HLTH SCI CTR,DEPT MED,DIV DERMATOL,ROOM 4B454, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.							BRESLOW N, 1978, BIOMETRICS, V34, P100, DOI 10.2307/2529594; BRESLOW NE, 1980, STATISTICAL METHODS; CHEN VL, 1986, J INVEST DERMATOL, V87, P334, DOI 10.1111/1523-1747.ep12524421; CRAIG S, 1985, PLAST RECONSTR SURG, V75, P842, DOI 10.1097/00006534-198506000-00015; DANIELL HW, 1971, ANN INTERN MED, V75, P873, DOI 10.7326/0003-4819-75-6-873; Fletcher CM, 1976, NATURAL HIST CHRONIC; Gilchrest BA., 1984, SKIN AGING PROCESSES; GILCHREST BA, 1986, AGING SKIN; GRAHAM S, 1985, AM J EPIDEMIOL, V122, P606, DOI 10.1093/oxfordjournals.aje.a114140; LEVER WF, 1983, HISTOPATHOLOGY SKIN, P30; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MODEL D, 1985, BMJ-BRIT MED J, V291, P1760, DOI 10.1136/bmj.291.6511.1760; NIEWOEHNER D, 1986, CURRENT PULMONOLOGY, V7, P23; READ RC, 1984, AM J SURG, V148, P706, DOI 10.1016/0002-9610(84)90421-5; REES TD, 1984, PLAST RECONSTR SURG, V73, P911, DOI 10.1097/00006534-198406000-00009; REUS WF, 1984, BRIT J PLAST SURG, V37, P213, DOI 10.1016/0007-1226(84)90011-0; SCOTTO J, 1983, DHHS NIH832433 PUBL; SOFFER A, 1986, ARCH INTERN MED, V146, P1496, DOI 10.1001/archinte.146.8.1496; WAEBER B, 1984, AM J PHYSIOL, V247, pH895, DOI 10.1152/ajpheart.1984.247.6.H895; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; 1982, DHHS PHS8250179 PUBL, P21; 1986, EPILOGUE VER 3	22	170	180	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					840	844		10.7326/0003-4819-114-10-840	http://dx.doi.org/10.7326/0003-4819-114-10-840			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014944				2022-12-28	WOS:A1991FL65000002
J	LO, B; STEINBROOK, R				LO, B; STEINBROOK, R			BEYOND THE CRUZAN CASE - THE UNITED-STATES-SUPREME-COURT AND MEDICAL-PRACTICE	ANNALS OF INTERNAL MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; RIGHT-TO-DIE; PRACTICE POLICIES; PHYSICIANS; GUIDELINES; DECISIONS; PATIENT	In a landmark decision, the U.S. Supreme Court affirmed a Missouri ruling that sharply limited family decisions about life-sustaining treatment for incompetent patients. The Court held that the Constitution protects the refusal of life-sustaining treatment by competent patients. For incompetent patients, states may require "clear and convincing" evidence of refusal, specifically for the withdrawal of tube feedings, if such a person were in a persistent vegetative state. The ruling left many clinical questions unanswered, such as whether life-sustaining treatment must be given to terminally ill incompetent patients, whether patients may refuse artificial feedings, and what constitutes clear and convincing evidence of refusal. The decision also has potentially harmful consequences. It may undermine family decision making, encourage cynicism and disregard of the law, and promote defensive medicine. Physicians can minimize such consequence by encouraging patients to provide advance directives, such as the durable power of attorney for health care, by urging legislative action, and by setting national practice standard for decisions regarding incompetent patients.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; LOS ANGELES TIMES, LOS ANGELES, CA 90053 USA	University of California System; University of California San Francisco					NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGELI M, 1990, NEW ENGL J MED, V322, P1226, DOI 10.1056/NEJM199004263221710; ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; ANNAS GJ, 1982, LEGAL ETHICAL ASPECT, P28; [Anonymous], 1989, NEUROLOGY, V39, P125; AREEN J, 1987, JAMA-J AM MED ASSOC, V258, P229, DOI 10.1001/jama.258.2.229; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P179; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P194; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; Buchanan AE, 1989, DECIDING OTHERS; COYLE M, 1990, NATL LJ         0226, P1; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1265, DOI 10.1001/jama.263.9.1265; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1839, DOI 10.1001/jama.263.13.1839; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; GLOVER JJ, 1990, J AM GERIATR SOC, V38, P570, DOI 10.1111/j.1532-5415.1990.tb02410.x; Jonsen Albert R., 1998, CLIN ETHICS, V4th; KOLBERT E, 1990, NY TIMES        0708, pE5; Lantos J D, 1989, Law Med Health Care, V17, P308; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LO B, 1990, NEW ENGL J MED, V322, P1228, DOI 10.1056/NEJM199004263221711; Lo B, 1990, Law Med Health Care, V18, P193, DOI 10.1111/j.1748-720X.1990.tb00022.x; MCCLUNG JA, 1990, NEW ENGL J MED, V323, P270, DOI 10.1056/NEJM199007263230411; MEISEL A, 1989, RIGHT DIE; MILES SH, 1989, NEW ENGL J MED, V321, P48, DOI 10.1056/NEJM198907063210110; MOSS AH, 1989, J GEN INTERN MED, V4, P349, DOI 10.1007/BF02597409; MUNSAT TL, 1989, NEUROLOGY, V39, P123, DOI 10.1212/WNL.39.1.123; Nelson L J, 1989, Law Med Health Care, V17, P316; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V264, P2444, DOI 10.1001/jama.264.18.2444; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SNYDER L, 1990, ANN INTERN MED, V112, P802, DOI 10.7326/0003-4819-112-11-802; SOLOMON DH, 1990, J AM GERIATR SOC, V38, P569, DOI 10.1111/j.1532-5415.1990.tb02409.x; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; VEATCH RM, 1984, J AM GERIATR SOC, V32, P665, DOI 10.1111/j.1532-5415.1984.tb02257.x; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1990, NY TIMES        0627, pA18; 1987, REPORT HASTINGS CTR; 1986, JAMA-J AM MED ASSOC, V256, P471; 1991, NY TIMES        0102, pA8	41	38	40	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					895	901		10.7326/0003-4819-114-10-895	http://dx.doi.org/10.7326/0003-4819-114-10-895			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014952				2022-12-28	WOS:A1991FL65000011
J	DONADIO, S; STAVER, MJ; MCALPINE, JB; SWANSON, SJ; KATZ, L				DONADIO, S; STAVER, MJ; MCALPINE, JB; SWANSON, SJ; KATZ, L			MODULAR ORGANIZATION OF GENES REQUIRED FOR COMPLEX POLYKETIDE BIOSYNTHESIS	SCIENCE			English	Article							FATTY-ACID SYNTHASE; SACCHAROPOLYSPORA-ERYTHRAEA STREPTOMYCES; ERYTHROMYCIN RESISTANCE; MACROLIDE BIOSYNTHESIS; ANTIBIOTICS; SEQUENCE; CLONING; CDNA	In Saccharopolyspora erythraea, the genes that govern synthesis of the polyketide portion of the macrolide antibiotic erythromycin are organized in six repeated units that encode fatty acid synthase (FAS)-like activities. Each repeated unit is designated a module, and two modules are contained in a single open reading frame. A model for the synthesis of this complex polyketide is proposed, where each module encodes a functional synthase unit and each synthase unit participates specifically in one of the six FAS-like elongation steps required for formation of the polyketide. In addition, genetic organization and biochemical order of events appear to be colinear. Evidence for the model is provided by construction of a selected mutant and by isolation of a polyketide of predicted structure.	ABBOTT LABS,BIOACT MICROBIAL METABOLITE PROJECT,N CHICAGO,IL 60064	Abbott Laboratories	DONADIO, S (corresponding author), ABBOTT LABS,DEPT CORP MOLEC BIOL,N CHICAGO,IL 60064, USA.							BALTZ RH, 1988, ANNU REV MICROBIOL, V42, P547; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1985, GENE, V38, P215, DOI 10.1016/0378-1119(85)90220-3; BIRCH AJ, 1953, AUST J CHEM, V6, P360, DOI 10.1071/CH9530360; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CHIRALA SS, 1989, J BIOL CHEM, V264, P3750; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWITT JP, 1985, J BACTERIOL, V164, P969, DOI 10.1128/JB.164.2.969-971.1985; DONADIO S, IN PRESS GENE; HALE RS, 1987, FEBS LETT, V224, P133, DOI 10.1016/0014-5793(87)80436-2; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUBER MLB, 1990, ANTIMICROB AGENTS CH, V34, P1535, DOI 10.1128/AAC.34.8.1535; KINOSHITA K, 1988, J CHEM SOC CHEM COMM, V943; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; MACNEIL DJ, 1990, J CELL BIOL A S, V14, P92; Maniatis T., 1982, MOL CLONING; MARTIN JR, 1968, BIOCHEMISTRY-US, V7, P1728, DOI 10.1021/bi00845a016; MCALPINE JB, 1987, J ANTIBIOT, V40, P1115, DOI 10.7164/antibiotics.40.1115; MCALPINE JR, UNPUB; OMURA S, 1984, MACROLIDE ANTIBIOTIC, P199; RICHARDSON MA, 1990, J BACTERIOL, V172, P3790, DOI 10.1128/jb.172.7.3790-3798.1990; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; STAVER MJ, UNPUB; TUAN JS, 1990, GENE, V90, P21, DOI 10.1016/0378-1119(90)90435-T; UCHIYAMA H, 1985, GENE, V38, P103, DOI 10.1016/0378-1119(85)90208-2; VARA J, 1989, J BACTERIOL, V171, P5872, DOI 10.1128/jb.171.11.5872-5881.1989; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; WEBER JM, 1988, GENE, V68, P173, DOI 10.1016/0378-1119(88)90019-4; YUAN ZY, 1988, P NATL ACAD SCI USA, V85, P6328, DOI 10.1073/pnas.85.17.6328; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	39	758	830	3	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					675	679		10.1126/science.2024119	http://dx.doi.org/10.1126/science.2024119			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024119				2022-12-28	WOS:A1991FK18500039
J	SEABRA, MC; REISS, Y; CASEY, PJ; BROWN, MS; GOLDSTEIN, JL				SEABRA, MC; REISS, Y; CASEY, PJ; BROWN, MS; GOLDSTEIN, JL			PROTEIN FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE SHARE A COMMON ALPHA-SUBUNIT	CELL			English	Article							DENSITY LIPOPROTEIN RECEPTOR	Mammalian farnesyltransferase, which attaches a 15 carbon isoprenoid, farnesyl, to a cysteine in p21ras proteins, contains two subunits, alpha and beta. The beta-subunit is known to bind p21ras proteins. We show here that the alpha-subunit is shared with another prenyltransferase that attaches 20 carbon geranylgeranyl to Ras-related proteins. Farnesyltransferase and geranylgeranyltransferase have similar molecular weights on gel filtration, but are separated by ion exchange chromatography. Both enzymes are precipitated and immunoblotted by multiple antibodies directed against the alpha-subunit of farnesyltransferase. The two transferases have different specificities for the protein acceptor; farnesyltransferase prefers methionine or serine at the COOH-terminus and geranylgeranyltransferase prefers leucine. The current data indicate that both prenyltransferases are heterodimers that share a common alpha-subunit with different beta-subunits.	DUKE UNIV, MED CTR, CELL GROWTH REGULAT & ONCOGENESIS SECT, DURHAM, NC 27710 USA	Duke University	SEABRA, MC (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA.		Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; Casey, Patrick/0000-0002-7366-9309	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; REISS Y, 1990, Methods (Orlando), V1, P241, DOI 10.1016/S1046-2023(05)80323-8; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REISS Y, 1991, IN PRESS J BIOL CHEM; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	25	375	385	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					429	434		10.1016/0092-8674(91)90460-G	http://dx.doi.org/10.1016/0092-8674(91)90460-G			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018975				2022-12-28	WOS:A1991FK18200009
J	SULLIVAN, SJ; MAKI, T; BORLAND, KM; MAHONEY, MD; SOLOMON, BA; MULLER, TE; MONACO, AP; CHICK, WL				SULLIVAN, SJ; MAKI, T; BORLAND, KM; MAHONEY, MD; SOLOMON, BA; MULLER, TE; MONACO, AP; CHICK, WL			BIOHYBRID ARTIFICIAL PANCREAS - LONG-TERM IMPLANTATION STUDIES IN DIABETIC, PANCREATECTOMIZED DOGS	SCIENCE			English	Article							ISLET XENOGRAFT SURVIVAL; BIOARTIFICIAL PANCREAS; ENDOCRINE PANCREAS; CAPILLARY UNITS; TRANSPLANTATION; CULTURE; MOUSE; SERUM; CELLS; MICE	Diabetic complications such as neuropathy, retinopathy, and renal and cardiovascular disease continue to pose major health risks for diabetic patients. Consequently, much effort has focused on approaches that could replace conventional insulin therapy and provide more precise regulation of blood glucose levels. The biohybrid perfused artificial pancreas was designed to incorporate islet tissue and a selectively permeable membrane that isolates this tissue from the immune system of the recipient. Biohybrid pancreas devices containing canine islet allografts were implanted in ten pancreatectomized dogs requiring 18 to 32 units of injected insulin daily. These implants resulted in good control of fasting glucose levels in six of these animals without further exogenous insulin for periods of up to 5 months.	NEW ENGLAND DEACONESS HOSP, BROOKLINE, MA 02212 USA; HARVARD UNIV, SCH MED, DIV ORGAN TRANSPLANTAT, BROOKLINE, MA 02212 USA; WR GRACE & CO CONN, DIV RES, LEXINGTON, MA 02173 USA	Harvard University	SULLIVAN, SJ (corresponding author), BIOHYBRID TECHNOL INC, 910 TURNPIKE RD, SHREWSBURY, MA 01545 USA.							AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; BONNEVIENIELSEN V, 1983, ENDOCRINOLOGY, V112, P1049, DOI 10.1210/endo-112-3-1049; BORLAND KM, UNPUB; CHICK WL, 1977, SCIENCE, V197, P780, DOI 10.1126/science.407649; CHICK WL, 1975, SCIENCE, V187, P847, DOI 10.1126/science.187.4179.847; FAN MY, 1990, DIABETES, V39, P519, DOI 10.2337/diabetes.39.4.519; GOTOH M, 1988, TRANSPLANT P, V20, P997; HALL FF, 1970, AM J CLIN PATHOL, V53, P627; JONSSON S, 1974, EUR J IMMUNOL, V4, P29, DOI 10.1002/eji.1830040108; KAVAI M, 1989, TRANSPL P, V21, P2709; KRAEGEN EW, 1981, HORM METAB RES, V13, P365, DOI 10.1055/s-2007-1019271; KUPIECWEGLINSKI JW, 1988, TRANSPLANTATION, V46, P785, DOI 10.1097/00007890-198812000-00001; LIKE AA, 1978, LAB INVEST, V38, P470; MAKI T, IN PRESS; MAKI T, 1990, 16TH ANN M AM SOC TR; Michaels A.S., 1971, U.S. Patent, Patent No. [3,615,024, 3615024]; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; REACH G, 1984, DIABETES, V33, P752, DOI 10.2337/diabetes.33.8.752; REACH G, 1984, BIOMED BIOCHIM ACTA, V43, P569; RICORDI C, 1988, TRANSPLANTATION, V45, P994, DOI 10.1097/00007890-198805000-00035; SCHARP DW, 1989, INT HDB PANCREAS TRA, P455; SELAWRY HP, 1984, DIABETES, V33, P405, DOI 10.2337/diabetes.33.4.405; SOELDNER JS, 1971, DIABETES MELLITUS DI, V3, P107; SORENSEN JT, 1982, DIABETES CARE, V5, P148, DOI 10.2337/diacare.5.3.148; SULLIVAN FP, 1987, TRANSPLANTATION, V44, P465, DOI 10.1097/00007890-198710000-00001; SUN AM, 1977, DIABETES, V26, P1136, DOI 10.2337/diabetes.26.12.1136; SWOPE SL, 1984, P NATL ACAD SCI-BIOL, V81, P1822, DOI 10.1073/pnas.81.6.1822; TZE WJ, 1983, DIABETES, V32, P1185, DOI 10.2337/diabetes.32.12.1185; TZE WJ, 1980, DIABETOLOGIA, V19, P541; WARNOCK GL, 1988, DIABETES, V37, P467, DOI 10.2337/diabetes.37.4.467; 1989, DIABETES, V38; 1990, TRANSPLANT P, V22	32	181	210	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					718	721		10.1126/science.2024124	http://dx.doi.org/10.1126/science.2024124			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024124				2022-12-28	WOS:A1991FK18500053
J	LEE, TH; JUAREZ, G; COOK, EF; WEISBERG, MC; ROUAN, GW; BRAND, DA; GOLDMAN, L				LEE, TH; JUAREZ, G; COOK, EF; WEISBERG, MC; ROUAN, GW; BRAND, DA; GOLDMAN, L			RULING OUT ACUTE MYOCARDIAL-INFARCTION - A PROSPECTIVE MULTICENTER VALIDATION OF A 12-HOUR STRATEGY FOR PATIENTS AT LOW-RISK	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMERGENCY ROOM PATIENTS; ACUTE CHEST PAIN; CLINICAL CHARACTERISTICS; HOSPITALIZATION	Background. Although previous investigations have suggested that 24 hours is required to exclude acute myocardial infarction in patients who are admitted to a coronary care unit for the evaluation of acute chest pain, we hypothesized that a 12-hour period might be adequate for patients with a low probability of infarction at the time of admission. Methods. Using a Bayesian model, we developed a strategy to identify candidates for a shorter period of observation from an analysis of a derivation set of 976 patients with acute chest pain who were admitted to three teaching and four community hospitals. In the derivation set, patients whose clinical characteristics in the emergency room predicted a low (less-than-or-equal-to 7 percent) probability of myocardial infarction had only a 0.4 percent risk of infarction if they had neither abnormal levels of cardiac enzymes nor recurrent ischemic pain during the first 12 hours of hospitalization. In an independent testing set of 2684 patients from the seven hospitals, 957 admitted patients (36 percent) were classified as candidates for this 12-hour period of observation according to a previously published multivariate algorithm. Few of these patients were actually transferred from a monitored setting at 12 hours. Results. Of the 771 candidates for a 12-hour period of observation who did not have enzyme abnormalies or recurrent pain during the first 12 hours, 4 (0.5 percent) were subsequently found to have acute myocardial infarction, and only 3 (0.4 percent) died after primary cardiac arrests, all of which occurred three to five days after admission. Rates of other major cardiovascular complications were low in the patients who might have been transferred from the coronary care unit after 12 hours with this strategy. In patients with a higher initial risk of infarction, the standard strategy of 24-hour observation identified all but 11 of 739 acute myocardial infarctions (1 percent). Conclusions. Emergency room clinical data can be used to identify a large subgroup of patients for whom a 12-hour period of observation is normally sufficient to exclude acute myocardial infarction. Patient-specific evaluation and treatment can then proceed without the restrictions imposed by "rule-out" protocols for myocardial infarction.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; UNIV CINCINNATI,CINCINNATI,OH 45221	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Yale University; University System of Ohio; University of Cincinnati	LEE, TH (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CLIN EPIDEMIOL,75 FRANCIS ST,BOSTON,MA 02115, USA.				AHRQ HHS [HS 06452] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BEAMER AD, 1987, AM J CARDIOL, V60, P998, DOI 10.1016/0002-9149(87)90340-7; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; CUNNINGHAM MA, 1989, J GEN INTERN MED, V4, P392, DOI 10.1007/BF02599688; EAGLE KA, 1990, JAMA-J AM MED ASSOC, V264, P992, DOI 10.1001/jama.264.8.992; FIEBACH NH, 1990, AM J MED, V89, P15, DOI 10.1016/0002-9343(90)90091-Q; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; LEE TH, 1989, ANN INTERN MED, V110, P957, DOI 10.7326/0003-4819-110-12-957; LEE TH, 1988, J GEN INTERN MED, V3, P21, DOI 10.1007/BF02595752; LEE TH, 1988, ANN INTERN MED, V108, P887, DOI 10.7326/0003-4819-108-6-887; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEE TH, 1987, ARCH INTERN MED, V147, P115, DOI 10.1001/archinte.147.1.115; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; LEE TH, 1990, MED CARE, V28, P737, DOI 10.1097/00005650-199008000-00006; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; MULLEY AG, 1980, NEW ENGL J MED, V302, P493; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; ROUAN GW, 1989, AM J CARDIOL, V64, P1087, DOI 10.1016/0002-9149(89)90857-6; SCHROEDER JS, 1980, NEW ENGL J MED, V303, P1, DOI 10.1056/NEJM198007033030101; SLATER DK, 1987, AM J CARDIOL, V60, P766, DOI 10.1016/0002-9149(87)91020-4; SOLOMON CG, 1989, AM J CARDIOL, V63, P772, DOI 10.1016/0002-9149(89)90040-4; TIERNEY WM, 1985, CRIT CARE MED, V13, P526, DOI 10.1097/00003246-198507000-00002; WEINGARTEN S, 1990, ANN INTERN MED, V113, P283, DOI 10.7326/0003-4819-113-4-283; WEINGARTEN SR, 1989, AM J MED, V87, P494, DOI 10.1016/S0002-9343(89)80603-5; WHITE LD, 1990, J AM COLL CARDIOL, V16, P304, DOI 10.1016/0735-1097(90)90577-C	24	218	220	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1239	1246		10.1056/NEJM199105023241803	http://dx.doi.org/10.1056/NEJM199105023241803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	2014037				2022-12-28	WOS:A1991FJ82300003
J	WARING, DA; KENYON, C				WARING, DA; KENYON, C			REGULATION OF CELLULAR RESPONSIVENESS TO INDUCTIVE SIGNALS IN THE DEVELOPING C-ELEGANS NERVOUS-SYSTEM	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GENE; LINEAGES; HOMEOBOX	IN Caenorhabditis elegans, cell-cell communication is required to form a simple pattern of sensory ray neurons and cuticular structures (alae). The C. elegans pal-1 gene initiates one developmental pathway (ray lineages) simply by blocking a cell-cell interaction that induces an alternative pathway 1. Here we show by mosaic analysis that pal-1+ acts by preventing specific cells from responding to inductive signals. The results indicate that although cell signals play a critical role in generating this pattern, they do not provide spatial information. Instead, signals are sent to many, if not all, of the precursor cells, and the ability to respond is spatially restricted. This patterning strategy thus differs from many well known models for pattern formation in which localized inductive signals influence a subset of cells within a field. We find that pal-1 encodes a homeodomain protein and so is likely to regulate transcription. The pal-1+ protein could block the response to cell signals either by repressing genes involved in signal transduction or by acting directly on downstream genes in a way that neutralizes the effects of the intercellular signals. Genetic experiments indicate that one candidate for such a downstream gene is the Antennapedia-like homeotic selector gene mab-5.			WARING, DA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HORVITZ HR, 1983, COLD SPRING HARB SYM, V48, P453, DOI 10.1101/SQB.1983.048.01.050; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; ROSENBLUTH RE, 1985, GENETICS, V109, P493; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q	14	51	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					712	715		10.1038/350712a0	http://dx.doi.org/10.1038/350712a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023634				2022-12-28	WOS:A1991FJ13000062
J	MASON, JO				MASON, JO			UNITED-STATES-PUBLIC-HEALTH-SERVICES STRATEGIC PLAN TO ELIMINATE CHILDHOOD LEAD-POISONING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,WASHINGTON,DC	United States Public Health Service	MASON, JO (corresponding author), US DEPT HHS,WASHINGTON,DC 20201, USA.							1988, NATURE EXTENT CHILDH; 1990, NEW ENGL J MED, V322, P83	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2049	2049						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG907	2013918				2022-12-28	WOS:A1991FG90700004
J	SCALLON, BJ; FUNG, WJC; TSANG, TC; LI, S; KADOFONG, H; HUANG, KS; KOCHAN, JP				SCALLON, BJ; FUNG, WJC; TSANG, TC; LI, S; KADOFONG, H; HUANG, KS; KOCHAN, JP			PRIMARY STRUCTURE AND FUNCTIONAL-ACTIVITY OF A PHOSPHATIDYLINOSITOL-GLYCAN SPECIFIC PHOSPHOLIPASE-D	SCIENCE			English	Article							AMINO-ACID SEQUENCE; CELL-SURFACE PROTEINS; GLYCOSYL-PHOSPHATIDYLINOSITOL; ALPHA-SUBUNIT; ALKALINE-PHOSPHATASE; FIBRONECTIN RECEPTOR; ANCHOR; GLYCOPROTEIN; HOMOLOGY; VITRONECTIN	A phosphatidylinositol-glycan-specific phospholipase D (PI-G PLD) that specifically hydrolyzes the inositol phosphate linkage in proteins anchored by phosphatidylinositol-glycans (PI-Gs) has recently been purified from human and bovine sera. The primary structure of bovine PI-G PLD has now been determined and the functional activity of the enzyme has been studied. Expression of PI-G PLD complementary DNA in COS cells produced a protein that specifically hydrolyzed the inositol phosphate linkage of the PI-G anchor. Cotransfection of PI-G PLD with a PI-G-anchored protein resulted in the secretion of the PI-G-anchored protein. The results suggest that the expression of PI-G PLD may influence the expression and location of PI-G-anchored proteins.	HOFFMANN LA ROCHE INC,DEPT MOLEC CELLULAR BIOL & BIOCHEM,NUTLEY,NJ 07110	Roche Holding								ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BERGER J, 1988, J BIOL CHEM, V263, P10016; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DOERING TL, 1990, J BIOL CHEM, V265, P611; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FREMISCO JR, 1980, J BIOL CHEM, V255, P4240; FUNG WJ, UNPUB; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HODGSON ALM, 1990, J BACTERIOL, V172, P1256, DOI 10.1128/jb.172.3.1256-1261.1990; HOWARD AD, 1987, P NATL ACAD SCI USA, V84, P6055, DOI 10.1073/pnas.84.17.6055; HUANG KS, 1990, J BIOL CHEM, V265, P17738; HUANG KS, IN PRESS METHODS ENZ; JEMMERSON R, 1987, BIOCHEMISTRY-US, V26, P5703, DOI 10.1021/bi00392a019; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; Li S., UNPUB; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; PONCZ M, 1987, J BIOL CHEM, V262, P8476; SCALLON BJ, UNPUB; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; Szebenyi DME, 1981, NATURE, V294, P327, DOI 10.1038/294327a0; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TOUTANT JP, 1989, EUR J BIOCHEM, V180, P503, DOI 10.1111/j.1432-1033.1989.tb14674.x	39	118	126	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					446	448		10.1126/science.2017684	http://dx.doi.org/10.1126/science.2017684			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017684				2022-12-28	WOS:A1991FH10300045
J	LARSON, EB				LARSON, EB			GERIATRIC-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; BONE-DENSITY; HIP FRACTURE; THERAPY; WOMEN		UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	LARSON, EB (corresponding author), UNIV WASHINGTON, MED CTR, SEATTLE, WA 98195 USA.							CUMMINGS SR, 1990, ANN INTERN MED, V113, P565, DOI 10.7326/0003-4819-113-8-565; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003-4819-113-9-649; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; MURPHY DJ, 1990, J AM GERIATR SOC, V38, P1251, DOI 10.1111/j.1532-5415.1990.tb01507.x; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; REIFLER BV, 1989, AM J PSYCHIAT, V146, P45; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; THOMPSON TL, 1990, NEW ENGL J MED, V323, P445, DOI 10.1056/NEJM199008163230704; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	17	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3125	3126		10.1001/jama.265.23.3125	http://dx.doi.org/10.1001/jama.265.23.3125			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041122				2022-12-28	WOS:A1991FQ77000020
J	PELLEGRINO, ED				PELLEGRINO, ED			ETHICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EUTHANASIA; DOCTORS; KILL				PELLEGRINO, ED (corresponding author), GEORGETOWN UNIV,CTR ADV STUDY ETH,WASHINGTON,DC, USA.							[Anonymous], 1989, REPORT COUNCIL ETHIC; Callahan Daniel, 1988, Commonweal, V115, P397; Carrick P, 1985, MED ETHICS ANTIQUITY; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COYLE N, 1990, AM J NURS        DEC, P75; DEWACHTER MAH, 1989, JAMA-J AM MED ASSOC, V26, P3316; DOERFLINGER R, 1989, HASTINGS CENT REP, P16; ENGELHARDT HT, 1989, HASTINGS CENT REP S, P13; Fenigsen R, 1989, Hastings Cent Rep, V19, P22, DOI 10.2307/3561967; FENIGSEN R, 1990, ISSUES LAW MED, V6, P229; FLETCHER F, 1973, AM J NURS, V73, P670; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; HARRIS J, 1981, J MED ETHICS, V7, P117, DOI 10.1136/jme.7.3.117; HENK AMJ, 1989, HOSPITAL ETHICS COMM, V1, P41; KASS LR, 1989, PUBLIC INTEREST, P25; LACHS J, 1990, J CLIN ETHICS    SUM, P113; NOWELLSMITH P, 1989, J MED ETHICS, V15, P124, DOI 10.1136/jme.15.3.124; PARACHINI A, 1989, HASTINGS CENT RE JAN, P10; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; THOMASMA DC, 1990, EUTHANASIA ETHICAL S, P2; TRICHE CW, 1975, EUTHANASIA CONTROVER; VANDENBERG JH, 1978, MED POWER MED ETHICS; VAUX KL, 1988, JAMA-J AM MED ASSOC, V259, P2140, DOI 10.1001/jama.259.14.2140; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WOLF SM, 1989, HASTINGS CENT REP, P13; 1988, JAMA-J AM MED ASSOC, V258, P272; 1990, NEW ENGL J MED, V323, P1770; 1988, JAMA-J AM MED ASSOC, V259, P2094; 1988, JAMA-J AM MED ASSOC, V260, P787; 1988, EUTHANASIA REPORT WO, P69	31	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3118	3119		10.1001/jama.265.23.3118	http://dx.doi.org/10.1001/jama.265.23.3118			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ770	2041119				2022-12-28	WOS:A1991FQ77000016
J	ENOCH, T; NURSE, P				ENOCH, T; NURSE, P			COUPLING M-PHASE AND S-PHASE - CONTROLS MAINTAINING THE DEPENDENCE OF MITOSIS ON CHROMOSOME-REPLICATION	CELL			English	Review							CELL-CYCLE; DNA-REPLICATION; DROSOPHILA; COMPLEMENTATION; COMPLETION; MUTATION; HOMOLOG; GENES; G2		UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	University of Oxford	ENOCH, T (corresponding author), UNIV OXFORD,MICROBIOL UNIT,IMPERIAL CANC RES FUND,CELL CYCLE GRP,OXFORD OX1 3QU,ENGLAND.							DARI R, 1990, TRENDS BIOCHEM SCI, V15, P191, DOI 10.1016/0968-0004(90)90160-D; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; JOHNSON RT, 1970, NATURE, V225, P159; KUMIGAI A, 1991, CELL, V64, P903; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NISHITANI H, 1991, IN PRESS EMBO J; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	21	164	165	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					921	923		10.1016/0092-8674(91)90542-7	http://dx.doi.org/10.1016/0092-8674(91)90542-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044152				2022-12-28	WOS:A1991FR04700003
J	SMITH, NG				SMITH, NG			PACE, PACE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2948	2948						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033759				2022-12-28	WOS:A1991FP63500014
J	MILNER, J; MEDCALF, EA				MILNER, J; MEDCALF, EA			COTRANSLATION OF ACTIVATED MUTANT P53 WITH WILD-TYPE DRIVES THE WILD-TYPE P53 PROTEIN INTO THE MUTANT CONFORMATION	CELL			English	Article							TUMOR SUPPRESSOR PROTEIN; HEAT-SHOCK PROTEINS; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; LUNG-CANCER; IMMUNOLOGICAL VARIANTS; TRANSFORMED-CELLS; ONCOGENE; GENE; MUTATIONS	Activating mutations of p53 promote tumor progression. The mutant protein adopts a characteristic conformation, which lacks the growth suppressor function of wild-type p53. We show that mutant p53 can drive cotranslated wild-type p53 into the mutant conformation: a similar effect in vivo would block wild-type suppressor function with dominant negative effect. The cotranslational effect of mutant p53 on wild-type conformation depends upon interaction between nascent polypeptides and oligomerization of the full-length proteins. We also show that oligomers of p53 proteins can be induced to change conformation in a cooperative manner. Cell growth stimulation induces a similar conformational change in p53, and our present results indicate that this may involve allosteric regulation.			MILNER, J (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; CHIBA I, 1990, ONCOGENE, V5, P1603; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1591; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1222; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	38	620	638	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					765	774		10.1016/0092-8674(91)90384-B	http://dx.doi.org/10.1016/0092-8674(91)90384-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040013				2022-12-28	WOS:A1991FP51600007
J	WALKER, JL; GINALSKAMALINOWSKA, M; ROMER, TE; PUCILOWSKA, JB; UNDERWOOD, LE				WALKER, JL; GINALSKAMALINOWSKA, M; ROMER, TE; PUCILOWSKA, JB; UNDERWOOD, LE			EFFECTS OF THE INFUSION OF INSULIN-LIKE GROWTH FACTOR-I IN A CHILD WITH GROWTH-HORMONE INSENSITIVITY SYNDROME (LARON DWARFISM)	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							BINDING-PROTEIN; RECEPTOR GENE; SOMATOMEDIN-C; SERUM; RAT; METABOLISM; SECRETION; GLUCOSE; EXPRESSION; FILTRATION		CHILD HLTH CTR,DIV ENDOCRINOL,WARSAW,POLAND	Children's Memorial Health Institute	WALKER, JL (corresponding author), UNIV N CAROLINA,DEPT PEDIAT,DIV PEDIAT ENDOCRINOL,CB 7220,509 BURNETT WOMACK,CHAPEL HILL,NC 27599, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD008299] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00046] Funding Source: Medline; NICHD NIH HHS [HD-08299] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALEXANDRIDES T, 1989, ENDOCRINOLOGY, V124, P1064, DOI 10.1210/endo-124-2-1064; AMSELEM S, 1989, NEW ENGL J MED, V321, P989, DOI 10.1056/NEJM198910123211501; BERELOWITZ M, 1981, SCIENCE, V212, P1279, DOI 10.1126/science.6262917; BIGLIERI EG, 1961, J CLIN ENDOCR METAB, V21, P361, DOI 10.1210/jcem-21-4-361; BOLINDER J, 1987, J CLIN ENDOCR METAB, V65, P732, DOI 10.1210/jcem-65-4-732; CANALIS E, 1988, BONE, V9, P243, DOI 10.1016/8756-3282(88)90037-3; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; CAVERZASIO J, 1990, ENDOCRINOLOGY, V127, P453, DOI 10.1210/endo-127-1-453; COPELAND KC, 1980, J CLIN ENDOCR METAB, V50, P690, DOI 10.1210/jcem-50-4-690; DAHMS WT, 1989, METABOLISM, V38, P197, DOI 10.1016/0026-0495(89)90075-9; DAUGHADAY WH, 1987, P NATL ACAD SCI USA, V84, P4636, DOI 10.1073/pnas.84.13.4636; DAUGHADAY WH, 1985, WILLIAMS TXB ENDOCRI, P577; DAVENPORT ML, 1988, J CLIN ENDOCR METAB, V67, P1231, DOI 10.1210/jcem-67-6-1231; DERCOLE AJ, 1976, INT C SERIES, V381, P190; ELDERS MJ, 1973, J PEDIATR-US, V83, P253, DOI 10.1016/S0022-3476(73)80485-8; ESHET R, 1984, ISRAEL J MED SCI, V20, P8; GEFFNER ME, 1987, J CLIN ENDOCR METAB, V64, P1042, DOI 10.1210/jcem-64-5-1042; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P101, DOI 10.1530/acta.0.1210101; GULER HP, 1989, P NATL ACAD SCI USA, V86, P2868, DOI 10.1073/pnas.86.8.2868; HARBISON MD, 1990, J CLIN ENDOCR METAB, V70, P1035, DOI 10.1210/jcem-70-4-1035; HIRSCHBERG RR, 1988, AM J NEPHROL, V8, P249, DOI 10.1159/000167592; HIZUKA N, 1988, BASIC CLIN ASPECTS G, P223; HO KY, 1990, METABOLISM, V39, P133, DOI 10.1016/0026-0495(90)90065-K; JACOB R, 1989, J CLIN INVEST, V83, P1717, DOI 10.1172/JCI114072; JOHANSEN JS, 1990, J CLIN ENDOCR METAB, V70, P916, DOI 10.1210/jcem-70-4-916; LARON Z, 1988, LANCET, V2, P1170; LARON Z, 1971, J CLIN ENDOCR METAB, V33, P332, DOI 10.1210/jcem-33-2-332; LARON Z, 1990, 72ND ANN M END SOC A; LEAHY JL, 1990, ENDOCRINOLOGY, V126, P1593, DOI 10.1210/endo-126-3-1593; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MARCUS R, 1990, J CLIN ENDOCR METAB, V70, P519, DOI 10.1210/jcem-70-2-519; MOXLEY RT, 1990, AM J PHYSIOL, V259, pE561, DOI 10.1152/ajpendo.1990.259.4.E561; NAMBA H, 1989, ENDOCRINOLOGY, V124, P1794, DOI 10.1210/endo-124-4-1794; SLOVIK DM, 1984, J CLIN ENDOCR METAB, V59, P228, DOI 10.1210/jcem-59-2-228; SPANOS E, 1978, NATURE, V273, P246, DOI 10.1038/273246a0; TAKAMOTO S, 1985, J CLIN ENDOCR METAB, V61, P7, DOI 10.1210/jcem-61-1-7; TAR A, 1990, J CLIN ENDOCR METAB, V71, P1202, DOI 10.1210/jcem-71-5-1202; WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140-6736(75)92736-1	41	129	133	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1483	1488		10.1056/NEJM199105233242107	http://dx.doi.org/10.1056/NEJM199105233242107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM460	2023608				2022-12-28	WOS:A1991FM46000007
J	FEIN, R				FEIN, R			THE HEALTH SECURITY PARTNERSHIP - A FEDERAL-STATE UNIVERSAL INSURANCE AND COST-CONTAINMENT PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The Health Security Partnership attempts to assure (1) that all Americans have insurance coverage for a set of comprehensive health care benefits, (2) that cost-containment issues are addressed in a manner that does not impinge negatively on the quality of care, and (3) that provider freedom to deliver appropriate clinical care is strengthened. It assigns important responsibilities to the federal government (eg, specification of benefits, review of proposed state health care budgets), while permitting states to select, develop, and administer specific program design features they deem appropriate (eg, states could build on and expand the existing health system infrastructure, including private insurance, and/or extend the role of tax-supported programs). It is estimated that in its first year the program would add about 5% to America's health expenditures, but within a few years, cost-containment efforts and administrative efficiencies would reduce overall expenditures below what they otherwise would be.			FEIN, R (corresponding author), HARVARD UNIV,SCH MED,DEPT SOCIAL MED,643 HUNTINGTON AVE,BOSTON,MA 02115, USA.							UROFSKY MI, 1981, LD BRANDEIS PROGR TR	1	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2555	2558						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK903	2020075				2022-12-28	WOS:A1991FK90300032
J	FINNIE, IA; TOBIN, MV; MORRIS, AI; GILMORE, IT				FINNIE, IA; TOBIN, MV; MORRIS, AI; GILMORE, IT			LATE BLEEDING AFTER ENDOSCOPIC SPHINCTEROTOMY FOR BILE-DUCT CALCULI	BRITISH MEDICAL JOURNAL			English	Article							CONSECUTIVE PATIENTS		ROYAL LIVERPOOL HOSP,GASTROENTEROL UNIT,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital								GOODALL RJR, 1985, ANN ROY COLL SURG, V67, P87; HILL J, 1990, GUT, V31, pA608; LEESE T, 1985, BRIT J SURG, V72, P215, DOI 10.1002/bjs.1800720325; VAIRA D, 1989, LANCET, V2, P431	4	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1144	1144		10.1136/bmj.302.6785.1144	http://dx.doi.org/10.1136/bmj.302.6785.1144			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	2043789	Green Published, Bronze			2022-12-28	WOS:A1991FL43900026
J	BITTLES, AH; MASON, WM; GREENE, J; RAO, NA				BITTLES, AH; MASON, WM; GREENE, J; RAO, NA			REPRODUCTIVE-BEHAVIOR AND HEALTH IN CONSANGUINEOUS MARRIAGES	SCIENCE			English	Article							SOUTH-INDIA; PARENTAL CONSANGUINITY; PREREPRODUCTIVE MORTALITY; GENETIC-DISEASE; TAMIL-NADU; CONGENITAL-ABNORMALITIES; PARNETAL CONSANGUINITY; POSTNATAL MORTALITY; FETAL GROWTH; JAPAN	In many regions of Asia and Africa, consanguineous marriages currently account for approximately 20 to 50% of all unions, and preliminary observations indicate that migrants from these areas continue to contract marriages with close relatives when resident in North America and Western Europe. Consanguinity is associated with increased gross fertility, due at least in part to younger maternal age at first livebirth. Morbidity and mortality also may be elevated, resulting in comparable numbers of surviving offspring in consanguineous and nonconsanguineous families. With advances in medicine and public health, genetic disorders will account for an increased proportion of disease worldwide. Predictably, this burden will fall more heavily on countries and communities in which consanguinity is strongly favored, as the result of the expression of deleterious recessive genes. However, studies conducted in such populations indicate that the adverse effects associated with inbreeding are experienced by a minority of families.	UNIV CALIF LOS ANGELES,SOCIOL,LOS ANGELES,CA 90024; UNIV MICHIGAN,CTR POPULAT STUDIES,ANN ARBOR,MI 48104; INDIAN INST SCI,BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA	University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; Indian Institute of Science (IISC) - Bangalore	BITTLES, AH (corresponding author), UNIV LONDON KINGS COLL,LONDON WC2R 2LS,ENGLAND.			Bittles, Alan/0000-0002-8176-2730				AFZAL M, 1988, BEHAV GENET, V18, P583, DOI 10.1007/BF01082310; AGRAWAL N, 1984, BEHAV GENET, V14, P579, DOI 10.1007/BF01068128; ALAWADI SA, 1986, CLIN GENET, V29, P384; Ansari SA, 1978, INDIAN J MED RES, V68, P295; B K, 1979, IND J HERED, V11, P77; Barth F, 1954, SOUTHWEST J ANTHROP, V10, P164, DOI 10.1086/soutjanth.10.2.3628823; BASHI J, 1977, NATURE, V266, P440, DOI 10.1038/266440a0; BASSARAN N, 1988, CLIN GENET, V34, P339; Basu S K, 1975, J Popul Res, V2, P57; BEER AE, 1981, AM J OBSTET GYNECOL, V141, P987; BEMISS SM, 1858, T AM MED ASS, V11, P319; BENALLEGUE A, 1984, ARCH FR PEDIATR, V41, P435; Bittles A. H, 1988, HUMAN MATING PATTERN, P153; BITTLES AH, 1987, MAN, V22, P736, DOI 10.2307/2803361; BITTLES AH, 1988, ANN HUM BIOL, V15, P455, DOI 10.1080/03014468800000062; BITTLES AH, 1990, FERTILITY RESOURCES, P62; BOOK JA, 1957, ANN HUM GENET, V21, P191; BRATT CS, 1984, FAM LAW QUART, V18, P257; BUMPASS LL, 1978, DEMOGRAPHY, V15, P75, DOI 10.2307/2060491; BUMPASS LL, 1977, SOC BIOL, V24, P31, DOI 10.1080/19485565.1977.9988259; BUNDEY S, 1990, J EPIDEMIOL COMMUN H, V44, P130, DOI 10.1136/jech.44.2.130; Bundey S, 1991, Paediatr Perinat Epidemiol, V5, P101, DOI 10.1111/j.1365-3016.1991.tb00689.x; CALDWELL JC, 1988, CAUSES DEMOGRAPHIC C, P239; Carr D H, 1971, Adv Hum Genet, V2, P201; CHAKRABORTY R, 1977, HUM GENET, V36, P47, DOI 10.1007/BF00390435; CHALEBY K, 1987, BRIT J PSYCHIAT, V150, P547, DOI 10.1192/bjp.150.4.547; CHITTY LS, 1989, ARCH DIS CHILD, V64, P1036, DOI 10.1136/adc.64.7.1036; COLEMAN DA, 1980, HUM HERED, V30, P278, DOI 10.1159/000153144; COOK ROBERT, 1966, J TROP PEDIAT AFR CHILD HEALTH, V11, P95; DARR A, 1988, J MED GENET, V25, P186, DOI 10.1136/jmg.25.3.186; DARWIN F, 1887, LIFE LETT C DARWIN, V2, P309; Darwin George, 1875, J STAT SOC, V38, P344; DARWIN GH, 1875, J STAT ASS, V37, P153; DECOSTA C, 1986, MED J AUSTRALIA, V144, P721; DEVI ARR, 1987, J MED GENET, V24, P362, DOI 10.1136/jmg.24.6.362; DIAMOND JM, 1987, NATURE, V329, P487, DOI 10.1038/329487a0; DRONAMRAJU KR, 1963, ACTA GENET STAT MED, V13, P21; DRONAMRAJU KR, 1963, J GENET, V58, P387, DOI 10.1007/BF02986307; ELALFI S, 1969, J KWT MED ASS, V3, P227; EMERY AEH, 1990, PRINCIPLES PRACTICE, P3; FARAG TI, 1988, CLIN GENET, V33, P78; Fei Hsiao-eung, 1939, PEASANT LIFE CHINA, P50; FREIREMAIA N, 1968, EUGEN QUART, V15, P22, DOI 10.1080/19485565.1968.9987749; FREIREMAIA N, 1984, AM J MED GENET, V18, P391, DOI 10.1002/ajmg.1320180306; FREIREMAIA N, 1983, AM J MED GENET, V16, P331, DOI 10.1002/ajmg.1320160306; FREUNDLICH E, 1984, ISRAEL J MED SCI, V20, P1035; GEDDES WR, 1963, PEASANT LIFE COMMUNI, P28; GINTER EK, 1987, HUM GENET, P547; GOLDSCHMIDT E, 1960, ANN HUM GENET, V24, P191, DOI 10.1111/j.1469-1809.1960.tb01732.x; GORDON RR, 1988, BMJ-BRIT MED J, V297, P774, DOI 10.1136/bmj.297.6651.774; GOSWAMI HK, 1970, ACTA GENET MED GEMEL, V19, P486, DOI 10.1017/S112096230001489X; HAFEZ M, 1983, J MED GENET, V20, P58, DOI 10.1136/jmg.20.1.58; HALL JG, 1978, AM J MED GENET, V1, P417, DOI 10.1002/ajmg.1320010405; HAMAMY HA, 1989, HUM HERED, V39, P271, DOI 10.1159/000153871; HENDRICKS CH, 1955, OBSTET GYNECOL, V6, P592, DOI 10.1097/00006250-195512000-00003; HONEYMAN MM, 1987, ARCH DIS CHILD, V62, P231, DOI 10.1136/adc.62.3.231; IMAIZUMI Y, 1975, JPN J HUM GENET, V20, P91; IMAIZUMI Y, 1986, CLIN GENET, V30, P230; KABARITY A, 1981, HUM GENET, V57, P444, DOI 10.1007/BF00281704; KHLAT M, 1986, AM J MED GENET, V25, P299, DOI 10.1002/ajmg.1320250215; KHLAT M, 1988, AM J HUM GENET, V43, P188; KHLAT M, 1989, AM J PHYS ANTHROPOL, V80, P481, DOI 10.1002/ajpa.1330800407; Khlat M, 1984, J BIOSOC SCI, V16, P369; KHOURY MJ, 1987, AM J EPIDEMIOL, V125, P251, DOI 10.1093/oxfordjournals.aje.a114524; Krishan G, 1986, AM J PHYS ANTHROPOL, V70, P60; KULKARNI ML, 1990, J MED GENET, V27, P348, DOI 10.1136/jmg.27.6.348; KUMAR S, 1967, ANN HUM GENET, V31, P141, DOI 10.1111/j.1469-1809.1967.tb00545.x; LEBEL RR, 1983, AM J MED GENET, V15, P543, DOI 10.1002/ajmg.1320150404; Lesthaeghe Ron., 1989, REPROD SOCIAL ORG SU, P238; MAGNUS P, 1985, CLIN GENET, V28, P335; MARCALLO FA, 1964, ANN HUM GENET, V27, P203, DOI 10.1111/j.1469-1809.1963.tb00787.x; McKusick Victor., 1978, MED GENETIC STUDIES; MORTON NE, 1956, P NATL ACAD SCI USA, V42, P855, DOI 10.1073/pnas.42.11.855; NADERI S, 1979, OBSTET GYNECOL, V53, P195; NEEL JV, 1962, P NATL ACAD SCI USA, V48, P573, DOI 10.1073/pnas.48.4.573; NEEL JV, 1962, AM J HUM GENET, V48, P573; OBER CL, 1983, AM J HUM GENET, V35, P994; OBRIEN E, 1988, AM J PHYS ANTHROPOL, V75, P477, DOI 10.1002/ajpa.1330750405; OBRIEN E, 1988, AM J PHYS ANTHROPOL, V77, P335, DOI 10.1002/ajpa.1330770306; OKSENBERG JR, 1984, FERTIL STERIL, V42, P389; PARISH WL, 1978, VILLAGE FAMILY CONT, P170; RAO NA, 1988, CLIN GENET, V34, P60; RAO PSS, 1977, SOC BIOL, V24, P281, DOI 10.1080/19485565.1977.9988298; RAO PSS, 1979, J MED GENET, V16, P24, DOI 10.1136/jmg.16.1.24; RAO PSS, 1977, ANN HUM GENET, V41, P87, DOI 10.1111/j.1469-1809.1977.tb01964.x; RAO PSSS, 1979, ANN HUM GENET, V42, P401, DOI 10.1111/j.1469-1809.1979.tb00672.x; REDDY PG, 1988, ANN HUM BIOL, V15, P263, DOI 10.1080/03014468800009731; REID RM, 1976, HUM BIOL, V48, P139; SAEDIWONG S, 1989, J ASIAN AFR STUD, V24, P247, DOI DOI 10.1177/002190968902400308; SAHA N, 1988, J BIOSOC SCI, V20, P333, DOI 10.1017/S0021932000006660; SANGHVI LD, 1966, EUGEN QUART, V13, P291, DOI 10.1080/19485565.1966.9987682; Sanghvi LD, 1956, ACTA GENET STAT MED, V6, P41; SAUGSTAD LF, 1977, ANN HUM GENET, V40, P481, DOI 10.1111/j.1469-1809.1977.tb01865.x; SCHORK MA, 1964, AM J HUM GENET, V16, P292; SCHULL WJ, 1970, AM J HUM GENET, V22, P239; SCHULL WJ, 1970, HUMANGENETIK, V9, P294, DOI 10.1007/BF00286995; SCHULL WJ, 1962, HUM BIOL, V34, P271; SCHULL WJ, 1972, AM J HUM GENET, V24, P425; SCHULL WJ, 1958, AM J HUM GENET, V10, P294; Schull WJ, 1965, EFFECTS INBREEDING J; SCOTTEMUAKPOR AB, 1974, AM J HUM GENET, V26, P674; SHAMI S A, 1982, Biologia (Lahore), V28, P1; SHAMI SA, 1989, J MED GENET, V26, P267, DOI 10.1136/jmg.26.4.267; SHAMI SA, 1990, ANN HUM BIOL, V17, P97, DOI 10.1080/03014469000000842; TANAKA K, 1964, P JPN ACAD, V40, P852, DOI 10.2183/pjab1945.40.852; Tanner R E, 1958, Eugen Rev, V49, P197; THOMAS ML, 1985, AM J OBSTET GYNECOL, V151, P1053, DOI 10.1016/0002-9378(85)90379-5; Tuncbilek E, 1989, Nufusbil Derg, V11, P35; WHYTE MK, 1984, URBAN LIFE CONT CHIN, P133; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; YADAV GC, 1988, J INHERIT METAB DIS, V11, P277, DOI 10.1007/BF01800370; 1989, STATE WORLDS CHILDRE, P94	112	236	237	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					789	794		10.1126/science.2028254	http://dx.doi.org/10.1126/science.2028254			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FL123	2028254				2022-12-28	WOS:A1991FL12300035
J	BRIDGES, ND; PERRY, SB; KEANE, JF; GOLDSTEIN, SAN; MANDELL, V; MAYER, JE; JONAS, RA; CASTENEDA, AR; LOCK, JE				BRIDGES, ND; PERRY, SB; KEANE, JF; GOLDSTEIN, SAN; MANDELL, V; MAYER, JE; JONAS, RA; CASTENEDA, AR; LOCK, JE			PREOPERATIVE TRANSCATHETER CLOSURE OF CONGENITAL MUSCULAR VENTRICULAR SEPTAL-DEFECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-DISEASE; MULTIPLE	Background. Surgical repair of muscular ventricular septal defects, particularly those associated with complex heart lesions, carries a higher risk of reoperation and death than the repair of membranous defects. Closing a muscular defect through an incision in the systemic ventricle may cause late ventricular dysfunction. In a collaborative approach to this problem, we undertook preoperative transcatheter closure of muscular ventricular septal defects remote from the atrioventricular and semilunar valves, followed by the surgical repair of associated conditions. Methods. In 12 patients selected jointly by a cardiologist and a cardiac surgeon, we attempted preoperative transcatheter umbrella closure of 21 defects. Half the patients had associated complex heart lesions; the others had had pulmonary-artery banding to reduce the amount of left-to-right shunting. Half had severe ventricular septal deficiency. Results. All 21 defects were successfully closed without major complications. Subsequent cardiac surgery for associated conditions in 11 of the 12 patients resulted in a mean pulmonary-to-systemic flow ratio of 1.1, indicating minimal residual left-to-right shunting; 1 patient awaited surgical repair. No deaths, reoperations, or late complications have occurred after a follow-up of 7 to 20 months. Conclusions. A collaborative approach using transcatheter closure followed by the surgical repair of associated cardiac lesions may decrease rates of operative mortality, reoperation, and left ventricular dysfunction in patients with muscular ventricular septal defects.	CHILDRENS HOSP MED CTR,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT RADIOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT CARDIOVASC SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			miaoyue, chen/A-6575-2012; Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				Breckenridge I M, 1972, Ann Thorac Surg, V13, P128; BRIDGES ND, 1990, CIRCULATION, V82, P1681, DOI 10.1161/01.CIR.82.5.1681; Elliott L P, 1977, Circulation, V56, P1048; FELLOWS KE, 1977, CIRCULATION, V56, P485, DOI 10.1161/01.CIR.56.3.485; FOX KM, 1978, BRIT HEART J, V40, P141; FRIEDMAN WF, 1965, CIRCULATION, V32, P35, DOI 10.1161/01.CIR.32.1.35; GRIFFITHS SP, 1981, AM J CARDIOL, V48, P877, DOI 10.1016/0002-9149(81)90353-2; HANNA B, 1991, Journal of the American College of Cardiology, V17, p110A; KIRKLIN JK, 1980, J THORAC CARDIOVASC, V80, P458; KIRKLIN JW, 1986, CARDIAC SURG MORPHOL, P637; LOCK JE, 1988, CIRCULATION, V78, P361, DOI 10.1161/01.CIR.78.2.361; LOCK JE, 1989, CIRCULATION, V79, P1091, DOI 10.1161/01.CIR.79.5.1091; OLAUGHLIN MP, 1989, CATHETER CARDIO DIAG, V17, P175, DOI 10.1002/ccd.1810170311; RIZZOLI G, 1980, J THORAC CARDIOV SUR, V80, P494; RIZZOLI G, 1983, THORAC CARDIOV SURG, V31, P382, DOI 10.1055/s-2007-1022024; ROME JJ, 1990, CIRCULATION, V82, P751, DOI 10.1161/01.CIR.82.3.751; ROME JJ, 1988, CIRCULATION S2, V78, P291; SINGH AK, 1977, ANN SURG, V186, P577, DOI 10.1097/00000658-197711000-00006; TAYLOR JFN, 1971, BRIT HEART J, V33, P285; VANPRAAGH R, 1977, CIRCULATION, V56, P139, DOI 10.1161/01.CIR.56.2.139; VANPRAAGH R, 1978, HEART DISEASE INFANC, P68; WALDHAUSEN JA, 1964, SURGERY, V56, P868; ZAVANELLA C, 1977, ANN THORAC SURG, V24, P537, DOI 10.1016/S0003-4975(10)63453-4	23	116	124	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1312	1317		10.1056/NEJM199105093241903	http://dx.doi.org/10.1056/NEJM199105093241903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017227	Green Published			2022-12-28	WOS:A1991FK18600003
J	GOLDSTEIN, JH				GOLDSTEIN, JH			OF MUGS AND MARKETING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DRUG ADVERTISEMENTS; DOCTORS				GOLDSTEIN, JH (corresponding author), RANDLEMAN FAMILY HLTH CTR,702 S MAIN ST,RANDLEMAN,NC 27317, USA.							BRICKER EM, 1989, NEW ENGL J MED, V320, P1690, DOI 10.1056/NEJM198906223202511; CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; GOLDFINGER SE, 1987, NEW ENGL J MED, V316, P1408, DOI 10.1056/NEJM198705283162211; GOLDMAN R, 1986, SOC SCI MED, V22, P1047, DOI 10.1016/0277-9536(86)90205-4; Goldstein J H, 1991, J Med Humanit, V12, P73, DOI 10.1007/BF01142871; JENIKE MA, 1990, NEW ENGL J MED, V322, P557; KING E, 1980, PSYCHIATRY, V43, P129, DOI 10.1080/00332747.1980.11024058; KRUPKA LR, 1985, SOC SCI MED, V20, P191, DOI 10.1016/0277-9536(85)90231-X; KUNIN CM, 1977, NEW ENGL J MED, V297, P113; LUNDBERG GD, 1990, JAMA-J AM MED ASSOC, V263, P86, DOI 10.1001/jama.263.1.86; NELSON JC, 1990, JAMA-J AM MED ASSOC, V264, P742; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; RENNIE D, 1989, JAMA-J AM MED ASSOC, V261, P2543, DOI 10.1001/jama.261.17.2543; SCHIFF G, 1990, JAMA-J AM MED ASSOC, V263, P658, DOI 10.1001/jama.1990.03440050052019; SMITH MC, 1977, AM J HOSP PHARM, V34, P1208, DOI 10.1093/ajhp/34.11.1208; SMITH R, 1986, BRIT MED J, V293, P905, DOI 10.1136/bmj.293.6552.905; SPRINGER MD, 1990, JAMA-J AM MED ASSOC, V263, P2931, DOI 10.1001/jama.263.21.2931; 1983, BR J RHEUMATOL, V22, P65	18	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2391	2392		10.1001/jama.265.18.2391	http://dx.doi.org/10.1001/jama.265.18.2391			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ955	2016837				2022-12-28	WOS:A1991FJ95500037
J	TOMIE, T; SHIMIZU, H; MAJIMA, T; YAMADA, M; KANAYAMA, T; KONDO, H; YANO, M; ONO, M				TOMIE, T; SHIMIZU, H; MAJIMA, T; YAMADA, M; KANAYAMA, T; KONDO, H; YANO, M; ONO, M			3-DIMENSIONAL READOUT OF FLASH X-RAY IMAGES OF LIVING SPERM IN WATER BY ATOMIC-FORCE MICROSCOPY	SCIENCE			English	Article								The imaging of living specimens in water by x-ray microscopy can be greatly enhanced with the use of an intense flash x-ray source and sophisticated technologies for reading x-ray images. A subpicosecond x-ray pulse from a laser-produced plasma was used to record the x-ray image of living sea urchin sperm in an x-ray resist. The resist relief was visualized at high resolution by atomic-force microscopy. Internal structure of the sperm head was evident, and the carbon density in a flagellum was estimated from the relief height.	NIKON INC,TSUKUBA LAB,TSUKUBA,IBARAKI 30026,JAPAN	Nikon Corporation	TOMIE, T (corresponding author), ELECTROTECH LAB,TSUKUBA,IBARAKI 305,JAPAN.							ALLEN RD, 1968, J CELL BIOL, V37, P825, DOI 10.1083/jcb.37.3.825; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Cheng P.C., 1987, XRAY MICROSCOPY INST, P65; EASON RW, 1985, ANN REPORT; FEDER R, 1985, SCIENCE, V227, P63, DOI 10.1126/science.3964958; FEDER R, 1977, SCIENCE, V197, P259, DOI 10.1126/science.406670; GIUDICE G, 1987, SEA URCHIN EMBRYO, P23; JACOBSEN C, 1988, XRAY MICROSCOPY, V2, P253; KIRZ J, 1984, XRAY MICROSCOPY, P262; LONDON RA, 1989, APPL OPTICS, V28, P3397, DOI 10.1364/AO.28.003397; ROSSER RJ, 1987, APPL OPTICS, V26, P4313, DOI 10.1364/AO.26.004313; SAYRE D, 1988, XRAY MICROSCOPY, V2; SOLEM JC, 1986, J OPT SOC AM B, V3, P1551, DOI 10.1364/JOSAB.3.001551; 1990, INT C XRAY MICROSCOP	14	80	81	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					691	693		10.1126/science.2024121	http://dx.doi.org/10.1126/science.2024121			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024121				2022-12-28	WOS:A1991FK18500043
J	HENKIN, RI				HENKIN, RI			SALTY AND BITTER TASTE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HENKIN, RI (corresponding author), TASTE & SMELL CLIN,WASHINGTON,DC, USA.							GOLDBERG RL, 1983, PSYCHOSOMATICS, V26, P326; HENKIN RI, 1971, J AMER MED ASSOC, V218, P1946, DOI 10.1001/jama.218.13.1946; HENKIN RI, 1988, FASEB J, V3, P338; HENKIN RI, DIFFICULT DIAGNOSIS, V2	4	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2253	2253						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013958				2022-12-28	WOS:A1991FH87700041
J	KENNELL, J; KLAUS, M; MCGRATH, S; ROBERTSON, S; HINKLEY, C				KENNELL, J; KLAUS, M; MCGRATH, S; ROBERTSON, S; HINKLEY, C			CONTINUOUS EMOTIONAL SUPPORT DURING LABOR IN A UNITED-STATES HOSPITAL - A RANDOMIZED CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CESAREAN BIRTH; FETAL ASPHYXIA; EPINEPHRINE; MOTHER; MONKEY; RATES	The continuous presence of a supportive companion (doula) during labor and delivery in two studies in Guatemala shortened labor and reduced the need for cesarean section and other interventions. In a US hospital with modern obstetric practices, 412 healthy nulliparous women in labor were randomly assigned to a supported group (n = 212) that received the continuous support of a doula or an observed group (n = 200) that was monitored by an inconspicuous observer. Two hundred four women were assigned to a control group after delivery. Continuous labor support significantly reduced the rate of cesarean section deliveries (supported group, 8%; observed group, 13%; and control group, 18%) and forceps deliveries. Epidural anesthesia for spontaneous vaginal deliveries varied across the three groups (supported group, 7.8%; observed group, 22.6%; and control group, 55.3%). Oxytocin use, duration of labor, prolonged infant hospitalization, and maternal fever followed a similar pattern. The beneficial effects of labor support underscore the need for a review of current obstetric practices.	CHILDRENS HOSP,DEPT PEDIAT,OAKLAND,CA; CASE WESTERN RESERVE UNIV,DEPT PEDIAT,CLEVELAND,OH 44106; CORNELL UNIV,DEPT HUMAN DEV & FAMILY STUDIES,ITHACA,NY 14853; BAYLOR UNIV,DEPT OBSTET & GYNECOL,HOUSTON,TX 77030	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; Case Western Reserve University; Cornell University; Baylor University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016915] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 16915] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMSONS K, 1971, AM J OBSTET GYNECOL, V109, P248, DOI 10.1016/0002-9378(71)90873-8; BARTON MD, 1974, P SOC EXP BIOL MED, V145, P996; BERTSCH TD, 1990, J PSYCHOSOM OBST GYN, V11, P251, DOI 10.3109/01674829009084421; FUSI L, 1989, LANCET, V1, P1250, DOI 10.1016/S0140-6736(89)92341-6; Halpin G J, 1989, N J Med, V86, P867; KEIRSE MJN, 1989, EFFECTIVE CARE PREGN, V2, P805; KLAUS MH, 1986, BMJ-BRIT MED J, V293, P585, DOI 10.1136/bmj.293.6547.585; LEDERMAN RP, 1985, AM J OBSTET GYNECOL, V153, P870, DOI 10.1016/0002-9378(85)90692-1; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MYERS RE, 1975, AM J OBSTET GYNECOL, V122, P47, DOI 10.1016/0002-9378(75)90614-6; NEWTON ER, 1989, J REPROD MED, V34, P407; NOTZON FC, 1990, JAMA-J AM MED ASSOC, V263, P3286, DOI 10.1001/jama.263.24.3286; SHIONO PH, 1987, JAMA-J AM MED ASSOC, V257, P494, DOI 10.1001/jama.257.4.494; SOSA R, 1980, NEW ENGL J MED, V303, P597, DOI 10.1056/NEJM198009113031101; STAFFORD RS, 1990, JAMA-J AM MED ASSOC, V263, P683, DOI 10.1001/jama.263.5.683; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; THORP JA, 1989, AM J OBSTET GYNECOL, V161, P670, DOI 10.1016/0002-9378(89)90377-3; ZUSPAN FP, 1962, AM J OBSTET GYNECOL, V84, P841, DOI 10.1016/0002-9378(62)90057-1	18	286	297	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2197	2201		10.1001/jama.265.17.2197	http://dx.doi.org/10.1001/jama.265.17.2197			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013951				2022-12-28	WOS:A1991FH87700030
J	HICKS, NR; BAKER, IA				HICKS, NR; BAKER, IA			GENERAL-PRACTITIONERS OPINIONS OF HEALTH-SERVICES AVAILABLE TO THEIR PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To establish a means for general practitioners to express their views about health services available to their patients, to identifiy services that general practitioners perceive as most in need of improvement, and to establish good working relations between the health authority's purchasing team and local general practitioners. Design-Postal questionnaire survey of general practitioners. Setting-Bristol and Weston health district. Subjects-226 general practitioners, of whom 171 replied. Main outcome measures-Scores of quality and quantity of hospital and community services, frequency that services were identified as priorities for improvement, and the nature of written comments received about services. Results-There was considerable agreement among respondents about which services were adequate and which were inadequate. Most services were perceived as at least adequate in both quality and quantity, but seven services were perceived by more than 60% (102) of doctors as inadequate or worse in quantity and eight by 10% (17) of doctors as poor in quality. Orthopaedics, ophthalmology, care of elderly people, and physiotherapy were the services doctors most wanted improved. Conclusions-A postal questionnaire is an acceptable and accurate method of obtaining general practitioners' views about services available to their patients. General practitioners' priorities differ from those obtained from hospital medical advisory mechanisms.	BRISTOL & WESTON DIST HLTH AUTHOR,PUBL HLTH,BRISTOL BS1 3NP,ENGLAND		HICKS, NR (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,BRISTOL BS8 2PR,ENGLAND.			Hicks, Nicholas/0000-0002-7214-9678				FARMER A, 1990, BRIT J GEN PRACT, V40, P56; MAXWELL RJ, 1984, BRIT MED J, V288, P1470, DOI 10.1136/bmj.288.6428.1470; MORGAN DR, 1990, BRIT MED J, V300, P1379, DOI 10.1136/bmj.300.6736.1379; 1981, J R COLL GEN PRACT, V31, P698; 1988, SPSS PCPLUS COMPUTER; 1990, BRISTOL HLTH CARE TR; 1990, WORKING PATIENTS DEV; 1989, LOTUS 1 2 3 RELEASE	8	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					991	993		10.1136/bmj.302.6783.991	http://dx.doi.org/10.1136/bmj.302.6783.991			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039896	Bronze, Green Published			2022-12-28	WOS:A1991FJ50800017
J	BUCHANAN, CR; PREECE, MA; MILNER, RDG				BUCHANAN, CR; PREECE, MA; MILNER, RDG			MORTALITY, NEOPLASIA, AND CREUTZFELDT-JAKOB DISEASE IN PATIENTS TREATED WITH HUMAN PITUITARY GROWTH-HORMONE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							DIABETES-INSIPIDUS; TURNERS SYNDROME; THERAPY; CHILDREN; TUMORS; LEUKEMIA; EXPERIENCE; DEFICIENCY; RECURRENCE; CHILDHOOD	Objective-To determine the cause of death and incidence of neoplasia in patients treated with human pituitary growth hormone. Design-A long term cohort study established to receive details of death certification and tumour registrations through the Office of Population Censuses and Surveys and NHS central register. Patients-All patients (1246 male, 662 female) treated for short stature with pituitary growth hormone under the Medical Research Council working party and health services human growth hormone committee. Main outcome measures-Death or development of neoplasia. Results-110 patients died (68 male, 42 female; aged 0.9-57 years) from 1972 to 1990. Fifty three deaths were from neoplasia responsible for growth hormone deficiency (27 craniopharyngioma, 24 other intracranial tumour, two leukaemia); two from histiocytosis X; and 13 from pituitary insufficiency. Six patients died of Creutzfeldt-Jakob disease, six of other neurological disorders, and eight of acute infection. Other deaths were apparently unrelated to growth hormone deficiency or its treatment. Seventeen tumours (in 16 patients) were identified during or after growth hormone treatment. Four were in patients with previous intracranial neoplasia and two were after cranial irradiation. Thirteen were intracranial, the others being Hodgkin's lymphoma, osteosarcoma, carcinoma of colon, and basal cell carcinoma. Conclusions-Recurrence or progression of intracranial tumours and potentially avoidable metabolic consequences of hypopituitarism were the main causes of death. Growth hormone treatment probably did not contribute to new tumour development. Creutzfeldt-Jakob disease after pituitary growth hormone treatment continues to occur in the United Kingdom. This cohort must remain under long term review.	INST CHILD HLTH,DEPT GROWTH & DEV,LONDON WC1N 1EH,ENGLAND; SHEFFIELD UNIV,CHILDRENS HOSP,DEPT PAEDIAT,SHEFFIELD S10 2TH,ENGLAND	University of London; University College London; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield								ARSLANIAN SA, 1985, AM J DIS CHILD, V139, P347, DOI 10.1001/archpedi.1985.02140060029020; BROWN P, 1985, NEW ENGL J MED, V313, P728, DOI 10.1056/NEJM198509193131205; BROWN P, 1988, NEUROLOGY, V38, P1135, DOI 10.1212/WNL.38.7.1135; BUCHANAN CR, 1987, ARCH DIS CHILD, V62, P912, DOI 10.1136/adc.62.9.912; CLAYTON PE, 1988, LANCET, V1, P642; CLAYTON PE, 1987, LANCET, V1, P711; COCHIUS JI, 1990, AUST NZ J MED, V20, P592, DOI 10.1111/j.1445-5994.1990.tb01322.x; DELEMARREVANDEWAAL HA, 1988, LANCET, V1, P1159; FARWELL J, 1984, J NEURO-ONCOL, V2, P371; FISHER DA, 1988, LANCET, V1, P1159; FRISCH H, 1988, LANCET, V1, P1335; GOUJARD J, 1988, INT J EPIDEMIOL, V17, P423, DOI 10.1093/ije/17.2.423; KINGSTON JE, 1987, BRIT J CANCER, V56, P331, DOI 10.1038/bjc.1987.199; MILNER RDG, 1979, CLIN ENDOCRINOL, V11, P15, DOI 10.1111/j.1365-2265.1979.tb03043.x; MILNER RDG, 1987, ARCH DIS CHILD, V62, P776, DOI 10.1136/adc.62.8.776; NW MI, 1988, NEUROLOGY, V38, P1133; POWELLJACKSON J, 1985, LANCET, V2, P244; PREECE MA, 1986, NEUROPATH APPL NEURO, V12, P509, DOI 10.1111/j.1365-2990.1986.tb00061.x; PREECE MA, 1986, IMMUNOLOGICAL ASPECT, P9; RABEN MS, 1958, J CLIN ENDOCR METAB, V18, P901, DOI 10.1210/jcem-18-8-901; REDMAN GP, 1988, LANCET, V1, P1335; RODENS KP, 1987, ACTA ENDOCR-COP    S, V283, P188; SHERWOOD MC, 1986, ARCH DIS CHILD, V61, P1222, DOI 10.1136/adc.61.12.1222; STAHNKE N, 1989, EUR J PEDIATR, V148, P591, DOI 10.1007/BF00441506; STANDEN GR, 1989, AM J HEMATOL, V31, P280, DOI 10.1002/ajh.2830310413; STANHOPE R, 1989, BRIT J HOSP MED, V41, P490; TANNER JM, 1971, ARCH DIS CHILD, V46, P745, DOI 10.1136/adc.46.250.745; WATANABE S, 1988, LANCET, V1, P1159; WELLER RO, 1986, NEUROPATH APPL NEURO, V12, P117, DOI 10.1111/j.1365-2990.1986.tb00045.x; WHITEHEAD HM, 1989, ULSTER MED J, V58, P153; 1986, ANN NEUROL, V19, P75; 1986, MORTALITY STATIS DH2	32	108	126	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					824	828		10.1136/bmj.302.6780.824	http://dx.doi.org/10.1136/bmj.302.6780.824			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025705	Green Published, Bronze			2022-12-28	WOS:A1991FF37700025
J	LOWE, D				LOWE, D			SET A MULTIPLE-CHOICE QUESTION (MCQ) EXAMINATION	BRITISH MEDICAL JOURNAL			English	Article							CONTROVERSY				LOWE, D (corresponding author), ST BARTHOLOMEWS HOSP & MED COLL,DEPT HISTOPATHOL,LONDON EC1A 7BE,ENGLAND.							ANDERSON J, 1981, MED TEACH, V3, P150, DOI 10.3109/01421598109064475; ANDERSON J, 1979, MED TEACH, V1, P37, DOI 10.3109/01421597909010580; ANDERSON J, 1976, MULTIPLE CHOICE QUES; LENNOX B, 1974, HINTS SETTING EVALUA; SLADE PD, 1983, MED TEACH, V5, P146, DOI 10.3109/01421598309146431	5	10	10	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					780	782		10.1136/bmj.302.6779.780	http://dx.doi.org/10.1136/bmj.302.6779.780			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021771	Bronze, Green Published			2022-12-28	WOS:A1991FF22900031
J	WARREN, N; HOLMES, JA; ALJADER, L; WEST, RR; LEWIS, DC; PADUA, RA				WARREN, N; HOLMES, JA; ALJADER, L; WEST, RR; LEWIS, DC; PADUA, RA			FREQUENCY OF CARRIERS OF CYSTIC-FIBROSIS GENE AMONG PATIENTS WITH MYELOID MALIGNANCY AND MELANOMA	BRITISH MEDICAL JOURNAL			English	Article									UNIV COLL CARDIFF,DEPT HAEMATOL,PRELEUKAEMIA UNIT,LEUKAEMIA RES FUND,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University			PADUA, Rose Ann/E-8621-2019; Padua, Rose Ann/GVT-5961-2022	PADUA, Rose Ann/0000-0001-9964-7864; 				ALJADER LN, 1989, BRIT MED J, V298, P164, DOI 10.1136/bmj.298.6667.164; ALJADER LN, 1991, ARCH DIS CHILD, V66, P317, DOI 10.1136/adc.66.3.317; ESTIVILL X, 1989, LANCET, V2, P140; MCINTOSH I, 1989, LANCET, V2, P1404; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657	5	19	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					760	761		10.1136/bmj.302.6779.760	http://dx.doi.org/10.1136/bmj.302.6779.760			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021766	Green Published, Bronze			2022-12-28	WOS:A1991FF22900023
J	BARSAN, WG				BARSAN, WG			EMERGENCY-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR-FIBRILLATION; CHEST PAIN; COCAINE; RESUSCITATION; INFECTION; PATIENT				BARSAN, WG (corresponding author), UNIV CINCINNATI,MED CTR,CINCINNATI,OH 45267, USA.							ANGELOS MG, 1990, ANN EMERG MED, V19, P1122, DOI 10.1016/S0196-0644(05)81515-X; AUFDERHEIDE TP, 1990, ANN EMERG MED, V19, P1280, DOI 10.1016/S0196-0644(05)82288-7; BRODY SL, 1990, ANN EMERG MED, V19, P1137, DOI 10.1016/S0196-0644(05)81518-5; CALLAHAM M, 1991, JAMA-J AM MED ASSOC, V265, P1117, DOI 10.1001/jama.265.9.1117; COLLINS MS, 1990, ANN EMERG MED, V19, P114, DOI 10.1016/S0196-0644(05)81792-5; GIBLER WB, 1990, ANN EMERG MED, V19, P1359, DOI 10.1016/S0196-0644(05)82598-3; HARGARTEN KM, 1990, ANN EMERG MED, V19, P157, DOI 10.1016/S0196-0644(05)81801-3; HONIGMAN B, 1990, ANN EMERG MED, V19, P145, DOI 10.1016/S0196-0644(05)81799-8; KELEN GD, 1990, ANN EMERG MED, V19, P963, DOI 10.1016/S0196-0644(05)82555-7; KELEN GD, 1989, ANN EMERG MED, V18, P378, DOI 10.1016/S0196-0644(89)80574-8; KIRSHENBAUM K J, 1990, Journal of Emergency Medicine, V8, P183, DOI 10.1016/0736-4679(90)90230-S; LEVINE SR, 1990, NEW ENGL J MED, V323, P699, DOI 10.1056/NEJM199009133231102; LEWANDOWSKI D, 1989, 5TH P INT C AIDS MON, P142; MERIGIAN KS, 1990, AM J EMERG MED, V8, P479, DOI 10.1016/0735-6757(90)90146-Q; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; REECH H, 1990, ANN EMERG MED, V19, P887; RHEE KJ, 1990, ANN EMERG MED, V19, P511, DOI 10.1016/S0196-0644(05)82179-1; ROINE RO, 1990, JAMA-J AM MED ASSOC, V264, P3171; TOKARSKI GF, 1990, ANN EMERG MED, V19, P1088, DOI 10.1016/S0196-0644(05)81509-4	20	4	4	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3115	3118						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041118				2022-12-28	WOS:A1991FQ77000015
J	BROOK, RH				BROOK, RH			HEALTH, HEALTH-INSURANCE, AND THE UNINSURED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE PAYMENT SYSTEM; CONTROLLED TRIAL; MEDICAL-CARE; CAROTID ENDARTERECTOMY; INAPPROPRIATE USE; BYPASS-SURGERY; QUALITY; COST; APPROPRIATENESS; OUTCOMES		UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT HLTH SERV,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	BROOK, RH (corresponding author), RAND CORP,HLTH SCI PROGRAM,1700 MAIN ST,SANTA MONICA,CA 90406, USA.							Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BROOK RH, 1986, ISSUES SCI TECHNOL, V3, P68; BROOK RH, 1990, MED CARE, V28, P392, DOI 10.1097/00005650-199005000-00002; BROOK RH, 1979, MED CARE, V17, P1; BROOK RH, 1978, MED CARE, V16, P1; BROOK RH, 1977, MED CARE, V15, P1; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BROOK RH, 1990, HEALTH POLICY, V14, P225, DOI 10.1016/0168-8510(90)90037-E; BROOK RH, 1985, MED CARE, V23, P710, DOI 10.1097/00005650-198505000-00030; BROOK RH, 1973, NEW ENGL J MED, V288, P1323, DOI 10.1056/NEJM197306212882504; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; Field MJ, 1990, CLIN PRACTICE GUIDEL; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KEELER EB, 1987, HEALTH SERV RES, V22, P279; KEELER EB, 1985, JAMA-J AM MED ASSOC, V254, P1926; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; Lohr K N, 1986, Med Care, V24, pS1; LOHR KN, 1980, MED CARE           S, V18, P1; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; LURIE N, 1989, AM J PUBLIC HEALTH, V79, P640, DOI 10.2105/AJPH.79.5.640; MERRICK NJ, 1986, JAMA-J AM MED ASSOC, V256, P2531, DOI 10.1001/jama.256.18.2531; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; SIU AL, 1991, HEALTH AFFAIR, V10, P62, DOI 10.1377/hlthaff.10.1.62; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; SLOSS EM, 1987, ANN INTERN MED, V106, P130, DOI 10.7326/0003-4819-106-1-130; VALDEZ RB, 1989, PEDIATRICS, V83, P168; VALDEZ RB, 1985, PEDIATRICS, V75, P952; WARE JE, 1986, LANCET, V1, P1017; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201	35	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2998	3002		10.1001/jama.265.22.2998	http://dx.doi.org/10.1001/jama.265.22.2998			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP635	2033774				2022-12-28	WOS:A1991FP63500040
J	MASON, JO				MASON, JO			A MESSAGE TO HEALTH-PROFESSIONALS ABOUT FLUOROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MASON, JO (corresponding author), US PHS,DIV NEWS,ROOM 719H,200 INDEPENDENCE AVE SW,WASHINGTON,DC 20201, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2939	2939						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033755				2022-12-28	WOS:A1991FP63500009
J	BARNES, PF; BLOCH, AB; DAVIDSON, PT; SNIDER, DE				BARNES, PF; BLOCH, AB; DAVIDSON, PT; SNIDER, DE			TUBERCULOSIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IMMUNE-DEFICIENCY SYNDROME; NON-HAITIAN PATIENTS; PULMONARY TUBERCULOSIS; MYCOBACTERIAL DISEASE; KAPOSIS SARCOMA; UNITED-STATES; SYNDROME AIDS; DIAGNOSIS; EPIDEMIOLOGY; PREVENTION		CTR DIS CONTROL,CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333; CTY LOS ANGELES DEPT HLTH HLTH SERV,DOWNEY,CA	Centers for Disease Control & Prevention - USA	BARNES, PF (corresponding author), UNIV SO CALIF,SCH MED,DEPT MED,HMR 904,LOS ANGELES,CA 90033, USA.				PHS HHS [CCU901877] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARNES PF, 1988, CHEST, V94, P316, DOI 10.1378/chest.94.2.316; BENDER BS, 1988, REV INFECT DIS, V10, P1142; BISHBURG E, 1986, ANN INTERN MED, V105, P210, DOI 10.7326/0003-4819-105-2-210; Bloch A B, 1989, Semin Respir Infect, V4, P157; BRONNIMANN DA, 1987, ANN INTERN MED, V106, P372, DOI 10.7326/0003-4819-106-3-372; CHAISSON RE, 1990, AM REV RESPIR DIS, V142, P259, DOI 10.1164/ajrccm/142.1.259; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DAMSKER B, 1985, J INFECT DIS, V151, P179, DOI 10.1093/infdis/151.1.179; DAVIDSON PT, 1987, AM REV RESPIR DIS, V136, P255, DOI 10.1164/ajrccm/136.2.255; DIPERRI G, 1989, LANCET, V2, P1502; ENGELHARD D, 1984, NEW ENGL J MED, V311, P1681, DOI 10.1056/NEJM198412273112606; FLORA GS, 1990, CHEST, V98, P1056, DOI 10.1378/chest.98.5.1056; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; HEWLETT D, 1988, AM REV RESPIR DIS, V137, P1275, DOI 10.1164/ajrccm/137.6.1275; JOHNSON PC, 1988, AM J MED, V85, P152, DOI 10.1016/S0002-9343(88)80334-6; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; KAVESH NG, 1989, AM REV RESPIR DIS, V139, P1094, DOI 10.1164/ajrccm/139.5.1094; KLEIN NC, 1989, CHEST, V95, P1190, DOI 10.1378/chest.95.6.1190; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; LAZAR JD, 1990, REV INFECT DIS, V12, pS327; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; MANOFF SB, 1988, 4TH INT C AIDS STOCK, P260; MCCRAY E, 1990, PUBLIC HEALTH REP, V105, P135; MEDURI GU, 1986, AM J MED, V81, P11, DOI 10.1016/0002-9343(86)90175-0; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; NARDELL EA, 1990, AM REV RESPIR DIS, V142, P501, DOI 10.1164/ajrccm/142.3.501; OBRIEN RF, 1989, CHEST, V96, P460, DOI 10.1378/chest.96.3.460; PITCHENIK AE, 1988, CLIN CHEST MED, V9, P425; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1990, LANCET, V336, P440, DOI 10.1016/0140-6736(90)91987-L; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; PITCHENIK AE, 1987, AM REV RESPIR DIS, V135, P875, DOI 10.1164/arrd.1987.135.4.875; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; RIEDER HL, 1986, CHEST, V90, P469, DOI 10.1378/chest.90.4.469; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHAFER RW, 1989, AM REV RESPIR DIS, V140, P1611, DOI 10.1164/ajrccm/140.6.1611; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SO SY, 1982, TUBERCLE, V63, P195, DOI 10.1016/S0041-3879(82)80030-5; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; WALKER A T, 1990, American Review of Respiratory Disease, V141, pA268; YOUNG LS, 1988, J INFECT DIS, V157, P863, DOI 10.1093/infdis/157.5.863; 1989, MMWR, V38, P256; 1991, MMWR, V39, P944; 1982, B WORLD HEALTH ORGAN, V60, P555; 1989, MMWR, V38, P236; 1989, MMWR, V38, P243; 1990, MMWR, V39, P718; 1990, DHHS HIVCID990006 PU; 1987, MMWR, V36, P795; 1990, MMWR, V39, P110; 1986, NEW ENGL J MED, V35, P74; [No title captured]; 1990, MMWR, V39, P153; 1986, MMWR, V35, P699; 1990, MMWR, V39, P1	60	942	961	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1644	1650		10.1056/NEJM199106063242307	http://dx.doi.org/10.1056/NEJM199106063242307			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	2030721				2022-12-28	WOS:A1991FP30700007
J	COLE, MD				COLE, MD			MYC MEETS ITS MAX	CELL			English	Review							C-MYC; DNA-BINDING; PROTEINS; TRANSCRIPTION; TRANSFORMATION; SEQUENCE; COMMON; DIMER; FOS				COLE, MD (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.							BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1991, MOL CELL BIOL, V65, P395; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P767	21	66	69	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					715	716		10.1016/0092-8674(91)90377-B	http://dx.doi.org/10.1016/0092-8674(91)90377-B			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040011				2022-12-28	WOS:A1991FP51600001
J	RANIERI, E; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; POLLARD, AC; ROBERTSON, EF				RANIERI, E; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; POLLARD, AC; ROBERTSON, EF			NEONATAL SCREENING STRATEGY FOR CYSTIC-FIBROSIS USING IMMUNOREACTIVE TRYPSINOGEN AND DIRECT GENE ANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							ASSAY; POPULATION; MUTATIONS	Objective - To assess the effectiveness of a two tier neonatal screening strategy for cystic fibrosis, which combines estimation of immunoreactive trypsinogen followed by direct gene analysis in dried blood spot samples collected at age 5 days. Design - Prospective study of two tier screening strategy. The first tier of testing immunoreactive trypsinogen concentration was measured in dried blood spot samples from neonates aged 4-5 days. In the second tier direct gene analysis to detect cystic fibrosis mutations DELTA-F508 and DELTA-I506 was performed in those blood spot ssmples which produced the highest 1% of immunoreactive trypsinogen values. Direct gene analysis was also performed on blood spot samples from infants with suspected or confirmed meconium ileus, regardless of the immunoreactive trypsinogen value. Setting - The South Australian Neonatal Screening Programme, operating from the department of chemical pathology at Adelaide Children's Hospital. Subjects - All 12 056 neonates born in South Australia between December 1989 and June 1990. No selection criteria were applied. Interventions - All infants found to have two recognised cystic fibrosis mutations on direct gene analysis were referred directly for clinical management, and those with one recognised cystic fibrosis mutation were recalled for a sweat test; their families were given genetic counselling. Main outcome measures - Diagnosis or exclusion of cystic fibrosis by sweat testing of neonates identified as being at high risk of cystic fibrosis on screening and of those at minimum risk but whose subsequent clinical history raised suspicion about the disease. Results - Of the 12 056 infants screened, 11 907 (98.8%) were reported as "cystic fibrosis not indicated" on the basis of low immunoreactive trypsinogen values. Of the 148 (1.23%) infants with raised immunoreactive trypsinogen values and one (0.008%) with meconium ileus, 132 (1.09%) were reported as cystic fibrosis not indicated, four (0.033%) were identified as having cystic fibrosis, and 13 (0.108%) were recalled for sweat testing after direct gene analysis for the presence of the DELTA-F508 and DELTA-I506 cystic fibrosis mutations. No cases of affected infants are known to have been missed to date. Conclusion - The strategy of measurement of immunoreactive trypsinogen followed by direct gene analysis is a highly specific neonatal screen for cystic fibrosis, requiring only 2.8 families to be contacted for every case of cystic fibrosis diagnosed.	ADELAIDE CHILDRENS HOSP INC,DEPT CHEM PATHOL,ADELAIDE,SA 5006,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,SCREENING LAB,ADELAIDE,SA 5006,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,SPECIAL DIAGNOST LAB,ADELAIDE,SA 5006,AUSTRALIA					Morris, Phillip/0000-0001-8976-619X				ADRIAENSSENS K, 1981, LANCET, V1, P833; [Anonymous], 1983, PEDIATRICS; BOWLING FG, 1987, ADV NEONATAL SCREENI, P391; CASSIO A, 1984, ACTA PAEDIATR SCAND, V73, P554, DOI 10.1111/j.1651-2227.1984.tb09970.x; CHATFIELD S, 1991, ARCH DIS CHILD-FETAL, V66, P29, DOI 10.1136/adc.66.1_Spec_No.29; CORSSLEY JP, 1979, LANCET, V2, P472; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DANKERTROELSE JE, 1989, J PEDIATR-US, V114, P362, DOI 10.1016/S0022-3476(89)80552-9; DIAMANDIS EP, 1988, CLIN BIOCHEM, V21, P139, DOI 10.1016/S0009-9120(88)80104-8; GIBSON LE, 1959, PEDIATRICS, V23, P545; HAMMOND K, 1987, ADV NEONATAL SCREENI, P377; HEELEY AF, 1982, ARCH DIS CHILD, V57, P18; KEREM B, 1989, SCIENCE, V284, P1073; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KING DN, 1979, LANCET, V2, P1217; NELSON PV, 1990, MED J AUSTRALIA, V152, P328, DOI 10.5694/j.1326-5377.1990.tb120962.x; PEDERZINI F, 1984, LANCET, V1, P959; ROCK MJ, 1990, PEDIATRICS, V85, P1001; RYLEY HC, 1988, J CLIN PATHOL, V41, P726, DOI 10.1136/jcp.41.7.726; WESLEY AW, 1989, AUST PAEDIATR J, V25, P151; WILKEN B, 1985, LANCET, V2, P1319; WILKEN B, 1987, ADV NEONATAL SCREENI, P385; WILKEN B, 1983, J PEDIATR, V102, P383	23	54	54	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1237	1240		10.1136/bmj.302.6787.1237	http://dx.doi.org/10.1136/bmj.302.6787.1237			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043846	Green Published, Bronze			2022-12-28	WOS:A1991FP27200021
J	VAGELOS, PR				VAGELOS, PR			ARE PRESCRIPTION DRUG PRICES HIGH	SCIENCE			English	Article							COENZYME-A REDUCTASE; FAMILIAL HYPERCHOLESTEROLEMIA; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; HYDROXYMETHYLGLUTARYL-COENZYME; CHOLESTEROL; MEVINOLIN; INHIBITOR; FIBROBLASTS; ML-236A; COSTS	The U.S. pharmaceutical industry has been criticized because its products are perceived to be too expensive, yet prescription medicines remain the least expensive form of therapy. At this time, we are experiencing a dramatic increase in the risks and costs of pharmaceutical research and development (R&D). An example may be seen in the R&D history of lovastatin. The U.S. pharmaceutical industry continues to lead the world in the discovery and development of important new medicines because it assumes greater financial risk and invests more of its sales dollar in R&D than virtually any other industry. Where such a risk is posed, there must continue to be the potential for profits. Pharmaceutical companies must set responsible prices, must keep price increases down, and must help improve access to important medicines.			VAGELOS, PR (corresponding author), MERCK & CO INC,RAHWAY,NJ 07065, USA.							ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ALBERTSSCHONBERG G, 1980, Patent No. 4231938; Anitschkow N, 1913, BEITR PATHOL ANAT AL, V56, P379; BILHEIMER DW, 1983, T ASSOC AM PHYSICIAN, V96, P1; Bloch K, 1942, J BIOL CHEM, V145, P625; BROUN M, 1990, J NATL CANCER I, V82, P1811; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BUCHER NLR, 1960, BIOCHIM BIOPHYS ACTA, V40, P491, DOI 10.1016/0006-3002(60)91390-1; CHANG TY, 1976, P NATL ACAD SCI USA, V73, P24, DOI 10.1073/pnas.73.1.24; CHANG TY, 1977, P NATL ACAD SCI USA, V74, P832, DOI 10.1073/pnas.74.3.832; CLAYTON RB, 1956, J BIOL CHEM, V218, P319; DIMASI JA, IN PRESS J HLTH; ECKHOLM E, 1989, NY TIMES MAGAZI 0108, P20; EISENBERG JM, 1984, REV INFECT DIS S4, V6, P909; ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9; ENDO A, 1979, J ANTIBIOT, V32, P852, DOI 10.7164/antibiotics.32.852; ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346; GOLDSTEIN JL, 1973, P NATL ACAD SCI USA, V70, P2804, DOI 10.1073/pnas.70.10.2804; GOULD RG, 1950, FED PROC, V9, P179; GRABOWSKI H, 1990, MANAGE SCI, V36, P804, DOI 10.1287/mnsc.36.7.804; HANSEN R, 1976, THESIS U ROCHESTER; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HUANG LF, 1988, PUBLIC HEALTH REP, V103, P3; ILLINGWORTH DR, 1984, J CLIN INVEST, V74, P1972, DOI 10.1172/JCI111618; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; Lubitz J, 1985, Health Care Financ Rev, V6, P103; LYNEN F, 1959, ANGEW CHEM INT EDIT, V71, P657, DOI 10.1002/ange.19590712102; MACDONALD JS, 1988, AM J CARDIOL, V62, pJ16, DOI 10.1016/0002-9149(88)90003-3; MANDELLBROWN M, 1984, OTOLARYNG HEAD NECK, V92, P520, DOI 10.1177/019459988409200504; MOSSINGHOFF G, 1989, COMMUNICATION   0718; NARIN F, 1989, SCIENCE, V245, P600, DOI 10.1126/science.245.4918.600; OTTKE RC, 1951, J BIOL CHEM, V189, P429; RISTOW W, 1990, NOV IMS INT PLYM M; SILVERBERG SH, 1990, COMMUNICATION    NOV; SLOAN FA, 1989, UNPUB DRUG FORMULARI; TAVORMINA PA, 1956, J AM CHEM SOC, V78, P4498, DOI 10.1021/ja01598a089; TOBERT JA, 1982, ATHEROSCLEROSIS, V41, P61, DOI 10.1016/0021-9150(82)90070-3; TOBERT JA, 1982, J CLIN INVEST, V69, P913, DOI 10.1172/JCI110530; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; WOODWARD RB, 1953, J AM CHEM SOC, V75, P2023, DOI 10.1021/ja01104a535; WRIGHT LD, 1956, J AM CHEM SOC, V78, P5273, DOI 10.1021/ja01601a033; 1985, MODERN MED SAVINGS L; 1986, JAMA-J AM MED ASSOC, V256, P2829; 1988, JAMA-J AM MED ASSOC, V260, P359; 1988, PUBLIC HLTH REP, V103, P206; 1989, HLTH US 1989, P228; 1983, VITAL HLTH STATISTIC, V10; 1987, METROPOLITAN LIF JUL, P15; 1989, STATISTICAL ABSTRACT	50	95	98	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1080	1084		10.1126/science.252.5009.1080	http://dx.doi.org/10.1126/science.252.5009.1080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN056	2031182				2022-12-28	WOS:A1991FN05600032
J	FLEISHER, M; WINAWER, SJ; ZAUBER, AG; SMITH, C; SCHWARTZ, MK				FLEISHER, M; WINAWER, SJ; ZAUBER, AG; SMITH, C; SCHWARTZ, MK			ACCURACY OF FECAL OCCULT BLOOD-TEST INTERPRETATION	ANNALS OF INTERNAL MEDICINE			English	Note								The fecal occult blood test is viewed as a simple test for colorectal cancer detection; however, there has not been sufficient emphasis on its proper performance and interpretation. Accuracy of interpretation was studied in a proficiency test program within the framework of the National Polyp Study. Eight study coordinators were tested for their accuracy in reading the fecal occult blood test during three periods: before an instructional seminar on correct test performance, immediately after instruction, and several months after instruction. The overall accuracy in the pre-instructional period of 60% (58 of 96) improved to 91% accuracy (174 of 192) after an instructional seminar; this higher level of accuracy (91% [175 of 192]), continued for the subsequent period. The significant change (P < 0.001) in overall accuracy over time was due to a markedly increased accuracy in interpreting the moderately positive test; accuracy increased from 38% (18 of 48) to 94% (90 of 96). For the strongly positive areas, accuracy improved from 78% (25 of 32) to 100% (16 of 16). There was no change over time in the accuracy of reading a negative test. Our study shows the need for instruction in the interpretation of the test.	MEM SLOAN KETTERING CANC CTR, NATL POLYP STUDY, 1275 YORK AVE, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA 26852] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026852] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; FLEISHER M, 1985, SCREENING CANCER, P237; GNAUCK R, 1984, CA-CANCER J CLIN, V34, P134, DOI 10.3322/canjclin.34.3.134; GREEGOR DH, 1967, J AMER MED ASSOC, V201, P943, DOI 10.1001/jama.201.12.943; SHIKE M, 1990, CANCER PREVENTION, P1; WINAWER SJ, 1988, BASIC CLIN PERSPECTI, P35; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; 1988, BMDP STATISTICAL SOF	8	39	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					875	876		10.7326/0003-4819-114-10-875	http://dx.doi.org/10.7326/0003-4819-114-10-875			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014949				2022-12-28	WOS:A1991FL65000008
J	NUTTER, DO; HELMS, CM; WHITCOMB, ME; WESTON, WD				NUTTER, DO; HELMS, CM; WHITCOMB, ME; WESTON, WD			RESTRUCTURING HEALTH-CARE IN THE UNITED-STATES - A PROPOSAL FOR THE 1990S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROMOTE QUALITY; CHOICE; INSURANCE; ECONOMY; PLAN		UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV WASHINGTON,SCH MED,DEPT INTERNAL MED,SEATTLE,WA 98195; MICHIGAN STATE UNIV,COLL HUMAN MED,DEPT RADIOL,E LANSING,MI 48824	University of Iowa; University of Washington; University of Washington Seattle; Michigan State University; Michigan State University College of Human Medicine	NUTTER, DO (corresponding author), NORTHWESTERN UNIV,SCH MED,OFF VICE DEAN,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.							AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; BLUGER RJ, 1988, TECHNOLOGY BUREAUCRA; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; FUCHS VR, 1990, SCIENCE, V247, P534, DOI 10.1126/science.2300814; GINZBERG E, 1988, JAMA-J AM MED ASSOC, V260, P3647; GINZBERG E, 1990, JAMA-J AM MED ASSOC, V263, P1820, DOI 10.1001/jama.263.13.1820; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; LOHR KN, 1990, NEW ENGL J MED, V322, P707, DOI 10.1056/NEJM199003083221031; MOHEIT AC, 1989, HLTH AFF, V8, P22; REINHARDT UE, 1989, HEALTH AFFAIR, V8, P5, DOI 10.1377/hlthaff.8.4.5; REINHARDT UE, 1989, HLTH AFF, V8, P4; THORPE KE, 1989, JAMA-J AM MED ASSOC, V262, P2114; 1990, PRELIMINARY RECOMMEN; 1990, HLTH ACCESS AM AMA P; 1989, HLTH NATION SHARED R	16	11	11	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2516	2520		10.1001/jama.265.19.2516	http://dx.doi.org/10.1001/jama.265.19.2516			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK903	2020068				2022-12-28	WOS:A1991FK90300024
J	MADSEN, EL; SINCLAIR, JL; GHIORSE, WC				MADSEN, EL; SINCLAIR, JL; GHIORSE, WC			INSITU BIODEGRADATION - MICROBIOLOGICAL PATTERNS IN A CONTAMINATED AQUIFER	SCIENCE			English	Article							DEEP SUBSURFACE SEDIMENTS; MICROBIAL ECOLOGY; ORGANIC-COMPOUNDS; WASTE SITE; BACTERIA; DEGRADATION; PROTOZOA; OKLAHOMA; WATER; FIELD	Conventional approaches for proving in situ biodegradation of organic pollutants in aquifers have severe limitations. In the approach described here, patterns in a comprehensive set of microbiological activity and distribution data were analyzed. Measurements were performed on sediment samples gathered at consistent depths in aquifer boreholes spanning a gradient of contaminant concentrations at a buried coal tar site. Microbial adaptation to polyaromatic hydrocarbons (PAHs) was demonstrated by mineralization of naphthalene and phenanthrene in samples from PAH-contaminated, but not adjacent pristine, zones. Furthermore, contaminant-stimulated in situ bacterial growth was indicated because enhanced numbers of protozoa and their bacterial prey were found exclusively in contaminated subsurface samples. The data suggest that many convergent lines of logically linked indirect evidence can effectively document in situ biodegradation of aquifer contaminants.			MADSEN, EL (corresponding author), CORNELL UNIV,DIV BIOL SCI,MICROBIOL SECT,ITHACA,NY 14853, USA.							ALEXANDER M, 1981, SCIENCE, V211, P132, DOI 10.1126/science.7444456; [Anonymous], 1984, PETROLEUM MICROBIOLO; BALKWILL DL, 1985, APPL ENVIRON MICROB, V50, P580, DOI 10.1128/AEM.50.3.580-588.1985; BORDEN RC, 1987, WATER RESOUR BULL, V23, P629; BROCK TD, 1988, BIOL MICROORGANISMS, P5; CHAPELLE FH, 1990, APPL ENVIRON MICROB, V56, P1865, DOI 10.1128/AEM.56.6.1865-1874.1990; CHIANG CY, 1989, GROUND WATER, V27, P823, DOI 10.1111/j.1745-6584.1989.tb01046.x; CLINE PV, 1985, WASTE MANAGE RES, V3, P351, DOI 10.1016/0734-242X(85)90128-4; CURDS CR, 1982, ANNU REV MICROBIOL, V36, P27, DOI 10.1146/annurev.mi.36.100182.000331; DAGLEY S, 1977, SURV PROG CHEM, V8, P121; EVANS WC, 1977, NATURE, V270, P17, DOI 10.1038/270017a0; FEDERLE TW, 1988, GROUND WATER, V26, P761, DOI 10.1111/j.1745-6584.1988.tb00427.x; Fenchel T., 1987, ECOLOGY OF PROTOZOA, DOI [10.1007/978-3-662-06817-5, DOI 10.1007/978-3-662-06817-5, DOI 10.1007/978-3-662-25981-8]; Floodgate G.D., 1984, PETROLEUM MICROBIOLO, P355; Foissner W., 1987, Progress in Protistology, V2, P69; FREDRICKSON JK, 1989, GEOMICROBIOL J, V7, P53, DOI 10.1080/01490458909377849; GHIORSE WC, 1988, ADV APPL MICROBIOL, V33, P107, DOI 10.1016/S0065-2164(08)70206-5; HARTWIG E, 1984, Senckenbergiana Maritima, V16, P121; Karl DM., 1986, METHODS SPECIAL APPL, V2, P85; KLECKA GM, 1990, GROUND WATER, V28, P534, DOI 10.1111/j.1745-6584.1990.tb01709.x; Kolwitz R., 1909, INT REV GES HYDROBIO, V2, P126; LEAHY JG, 1990, MICROBIOL REV, V54, P305, DOI 10.1128/MMBR.54.3.305-315.1990; LEE MD, 1988, CRIT REV ENV CONTR, V18, P29, DOI 10.1080/10643388809388342; LEVINS SN, 1991, 1ST P INT S MICR DEE; MARTIN JP, 1980, LIGNIN BIODEGRADATIO, V1, P77; Moriarty F., 1988, ECOTOXICOLOGY STUDY; PIATT JF, 1990, AUK, V107, P387, DOI 10.2307/4087623; QUENSEN JF, 1988, SCIENCE, V242, P752, DOI 10.1126/science.242.4879.752; RAYMOND RL, 1976, APPL ENVIRON MICROB, V31, P522, DOI 10.1128/AEM.31.4.522-535.1976; RIDGWAY HF, 1990, APPL ENVIRON MICROB, V56, P3565, DOI 10.1128/AEM.56.11.3565-3575.1990; ROGERSON A, 1983, J GEN APPL MICROBIOL, V29, P41, DOI 10.2323/jgam.29.41; ROSZAK DB, 1987, MICROBIOL REV, V51, P365, DOI 10.1128/MMBR.51.3.365-379.1987; SINCLAIR JL, 1989, GEOMICROBIOL J, V7, P15, DOI 10.1080/01490458909377847; SINCLAIR JL, 1987, APPL ENVIRON MICROB, V53, P1157, DOI 10.1128/AEM.53.5.1157-1163.1987; SINCLAIR JL, 1991, 1ST P INT S MICR DEE; SPAIN JC, 1984, APPL ENVIRON MICROB, V48, P944, DOI 10.1128/AEM.48.5.944-950.1984; Stout J.D., 1980, Advances in Microbial Ecology, V4, P1; TAYLOR BB, P ENV RES C GROUNDWA; THOMAS JM, 1989, J IND MICROBIOL, V4, P109, DOI 10.1007/BF01569795; TRIBE H. T., 1961, Soil Science, V92, P61, DOI 10.1097/00010694-196107000-00009; VESTAL JR, 1984, PETROLEUM MICROBIOLO, P475; VILLAUME JF, 1984, HAZARDOUS TOXIC WAST, P362; WILSON JT, 1985, ENVIRON TOXICOL CHEM, V4, P721, DOI 10.1002/etc.5620040602; WILSON JT, 1983, GROUND WATER, V21, P134, DOI 10.1111/j.1745-6584.1983.tb00710.x; 1990, GROUND WATER, V28, P715	45	168	170	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					830	833		10.1126/science.2028258	http://dx.doi.org/10.1126/science.2028258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	2028258				2022-12-28	WOS:A1991FL12300042
J	RAUB, WF				RAUB, WF			TRANSGENIC MICE ALLOW RAPID TESTING OF AGENTS THAT REVERSE MULTIDRUG RESISTANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, WF (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, P NATL ACAD SCI USA, V88, P547	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2173	2173		10.1001/jama.265.17.2173	http://dx.doi.org/10.1001/jama.265.17.2173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013940				2022-12-28	WOS:A1991FH87700007
J	SMITH, R				SMITH, R			MEDICAL-RESEARCH IN AUSTRALIA - LIFE ON THE BROAD SIDE - MEDICAL-RESEARCH	BRITISH MEDICAL JOURNAL			English	Article																		LUMBERS ER, 1990, REV NATIONAL HLTH ME; 1990, ALLOCATION RESOURCES; 1990, REV NATIONAL HLTH ME; 1990, MED RES 1989	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					897	899		10.1136/bmj.302.6781.897	http://dx.doi.org/10.1136/bmj.302.6781.897			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025731	Bronze, Green Published			2022-12-28	WOS:A1991FG42100029
J	MCHEYZERWILLIAMS, MG; NOSSAL, GJV; LALOR, PA				MCHEYZERWILLIAMS, MG; NOSSAL, GJV; LALOR, PA			MOLECULAR CHARACTERIZATION OF SINGLE MEMORY B-CELLS	NATURE			English	Article							SOMATIC MUTATION; IMMUNE-RESPONSE; ANTIBODY REPERTOIRE; MOUSE; HYPERMUTATION; GENERATION; ANTIGEN; MICE; DNA; NP	PRIMARY antigenic exposure results in an initial antibody response and the T cell-dependent induction of B-cell memory 1,2. Memory B-cell differentiation is characterized by somatic hypermutation in antibody variable region genes (V) and selection of B cells expressing high-affinity variants of this antigen receptor 3-5. Despite our current understanding of B-cell memory 6-8, the origin of memory B cells and the regulation of their differentiation remain elusive. This is largely due to the difficulties in observing and purifying this minor component of the immunized spleen. Further, molecular characterization of memory B cells requires hybridoma formation which restricts analyses to only those clones capable of fusion and does not allow isolation of cells in a normal physiological state. We have therefore developed a unique system which allows isolation and unambiguous enumeration of IgG1+ memory B cells, based on six-parameter flow cytometry, secretion of antibody in clonal cultures and analysis of clonally expressed V genes using the polymerase chain reaction 9. Here we report that single IgG1+ antigen-binding B cells from an early secondary immune response proliferate in lipopolysaccharide-driven microcultures and produce antigen-specific IgG1 antibodies. Individual B-cell clones in these cultures express somatically mutated heavy chain V genes, confirming their designation as memory B cells. Although isolated memory B cells undergo extensive proliferation in vitro, V gene sequence analysis of their individual progeny shows that further hypermutation does not occur.			MCHEYZERWILLIAMS, MG (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA.							ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; GRAY D, 1990, CURR TOP MICROBIOL, V159, P1; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; HAYAKAWA K, 1987, P NATL ACAD SCI USA, V84, P1379, DOI 10.1073/pnas.84.5.1379; IMANISHI T, 1973, EUR J IMMUNOL, V3, P323, DOI 10.1002/eji.1830030602; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; LALOR PA, 1990, EUR J IMMUNOL, V20, P485, DOI 10.1002/eji.1830200305; LALOR PA, 1989, EUR J IMMUNOL, V19, P501, DOI 10.1002/eji.1830190314; LEBECQUE SG, IN PRESS J EXP MED; LEVY NS, 1989, J EXP MED, V169, P2007, DOI 10.1084/jem.169.6.2007; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MANSER T, 1990, IMMUNOL TODAY, V11, P305, DOI 10.1016/0167-5699(90)90124-R; MCHEYZERWILLIAMS MG, 1989, EUR J IMMUNOL, V19, P2025, DOI 10.1002/eji.1830191109; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; PIKE BL, 1982, P NATL ACAD SCI-BIOL, V79, P6350, DOI 10.1073/pnas.79.20.6350; RAJEWSKY K, 1987, SCIENCE, V238, P1088, DOI 10.1126/science.3317826; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; TAO W, 1990, J IMMUNOL, V145, P3216; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	30	136	137	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1991	350	6318					502	505		10.1038/350502a0	http://dx.doi.org/10.1038/350502a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	2014051				2022-12-28	WOS:A1991FG14300052
J	RITTER, AM; LEWIN, GR; KREMER, NE; MENDELL, LM				RITTER, AM; LEWIN, GR; KREMER, NE; MENDELL, LM			REQUIREMENT FOR NERVE GROWTH-FACTOR IN THE DEVELOPMENT OF MYELINATED NOCICEPTORS INVIVO	NATURE			English	Article							HAIRY SKIN; RAT; MECHANORECEPTORS; RECEPTOR; SURVIVAL	IN adult animals, sensory neurons innervating the skin are phenotypically diverse 1-3. We have now investigated whether nerve growth factor (NGF) has a physiological role in the development of this diversity. We gave antisera against NGF to rats from postnatal day 1 (PND 1) to adulthood (5 weeks). We found a virtually complete depletion of high threshold mechanoreceptors conducting in the A-delta range (2-13 m s-1) in the sural nerve. This afferent type, normally present in large numbers, appeared to have been replaced by D-hair afferents, sensitive mechanoreceptors which normally are relatively rare. NGF deprivation had this effect only in early postnatal life; treatment from postnatal day 14 to adulthood had no effect. We conclude that the presence of NGF postnatally in skin is necessary for the proper phenotypic development of A-delta cutaneous nociceptors.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Lewin, Gary R/B-8028-2011	Lewin, Gary/0000-0002-2890-6352; Mendell, Lorne/0000-0003-1540-8837				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BURGESS PR, 1967, J PHYSIOL-LONDON, V190, P541, DOI 10.1113/jphysiol.1967.sp008227; Burgess PR, 1973, HDB SENSORY PHYSIOLO, VII, P29; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; FITZGERALD M, 1987, J PHYSIOL-LONDON, V383, P79; FITZGERALD MI, 1966, J COMP NEUROL, V126, P37, DOI 10.1002/cne.901260103; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; HANDWERKER HO, 1985, DEV ORG PROCESSING S, P289; HORCH KW, 1977, J INVEST DERMATOL, V69, P75, DOI 10.1111/1523-1747.ep12497887; HULSEBOSCH CE, 1987, J COMP NEUROL, V259, P445, DOI 10.1002/cne.902590310; KOERBER HR, 1988, J NEUROPHYSIOL, V60, P1584, DOI 10.1152/jn.1988.60.5.1584; KRUGER L, 1981, J COMP NEUROL, V198, P137, DOI 10.1002/cne.901980112; LEWIN GR, 1989, J PHYSIOL-LONDON, V412, pP26; LYNN B, 1982, BRAIN RES, V238, P29, DOI 10.1016/0006-8993(82)90768-5; LYNN B, 1988, NEUROSCI LETT, V85, P71, DOI 10.1016/0304-3940(88)90431-4; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; YIP HK, 1984, J NEUROSCI, V4, P2986	17	140	141	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					500	502		10.1038/350500a0	http://dx.doi.org/10.1038/350500a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	2014050				2022-12-28	WOS:A1991FG14300051
J	HOVENDEN, JL; NICKLASON, F; BARNES, RA				HOVENDEN, JL; NICKLASON, F; BARNES, RA			LESSON OF THE WEEK - INVASIVE PULMONARY ASPERGILLOSIS IN NONIMMUNOCOMPROMISED PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							OPEN LUNG-BIOPSY; ACUTE-LEUKEMIA; INFLUENZA; DIAGNOSIS		UNIV COLL CARDIFF,DEPT GERIATR MED,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University	HOVENDEN, JL (corresponding author), UNIV COLL CARDIFF,DEPT MED MICROBIOL,CARDIFF CF4 4XN,S GLAM,WALES.							ASCAH KJ, 1984, CAN MED ASSOC J, V131, P332; BARNES RA, 1989, J HOSP INFECT, V14, P89, DOI 10.1016/0195-6701(89)90110-2; BARTLETT JG, 1988, RESPIRATORY INFECTIO, P69; DSILVA H, 1982, JAMA-J AM MED ASSOC, V248, P1495, DOI 10.1001/jama.248.12.1495; FISCHER JJ, 1979, JAMA-J AM MED ASSOC, V241, P1493, DOI 10.1001/jama.241.14.1493; GERSON SL, 1984, ANN INTERN MED, V100, P345, DOI 10.7326/0003-4819-100-3-345; GERSON SL, 1985, J CLIN ONCOL, V3, P1109, DOI 10.1200/JCO.1985.3.8.1109; HORN CR, 1983, BRIT J DIS CHEST, V77, P407, DOI 10.1016/S0007-0971(83)80079-5; KAHN FW, 1986, AM J CLIN PATHOL, V86, P518, DOI 10.1093/ajcp/86.4.518; KARAN GH, 1986, REV INFECT DIS, V3, P357; LAZRUS GH, 1975, J PEDIATR, V86, P415; LOURIA DB, 1963, T ASSOC AM PHYSICIAN, V76, P102; MCCABE RE, 1985, AM J MED, V78, P609, DOI 10.1016/0002-9343(85)90403-6; RINALDI MG, 1983, REV INFECT DIS, V5, P1061; ROGERS TR, 1990, LANCET, P1210; ROSSITER SJ, 1979, J THORAC CARDIOV SUR, V77, P338; SCHEINBERG MA, 1976, NEW ENGL J MED, V294, P1208, DOI 10.1056/NEJM197605272942204; YU LV, 1986, AM J MED, V81, P249	18	22	22	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					583	584		10.1136/bmj.302.6776.583	http://dx.doi.org/10.1136/bmj.302.6776.583			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021725	Bronze, Green Published			2022-12-28	WOS:A1991FB93600027
J	LILJA, GMC				LILJA, GMC			SINGLE UMBILICAL ARTERY AND MATERNAL SMOKING	BRITISH MEDICAL JOURNAL			English	Article											LILJA, GMC (corresponding author), UNIV LUND,DEPT EMBRYOL,S-22362 LUND,SWEDEN.							ASMUSSEN I, 1975, CIRC RES, V36, P579, DOI 10.1161/01.RES.36.5.579; BRYAN EM, 1974, ARCH DIS CHILD, V49, P844, DOI 10.1136/adc.49.11.844; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; LILJA M, 1991, PAEDIATRIC PERINATAL, V1, P27; MANTEL N, 1959, J NATL CANCER I, V22, P719	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					569	570		10.1136/bmj.302.6776.569	http://dx.doi.org/10.1136/bmj.302.6776.569			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB936	2021721	Bronze, Green Published			2022-12-28	WOS:A1991FB93600020
J	ROSE, GE; PEARSON, RV				ROSE, GE; PEARSON, RV			UNEQUAL PUPIL SIZE IN PATIENTS WITH UNILATERAL RED EYE	BRITISH MEDICAL JOURNAL			English	Article											ROSE, GE (corresponding author), MOORFIELDS EYE HOSP,LONDON EC1V 2PD,ENGLAND.							ALEXANDRIDIS E, 1985, PUPIL; ARMITAGE P, 1985, STATISTICAL METHODS, P111; ELKINGTON AR, 1988, BRIT MED J, V296, P1720, DOI 10.1136/bmj.296.6638.1720; Loewenfeld IE., 1979, TOPICS NEUROOPHTHALM, P124; MEYER BC, 1947, ARCH NEURO PSYCHIATR, V57, P464, DOI 10.1001/archneurpsyc.1947.02300270082005	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					571	572		10.1136/bmj.302.6776.571	http://dx.doi.org/10.1136/bmj.302.6776.571			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021723	Bronze, Green Published			2022-12-28	WOS:A1991FB93600022
J	BUKANTZ, SC; LOCKEY, RF				BUKANTZ, SC; LOCKEY, RF			ALLERGY AND IMMUNOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; DOUBLE-BLIND; FOOD SENSITIVITY; DEPENDENT ASTHMA; GENE-TRANSFER; IMMUNOTHERAPY; METHOTREXATE; MELANOMA; THERAPY; HUMANS				BUKANTZ, SC (corresponding author), UNIV S FLORIDA,COLL MED,TAMPA,FL 33612, USA.							ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; BENNETT JE, 1990, NEW ENGL J MED, V323, P1766, DOI 10.1056/NEJM199012203232509; COURNOYER D, 1990, NEW ENGL J MED, V323, P601, DOI 10.1056/NEJM199008303230909; DISMUKES WE, 1990, NEW ENGL J MED, V323, P1717, DOI 10.1056/NEJM199012203232501; FERGUSON A, 1990, NEW ENGL J MED, V323, P476, DOI 10.1056/NEJM199008163230709; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MATHIESON PW, 1990, NEW ENGL J MED, V323, P250, DOI 10.1056/NEJM199007263230407; MAYFORTH RD, 1990, NEW ENGL J MED, V323, P173; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; STECHSCHULTE DJ, 1990, NEW ENGL J MED, V33, P1769; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P	19	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3101	3103						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041111				2022-12-28	WOS:A1991FQ77000008
J	KLEBANOFF, MA; SHIONO, PH; RHOADS, GG				KLEBANOFF, MA; SHIONO, PH; RHOADS, GG			SPONTANEOUS AND INDUCED-ABORTION AMONG RESIDENT PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANESTHETIC-GASES; PREGNANCY; COMPLICATIONS; EXPOSURE; OUTCOMES	Female resident physicians are believed to be at an increased risk for a variety of third-trimester pregnancy complications. However, early pregnancy complications have been less well studied. This report compares spontaneous and induced abortions in a nationally representative sample of 5096 female medical school graduates (who experienced 1284 pregnancies) and of the sexual partners of 5000 of their male classmates (who experienced 1481 pregnancies). The response to the survey was 86.1%. The life-table probability of spontaneous abortion was 14.8% for female residents compared with 12.6% for the sexual partners of male residents. However, female residents were more likely than the male residents' sexual partners to terminate a pregnancy voluntarily (8.2% vs 2.7%). The increased risk of voluntary termination persisted when only married women were studied (3.6% vs 1.4%). However, female residents' pregnancies were at approximately half the risk of voluntary termination compared with pregnancies among the general US population of women aged 25 to 34 years. These results provide reassurance to those residents who would like to become pregnant but are concerned about the possible effect of their occupation on the course of the pregnancy.	DAVID & LUCILE PACKARD FDN,CTR FUTURE CHILDREN,LOS ALTOS,CA; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	KLEBANOFF, MA (corresponding author), NICHHD,DIV PREVENT RES,BLDG EPN,ROOM 640,BETHESDA,MD 20892, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092923] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-9-2923] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AXELSSON G, 1982, INT J EPIDEMIOL, V11, P250, DOI 10.1093/ije/11.3.250; CUNNINGHAM FG, 1989, WILLIAMS OBSTETRICS, P489; DIXON WJ, 1985, BMDP STATISTICAL SOF, P576; GRUNEBAUM A, 1987, AM J OBSTET GYNECOL, V157, P79, DOI 10.1016/S0002-9378(87)80350-2; HARLAP S, 1980, LANCET, V2, P173, DOI 10.1016/S0140-6736(80)90061-6; KATZ VL, 1988, WESTERN J MED, V149, P704; KLEBANOFF MA, 1990, NEW ENGL J MED, V323, P1040, DOI 10.1056/NEJM199010113231506; KNILLJONES RP, 1975, LANCET, V2, P807; LEE ET, 1980, STATISTICAL METHODS; MILLER NH, 1989, J REPROD MED, V34, P790; OSBORN LM, 1990, J FAM PRACTICE, V31, P618; PHELAN ST, 1988, OBSTET GYNECOL, V72, P431; SCHENKER MB, 1990, AM J EPIDEMIOL, V132, P96, DOI 10.1093/oxfordjournals.aje.a115648; SCHWARTZ RW, 1985, OBSTET GYNECOL, V66, P672; SELEVAN SG, 1985, NEW ENGL J MED, V313, P1173, DOI 10.1056/NEJM198511073131901; TANNENBAUM TN, 1985, J OCCUP ENVIRON MED, V27, P659; VENTURA S J, 1988, American Journal of Public Health, V78, P506, DOI 10.2105/AJPH.78.5.506; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; 1985, SAS USERS GUIDE STAT, P529	19	34	34	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2821	2825		10.1001/jama.265.21.2821	http://dx.doi.org/10.1001/jama.265.21.2821			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033738				2022-12-28	WOS:A1991FN85500030
J	MONTANER, JSG; LAWSON, LM; GERVAIS, A; HYLAND, RH; CHAN, CK; FALUTZ, JM; RENZI, PM; MACFADDEN, D; RACHLIS, AR; FONG, IW; GARBER, GE; SIMOR, A; GILMORE, N; FANNING, M; TAYLOR, GD; MARTEL, AY; SCHLECH, WF; SCHECHTER, MT				MONTANER, JSG; LAWSON, LM; GERVAIS, A; HYLAND, RH; CHAN, CK; FALUTZ, JM; RENZI, PM; MACFADDEN, D; RACHLIS, AR; FONG, IW; GARBER, GE; SIMOR, A; GILMORE, N; FANNING, M; TAYLOR, GD; MARTEL, AY; SCHLECH, WF; SCHECHTER, MT			AEROSOL PENTAMIDINE FOR SECONDARY PROPHYLAXIS OF AIDS-RELATED PNEUMOCYSTIS-CARINII PNEUMONIA - A RANDOMIZED, PLACEBO-CONTROLLED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CORTICOSTEROIDS; CHEMOPROPHYLAXIS; SULFAMETHOXAZOLE; PREVENTION; EFFICACY; TRIAL	Objective: To assess the safety and efficacy of aerosol pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Participants: Patients recovering from a first confirmed episode of AIDS-related P. carinii pneumonia who had no evidence of either another active AIDS-defining opportunistic infection or another pulmonary abnormality were considered eligible for the study but were included only if they had received no immunomodulators or antiretroviral agents other than zidovudine within 30 days of entry. One hundred sixty-two patients were randomized and started on the study drug. Intervention: Patients were randomly assigned to receive aerosol pentamidine, 60 mg per dose, or placebo, delivered using a hand-held, patient-triggered, ultrasonic nebulizer. The induction phase of treatment consisted of 5 doses over 14 days, followed by a maintenance phase beginning on day 21 and consisting of one dose every 2 weeks. Results: Thirty-two cases of P. carinii pneumonia were diagnosed before the termination of the trial; 27 cases occurred among 78 patients receiving placebo and 5 occurred among 84 patients receiving aerosol pentamidine. Estimates of the cumulative relapse rate of P. carinii pneumonia by 24 weeks were 50% and 9% for the placebo and pentamidine groups, respectively (P < 0.001). Adverse reactions attributed to the study drug occurred in 15 of 78 patients receiving placebo and in 28 of 84 patients receiving pentamidine (P = 0.04). These were all mild or moderate in severity and did not preclude continued administration of the study drug. Conclusion: Intermittent therapy with aerosol pentamidine is highly effective and well tolerated as secondary prophylaxis for AIDS-related P. carinii pneumonia.	NOTRE DAME HOSP, MONTREAL H2L 4M1, QUEBEC, CANADA; MONTREAL GEN HOSP, MONTREAL H3G 1A4, QUEBEC, CANADA; ST LUKES HOSP, MONTREAL H2X 3J4, QUEBEC, CANADA; ROYAL VICTORIA HOSP, DIV CLIN IMMUNOL, MONTREAL H3A 1A1, QUEBEC, CANADA; MCGILL UNIV, MONTREAL H3A 2T5, QUEBEC, CANADA; WELLESLEY COLL HOSP, TORONTO M4Y 1J3, ONTARIO, CANADA; TORONTO WESTERN HOSP, TORONTO M5T 2S8, ONTARIO, CANADA; ST MICHAELS HOSP, TORONTO M5B 1W8, ONTARIO, CANADA; MT SINAI HOSP, DEPT MICROBIOL, TORONTO M5G 1X5, ONTARIO, CANADA; TORONTO GEN HOSP, DIV INFECT DIS, TORONTO M5G 1L7, ONTARIO, CANADA; SUNNYBROOK MED CTR, TORONTO M4N 3M5, ONTARIO, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA; OTTAWA GEN HOSP, DEPT INFECT DIS, OTTAWA K1H 8L6, ONTARIO, CANADA; UNIV ALBERTA HOSP, INFECT DIS UNIT, EDMONTON T6G 2B7, ALBERTA, CANADA; CHU LAVAL, QUEBEC CITY G1V 4G2, QUEBEC, CANADA; VICTORIA GEN HOSP, HALIFAX B3H 2Y9, NS, CANADA	Universite de Montreal; McGill University; Universite de Montreal; McGill University; Royal Victoria Hospital; McGill University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Ottawa; Ottawa Hospital Research Institute; University of Alberta; Laval University; Dalhousie University; University of Victoria	MONTANER, JSG (corresponding author), UNIV BRITISH COLUMBIA, ST PAULS HOSP, AIDS RES PROGRAMME, SUITE 210, 1033 DAVIE ST, VANCOUVER V6E 1M7, BC, CANADA.			Schechter, Martin/0000-0001-6063-2155				ARMSTRONG D, 1988, ANN INTERN MED, V109, P852, DOI 10.7326/0003-4819-109-11-852; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1988, AIDS, V2, pS143, DOI 10.1097/00002030-198800001-00022; GIRARD PM, 1987, ANTIMICROB AGENTS CH, V31, P978, DOI 10.1128/AAC.31.7.978; GIRARD PM, 1989, LANCET, V1, P1348; GOLDEN JA, 1989, LANCET, V1, P654; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1973, J INFECT DIS, V128, P607; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACS JA, 1990, ANN INTERN MED, V113, P1, DOI 10.7326/0003-4819-113-1-1; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LUCE JM, 1988, AM REV RESPIR DIS, V137, P1261, DOI 10.1164/ajrccm/137.6.1261; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; MONTANER JSG, 1989, CHEST, V95, P881, DOI 10.1378/chest.95.4.881; MURPHY R, 1989, CLIN RES, V37, pA944; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; ODOHERTY MJ, 1988, LANCET, V2, P1283; ROSSI MR, 1987, EUR J CANCER CLIN ON, V23, P1679, DOI 10.1016/0277-5379(87)90449-4; SMALDONE GC, 1988, J AEROSOL MED, V1, P113; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; TELZAK EE, 1990, REV INFECT DIS, V12, P380; 1989, MMWR S5, V38, P1	26	92	92	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					948	953		10.7326/0003-4819-114-11-948	http://dx.doi.org/10.7326/0003-4819-114-11-948			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024862				2022-12-28	WOS:A1991FM97900006
J	POHL, MA; LAN, SP; BERL, T				POHL, MA; LAN, SP; BERL, T			PLASMAPHERESIS DOES NOT INCREASE THE RISK FOR INFECTION IN IMMUNOSUPPRESSED PATIENTS WITH SEVERE LUPUS NEPHRITIS	ANNALS OF INTERNAL MEDICINE			English	Article							PLASMA-EXCHANGE; GLOMERULONEPHRITIS; THERAPY; TRIAL	Objective: To determine whether plasmapheresis increases the risk for infection in immunosuppressed patients. Design: Randomized, controlled trial. Setting: Multicenter. Patients: Eighty-six patients enrolled in a trial of plasmapheresis for severe diffuse proliferative lupus nephritis. Interventions: Forty-six of the patients received high-dose steroid therapy plus cyclophosphamide therapy for 8 weeks. Thereafter, cyclophosphamide therapy was discontinued, and steroid therapy was tapered (standard treatment group). Forty patients received identical treatment and had 12 plasmapheresis procedures during the first 4 weeks of the treatment. Measurements: Patients were examined for the development of infection. Main Results: No statistical difference in age, sex, race, serum creatinine level, proteinuria, or complement levels was found between the two groups. Over a follow-up period of 5376 patient-weeks, 74% of patients in the standard treatment group had 62 infections, yielding an aggregate infection rate of 1.15 infections per 100 weeks (median individual infection rate, 1.08: 25th and 75th percentiles,0.0 and 2.44). This rate was comparable to that seen in the plasmapheresis-treated patients who were followed for 4187 patient-weeks: 68% had 51 infections, for an aggregate infection rate of 1.22 infections per 100 weeks (median individual infections rate, 0.94; 25th and 75th percentiles, 0.0 and 2.32). The infection rate was also comparable in the initial acute phase of the study, despite the fact that patients who received plasmapheresis then had significantly lower immunoglobulin (IgG) levels (P < 0.001). Neither the site (superficial compared with systemic) nor the nature (conventional compared with unconventional) of infection differed statistically between the two groups. Of 14 patient deaths, 7 were from infection (4 in the control group and 3 in the plasmapheresis group). Conclusion: Plasmapheresis did not increase the risk for infection in immunosuppressed patients with severe lupus nephritis.	GEORGE WASHINGTON UNIV, CTR BIOSTAT, WASHINGTON, DC 20052 USA; UNIV COLORADO, SCH MED, DENVER, CO 80202 USA	George Washington University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	POHL, MA (corresponding author), CLEVELAND CLIN FDN, DEPT HYPERTENS & NEPHROL, 1 CLIN CTR, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.				NIDDK NIH HHS [R01-DK-27770] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027770] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CLOUGH JD, 1990, PROG CLIN BIOL RES, P301; Cochran W.G, 1957, STAT METHODS, V6th ed; COHEN A S, 1971, Bulletin on the Rheumatic Diseases, V21, P643; CONOVER W. J, 1980, PRACTICAL NONPARAMET; DWOSH IL, 1983, NEW ENGL J MED, V308, P1124, DOI 10.1056/NEJM198305123081903; Fleiss JL, 1981, STAT METHODS RATES P; HERBERT L, 1987, KIDNEY INT, V31, P201; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUESTIS DW, 1983, LANCET, V1, P1043; KASHGARIAN M, 1982, AM J KIDNEY DIS, V2, P164; KRAKAUER R, 1982, Arthritis and Rheumatism, V25, pS80; LEWIS E, 1987, KIDNEY INT, V31, P208; LOCKWOOD CM, 1977, LANCET, V1, P63; RUBIN RH, 1981, AM J MED, V70, P405, DOI 10.1016/0002-9343(81)90780-4; SCHWARTZ MM, 1989, AM J KIDNEY DIS, V13, P273, DOI 10.1016/S0272-6386(89)80033-2; SHUMAK KH, 1984, NEW ENGL J MED, V310, P762, DOI 10.1056/NEJM198403223101206; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WALKER RG, 1977, MED J AUSTRALIA, V1, P875, DOI 10.5694/j.1326-5377.1977.tb131209.x; WING EJ, 1980, JAMA-J AM MED ASSOC, V244, P2423, DOI 10.1001/jama.244.21.2423; 1982, LANCET, V2, P1025; 1986, J CLIN APHRESIS, V3, P1; 1985, SAS USERS GUIDE BASI	22	70	70	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					924	929		10.7326/0003-4819-114-11-924	http://dx.doi.org/10.7326/0003-4819-114-11-924			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024858				2022-12-28	WOS:A1991FM97900002
J	SATTLER, FR; KO, R; ANTONISKIS, D; SHIELDS, M; COHEN, J; NICOLOFF, J; LEEDOM, J; KODA, R				SATTLER, FR; KO, R; ANTONISKIS, D; SHIELDS, M; COHEN, J; NICOLOFF, J; LEEDOM, J; KODA, R			ACETAMINOPHEN DOES NOT IMPAIR CLEARANCE OF ZIDOVUDINE	ANNALS OF INTERNAL MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; AZIDOTHYMIDINE AZT; DOUBLE-BLIND; PHARMACOKINETICS	Objective: To determine whether concurrent treatment with acetaminophen and zidovudine impairs clearance of zidovudine, thereby increasing the risk for zidovudine-induced hematologic toxicity. Design: Dose escalation, drug interaction study. Setting: University clinical research center. Patients: Patients with the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Interventions: Acetaminophen and 200 mg of zidovudine simultaneously every 4 hours. For 13 patients, the unit dosage of acetaminophen was 325 mg for 3 days; for 8 patients, the dosage was 650 mg for 3 days; and, for 6 patients, the dosage was 650 mg for 7 days. Measurements: Zidovudine clearance and production of the glucuronide conjugate of zidovudine were assessed after acetaminophen treatment. Main Results: Neither zidovudine clearance nor production of the glucuronide conjugate of zidovudine was impaired after treatment with acetaminophen. Clearance of zidovudine was actually accelerated by 5%, 11%, and 33% with the three acetaminophen regimens,respectively (P = 0.002 by analysis of variance; P = 0.04 for linear trend when changes in the area-under-the-curve for zidovudine were compared). Conclusion: Because serum concentrations of zidovudine decrease after the coadministration of acetaminophen, a pharmacokinetic interaction between zidovudine and acetaminophen is unlikely to increase the risk for hematologic toxicity associated with zidovudine.			SATTLER, FR (corresponding author), UNIV SO CALIF, LOS ANGELES CTY MED CTR, 1175 N CUMMINGS ST, LOS ANGELES, CA 90033 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI062540] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR-43] Funding Source: Medline; NIAID NIH HHS [N0I-AI-62540] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLUM MR, 1988, AM J MED, V85, P189; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOOD SS, 1988, J CHROMATOGR-BIOMED, V431, P123, DOI 10.1016/S0378-4347(00)83075-3; JENNRICH R, 1988, BMDP STATISTICAL SOF, V1, P483; KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49; LEVY G, 1971, J PHARM SCI, V60, P215, DOI 10.1002/jps.2600600212; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROCCI ML, 1983, COMPUT PROG BIOMED, V16, P203, DOI 10.1016/0010-468X(83)90082-X; SINGLAS E, 1989, EUR J CLIN PHARMACOL, V36, P639, DOI 10.1007/BF00637752; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	12	22	22	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					937	940		10.7326/0003-4819-114-11-937	http://dx.doi.org/10.7326/0003-4819-114-11-937			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024860				2022-12-28	WOS:A1991FM97900004
J	[Anonymous]				[Anonymous]			ENGLAND IMPOSES 72-HOUR LIMIT ON RESIDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2742	2742						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023358				2022-12-28	WOS:A1991FL98900042
J	MURPHY, TJ; ALEXANDER, RW; GRIENDLING, KK; RUNGE, MS; BERNSTEIN, KE				MURPHY, TJ; ALEXANDER, RW; GRIENDLING, KK; RUNGE, MS; BERNSTEIN, KE			ISOLATION OF A CDNA-ENCODING THE VASCULAR TYPE-1 ANGIOTENSIN-II RECEPTOR	NATURE			English	Article							SMOOTH-MUSCLE CELLS; CONVERTING ENZYME; MOLECULAR-CLONING; SYSTEM; EXPRESSION; CAPTOPRIL; PROTEINS; SUBTYPES; CALCIUM; FAMILY	ANGIOTENSIN II is an important effector molecule controlling blood pressure and volume in the cardiovascular system 1. Its importance is manifested by the efficacy of angiotensin-converting enzyme inhibitors in the treatment of hypertension and congestive heart failure 2,3. Angiotensin II interacts with two pharmacologically distinct subtypes of cell-surface receptors, AT1 and AT2 (ref. 4). AT1 receptors seem to mediate the major cardiovascular effects of angiotensin II 5,6. Here we report the isolation by expression cloning of a complementary DNA encoding a unique protein with the pharmacological specificity of a vascular AT1 receptor. Hydropathic modelling of the deduced protein suggests that it shares the seven-transmembrane-region motif with the G protein-coupled receptor superfamily 7. Knowledge of the AT1 receptor primary sequence should now permit structural analysis, definition of the angiotensin II receptor gene family and delineation of the contribution of AT receptors to the genetic component of hypertension.	EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOL,ATLANTA,GA 30322	Emory University	MURPHY, TJ (corresponding author), EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322, USA.			Bernstein, Kenneth/0000-0001-8097-3272; Griendling, Kathy/0000-0002-9456-8582				ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAUER JH, 1984, AM J MED, V77, P43, DOI 10.1016/S0002-9343(84)80057-1; BOUSCAREL B, 1988, J BIOL CHEM, V263, P14913; BUMPUS FM, IN PRESS HYPERTENSIO; CAPPONI AM, 1981, BIOCH REGULATION BLO, P205; CHANG RSL, 1990, MOL PHARMACOL, V29, P347; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHIU AT, 1989, J PHARMACOL EXP THER, V250, P867; CHIU AT, 1989, EUR J PHARMACOL, V170, P117, DOI 10.1016/0014-2999(89)90145-3; DAVIS R, 1979, NEW ENGL J MED, V301, P117, DOI 10.1056/NEJM197907193010301; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOUGLAS JG, 1987, AM J PHYSIOL, V253, pF1, DOI 10.1152/ajprenal.1987.253.1.F1; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ESCHER E, 1988, PHARMACOL THERAPEUT, V37, P37, DOI 10.1016/0163-7258(88)90018-6; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MILLAN MA, 1989, SCIENCE, V244, P1340, DOI 10.1126/science.2734613; MURPHY TJ, 1988, J PHARMACOL EXP THER, V244, P571; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PHILLIPS MI, 1987, ANNU REV PHYSIOL, V49, P413, DOI 10.1146/annurev.physiol.49.1.413; Sakarai T., 1990, NATURE, V348, P732; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SOCORRO L, 1990, BIOCHEM J, V265, P799, DOI 10.1042/bj2650799; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WONG PC, 1990, J PHARMACOL EXP THER, V255, P584; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	31	1237	1263	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1991	351	6323					233	236		10.1038/351233a0	http://dx.doi.org/10.1038/351233a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041570				2022-12-28	WOS:A1991FL99000057
J	ODEH, M				ODEH, M			MECHANISMS OF DISEASE - THE ROLE OF REPERFUSION-INDUCED INJURY IN THE PATHOGENESIS OF THE CRUSH SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE-RENAL-FAILURE; POSTISCHEMIC SKELETAL-MUSCLE; FREE-RADICAL SCAVENGERS; SUPEROXIDE-DISMUTASE; RAT HEARTS; TRAUMATIC RHABDOMYOLYSIS; NEUTROPHIL INFILTRATION; MYOCARDIAL REPERFUSION; SARCOLEMMAL ENZYMES; NA+-CA2+ EXCHANGE		BNAI ZION MED CTR,DEPT INTERNAL MED B,HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC MED,HAIFA,ISRAEL	Bnai Zion Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine								AKERA T, 1982, ANNU REV PHYSIOL, V44, P375, DOI 10.1146/annurev.ph.44.030182.002111; ALLEN DG, 1987, CIRC RES, V60, P153, DOI 10.1161/01.RES.60.2.153; BAGGE U, 1980, ACTA PHYSIOL SCAND, V108, P159, DOI 10.1111/j.1748-1716.1980.tb06513.x; BAKER GL, 1985, ANN SURG, V202, P628, DOI 10.1097/00000658-198511000-00016; BARTON R, 1989, CHEST, V96, P1153, DOI 10.1378/chest.96.5.1153; BELKIN M, 1989, J VASC SURG, V10, P14, DOI 10.1067/mva.1989.vs0100014; BERSOHN MM, 1982, AM J PHYSIOL, V242, pC288, DOI 10.1152/ajpcell.1982.242.5.C288; BETTER OS, 1990, NEW ENGL J MED, V322, P825; BETTER OS, 1989, ISRAEL J MED SCI, V25, P69; BETTER OS, 1990, NEPHRON, V55, P97, DOI 10.1159/000185934; BETTER OS, 1990, MINER ELECTROL METAB, V16, P181; BRAUGHLER JM, 1988, OXYGEN RADICALS TISS, P99; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; CAMBRIA RP, 1984, ARCH SURG-CHICAGO, V119, P784; CARDEN DL, 1990, CIRC RES, V66, P1436, DOI 10.1161/01.RES.66.5.1436; CIUFFETTI G, 1989, BRIT MED J, V298, P930, DOI 10.1136/bmj.298.6678.930; CRAKE T, 1986, J MOL CELL CARDIOL, V18, P31, DOI 10.1016/S0022-2828(86)80023-2; CURRY SC, 1989, ANN EMERG MED, V18, P1068, DOI 10.1016/S0196-0644(89)80933-3; DALY MJ, 1984, AM J PHYSIOL, V247, pH237, DOI 10.1152/ajpheart.1984.247.2.H237; DENNIS SC, 1990, CIRC RES, V66, P1156, DOI 10.1161/01.RES.66.4.1156; DUNCAN CJ, 1987, J CELL SCI, V87, P183; ENEAS JF, 1979, ARCH INTERN MED, V139, P801, DOI 10.1001/archinte.139.7.801; FREEMAN BA, 1982, LAB INVEST, V47, P412; GRINWALD PM, 1981, J MOL CELL CARDIOL, V13, P867, DOI 10.1016/0022-2828(81)90286-8; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; HAIMOVICI H, 1979, J CARDIOVASC SURG, V20, P349; HEARSE DJ, 1978, J MOL CELL CARDIOL, V10, P641, DOI 10.1016/S0022-2828(78)80004-2; HONDA N, 1983, KIDNEY INT, V23, P888, DOI 10.1038/ki.1983.112; HORGAN MJ, 1989, AM REV RESPIR DIS, V140, P1421, DOI 10.1164/ajrccm/140.5.1421; JACKSON RM, 1989, AM J MED SCI, V298, P44, DOI 10.1097/00000441-198907000-00009; JENNINGS RB, 1964, CIRC RES, V14, P260, DOI 10.1161/01.RES.14.3.260; JENNISCHE E, 1984, ACTA PATH MICRO IM A, V92, P139; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; KLAUSNER JM, 1988, ANN SURG, V208, P755, DOI 10.1097/00000658-198812000-00014; KLAUSNER JM, 1988, ANN SURG, V208, P761, DOI 10.1097/00000658-198812000-00015; KNOCHEL JP, 1981, SEMIN NEPHROL, V1, P75; KORTHUIS RJ, 1985, CIRC RES, V57, P599, DOI 10.1161/01.RES.57.4.599; KORTHUIS RJ, 1988, AM J PHYSIOL, V254, pH823, DOI 10.1152/ajpheart.1988.254.5.H823; KORTHUIS RJ, 1989, AM J PHYSIOL, V256, pH315, DOI 10.1152/ajpheart.1989.256.1.H315; LABBE R, 1987, J VASC SURG, V6, P152, DOI 10.1067/mva.1987.avs0060152; LAKATTA EG, 1979, EUR J CARDIOL, V10, P77; LEE KR, 1987, J SURG RES, V42, P24, DOI 10.1016/0022-4804(87)90060-6; LINAS SL, 1990, AM J PHYSIOL, V258, pF711, DOI 10.1152/ajprenal.1990.258.3.F711; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCORD JM, 1987, FASEB J, V46, P2402; MCCULLY KK, 1985, J APPL PHYSIOL, V59, P119, DOI 10.1152/jappl.1985.59.1.119; MCCUTCHAN HJ, 1990, AM J PHYSIOL, V258, pH1415, DOI 10.1152/ajpheart.1990.258.5.H1415; NAYLER WG, 1979, J MOL CELL CARDIOL, V11, P683, DOI 10.1016/0022-2828(79)90381-X; OGILVIE RW, 1988, AM J ANAT, V182, P335, DOI 10.1002/aja.1001820405; OURIEL K, 1985, J VASC SURG, V2, P49, DOI 10.1067/mva.1985.avs0020049; PALLER MS, 1988, AM J PHYSIOL, V255, pF539, DOI 10.1152/ajprenal.1988.255.3.F539; PANAGIOTOPOULOS S, 1990, AM J PHYSIOL, V258, pH821, DOI 10.1152/ajpheart.1990.258.3.H821; PARKS DA, 1986, AM J PHYSIOL, V250, pG749, DOI 10.1152/ajpgi.1986.250.6.G749; PERRY MO, 1984, J VASC SURG, V1, P536, DOI 10.1067/mva.1984.avs0010536; PHILIPSON KD, 1982, CIRC RES, V50, P287, DOI 10.1161/01.RES.50.2.287; PIERCE GN, 1990, AM J PHYSIOL, V258, pH17, DOI 10.1152/ajpheart.1990.258.1.H17; POOLEWILSON PA, 1984, J MOL CELL CARDIOL, V16, P175, DOI 10.1016/S0022-2828(84)80706-3; PRESTA M, 1981, CLIN CHEM, V27, P297; Ramsay G, 1988, Prog Clin Biol Res, V272, P237; REGAN TJ, 1980, AM J PHYSIOL, V238, pH575, DOI 10.1152/ajpheart.1980.238.4.H575; REYNOLDS JM, 1989, AM J PHYSIOL, V256, pH982, DOI 10.1152/ajpheart.1989.256.4.H982; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; Roy R.S., 1983, CELLULAR MED ASPECTS, VII, P145; SEXTON WL, 1990, J APPL PHYSIOL, V68, P387, DOI 10.1152/jappl.1990.68.1.387; SHAH SV, 1988, AM J PHYSIOL, V255, pF438, DOI 10.1152/ajprenal.1988.255.3.F438; SHEN AC, 1972, AM J PATHOL, V67, P441; SIMPSON PJ, 1990, CIRCULATION, V81, P226, DOI 10.1161/01.CIR.81.1.226; SMITH JK, 1989, AM J PHYSIOL, V256, pH789, DOI 10.1152/ajpheart.1989.256.3.H789; SMITH JK, 1988, PHYSIOLOGIST, V31, pA31; STEENBERGEN C, 1987, CIRC RES, V60, P700, DOI 10.1161/01.RES.60.5.700; SUZUKI M, 1989, AM J PHYSIOL, V257, pH1740, DOI 10.1152/ajpheart.1989.257.5.H1740; TANI M, 1989, CIRC RES, V65, P1045, DOI 10.1161/01.RES.65.4.1045; TRACEY KJ, 1989, LANCET, V1, P1122; Trump B F, 1980, Scan Electron Microsc, P437; TRUMP BF, 1980, SCANNING ELECTRON MI, V2, P492; VANGILST WH, 1989, J CARDIOVASC PHARM, V14, pS49; WALKER PM, 1987, J VASC SURG, V5, P68; WARD MM, 1988, ARCH INTERN MED, V148, P1553, DOI 10.1001/archinte.148.7.1553; WATTS JA, 1980, AM J PHYSIOL, V238, pH909, DOI 10.1152/ajpheart.1980.238.6.H909; WEISS RG, 1990, CIRC RES, V66, P1012, DOI 10.1161/01.RES.66.4.1012; WROGEMANN K, 1976, LANCET, V1, P672	81	172	187	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1417	1422						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020298				2022-12-28	WOS:A1991FL12500007
J	CHEN, JH; SEEMAN, NC				CHEN, JH; SEEMAN, NC			SYNTHESIS FROM DNA OF A MOLECULE WITH THE CONNECTIVITY OF A CUBE	NATURE			English	Article							NUCLEIC-ACID JUNCTIONS; DESIGN	A PRINCIPAL goal of biotechnology is the assembly of novel biomaterials for analytical, industrial and therapeutic purposes. The advent of stable immobile nucleic acid branched junctions 1-4 makes DNA a good candidate for building frameworks to which proteins or other functional molecules can be attached and thereby juxtaposed 5-7. The addition of single-stranded 'sticky' ends 8 to branched DNA molecules converts them into macromolecular valence clusters that can be ligated together 1. The edges of these frameworks are double-helical DNA, and the vertices correspond to the branch points of junctions. Here, we report the construction from DNA of a covalently closed cube-like molecular complex containing twelve equal-length double-helical edges arranged about eight vertices. Each of the six 'faces' of the object is a single-stranded cyclic molecule, doubly catenated to four neighbouring strands, and each vertex is connected by an edge to three others. Each edge contains a unique restriction site for analytical purposes. This is the first construction of a closed polyhedral object from DNA.			CHEN, JH (corresponding author), NYU,DEPT CHEM,NEW YORK,NY 10003, USA.		Chen, Junghuei/B-5217-2011					CARUTHERS MH, 1981, CHEM ENZYMATIC SYNTH, P71; CHEN JH, 1989, J AM CHEM SOC, V111, P6402, DOI 10.1021/ja00198a063; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; HOPFIELD JJ, 1988, SCIENCE, V241, P817, DOI 10.1126/science.241.4867.817; KALLENBACH NR, 1983, NATURE, V305, P829, DOI 10.1038/305829a0; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; ROBINSON BH, 1987, PROTEIN ENG, V1, P295, DOI 10.1093/protein/1.4.295; SEEMAN NC, 1988, J BIOMOL STRUCT DYN, V5, P997, DOI 10.1080/07391102.1988.10506445; SEEMAN NC, 1983, BIOPHYS J, V44, P201, DOI 10.1016/S0006-3495(83)84292-1; SEEMAN NC, 1982, J THEOR BIOL, V99, P237, DOI 10.1016/0022-5193(82)90002-9; SEEMAN NC, 1990, J BIOMOL STRUCT DYN, V8, P573, DOI 10.1080/07391102.1990.10507829; SEEMAN NC, 1985, J BIOMOL STRUCT DYN, V3, P11, DOI 10.1080/07391102.1985.10508395; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; Wells A. F., 1977, 3 DIMENSIONAL NETS P; [No title captured]	15	1028	1094	13	354	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					631	633		10.1038/350631a0	http://dx.doi.org/10.1038/350631a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017259				2022-12-28	WOS:A1991FH11200067
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - NORMAL ANTENATAL MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					774	779		10.1136/bmj.302.6779.774	http://dx.doi.org/10.1136/bmj.302.6779.774			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021770	Green Published, Bronze			2022-12-28	WOS:A1991FF22900030
J	BALARAJAN, R				BALARAJAN, R			ETHNIC-DIFFERENCES IN MORTALITY FROM ISCHEMIC-HEART-DISEASE AND CEREBROVASCULAR-DISEASE IN ENGLAND AND WALES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIGH-DENSITY-LIPOPROTEIN; ASIAN POPULATION GROUPS; CORONARY RISK-FACTORS; BLOOD-PRESSURE; INDIAN DESCENT; EAST LONDON; BIRMINGHAM; PREVALENCE; WHITE; MEN	Objective - To examine mortality from ischaemic heart disease and cerebrovascular disease in England and Wales by country of birth of the deceased. Design - Standardised mortality ratios were computed by country of birth groups for ischaemic heart disease and cerebrovascular disease for 1979-83 and 1970-2 by using the five year age-sex specific rates for England and Wales for 1979-83 as standard. Setting - England and Wales 1970-2 and 1979-83. Results - In 1979-83 mortality from ischaemic heart disease was highest in men and women born in the Indian subcontinent (standardised mortality ratio 136 and 146 respectively). Young Indian men suffered the greatest excess (313 at ages 20-29). Other groups with raised mortality included Irish, Scottish, and Polish born immigrants. Those born in the Caribbean, the old Commonwealth, west Europe, and the United States had low death rates. In England and Wales mortality from ischaemic heart disease declined by 5% in men and 1% in women between 1970-2 and 1979-83, with greatest percentage declines in immigrants born in the United States, South Africa, the old Commonwealth, the Caribbean, and France. Immigrant groups with raised mortality in the earlier period showed little improvement, and mortality from ischaemic heart disease increased among Indians (6% in men and 13% in women). In 1979-83 mortality from cerebrovascular disease was highest in Caribbeans (standardised mortality ratios 176 in men and 210 in women), followed by Africans, Indians, and Irish. Rates were low in west Europeans. Mortality from stroke declined by 28% overall in this period, a rate of decline shared by most groups. Men from the Indian subcontinent showed a decline of only 3%. Conclusion - In the 1980s mortality from ischaemic heart disease and cerebrovascular disease differed significantly between ethnic groups in England and Wales. In general, ethnic groups that experienced lower mortality from ischaemic heart disease in the 1970s showed the greatest improvement over the following decade.			BALARAJAN, R (corresponding author), UNIV SURREY, EPIDEMIOL & PUBL HLTH RES UNIT, GUILDFORD GU2 5XH, SURREY, ENGLAND.							BALARAJAN R, 1986, COMMUNITY MED, V8, P237; BALARAJAN R, 1990, DS9 OFF POP CENS SUR; BALARAJAN R, 1984, BRIT MED J, V289, P185; BECKLES GLA, 1986, LANCET, V1, P1298; CRUICKSHANK JK, 1980, BRIT MED J, V281, P1108, DOI 10.1136/bmj.281.6248.1108; CRUICKSHANK JK, 1983, POSTGRAD MED J, V59, P622, DOI 10.1136/pgmj.59.696.622; DEGIOVANNI JV, 1983, POSTGRAD MED J, V59, P627, DOI 10.1136/pgmj.59.696.627; DERRY CW, 1987, S AFR MED J, V72, P698; DISLER PB, 1987, S AFR MED J, V72, P408; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GRELL GAC, 1983, POSTGRAD MED J, V59, P616, DOI 10.1136/pgmj.59.696.616; KEIL JE, 1980, J EPIDEMIOL COMMUN H, V34, P45, DOI 10.1136/jech.34.1.45; Malhotra S L, 1971, J Assoc Physicians India, V19, P211; MARMOR MG, 1984, 47 OFF POP CENS SURV; MARMOT MG, 1984, SCI F CARDIOLOGY; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1985, LANCET, V2, P1086; MILLER GJ, 1982, LANCET, V2, P200; MILLER GJ, 1975, LANCET, V1, P16; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; OMAR MAK, 1985, S AFR MED J, V67, P924; POCOCK SJ, 1986, BMJ-BRIT MED J, V292, P515, DOI 10.1136/bmj.292.6519.515; POONKING T, 1968, LANCET, V1, P155; Seedat Y K, 1983, J Hypertens, V1, P7; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SILMAN A, 1985, J EPIDEMIOL COMMUN H, V39, P301, DOI 10.1136/jech.39.4.301; STOUT RW, 1987, LANCET, V1, P1077; STOUT RW, 1969, LANCET, V1, P1078; ZIMMET P, 1983, AM J EPIDEMIOL, V118, P673, DOI 10.1093/oxfordjournals.aje.a113678; 1986, LANCET, V1, P1307; 1988, CORONARY HEART DISEA, V1; 1989, NATIONAL HLTH SERVIC	34	328	328	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	1991	302	6776					560	564		10.1136/bmj.302.6776.560	http://dx.doi.org/10.1136/bmj.302.6776.560			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021718	Bronze, Green Published			2022-12-28	WOS:A1991FB93600017
J	CECCARELLI, A; MAHBUBANI, H; WILLIAMS, JG				CECCARELLI, A; MAHBUBANI, H; WILLIAMS, JG			POSITIVELY AND NEGATIVELY ACTING SIGNALS REGULATING STALK CELL AND ANTERIOR-LIKE CELL-DIFFERENTIATION IN DICTYOSTELIUM	CELL			English	Article							PRESTALK GENE-EXPRESSION; DISCOIDEUM; DIF; CAMP; TRANSFORMATION; MORPHOGEN; PROTEINS; FATE; SLUG	The Dictyostelium ecmB gene encodes an extracellular matrix protein and is inducible by the stalk cell morphogen DIF. It is expressed in a subset of prestalk (pstB) cells in the slug and surrounding pstA cells first express it at culmination. A region of the ecmB promoter can direct transcription in all anterior prestalk cells, but a separate, downstream region acts to prevent its expression in pstA cells prior to culmination. Th is may be the site of interaction of a repressor, regulated by an extracellular antagonist to DIF. At culmination, expression of the ecmB gene also becomes greatly elevated in anterior-like cells as they move to surround the spore mass. A distal region of the ecmB promoter directs increased expression in those anterior-like cells that surmount the spore head. This divergence in gene expression suggests that anterior-like cells and anterior prestalk cells experience different inductive conditions at culmination.			CECCARELLI, A (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,BLANCHE LANE,POTTERS BAR EN6 3LD,HERTS,ENGLAND.							AYRES K, 1987, MOL CELL BIOL, V7, P1823, DOI 10.1128/MCB.7.5.1823; BERKS M, 1988, DEV BIOL, V126, P108, DOI 10.1016/0012-1606(88)90244-8; BERKS M, 1990, DEVELOPMENT, V110, P977; BLASCHKE A, 1986, DIFFERENTIATION, V32, P1, DOI 10.1111/j.1432-0436.1986.tb00549.x; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BROOKMAN JJ, 1987, DEVELOPMENT, V100, P119; DEVINE KM, 1985, DEV BIOL, V107, P364, DOI 10.1016/0012-1606(85)90318-5; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; GREGG JH, 1982, DIFFERENTIATION, V21, P200, DOI 10.1111/j.1432-0436.1982.tb01214.x; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JERMYN KA, 1987, DEVELOPMENT, V100, P745; KAKUTANI T, 1986, DEV BIOL, V115, P439, DOI 10.1016/0012-1606(86)90264-2; MASENTO MS, 1988, BIOCHEM J, V256, P23, DOI 10.1042/bj2560023; MCROBBIE SJ, 1988, DEV BIOL, V125, P59, DOI 10.1016/0012-1606(88)90058-9; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MORRISSEY JH, 1984, DEV BIOL, V103, P414, DOI 10.1016/0012-1606(84)90329-4; NEAVE N, 1986, BIOCHEM CELL BIOL, V64, P85, DOI 10.1139/o86-015; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; RILEY BB, 1990, DEVELOPMENT, V109, P715; SCHAAP P, 1985, DEV BIOL, V111, P51, DOI 10.1016/0012-1606(85)90434-8; SCHINDLER J, 1977, J MOL BIOL, V116, P161, DOI 10.1016/0022-2836(77)90124-3; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; THALLER C, 1987, NATURE, V327, P626; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WANG M, 1990, DEV BIOL, V140, P182, DOI 10.1016/0012-1606(90)90065-Q; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9	34	112	113	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					983	989		10.1016/0092-8674(91)90550-I	http://dx.doi.org/10.1016/0092-8674(91)90550-I			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044155				2022-12-28	WOS:A1991FR04700009
J	GEISER, JR; VANTUINEN, D; BROCKERHOFF, SE; NEFF, MM; DAVIS, TN				GEISER, JR; VANTUINEN, D; BROCKERHOFF, SE; NEFF, MM; DAVIS, TN			CAN CALMODULIN FUNCTION WITHOUT BINDING CALCIUM	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; YEAST CALMODULIN; SCHIZOSACCHAROMYCES-POMBE; GENETIC-EVIDENCE; DNA-POLYMERASE; PROTEIN-KINASE; CA-2+; CELLS; VERTEBRATE	Calmodulin is a small Ca2+-binding protein proposed to act as the intracellular Ca2+ receptor that translates Ca2+ signals into cellular responses. We have constructed mutant yeast calmodulins in which the Ca2+-binding loops have been altered by site-directed mutagenesis. Each of the mutant proteins has a dramatically reduced affinity for Ca2+; one does not bind detectable levels of Ca-45(2+) either during gel filtration or when bound to a solid support. Furthermore, none of the mutant proteins change conformation even in the presence of high Ca2+ concentrations. Surprisingly, yeast strains relying on any of the mutant calmodulins not only survive but grow well. In contrast, yeast strains deleted for the calmodulin gene are not viable. Thus, calmodulin is required for growth, but it can perform its essential function without the apparent ability to bind Ca2+.			GEISER, JR (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195, USA.		Davis, Trisha/F-8584-2010	Davis, Trisha/0000-0003-4797-3152				ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACHS O, 1990, J BIOL CHEM, V265, P18595; BLUMBERG H, 1987, NATURE, V328, P443, DOI 10.1038/328443a0; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRADLEY DE, 1980, J BACTERIOL, V143, P1466, DOI 10.1128/JB.143.3.1466-1470.1980; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COHEN P, 1988, MOL ASPECTS CELL REG, V5, P123; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; COOPER JA, 1987, ONCOGENE RES, V1, P297; COX JA, 1981, BIOCHIM BIOPHYS ACTA, V670, P441, DOI 10.1016/0005-2795(81)90119-7; CRABTREE S, 1984, J BACTERIOL, V158, P354, DOI 10.1128/JB.158.1.354-356.1984; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DINSMORE JH, 1988, CELL, V53, P769, DOI 10.1016/0092-8674(88)90094-3; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GARRETT J, 1981, MOL GEN GENET, V182, P326, DOI 10.1007/BF00269678; GRATZNER WB, 1988, CALMODULIN, V5, P329; GREENLEE DV, 1982, BIOCHEMISTRY-US, V21, P2759, DOI 10.1021/bi00540a028; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HARMON AC, 1985, BIOCHEM BIOPH RES CO, V127, P31, DOI 10.1016/S0006-291X(85)80121-2; HINRICHSEN RD, 1986, SCIENCE, V232, P503, DOI 10.1126/science.2421410; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; IIDA H, 1990, J BIOL CHEM, V265, P13391; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KEITH CH, 1987, CELL MOTIL CYTOSKEL, V7, P1, DOI 10.1002/cm.970070102; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; KLEE CB, 1988, CALMODULIN MOL ASPEC, V5, P35; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LONDESBOROUGH J, 1987, FEBS LETT, V219, P249, DOI 10.1016/0014-5793(87)81226-7; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; Marme D., 1983, CALCIUM CELL FUNCTIO, VIV, p263 ; Miller J.H., 1972, EXPT MOL GENETICS; MINDICH L, 1976, J BACTERIOL, V126, P177, DOI 10.1128/JB.126.1.177-182.1976; MIYAKAWA T, 1989, J BACTERIOL, V171, P1417, DOI 10.1128/jb.171.3.1417-1422.1989; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; OHYA Y, 1989, BIOCHEM BIOPH RES CO, V158, P541, DOI 10.1016/S0006-291X(89)80083-X; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; PERSECHINI A, 1991, P NATL ACAD SCI USA, V88, P449, DOI 10.1073/pnas.88.2.449; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; RATAN RR, 1986, TRENDS BIOCHEM SCI, V11, P456, DOI 10.1016/0968-0004(86)90246-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFER WH, 1987, P NATL ACAD SCI USA, V84, P3931, DOI 10.1073/pnas.84.11.3931; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; Sherman F., 1986, METHODS YEAST GENETI; SLOTBOOM AJ, 1978, BIOCHEMISTRY-US, V17, P4593, DOI 10.1021/bi00615a003; STABEN C, 1986, J BIOL CHEM, V261, P4629; STULL JT, 1988, MOL ASPECTS CELLULAR, V5, P91; SWEET SC, 1988, J CELL BIOL, V107, P2243, DOI 10.1083/jcb.107.6.2243; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKEDA T, 1989, P NATL ACAD SCI USA, V86, P9737, DOI 10.1073/pnas.86.24.9737; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; YOUDERIAN P, 1980, VIROLOGY, V107, P258, DOI 10.1016/0042-6822(80)90291-3	65	277	280	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					949	959		10.1016/0092-8674(91)90547-C	http://dx.doi.org/10.1016/0092-8674(91)90547-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044154	Green Published			2022-12-28	WOS:A1991FR04700006
J	KULICK, DL; RAHIMTOOLA, SH				KULICK, DL; RAHIMTOOLA, SH			CURRENT ROLE OF DIGITALIS THERAPY IN PATIENTS WITH CONGESTIVE-HEART-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR FUNCTION; MYOCARDIAL-INFARCTION; VASODILATOR THERAPY; CONTROLLED TRIAL; ISOSORBIDE DINITRATE; MAINTENANCE DIGOXIN; SINUS RHYTHM; DOUBLE-BLIND; 1ST CHOICE; CAPTOPRIL	Digitalis has been used in the treatment of chronic congestive heart failure for 215 years. In this article, numerous clinical studies and trials that have evaluated the efficacy of digitalis in the treatment of patients with congestive heart failure are reviewed. The data indicate that digitalis is a valuable therapeutic agent for relieving symptoms and improving exercise performance and left ventricular function in patients with congestive heart failure. Comparison of the various advantages and disadvantages of digitalis with alternative therapies in patients with congestive heart failure shows an important continuing role for digitalis therapy.	UNIV SO CALIF,LOS ANGELES CTY MED CTR,SCH MED,DEPT MED,DIV CARDIOL,2025 ZONAL AVE,LOS ANGELES,CA 90033	University of Southern California								ANTMAN EM, 1990, CIRCULATION, V81, P1744, DOI 10.1161/01.CIR.81.6.1744; ARNOLD SB, 1980, NEW ENGL J MED, V303, P1443, DOI 10.1056/NEJM198012183032503; BEAUNE J, 1989, AM J CARDIOL, V63, pD22, DOI 10.1016/0002-9149(89)90413-X; CLELAND JGF, 1985, BRIT HEART J, V54, P305; COHN JN, 1987, CIRCULATION, V75, P49; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; CREAGER MA, 1985, J AM COLL CARDIOL, V6, P163, DOI 10.1016/S0735-1097(85)80269-2; DEMOTS H, 1976, J CLIN INVEST, V58, P312, DOI 10.1172/JCI108474; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; DOBBS SM, 1977, BMJ-BRIT MED J, V1, P749, DOI 10.1136/bmj.1.6063.749; FERGUSON DW, 1989, CIRCULATION, V80, P65, DOI 10.1161/01.CIR.80.1.65; FLEG JL, 1982, AM J MED, V73, P244, DOI 10.1016/0002-9343(82)90186-3; GHEORGHIADE M, 1983, AM J CARDIOL, V51, P1243, DOI 10.1016/0002-9149(83)90293-X; GHEORGHIADE M, 1989, J AM COLL CARDIOL, V13, P134, DOI 10.1016/0735-1097(89)90561-5; GHEORGHIADE M, 1987, J AM COLL CARDIOL, V9, P849, DOI 10.1016/S0735-1097(87)80241-3; GREENBERG RN, 1984, CLIN THER, V6, P592; GUYATT GH, 1988, AM J CARDIOL, V61, P371, DOI 10.1016/0002-9149(88)90947-2; KIMMELSTIEL C, 1988, AM HEART J, V116, P1063, DOI 10.1016/0002-8703(88)90161-5; KRAMER BL, 1983, CIRCULATION, V67, P807, DOI 10.1161/01.CIR.67.4.807; KULICK D, 1988, J AM COLL CARDIOL, V12, P1023, DOI 10.1016/0735-1097(88)90471-8; KULICK DL, 1990, AM J CARDIOL, V66, P435, DOI 10.1016/0002-9149(90)90700-B; LEE DCS, 1982, NEW ENGL J MED, V306, P699, DOI 10.1056/NEJM198203253061202; MARCUS FI, 1985, J AM COLL CARDIOL, V5, pA82, DOI 10.1016/S0735-1097(85)80466-6; MASSIE BM, 1987, CIRCULATION, V75, P11; MURRAY RG, 1982, BRIT MED J, V284, P1526, DOI 10.1136/bmj.284.6328.1526; PACKER M, 1986, J AM COLL CARDIOL, V7, pA181; PACKER M, 1988, J AM COLL CARDIOL, V12, P1299, DOI 10.1016/0735-1097(88)92615-0; PACKER M, 1989, CIRCULATION, V79, P198, DOI 10.1161/01.CIR.79.1.198; PACKER M, 1986, NEW ENGL J MED, V315, P847, DOI 10.1056/NEJM198610023151402; PARMLEY WW, 1988, J AM COLL CARDIOL, V12, P265, DOI 10.1016/0735-1097(88)90385-3; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; RAHIMTOOLA SH, 1971, CIRCULATION, V44, P866, DOI 10.1161/01.CIR.44.5.866; RAHIMTOOLA SH, 1989, CIRCULATION, V80, P693, DOI 10.1161/01.CIR.80.3.693; RIBNER HS, 1985, AM J CARDIOL, V56, P896, DOI 10.1016/0002-9149(85)90778-7; RICHARDSON A, 1987, LANCET, V2, P709; SHARPE N, 1988, LANCET, V1, P255; SULLIVAN M, 1989, J AM COLL CARDIOL, V13, P1138, DOI 10.1016/0735-1097(89)90276-3; WALSH WF, 1981, CIRCULATION, V64, P499, DOI 10.1161/01.CIR.64.3.499; 1983, J AM COLL CARDIOL, V2, P755; 1988, LANCET, V1, P489; 1987, NEW ENGL J MED, V316, P1429; 1988, JAMA-J AM MED ASSOC, V259, P539	43	25	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2995	2997						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033773				2022-12-28	WOS:A1991FP63500039
J	CULYER, AJ				CULYER, AJ			THE PROMISE OF A REFORMED NHS - AN ECONOMISTS ANGLE	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL LITERATURE; CARE		UNIV YORK,DEPT ECON & RELATED STUDIES,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; COOPER MH, 1970, HLTH SERVICES FINANC; CULYER AJ, 1990, IN PRESS NOV P C EQ; CULYER AJ, 1976, NEED NATIONAL HLTH S; CULYER AJ, 1991, HLTH POLICY COMMENTA; CULYER AJ, 1978, EC ASPECTS HLTH SERV, P9; CULYER AJ, 1990, COMPETITION HLTH CAR, P12; GLANTZ SA, 1980, CIRCULATION, V61, P1, DOI 10.1161/01.CIR.61.1.1; LEGRAND J, 1978, ECONOMICA, V45, P125, DOI 10.2307/2553499; LEGRAND J, 1990, 3 ESSAYS EQUITY; LEGRAND J, 1990, STRATEGY EQUALITY; McKeown Thomas, 1976, MODERN RISE POPULATI; MCPHERSON K, 1990, HLTH CARE FINANCIN S, P9; PICKARD JD, 1990, BRIT MED J, V301, P629, DOI 10.1136/bmj.301.6753.629; RACHLIS M, 1989, 2ND OPINION WHATS WR; SACKETT DL, 1980, PUBLIC HLTH PREVENTI, P1800; SHEEHAN TJ, 1980, ARCH INTERN MED, V140, P472, DOI 10.1001/archinte.140.4.472; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; Williams A., 1974, EC POLICIES SOCIAL G, P60; Williams A., 1978, EC ASPECTS HLTH SERV, P32	20	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1253	1256		10.1136/bmj.302.6787.1253	http://dx.doi.org/10.1136/bmj.302.6787.1253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP272	2043852	Green Published			2022-12-28	WOS:A1991FP27200028
J	KIM, CM; KOIKE, K; SAITO, I; MIYAMURA, T; JAY, G				KIM, CM; KOIKE, K; SAITO, I; MIYAMURA, T; JAY, G			HBX GENE OF HEPATITIS-B VIRUS INDUCES LIVER-CANCER IN TRANSGENIC MICE	NATURE			English	Article							HEPATOCELLULAR-CARCINOMA; X-PROTEIN; MOUSE MODEL; TAT GENE; EXPRESSION; ANTIGEN; TUMORS; ACTIVATION; INTEGRATION; SECRETION	THE exact role of hepatitis B virus in the development of liver cancer is not known. The recent identification of a viral regulatory gene HBx suggests a possible direct involvement of the virus whereby the HBx protein, acting as a transcriptional transactivator of viral genes, may alter host gene expression and lead to the development of hepatocellular carcinoma. We have tested this possibility by placing the entire HBx gene under its own regulatory elements directly into the germline of mice. Transgenic animals harbouring this viral gene succumbed to progressive histopathological changes specifically in the liver, beginning with multifocal areas of altered hepatocytes, followed by the appearance of benign adenomas, and proceeding to the development of malignant carcinomas. Male mice developed disease and died much earlier than females. This transgenic animal model appears ideal for defining the molecular events that follow the expression of the viral HBx gene and are responsible for the development of liver cancer.	AMER RED CROSS,JEROME H HOLLAND LAB,VIROL LAB,ROCKVILLE,MD 20855; NATL INST HLTH,DEPT ENTEROVIRUSES,HEPATITIS VIRUSES LAB,TOKYO 141,JAPAN	American Red Cross; National Institute of Health Sciences - Japan			Ibrahim, Essam Hassan/G-1960-2018; Jay, Gregory/C-6346-2013	Ibrahim, Essam Hassan/0000-0003-0130-2257; 				ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; BABINET C, 1985, SCIENCE, V230, P1160, DOI 10.1126/science.3865370; BANNASCH P, 1985, DIGESTIVE SYSTEM, P10; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BEASLEY RP, 1981, LANCET, V2, P1129; BECKER FF, 1982, CANCER RES, V42, P3918; BROOKS PN, 1985, DIGESTIVE SYSTEM, P47; BURK RD, 1988, J VIROL, V62, P649, DOI 10.1128/JVI.62.2.649-654.1988; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; COSMAN D, 1982, P NATL ACAD SCI-BIOL, V79, P4947, DOI 10.1073/pnas.79.16.4947; DEJEAN A, 1984, J GEN VIROL, V65, P651, DOI 10.1099/0022-1317-65-3-651; DEJEAN A, 1984, P NATL ACAD SCI-BIOL, V81, P5350, DOI 10.1073/pnas.81.17.5350; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; FARZA H, 1988, J VIROL, V62, P4149; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; KANEKO S, 1988, J VIROL, V62, P3979, DOI 10.1128/JVI.62.11.3979-3984.1988; KLIMEK F, 1984, CARCINOGENESIS, V5, P265, DOI 10.1093/carcin/5.2.265; KOIKE K, 1989, P NATL ACAD SCI USA, V86, P5615, DOI 10.1073/pnas.86.14.5615; KOIKE K, 1988, VIROLOGY, V163, P233, DOI 10.1016/0042-6822(88)90256-5; KRESS M, 1983, CELL, V34, P189, DOI 10.1016/0092-8674(83)90149-6; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POPP JA, 1985, DIGESTIVE SYSTEM, P39; ROGLER CE, 1985, SCIENCE, V230, P319, DOI 10.1126/science.2996131; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TREININ M, 1987, MOL CELL BIOL, V7, P545, DOI 10.1128/MCB.7.1.545; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545	39	1013	1054	8	57	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					317	320		10.1038/351317a0	http://dx.doi.org/10.1038/351317a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034275				2022-12-28	WOS:A1991FM97600061
J	GERSONY, WM				GERSONY, WM			DIAGNOSIS AND MANAGEMENT OF KAWASAKI-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS GAMMA-GLOBULIN; CORONARY-ARTERY ANEURYSMS; LYMPH-NODE SYNDROME; UNITED-STATES; FOLLOW-UP; ANGIOGRAPHY; THERAPY; JAPAN	Kawasaki disease is an acute vasculitis characterized by mucosal inflammation, rash, cervical adenopathy, indurative edema of the hands and feet, and late membranous desquamation of the fingertips. Early cardiac effects include myocarditis (occasionally with congestive heart failure), pericardial inflammation, and,rarely, valve involvement. Coronary artery aneurysms are a long-term concern becausecoronary thrombosis with myocardial infarction can be a late manifestation. The origin of Kawasaki disease is unknown, but an infectious agent is most likely. Management consists of aspirin for control of fever and inflammatory manifestations and intravenous gamma globulin for the prevention of coronary aneurysm formation. Careful late follow-up is required, especially for patients with persistent coronary abnormalities. Giant aneurysms (> 8 mm) are more likely to progress to coronary obstructive disease, and coronary bypass grafts have been required for some patients. Late coronary artery manifestations in patients with mild early coronary dilatation have not been described. However, since long-term epidemiologic studies have not yet been performed, it is prudent to consider childhood Kawasaki disease to be a potential risk factor for coronary disease, especially in atherosclerosis-prone Western societies.			GERSONY, WM (corresponding author), COLUMBIA UNIV,BABIES HOSP,COLL PHYS & SURG,DIV PEDIAT CARDIOL,3959 BROADWAY,NEW YORK,NY 10032, USA.							ARJUNAN K, 1986, J AM COLL CARDIOL, V8, P1119, DOI 10.1016/S0735-1097(86)80390-4; BELL DM, 1981, NEW ENGL J MED, V304, P1568, DOI 10.1056/NEJM198106253042603; BIERMAN FZ, 1987, J PEDIATR, V11, P789; BURTT DM, 1986, PEDIATR CARDIOL, V6, P307; CAPANNARI TE, 1986, J AM COLL CARDIOL, V7, P355, DOI 10.1016/S0735-1097(86)80505-8; CHUNG KJ, 1989, CIRCULATION S2, V80, P282; COOK DH, 1989, CAN J CARDIOL, V5, P389; CREMER H, 1988, 3 INT KAW DIS S P TO, P297; ECHIGO S, 1988, 3RD INT KAW DIS S NO, P351; FURUSHO K, 1984, LANCET, V2, P1055; Furusho K, 1987, Prog Clin Biol Res, V250, P425; GIDDING SS, 1988, 3 INT KAW DIS S NOV, P229; HIROSE H, 1986, CIRCULATION S, V74, P177; Inoue O, 1989, CIRCULATION S2, V80, P262; KATO H, 1982, AM J CARDIOL, V49, P1758, DOI 10.1016/0002-9149(82)90256-9; Kato H, 1987, Prog Clin Biol Res, V250, P445; Kato H, 1988, Pediatr Rev, V9, P209, DOI 10.1542/pir.9-7-209; KAWASAKI T, 1974, PEDIATRICS, V54, P271; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; KAWASHIMA Y, 1988, 3RD INT KAW DIS S TO, P455; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; LEUNG DYM, 1986, J CLIN INVEST, V77, P1428, DOI 10.1172/JCI112454; MELISH ME, 1976, AM J DIS CHILD, V130, P599, DOI 10.1001/archpedi.1976.02120070025006; NAGASHIMA M, 1987, J PEDIATR-US, V110, P710, DOI 10.1016/S0022-3476(87)80007-0; NAKAMURA Y, 1988, 3 INT KD S NOV 29, P23; NAKANO H, 1986, AM J CARDIOL, V58, P739, DOI 10.1016/0002-9149(86)90348-6; Newburger J W, 1989, Cardiol Clin, V7, P453; NEWBURGER JW, 1990, PEDIATR RES, V27, pA22; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; NEWBURGER JW, 1989, CIRCULATION, V79, P1237, DOI 10.1161/01.CIR.79.6.1237; PAHL E, 1989, J AM COLL CARDIOL, V14, P1318, DOI 10.1016/0735-1097(89)90435-X; PARIDON SM, 1990, J PEDIATR-US, V116, P52, DOI 10.1016/S0022-3476(05)81644-0; Rauch A M, 1987, Prog Clin Biol Res, V250, P33; ROWLEY AH, 1988, J PEDIATR-US, V113, P290, DOI 10.1016/S0022-3476(88)80267-1; SUZUKI A, 1988, PEDIATR CARDIOL, P9; TAKAHASHI K, 1988, 3RD INT KAW DIS S NO, P175; TAKAHASHI M, 1987, CIRCULATION, V75, P387, DOI 10.1161/01.CIR.75.2.387; TAUBERT KA, IN PRESS J PEDIATR; YANAGAWA H, 1987, PEDIATRICS, V80, P58; 1989, PEDIATR INFECT DIS J, V8, P663; 1990, JAMA-J AM MED ASSOC, V264, P3189; 1989, DIAGNOSTIC GUIDELINE	42	49	49	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2699	2703		10.1001/jama.265.20.2699	http://dx.doi.org/10.1001/jama.265.20.2699			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023352				2022-12-28	WOS:A1991FL98900036
J	BOULTON, TG; NYE, SH; ROBBINS, DJ; IP, NY; RADZIEJEWSKA, E; MORGENBESSER, SD; DEPINHO, RA; PANAYOTATOS, N; COBB, MH; YANCOPOULOS, GD				BOULTON, TG; NYE, SH; ROBBINS, DJ; IP, NY; RADZIEJEWSKA, E; MORGENBESSER, SD; DEPINHO, RA; PANAYOTATOS, N; COBB, MH; YANCOPOULOS, GD			ERKS - A FAMILY OF PROTEIN-SERINE THREONINE KINASES THAT ARE ACTIVATED AND TYROSINE PHOSPHORYLATED IN RESPONSE TO INSULIN AND NGF	CELL			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; EPIDERMAL GROWTH-FACTOR; STIMULATED PROTEIN; MAP-2 KINASE; CELLULAR PROTEINS; 3T3-L1 ADIPOCYTES; SWISS 3T3-CELLS; OKADAIC ACID; S6 KINASE; FIBROBLASTS	We recently described the purification and cloning of extracellular signal-regulated kinase 1 (ERK1), which appears to play a pivotal role in converting tyrosine phosphorylation into the serine/threonine phosphorylations that regulate downstream events. We now describe cloning and characterization of two ERK1-related kinases, ERK2 and ERK3, and provide evidence suggesting that there are additional ERK family members. At least two of the ERKs are activated in response to growth factors; their activations correlate with tyrosine phophorylation, but also depend on additional modifications. Transcripts corresponding to the three cloned ERKs are distinctly regulated both in vivo and in a differentiating cell line. Thus, this family of kinases may serve as intermediates that depend on tyrosine phosphorylation to activate serine/threonine phosphorylation cascades. Individual family members may mediate responses in different developmental stages, in different cell types, or following exposure to different extracellular signals.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461	Regeneron; Yeshiva University; Albert Einstein College of Medicine	BOULTON, TG (corresponding author), UNIV TEXAS,SW GRAD SCH BIOMED SCI,DEPT PHARMACOL,DALLAS,TX 75235, USA.			Ip, Nancy Yuk-Yu/0000-0002-2763-8907; Cobb, Melanie/0000-0003-0833-5473; DePinho, Ronald/0000-0002-5625-577X	NIDDK NIH HHS [DK 01918, DK 34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, K04DK001918, R37DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BORTHWICK AC, 1990, BIOCHEM J, V270, P795, DOI 10.1042/bj2700795; BOTHWELL A, 1990, METHODS CLONING ANAL, P15; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, IN PRESS CELL REGULA; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P577; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FERRELL JE, 1991, IN PRESS MOL CELL BI; GIBBS CS, 1991, IN PRESS MOL CELL BI, V266; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HOSHI M, 1988, J BIOL CHEM, V263, P5396; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KVOACINA KS, 1990, J BIOL CHEM, V265, P12115; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MAHMOUDI M, 1989, BIOTECHNIQUES, V7, P331; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINEZ R, 1982, MOL CELL BIOL, V2, P653, DOI 10.1128/MCB.2.6.653; MAYTIN EV, 1984, J BIOL CHEM, V259, P2135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1991, IN PRESS P NATL ACAD; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NEL AE, 1990, J IMMUNOL, V145, P971; NEL AE, 1990, J IMMUNOL, V144, P2683; PANAYOTATOS N, 1988, GENE, V74, P357, DOI 10.1016/0378-1119(88)90169-2; POSADA J, 1991, IN PRESS MOL CELL BI; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SMITH CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2641, DOI 10.1073/pnas.77.5.2641; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TSAO H, 1990, J BIOL CHEM, V265, P15471; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YU KT, 1987, P NATL ACAD SCI USA, V84, P3972, DOI 10.1073/pnas.84.12.3972	66	1705	1791	3	71	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					663	675		10.1016/0092-8674(91)90098-J	http://dx.doi.org/10.1016/0092-8674(91)90098-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032290				2022-12-28	WOS:A1991FM03700016
J	ROCK, KL; GAMBLE, S; ROTHSTEIN, L; GRAMM, C; BENACERRAF, B				ROCK, KL; GAMBLE, S; ROTHSTEIN, L; GRAMM, C; BENACERRAF, B			DISSOCIATION OF BETA-2-MICROGLOBULIN LEADS TO THE ACCUMULATION OF A SUBSTANTIAL POOL OF INACTIVE CLASS-I MHC HEAVY-CHAINS ON THE CELL-SURFACE	CELL			English	Article							RESTRICTED T-CELLS; HISTOCOMPATIBILITY MOLECULES; ANTIGEN PRESENTATION; DENOVO SYNTHESIS; LYMPHOMA-CELLS; MOUSE LYMPHOMA; LYMPHOCYTES-T; RECOGNITION; PEPTIDES; BINDING	A large pool of free class I heavy chains is detected in situ on the plasma membrane of living cells. These chains are present on cells of different MHC genotypes and appear to exist under physiological conditions in vivo. These molecules arise from the dissociation of previously assembled class I heterodimers at the cell surface. The ratio of intact to dissociated heterodimers is strongly affected by the occupancy of the peptide-binding site of the class I molecule. Upon dissociation of the heterodimer, the class I molecule is functionally inactive. These finding may help to explain why class I molecules on the cell surface are unreceptive to binding peptides yet readily associated with peptides in the presence of exogenous beta-2-microglobulin. These results have implications for understanding the distinct functions of class I versus class II molecules and how the immunological identify of cells is preserved.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	ROCK, KL (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV LYMPHOCYTE BIOL, BOSTON, MA 02115 USA.				PHS HHS [A120248] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BEVAN MJ, 1989, NATURE, V342, P478, DOI 10.1038/342478a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CORNETTE JL, 1989, METHOD ENZYMOL, V178, P611; CRESSWEL.P, 1974, P NATL ACAD SCI USA, V71, P2123, DOI 10.1073/pnas.71.5.2123; FALO LD, 1985, P NATL ACAD SCI USA, V82, P6647, DOI 10.1073/pnas.82.19.6647; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HANSEN TH, 1988, J IMMUNOL, V140, P3522; HAUSTEIN D, 1975, BIOCHEMISTRY-US, V14, P1826, DOI 10.1021/bi00680a004; HICKLING JK, 1990, INT IMMUNOL, V2, P435, DOI 10.1093/intimm/2.5.435; HYAFIL F, 1979, P NATL ACAD SCI USA, V76, P5834, DOI 10.1073/pnas.76.11.5834; HYMAN R, 1976, IMMUNOGENETICS, V3, P75, DOI 10.1007/BF01576940; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; KVIST S, 1979, EUR J IMMUNOL, V9, P991, DOI 10.1002/eji.1830091214; KVIST S, 1978, BIOCHEMISTRY-US, V17, P4794, DOI 10.1021/bi00615a029; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MYERS NB, 1989, J IMMUNOL, V142, P2751; NATORI T, 1976, J IMMUNOGENET, V3, P123; OZATO K, 1981, J IMMUNOL, V126, P317; PARHAM P, 1983, HUM IMMUNOL, V8, P207, DOI 10.1016/0198-8859(83)90038-1; PARKER KC, 1985, BIOCHEMISTRY-US, V24, P5543, DOI 10.1021/bi00341a039; PERKINS DL, 1989, J EXP MED, V170, P279, DOI 10.1084/jem.170.1.279; REISER H, 1986, CELL, V47, P365, DOI 10.1016/0092-8674(86)90593-3; ROBINSON PJ, 1983, TRANSPLANT P, V15, P2051; ROCK KL, 1983, J EXP MED, V157, P1618, DOI 10.1084/jem.157.5.1618; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SMITH MH, 1990, MOL IMMUNOL, V27, P169, DOI 10.1016/0161-5890(90)90112-D; STALLCUP KC, 1981, J IMMUNOL, V127, P923; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TADA N, 1980, IMMUNOGENETICS, V11, P441, DOI 10.1007/BF01567813; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796	49	161	163	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					611	620		10.1016/0092-8674(91)90093-E	http://dx.doi.org/10.1016/0092-8674(91)90093-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032286				2022-12-28	WOS:A1991FM03700011
J	GINZBERG, E; OSTOW, M				GINZBERG, E; OSTOW, M			BEYOND UNIVERSAL HEALTH-INSURANCE TO EFFECTIVE HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GINZBERG, E (corresponding author), COLUMBIA UNIV,EISENHOWER CTR CONSERVAT HUMAN RESOURCES,NEW YORK,NY 10027, USA.							ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P238, DOI 10.1001/jama.265.2.238; GINZBERG E, 1989, VA PRACTITIONER, V6, P39; GINZBERG E, IN PRESS CHANGING US; 1990, HLTH CARE FIN REV, V11, P1; 1990, CALL ACTION; 1990, GAOHRD90128 US GEN A; [No title captured]; 1989, HCFA PUBLICATION, V2082; 1990, STATISTICAL ABSTRACT; 1990, 791 OFF STAT COMPTR	11	18	18	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2559	2562		10.1001/jama.265.19.2559	http://dx.doi.org/10.1001/jama.265.19.2559			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK903	2020076				2022-12-28	WOS:A1991FK90300033
J	ROLAND, MO; PORTER, RW; MATTHEWS, JG; REDDEN, JF; SIMONDS, GW; BEWLEY, B				ROLAND, MO; PORTER, RW; MATTHEWS, JG; REDDEN, JF; SIMONDS, GW; BEWLEY, B			IMPROVING CARE - A STUDY OF ORTHOPEDIC OUTPATIENT REFERRALS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; PERCEPTIONS; CONSULTANTS	Objective - To identify aspects of outpatient referral in which general practitioners', consultants', and patients' satisfaction could be improved. Design - Questionnaire survey of general practitioners, consultant orthopaedic surgeons, and patients referred to an orthopaedic clinic. Setting - Orthopaedic clinic, Doncaster Royal Infirmary. Subjects - 628 consecutive patients booked into the orthopaedic clinic. Main outcome measures - Views of the general practitioners as recorded both when the referral letter was received and again after the patient had been seen, views of the consultants as recorded at the time of the clinic attendance, and views of the patients as recorded immediately after the clinic visit and some time later. Results - Consultants rated 213 of 499 referrals (42.7%) as possibly or definitely inappropriate, though 373 of 451 patients (82.7%) reported that they were helped by seeing the consultant. Targets for possible improvement included information to general practitioners about available services, communication between general practitioners and consultants, and administrative arrangements in clinics. Long waiting times were a problem, and it seemed that these might be reduced if general practitioners could provide more advice on non-surgical management. Some general practitioners stated that they would value easier telephone access to consultants for management advice. It was considered that an alternative source of management advice on musculoskeletal problems might enable more effective use to be made of specialist orthopaedic resources. Conclusion - A survey of patients' and doctors' views of referrals may be used to identify aspects in which the delivery of care could be made more efficient. Developing agreed referral guidelines might help general practitioners to make more effective use of hospital services.	DONCASTER ROYAL INFIRM,DONCASTER DN2 5LT,ENGLAND		ROLAND, MO (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,CAMBRIDGE CB2 2QQ,ENGLAND.							[Anonymous], 1980, CLASSIFICATION OCCUP; EMMANUEL J, 1989, BRIT MED J, V299, P722, DOI 10.1136/bmj.299.6701.722; GRACE JF, 1986, FAM PRACT, V3, P143, DOI 10.1093/fampra/3.3.143; GRACE JF, 1987, FAM PRACT, V4, P170, DOI 10.1093/fampra/4.3.170; GRAHAME R, 1986, BRIT J RHEUMATOL, V25, P7; Griffin G A, 1981, J R Coll Gen Pract, V31, P661; GROL R, 1990, BRIT J GEN PRACT, V40, P361; HARTOG M, 1988, J ROY COLL PHYS LOND, V22, P51; HUSTON GJ, 1988, BRIT MED J, V296, P1773, DOI 10.1136/bmj.296.6639.1773-a; ROSS AK, 1984, BRIT MED J, V288, P609, DOI 10.1136/bmj.288.6417.609; 1989, GENERAL PRACTICE NAT; 1989, CMND555	12	54	54	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1124	1128		10.1136/bmj.302.6785.1124	http://dx.doi.org/10.1136/bmj.302.6785.1124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	2043784	Bronze, Green Published			2022-12-28	WOS:A1991FL43900020
J	HORSBURGH, CR				HORSBURGH, CR			CURRENT CONCEPTS - MYCOBACTERIUM-AVIUM COMPLEX INFECTION IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IMMUNE-DEFICIENCY SYNDROME; AIDS PATIENTS; INTRACELLULARE BACTEREMIA; INVITRO SUSCEPTIBILITY; ANTITUBERCULOSIS DRUGS; GAMMA-INTERFERON; ETHAMBUTOL; THERAPY; DISEASE; EPIDEMIOLOGY		EMORY UNIV,DEPT MED,DIV INFECT DIS,ATLANTA,GA 30322; GRADY MEM HOSP,ATLANTA,GA 30303	Emory University	HORSBURGH, CR (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,MAILSTOP E-45,ATLANTA,GA 30333, USA.			Horsburgh, C./0000-0001-6838-7895				AGINS BD, 1989, J INFECT DIS, V159, P784, DOI 10.1093/infdis/159.4.784; BARON EJ, 1986, DIAGN MICR INFEC DIS, V5, P215, DOI 10.1016/0732-8893(86)90004-0; BENSON C, 1990, 6TH INT C AIDS SAN F, V1, P251; BERLIN OGW, 1987, 27TH INT C ANT AG CH, P242; BERMUDEZ LE, 1990, J INFECT DIS, V161, P1262, DOI 10.1093/infdis/161.6.1262; BERMUDEZ LEM, 1988, J IMMUNOL, V140, P3006; BERMUDEZ LEM, 1990, J LEUKOCYTE BIOL, V47, P135, DOI 10.1002/jlb.47.2.135; BERMUDEZ LEM, 1990, J LEUKOCYTE BIOL, V48, P67, DOI 10.1002/jlb.48.1.67; BLUMENTHAL DR, 1988, ARTHRITIS RHEUM, V109, P389; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; COHEN JI, 1990, ANN OPHTHALMOL, V22, P47; CRAWFORD JT, 1986, AM REV RESPIR DIS, V134, P659; CROWLE AJ, 1989, INFECT IMMUN, V57, P1445, DOI 10.1128/IAI.57.5.1445-1451.1989; DAUTZENBERG B, 1990, American Review of Respiratory Disease, V141, pA615; DAVIDSON PT, 1981, REV INFECT DIS, V3, P1052; DEMOPULOS P, 1985, 25TH INT C ANT AG CH, P230; DOUVAS GS, 1985, INFECT IMMUN, V50, P1; DUMOULIN GC, 1988, JAMA-J AM MED ASSOC, V260, P1599, DOI 10.1001/jama.260.11.1599; EDWARDS LB, 1969, AM REV RESPIR DIS, V99, P1; EDWARDS LB, 1959, AM REV RESPIR DIS, V80, P747, DOI 10.1164/arrd.1959.80.5.747; FARBER CM, 1990, J INFECT DIS, V162, P279, DOI 10.1093/infdis/162.1.279-a; GANGADHARAM PRJ, 1988, AM REV RESPIR DIS, V137, P212, DOI 10.1164/ajrccm/137.1.212; GRAHAM DY, 1987, GASTROENTEROLOGY, V92, P436, DOI 10.1016/0016-5085(87)90139-9; GRAHAM L, 1988, J CLIN MICROBIOL, V26, P1034, DOI 10.1128/JCM.26.5.1034-1036.1988; GRAY JR, 1989, AM J GASTROENTEROL, V84, P1521; GUTHERTZ LS, 1989, J INFECT DIS, V160, P1037, DOI 10.1093/infdis/160.6.1037; HAMPSON SJ, 1989, LANCET, V1, P65; HAVLIK JA, 1990, 6TH INT C AIDS SAN F, V1, P250; HAWKINS CC, 1986, ANN INTERN MED, V105, P184, DOI 10.7326/0003-4819-105-2-184; HEIFETS L, 1988, ANTIMICROB AGENTS CH, V32, P1131, DOI 10.1128/AAC.32.8.1131; HEIFETS LB, 1990, NEW ENGL J MED, V323, P419, DOI 10.1056/NEJM199008093230615; HEIFETS LB, 1988, AM REV RESPIR DIS, V137, P711, DOI 10.1164/ajrccm/137.3.711; HORSBURGH C R, 1991, American Review of Respiratory Disease, V143, pA279; HORSBURGH C R, 1991, American Review of Respiratory Disease, V143, pA115; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; HORSBURGH CR, 1985, MEDICINE, V64, P36, DOI 10.1097/00005792-198501000-00003; HORSBURGH CR, 1987, AM REV RESPIR DIS, V135, P418; HORSBURGH CR, 1986, ANN INTERN MED, V105, P968, DOI 10.7326/0003-4819-105-6-968; HOY J, 1990, J INFECT DIS, V161, P801, DOI 10.1093/infdis/161.4.801; INDERLIED CB, 1989, J INFECT DIS, V159, P994, DOI 10.1093/infdis/159.5.994; INDERLIED CB, 1987, ANTIMICROB AGENTS CH, V31, P1697, DOI 10.1128/AAC.31.11.1697; INDERLIED CB, 1989, J INFECT DIS, V160, P1095; KEMPER CA, 1990, 30TH INT C ANT AG CH, P297; KLATT EC, 1987, HUM PATHOL, V18, P709, DOI 10.1016/S0046-8177(87)80242-3; MASUR H, 1987, J INFECT DIS, V155, P127, DOI 10.1093/infdis/155.1.127; MESS TP, 1987, 3RD P INT C AIDS WAS, P146; METROKA C, 1990, AIDS TARGETED NEWSLE, V4, P1; MILLS CC, 1972, APPL MICROBIOL, V24, P307, DOI 10.1128/AEM.24.3.307-310.1972; NAIK S, 1989, ANTIMICROB AGENTS CH, V33, P1614, DOI 10.1128/AAC.33.9.1614; NOEL SB, 1988, J AM ACAD DERMATOL, V19, P492, DOI 10.1016/S0190-9622(88)70203-0; OKELLO DO, 1990, J INFECT DIS, V162, P208, DOI 10.1093/infdis/162.1.208; PERLMAN DM, 1988, ANN INTERN MED, V108, P50; PETHEL ML, 1989, INFECT IMMUN, V57, P1714, DOI 10.1128/IAI.57.6.1714-1718.1989; PORTAELS F, 1988, INT J LEPROSY, V56, P468; ROTH RI, 1985, DIGEST DIS SCI, V30, P497, DOI 10.1007/BF01318186; RUF B, 1990, American Review of Respiratory Disease, V141, pA611; SIMBERKOFF MS, 1984, AM REV RESPIR DIS, V130, P1174; STINE TM, 1987, JAMA-J AM MED ASSOC, V258, P809, DOI 10.1001/jama.258.6.809; TENHOLDER MF, 1988, ARCH INTERN MED, V148, P953, DOI 10.1001/archinte.148.4.953; TOBA H, 1989, INFECT IMMUN, V57, P239, DOI 10.1128/IAI.57.1.239-244.1989; TSUKAMURA M, 1988, AM REV RESPIR DIS, V137, P144, DOI 10.1164/ajrccm/137.1.144; WALLACE JM, 1988, CHEST, V93, P926, DOI 10.1378/chest.93.5.926; WAYNE LG, 1986, EUR J CLIN MICROBIOL, V5, P363, DOI 10.1007/BF02017802; WENDT SL, 1980, AM REV RESPIR DIS, V122, P259; WINTER SM, 1985, J INFECT DIS, V151, P523, DOI 10.1093/infdis/151.3.523; WOLINSKY E, 1979, AM REV RESPIR DIS, V119, P107; WOLKE A, 1984, J CLIN GASTROENTEROL, V6, P225; WONG B, 1985, AM J MED, V78, P35, DOI 10.1016/0002-9343(85)90458-9; YAGUPSKY P, 1990, ARCH PATHOL LAB MED, V114, P923; YAJKO DM, 1988, ANTIMICROB AGENTS CH, V32, P1392, DOI 10.1128/AAC.32.9.1392; YAKRUS MA, 1990, J CLIN MICROBIOL, V28, P926, DOI 10.1128/JCM.28.5.926-929.1990; YOUNG LS, 1986, REV INFECT DIS, V8, P1024	72	776	790	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1332	1338		10.1056/NEJM199105093241906	http://dx.doi.org/10.1056/NEJM199105093241906			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017230				2022-12-28	WOS:A1991FK18600006
J	EDDY, DM				EDDY, DM			THE INDIVIDUAL VS SOCIETY - RESOLVING THE CONFLICT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									DUKE UNIV,DURHAM,NC 27706	Duke University								EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P105, DOI 10.1001/jama.265.1.105; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P782, DOI 10.1001/jama.265.6.782; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P1446, DOI 10.1001/jama.265.11.1446; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P1449; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P786	6	49	50	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2399	2406		10.1001/jama.265.18.2399	http://dx.doi.org/10.1001/jama.265.18.2399			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ955	2016839				2022-12-28	WOS:A1991FJ95500040
J	BACHELERIE, F; ALCAMI, J; ARENZANASEISDEDOS, F; VIRELIZIER, JL				BACHELERIE, F; ALCAMI, J; ARENZANASEISDEDOS, F; VIRELIZIER, JL			HIV ENHANCER ACTIVITY PERPETUATED BY NF-KAPPA-B INDUCTION ON INFECTION OF MONOCYTES	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; GENE-EXPRESSION; ALPHA; TRANSCRIPTION; INTERLEUKIN-1; ACTIVATION; MITOGENS	PERMISSIVENESS to replication of human immunodeficiency virus (HIV) differs in T lymphocytes and macrophages. In T cells, HIV transcription is poorly detected in vivo 1. Cloned, normal T lymphocytes show very little, if any, basal activity of the HIV enhancer and low nuclear expression of NF-kappa-B 2, a potent transcriptional activator of the HIV enhancer 3-5. In contrast, fixed tissue macrophages express detectable HIV proteins, indicating permanent virus transcription 6. One explanation for the perpetuation of virus infection in macrophages could be sustained nuclear NF-kappa-B expression. However, the U937 monocytic cell line, which is fully permissive to HIV replication, is known to express only low levels of nuclear NF-kappa-B 7. We show here that chronic HIV infection results in both induction of a nuclear factor with antigenic properties indistinguishable from those of NF-kappa-B and permanently increased HIV enhancer activity. This phenomenon, which is independent of tumour necrosis factor, is associated with HIV replication, and is thus likely to explain at least in part the perpetuation of HIV infection in monocytes.	INST PASTEUR,UNITE IMMUNOL VIRALE,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Alcami, Pepe/T-2242-2018; BACHELERIE, FRANCOISE/F-8823-2013; Arenzana-Seisdedos, Fernando/E-5835-2016	Alcami, Pepe/0000-0003-0023-7377; BACHELERIE, FRANCOISE/0000-0002-0399-3277; 				BACHELERIE F, 1990, J VIROL, V64, P3059, DOI 10.1128/JVI.64.6.3059-3062.1990; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; DU EJ, 1990, P NATL ACAD SCI USA, V86, P5974; GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001; GHOSH R, 1990, CELL, V62, P1019; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRIFFIN G, 1990, NATURE, V343, P219, DOI 10.1038/343219a0; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HAASE AT, 1984, METHOD VIROL, V7, P189; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISRAEL N, 1989, J IMMUNOL, V143, P3956; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SCHWARTZ O, 1988, AIDS RES HUM RETROV, V4, P441, DOI 10.1089/aid.1988.4.441; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WANG Y, 1987, J EXP MED, V166, P625, DOI 10.1084/jem.166.3.625	26	179	182	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					709	712		10.1038/350709a0	http://dx.doi.org/10.1038/350709a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023633				2022-12-28	WOS:A1991FJ13000061
J	BEEN, MD; PERROTTA, AT				BEEN, MD; PERROTTA, AT			GROUP-I INTRON SELF-SPLICING WITH ADENOSINE - EVIDENCE FOR A SINGLE NUCLEOSIDE-BINDING SITE	SCIENCE			English	Article							TETRAHYMENA PRE-RRNA; BIOLOGICAL CATALYSIS; SECONDARY STRUCTURE; RNA; SEQUENCE; MITOCHONDRIA; RIBOZYME; IVS	For self-splicing of Tetrahymena ribosomal RNA precursor, guanosine binding is required for 5' splice-site cleavage and exon ligation. Whether these two reactions use the same or different guanosine-binding sites has been debated. A double mutation in a previously identified guanosine-binding site within the intron resulted in preference for adenosine (or adenosine triphosphate) as the substrate for cleavage at the 5' splice site. However, splicing was blocked in the exon ligation step. Blockage was reversed by a change from guanine to adenine at the 3' splice site. These results indicate that a single determinant specifies nucleoside binding for both steps of splicing. Furthermore, it suggests that RNA could form an active site specific for adenosine triphosphate.			BEEN, MD (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-40689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEEN MD, 1985, NUCLEIC ACIDS RES, V13, P8389, DOI 10.1093/nar/13.23.8389; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; GARRIGA G, 1984, CELL, V39, P631, DOI 10.1016/0092-8674(84)90470-7; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; KAY PS, 1988, EMBO J, V7, P3531, DOI 10.1002/j.1460-2075.1988.tb03229.x; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; PERROTTA AJ, UNPUB; PRICE JV, 1988, GENE DEV, V2, P1439, DOI 10.1101/gad.2.11.1439; TANNER NK, 1987, BIOCHEMISTRY-US, V26, P3330, DOI 10.1021/bi00386a013; VANDERHORST G, 1987, EMBO J, V6, P2139, DOI 10.1002/j.1460-2075.1987.tb02481.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	20	105	108	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					434	437		10.1126/science.2017681	http://dx.doi.org/10.1126/science.2017681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017681				2022-12-28	WOS:A1991FH10300041
J	LEONE, A; FLATOW, U; KING, CR; SANDEEN, MA; MARGULIES, IMK; LIOTTA, LA; STEEG, PS				LEONE, A; FLATOW, U; KING, CR; SANDEEN, MA; MARGULIES, IMK; LIOTTA, LA; STEEG, PS			REDUCED TUMOR-INCIDENCE, METASTATIC POTENTIAL, AND CYTOKINE RESPONSIVENESS OF NM23-TRANSFECTED MELANOMA-CELLS	CELL			English	Article							GENE; NM23; DROSOPHILA; PROTEIN	Reduced expression of the nm23 gene in certain rodent model systems and human breast tumors has been correlated with high tumor metastatic potential. To investigate the functional effects of nm23 expression, we have transfected a constitutive murine nm23-1 expression construct into highly metastatic K-1735 TK murine melanoma cells. TK clones expressing the exogenous nm23-1 construct exhibited a reduced incidence of primary tumor formation, significant reductions in tumor metastatic potential independent of tumor cell growth, and altered responses to the cytokine transforming growth factor-beta-1 in soft agar colonization assays, compared with control-transfected TK clones. In contrast, nm23-1-transfected TK clones exhibited no significant differences in intrinsic tumor cell growth, i.e., primary tumor size in vivo, anchorage-dependent growth rate in vitro, and anchorage-independent colony formation in soft agar in vitro. The data demonstrate a suppressive effect of nm23 on several aspects of the cancer process, including tumor metastasis.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,FREDERICK,MD 21740; MOLEC ONCOL INC,GAITHERSBURG,MD 20878	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LEONE, A (corresponding author), NCI,PATHOL LAB,BETHESDA,MD 20892, USA.		Leone, Alvaro/K-6410-2016; leone, alvaro/AAQ-7051-2020	Leone, Alvaro/0000-0003-3815-9052; 				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; DAROLF CR, 1988, DEV BIOL, V129, P169; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KALEBIC T, 1988, CLIN EXP METASTAS, V6, P301, DOI 10.1007/BF01753577; KIKKAWA S, 1991, IN PRESS J BIOL CHEM; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KUMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; ROSENBERG SA, 1987, SURGICAL TREATMENT M; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHWARZ LC, 1988, CANCER RES, V48, P6999; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199	23	575	614	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					25	35		10.1016/0092-8674(91)90404-M	http://dx.doi.org/10.1016/0092-8674(91)90404-M			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013093	Bronze			2022-12-28	WOS:A1991FF77300005
J	SALONEN, JT; SALONEN, R; SEPPANEN, K; KANTOLA, M; SUNTIOINEN, S; KORPELA, H				SALONEN, JT; SALONEN, R; SEPPANEN, K; KANTOLA, M; SUNTIOINEN, S; KORPELA, H			INTERACTIONS OF SERUM COPPER, SELENIUM, AND LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN ATHEROGENESIS	BRITISH MEDICAL JOURNAL			English	Article							PLASMA; OXIDATION; MAGNESIUM; SMOKING; ADULTS; ZINC	Objective-To investigate the interactions between serum cooper, selenium, and low density lipoprotein cholesterol concentrations with regard to the progression of carotid atherosclerosis. Design-Longitudinal study of a cohort of middle aged men followed up for 24 months. Setting-Epidemiological survey of the population of seven communities in eastern Finland. Subjects-126 men aged 42, 48, 54, or 60 at examination randomly selected from a population based sample of 2682 men. Main outcome measures-Increase in maximal carotid intima media thickness. Results-The mean increase in the maximal common carotid intima media thickness after two years was greater in men with high serum copper concentrations (0.16 mm compared with 0.08 mm in men with concentrations < 17.6-mu-mol/l; p = 0.010), those with low serum selenium concentrations (0.15 mm compared with 0.09 mm in men with concentrations greater-than-or-equal-to 1.40-mu-mol/l; p = 0.035), and those with raised serum low density lipoprotein cholesterol concentrations (0.15 mm compared with 0.08 mm in men with concentrations < 4.0-mmol/l; p = 0.032) after adjustment for age and cigarette pack years in a three way analysis of covariance. A raised serum low density lipoprotein concentration was associated with accelerated progression of atherosclerosis only in men with higher than median serum copper concentrations (net difference 0.22 mm; p < 0.001 for two way interaction), and this synergism was even more pronounced in men with serum selenium concentrations below the median value (net difference 0.41 mm; p = 0.042 for three way interaction). Conclusion-These data provide evidence of a synergistic effect of copper (a pro-oxidant), a low serum concentration of selenium (a cofactor of an enzyme that scavenges free radicals), and low density lipoprotein cholesterol concentration in atherogenesis.	KUOPIO RES INST EXERCISE MED,KUOPIO,FINLAND; UNIV KUOPIO,DEPT CHEM,KUOPIO,FINLAND; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,KUOPIO,FINLAND	University of Eastern Finland; University of Eastern Finland	SALONEN, JT (corresponding author), UNIV KUOPIO,PUBL HLTH RES INST,POB 6,SF-70211 KUOPIO,FINLAND.							AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BLANKENHORN DH, 1990, CIRCULATION, V81, P470, DOI 10.1161/01.CIR.81.2.470; CARLSON K, 1973, J CLIN PATHOL S5, V26, P32; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P342; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HATANO S, 1982, AM J CLIN NUTR, V35, P120, DOI 10.1093/ajcn/35.1.120; HIISVIRTA L, 1985, FINN J WATER EC HYDR, V26, P30; JEANDEL C, 1989, GERONTOLOGY, V35, P275, DOI 10.1159/000213037; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KANT AK, 1989, NUTR RES, V9, P717, DOI 10.1016/S0271-5317(89)80015-6; LEWIS KO, 1982, LANCET, V2, P188; LLOYD B, 1983, J EPIDEMIOL COMMUN H, V37, P213, DOI 10.1136/jech.37.3.213; LUDWIG PW, 1982, LANCET, V1, P348; MAKINEN P, 1989, WATER ENV, V38; MOORE JA, 1984, CLIN CHEM, V30, P1171; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARVIAINEN MT, 1986, J LIQ CHROMATOGR, V9, P2185, DOI 10.1080/01483918608074142; PUNSAR S, 1975, J CHRON DIS, V28, P259, DOI 10.1016/0021-9681(75)90009-0; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1982, LANCET, V2, P175; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SALONEN R, IN PRESS ULTRASOUND; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SHAMBERGER RJ, 1984, BIOCH ESSENTIAL ULTR, P201; SINGH A, 1989, AM J CLIN NUTR, V49, P695, DOI 10.1093/ajcn/49.4.695; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; 1983, SPSS X USERS GUIDE C; 1988, ARCH INTERN MED, V148, P36; 1989, INT J EPIDEMIOL S1, V18, pS46; 1988, EUR HEART J, V9, P571	33	196	202	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					756	760		10.1136/bmj.302.6779.756	http://dx.doi.org/10.1136/bmj.302.6779.756			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021765	Green Published, Bronze			2022-12-28	WOS:A1991FF22900022
J	JOYNT, RJ				JOYNT, RJ			NEUROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; PARKINSONS-DISEASE				JOYNT, RJ (corresponding author), UNIV ROCHESTER,SCH MED & DENT,ROCHESTER,NY 14642, USA.							[Anonymous], 1990, LANCET, V336, P1033; BARINAGA M, 1990, SCIENCE, V247, P524, DOI 10.1126/science.2300812; DAMASIO K, 1990, SEMIN NEUROSCI, V2, P277; ELIZAN TS, 1991, ARCH NEUROL-CHICAGO, V48, P31, DOI 10.1001/archneur.1991.00530130039017; FREED CR, 1990, ARCH NEUROL-CHICAGO, V47, P505, DOI 10.1001/archneur.1990.00530050021007; HOUSE A, 1990, J NEUROL NEUROSUR PS, V53, P1024, DOI 10.1136/jnnp.53.12.1024; LILIENFELD DE, 1990, ARCH NEUROL-CHICAGO, V47, P731, DOI 10.1001/archneur.1990.00530070019005; PERRY TL, 1990, ANN NEUROL, V28, P12, DOI 10.1002/ana.410280105; POMEROY SL, 1990, NEW ENGL J MED, V323, P1651, DOI 10.1056/NEJM199012133232402; RINNE UK, 1989, NEUROLOGY, V39, P336, DOI 10.1212/WNL.39.3.336; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; SELKOE DJ, 1990, SCIENCE, V248, P1058, DOI 10.1126/science.2111582; TINETTI ME, 1991, JAMA-J AM MED ASSOC, V265, P468, DOI 10.1001/jama.265.4.468; YOUNG AB, 1990, ANN NEUROL, V28, P9, DOI 10.1002/ana.410280104; [No title captured]	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3134	3135						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041127				2022-12-28	WOS:A1991FQ77000025
J	HSIA, DC				HSIA, DC			QUI-TAM - SUING PHYSICIANS WHO MAKE FALSE CLAIMS	ANNALS OF INTERNAL MEDICINE			English	Article						LEGISLATION, MEDICAL FRAUD; MEDICAID; MEDICARE; HEALTH BENEFIT PLANS, EMPLOYEE		The 1986 False Claims Act Amendments authorize private citizens to sue on behalf of the U.S. government to recover federal funds from fraudulent recipients. The "relator" receives a share of any proceeds from a successful lawsuit. (Originally enacted because of defense procurement scandals, this statute also applies to federal payments for health care (for example, Medicare, Medicaid, Civilian Health and Medical Program for Uniformed Services payments; veterans benefits; and research grants). Physicians can expect qui tam litigation to increase in the future.			HSIA, DC (corresponding author), US DEPT HHS, OFF INSPECTOR GEN, COHEN 5650, 330 INDEPENDENCE AVE SW, WASHINGTON, DC 20201 USA.							EVAN C, 1989, YALE LAW J, V99, P341; FRANCE S, 1990, ABA J, V76, P46; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; LACHS MS, 1990, NEW ENGL J MED, V322, P1599, DOI 10.1056/NEJM199005313222210; MAY AW, 1971, CASE W RESERVE LAW R, V23, P173; NOLAN JR, 1979, BLACKS LAW DICT, P1126; SAX BM, 1986, CALIFORNIA LAWYER, V2, P25; WALL JR, 1987, WISCONSIN BAR B, V60, P16	8	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1050	1053		10.7326/0003-4819-114-12-1050	http://dx.doi.org/10.7326/0003-4819-114-12-1050			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029100				2022-12-28	WOS:A1991FQ55500009
J	NWASOKWA, ON; KOSS, JH; FRIEDMAN, GH; GRUNWALD, AM; BODENHEIMER, MM				NWASOKWA, ON; KOSS, JH; FRIEDMAN, GH; GRUNWALD, AM; BODENHEIMER, MM			BYPASS-SURGERY FOR CHRONIC STABLE ANGINA - PREDICTORS OF SURVIVAL BENEFIT AND STRATEGY FOR PATIENT SELECTION	ANNALS OF INTERNAL MEDICINE			English	Article						ANGINA PECTORIS; CORONARY DISEASE; CORONARY ARTERY BYPASS; VENTRICULAR FUNCTION; CARDIOVASCULAR DISEASE	CORONARY-ARTERY-SURGERY; LEFT-VENTRICULAR FUNCTION; MEDICALLY TREATED PATIENTS; LEFT MAIN EQUIVALENT; MYOCARDIAL-INFARCTION; SURGICAL THERAPY; CASS REGISTRY; FOLLOW-UP; PROGNOSTIC IMPORTANCE; IDENTIFYING PATIENTS	The variable mortality risk associated with chronic stable angina calls for careful selection of patients for coronary artery bypass grafting (CABG) if the aim of management is to prolong life. The randomized and observational studies done in the last 20 years have identified the variables relevant to patient selection and thus have provided a rational basis for such clinical decisions. These studies showed that the sicker the patient, as gauged by relevant measures of coronary disease and cardiovascular morbidity, the more likely it is that CABG will prolong life. A CABG-related improvement in survival is therefore more likely to occur the worse the left ventricular function; the greater the number of diseased vessels; the more proximal the location of coronary lesions (more muscle is threatened by such lesions); the greater the severity of the lesions as determined by angiography; the more severe the angina; the more easily provocable the ischemia or the more extreme the measures of ischemia; and, within limits, the older the patient. Greater survival gain after CABG also occurs in patients with peripheral vascular disease, in patients with baseline electrocardiographic ST-segment and T-wave changes, and probably in women. Thus, patients are likely to live longer after CABG if they have left main disease; three-vessel disease with left ventricular dysfunction (ejection fraction less than 50%), class III or IV angina, provocable ischemia, or disease in the proximal left anterior descending coronary artery; two-vessel disease with proximal left anterior descending artery involvement; and two-vessel disease with class III or IV angina as well as either severe left ventricular dysfunction alone or moderate left ventricular dysfunction together with at least one proximal lesion. When the decision of whether to do CABG is less clear-cut, the presence of peripheral vascular disease, female sex, baseline electrocardiographic ST-segment and T-wave changes, or older age (over 60 but under 80 years) should weigh in favor of doing CABG. In general, patients with single-vessel disease do not seem to derive survival benefit from CABG.			NWASOKWA, ON (corresponding author), LONG ISL JEWISH MED CTR, HARRIS CHASANOFF HEART INST, DIV CARDIOL, ROOM 2135, NEW HYDE PK, NY 11042 USA.							ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; ALDERMAN EL, 1983, CIRCULATION, V68, P785, DOI 10.1161/01.CIR.68.4.785; [Anonymous], 1982, Lancet, V2, P1173; [Anonymous], 1987, LANCET, V2, P871; [Anonymous], 1986, LANCET, V1, P397; BELLER GA, 1985, CIRCULATION, V72, P9; BONOW RO, 1984, NEW ENGL J MED, V311, P1339, DOI 10.1056/NEJM198411223112103; BROWN KA, 1982, AM J CARDIOL, V49, P967, DOI 10.1016/0002-9149(82)92274-3; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CALIFF RM, 1984, AM J CARDIOL, V53, P1489, DOI 10.1016/0002-9149(84)90565-4; CALIFF RM, 1983, CIRCULATION, V67, P283, DOI 10.1161/01.CIR.67.2.283; CALIFF RM, 1986, CIRCULATION, V74, P1191, DOI 10.1161/01.CIR.74.6.1191; CAMERON A, 1988, CIRCULATION, V77, P815, DOI 10.1161/01.CIR.77.4.815; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CAMPEAU L, 1984, NEW ENGL J MED, V311, P1329, DOI 10.1056/NEJM198411223112101; CAMPEAU L, 1984, HEART TRANSPLANT, V3, P220; CHAITMAN BR, 1981, AM J CARDIOL, V48, P765, DOI 10.1016/0002-9149(81)90156-9; CHAITMAN BR, 1986, CIRCULATION, V74, P17; CHESEBRO JH, 1982, NEW ENGL J MED, V307, P73, DOI 10.1056/NEJM198207083070201; COHN PF, 1981, AM J CARDIOL, V47, P233, DOI 10.1016/0002-9149(81)90391-X; CONLEY MJ, 1978, CIRCULATION, V57, P947, DOI 10.1161/01.CIR.57.5.947; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; COX DR, 1972, J R STAT SOC B, V34, P187; DETRE K, 1989, CIRCULATION, V80, P421, DOI 10.1161/01.CIR.80.3.421; DETRE K, 1985, PROG CARDIOVASC DIS, V28, P235, DOI 10.1016/0033-0620(85)90019-2; DETRE K, 1981, CIRCULATION, V63, P1329, DOI 10.1161/01.CIR.63.6.1329; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; DIMAS A, 1990, CLEV CLIN J MED, V57, P19, DOI 10.3949/ccjm.57.1.19; EDMUNDS LH, 1988, NEW ENGL J MED, V319, P131, DOI 10.1056/NEJM198807213190302; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FISHER L, 1983, CIRCULATION, V68, P951; FISHER LD, 1985, CIRCULATION, V72, P110; FISHER LD, 1989, ANN THORAC SURG, V48, P465, DOI 10.1016/S0003-4975(10)66840-3; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; GERSH BJ, 1983, CIRCULATION, V67, P483, DOI 10.1161/01.CIR.67.3.483; GERSH BJ, 1985, NEW ENGL J MED, V313, P217, DOI 10.1056/NEJM198507253130403; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; HAMMERMEISTER KE, 1982, CIRCULATION, V65, P53, DOI 10.1161/01.CIR.65.7.53; HLATKY MA, 1988, J AM COLL CARDIOL, V11, P237, DOI 10.1016/0735-1097(88)90086-1; HUTTER AM, 1980, CIRCULATION, V62, P207, DOI 10.1161/01.CIR.62.2.207; JONES RH, 1983, ANN SURG, V197, P743, DOI 10.1097/00000658-198306000-00014; KAISER GC, 1985, J THORAC CARDIOV SUR, V89, P513; KANNEL WB, 1990, CIRCULATION, V82, P1859, DOI 10.1161/01.CIR.82.5.1859; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KENNEDY JW, 1981, CIRCULATION, V63, P793, DOI 10.1161/01.CIR.63.4.793; Kindwall K E, 1989, Cardiovasc Clin, V19, P195; KING SB, 1988, AM J CARDIOL, V62, pK2, DOI 10.1016/0002-9149(88)90098-7; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MILLER DC, 1983, J THORAC CARDIOV SUR, V85, P197; MOCK MB, 1982, CIRCULATION, V66, P562, DOI 10.1161/01.CIR.66.3.562; MOCK MB, 1988, AM J CARDIOL, V61, P1198, DOI 10.1016/0002-9149(88)91154-X; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MURPHY ML, 1977, NEW ENGL J MED, V297, P621, DOI 10.1056/NEJM197709222971201; PASSAMANI E, 1985, NEW ENGL J MED, V312, P1665, DOI 10.1056/NEJM198506273122603; PIGOTT JD, 1985, J AM COLL CARDIOL, V5, P1036, DOI 10.1016/S0735-1097(85)80003-6; PROUDFIT WJ, 1983, CIRCULATION, V68, P986, DOI 10.1161/01.CIR.68.5.986; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; RAHIMTOOLA SH, 1985, CIRCULATION, V72, P123; RAHIMTOOLA SH, 1984, AM J CARDIOL, V53, P1719, DOI 10.1016/0002-9149(84)90609-X; RYAN TJ, 1985, CIRCULATION, V72, P31; SAMAHA JK, 1985, CLIN CARDIOL, V8, P415, DOI 10.1002/clc.4960080802; Shawl F A, 1989, Cardiol Clin, V7, P865; TAKARO T, 1976, CIRCULATION, V54, P107; TAKARO T, 1985, PROG CARDIOVASC DIS, V28, P229, DOI 10.1016/0033-0620(85)90018-0; TALLEY JD, 1988, CIRCULATION, V77, P820, DOI 10.1161/01.CIR.77.4.820; TAYLOR HA, 1989, CIRCULATION, V79, P1171, DOI 10.1161/01.CIR.79.6.1171; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; TYRAS DH, 1978, ANN THORAC SURG, V25, P449, DOI 10.1016/S0003-4975(10)63583-7; TYRAS DH, 1981, CIRCULATION, V64, P7; VARNAUSKAS E, 1986, CARDIOLOGY, V73, P204, DOI 10.1159/000174014; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; VARNAUSKAS E, 1985, CIRCULATION, V72, P90; VOGEL RA, 1988, AM J CARDIOL, V62, pK11, DOI 10.1016/0002-9149(88)90100-2; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WEINER DA, 1986, J AM COLL CARDIOL, V8, P741, DOI 10.1016/S0735-1097(86)80412-0; WEINSTEIN GS, 1985, J THORAC CARDIOV SUR, V90, P541; WEINSTEIN GS, 1989, ANN THORAC SURG, V48, P490, DOI 10.1016/S0003-4975(10)66846-4; Wenger N K, 1989, Cardiovasc Clin, V19, P173; WILLERSON JT, 1985, CIRCULATION, V72, P3; ZUBIATE P, 1984, WESTERN J MED, V140, P745	81	37	37	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1035	1049		10.7326/0003-4819-114-12-1035	http://dx.doi.org/10.7326/0003-4819-114-12-1035			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029099				2022-12-28	WOS:A1991FQ55500008
J	CALKINS, H; SOUSA, J; ELATASSI, R; ROSENHECK, S; DEBUITLEIR, M; KOU, WH; KADISH, AH; LANGBERG, JJ; MORADY, F				CALKINS, H; SOUSA, J; ELATASSI, R; ROSENHECK, S; DEBUITLEIR, M; KOU, WH; KADISH, AH; LANGBERG, JJ; MORADY, F			DIAGNOSIS AND CURE OF THE WOLFF-PARKINSON-WHITE SYNDROME OR PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIAS DURING A SINGLE ELECTROPHYSIOLOGIC TEST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NODAL REENTRANT TACHYCARDIA; ATRIOVENTRICULAR NODE; CATHETER ABLATION; ACCESSORY PATHWAY; MULTIPLE-DRUGS; SURGERY; EXPERIENCE	Background. We conducted this study to determine the feasibility of an abbreviated therapeutic approach to the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardia, in which the diagnosis is established and radiofrequency ablation carried out during a single electrophysiologic test. Methods. One hundred six consecutive patients were referred for the management of documented, symptomatic paroxysmal supraventricular tachycardias (66 patients) or the Wolff-Parkinson-White syndrome (40 patients). All agreed to undergo a diagnostic electrophysiologic test and catheter ablation with radiofrequency current. No patient had had such a test previously. Results. Among the 66 patients with paroxysmal supraventricular tachycardias, the mechanism was found to be atrioventricular nodal reentry in 46 (70 percent) (typical in 44 and atypical in 2), atrioventricular reciprocating tachycardia involving a concealed accessory pathway in 16 (24 percent), atrial tachycardia in 2 (3 percent), and noninducible paroxysmal supraventricular tachycardia in 2 (3 percent). A successful long-term outcome was achieved in 57 of 62 patients (92 percent) with paroxysmal supraventricular tachycardia in whom ablation was attempted and in 37 of 40 patients (93 percent) with the Wolff-Parkinson-White syndrome. The only complications were one instance of occlusion of the left circumflex coronary artery, leading to acute myocardial infarction, and one instance of complete atrioventricular block. The mean (+/- SD) duration of the electrophysiologic procedures was 114 +/- 55 minutes. Conclusions. The diagnosis and cure of paroxysmal supraventricular tachycardia or the Wolff-Parkinson-White syndrome during a single electrophysiologic test are feasible and practical and have a favorable risk-benefit ratio. This abbreviated therapeutic approach may eliminate the need for serial electropharmacologic testing, long-term drug therapy, antitachycardia pacemakers, and surgical ablation.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV CARDIOL,1500 E MED CTR DR,B1 F245,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan				de Sousa, Joao/0000-0003-2782-8214				BARDY GH, 1988, AM J CARDIOL, V61, P309, DOI 10.1016/0002-9149(88)90936-8; BAUERNFEIND RA, 1980, CIRCULATION, V62, P1341, DOI 10.1161/01.CIR.62.6.1341; BORGGREFE M, 1987, J AM COLL CARDIOL, V10, P576, DOI 10.1016/S0735-1097(87)80200-0; COX JL, 1985, CIRCULATION, V71, P413, DOI 10.1161/01.CIR.71.3.413; COX JL, 1987, CIRCULATION, V76, P1329, DOI 10.1161/01.CIR.76.6.1329; DENDULK K, 1990, PACE, V13, P1020; EPSTEIN LM, 1989, CIRCULATION, V80, P757, DOI 10.1161/01.CIR.80.4.757; FUJIMURA O, 1989, AM J CARDIOL, V64, P1327, DOI 10.1016/0002-9149(89)90576-6; GRIFFIN JC, 1980, AM HEART J, V100, P1093, DOI 10.1016/0002-8703(80)90219-7; GUIRAUDON GM, 1986, CIRCULATION, V74, P525, DOI 10.1161/01.CIR.74.3.525; HAISSAGUERRE M, 1989, NEW ENGL J MED, V320, P426, DOI 10.1056/NEJM198902163200704; JACKMAN W, 1990, CIRCULATION, V82, P689; JOSEPHSON ME, 1990, CARDIOL CLIN, V8, P465; KUCK KH, 1989, PACE, V12, P1681, DOI 10.1111/j.1540-8159.1989.tb01847.x; KUCK KH, 1989, CIRCULATION S2, V80, P323; LEE MA, 1991, CIRCULATION, V83, P827, DOI 10.1161/01.CIR.83.3.827; MORADY F, 1989, CIRCULATION, V79, P1160, DOI 10.1161/01.CIR.79.6.1160; ROMAN CA, 1989, CIRCULATION S2, V80, P323; ROSS DL, 1985, J AM COLL CARDIOL, V6, P1383, DOI 10.1016/S0735-1097(85)80229-1; SCHEINMAN MM, 1984, CIRCULATION, V70, P1024, DOI 10.1161/01.CIR.70.6.1024; WALDO AL, 1988, J AM COLL CARDIOL, V11, P1124, DOI 10.1016/S0735-1097(98)90074-2; WARIN JF, 1988, CIRCULATION, V78, P800, DOI 10.1161/01.CIR.78.4.800; WARIN JF, 1990, PACE, V13, P1609, DOI 10.1111/j.1540-8159.1990.tb06862.x; WU D, 1977, CIRCULATION, V56, P727, DOI 10.1161/01.CIR.56.5.727	24	650	655	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1612	1618		10.1056/NEJM199106063242302	http://dx.doi.org/10.1056/NEJM199106063242302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	2030717				2022-12-28	WOS:A1991FP30700002
J	PIATIGORSKY, J; WISTOW, G				PIATIGORSKY, J; WISTOW, G			THE RECRUITMENT OF CRYSTALLINS - NEW FUNCTIONS PRECEDE GENE DUPLICATION	SCIENCE			English	Editorial Material							ALPHA-B-CRYSTALLIN; LENS CRYSTALLINS; TRANSGENIC MICE; ALDEHYDE DEHYDROGENASE; ENZYME-CRYSTALLINS; STRUCTURAL PROTEIN; DELTA-CRYSTALLIN; DUCK LENS; EYE LENS; EXPRESSION				PIATIGORSKY, J (corresponding author), NEI,MOLEC & DEV BIOL LAB,BETHESDA,MD 20892, USA.							ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CHAPUT M, 1988, NATURE, V332, P454, DOI 10.1038/332454a0; CHEPELINSKY AB, 1987, MOL CELL BIOL, V7, P1807, DOI 10.1128/MCB.7.5.1807; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; EVCES S, 1989, ARCH BIOCHEM BIOPHYS, V274, P518, DOI 10.1016/0003-9861(89)90465-7; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; HENDRIKS W, 1988, P NATL ACAD SCI USA, V85, P7114, DOI 10.1073/pnas.85.19.7114; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KIMURA M, 1974, P NATL ACAD SCI USA, V71, P2848, DOI 10.1073/pnas.71.7.2848; KLEMENT JF, 1989, J BIOL CHEM, V264, P19837; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KONDOH H, 1987, DEV BIOL, V120, P177, DOI 10.1016/0012-1606(87)90116-3; LOK S, 1985, MOL CELL BIOL, V5, P2221, DOI 10.1128/MCB.5.9.2221; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1989, J COMP PHYSIOL A, V164, P577, DOI 10.1007/BF00614500; PIATIGORSKY J, ADV DEV BIOCH, V1; RAO PSS, COMMUNICATION; THOMAS G, 1990, New Biologist, V2, P903; WAWROUSEK EF, 1990, DEV BIOL, V137, P68, DOI 10.1016/0012-1606(90)90008-7; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1990, P NATL ACAD SCI USA, V87, P6277, DOI 10.1073/pnas.87.16.6277; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; WISTOW GJ, 1990, GENE, V96, P263, DOI 10.1016/0378-1119(90)90262-P; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZIGLER JS, 1991, FASEB J, V5, P223, DOI 10.1096/fasebj.5.2.2004667	39	274	275	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1078	1079		10.1126/science.252.5009.1078	http://dx.doi.org/10.1126/science.252.5009.1078			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031181				2022-12-28	WOS:A1991FN05600031
J	YANG, KL; TOBIN, MJ				YANG, KL; TOBIN, MJ			A PROSPECTIVE-STUDY OF INDEXES PREDICTING THE OUTCOME OF TRIALS OF WEANING FROM MECHANICAL VENTILATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXTUBATION CRITERIA; PRESSURE; PRINCIPLES; OXYGEN; TESTS	Background. The traditional predictors of the outcome of weaning from mechanical ventilation - minute ventilation (V(E)) and maximal inspiratory pressure (P(I)max) - are frequently inaccurate. We developed two new indexes: the first quantitates rapid shallow breathing as the ratio of respiratory frequency to tidal volume (f/V(T)), and the second is termed CROP, because it integrates thoracic compliance, respiratory rate, arterial oxygenation, and P(I)max. Methods. The threshold values for each index that discriminated best between a successful and an unsuccessful outcome of weaning were determined in 36 patients, and the predictive accuracy of these values was then tested prospectively in an additional 64 patients. Sensitivity and specificity were calculated, and the data were also analyzed with receiver-operating-characteristic (ROC) curves, in which the proportions of true positive results and false positive results are plotted against each other for a number of threshold values of an index; the area under the curve reflects the accuracy of the index. Results. Sensitivity was highest for P(I)max (1.00), followed closely by the f/V(T) ratio (0.97). Specificity was highest for the f/V(T) ratio (0.64) and lowest for P(I)max (0.11). The f/V(T) ratio was the best predictor of successful weaning, and P(I)max and the f/V(T) ratio were the best predictors of failure. The area under the ROC curve for the f/V(T) ratio (0.89) was larger than that under the curves for the CROP index (0.78, P < 0.05), P(I)max (0.61, P < 0.001), and V(E) (0.40, P < 0.001). Conclusions. Rapid shallow breathing, as reflected by the f/V(T) ratio, was the most accurate predictor of failure, and its absence the most accurate predictor of success, in weaning patients from mechanical ventilation.	HINES VET AFFAIRS HOSP,DIV PULM & CRIT CARE MED,HINES,IL; LOYOLA UNIV,STRITCH SCH MED,CHICAGO,IL 60611	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago	YANG, KL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DIV PULM & CRIT CARE MED,6431 FANNIN,SUITE 1274,HOUSTON,TX 77030, USA.							BECK JR, 1986, ARCH PATHOL LAB MED, V110, P958; BECK JR, 1989, SEMIN RESPIR MED, V10, P211, DOI 10.1055/s-2007-1006174; CENTOR RM, 1985, MED DECIS MAKING, V5, P149; DEHAVEN CB, 1986, CRIT CARE MED, V14, P92, DOI 10.1097/00003246-198602000-00003; FEELEY TW, 1975, NEW ENGL J MED, V292, P903, DOI 10.1056/NEJM197504242921707; FIASTRO JF, 1988, CHEST, V94, P232, DOI 10.1378/chest.94.2.232; GILBERT R, 1974, AM REV RESPIR DIS, V109, P142; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; KRIEGER BP, 1989, CRIT CARE MED, V17, P858, DOI 10.1097/00003246-198909000-00002; MARINI J J, 1986, Journal of Critical Care, V1, P32, DOI 10.1016/S0883-9441(86)80114-9; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; MILBERN SM, 1978, ARCH SURG-CHICAGO, V113, P1441; MILICEMILI J, 1986, AM REV RESPIR DIS, V134, P1107; MORGANROTH ML, 1984, ARCH INTERN MED, V144, P1012, DOI 10.1001/archinte.144.5.1012; PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; Pierson DJ, 1983, RESPIR CARE, V28, P646; ROUSSOS CS, 1977, J APPL PHYSIOL, V43, P189, DOI 10.1152/jappl.1977.43.2.189; SAHN SA, 1973, CHEST, V63, P1002, DOI 10.1378/chest.63.6.1002; SASSOON CSH, 1987, AM REV RESPIR DIS, V135, P107; STETSON JB, 1970, INT ANESTHESIOL CLIN, V8, P767; SWARTZ MA, 1985, CHEST, V88, P736, DOI 10.1378/chest.88.5.736; TAHVANAINEN J, 1983, CRIT CARE MED, V11, P702, DOI 10.1097/00003246-198309000-00006; TOBIN MJ, 1986, AM REV RESPIR DIS, V134, P1111; TOBIN MJ, 1988, CHEST, V94, P227, DOI 10.1378/chest.94.2.227b; TOBIN MJ, 1988, AM REV RESPIR DIS, V138, P1625, DOI 10.1164/ajrccm/138.6.1625; TOBIN MJ, 1990, CURR PULMONOL, V11, P47; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	28	806	866	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1445	1450		10.1056/NEJM199105233242101	http://dx.doi.org/10.1056/NEJM199105233242101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM460	2023603				2022-12-28	WOS:A1991FM46000001
J	ALCOLADO, JC; ALCOLADO, R				ALCOLADO, JC; ALCOLADO, R			IMPORTANCE OF MATERNAL HISTORY OF NON-INSULIN-DEPENDENT DIABETIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the family history of diabetes in non-insulin dependent diabetes mellitus with particular emphasis on parental phenotype. Design - Family histories were obtained from an existing computerised database and supplemented by postal questionnaires. Setting - Diabetic service of a provincial teaching hospital. Subjects - A total of 1326 patients with non-insulin dependent diabetes who had been referred to diabetic clinics over the past 10 years and from whom data had been collected for inclusion in the database, of whom 347 had affected first degree relatives. Nineteen non-white patients were excluded because of the differential hereditability of the disease, and 230 (70%) patients with an affected first degree relative responded to the postal questionnaire. Results - Mothers were implicated in significantly more cases than fathers in patients with a single affected parent: 125 mothers and 48 fathers from database; 82 mothers and 34 fathers from postal questionnaire; p < 0.001 in both cases. Conclusions - Maternal influences seem to have an important role in the inheritance of non-insulin dependent diabetes.	SOUTHAMPTON GEN HOSP,MED PROFESSORIAL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton	ALCOLADO, JC (corresponding author), ST BARTHOLOMEWS HOSP,MED PROFESSORIAL UNIT,LONDON EC1A 7BE,ENGLAND.		Alcolado, John/B-4999-2009	Alcolado, John/0000-0003-0666-0352				Bell G I, 1987, Ciba Found Symp, V130, P167; HARDING AE, 1988, J MED GENET, V25, P528, DOI 10.1136/jmg.25.8.528; KAHN LB, 1990, DIABETES CARE, V7, P796; Mohan V., 1986, PRACT DIAB, V3, P254; ORAHILLY S, 1988, DIABETOLOGIA, V31, P407, DOI 10.1007/BF00271584; PETTITT DJ, 1986, DIABETES, V37, P622; 1983, CENSUS 1981 NATIONAL	7	175	177	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1178	1180		10.1136/bmj.302.6786.1178	http://dx.doi.org/10.1136/bmj.302.6786.1178			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043812	Green Published, Bronze			2022-12-28	WOS:A1991FN04500019
J	WAINHOBSON, S; VARTANIAN, JP; HENRY, M; CHENCINER, N; CHEYNIER, R; DELASSUS, S; MARTINS, LP; SALA, M; NUGEYRE, MT; GUETARD, D; KLATZMANN, D; GLUCKMAN, JC; ROZENBAUM, W; BARRESINOUSSI, F; MONTAGNIER, L				WAINHOBSON, S; VARTANIAN, JP; HENRY, M; CHENCINER, N; CHEYNIER, R; DELASSUS, S; MARTINS, LP; SALA, M; NUGEYRE, MT; GUETARD, D; KLATZMANN, D; GLUCKMAN, JC; ROZENBAUM, W; BARRESINOUSSI, F; MONTAGNIER, L			LAV REVISITED - ORIGINS OF THE EARLY HIV-1 ISOLATES FROM INSTITUT-PASTEUR	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHADENOPATHY-ASSOCIATED VIRUS; IMMUNE-DEFICIENCY SYNDROME; RETROVIRUSES HTLV-III; NUCLEOTIDE-SEQUENCE; AIDS VIRUS; LYMPHOTROPIC RETROVIRUS; MOLECULAR-CLONING; AFRICAN PATIENTS; ENVELOPE GENE	Two of the first human immunodeficiency virus type-1 (HIV-1) strains isolated were authenticated by reanalyzing original cultured samples stored at the Collection Nationale de Culture des Microorganismes as well as uncultured primary material. Cloned polymerase chain reaction products were used to analyze coding sequences of the V3 loop in the gp 120 glycoprotein. The original isolate HIV-1 Bru, formerly called LAV, was derived from patient BRU. HIV-1 Lai was derived from patient LAI and contaminated a HIV-1 Bru culture between 20 July and 3 August 1983. The culture became, in effect, HIV-1 Lai, identifiable by a unique motif in the V3 loop. Because of this contamination two, rather than one, HIV-1 isolates were sent to the Laboratory of Tumor Cell Biology at the National Cancer Institute on 23 September 1983. Original HIV-1 Bru was indeed present in the sample marked JBB/LAV. However the M2T-/B sample harbored HIV-1 Lai, a strain capable of growing on established cell lines. The striking similarity between HIV-1 Lai (formerly LAV-Bru) and HTLV-3B sequences remains.	HOP LA PITIE SALPETRIERE,CNRS 1463,F-75013 PARIS,FRANCE; INST PASTEUR,UNITE ONCOL,F-75724 PARIS 15,FRANCE; HOP ROTHSCHILD,F-75571 PARIS 12,FRANCE; INST PASTEUR,BIOL RETROVIRUS LAB,F-75724 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	WAINHOBSON, S (corresponding author), INST PASTEUR,RETROVIROL MOLEC LAB,F-75724 PARIS 15,FRANCE.		Pedroza-Martins, Livia/C-4258-2008; Cheynier, Remi/E-9921-2010	Cheynier, Remi/0000-0003-1146-660X; Pedroza-Martins, Livia/0000-0002-5243-9563; Rozenbaum, Willy/0000-0003-1975-3566; Vartanian, Jean-Pierre/0000-0001-8079-8814				ALDOUS P, 1991, NATURE, V349, P359; ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; ALIZON M, 1984, NATURE, V312, P757, DOI 10.1038/312757a0; ASJO B, 1986, LANCET, V2, P660; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENN S, 1985, SCIENCE, V230, P949, DOI 10.1126/science.2997922; BRUNVEZINET F, 1984, LANCET, V1, P753; BRUNVEZINET F, 1984, ACQUIRED IMMUNE DEFI, P83; CHIU IM, 1985, NATURE, V317, P366, DOI 10.1038/317366a0; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; COFFIN J, 1986, SCIENCE, V232, P697, DOI 10.1126/science.3008335; CONCAR D, 1990, NATURE, V347, P3, DOI 10.1038/347003a0; DELASSUS S, 1991, J VIROL, V65, P225, DOI 10.1128/JVI.65.1.225-231.1991; EPSTEIN LG, 1991, VIROLOGY, V180, P583, DOI 10.1016/0042-6822(91)90072-J; ESSEX M, 1988, NATURE, V331, P621, DOI 10.1038/331621a0; FEORINO PM, 1984, SCIENCE, V225, P69, DOI 10.1126/science.6328663; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GOLUB EI, 1990, J VIROL, V64, P3654, DOI 10.1128/JVI.64.8.3654-3660.1990; GONDA MA, 1985, SCIENCE, V227, P173, DOI 10.1126/science.2981428; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GUO HG, 1991, NATURE, V349, P745, DOI 10.1038/349745a0; HAHN BH, 1984, NATURE, V312, P166, DOI 10.1038/312166a0; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; KESTLER HW, 1988, NATURE, V331, P619, DOI 10.1038/331619a0; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; MONTAGNIER L, 1984, SCIENCE, V225, P63, DOI 10.1126/science.6328661; MONTAGNIER L, 1984, ANN INST PASTEUR VIR, V135, P119, DOI 10.1016/S0769-2617(84)80046-5; MONTAGNIER L, 1984, PROGR IMMUNODEFICIEN, V1, P367; MONTAGNIER Luc, 1984, HUMAN T CELL LEUKEMI, P363; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; MULDER C, 1988, NATURE, V331, P562, DOI 10.1038/331562a0; MYERS G, 1991, HUMAN RETROVIRUSES A; PALCA J, 1991, SCIENCE, V251, P1306, DOI 10.1126/science.2003216; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SIMMONDS P, 1990, J VIROL, V64, P5840, DOI 10.1128/JVI.64.12.5840-5850.1990; SONIGO P, 1985, CELL, V42, P369, DOI 10.1016/S0092-8674(85)80132-X; SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; STEINHAUER DA, 1987, ANNU REV MICROBIOL, V41, P409, DOI 10.1146/annurev.mi.41.100187.002205; STEPHENSON M, 1990, J VIROL, V64, P3792; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; VILMER E, 1984, LANCET, V1, P753; WAINHOBSON S, 1990, NATURE, V347, P18, DOI 10.1038/347018a0; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WEISS RA, 1991, NATURE, V349, P374, DOI 10.1038/349374b0; WILLEY RL, 1986, P NATL ACAD SCI USA, V83, P5038, DOI 10.1073/pnas.83.14.5038	64	191	196	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					961	965		10.1126/science.2035026	http://dx.doi.org/10.1126/science.2035026			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	2035026				2022-12-28	WOS:A1991FM04000035
J	BREO, DL; SULLIVAN, L				BREO, DL; SULLIVAN, L			HHS SECRETARY SULLIVAN,LOUIS SPEAKS OUT FOR IMPROVED HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US DEPT HHS,WASHINGTON,DC 20201										0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2573	&		10.1001/jama.265.19.2573	http://dx.doi.org/10.1001/jama.265.19.2573			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK903	2020079				2022-12-28	WOS:A1991FK90300036
J	MAKI, DG; RINGER, M				MAKI, DG; RINGER, M			RISK-FACTORS FOR INFUSION-RELATED PHLEBITIS WITH SMALL PERIPHERAL VENOUS CATHETERS - A RANDOMIZED CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							IN-LINE FILTRATION; TRANSDERMAL GLYCERYL TRINITRATE; CHANGING ADMINISTRATION SETS; SODIUM-CHLORIDE INJECTION; INTRAVENOUS THERAPY; MATERIAL THROMBOGENICITY; INTRAVASCULAR CATHETERS; ANTEBRACHIAL CATHETERS; SILICONE ELASTOMER; NATURAL-HISTORY	Objective: To identify risk factors for infusion-related phlebitis with peripheral intravenous catheters. Design: A randomized trial of two catheter materials, with consideration of 21 potential risk factors. Setting: A university hospital. Patients: Hospitalized adults without granulocytopenia who received a peripheral intravenous catheter. Interventions: House officers or ward nurses inserted the catheters, and each insertion was randomized to a catheter made of tetrafluoroethylene-hexafluoropropylene (FEP-Teflon) or a novel polyetherurethane without leachable additives (PEU-Vialon). Measurements: Research nurses scored insertion sites each day for inflammation and cultured catheters at removal. Results: The Kaplan-Meier risk for phlebitis exceeded 50% by day 4 after catheterization. Intravenous antibiotics (relative risk, 2.00), female sex (relative risk, 1.88), prolonged (> 48 hours) catheterization(relative risk, 1.79), and catheter material (PEU-Vialon: FEP-Teflon) (relative risk, 0.73) strongly predicted phlebitis in a Cox proportional hazards model (each, P < 0.003). The best-fit model for severe phlebitis identified the same predictors plus catheter-related infection (relative risk, 6.19), phlebitis with a previous catheter (relative risk, 1.54), and anatomic site (hand: forearm, relative risk, 0.71; wrist:forearm, relative risk, 0.60). The low incidence of local catheter-related infection was comparable wwith the two catheter materials (5.4% [95% CI, 3.8% to 7.6%] and 6.9% [CI, 4.9% to 9.6%]); none of the 1054 catheters prospectively studied caused bacteremia. Conclusions: Multiple factors, including the infusate and the duration of cannulation, contribute to the development of infusion-related phlebitis. The use of peripheral intravenous catheters made of PEU-Vialon appears to pose the same risk for catheter-related infection as the use of catheters made of FEP-Teflon, and PEU-Vialon can permit longer cannulation with less risk for phlebitis. The risk for catheter-related bacteremia with FEP-Teflon and PEU-Vialon catheters is sufficiently low that it no longer seems justifiable to recommend the use of small steel needles for most peripheral intravenous therapy.	UNIV WISCONSIN, SCH MED, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	MAKI, DG (corresponding author), UNIV WISCONSIN HOSP & CLIN, DEPT MED, H4-574, MADISON, WI 53792 USA.							ADAMS SD, 1986, HEART LUNG, V15, P134; ASHKENAZI S, 1984, LANCET, V1, P1075; BAPTISTA RJ, 1987, CLIN PHARMACY, V6, P314; BASSAN MM, 1983, CHEST, V84, P439, DOI 10.1378/chest.84.4.439; BIVINS BA, 1979, SURGERY, V85, P388; BRESLOW NE, 1988, 76 U WASH SCH PUBL H, V76, P1; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P146; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P1; BUXTON AE, 1979, ANN INTERN MED, V90, P764, DOI 10.7326/0003-4819-90-5-764; CHEESBROUGH JS, 1984, J HYG-CAMBRIDGE, V93, P497, DOI 10.1017/S0022172400065086; COLLIN J, 1975, LANCET, V2, P150; CURELARU I, 1983, ACTA ANAESTH SCAND, V27, P158, DOI 10.1111/j.1399-6576.1983.tb01927.x; DABIR R, 1982, BRIT J SURG, V69, P136, DOI 10.1002/bjs.1800690305; DABRERA VC, 1988, INTENS THER CLIN MON, V9, P8; DANIELL HW, 1973, JAMA-J AM MED ASSOC, V226, P1317, DOI 10.1001/jama.226.11.1317; ELFVING G, 1966, LANCET, V1, P953; EPPERSON EL, 1984, CLIN PHARMACY, V3, P626; FALCHUK KH, 1985, NEW ENGL J MED, V312, P78, DOI 10.1056/NEJM198501103120203; FONKALSRUD EW, 1971, SURG GYNECOL OBSTETR, V133, P253; FRIEDLAND G, 1985, NEW ENGL J MED, V312, P113, DOI 10.1056/NEJM198501103120209; GANTZ NM, 1984, DIAGN MICR INFEC DIS, V2, P325, DOI 10.1016/0732-8893(84)90064-6; GARRELTS JC, 1988, CLIN PHARMACY, V7, P760; GARRELTS JC, 1989, CLIN PHARMACY, V8, P34; GAUKROGER PB, 1988, ANAESTH INTENS CARE, V16, P265, DOI 10.1177/0310057X8801600305; GAZE NR, 1978, LANCET, V2, P417; GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258; HECKER JF, 1989, ANAESTH INTENS CARE, V17, P433, DOI 10.1177/0310057X8901700406; HERSHEY CO, 1984, ARCH INTERN MED, V144, P1373, DOI 10.1001/archinte.144.7.1373; HESSOV IB, 1985, ACTA ANAESTH SCAND, V29, P33, DOI 10.1111/j.1399-6576.1985.tb02339.x; HOFFMANN KK, 1988, AM J INFECT CONTROL, V16, P101, DOI 10.1016/0196-6553(88)90046-6; JACQUOT C, 1989, ANN FR ANESTH, V8, P620, DOI 10.1016/S0750-7658(89)80178-9; JAKOBSEN CJ, 1986, J HOSP INFECT, V8, P217, DOI 10.1016/0195-6701(86)90116-7; JOSEPHSON A, 1985, INFECT CONT HOSP EP, V6, P367, DOI 10.1017/S0195941700063335; KHAWAJA HT, 1988, BRIT J SURG, V75, P1212, DOI 10.1002/bjs.1800751223; LARSON E, 1984, AM J INFECT CONTROL, V12, P177, DOI 10.1016/0196-6553(84)90095-6; LEE ET, 1980, STATISTICAL METHODS, P1; LEWIS GBH, 1985, BRIT J ANAESTH, V57, P220, DOI 10.1093/bja/57.2.220; LINDER LE, 1984, JPEN-PARENTER ENTER, V8, P399, DOI 10.1177/0148607184008004399; MADDOX RR, 1983, CLIN PHARMACY, V2, P58; MAKI DG, 1987, JAMA-J AM MED ASSOC, V258, P1777, DOI 10.1001/jama.258.13.1777; MAKI DG, 1981, AM J MED, V70, P739, DOI 10.1016/0002-9343(81)90605-7; MAKI DG, 1987, JAMA-J AM MED ASSOC, V258, P2396, DOI 10.1001/jama.258.17.2396; MAKI DG, 1973, ANN INTERN MED, V79, P867, DOI 10.7326/0003-4819-79-6-867; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MAKI DG, 1988, CLIN RES, V36, pA345; MAKI DG, 1987, 27TH INT C ANT AG CH; McKee J M, 1989, J Intraven Nurs, V12, P288; NELSON DB, 1987, AM J DIS CHILD, V141, P1090, DOI 10.1001/archpedi.1987.04460100068028; Noble C J, 1980, J Hosp Infect, V1, P47, DOI 10.1016/0195-6701(80)90031-6; SHETH NK, 1983, J SURG RES, V34, P213, DOI 10.1016/0022-4804(83)90062-8; SHETH NK, 1983, J CLIN MICROBIOL, V18, P1061, DOI 10.1128/JCM.18.5.1061-1063.1983; SIMMONS B, 1985, INFECT CONT HOSP EP, V6, P342, DOI 10.1017/S019594170006327X; SKETCH MH, 1972, CHEST, V62, P684, DOI 10.1378/chest.62.6.684; SMALLMAN L, 1980, BRIT J SURG, V67, P861, DOI 10.1002/bjs.1800671208; SOIFER NE, 1989, 29 INT C ANT AG CHEM, P1076; TAGER IB, 1983, AM J EPIDEMIOL, V118, P839; THOMPSON DR, 1983, J HOSP INFECT, V4, P285, DOI 10.1016/0195-6701(83)90029-4; TOMFORD JW, 1984, ARCH INTERN MED, V144, P1191, DOI 10.1001/archinte.144.6.1191; TULLY JL, 1981, AM J MED, V70, P702, DOI 10.1016/0002-9343(81)90600-8; TURCO SJ, 1987, PARENTERALS, V14, P37; TURNIDGE J, 1984, MED J AUSTRALIA, V141, P37, DOI 10.5694/j.1326-5377.1984.tb132666.x; Williams D N, 1982, NITA, V5, P379; WOODHOUSE CRJ, 1979, BRIT MED J, V1, P454, DOI 10.1136/bmj.1.6161.454-a; WRIGHT A, 1985, LANCET, V2, P1148; ZDRAHALA RJ, 1987, POLYURETHANES BIOMED, V2, P1; ZINNER SH, 1969, J INFECT DIS, V120, P616, DOI 10.1093/infdis/120.5.616; 1981, INFECT CONTROL, V3, P62	67	345	356	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					845	854		10.7326/0003-4819-114-10-845	http://dx.doi.org/10.7326/0003-4819-114-10-845			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014945				2022-12-28	WOS:A1991FL65000003
J	WIRSCHING, P; ASHLEY, JA; BENKOVIC, SJ; JANDA, KD; LERNER, RA				WIRSCHING, P; ASHLEY, JA; BENKOVIC, SJ; JANDA, KD; LERNER, RA			AN UNEXPECTEDLY EFFICIENT CATALYTIC ANTIBODY OPERATING BY PING-PONG AND INDUCED FIT MECHANISMS	SCIENCE			English	Article							ENZYME INTERMEDIATE; ENERGETICS	A transition state analogue was used to produce a mouse antibody that catalyzes transesterification in water. The antibody behaves as a highly efficient catalyst with a covalent intermediate and the characteristic of induced fit. While some features of the catalytic pathway were programmed when the hapten was designed and reflect favorable substrate-antibody interactions, other features are a manifestation of the chemical potential of antibody diversity. The fact that antibodies recapitulate mechanisms and pathways previously thought to be a characteristic of highly evolved enzymes suggests that once an appropriate binding cavity is achieved, reaction pathways commensurate with the intrinsic chemical potential of proteins ensue.	Scripps Res Inst, RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; PENN STATE UNIV, DEPT CHEM, UNIVERSITY PK, PA 16802 USA	Scripps Research Institute; Scripps Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043858, R29GM043858] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43858-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BRUICE TC, 1959, J AM CHEM SOC, V81, P4552, DOI 10.1021/ja01526a028; BRUICE TC, 1976, ANNU REV BIOCHEM, V45, P331, DOI 10.1146/annurev.bi.45.070176.001555; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1970, ENZYMES, V2, pCH1; CLELAND WW, 1979, METHODS ENZYMOL A, V63, pCH6; DELAFUEN.G, 1970, EUR J BIOCHEM, V16, P226; EPAND RM, 1963, J BIOL CHEM, V238, P1718; FARKAS L, 1949, J AM CHEM SOC, V71, P1991, DOI 10.1021/ja01174a026; FERSHT AR, 1980, BIOCHEMISTRY-US, V19, P5520, DOI 10.1021/bi00565a009; FOLK JE, 1967, J BIOL CHEM, V242, P4329; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; HARTLEY BS, 1954, BIOCHEM J, V56, P288, DOI 10.1042/bj0560288; Hatch GB, 1937, J AM CHEM SOC, V59, P1694, DOI 10.1021/ja01288a038; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JENCKS WP, 1962, J AM CHEM SOC, V84, P2910, DOI 10.1021/ja00874a013; JENCKS WP, 1972, J BIOL CHEM, V247, P3756; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JENCKS WP, 1987, COLD SPRING HARB SYM, V52, P65, DOI 10.1101/SQB.1987.052.01.010; KNOWLES JR, 1987, SCIENCE, V236, P1252; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; KOSHLAND DE, 1987, COLD SPRING HARB SYM, V52, P1; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KOSHLAND DE, 1976, FEBS LETT, V62, pE47, DOI 10.1016/0014-5793(76)80853-8; KOSHLAND DE, 1963, COLD SPRING HARB SYM, V28, P473, DOI 10.1101/SQB.1963.028.01.063; MIEYAL JJ, 1972, ENZYMES, V7, pCH17; MOORE SA, 1982, J BIOL CHEM, V257, P893; PAGE MI, 1973, CHEM SOC REV, V2, P295, DOI 10.1039/cs9730200295; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RAY WJ, 1976, BIOCHEMISTRY-US, V15, P4006, DOI 10.1021/bi00663a015; Segel I.H., 1975, ENZYME KINETICS; SWEERS HM, 1986, J AM CHEM SOC, V108, P6421, DOI 10.1021/ja00280a068; WANG YF, 1988, J ORG CHEM, V53, P3127, DOI 10.1021/jo00248a046; WONG LJ, 1974, BIOCHEMISTRY-US, V13, P3889, DOI 10.1021/bi00716a011; YANKEELOV JA, 1965, J BIOL CHEM, V240, P1593; ZERNER B, 1964, J AM CHEM SOC, V86, P3674, DOI 10.1021/ja01072a016; 1972, 8TH P FEBS M AMST, V29, P45	39	90	90	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					680	685		10.1126/science.2024120	http://dx.doi.org/10.1126/science.2024120			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024120				2022-12-28	WOS:A1991FK18500040
J	DANIELS, N				DANIELS, N			IS THE OREGON RATIONING PLAN FAIR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											DANIELS, N (corresponding author), TUFTS UNIV,DEPT PHILOSOPHY,MEDFORD,MA 02155, USA.				NLM NIH HHS [1R01LM05005] Funding Source: Medline; PHS HHS [RH-20917] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [R01LM005005] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		AARON HJ, 1984, PAINFUL PRESCRIPTION; BLENDON RJ, 1990, HLTH AFF MILLWOO SUM, P185; Bobbitt P., 1978, TRAGIC CHOICES; COHEN J, 1989, ETHICS, V99, P727, DOI 10.1086/293119; DANIELS N, 1985, JUST HLTH CARE; Daniels N, 1988, AM I MY PARENTS KEEP; GOLENSKI J, 1990, REPORT OREGON MED PR; HASNAIN R, 1990, HLTH CARE COMMON REP; KITZHABER J, 1990, OREGON BASIC HLTH SE; KITZHABER J, 1990, SUMMARY HLTH SERVICE; RAWLS J, 1980, J PHILOS, V77, P515, DOI 10.2307/2025790; Rawls J., 1971, THEORY JUSTICE; Scanlon T. M., 1982, UTILITARIANISM, P103, DOI DOI 10.1017/CBO9780511611964.007; TEMKIN LS, 1986, PHILOS PUBLIC AFF, V15, P99; 1990, ANAL IMPACT OREGON M, P1; 1990, PRELIMINARY REPORT	16	76	76	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2232	2235		10.1001/jama.265.17.2232	http://dx.doi.org/10.1001/jama.265.17.2232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH877	2013956				2022-12-28	WOS:A1991FH87700037
J	PARK, JK; ROSENSTEIN, YJ; REMOLDODONNELL, E; BIERER, BE; ROSEN, FS; BURAKOFF, SJ				PARK, JK; ROSENSTEIN, YJ; REMOLDODONNELL, E; BIERER, BE; ROSEN, FS; BURAKOFF, SJ			ENHANCEMENT OF T-CELL ACTIVATION BY THE CD43 MOLECULE WHOSE EXPRESSION IS DEFECTIVE IN WISKOTT-ALDRICH SYNDROME	NATURE			English	Article							LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODY; SIALOPHORIN CD43; HUMAN-LEUKOCYTES; LEUKOSIALIN; PROLIFERATION; ANTIGEN; CD2; PHOSPHORYLATION; RECEPTOR	CD43 (sialophorin, leukosialin, leukocyte large sialoglycoprotein), a heavily sialylated molecule found on most leukocytes and platelets, was initially identified as a major glycoprotein of mouse, rat and human T cells 1-8. CD43 expression is defective on the T cells of males with the Wiskott-Aldrich syndrome, an X chromosome-linked recessive immunodeficiency disorder 9. Affected males are susceptible to opportunistic infections and do not respond to polysaccharide antigens, reflecting defects in cytotoxic and helper T-cell functions. Anti-CD43 monoclonal antibodies have a modest costimulatory effect on T cells, natural killer cells, B cells and monocytes 10-14, and one such antibody has been shown to activate T cells directly 15. To investigate a possible physiological role for CD43, a complementary DNA encoding the human protein 16,17 was introduced into an antigen-responsive murine T-cell hybridoma 18. We observed that CD43 enhances the antigen-specific activation of T cells and that the intracellular domain of CD43, which is hyperphosphorylated during T-cell activation 19-21, is required for this function. We also found that antigen-presenting cells can bind specifically to immobilized purified CD43 and that the binding can be inhibited by liposomes containing CD43 as well as by anti-CD43 monoclonal antibodies.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,SCH MED,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	PARK, JK (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115, USA.			Bierer, Barbara/0000-0001-6448-8170				AXELSSON B, 1985, EUR J IMMUNOL, V15, P427, DOI 10.1002/eji.1830150503; AXELSSON B, 1988, J IMMUNOL, V141, P2912; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; BEYERS AD, 1989, IMMUNOL REV, V111, P59, DOI 10.1111/j.1600-065X.1989.tb00542.x; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CHATILA TA, 1988, J IMMUNOL, V140, P4308; GAHMBERG CG, 1976, J CELL BIOL, V68, P642, DOI 10.1083/jcb.68.3.642; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARKMAN R, 1981, LANCET, V2, P1387; PILLER V, 1989, J BIOL CHEM, V264, P18824; POTTER H, 1987, CURRENT PROTOCOLS MO; REMOLDODONNELL E, 1987, BLOOD, V70, P104; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKAI Y, 1987, P NATL ACAD SCI USA, V84, P6864, DOI 10.1073/pnas.84.19.6864; VARGASCORTES M, 1988, SCAND J IMMUNOL, V27, P661, DOI 10.1111/j.1365-3083.1988.tb02399.x; WIKEN M, 1989, SCAND J IMMUNOL, V29, P363, DOI 10.1111/j.1365-3083.1989.tb01135.x	26	138	141	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					706	709		10.1038/350706a0	http://dx.doi.org/10.1038/350706a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023632				2022-12-28	WOS:A1991FJ13000060
J	CHAPMAN, S; WOODWARD, S				CHAPMAN, S; WOODWARD, S			AUSTRALIAN COURT RULES THAT PASSIVE SMOKING CAUSES LUNG-CANCER, ASTHMA ATTACKS, AND RESPIRATORY-DISEASE	BRITISH MEDICAL JOURNAL			English	Editorial Material									ACT SMOKING & HLTH,SURREY HILLS 2010,AUSTRALIA		CHAPMAN, S (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,WESTMEAD 2145,AUSTRALIA.							BORLAND R, 1990, AM J PUBLIC HEALTH, V80, P178, DOI 10.2105/AJPH.80.2.178; CHAPMAN S, 1980, BRIT MED J, V281, P1187, DOI 10.1136/bmj.281.6249.1187; CHAPMAN S, 1990, INT J HEALTH SERV, V20, P417, DOI 10.2190/YYKC-PGTC-VUMM-3A5P; Chapman S, 1984, MEDIA INFORMATION AU, V31, P47; LEE PN, 1986, BRIT J CANCER, V54, P97, DOI 10.1038/bjc.1986.157; WINSTANLEY M, 1989, TOBACCO AUSTR FACTS; WOODWARD SD, 1990, MED J AUSTRALIA, V153, P682, DOI 10.5694/j.1326-5377.1990.tb126321.x; 1987, EFFECTS PASSIVE SMOK; 1978, STUDY PUBLIC ATTITUD, V1	9	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					943	945		10.1136/bmj.302.6782.943	http://dx.doi.org/10.1136/bmj.302.6782.943			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH487	2032037	Green Published, Bronze			2022-12-28	WOS:A1991FH48700022
J	STAMATOYANNOPOULOS, G				STAMATOYANNOPOULOS, G			HUMAN HEMOGLOBIN SWITCHING	SCIENCE			English	Editorial Material							BETA-GLOBIN GENE; DOMINANT CONTROL REGION; TRANSGENIC MICE; EXPRESSION				STAMATOYANNOPOULOS, G (corresponding author), UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195, USA.							BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; LI QL, 1990, P NATL ACAD SCI USA, V87, P8207, DOI 10.1073/pnas.87.21.8207; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RYAN TM, 1989, P NATL ACAD SCI USA, V86, P37, DOI 10.1073/pnas.86.1.37; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; SPANGLER EA, 1990, NUCLEIC ACIDS RES, V18, P7093, DOI 10.1093/nar/18.23.7093; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2	17	53	53	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					383	383		10.1126/science.2017679	http://dx.doi.org/10.1126/science.2017679			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017679				2022-12-28	WOS:A1991FH10300029
J	SILVER, ML; PARKER, KC; WILEY, DC				SILVER, ML; PARKER, KC; WILEY, DC			RECONSTITUTION BY MHC-RESTRICTED PEPTIDES OF HLA-A2 HEAVY-CHAIN WITH BETA-2-MICROGLOBULIN, INVITRO	NATURE			English	Article							TOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGENS; ASSOCIATION; MOLECULES; EPITOPES; BINDING	CYTOTOXIC T lymphocytes kill virally infected cells when they detect antigenic fragments presented by class I major histocompatibility complex (MHC) antigens (HLA in humans). The crystal structures of HLA-A2 and HLA-Aw68 reveal that peptide-antigen forms an integral part of the HLA structure, being retained in a prominent groove even after purification and crystallization 1-3. Here we report that the heavy chain and beta-2-microglobulin of HLA-A2, after separation and fractionation in denaturants, reassemble efficiently under renaturing conditions only in the presence of MHC-restricted 4 peptides. A complex of heavy chain, beta-2-microglobulin, and viral peptide in the ratio 1:1:1 is formed in up to 46% yield. Reconstitution is not stimulated by either of two peptides not restricted to HLA-A2. The reconstituted complex of HLA-A2 and the influenza virus (B/Lee/40) nucleoprotein peptide, Np (85-94), crystallizes under conditions previously used to crystallize HLA-A2 (ref. 5). Peptide-linked folding and assembly suggests mechanisms for the unusual capacity of HLA to bind many peptides of diverse sequence.	HARVARD UNIV,HOWARD HUGHES MED INST,7 DIVIN AVE,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University				Parker, Kenneth/0000-0002-6282-2478				BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BJORKMAN PJ, 1985, J MOL BIOL, V186, P205, DOI 10.1016/0022-2836(85)90271-2; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BUSHKIN Y, 1984, MOL IMMUNOL, V21, P821, DOI 10.1016/0161-5890(84)90135-4; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; CARRENO BM, 1990, P NATL ACAD SCI USA, V87, P3420, DOI 10.1073/pnas.87.9.3420; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOTCH FM, 1987, NATURE, V326, P882; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; PARHAM P, 1978, NATURE, V276, P397, DOI 10.1038/276397a0; ROBBINS PA, 1989, J IMMUNOL, V143, P4098; SAPER MA, IN PRESS J MOL BIOL; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TURNER MJ, 1975, J BIOL CHEM, V250, P4512; ZINKERNAGEL RM, 1974, NATURE, V251, P548	24	110	117	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					619	622		10.1038/350619a0	http://dx.doi.org/10.1038/350619a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017257				2022-12-28	WOS:A1991FH11200062
J	LAURANCE, J				LAURANCE, J			THE NEW NHS - FREEMAN-HOSPITAL - COUNTDOWN TO SELF GOVERNMENT	BRITISH MEDICAL JOURNAL			English	Editorial Material								We are three weeks away from the beginning of what will be the most profound change in the NHS since its birth over 40 years ago - and the whole world is watching. Many countries are struggling to find more cost effective ways of delivering health care, and they will be as interested as the British to see whether the NHS experiment will enhance or destroy the service. As one of our contributions to monitoring the changes we have identified an NHS trust, a predominantly urban and a predominantly rural health district, and a fund holding practice. The experiences of each will be described in a series running over the next four weeks, and we will then plan to return to them several times over the next few years. We are grateful to the doctors, managers, and others who have been generous with their hard pressed time and spoken to us frankly. We begin today with an account of the Freeman group of hospitals in Newcastle upon Tyne, which has become an NHS trust.											0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					580	582		10.1136/bmj.302.6776.580	http://dx.doi.org/10.1136/bmj.302.6776.580			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021724	Green Published, Bronze			2022-12-28	WOS:A1991FB93600026
J	OGIRALA, RG; ALDRICH, TK; PREZANT, DJ; SINNETT, MJ; ENDEN, JB; WILLIAMS, MH				OGIRALA, RG; ALDRICH, TK; PREZANT, DJ; SINNETT, MJ; ENDEN, JB; WILLIAMS, MH			HIGH-DOSE INTRAMUSCULAR TRIAMCINOLONE IN SEVERE, CHRONIC, LIFE-THREATENING ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORTICOSTEROID-DEPENDENT ASTHMA; TROLEANDOMYCIN; INFLAMMATION	Background. Despite oral corticosteroid therapy, some patients with asthma have frequent exacerbations requiring emergency room visits, hospitalization, and occasionally, mechanical ventilation. We compared the effects of high-dose intramuscular triamcinolone with oral prednisone in patients with severe chronic asthma. Methods. In a double-blind, placebo-controlled, cross-over study that spanned all seasons, we treated 12 patients with high-dose intramuscular triamcinolone (360 mg over the first three days of the treatment period) or low-dose oral prednisone (median dose, 12.5 mg per day throughout the period; range, 0 to 30). The two three-month treatment periods were separated by a three-month washout period. During all periods the patients were allowed to take additional doses of prednisone for acute exacerbations of asthma. Results. After receiving triamcinolone, the patients had significantly better peak expiratory flow rates than while receiving prednisone (the average [+/- SEM] weekly percent of the predicted value during the triamcinolone period was 91.5 +/- 6.9, as compared with 75.0 +/- 5.9 for the prednisone period; P < 0.05). During the prednisone period there were 21 emergency room visits and 10 hospitalizations, but there were none during the triamcinolone period (P < 0.05). There were two episodes of ventilatory failure during the prednisone period. Total steroid doses were significantly smaller during the triamcinolone period than during the prednisone period (P < 0.04). Steroidal side effects were more pronounced after treatment with triamcinolone than after treatment with prednisone (P < 0.1). Conclusions. We conclude that high-dose intramuscular triamcinolone is more effective than low-dose prednisone in patients with severe, chronic, life-threatening asthma, but steroidal side effects are somewhat worse.	MONTEFIORE MED CTR,DEPT PHARM,BRONX,NY 10467	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	OGIRALA, RG (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT MED,DIV PULM,CENTENNIAL BLDG,BRONX,NY 10467, USA.							CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; Fleiss JL, 1986, DESIGN ANAL CLIN EXP, P263; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KLAUSTERMEYER WB, 1987, J ALLERGY CLIN IMMUN, V79, P720, DOI 10.1016/0091-6749(87)90202-8; MULLARKEY MF, 1990, ANN INTERN MED, V112, P577, DOI 10.7326/0003-4819-112-8-577; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MURANAKA M, 1978, ANN ALLERGY, V40, P132; NADEL JA, 1984, J ALLERGY CLIN IMMUN, V73, P651, DOI 10.1016/0091-6749(84)90299-9; OGIRALA RG, 1989, CHEST, V96, pS180; PAULOZZI LJ, 1986, ANN ALLERGY, V56, P392; PEAKE MD, 1979, BRIT J DIS CHEST, V73, P39, DOI 10.1016/0007-0971(79)90005-6; SLY RM, 1984, ANN ALLERGY, V53, P20; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; WALD JA, 1986, J ALLERGY CLIN IMMUN, V78, P36, DOI 10.1016/0091-6749(86)90112-0; WILLEY RF, 1984, THORAX, V39, P340, DOI 10.1136/thx.39.5.340; WILLIAMS MH, 1989, NEW ENGL J MED, V320, P1015; WILLIAMS MH, 1980, ARCH INTERN MED, V140, P1604, DOI 10.1001/archinte.140.12.1604; 1987, AM REV RESPIR DIS, V136, P225	18	50	51	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 28	1991	324	9					585	589		10.1056/NEJM199102283240903	http://dx.doi.org/10.1056/NEJM199102283240903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY886	2021388				2022-12-28	WOS:A1991EY88600003
J	LITT, IF				LITT, IF			ADOLESCENT MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											LITT, IF (corresponding author), STANFORD UNIV,MED CTR,STANFORD,CA 94305, USA.							BACHRACH LK, 1990, PEDIATRICS, V86, P440; DAVIS AJ, 1989, J PEDIATR-US, V115, P1, DOI 10.1016/S0022-3476(89)80320-8; HALLAGAN JB, 1989, NEW ENGL J MED, V321, P1042, DOI 10.1056/NEJM198910123211510; HEIN K, 1990, AM J DIS CHILD, V144, P46, DOI 10.1001/archpedi.1990.02150250052030; SHOUPE D, 1989, AM J OBSTET GYNECOL, V160, P1286, DOI 10.1016/S0002-9378(89)80014-6; 1989, MMWR, V38, P863; 1990, MED LETT DRUGS THER, V32, P112; 1989, PEDIATRICS, V84, P110	8	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3100	3101						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041110				2022-12-28	WOS:A1991FQ77000007
J	SRA, JS; ANDERSON, AJ; SHEIKH, SH; AVITALL, B; TCHOU, PJ; TROUP, PJ; GILBERT, CJ; AKHTAR, M; JAZAYERI, MR				SRA, JS; ANDERSON, AJ; SHEIKH, SH; AVITALL, B; TCHOU, PJ; TROUP, PJ; GILBERT, CJ; AKHTAR, M; JAZAYERI, MR			UNEXPLAINED SYNCOPE EVALUATED BY ELECTROPHYSIOLOGIC STUDIES AND HEAD-UP TILT TESTING	ANNALS OF INTERNAL MEDICINE			English	Article							NEURALLY-MEDIATED SYNCOPE; VAGAL C-FIBERS; RECURRENT SYNCOPE; DISOPYRAMIDE; ISOPROTERENOL; BRADYCARDIA; HYPOTENSION; REVERSAL	Objective: To determine the clinical characteristics of subgroups of patients with unexplained syncope having electrophysiologic studies and head-up tilt testing and to assess the efficacy of various therapies. Design: Retrospective study. Setting: Inpatient services of a tertiary referral center. Patients: Eighty-six consecutively referred patients with unexplained syncope. Measurements: All patients had electrophysiologic examinations. Patients with negative results subsequently had head-up tilt testing. Main Results: Twenty-nine (34%) patients (group 1) had abnormal electrophysiologic results, with sustained monomorphic ventricular tachycardia induced in 72%. Thirty-four (40%) patients (group 2) had syncope provoked by head-up tilt testing. The cause of syncope remained unexplained in 23 (26%) patients (group 3). Structural heart disease was present in 76%, 6%, and 30% of groups 1, 2, and 3, respectively. In group 1, pharmacologic or nonpharmacologic therapy was recommended based on electrophysiologic evaluation. All group 2 patients had negative results on head-up tilt testing while receiving oral beta blockers (27 patients) or disopyramide (7 patients). Group 3 patients did not receive any specific therapy. During a median follow-up period of 18.5 months, syncope recurred in 9 (10%) patients. Conclusions: The combination of electrophysiologic evaluation and head-up tilt testing can identify the underlying cause of syncope in as many as 74% of patients presenting with unexplained syncope. Therapeutic strategies formulated according to the results of these diagnostic tests appear to prevent syncope effectively in most patients.	MILWAUKEE CARDIOVASC DATA REGISTRY, MILWAUKEE, WI 53215 USA; SANDAHA HOME, LAHORE, PAKISTAN; PRESBYTERIAN UNIV HOSP, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	SRA, JS (corresponding author), SINAI SAMARITAN MED CTR, 950 N 12TH ST, POB 342, MILWAUKEE, WI 53201 USA.							ABBOUD FM, 1976, PROG CARDIOVASC DIS, V18, P371, DOI 10.1016/0033-0620(76)90003-7; ABISAMRA F, 1988, PACE, V11, P1202, DOI 10.1111/j.1540-8159.1988.tb03973.x; AKHTAR M, 1983, PACE, V6, P192, DOI 10.1111/j.1540-8159.1983.tb04346.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; DANILO P, 1976, AM HEART J, V92, P532; DERMKSIAN G, 1958, JAMA-J AM MED ASSOC, V168, P1200, DOI 10.1001/jama.1958.03000090030007; DIMARCO JP, 1981, ANN INTERN MED, V95, P542, DOI 10.7326/0003-4819-95-5-542; GOLDENBERG IF, 1987, CIRCULATION, V76, P133; JAZAYERI MR, 1989, J AM COLL CARDIOL, V14, P705, DOI 10.1016/0735-1097(89)90114-9; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; KUSHNER JA, 1989, J AM COLL CARDIOL, V14, P391, DOI 10.1016/0735-1097(89)90191-5; Lewis T, 1932, BRIT MED J, V1932, P873, DOI 10.1136/bmj.1.3723.873; LUBROOK J, 1989, INT UNION PHYSL SCI, V4, P120; MILSTEIN S, 1987, CIRCULATION, V76, P175; OBERG B, 1972, ACTA PHYSIOL SCAND, V85, P164, DOI 10.1111/j.1748-1716.1972.tb05247.x; PODRID PJ, 1980, NEW ENGL J MED, V302, P614, DOI 10.1056/NEJM198003133021106; SHALEV Y, 1990, Journal of the American College of Cardiology, V15, p98A; SHARPEYSCHAFER EP, 1958, BMJ-BRIT MED J, V2, P878, DOI 10.1136/bmj.2.5101.878; SILVERSTEIN MD, 1982, JAMA-J AM MED ASSOC, V248, P1185, DOI 10.1001/jama.248.10.1185; SJOSTRAND T, 1952, ACTA PHYSIOL SCAND, V26, P312, DOI 10.1111/j.1748-1716.1952.tb00912.x; THAMES MD, 1980, AM J PHYSIOL, V238, pH465, DOI 10.1152/ajpheart.1980.238.4.H465; Thoren P, 1979, Rev Physiol Biochem Pharmacol, V86, P1, DOI 10.1007/BFb0031531; TONKIN AM, 1978, AUST NZ J MED, V8, P594, DOI 10.1111/j.1445-5994.1978.tb04846.x; WALTER PF, 1978, AM J CARDIOL, V42, P396, DOI 10.1016/0002-9149(78)90934-7	24	209	209	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1013	1019		10.7326/0003-4819-114-12-1013	http://dx.doi.org/10.7326/0003-4819-114-12-1013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029096				2022-12-28	WOS:A1991FQ55500004
J	ATTIE, M				ATTIE, M			HYPOCALCEMIC SYMPTOMS FOLLOWING PARATHYROIDECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ATTIE, M (corresponding author), UNIV PENN,SCH MED,PHILADELPHIA,PA 19104, USA.							Parfitt A. M., 1989, ENDOCRINOLOGY, P1049; PORTER RH, 1978, NEW ENGL J MED, V298, P577, DOI 10.1056/NEJM197803162981101	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2888	2888						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033749				2022-12-28	WOS:A1991FN85500043
J	STEINBERG, D; PEARSON, TA; KULLER, LH				STEINBERG, D; PEARSON, TA; KULLER, LH			ALCOHOL AND ATHEROSCLEROSIS	ANNALS OF INTERNAL MEDICINE			English	Discussion							LOW-DENSITY LIPOPROTEIN; CORONARY HEART-DISEASE; LIPID-METABOLISM; RISK-FACTORS; MYOCARDIAL-INFARCTION; PLASMA-LIPOPROTEINS; HEALTHY-VOLUNTEERS; ACUTE-PANCREATITIS; ENDOTHELIAL-CELLS; ARTERY DISEASE	Considerable progress has been made in recent years in our understanding of atherogenesis and, in particular, of how it relates to lipoprotein metabolism. In this conference, we attempt to re-evaluate the data on the relation between alcohol intake and coronary heart disease, emphasizing the effects of alcohol on lipoprotein metabolism. Epidemiologic data generally show an inverse correlation between coronary heart disease risk and moderate alcohol intake (variously defined but generally corresponding to 2 to 4 drinks per day). The potentially drastic effects of excessive alcohol intake on health, however, preclude any recommendation that patients increase their alcohol consumption. Equally, there may be no basis for proscribing moderate alcohol intake but, even here, the data are far from complete. The mechanism by which moderate alcohol intake "protects" remains unclear. Perhaps the best available hypothesis relates to the increased concentration of high-density lipoprotein (HDL) cholesterol associated with moderate alcohol intake. However, it should be stressed that we are still uncertain about the mechanisms linking a high HDL level to protection against coronary heart disease. If a high HDL level is only a marker (and not directly protective), raising HDL levels need not confer protection. Alcoholism, on the other hand, is associated with marked elevation of triglyceride-rich lipoproteins and is among the most common causes of hypertriglyceridemia. Moreover, once hepatic damage occurs, plasma HDL levels may actually be lower than normal. The determining point is that high alcohol intakes are associated with increased overall mortality. Until we know more about the metabolic and behavioral effects of alcohol and about its linkage to atherosclerosis, we have no basis for recommending either that patients increase their alcohol intake or that they start to drink if they do not already.	UNIV CALIF SAN DIEGO, DEPT MED, DIV ENDOCRINOL & METAB, LA JOLLA, CA 92093 USA; MARY IMOGENE BASSETT RES INST, COOPERSTOWN, NY 13326 USA; COLUMBIA UNIV, DEPT EPIDEMIOL, NEW YORK, NY 10027 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, PITTSBURGH, PA 15261 USA	University of California System; University of California San Diego; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BALLANTYNE FC, 1982, METABOLISM, V31, P433, DOI 10.1016/0026-0495(82)90230-X; BARAONA E, 1979, J LIPID RES, V20, P289; BARBORIAK JJ, 1982, ATHEROSCLEROSIS, V43, P277, DOI 10.1016/0021-9150(82)90028-4; BEARD CM, 1986, MAYO CLIN PROC, V61, P186, DOI 10.1016/S0025-6196(12)61847-3; BELFRAGE P, 1977, EUR J CLIN INVEST, V7, P127, DOI 10.1111/j.1365-2362.1977.tb01584.x; BERGSTRAND R, 1983, J CHRON DIS, V36, P289, DOI 10.1016/0021-9681(83)90064-4; BOROWSKY SA, 1980, DIGEST DIS SCI, V25, P22, DOI 10.1007/BF01312728; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Buch A, 1980, World J Surg, V4, P307; BURR ML, 1988, P NUTR SOC, V47, P129, DOI 10.1079/PNS19880022; BURR ML, 1986, BRIT J NUTR, V56, P81, DOI 10.1079/BJN19860087; CAHALAN D, 1981, CIRCULATION, V64, P7; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; CAMARGO CA, 1985, JAMA-J AM MED ASSOC, V253, P2854; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; CAMERON JL, 1974, AM J MED, V56, P482, DOI 10.1016/0002-9343(74)90480-X; CAMERON JL, 1973, ANN SURG, V177, P483, DOI 10.1097/00000658-197304000-00017; CASTELLI WP, 1977, LANCET, V2, P153; COUZIGOU P, 1984, ANN NUTR METAB, V28, P377, DOI 10.1159/000176849; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1987, ACTA MED SCAND, P73; CROUSE JR, 1984, J LIPID RES, V25, P486; DAI WS, 1985, AM J EPIDEMIOL, V122, P620, DOI 10.1093/oxfordjournals.aje.a114141; DYER AR, 1977, CIRCULATION, V56, P1067, DOI 10.1161/01.CIR.56.6.1067; FERRENCE RG, 1986, J STUD ALCOHOL, V47, P394, DOI 10.15288/jsa.1986.47.394; Flegal K M, 1985, Recent Dev Alcohol, V3, P165; FRIED LP, 1986, AM J MED, V80, P37, DOI 10.1016/0002-9343(86)90046-X; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; FRIMPONG NA, 1989, AM J CLIN NUTR, V50, P987, DOI 10.1093/ajcn/50.5.987; GERRITY RG, 1981, AM J PATHOL, V103, P191; GLUECK CJ, 1980, AM J CLIN NUTR, V33, P2287, DOI 10.1093/ajcn/33.11.2287; GORDON T, 1981, CIRCULATION, V64, P63; GRUCHOW HW, 1985, AM J CLIN NUTR, V42, P289, DOI 10.1093/ajcn/42.2.289; HARTUNG GH, 1983, JAMA-J AM MED ASSOC, V249, P747, DOI 10.1001/jama.249.6.747; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HENRIKSEN T, 1982, ANN NY ACAD SCI, V401, P102, DOI 10.1111/j.1749-6632.1982.tb25711.x; HOLME I, 1985, AM J CARDIOL, V55, P40, DOI 10.1016/0002-9149(85)90296-6; HULLEY SB, 1981, CIRCULATION, V64, P57; KANNEL WB, 1988, P NUTR SOC, V47, P99, DOI 10.1079/PNS19880018; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KITTNER SJ, 1983, AM J EPIDEMIOL, V117, P538, DOI 10.1093/oxfordjournals.aje.a113576; KLATSKY AL, 1989, CIRCULATION S2, V80, P614; KRAMER K, 1968, ANN INTERN MED, V69, P273, DOI 10.7326/0003-4819-69-2-273; KULLER LH, 1989, CIRCULATION, V80, P261, DOI 10.1161/01.CIR.80.2.261; Laporte R E, 1980, J Public Health Policy, V1, P198, DOI 10.2307/3342085; LAPORTE RE, 1980, PREV MED, V9, P22, DOI 10.1016/0091-7435(80)90057-2; MAEIEJKO JJ, 1983, NEW ENGL J MED, V309, P385; MANOLIO TA, 1989, CIRCULATION S2, V80, P678; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MEADE TW, 1987, LANCET, V2, P986; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MOORE RD, 1988, AM J MED, V84, P884, DOI 10.1016/0002-9343(88)90067-8; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MYERSON RM, 1971, BIOL BASIS ALCOHOLIS, P183; OKAMOTO Y, 1988, J LAB CLIN MED, V111, P482; ROSENGREN A, 1987, ACTA MED SCAND, V222, P201; ROSENGREN A, 1987, ACTA MED SCAND, P87; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; SABESIN SM, 1981, CIRCULATION, V64, P72; SALONEN JT, 1989, CIRCULATION S2, V80, P281; SHAPER AG, 1987, BMJ-BRIT MED J, V294, P733, DOI 10.1136/bmj.294.6574.733; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1989, CIRCULATION S2, V80, P281; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SUHONEN O, 1987, ACTA MED SCAND, V221, P335; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TASKINEN MR, 1982, METABOLISM, V31, P1168, DOI 10.1016/0026-0495(82)90169-X; THOMSON M, 1988, AM J CLIN NUTR, V47, P139, DOI 10.1093/ajcn/47.1.139; THORNTON J, 1983, LANCET, V2, P819; TURNER TB, 1981, JOHNS HOPKINS MED J, V148, P53; WILHELMSEN L, 1983, ACTA MED SCAND, V213, P263; Wolf P A, 1983, Neurol Clin, V1, P317; 1989, J AM COLL CARDIOL, V13, pA11	79	111	111	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					967	976		10.7326/0003-4819-114-11-967	http://dx.doi.org/10.7326/0003-4819-114-11-967			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024865				2022-12-28	WOS:A1991FM97900009
J	IMANISHIKARI, T				IMANISHIKARI, T			OSIS CONCLUSIONS WRONG	NATURE			English	Editorial Material																		HADLEY S, 1991, NY TIMES        0503	1	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					344	345		10.1038/351344a0	http://dx.doi.org/10.1038/351344a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034282				2022-12-28	WOS:A1991FN85600019
J	OLSON, DJ; CHRISTIAN, JL; MOON, RT				OLSON, DJ; CHRISTIAN, JL; MOON, RT			EFFECT OF WNT-1 AND RELATED PROTEINS ON GAP JUNCTIONAL COMMUNICATION IN XENOPUS EMBRYOS	SCIENCE			English	Article							EARLY AMPHIBIAN EMBRYO; PROTO-ONCOGENE INT-1; MURINE INT-1; DROSOPHILA HOMOLOG; CELL COMMUNICATION; GENE; PROTOONCOGENE; EXPRESSION; WINGLESS; PATTERNS	The proto-oncogene wnt-1 (previously referred to as int-1) is thought to be important in embryonic pattern formation although its mechanisms of action are unknown. Premature and increased expression of the Wnt-1 protein, achieved by injection of synthetic wnt-1 RNA into fertilized Xenopus eggs, enhanced gap junctional communication between ventral cells of the developing embryo. This result is consistent with the hypothesis that Wnt proteins activate a receptor-mediated signal transduction pathway and that gap junctional communication can be a target of this pathway. The effects of two Wnt-1-related proteins on gap junctional communication were also investigated: overexpression of Xwnt-8 increased gap junctional coupling in a manner similar to Wnt-1, whereas Xwnt-5A did not. These findings are consistent with the existence of multiple receptors for Wnt proteins.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040089, K04AR001837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007023] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR40089, KO4-AR01837] Funding Source: Medline; NIDCR NIH HHS [DE-07023] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BERRIDGE MJ, 1982, BIOCHEM J, V206, P507; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, IN PRESS DEVELOPMENT; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; FAWCETT DW, 1981, CELL, P124; FRASER SE, 1987, SCIENCE, V237, P49, DOI 10.1126/science.3037697; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GUTHRIE S, 1988, DEVELOPMENT, V103, P769; GUTHRIE SC, 1984, NATURE, V311, P149, DOI 10.1038/311149a0; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Moon R. T., 1989, TECHNIQUE, V1, P76; MOON RT, UNPUB; NAGAJSKI DJ, 1989, DEVELOPMENT, V105, P747; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; OLSON DA, UNPUB; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, IN PRESS GENES DEV; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; UZVOLGYI E, 1988, P NATL ACAD SCI USA, V85, P3034, DOI 10.1073/pnas.85.9.3034; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WARNER AE, 1982, CELL, V28, P243, DOI 10.1016/0092-8674(82)90342-7; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WARNER AE, 1986, SOMITES DEV EMBRYOS, P91; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	42	128	129	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1173	1176		10.1126/science.252.5009.1173	http://dx.doi.org/10.1126/science.252.5009.1173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031187				2022-12-28	WOS:A1991FN05600051
J	KUNG, AWC; PUN, KK				KUNG, AWC; PUN, KK			BONE-MINERAL DENSITY IN PREMENOPAUSAL WOMEN RECEIVING LONG-TERM PHYSIOLOGICAL DOSES OF LEVOTHYROXINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE; OSTEOPOROSIS; HYPERTHYROIDISM; THYROTOXICOSIS; CALCITONIN; HYPOTHYROIDISM; REPLACEMENT; DEFICIENCY; THERAPY	Total body and regional bone mineral density (BMD) levels were determined in 26 premenopausal women with Hashimoto's thyroiditis receiving long-term physiological doses of levothyroxine sodium replacement therapy. The BMD levels of each patient were compared with the mean of the BMD levels of age-matched normal controls. The mean levothyroxine sodium dose was 111 +/- 6-mu-g/d, and the mean duration of treatment was 7.5 +/- 5.3 years (range, 1 to 24 years). Dietary calcium intake was similar in both groups, as were serum thyroxine, triiodothyronine, free thyroxine index, and thyrotropin levels. Women receiving the levothyroxine treatment had normal total body BMD levels but had significantly lower BMD levels at the femoral neck (-5.7%), femoral trochanter (-7.0%), Ward's triangle (-10.6%), both arms (right,-7.8%; left, -8.9%), and pelvis (-4.9%). In contrast, lumbar spine BMD levels were similar in the two groups. There was no correlation between the total body or different regional BMD levels and the duration or dosage of levothyroxine treatment or thyroid function test results. However, the z score of the femoral neck of these patients showed a significant negative correlation with their serum free thyroxine index levels. We conclude that patients receiving physiological doses of levothyroxine may have decreased bone density. Thyroid functions in patients receiving long-term levothyroxine treatment should be closely monitored and bone densitometry should be performed in patients at risk for osteoporosis.			KUNG, AWC (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG.							CALDWELL G, 1985, LANCET, V1, P1117; COINDRE JM, 1986, ARCH INTERN MED, V146, P48, DOI 10.1001/archinte.146.1.48; DANIELL HW, 1974, NEW ENGL J MED, V291, P102; ERIKSEN EF, 1986, BONE, V7, P101, DOI 10.1016/8756-3282(86)90681-2; ETTINGER B, 1982, WESTERN J MED, V136, P473; FALLON MD, 1983, ARCH INTERN MED, V143, P442, DOI 10.1001/archinte.143.3.442; FLEISH H, 1987, OSTEOPOROSIS, P1159; FRAME B, 1983, ANN INTERN MED, V99, P725, DOI 10.7326/0003-4819-99-5-725; FRASER SA, 1971, LANCET, V1, P981; GARREL DR, 1986, J CLIN ENDOCR METAB, V62, P1052, DOI 10.1210/jcem-62-5-1052; GONZALEZ D, 1986, CALCIFIED TISSUE INT, V38, P71, DOI 10.1007/BF02556832; HENNESSEY JV, 1986, ANN INTERN MED, V105, P11, DOI 10.7326/0003-4819-105-1-11; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; LEE MS, 1990, J CLIN ENDOCR METAB, V70, P766, DOI 10.1210/jcem-70-3-766; MCDERMOTT MT, 1983, J CLIN ENDOCR METAB, V56, P936, DOI 10.1210/jcem-56-5-936; MEEMA HE, 1970, RADIOLOGY, V97, P9, DOI 10.1148/97.1.9; MELSEN F, 1977, ACTA PATH MICRO IM A, V85, P141; Meunier PJ, 1972, ORTHOPEDIA CLINICS N, V3, P745; MULLEN BJ, 1984, AM J CLIN NUTR, V39, P136, DOI 10.1093/ajcn/39.1.136; NIELSEN HE, 1979, ACTA RADIOL ONCOL, V18, P122, DOI 10.3109/02841867909128198; NORD RH, 1989, 21 EUR S CALC TISS J; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PERRY HM, 1986, ARCH INTERN MED, V146, P41, DOI 10.1001/archinte.146.1.41; PUN KK, IN PRESS OSTEOPOROSI; PUN KK, IN PRESS J APPL NUTR; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; TIEGS RD, 1985, NEW ENGL J MED, V312, P1097, DOI 10.1056/NEJM198504253121705; TIEGS RD, 1983, CALCIFIED TISSUE INT, V369, P479	30	74	75	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2688	2691		10.1001/jama.265.20.2688	http://dx.doi.org/10.1001/jama.265.20.2688			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023349				2022-12-28	WOS:A1991FL98900033
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - VAGINAL BLEEDING IN EARLY-PREGNANCY .2.	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1195	1197		10.1136/bmj.302.6786.1195	http://dx.doi.org/10.1136/bmj.302.6786.1195			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043819	Bronze, Green Published			2022-12-28	WOS:A1991FN04500029
J	KRONENBERG, M				KRONENBERG, M			SELF-TOLERANCE AND AUTOIMMUNITY	CELL			English	Editorial Material							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NONSELF DISCRIMINATION; CLONAL ANERGY; LYMPHOCYTE-T; CELLS; MICE				KRONENBERG, M (corresponding author), UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA.							ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BURKLY LC, 1990, SCIENCE, V248, P1364, DOI 10.1126/science.1694042; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GASPARI AA, 1988, J IMMUNOL, V141, P2216; GOODNOW CC, 1990, SCIENCE, V248, P1373, DOI 10.1126/science.2356469; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; GRIFFITHS MM, 1989, INT REV IMMUNOL, V4, P1; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	28	35	36	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					537	542		10.1016/0092-8674(91)90086-E	http://dx.doi.org/10.1016/0092-8674(91)90086-E			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032283				2022-12-28	WOS:A1991FM03700004
J	AXE, JD				AXE, JD			NEUTRON-SCATTERING - PROGRESS AND PROSPECTS	SCIENCE			English	Article							VITREOUS SILICA; MAGNETIC-STRUCTURE; CRITICAL-BEHAVIOR; CRYSTAL; DIFFRACTION; REFLECTION; SUPERCONDUCTIVITY; LA2-XBAXCUO4; LA2-XSRXCUO4; DEPENDENCE	Over the last decade the unique properties of neutrons have proven useful in a growing number of scientific disciplines. Neutron scattering, traditionally the probe of choice for many magnetic and spectroscopic studies, is now firmly established as an invaluable complement to x-ray scattering for structural and dynamic studies within many other areas of the material sciences, chemistry, and biology. In recent years the instruments and techniques have matured to the point where they are of increasing relevance to the understanding and design of improved practical, everyday materials.			AXE, JD (corresponding author), BROOKHAVEN NATL LAB,UPTON,NY 11973, USA.							AEPPLI G, 1989, PHYS REV LETT, V62, P2052, DOI 10.1103/PhysRevLett.62.2052; ALBINATI A, 1982, J APPL CRYSTALLOGR, V15, P361, DOI 10.1107/S0021889882012187; ALLEN AJ, 1985, ADV PHYS, V34, P445, DOI 10.1080/00018738500101791; ANASTASIADIS SH, 1990, J CHEM PHYS, V92, P5677, DOI 10.1063/1.458499; ANDERSON IS, 1986, PHYS REV LETT, V57, P2822, DOI 10.1103/PhysRevLett.57.2822; ANNILA AJ, 1990, PHYS REV LETT, V64, P1421, DOI 10.1103/PhysRevLett.64.1421; [Anonymous], 1985, PHYS TODAY, V38, P1985; AXE JD, 1989, PHYS REV LETT, V62, P2751, DOI 10.1103/PhysRevLett.62.2751; BATES FS, 1988, PHYS REV LETT, V61, P2229, DOI 10.1103/PhysRevLett.61.2229; BATES FS, 1985, PHYS REV LETT, V55, P2425, DOI 10.1103/PhysRevLett.55.2425; BIRGENEAU RJ, 1989, PHYS REV B, V39, P2868, DOI 10.1103/PhysRevB.39.2868; BONI P, 1988, PHYS REV B, V38, P185, DOI 10.1103/PhysRevB.38.185; BROHOLM C, 1987, PHYS REV LETT, V58, P1467, DOI 10.1103/PhysRevLett.58.1467; BUCHENAU U, 1984, PHYS REV LETT, V53, P2316, DOI 10.1103/PhysRevLett.53.2316; BUCHENAU U, 1988, PHYS REV LETT, V60, P1318, DOI 10.1103/PhysRevLett.60.1318; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CAVAGNAT D, 1985, PHYS REV LETT, V54, P193, DOI 10.1103/PhysRevLett.54.193; CHEETHAM AK, 1986, NATURE, V320, P46, DOI 10.1038/320046a0; CHENG XD, 1990, ACTA CRYSTALLOGR B, V46, P195, DOI 10.1107/S0108768189012607; De Gennes P.-G., 1979, SCALING CONCEPTS POL; DEEM MW, 1989, NATURE, V342, P260, DOI 10.1038/342260a0; EMERY VJ, 1987, PHYS REV LETT, V58, P2794, DOI 10.1103/PhysRevLett.58.2794; FELCHER GP, 1986, PHYSICA B & C, V136, P59, DOI 10.1016/S0378-4363(86)80021-3; FELCHER GP, 1984, PHYS REV LETT, V52, P1537; FISCHER P, 1971, J PHYS CHEM SOLIDS, V32, P543, DOI 10.1016/0022-3697(71)90003-5; FRELTOFT T, 1987, PHYS REV B, V36, P826, DOI 10.1103/PhysRevB.36.826; GRIMM H, 1987, PHYS REV LETT, V59, P1780, DOI 10.1103/PhysRevLett.59.1780; HAN CC, 1988, POLYMER, V29, P2002, DOI 10.1016/0032-3861(88)90174-7; HAYTER JB, 1989, PHYS REV LETT, V62, P1667, DOI 10.1103/PhysRevLett.62.1667; HEMPELMANN R, 1989, MOMENTUM DISTRIBUTIONS, P213; HOLDEN TM, 1988, METALL TRANS A, V19, P2207, DOI 10.1007/BF02645044; JORGENSEN JD, 1990, PHYS REV B, V41, P1863, DOI 10.1103/PhysRevB.41.1863; JORGENSEN JD, 1988, NATO ASI SER C-MATH, V221, P159; JYRKKIO TA, 1989, J LOW TEMP PHYS, V74, P435, DOI 10.1007/BF00682669; KRAWITZ AD, 1990, MRS BULL, V15, P57, DOI 10.1557/S0883769400058371; KWEI GH, 1990, J MOL STRUCT, V223, P384; LANDER GH, 1985, NUCL INSTRUM METH B, V12, P525, DOI 10.1016/0168-583X(85)90510-5; LARESE JZ, 1988, PHYS REV LETT, V61, P432, DOI 10.1103/PhysRevLett.61.432; LEDERER H, 1989, EMBO J, V8, P1257, DOI 10.1002/j.1460-2075.1989.tb03499.x; LEE EM, 1989, CHEM PHYS LETT, V162, P196, DOI 10.1016/0009-2614(89)85124-3; LEE EM, 1989, THESIS OXFORD U; MAJKRZAK CF, 1985, J APPL PHYS, V57, P3657, DOI 10.1063/1.334978; MAJKRZAK CF, 1990, MRS BULL, V15, P65, DOI 10.1557/S0883769400058383; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MEZEI F, 1979, LECTURE NOTES PHYSIC, V128; MEZEI F, 1979, LECTURE NOTES PHYSIC, V128, P75; MOON RM, 1969, PHYS REV, V181, P920, DOI 10.1103/PhysRev.181.920; MOON RM, 1985, SCIENCE, V230, P274, DOI 10.1126/science.230.4723.274; NEWSAM JM, 1989, J PHYS CHEM-US, V93, P7689, DOI 10.1021/j100359a031; NOVOTNY V, 1986, RIBOSOMES STRUCTURE, P101; OSBORN R, 1990, PHYSICA B, V163, P37, DOI 10.1016/0921-4526(90)90123-C; PARKIN SSP, 1986, APPL PHYS LETT, V48, P604, DOI 10.1063/1.96481; PASSELL L, 1986, CHEM PHYSICS SOLID S, V6, P609; PENFOLD J, 1990, J PHYS-CONDENS MAT, V2, P1369, DOI 10.1088/0953-8984/2/6/001; PRICE DL, 1987, J NON-CRYST SOLIDS, V92, P153, DOI 10.1016/S0022-3093(87)80366-6; QUILICHINI M, 1990, J PHYS-PARIS, V51, P1785, DOI 10.1051/jphys:0199000510170178500; REICHARDT W, 1990, NEUTRON NEWS, V1, P20; REITER G, 1985, PHYS REV LETT, V54, P1047, DOI 10.1103/PhysRevLett.54.1047; REITVELD HM, 1969, J APPL CRYSTALLOGR, V2, P65; RENNIE AR, 1989, MACROMOLECULES, V22, P3466, DOI 10.1021/ma00198a044; RHYNE JJ, 1989, PHYSICA B, V159, P111, DOI 10.1016/0921-4526(89)90028-8; RICHTER D, 1990, PHYS REV LETT, V64, P1389, DOI 10.1103/PhysRevLett.64.1389; ROSSATMIGNOD J, 1988, J PHYS-PARIS, V49, P2119, DOI 10.1051/jphyscol:19888951; SAXENA AM, 1977, ACTA CRYSTALLOGR A, V33, P809; SCHWAHN D, 1987, PHYS REV LETT, V58, P1544, DOI 10.1103/PhysRevLett.58.1544; SIMMONS RO, 1986, PHYSICA B & C, V136, P156, DOI 10.1016/S0378-4363(86)80044-4; STEIN RS, 1985, PHYS TODAY, V38, P74, DOI 10.1063/1.881012; TIMMINS PA, 1988, EUR BIOPHYS J BIOPHY, V15, P257, DOI 10.1007/BF00256476; VACHER R, 1990, PHYS REV LETT, V65, P1008, DOI 10.1103/PhysRevLett.65.1008; WILLIS RF, 1988, J APPL PHYS, V63, P8; 1990, LOS ALAMOS SCI	71	3	3	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					795	802		10.1126/science.2028255	http://dx.doi.org/10.1126/science.2028255			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	2028255				2022-12-28	WOS:A1991FL12300036
J	KOOPMAN, P; GUBBAY, J; VIVIAN, N; GOODFELLOW, P; LOVELLBADGE, R				KOOPMAN, P; GUBBAY, J; VIVIAN, N; GOODFELLOW, P; LOVELLBADGE, R			MALE DEVELOPMENT OF CHROMOSOMALLY FEMALE MICE TRANSGENIC FOR SRY	NATURE			English	Article							TESTIS-DETERMINING GENE; SEX-REVERSED MICE; Y-CHROMOSOME; MOUSE; DUPLICATION; EXPRESSION	The initiation of male development in mammals requires one or more genes on the Y chromosome. A recently isolated gene, termed SRY in humans and Sry in mouse, has many of the genetic and biological properties expected of a Y-located testis-determining gene. It is now shown that Sry on a 14-kilobase genomic DNA fragment is sufficient to induce testis differentiation and subsequent male development when introduced into chromosomally female mouse embryos.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND; IMPERIAL CANC RES FUND,HUMAN MOLEC GENET LAB,LONDON WC2A 3PX,ENGLAND	MRC National Institute for Medical Research; Cancer Research UK			Koopman, Peter A/C-9416-2009	Koopman, Peter A/0000-0001-6939-0914; Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; BETA P, 1990, NATURE, V348, P448; BISHOP CE, 1985, NATURE, V315, P70, DOI 10.1038/315070a0; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; BURGOYNE PS, 1988, DEVELOPMENT, V102, P443; BURGOYNE PS, 1983, J REPROD FERTIL, V68, P387, DOI 10.1530/jrf.0.0680387; CATTANACH BM, 1971, CYTOGENETICS, V10, P318, DOI 10.1159/000130151; EICHER EM, 1988, PHILOS T R SOC B, V322, P109, DOI 10.1098/rstb.1988.0118; EICHER EM, 1980, CYTOGENET CELL GENET, V28, P104, DOI 10.1159/000131518; ELLIS NA, 1989, NATURE, V337, P81, DOI 10.1038/337081a0; FORD CE, 1959, LANCET, V1, P711; FREDGA K, 1988, PHILOS T R SOC B, V322, P83, DOI 10.1098/rstb.1988.0116; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1990, DEVELOPMENT, V109, P647; HOGAN B, 1986, MANIPULATING MOUSE E; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; JAGER RJ, 1990, HUM GENET, V85, P666; Josso N., 1981, Mechanisms of sex differentiation in animals and man., P165; Jost, 1947, ARCH ANAT MICR MORPH, V36, P271; JOST A, 1988, PHILOS T ROY SOC B, V322, P55, DOI 10.1098/rstb.1988.0113; Jost A., 1973, Recent Progress Hormone Res, V29, P1; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; LOVELLBADGE RH, 1987, TERATOCARCINOMAS EMB, P153; Maniatis T., 1982, MOL CLONING; MARDON G, 1989, SCIENCE, V243, P78, DOI 10.1126/science.2563173; MCLAREN A, 1982, NATURE, V300, P446, DOI 10.1038/300446a0; MCLAREN A, 1988, PHILOS T ROY SOC B, V322, P3, DOI 10.1098/rstb.1988.0109; MCLAREN A, 1988, TRENDS GENET, V4, P153, DOI 10.1016/0168-9525(88)90020-0; NAGAMINE CM, 1989, SCIENCE, V243, P80, DOI 10.1126/science.2563174; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; PALMER SJ, 1991, DEVELOPMENT, V111, P1017; ROBERTS C, 1988, P NATL ACAD SCI USA, V85, P6646; SCHERER G, 1989, HUM GENET, V81, P291; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; WELSHONS W. J., 1959, PROC NATL ACAD SCI, V45, P560, DOI 10.1073/pnas.45.4.560; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; [No title captured]	42	1679	1764	4	126	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					117	121		10.1038/351117a0	http://dx.doi.org/10.1038/351117a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	2030730				2022-12-28	WOS:A1991FL03500040
J	LAWRENCE, RA				LAWRENCE, RA			CORTICOSTEROID EFFECT ON LACTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PREDNISOLONE; MILK				LAWRENCE, RA (corresponding author), UNIV ROCHESTER,SCH MED & DENT,ROCHESTER,NY 14642, USA.							Bissell M. J., 1987, The mammary gland. Development, regulation, and function., P97; Dembinski T. C., 1987, The mammary gland. Development, regulation, and function., P355; LAWRENCE RA, 1989, BREASTFEEDING GUIDE, P256; MCKENZIE SA, 1975, ARCH DIS CHILD, V50, P894, DOI 10.1136/adc.50.11.894; Neville M. C., 1983, Lactation. Physiology, nutrition, and breast-feeding, P141; OST L, 1985, J PEDIATR-US, V106, P1008, DOI 10.1016/S0022-3476(85)80259-6; SIETSEMA WK, 1989, INT J CLIN PHARM TH, V27, P179; TAUBER U, 1984, INT J CLIN PHARM TH, V22, P48	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2409	2409						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016840				2022-12-28	WOS:A1991FJ95500041
J	SIDRANSKY, D; VONESCHENBACH, A; TSAI, YC; JONES, P; SUMMERHAYES, I; MARSHALL, F; PAUL, M; GREEN, P; HAMILTON, SR; FROST, P; VOGELSTEIN, B				SIDRANSKY, D; VONESCHENBACH, A; TSAI, YC; JONES, P; SUMMERHAYES, I; MARSHALL, F; PAUL, M; GREEN, P; HAMILTON, SR; FROST, P; VOGELSTEIN, B			IDENTIFICATION OF P53 GENE-MUTATIONS IN BLADDER CANCERS AND URINE SAMPLES	SCIENCE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; RAS ONCOGENE; SHORT ARM; TRANSFORMATION; DNA; CHROMOSOME-11; CARCINOMA; ANTIONCOGENES; COOPERATION	Although bladder cancers are very common, little is known about their molecular pathogenesis. In this study, invasive bladder cancers were evaluated for the presence of gene mutations in the p53 suppressor gene. Of 18 tumors evaluated, 11 (61 percent) were found to have genetic alterations of p53. The alterations included ten point mutations resulting in single amino acid substitutions, and one 24-base pair deletion. In all but one case, the mutations were associated with chromosome 17p allelic deletions, leaving the cells with only mutant forms of the p53 gene product. Through the use of the polymerase chain reaction and oligomer-specific hybridization, p53 mutations were identified in 1 to 7 percent of the cells within the urine sediment of each of three patients tested. The p53 mutations are the first genetic alterations demonstrated to occur in a high proportion of primary invasive bladder cancers. Detection of such mutations ex vivo has clinical implications for monitoring individuals whose tumor cells are shed extracorporeally.	JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD 21231; MD ANDERSON HOSP & TUMOR INST,DEPT UROL,HOUSTON,TX 77054; UNIV SO CALIF,KENNETH J NORRIS COMPREHENS CANC CTR,LOS ANGELES,CA 90033; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; JOHNS HOPKINS UNIV,DEPT UROL,BALTIMORE,MD 21215; JOHNS HOPKINS UNIV,DEPT PATHOL,BALTIMORE,MD 21231; MD ANDERSON HOSP & TUMOR INST,DEPT CELL BIOL,HOUSTON,TX 77054	Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; University of Southern California; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA43460, CA09071, CA49758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009071, R37CA043460, R01CA043460, R35CA049758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; Badalament R A, 1988, Semin Urol, V6, P22; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKER SJ, IN PRESS NUCLEAR PRO; BARTEK J, 1990, ONCOGENE, V5, P893; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; COON JM, COMMUNICATION; DEITCH AD, 1990, J UROLOGY, V143, P700, DOI 10.1016/S0022-5347(17)40064-4; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DELSENNO L, 1989, J UROLOGY, V142, P146; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOOT NC, 1958, CANCER BRUSSELS, V11, P137; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GIBAS Z, 1984, CANCER RES, V44, P1257; HANSEN MF, 1987, CANCER RES, V47, P5518; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; Koss L. G, 1979, DIAGNOSTIC CYTOLOGY; KOSS LG, 1985, ACTA CYTOL, V29, P810; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASKUS JR, 1988, UROL RES, V6, P341; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WF, 1990, J CELL BIOCHEM, V14, P285; MUNROE DG, 1988, ONCOGENE, V2, P621; NAKAZAWA H, 1990, MOL CARCINOGEN, V3, P202, DOI 10.1002/mc.2940030407; NEAL DE, 1985, LANCET, V1, P366; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SIDRANSKY D, UNPUB; SPEISSL B, 1982, UICC INT UNION CANCE; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TSAI YC, 1990, CANCER RES, V50, P40; VOGELSTEIN B, 1987, ANAL BIOCHEM, V160, P115, DOI 10.1016/0003-2697(87)90620-8; WEINBERG RA, 1989, CANCER RES, V49, P3713	54	839	869	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					706	709		10.1126/science.2024123	http://dx.doi.org/10.1126/science.2024123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024123				2022-12-28	WOS:A1991FK18500049
J	LIU, SC; DERICK, LH; ZHAI, S; PALEK, J				LIU, SC; DERICK, LH; ZHAI, S; PALEK, J			UNCOUPLING OF THE SPECTRIN-BASED SKELETON FROM THE LIPID BILAYER IN SICKLED RED-CELLS	SCIENCE			English	Article							HUMAN-ERYTHROCYTES; MEMBRANE SKELETON; ATP DEPLETION; FREE VESICLES; CATION; RELEASE; SODIUM; PHOSPHATIDYLCHOLINE; TRANSFORMATION	The distribution of spectrin and band 3 in deoxygenated reversibly sickled cells was visualized by immunofluorescence and immunoelectron microscopy. Antibodies against band 3, the major lipid-associated transmembrane protein, labeled the entire cell body, including the entire length of the long protruding spicule, whereas antibodies against spectrin labeled only the cell body and the base region of the spicules. The results suggest that the formation of long spicules during sickling is associated with a continuous polymerization of hemoglobin S polymers, presumably through gaps in the spectrin-actin meshwork, and a subsequent uncoupling of the lipid bilayer from the submembrane skeleton.	TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DEPT BIOMED RES,BOSTON,MA 02135; TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DEPT MED,BOSTON,MA 02135	Tufts University; Tufts University	LIU, SC (corresponding author), TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02135, USA.				NHLBI NIH HHS [HL-15157-7, HL-37462, HL-27215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037462, P60HL015157, R01HL027215, R37HL027215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN D, 1981, BIOCHEM J, V198, P433, DOI 10.1042/bj1980433; ALLAN D, 1982, NATURE, V295, P612, DOI 10.1038/295612a0; BERKOWITZ LR, 1985, AM J PHYSIOL, V249, pC208, DOI 10.1152/ajpcell.1985.249.3.C208; BERTLES JF, 1969, BLOOD-J HEMATOL, V33, P884, DOI 10.1182/blood.V33.6.884.884; BOOKCHIN RM, 1981, J PHYSIOL-LONDON, V312, P265, DOI 10.1113/jphysiol.1981.sp013628; BRUGNARA C, 1986, SCIENCE, V232, P388, DOI 10.1126/science.3961486; CANESSA M, 1987, BLOOD, V70, P1861; COAKLEY WT, 1978, BIOCHIM BIOPHYS ACTA, V512, P318, DOI 10.1016/0005-2736(78)90256-0; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; FRANCK PFH, 1983, J BIOL CHEM, V258, P8435; JENSEN WN, 1970, SEMIN HEMATOL, V7, P409; JOINER CH, 1986, J CLIN INVEST, V78, P1487, DOI 10.1172/JCI112740; JOINER CH, 1988, BLOOD CELLS, V13, P339; LIU SC, 1989, EUR J CELL BIOL, V49, P358; Liu Shun-Wei, UNPUB; LUTZ HU, 1977, J CELL BIOL, V73, P548, DOI 10.1083/jcb.73.3.548; MIDDELKOOP E, 1988, BIOCHIM BIOPHYS ACTA, V937, P281, DOI 10.1016/0005-2736(88)90250-7; MOHANDAS N, 1986, BLOOD, V68, P450; OTT P, 1981, BIOCHIM BIOPHYS ACTA, V641, P79, DOI 10.1016/0005-2736(81)90570-8; PALEK J, 1978, ERYTHROCYTE MEMBRANE, P75; RIS H, 1985, J CELL BIOL, V100, P1474, DOI 10.1083/jcb.100.5.1474; RUMSBY MG, 1977, BIOCHEM SOC T, V5, P126, DOI 10.1042/bst0050126; TOSTESON DC, 1952, J CLIN INVEST, V31, P406, DOI 10.1172/JCI102623; WAGNER GM, 1986, J LAB CLIN MED, V108, P315	24	67	67	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					574	576		10.1126/science.2020854	http://dx.doi.org/10.1126/science.2020854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	2020854				2022-12-28	WOS:A1991FJ12700050
J	BALDWIN, DC; HUGHES, PH; CONARD, SE; STORR, CL; SHEEHAN, DV				BALDWIN, DC; HUGHES, PH; CONARD, SE; STORR, CL; SHEEHAN, DV			SUBSTANCE USE AMONG SENIOR MEDICAL-STUDENTS - A SURVEY OF 23 MEDICAL-SCHOOLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-USE; RELIABILITY	Senior students at 23 regionally distributed medical schools received an anonymous questionnaire designed to examine current and prior use of tobacco, alcohol, and nine other drugs. The overall response rate was 67% (N = 2046). Substance use prevalence rates during the 30 days preceding the survey included alcohol, 87.5%; marijuana, 10.0%; cigarettes, 10.0%; cocaine, 2.8%; tranquilizers, 2.3%; opiates other than heroin, 1.1%; psychedelics other than LSD (lysergic acid diethylamide), 0.6%; amphetamines, 0.3%; barbiturates, 0.2%; LSD, 0.1%; and heroin, 0.0%. Compared with national, age-related comparison groups, senior medical students reported less use of all substances during the past 30 days and the past 12 months, except for alcohol, tranquilizers, and psychedelics other than LSD. Substantial new drug use after entry into medical school was reported only for tranquilizers. Seven students (0.2%) admitted to current dependence on a substance other than tobacco, four of these implicating marijuana. Thirty-three students (1.6%) believed that they currently needed help for substance abuse. Only 25.7% were aware of any policy on substance abuse at their own school.	UNIV S FLORIDA, DEPT PSYCHIAT & BEHAV MED, CTR STUDY IMPAIRED PROFESS, TAMPA, FL 33620 USA; UNIV TEXAS, HLTH SCI CTR, DEPT FAMILY & COMMUNITY MED, DALLAS, TX 75235 USA	State University System of Florida; University of South Florida; University of Texas System; University of Texas Dallas	BALDWIN, DC (corresponding author), AMER MED ASSOC, DIV MED EDUC RES & INFORMAT, 515 N STATE ST, CHICAGO, IL 60610 USA.		Sheehan, David V/L-6879-2013	Sheehan, David V/0000-0002-5118-7050				BACHMAN JG, 1990, J HEALTH SOC BEHAV, V31, P173, DOI 10.2307/2137171; BORKMAN T, 1986, ALCOHOL HEALTH RES W, V10, P54; CLARK DC, 1987, JAMA-J AM MED ASSOC, V257, P2921, DOI 10.1001/jama.257.21.2921; COLLINS J, 1989, NATIONAL ADOLESCENT; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; CONARD S, 1989, AM J PSYCHIAT, V146, P382; CROWLEY AE, 1986, JAMA-J AM MED ASSOC, V256, P1545, DOI 10.1001/jama.1986.03380120015003; CROWLEY AE, 1987, JAMA-J AM MED ASSOC, V258, P1013, DOI 10.1001/jama.258.8.1013; JOHNSTON LD, 1985, STUDYING DRUG USE, P117; JOHNSTON LD, 1989, ADM891638US DEP HLTH; KING FW, 1970, AM PSYCHOL, V25, P982, DOI 10.1037/h0029859; LUETGERT MJ, 1973, INT J ADDICT, V8, P683, DOI 10.3109/10826087309057494; MADDUX JF, 1986, AM J PSYCHIAT, V143, P187; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; OMALLEY PM, 1983, INT J ADDICT, V18, P805, DOI 10.3109/10826088309033049; ROWLEY BD, 1988, J MED EDUC, V63, P759; SCHWARTZ RH, 1990, ARCH INTERN MED, V150, P883, DOI 10.1001/archinte.150.4.883; SINGLE E, 1975, J DRUG ISSUES, V5, P426, DOI 10.1177/002204267500500411	18	103	106	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2074	2078		10.1001/jama.265.16.2074	http://dx.doi.org/10.1001/jama.265.16.2074			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013926				2022-12-28	WOS:A1991FG90700023
J	TARTOF, KD; HENIKOFF, S				TARTOF, KD; HENIKOFF, S			TRANS-SENSING EFFECTS FROM DROSOPHILA TO HUMANS	CELL			English	Review							ZESTE-WHITE INTERACTION; GENE-REGULATION; TRANSVECTION; REARRANGEMENTS; RECOMBINATION; MELANOGASTER; LEUKEMIA; LOCUS		FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	TARTOF, KD (corresponding author), FOX CHASE CANC INST,PHILADELPHIA,PA 19111, USA.			Henikoff, Steven/0000-0002-7621-8685				ARNOLDUS EPJ, 1989, HUM GENET, V83, P231, DOI 10.1007/BF00285162; ASHBURNER M, 1990, DROSOPHILA LABORATOR; BENDER W, 1985, COLD SPRING HARB SYM, V50, P173, DOI 10.1101/SQB.1985.050.01.023; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; BICKEL S, 1990, EMBO J, V9, P2959, DOI 10.1002/j.1460-2075.1990.tb07488.x; BITTER MA, 1985, BLOOD, V66, P1362; CASTELLIGAIR JE, 1990, GENETICS, V126, P177; DREESEN TD, 1991, GENE DEV, V5, P331, DOI 10.1101/gad.5.3.331; Ephrussi B, 1944, P NATL ACAD SCI USA, V30, P183, DOI 10.1073/pnas.30.8.183; GERMAN J, 1974, CHROMOSOMES CANCER, P601; GEYER PK, 1990, EMBO J, V9, P2247, DOI 10.1002/j.1460-2075.1990.tb07395.x; GOLDBERG ML, 1989, GENETICS, V123, P145; GUBB D, 1990, GENETICS, V126, P167; JACK JW, 1979, P NATL ACAD SCI USA, V76, P1368, DOI 10.1073/pnas.76.3.1368; LAIRD CD, 1990, TRENDS GENET, V6, P242, DOI 10.1016/0168-9525(90)90206-L; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; MATHOG D, 1990, GENETICS, V125, P371; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SMOLIKUTLAUT SM, 1987, GENETICS, V116, P285; WU CT, 1989, TRENDS GENET, V5, P189, DOI 10.1016/0168-9525(89)90074-7; ZACHAR Z, 1985, COLD SPRING HARB SYM, V50, P337, DOI 10.1101/SQB.1985.050.01.043	23	116	119	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					201	203		10.1016/0092-8674(91)90153-P	http://dx.doi.org/10.1016/0092-8674(91)90153-P			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015622				2022-12-28	WOS:A1991FH09200002
J	MOSS, GD; CARTLIDGE, PHT; SPEIDEL, BD; CHAMBERS, TL				MOSS, GD; CARTLIDGE, PHT; SPEIDEL, BD; CHAMBERS, TL			ROUTINE EXAMINATION IN THE NEONATAL-PERIOD	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the value of the second neonatal examination as a medical surveillance procedure. Design- Prospective survey of routine neonatal examinations and the abnormalities identified during 8 March-30 June 1988. Setting-Maternity unit with an annual birth rate of 5700. Subjects-For first neonatal examination: 1795 babies born in the unit during the 115 day observation period. For second routine examination: 1747 babies (97.3%) discharged from postnatal ward. Main outcome measures-Missed abnormalities (present but not previously noted); minor abnormalities (superficial infection or trivial or transient abnormalities not requiring intervention); and important abnormalities (unlikely to have been present at first examination but requiring intervention). Results-An abnormality was detected in 158 (8.8%) infants on first neonatal examination. 1428 (79.6%) babies had a routine second examination, which disclosed 63 previously undetected abnormalities. Of these, seven (11%) would have been present on first examination, 49 (78%) were considered minor, and seven (11%) important-the most consequential being dislocatable hips (four infants). Thus an important finding was detected by only 0.5% of second examinations. Conclusions-A second thorough examination in the early neonatal period cannot be justified as a screening procedure. A repeat examination of the hips alone in the first week of life is necessary.			MOSS, GD (corresponding author), SOUTHMEAD GEN HOSP,DEPT PAEDIAT,BRISTOL BS10 5NB,ENGLAND.							HALL DMB, 1989, HLTH ALL CHILDREN PR; 1985, 3RD MAT SERV ADV C 3	2	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					878	879		10.1136/bmj.302.6781.878	http://dx.doi.org/10.1136/bmj.302.6781.878			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025726	Bronze, Green Published			2022-12-28	WOS:A1991FG42100021
J	FROST, CD; LAW, MR; WALD, NJ				FROST, CD; LAW, MR; WALD, NJ			BY HOW MUCH DOES DIETARY SALT REDUCTION LOWER BLOOD-PRESSURE .2. ANALYSIS OF OBSERVATIONAL DATA WITHIN POPULATIONS	BRITISH MEDICAL JOURNAL			English	Article							URINARY SODIUM; POTASSIUM; VARIABILITY; EXCRETION; MEN; ASSOCIATION; CATIONS	Objective-To determine whether the estimates of the size of the association between blood pressure and sodium intake derived from studies of individuals within populations can be quantitatively reconciled with our estimates derived from comparisons of the average blood pressure and sodium intake between different populations. Design-Examination of data from 14 published studies that correlated blood pressure recordings in individuals against measurements of their 24 hour sodium intake (within population studies). Main outcome measure-Comparison of observed differences in blood pressure per 100 mmol/24 h difference in sodium intake in each within population study with predicted differences calculated from the between population data, after allowing for the underestimation of the true association of blood pressure with sodium intake caused by the large day to day variation in 24 hour sodium intake within individuals. Results-The underestimation bias inherent in the within population studies reduced the regression slope of blood pressure on single measures of 24 hour sodium intake to between a half and a quarter of the true value (for example, in one study from 6.0 to 2.4 mm Hg/100 mmol/24 h). Estimates from between population comparisons of the regression slope of blood pressure on sodium intake, after adjustment to take this underestimation bias into account, were similar to the values actually observed in the within population studies. Conclusion-The within population studies confirm our estimates from between population comparisons of the magnitude of the association between blood pressure and sodium intake.	ST BARTHOLOMEWS HOSP,COLL MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND	University of London; Queen Mary University London			Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					[Anonymous], 1988, BMJ, V297, P319; ARMITAGE P, 1987, STATISTICAL METHODS; BULPITT CJ, 1986, J CHRON DIS, V39, P211, DOI 10.1016/0021-9681(86)90026-3; CONNOR SL, 1984, CIRCULATION, V70, P76, DOI 10.1161/01.CIR.70.1.76; ELLIOTT P, 1988, J HUM HYPERTENS, V2, P89; Joossens J. V., 1980, EPIDEMIOLOGY ARTERIA, P45; KESTELOOT H, 1980, EUR J CARDIOL, V11, P169; KESTELOOT H, 1987, HYPERTENSION, V9, P654, DOI 10.1161/01.HYP.9.6.654; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LISHENG L, 1987, J HYPERTENS, V5, P331, DOI 10.1097/00004872-198706000-00011; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; LUFT FC, 1986, AM J KIDNEY DIS, V7, P375, DOI 10.1016/S0272-6386(86)80085-3; SIANI A, 1989, HYPERTENSION, V13, P38, DOI 10.1161/01.HYP.13.1.38; SMITH WCS, 1988, BRIT MED J, V297, P329, DOI 10.1136/bmj.297.6644.329; STAESSEN J, 1983, AM J EPIDEMIOL, V117, P676, DOI 10.1093/oxfordjournals.aje.a113601; STRAZZULLO P, 1983, EUR HEART J, V4, P608, DOI 10.1093/oxfordjournals.eurheartj.a061532; WATT GCM, 1982, J EPIDEMIOL COMMUN H, V36, P197, DOI 10.1136/jech.36.3.197; 1989, J HUM HYPERTENSION, V3, P279	19	169	171	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					815	818		10.1136/bmj.302.6780.815	http://dx.doi.org/10.1136/bmj.302.6780.815			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025704	Bronze, Green Published			2022-12-28	WOS:A1991FF37700021
J	ALEXANDERWILLIAMS, J; FIELDING, LP; GOLDBERG, S; GRACE, RH				ALEXANDERWILLIAMS, J; FIELDING, LP; GOLDBERG, S; GRACE, RH			RECIPE FOR SUCCESS IN INTERNATIONAL SPECIALIST MEETINGS	BRITISH MEDICAL JOURNAL			English	Editorial Material									ST MARYS HOSP,GEN SURG,WATERBURY,CT; UNIV MINNESOTA,MINNEAPOLIS,MN 55402; ROYAL HOSP WOLVERHAMPTON,WOLVERHAMPTON,ENGLAND	University of Minnesota System; University of Minnesota Twin Cities	ALEXANDERWILLIAMS, J (corresponding author), GEN HOSP,GASTROINTESTINAL SURG,BIRMINGHAM B4 6NH,W MIDLANDS,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					585	587		10.1136/bmj.302.6776.585	http://dx.doi.org/10.1136/bmj.302.6776.585			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021726	Green Published, Bronze			2022-12-28	WOS:A1991FB93600028
J	LONERGAN, ET; KREVANS, JR				LONERGAN, ET; KREVANS, JR			A NATIONAL AGENDA FOR RESEARCH ON AGING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											LONERGAN, ET (corresponding author), UNIV CALIF SAN FRANCISCO,INST MED STUDY,SAN FRANCISCO,CA 94143, USA.								0	52	52	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1825	1828		10.1056/NEJM199106203242527	http://dx.doi.org/10.1056/NEJM199106203242527			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR681	2038376				2022-12-28	WOS:A1991FR68100029
J	MATTHAY, MA; MATTHAY, RA				MATTHAY, MA; MATTHAY, RA			CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; HIGH-DOSE METHYLPREDNISOLONE; SEPTIC SHOCK; ESCHERICHIA-COLI; PULMONARY-ARTERY; DOUBLE-BLIND; LUNG INJURY; CATHETERIZATION; MULTICENTER; DEFINITION		YALE UNIV,SCH MED,NEW HAVEN,CT 06510	Yale University	MATTHAY, MA (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143, USA.							ASHBAUGH DG, 1967, LANCET, V2, P319; BAUMGARTNER JD, 1990, J EXP MED, V171, P889, DOI 10.1084/jem.171.3.889; BAUMGARTNER JD, 1985, LANCET, V2, P59; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CHEST, V96, P114, DOI 10.1378/chest.96.1.114; CALANDRA T, 1988, J INFECT DIS, V158, P312, DOI 10.1093/infdis/158.2.312; CARLON GC, 1983, CHEST, V84, P551, DOI 10.1378/chest.84.5.551; CONNORS AF, 1983, NEW ENGL J MED, V308, P263, DOI 10.1056/NEJM198302033080508; IBERTI TJ, 1990, JAMA-J AM MED ASSOC, V264, P2928, DOI 10.1001/jama.264.22.2928; LUCE JM, 1990, JAMA-J AM MED ASSOC, V263, P696, DOI 10.1001/jama.263.5.696; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; MATTHAY MA, 1988, ANN INTERN MED, V109, P826, DOI 10.7326/0003-4819-109-10-826; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SCHNAPP LM, 1990, CHEST, V98, P1244, DOI 10.1378/chest.98.5.1244; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; WIEDEMANN HP, 1990, CLIN CHEST MED, P11; WIENERKRONISH JP, 1990, BRIT J ANAESTH, V65, P107, DOI 10.1093/bja/65.1.107; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	24	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3109	3111						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041115				2022-12-28	WOS:A1991FQ77000012
J	[Anonymous]				[Anonymous]			STATEMENTS FROM THE INTERNATIONAL COMMITTEE OF MEDICAL JOURNAL EDITORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		LUNDBERG GD, 1988, JAMA-J AM MED ASSOC, V260, P2563; 1991, BMJ, V302, P6772; 1988, ANN INTERN MED, V108, P304; 1989, BMJ, V299, P1394; 1991, NEW ENGL J MED, V324, P424; IN PRESS BMJ	6	2	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2697	2698						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023351				2022-12-28	WOS:A1991FL98900035
J	GOLIC, KG				GOLIC, KG			SITE-SPECIFIC RECOMBINATION BETWEEN HOMOLOGOUS CHROMOSOMES IN DROSOPHILA	SCIENCE			English	Article							GENETIC MOSAICS; CELL LINEAGE; MELANOGASTER; PARAMETERS	The ability to mark a cell and its descendants genetically so that the resulting cell clone can be distinguished from neighboring cells facilitates studies in animal biology and development. A method of generating clones by inducing homologous mitotic recombination in Drosophila with a site-specific yeast recombinase is described. This method allows for frequent mosaicism after mitotic exchange is induced at predefined sites in the genome.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025874, R01GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25874-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER HJ, 1976, GENETICS BIOL DROS C, V1, pCH25; FRIESEN H., 1936, ZEITSCHR INDUKT ABSTAMM U VERER BUNGSL, V71, P501, DOI 10.1007/BF01848879; GARCIABE.A, 1972, MOL GEN GENET, V115, P54, DOI 10.1007/BF00272218; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GOLIC K, UNPUB; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HALL JC, 1976, GENETICS BIOL DROS A, V1, pCH6; HERMAN RK, 1984, GENETICS, V108, P165; KIMMEL CB, 1988, TRENDS GENET, V4, P68, DOI 10.1016/0168-9525(88)90043-1; Le Douarin N., 1984, CHIMERAS DEV BIOL; LINDSLEY DL, 1968, PUBLICATION CARNEGIE, V627; POETHIG S, 1989, TRENDS GENET, V5, P273, DOI 10.1016/0168-9525(89)90101-7; POSTLETHWAIT JH, 1978, GENETICS BIOL DROS C, V2, pCH24; RUSSELL LB, 1978, GENETIC MOSAICS CHIM; Stern C, 1936, GENETICS, V21, P625; SZABAD J, 1983, MUTAT RES, V113, P117, DOI 10.1016/0165-1161(83)90224-8; WOODRUFF RC, 1977, HEREDITY, V38, P291, DOI 10.1038/hdy.1977.92	17	353	362	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					958	961		10.1126/science.2035025	http://dx.doi.org/10.1126/science.2035025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	2035025				2022-12-28	WOS:A1991FM04000034
J	HYMAN, AA; MITCHISON, TJ				HYMAN, AA; MITCHISON, TJ			2 DIFFERENT MICROTUBULE-BASED MOTOR ACTIVITIES WITH OPPOSITE POLARITIES IN KINETOCHORES	NATURE			English	Article							CYTOPLASMIC DYNEIN; PROTEIN; SPINDLE; KINESIN; DROSOPHILA; POLEWARD; MITOSIS; FORCE; DEPHOSPHORYLATION; MICROMANIPULATION	The movement of microtubules on the kinetochores of isolated chromosomes has been examined by video microscopy. Two different microtubule-based motors on the kinetochore were identified, which have opposite directions of movement. The activities of these two motors can be regulated by factors that can influence phosphorylation.			HYMAN, AA (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.		Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; 				BAJER AS, 1972, INT REV CYTOL      S, V3, P1; BEGG DA, 1979, J CELL BIOL, V82, P528, DOI 10.1083/jcb.82.2.528; CHLEBOWSKI JF, 1972, J BIOL CHEM, V247, P6007; COHN SA, 1989, J BIOL CHEM, V264, P4290; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; Dustin P., 1984, MICROTUBULES; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; EUTENEUER U, 1982, J CELL BIOL, V94, P644, DOI 10.1083/jcb.94.3.644; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HAYMAN AA, IN PRESS J CELL SCI; HAYS TS, 1990, J CELL BIOL, V110, P391, DOI 10.1083/jcb.110.2.391; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1990, J CELL BIOL, V110, P1607, DOI 10.1083/jcb.110.5.1607; INOUE S, 1975, BIOPHYS J, V15, P725, DOI 10.1016/S0006-3495(75)85850-4; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KOSHLAND D, 1988, NATURE, V311, P499; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cellbio.4.1.527; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; MITCHISON TJ, 1989, CELL MOVEMENT, V2, P421; MITCHISON TJ, 1985, J CELL BIOL, V101, P767; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1981, CHROMOSOMA, V84, P145, DOI 10.1007/BF00293368; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; Salmon E. D., 1989, CELL MOVEMENT, P431; SAXTON WM, IN PRESS CELL; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WORDEMAN L, 1987, CELL, V50; WORDEMAN L, IN PRESS J CELL BIOL; WRIGHT BD, IN PRESS J CELL BIOL; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1846	43	179	180	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					206	211		10.1038/351206a0	http://dx.doi.org/10.1038/351206a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041567				2022-12-28	WOS:A1991FL99000047
J	NONET, ML; MEYER, BJ				NONET, ML; MEYER, BJ			EARLY ASPECTS OF CAENORHABDITIS-ELEGANS SEX DETERMINATION AND DOSAGE COMPENSATION ARE REGULATED BY A ZINC-FINGER PROTEIN	NATURE			English	Article							X-CHROMOSOME DOSAGE; C-ELEGANS; REGION; GENES; DNA	THE sdc-1 gene acts at an early step in the regulatory hierarchy that controls the choice of sexual fate in Caenorhabditis elegans. It functions at a point before the control of sex determination and X-chromosome dosage compensation diverge. Here we report that sdc-1 encodes a protein of 1,203 amino acids containing seven zinc fingers. This protein motif in combination with other genetic and molecular information suggests that sdc-1 is likely to function as an embryonic transcription factor regulating downstream genes involved specifically in the sex determination and dosage compensation pathways, or regulating other genes involved in the coordinate control of both processes. These results enhance our general understanding of sex determination strategies, which are already known to involve transcriptional regulation 1 and alternative RNA splicing 2,3 in Drosophila melanogaster, DNA rearrangements in Saccharomyces cerevisiae 4, and transcriptional regulation in mammals 5,6.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Meyer, Barbara/0000-0002-6530-4588	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM030702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DELONG L, 1990, THESIS MIT; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; Maniatis T., 1982, MOL CLONING; MCCOUBREY WK, 1988, SCIENCE, V242, P1146, DOI 10.1126/science.2973125; MELLO C, 1990, THESIS HARVARD U; MENEELY PM, 1979, GENETICS, V92, P99; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NAGAI K, 1988, NATURE, V332, P284, DOI 10.1038/332284a0; NUSBAUM C, 1989, GENETICS, V122, P579; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PLENEFISCH J, 1990, THESIS MIT; PLENEFISCH JD, 1989, GENETICS, V121, P57; SCHAUER IE, 1990, DEVELOPMENT, V110, P1303; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TRENT C, IN PRESS MECHANISMS; Villeneuve A.M., 1990, Advances in Genetics, V27, P117; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7; VILLENEUVE AM, 1990, GENETICS, V124, P91	35	54	62	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					65	68		10.1038/351065a0	http://dx.doi.org/10.1038/351065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027384				2022-12-28	WOS:A1991FK19300061
J	WU, AW; FOLKMAN, S; MCPHEE, SJ; LO, B				WU, AW; FOLKMAN, S; MCPHEE, SJ; LO, B			DO HOUSE OFFICERS LEARN FROM THEIR MISTAKES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FALLIBILITY; INTERNISTS; DOCTORS; DEATHS	Mistakes are inevitable in medicine. To learn how medical mistakes relate to subsequent changes in practice, we surveyed 254 internal medicine house officers. One hundred fourteen house officers (45%) completed an anonymous questionnaire describing their most significant mistake and their response to it. Mistakes included errors in diagnosis (33%), prescribing (29%), evaluation (21%), and communication (5%) and procedural complications (11%). Patients had serious adverse outcomes in 90% of the cases including death in 31% of cases. Only 54% of house officers discussed the mistake with their attending physicians, and only 24% told the patients or families. House officers who accepted responsibility for the mistake and discussed it were more likely to report constructive changes in practice. Residents were less likely to make constructive changes if they attributed the mistake to job overload. They were more likely to report defensive changes if they felt the institution was judgmental. Decreasing the work load and closer supervision may help prevent mistakes. To promote learning, faculty should encourage house officers to accept responsibility and to discuss their mistakes.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT VET AFFAIRS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCOLARS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Robert Wood Johnson Foundation (RWJF); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Wu, Albert/AAJ-4780-2021		DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [D28PE019179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline; BHP HRSA HHS [D28PE19179] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); BHP HRSA HHS		APPLEGATE WB, 1986, ARCH INTERN MED, V146, P2249, DOI 10.1001/archinte.146.11.2249; Bok S, 1978, LYING MORAL CHOICE P; BOSK CL, 1979, FORGIVE REMEMBER; CARMICHAEL DH, 1985, SOUTHERN MED J, V78, P1, DOI 10.1097/00007611-198501000-00001; COLFORD JM, 1989, JAMA-J AM MED ASSOC, V261, P889, DOI 10.1001/jama.261.6.889; DAWSON NV, 1987, J GEN INTERN MED, V2, P183, DOI 10.1007/BF02596149; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; DUBOVSKY SL, 1983, JAMA-J AM MED ASSOC, V250, P3057, DOI 10.1001/jama.250.22.3057; FOLKMAN S, 1988, WAYS COPING; FREIDSON E, 1975, DOCTORING TOGETHER S, P138; GILLON R, 1986, BMJ-BRIT MED J, V292, P466, DOI 10.1136/bmj.292.6518.466; GRUVER RH, 1957, ANN INTERN MED, V47, P108, DOI 10.7326/0003-4819-47-1-108; HART JT, 1987, BRIT MED J, V294, P871, DOI 10.1136/bmj.294.6576.871; HILFIKER D, 1984, NEW ENGL J MED, V310, P118, DOI 10.1056/NEJM198401123100211; Janis I. L., 1977, DECISION MAKING; KATZ J, 1984, HASTINGS CENT REP, V14, P35, DOI 10.2307/3560848; LEVINSON W, 1989, JAMA-J AM MED ASSOC, V261, P2252, DOI 10.1001/jama.261.15.2252; LIGHT D, 1979, BECOMING PSYCHIAT PR, P207; MCCUE JD, 1985, NEW ENGL J MED, V312, P449, DOI 10.1056/NEJM198502143120725; MILLMAN M, 1977, UNKINDEST CUT LIFE B, P90; MIZRAHI T, 1984, SOC SCI MED, V19, P135, DOI 10.1016/0277-9536(84)90280-6; NOVACK DH, 1989, JAMA-J AM MED ASSOC, V261, P2980, DOI 10.1001/jama.261.20.2980; PAGET M, 1988, UNITY MISTAKES PHENO; SANAZARO PJ, 1968, J MED EDUC, V43, P389; SANAZARO PJ, 1970, MED CARE, V8, P299, DOI 10.1097/00005650-197008040-00006; VOGEL J, 1980, UCLA LAW REV, V28, P51; VOYTOVICH AE, 1985, J MED EDUC, V60, P302; WARNER E, 1983, CAN MED ASSOC J, V129, P366	28	440	446	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2089	2094		10.1001/jama.265.16.2089	http://dx.doi.org/10.1001/jama.265.16.2089			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013929				2022-12-28	WOS:A1991FG90700026
J	FINCH, EA; TURNER, TJ; GOLDIN, SM				FINCH, EA; TURNER, TJ; GOLDIN, SM			CALCIUM AS A COAGONIST OF INOSITOL 1,4,5-TRISPHOSPHATE INDUCED CALCIUM RELEASE	SCIENCE			English	Article							CARDIAC PURKINJE-CELL; SARCOPLASMIC-RETICULUM; SUPERFUSION SYSTEM; TRISPHOSPHATE; RECEPTOR; CHANNELS; NUCLEOTIDES; MICROSOMES; ACTIVATION; VESICLES	Inositol 1,4,5-trisphosphate (IP3)-induced calcium release from intracellular stores is a regulator of cytosolic-free calcium levels. The subsecond kinetics and regulation of IP3-induced calcium-45 release from synaptosome-derived microsomal vesicles were resolved by rapid superfusion. Extravesicular calcium acted as a coagonist, potentiating the transient IP3-induced release of calcium-45. Thus, rapid elevation of cytosolic calcium levels may trigger IP3-induced calcium release in vivo. Extravesicular calcium also produced a more slowly developing, reversible inhibition of IP3-induced calcium-45 release. Sequential positive and negative feedback regulation by calcium of IP3-induced calcium release may contribute to transients and oscillations of cytosolic-free calcium in vivo.	HARVARD UNIV, SCH MED, DEPT NEUROBIOL, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; CAMBRIDGE NEUROSCI RES INC, CAMBRIDGE, MA 02139 USA	Harvard University; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School				Turner, Timothy/0000-0001-9770-2647	NIGMS NIH HHS [GM35423] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035423] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, UNPUB; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GARCIA AM, 1984, J GEN PHYSIOL, V83, P819, DOI 10.1085/jgp.83.6.819; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JEAN T, 1986, J BIOL CHEM, V261, P6414; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PEARCE LB, 1988, BIOCHEMISTRY-US, V27, P4396, DOI 10.1021/bi00412a029; RINK TJ, 1989, TRENDS NEUROSCI, V12, P43, DOI 10.1016/0166-2236(89)90133-1; SHAH J, 1987, BRAIN RES, V419, P1, DOI 10.1016/0006-8993(87)90562-2; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TURNER TJ, 1989, ANAL BIOCHEM, V178, P8, DOI 10.1016/0003-2697(89)90347-3; TURNER TJ, 1989, BIOCHEMISTRY-US, V28, P586, DOI 10.1021/bi00428a026; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Whittaker VP, 1969, HDB NEUROCHEMISTRY, VII, P327, DOI DOI 10.1007/978-1-4899-7321-4_14	35	788	795	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	1991	252	5004					443	446		10.1126/science.2017683	http://dx.doi.org/10.1126/science.2017683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017683				2022-12-28	WOS:A1991FH10300044
J	NEARING, BD; HUANG, AH; VERRIER, RL				NEARING, BD; HUANG, AH; VERRIER, RL			DYNAMIC TRACKING OF CARDIAC VULNERABILITY BY COMPLEX DEMODULATION OF THE T-WAVE	SCIENCE			English	Article							SYMPATHETIC NERVOUS-SYSTEM; VENTRICULAR-FIBRILLATION; MYOCARDIAL ISCHEMIA; NEURAL ACTIVITY; ALTERNATION; REPERFUSION; ARRHYTHMIAS; MECHANISMS; HEART	A link is found between T wave alternans and vulnerability to ventricular fibrillation, and a new approach is provided for quantification of susceptibility to malignant arrhythmias. Complex demodulation reveals that alternation of the electrocardiogram is concentrated during the first half of the T wave, coinciding with the vulnerable period of the cardiac cycle. During myocardial ischemia and reperfusion, there are marked increases in the degree of T wave alternans that parallel the established time course of changes in vulnerability. The influence of the sympathetic nervous system in arrhythmogenesis is also accurately detected. Ultimately, complex demodulation of the electrocardiogram could provide a technique for identification and management of individuals at risk for sudden cardiac death.			VERRIER, RL (corresponding author), GEORGETOWN UNIV,SCH MED,WASHINGTON,DC 20007, USA.		Verrier, Richard L/H-3083-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033567] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33567] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM DR, 1984, J ELECTROCARDIOL, V17, P209, DOI 10.1016/S0022-0736(84)80057-6; Bloomfield P., 1976, FOURIER ANAL TIME SE; CARSON DL, 1986, CARDIOVASC RES, V20, P521, DOI 10.1093/cvr/20.7.521; CHIALVO DR, 1987, NATURE, V330, P749, DOI 10.1038/330749a0; CHIALVO DR, 1990, CIRC RES, V66, P525, DOI 10.1161/01.RES.66.2.525; CORBALAN R, 1976, AM HEART J, V92, P223, DOI 10.1016/S0002-8703(76)80258-X; CORR PB, 1986, HEART CARDIOVASCULAR, pCH58; ELSHERIF N, 1988, CIRC RES, V63, P286, DOI 10.1161/01.RES.63.2.286; FRIEHLING TD, 1985, AM J CARDIOL, V55, P1339, DOI 10.1016/0002-9149(85)90500-4; GUEVARA MR, 1981, SCIENCE, V214, P1350, DOI 10.1126/science.7313693; HAN J, 1964, CIRC RES, V14, P44, DOI 10.1161/01.RES.14.1.44; LOMBARDI F, 1983, AM HEART J, V105, P958, DOI 10.1016/0002-8703(83)90397-6; LOWN B, 1976, NEW ENGL J MED, V294, P1165; Oppenheim A. V., 1975, DIGITAL SIGNAL PROCE; PRIORI SG, 1990, CIRCULATION, V81, P1911, DOI 10.1161/01.CIR.81.6.1911; RITZENBERG AL, 1984, NATURE, V307, P159, DOI 10.1038/307159a0; ROSEN MR, 1990, CARDIAC ELECTROPHYSI, pCH34; ROZANSKI JJ, 1982, PACE, V5, P359, DOI 10.1111/j.1540-8159.1982.tb02243.x; RUSSELL DC, 1979, BRIT HEART J, V42, P88; SCHWARTZ PJ, 1977, CIRC RES, V41, P51, DOI 10.1161/01.RES.41.1.51; SCHWARTZ PJ, 1975, AM HEART J, V89, P45, DOI 10.1016/0002-8703(75)90008-3; SCHWARTZ PJ, 1985, AM HEART J, V109, P399, DOI 10.1016/0002-8703(85)90626-X; SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, pCH37; SHIN SJ, 1989, IEEE T BIO-MED ENG, V36, P274; SMITH JM, 1984, P NATL ACAD SCI-BIOL, V81, P233, DOI 10.1073/pnas.81.1.233; SMITH JM, 1988, CIRCULATION, V77, P110, DOI 10.1161/01.CIR.77.1.110; SMITH JM, 1990, CARDIAC ELECTROPHYSI, pCH25; SURAWICZ B, 1985, J AM COLL CARDIOL, V5, pB43, DOI 10.1016/S0735-1097(85)80526-X; VERRIER RL, 1986, EUR HEART J, V7, P13; VERRIER RL, 1978, AM J PHYSIOL, V234, pH592, DOI 10.1152/ajpheart.1978.234.5.H592; ZIPES DP, 1990, CARDIAC ELECTROPHYSI, pCH36; 1990, AM J PHYSL, V259; 1985, PUBL NIH, V8623	33	252	271	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					437	440		10.1126/science.2017682	http://dx.doi.org/10.1126/science.2017682			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017682				2022-12-28	WOS:A1991FH10300042
J	MURPHY, JD; HENDERSON, K; BOWDEN, MI; LEWIS, M; COOPER, GM				MURPHY, JD; HENDERSON, K; BOWDEN, MI; LEWIS, M; COOPER, GM			BUPIVACAINE VERSUS BUPIVACAINE PLUS FENTANYL FOR EPIDURAL ANALGESIA - EFFECT ON MATERNAL SATISFACTION	BRITISH MEDICAL JOURNAL			English	Article							0.125-PERCENT BUPIVACAINE; EXTRADURAL ANALGESIA; LABOR; INFUSION; MORPHINE; TRIAL; PAIN	Objective - To compare a combination of epidural fentanyl and bupivacaine with bupivacaine alone for epidural analgesia in labour and to evaluate factors in addition to analgesia that may influence maternal satisfaction. Design - A prospective randomised pilot study. Setting - Birmingham Maternity Hospital. Subjects - 85 primiparous women who requested epidural analgesia in labour and their babies. Interventions - Group 1 mothers were treated with bupivacaine conventionally, group 2 mothers with bupivacaine and fentanyl in a more complex way designed to provide satisfactory analgesia but with less troublesome side effects. Main outcome measures - Overall maternal satisfaction, maternal perception of epidural analgesia and its side effects, and aspects of mothers' psychological states during labour, quantified using 100 mm visual linear analogue scales; the frequency of normal and operative deliveries; and measurements of neonatal wellbeing. Results - Satisfaction was higher in group 2 mothers (median group difference +3 mm, 95% confidence interval +1 to +5, p = 0.012): this was associated with more normal deliveries (difference between proportions 0.23, 95% confidence interval +0.03 to +0.42); greater self control (median group difference -7 mm, -17 to -2, p = 0.003); and reduced unpleasantness of motor blockade (-10 mm, -19 to -5, P < 0.001), sensory blockade (-5 mm, -11 to -2, p = 0.002) and shivering (-5 mm, -18 to 0, p = 0.046) at the expense of mild itching (0 mm, 0 to 0, p < 0.001). Group 1 mothers found restricted movements more unpleasant (-1 mm, -11 to 0, p = 0.006) and were more sleepy (-4 mm, -20 to 0, p = 0.032). The addition of fentanyl to bupivacaine reduced the requirement for local anaesthetic (-33 mg, -55 to -15, p < 0.001) without compromising analgesia. No adverse effects in neonates were attributed to the use of fentanyl. Conclusions - The already high maternal satisfaction from conventional epidural analgesia can be improved; epidural fentanyl may be combined with bupivacaine to reduce operative deliveries and confer other advantages that may increase maternal satisfaction. Further investigations should be performed to determine the exact mechanisms of these findings and, in particular, to develop a safe method of delivering such analgesia to women.	BIRMINGHAM MATERN HOSP,QUEEN ELIZABETH MED CTR,DEPT ANAESTHET,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND	Birmingham City University; University of Birmingham								BOGOD DG, 1987, BRIT J ANAESTH, V59, P325, DOI 10.1093/bja/59.3.325; BRAZELTON TB, 1984, NEONATAL BEHAVIORAL; BROCKWAY MS, 1990, BRIT J ANAESTH, V64, P243, DOI 10.1093/bja/64.2.243; CARRIE LES, 1981, ANAESTHESIA, V36, P965, DOI 10.1111/j.1365-2044.1981.tb08658.x; CHESTNUT DH, 1988, ANESTHESIOLOGY, V68, P754, DOI 10.1097/00000542-198805000-00013; CRAWFORD JS, 1981, ANAESTHESIA, V36, P207, DOI 10.1111/j.1365-2044.1981.tb08727.x; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P66, DOI 10.1093/bja/44.1.66; DEJONG RH, 1970, PHYSL PHARM LOCAL AN; DOUGHTY A, 1969, BRIT J ANAESTH, V41, P1058, DOI 10.1093/bja/41.12.1058; ENNIS M, 1990, BRIT MED J, V300, P1365, DOI 10.1136/bmj.300.6736.1365; GAMBLING DR, 1990, ANESTH ANALG, V70, P256; GAMBLING DR, 1988, CAN J ANAESTH, V35, P249, DOI 10.1007/BF03010618; HERMAN NL, 1990, BRIT J ANAESTH, V64, P528, DOI 10.1093/bja/64.4.528-b; HUSEMEYER RP, 1980, ANAESTHESIA, V35, P161, DOI 10.1111/j.1365-2044.1980.tb03797.x; JONES G, 1989, BRIT J ANAESTH, V63, P254, DOI 10.1093/bja/63.3.254; JUSTINS DM, 1982, BRIT J ANAESTH, V54, P409, DOI 10.1093/bja/54.4.409; KING MJ, 1990, ANAESTHESIA, V45, P285, DOI 10.1111/j.1365-2044.1990.tb14733.x; LAMONT RF, 1989, ANAESTHESIA, V44, P893, DOI 10.1111/j.1365-2044.1989.tb09142.x; LYSAK SZ, 1990, ANESTHESIOLOGY, V72, P44, DOI 10.1097/00000542-199001000-00009; PHILLIPS KC, 1983, ANAESTHESIA, V38, P972, DOI 10.1111/j.1365-2044.1983.tb12028.x; REYNOLDS F, 1989, ANAESTHESIA, V44, P341, DOI 10.1111/j.1365-2044.1989.tb11292.x; REYNOLDS F, 1989, BRIT J ANAESTH, V63, P251, DOI 10.1093/bja/63.3.251; VELLA LM, 1985, ANAESTHESIA, V40, P741, DOI 10.1111/j.1365-2044.1985.tb10997.x; 1989, REPORT CONFIDENTIAL	24	80	81	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					564	567		10.1136/bmj.302.6776.564	http://dx.doi.org/10.1136/bmj.302.6776.564			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021719	Bronze, Green Published			2022-12-28	WOS:A1991FB93600018
J	KARP, JE; BRODER, S				KARP, JE; BRODER, S			ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; TRANS RETINOIC ACID; BETA-CAROTENE; GENE; CELL; THERAPY; PRODUCT				KARP, JE (corresponding author), NCI,BETHESDA,MD 20892, USA.							BARKER SJ, 1990, SCIENCE, V249, P912; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHOMIENNE C, 1990, BLOOD, V76, P1710; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; GAREWAL HS, 1990, J CLIN ONCOL, V8, P1715, DOI 10.1200/JCO.1990.8.10.1715; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KOHN DB, 1989, CANCER INVEST, V7, P179, DOI 10.3109/07357908909038283; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1990, New Biologist, V2, P389; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	16	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3141	3143						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041130				2022-12-28	WOS:A1991FQ77000029
J	MASSRY, SG				MASSRY, SG			NEPHROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN ERYTHROPOIETIN; T-CELL				MASSRY, SG (corresponding author), UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA.							ALBERTAZZI A, 1989, CONTRIBUTION NEPHROL, P1; ALEXIEWICZ JM, 1990, AM J NEPHROL, V10, P495, DOI 10.1159/000168175; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; BERSON JA, 1960, SCIENCE, V154, P907; ESHBACH JW, 1989, AM J KIDNEY DIS S, V14, pS1; FADDA GZ, 1991, J CLIN INVEST, V87, P255, DOI 10.1172/JCI114979; KHAN BD, 1989, TXB NEPHROLOGY, P1487; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; LEEHUANG S, 1984, P NATL ACAD SCI-BIOL, V81, P2708, DOI 10.1073/pnas.81.9.2708; MASSRY SG, 1977, NEPHRON, V19, P125, DOI 10.1159/000180876; MASSRY SG, 1989, TXB NEPHROLOGY, P1126; SCHAEFER RM, 1989, AM J NEPHROL, V9, P353, DOI 10.1159/000167996; STROM TB, 1989, TXB NEPHROLOGY, P1499; TODO S, 1990, ANN SURG, V212, P295, DOI 10.1097/00000658-199009000-00008; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; WOLFSON M, 1990, AM J NEPHROL S2, V10, pS1; 1987, LANCET, V1, P781	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3135	3137						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041128				2022-12-28	WOS:A1991FQ77000026
J	MCMILLAN, JA; OSKI, FA				MCMILLAN, JA; OSKI, FA			PEDIATRICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONJUGATE VACCINE; VITAMIN-A; CHILDREN; EFFICACY; INFANTS; TRIAL				MCMILLAN, JA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.							[Anonymous], 1990, LANCET, V336, P1349; BLACK SB, 1990, PEDIATR RES, V27, P167; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; POMEROY SL, 1990, NEW ENGL J MED, V323, P1651, DOI 10.1056/NEJM199012133232402; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; WEST KP, 1987, STATE ART SERIES; 1990, JAMA-J AM MED ASSOC, V263, P3035; 1990, MMWR, V39, P698	11	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3156	3158						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041135				2022-12-28	WOS:A1991FQ77000034
J	DOUGLAS, JDM; MILNE, AH				DOUGLAS, JDM; MILNE, AH			DECOMPRESSION-SICKNESS IN FISH FARM-WORKERS - A NEW OCCUPATIONAL HAZARD	BRITISH MEDICAL JOURNAL			English	Article									ROBERT GORDONS INST TECHNOL,CTR SURVIVAL,ABERDEEN AB2 3BJ,SCOTLAND	Robert Gordon University	DOUGLAS, JDM (corresponding author), TWEEDDALE MED PRACTICE,FT WILLIAM PH33 6EU,SCOTLAND.							ADKISSON GH, 1989, LANCET, V2, P119; DOUGLAS JDM, 1985, BRIT MED J, V291, P1224, DOI 10.1136/bmj.291.6504.1224; Hallenbeck JM, 1982, PHYSL MED DIVING, P435; SPENCER MP, 1976, J APPL PHYSIOL, V40, P229, DOI 10.1152/jappl.1976.40.2.229; WILMSHURST PT, 1989, LANCET, V1, P513	5	17	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1244	1245		10.1136/bmj.302.6787.1244-a	http://dx.doi.org/10.1136/bmj.302.6787.1244-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043848	Green Published, Bronze			2022-12-28	WOS:A1991FP27200024
J	ARMSTRONG, D; FRY, J; ARMSTRONG, P				ARMSTRONG, D; FRY, J; ARMSTRONG, P			DOCTORS PERCEPTIONS OF PRESSURE FROM PATIENTS FOR REFERRAL	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS	Objective - To assess the effect of pressure from patients on patterns of general practitioners' outpatient referrals. Design - Survey of general practitioners' referrals to hospital outpatient departments during one week. Setting - One health district. Subjects - All (160) general practitioners in the health district. Main outcome measures - Specialty of the referral, the reason for it, and its status (NHS or private) and the general practitioner's assessment of the degree of pressure exerted by the patient for the referral (much, little, or none). Results - 122 (76%) general practitioners completed the survey. Younger general practitioners (aged less-than-or-equal-to 45) and those qualifying in the United Kingdom and Republic of Ireland reported greater pressure from patients to refer (p < 0.03, p < 0.001 respectively). Pressure was also greater for patients referred privately (p < 0.001), for those referred for reassurance (p < 0.05), and for those referred to clinics in psychiatry, rheumatology, dermatology, and orthopaedics. General practitioners with a higher referral rate (with total consultations in the week as the denominator) were more likely to report pressure (p < 0.01). Conclusions - The pressure from patients to refer reported by general practitioners is related both to general practitioners' characteristics and to the nature of the referral. Pressure to refer seems to explain some of the variation in referral rates among general practitioners.	ORPINGTON HOSP,BROMLEY LOCAL MED COMM,KENT,ENGLAND		ARMSTRONG, D (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT GEN PRACTICE,GUYS CAMPUS,LONDON SE1 9RT,ENGLAND.		Armstrong, David/AAI-4476-2021	Armstrong, David/0000-0003-3652-9662				CUMMINS RO, 1981, BRIT MED J, V282, P1037, DOI 10.1136/bmj.282.6269.1037; GRACE JF, 1987, FAM PRACT, V4, P170, DOI 10.1093/fampra/4.3.170; Morrell D C, 1971, J R Coll Gen Pract, V21, P77; WILKIN D, 1987, FAM PRACT, V4, P160, DOI 10.1093/fampra/4.3.160; WILKIN D, 1990, GENERAL PRACTITIONER	5	70	70	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1186	1188		10.1136/bmj.302.6786.1186	http://dx.doi.org/10.1136/bmj.302.6786.1186			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043816	Green Published, Bronze			2022-12-28	WOS:A1991FN04500024
J	CARTER, WG; RYAN, MC; GAHR, PJ				CARTER, WG; RYAN, MC; GAHR, PJ			EPILIGRIN, A NEW CELL-ADHESION LIGAND FOR INTEGRIN ALPHA-3-BETA-1 IN EPITHELIAL BASEMENT-MEMBRANES	CELL			English	Article							EXTRACELLULAR-MATRIX; LAMININ RECEPTOR; KERATINOCYTE ADHESION; FIBRONECTIN RECEPTOR; SURFACE RECEPTORS; ANCHORING FIBRILS; VII COLLAGEN; MULTIPLE; BINDING; ALPHA-2-BETA-1	Epiligrin is a new glycoprotein in most epithelial basement membranes (BMs) and is a ligand for cell adhesion via integrin alpha-3-beta-1. In the extracellular matrix of human foreskin keratinocytes (HFKs), epiligrin contains three disulfide-bonded, glycoprotein subunits, E170, E145, and E135, based on molecular size in kilo-daltons. Epiligrin, immunopurified with MAb P1E1, induced cell adhesion and localization of integrin alpha-3-beta-1 in focal adhesions (FAs). Cell adhesion to epiligrin was inhibited with an anti-alpha-3-beta-1 MAb. Epiligrin also colocalized with integrin alpha-6-beta-4 in hemidesmosome-like stable anchoring contacts (SACs). Alpha-3-beta-1-FAs encircled alpha-6-beta-4-SACs in a complex adhesion structure. Alpha-3-beta-1 and epiligrin localized in BM junctions of epithelial cells primarily in organs of endodermal/ectodermal origin. In epidermis, epiligrin was detected in the lamina lucida of BMs. Alpha-3-beta-1 localized in plasma membranes of basal cells in contact with epiligrin and also in lateral/apical membranes. Epiligrin is the ligand of an adhesion super complex composed of alpha-3-beta-1-FAs and alpha-6-beta-4-SACs (hemidesmosomes).	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98104	University of Washington; University of Washington Seattle	CARTER, WG (corresponding author), UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.				NATIONAL CANCER INSTITUTE [R01CA049259] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA49259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1982, J BIOL CHEM, V257, P13805; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111; DANG NH, 1990, J EXP MED, V172, P649, DOI 10.1084/jem.172.2.649; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GRIEPP EB, 1988, EPITHELIUM CELL TISS; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HEMLER ME, 1988, J BIOL CHEM, V263, P7660; HEMLER ME, 1989, J BIOL CHEM, V26, P1; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IZZARD CS, 1976, J CELL SCI, V21, P129; JONES JCR, 1986, CELL MOTIL CYTOSKEL, V6, P560, DOI 10.1002/cm.970060604; KATZ SI, 1984, J AM ACAD DERMATOL, V11, P1025, DOI 10.1016/S0190-9622(84)80189-9; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; Lever W. F., 1990, HISTOPATHOLOGY SKIN; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; MAR H, 1989, COLLOIDAL GOLD PRINC; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; NEYFAKH AA, 1983, EXP CELL RES, V149, P387, DOI 10.1016/0014-4827(83)90351-8; Oi V.T., 1980, SELECTED METHODS CEL, P351; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; POTTEN CS, 1988, J CELL SCI S, V10, P45; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SHIENVOLD FL, 1976, CELL TISSUE RES, V172, P289, DOI 10.1007/BF00399513; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WOLPERT L, 1988, J CELL SCI S, V10, P1; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	60	583	599	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					599	610		10.1016/0092-8674(91)90092-D	http://dx.doi.org/10.1016/0092-8674(91)90092-D			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032285				2022-12-28	WOS:A1991FM03700010
J	ABRAMSON, NS				ABRAMSON, NS			A RANDOMIZED CLINICAL-STUDY OF A CALCIUM-ENTRY BLOCKER (LIDOFLAZINE) IN THE TREATMENT OF COMATOSE SURVIVORS OF CARDIAC-ARREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLETE CEREBRAL-ISCHEMIA; BLOOD-FLOW; NEUROLOGIC RECOVERY; BRAIN-DAMAGE; CELL-DEATH; NIMODIPINE; RESUSCITATION; INJURY; AMELIORATION; PRIMATES	Background. Abnormalities of cellular calcium homeostasis have been implicated in the pathophysiology of postischemic encephalopathy. Calcium-entry-blocking drugs inhibit the influx of calcium into cells and have been shown to mitigate postischemic encephalopathy in animal models. Methods. Five hundred twenty patients with cardiac arrest who remained comatose after the restoration of spontaneous circulation were randomly assigned to receive three doses of lidoflazine, an experimental calcium-entry blocker, or a placebo and were followed for six months. Four patients were lost to follow-up. Treated patients received an intravenous loading dose (1 mg per kilogram of body weight) of lidoflazine and two subsequent doses (0.25 mg per kilogram) 8 and 16 hours after resuscitation. The investigators were blinded to treatment assignment. Results. There was no statistically significant difference between the lidoflazine group (n = 259) and the placebo group (n = 257) in the proportion of patients who died during the six-month follow-up (82 vs. 83 percent), who survived with good cerebral recovery (15 vs. 13 percent), or who survived with severe neurologic deficit (1.2 vs. 1.9 percent). Analysis of the best level of recovery achieved at any time during follow-up also did not show a difference between the treatment groups: 24 percent of those given lidoflazine and 23 percent of those given placebo recovered good cerebral function (normal or only moderately disabled cerebral performance) at some time. Conclusions. The administration of lidoflazine after cardiac arrest was not found to be beneficial. Our data do not support the routine use of this calcium-entry-blocking drug in comatose survivors of cardiac arrest.			ABRAMSON, NS (corresponding author), UNIV PITTSBURGH,INT RESUSCITAT RES CTR,3434 5TH AVE,PITTSBURGH,PA 15260, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015295] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15295] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON NS, 1990, ANN EMERG MED, V19, P781, DOI 10.1016/S0196-0644(05)81703-2; ABRAMSON NS, 1986, JAMA-J AM MED ASSOC, V255, P2466, DOI 10.1001/jama.255.18.2466; COBB LA, 1982, ANN NY ACAD SCI, V382, P330, DOI 10.1111/j.1749-6632.1982.tb55228.x; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMPTON R, 1982, ANN NY ACAD SCI, V382, P324, DOI 10.1111/j.1749-6632.1982.tb55227.x; ERNSTER L, 1988, CRIT CARE MED, V16, P947, DOI 10.1097/00003246-198810000-00005; FLAMENG W, 1981, CIRCULATION, V64, P796, DOI 10.1161/01.CIR.64.4.796; FLAMENG W, 1982, PROTECTION TISSUES H, P403; FLAMENG W, 1983, J THORAC CARDIOVASC, V5, P758; FLEISCHER JE, 1987, J CEREBR BLOOD F MET, V7, P366, DOI 10.1038/jcbfm.1987.74; Gail M. H., 1981, SURVIVAL ANAL, V2, P287; GELMERS HJ, 1988, NEW ENGL J MED, V318, P203, DOI 10.1056/NEJM198801283180402; HARRIS RJ, 1982, STROKE, V13, P759, DOI 10.1161/01.STR.13.6.759; HOSSMANN KA, 1983, J CEREBR BLOOD F MET, V3, P346, DOI 10.1038/jcbfm.1983.50; Iwatsuki N, 1990, J Anesth, V4, P337, DOI 10.1007/s0054000040337; JENNETT B, 1975, LANCET, V1, P480; KELSEY SF, IN PRESS CONTROLLED; Kollar D J, 1984, Am J Emerg Med, V2, P148; KRAUSE GS, 1988, CRIT CARE MED, V16, P714, DOI 10.1097/00003246-198807000-00015; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEYER FB, 1986, J NEUROSURG, V64, P617, DOI 10.3171/jns.1986.64.4.0617; MILLER BL, 1988, CRIT CARE MED, V16, P1059, DOI 10.1097/00003246-198810000-00020; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; REEDY DP, 1983, NEUROSURGERY, V12, P272; ROINE RO, 1990, JAMA-J AM MED ASSOC, V264, P3171; SAFAR P, 1990, AM J EMERG MED, V8, P55, DOI 10.1016/0735-6757(90)90298-E; SAFAR P, 1986, CIRCULATION, V74, P138; SAKABE T, 1986, J CEREBR BLOOD F MET, V6, P684, DOI 10.1038/jcbfm.1986.124; SAUTER A, 1986, STROKE, V17, P1228, DOI 10.1161/01.STR.17.6.1228; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHWARTZ AC, 1985, AM J EMERG MED, V3, P1, DOI 10.1016/0735-6757(85)90002-6; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SNEDECOR GW, 1980, STATISTICAL METHODS, P129; STEEN PA, 1984, J CEREBR BLOOD F MET, V4, P82, DOI 10.1038/jcbfm.1984.10; STEEN PA, 1985, ANESTHESIOLOGY, V62, P406, DOI 10.1097/00000542-198504000-00007; STEEN PA, 1983, J CEREBR BLOOD F MET, V3, P38, DOI 10.1038/jcbfm.1983.4; TEASDALE G, 1974, LANCET, V2, P81; VAAGENES P, 1984, CRIT CARE MED, V12, P846, DOI 10.1097/00003246-198410000-00002; VANNUETEN JM, 1980, BIOCHEM PHARMACOL, V29, P479, DOI 10.1016/0006-2952(80)90365-2; VANREEMPTS J, 1985, ANN EMERG MED, V14, P736, DOI 10.1016/S0196-0644(85)80048-2; WINEGAR CP, 1983, ANN EMERG MED, V12, P471, DOI 10.1016/S0196-0644(83)80640-4; 1986, AM J EMERG MED, V4, P72; 1986, NEW ENGL J MED, V314, P397	44	208	212	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1225	1231						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	2014035				2022-12-28	WOS:A1991FJ82300001
J	MEYRAND, P; SIMMERS, J; MOULINS, M				MEYRAND, P; SIMMERS, J; MOULINS, M			CONSTRUCTION OF A PATTERN-GENERATING CIRCUIT WITH NEURONS OF DIFFERENT NETWORKS	NATURE			English	Article								RHYTHMIC motor behaviours are generated within the central nervous system by neuronal circuits called central pattern generators (CPG) 1. Although a CPG can produce several forms of the same behaviour 2-5 and several circuits may interact to generate different behaviours 6, it is generally assumed that a given CPG consists of a predefined assemblage of neurons that is functionally distinguishable from other circuits. However, recent studies on the stomatogastric nervous system of crustacea have suggested that CPGs may not be immutable functional entities 7-10. We now report that under an identified neuromodulatory stimulus, the CPG that produces swallowing-like behaviour of the foregut in lobsters is constructed de novo from neurons belonging to other CPGs. Consequently neurons operating independently as members of different circuits may be reconfigured into a new pattern-generating circuit that operates differently from the original circuits. This not only challenges the concept of the CPG being a discrete functional entity, but also demonstrates that a modulatory input can specify an appropriate CPG from a pool of individual neurons of diverse origins.	UNIV BORDEAUX 1,CNRS,NEUROBIOL & PHYSIOL COMPAREES LAB,PL DR PEYNEAU,F-33120 ARCACHON,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux								CAZALETS JR, 1990, J NEUROSCI, V10, P448; CAZALETS JR, 1990, J NEUROSCI, V10, P458; DELCOMYN F, 1980, SCIENCE, V210, P492, DOI 10.1126/science.7423199; DICKINSON PS, 1990, NATURE, V344, P155, DOI 10.1038/344155a0; GRILLNER S, 1985, SCIENCE, V228, P143, DOI 10.1126/science.3975635; HOOPER SL, 1989, SCIENCE, V244, P1587, DOI 10.1126/science.2740903; MARDER E, 1988, NATURE, V335, P296, DOI 10.1038/335296a0; MEYRAND P, 1988, SOC NEUR ABSTR, V14; Nagy F., 1987, P205; ROBERTSON RM, 1979, PROC R SOC SER B-BIO, V206, P235, DOI 10.1098/rspb.1979.0103; Selverston A.I., 1987, CRUSTACEAN STOMATOGA; STEIN PSG, 1988, NEUROBIOLOGY VERTEBR, P201; WEIMANN JM, 1991, J NEUROPHYSIOL, V65, P111, DOI 10.1152/jn.1991.65.1.111; [No title captured]	14	179	179	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					60	63		10.1038/351060a0	http://dx.doi.org/10.1038/351060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027383				2022-12-28	WOS:A1991FK19300059
J	MULLERHILL, B				MULLERHILL, B			FUNDING OF MOLECULAR-BIOLOGY	NATURE			English	Editorial Material											MULLERHILL, B (corresponding author), UNIV COLOGNE,INST GENET,WEYERTAL 121,W-5000 COLOGNE 41,GERMANY.								0	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					11	12		10.1038/351011a0	http://dx.doi.org/10.1038/351011a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027374				2022-12-28	WOS:A1991FK19300024
J	KROBER, MS; STRACENER, CE; BASS, JW				KROBER, MS; STRACENER, CE; BASS, JW			DECREASED MEASLES ANTIBODY-RESPONSE AFTER MEASLES-MUMPS-RUBELLA VACCINE IN INFANTS WITH COLDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							INTERFERON-PRODUCTION	We examined the possibility that the common cold or afebrile upper respiratory tract infection might interfere with successful immunization in children who receive standard measles-mumps-rubella vaccine. Infants 15 to 18 months of age presenting at our well-child clinics for routine examination and immunizations were divided into two groups. Those infants with a history and physical findings of upper respiratory tract infection were compared with healthy control group infants who did not have upper respiratory tract infections, and who did not have a history of upper respiratory tract infection symptoms within the previous month. Both groups were studied for their serologic response to measles-mumps-rubella vaccination. Prevaccination serum samples were obtained prior to vaccine administration and postvaccination serum samples were obtained 6 to 8 weeks later. Measles antibody was measured in these serum samples by an indirect fluorescein-tagged antibody test. Ten (21%) of 47 infants with colds failed to develop measles antibody, while only one (2%) of 51 well infants failed to develop antibody. We conclude that infants with colds have a significant seroconversion failure rate associated with measles vaccine administration and that this may be the cause of some primary measles vaccine failures.	TRIPLER ARMY MED CTR,DEPT PEDIAT,HONOLULU,HI 96859	United States Department of Defense; United States Army	KROBER, MS (corresponding author), MADIGAN ARMY MED CTR,DEPT PEDIAT,BOX 295,TACOMA,WA 98431, USA.							BRUNELL PA, 1990, PEDIATRICS, V83, P474; CHESHIK SG, 1988, PEDIATRIIA, V9, P10; DESMYTER J, 1968, PROG MED VIROL, V10, P268; GRIFFIN DE, 1990, J INFECT DIS, V161, P449, DOI 10.1093/infdis/161.3.449; Grimes D E, 1989, J Pediatr Health Care, V3, P187, DOI 10.1016/0891-5245(89)90082-5; HALL CB, 1981, ANN INTERN MED, V94, P53, DOI 10.7326/0003-4819-94-1-53; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; HSIA J, 1990, J INFECT DIS, V162, P591, DOI 10.1093/infdis/162.3.591; IZBICKY A, 1977, J HYG EPID MICROB IM, V21, P191; MARKOWITZ L, 1990, PEDIATR INFECT DIS J, V9, P530; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; MIRCHAMSY H, 1969, J GEN VIROL, V4, P413; NAKAYAMA T, 1988, J INFECT DIS, V158, P1386, DOI 10.1093/infdis/158.6.1386; NDKUYEZE A, 1988, INT J EPIDEMIOL, V17, P448; NKOWANE BM, 1987, AM J PUBLIC HEALTH, V77, P434, DOI 10.2105/AJPH.77.4.434; RAY CG, 1967, J PEDIATR, V72, P27; TOLCHIN D, 1973, J PEDIATR-US, V83, P890, DOI 10.1016/S0022-3476(73)80401-9; WHEELOCK EF, 1964, LANCET, V2, P382	18	40	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2095	2096		10.1001/jama.265.16.2095	http://dx.doi.org/10.1001/jama.265.16.2095			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013930				2022-12-28	WOS:A1991FG90700027
J	HANSPAL, RS; FISHER, K				HANSPAL, RS; FISHER, K			ASSESSMENT OF COGNITIVE AND PSYCHOMOTOR FUNCTION AND REHABILITATION OF ELDERLY PEOPLE WITH PROSTHESES	BRITISH MEDICAL JOURNAL			English	Article									HAROLD WOOD HOSP,NE THAMES REG DISABLEMENT SERV CTR,ROMFORD,ESSEX,ENGLAND		HANSPAL, RS (corresponding author), ROYAL NATL ORTHOPAED HOSP,DISABLEMENT SERV CTR,REHABIL UNIT,STANMORE,MIDDX,ENGLAND.							GUTTMAN L, 1952, MEASUREMENT PREDICTI; NIE N, 1976, STATISTICAL PACKAGE; Pattie A., 1979, MANUAL CLIFTON ASSES; VITALI M, 1986, AMPUTATIONS PROSTHES	4	16	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					940	940		10.1136/bmj.302.6782.940	http://dx.doi.org/10.1136/bmj.302.6782.940			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH487	2032036	Bronze, Green Published			2022-12-28	WOS:A1991FH48700020
J	FRANCES, RJ				FRANCES, RJ			SUBSTANCE-ABUSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOPAMINE-D2 RECEPTOR GENE; DRUG-USE; ALCOHOL; ASSOCIATION; POPULATION				FRANCES, RJ (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEWARK,NJ 07103, USA.							BACHMAN JG, 1990, J HEALTH SOC BEHAV, V31, P173, DOI 10.2307/2137171; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS AM, 1990, JAMA-J AM MED ASSOC, V264, P3156; BROOK JS, 1989, GENETIC SOC GEN PSYC, V115, P223; DORUS W, 1989, JAMA-J AM MED ASSOC, V262, P1646, DOI 10.1001/jama.262.12.1646; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; GAWIN FH, 1989, ARCH GEN PSYCHIAT, V46, P117; GRONBLADH L, 1989, DRUG ALCOHOL DEPEN, V24, P31, DOI 10.1016/0376-8716(89)90005-7; GROVE WM, 1990, BIOL PSYCHIAT, V27, P1293, DOI 10.1016/0006-3223(90)90500-2; HELZER JE, 1990, ARCH GEN PSYCHIAT, V47, P313; KAPUR A, 1989, BRIT MED J, V299, P427, DOI 10.1136/bmj.299.6696.427; MELLO NK, 1989, SCIENCE, V245, P859, DOI 10.1126/science.2772637; NADEMANEE K, 1989, ANN INTERN MED, V111, P876, DOI 10.7326/0003-4819-111-11-876; NARANJO CA, 1989, CLIN PHARMACOL THER, V46, P301, DOI 10.1038/clpt.1989.142; POPE HG, 1990, AM J PSYCHIAT, V147, P998; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; ROSEN MI, 1991, HOSP COMMUNITY PSYCH, V42, P347	17	2	2	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3171	3172		10.1001/jama.265.23.3171	http://dx.doi.org/10.1001/jama.265.23.3171			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ770	2041142				2022-12-28	WOS:A1991FQ77000042
J	HUGHES, MR; CASKEY, CT				HUGHES, MR; CASKEY, CT			MEDICAL GENETICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TYPE-1 NEUROFIBROMATOSIS GENE; 3 NF1 PATIENTS; PHYSICAL MAP; CANCER; IDENTIFICATION; MUTATIONS; REGION; CELLS				HUGHES, MR (corresponding author), BAYLOR UNIV,HOUSTON,TX 77030, USA.							ANDERSON WF, 1990, HUM GENE THER, V4, P371; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CASTAIGNE S, 1990, BLOOD, V76, P1704; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; HANSEN MF, 1990, CANCER GENET CYTOGEN, V49, P15, DOI 10.1016/0165-4608(90)90159-8; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAGLE MK, 1990, P NATL ACAD SCI USA, V87, P7255, DOI 10.1073/pnas.87.18.7255	16	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3132	3134						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041126				2022-12-28	WOS:A1991FQ77000024
J	JORDAN, TJ; LEWIT, EM; MONTGOMERY, RL; REICHMAN, LB				JORDAN, TJ; LEWIT, EM; MONTGOMERY, RL; REICHMAN, LB			ISONIAZID AS PREVENTIVE THERAPY IN HIV-INFECTED INTRAVENOUS DRUG-ABUSERS - A DECISION-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; AGE THRESHOLD; TUBERCULOSIS; RISK; CHEMOTHERAPY; FLORIDA; LEAVE; AIDS	Tuberculin skin testing is a notoriously poor marker of tuberculosis infection in patients who are serologically positive for the human immunodeficiency virus. A decision analysis was performed to determine if and when isoniazid should be prescribed to prevent tuberculosis in these patients. The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied. The assumptions and parameter estimates selected for this investigation represent a highly conservative vantage point opposing the use of isoniazid as a preventive therapy. Nevertheless, results showed a benefit from the use of isoniazid as a preventive therapy for all groups, even without tuberculin testing, except tuberculin-negative black women. This benefit of isoniazid therapy increased patient life expectancy as much as 285 days. Further, the decisions continue to favor prescribing isoniazid even when the suspected incidence of tuberculosis infection falls as low as 3% to 8%. Tuberculin testing appears important primarily for black women, since those who have negative tuberculin skin tests may not be candidates for isoniazid therapy.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DIV PULM MED,150 BERGEN ST,I-354,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DIV INFORMAT,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MED,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NHLBI NIH HHS [1-K07-HL-02095-04, 1-HR-76032A] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR076032] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL002095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Thoracic Society, 1981, AM REV RESPIR DIS, V124, P356; BROWN LS, 1989, JAMA-J AM MED ASSOC, V262, P615; BRUDNEY D, 1989, 5TH INT C AIDS MONTR; CANESSA PA, 1989, CHEST, V96, P1215, DOI 10.1378/chest.96.5.1215; CHIASSON RE, 1987, AM REV RESPIR DIS, V136, P570; DIPERRI G, 1989, LANCET, V2, P1502; FREBEE SH, 1970, ADV TUBERC RES, V17, P28; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; LUI KJ, 1988, SCIENCE, V240, P1333, DOI 10.1126/science.3163848; MARKOWITZ N, 1990, AM REV RESPIR DIS, V141, P617; MEDLEY GF, 1988, PROC R SOC SER B-BIO, V233, P367, DOI 10.1098/rspb.1988.0026; MEHTA JB, 1988, CHEST, V94, P138, DOI 10.1378/chest.94.1.138; MOULDING TS, 1989, AM REV RESPIR DIS, V140, P700, DOI 10.1164/ajrccm/140.3.700; MURRAY JF, 1990, AM REV RESPIR DIS, V141, P1356, DOI 10.1164/ajrccm/141.5_Pt_1.1356; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1986, NEW ENGL J MED, V314, P447; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; REICHMAN LB, 1987, JAMA-J AM MED ASSOC, V257, P1728, DOI 10.1001/jama.1987.03390130046012; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SNIDER DE, 1987, AM REV RESPIR DIS, V136, P492; SNIDER DE, 1988, AM REV RESPIR DIS, V137, P2, DOI 10.1164/ajrccm/137.1.2; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; SUNDERAM G, 1987, AM REV RESPIR DIS, V136, P1475, DOI 10.1164/ajrccm/136.6.1475; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; THEUER CP, 1989, WESTERN J MED, V150, P700; TSEVAT J, 1988, AM REV RESPIR DIS, V137, P215, DOI 10.1164/ajrccm/137.1.215; 1989, MMWR S3, V38, P1; 1909, MMWR, V38, P236; 1989, MMWR, V38, P243; 1990, MMWR, V39, P645; [No title captured]; 1990, MMWR, V39, P638	38	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2987	2991		10.1001/jama.265.22.2987	http://dx.doi.org/10.1001/jama.265.22.2987			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP635	2033771				2022-12-28	WOS:A1991FP63500037
J	COWAN, DN; BRUNDAGE, JF; POMERANTZ, RS; MILLER, RN; BURKE, DS				COWAN, DN; BRUNDAGE, JF; POMERANTZ, RS; MILLER, RN; BURKE, DS			HIV-INFECTION AMONG MEMBERS OF THE UNITED-STATES-ARMY RESERVE COMPONENTS WITH MEDICAL AND HEALTH OCCUPATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARITAL-STATUS; CANCER; RISK; MEN; AIDS; PREVALENCE	Over 58 000 members of the US Army Reserve Components tested for human immunodeficiency virus (HIV) antibody had military or civilian medical occupations. The availability of HIV status and occupational information permits the assessment of prevalence and incidence of infection in this population. Levels of infection were not higher among women or among currently married men with medical occupations compared with those with nonmedical occupations. Prevalence and incidence were elevated among never-married men with either military or civilian medical occupations compared with never-married men with nonmedical occupations. Based on reported civilian occupation, male registered nurses and men with other medical occupations, excluding physicians and dentists, had a significantly higher prevalence of infection than men with nonmedical occupations. The patterns of infection suggest that the higher levels of infection found among never-married men with medical occupations may not be entirely due to occupational exposure. These findings may have applications in the design and interpretation of results of health care worker HIV surveillance programs.	WALTER REED ARMY MED CTR,DIV RETROVIROL,WASHINGTON,DC 20307; WALTER REED ARMY MED CTR,DIV PREVENT MED,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	COWAN, DN (corresponding author), SRA TECHNOL INC,4700 KING ST,SUITE 300,ALEXANDRIA,VA 22302, USA.		Brundage, John/Q-9244-2019	/0000-0002-5704-8094				BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; BEEKMANN SE, 1990, INFECT CONT HOSP EP, V11, P371; BERNSTEIN L, 1989, CANCER RES, V49, P466; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BLAND RC, 1988, ACTA PSYCHIAT SCAND, V77, P24, DOI 10.1111/j.1600-0447.1988.tb08544.x; BURKE DS, 1987, NEW ENGL J MED, V317, P132; CHAMBERLAND M, 1990, 6TYH INT C AIDS SAN; COWAN DN, 1990, J INFECT DIS, V162, P827, DOI 10.1093/infdis/162.4.827; FAY RE, 1989, SCIENCE, V243, P338, DOI 10.1126/science.2911744; GAGNON JH, 1989, AIDS SEXUAL DEHAVIOR, P102; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GUENEL P, 1990, BRIT J IND MED, V47, P473; HARRY J, 1990, J HOMOSEXUAL, V19, P89, DOI 10.1300/J082v19n01_05; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; KATO I, 1989, JPN J CANCER RES, V80, P306, DOI 10.1111/j.1349-7006.1989.tb02311.x; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; LEMESHOW S, 1984, AM J EPIDEMIOL, V119, P147, DOI 10.1093/oxfordjournals.aje.a113732; MCKUSICK L, 1985, PUBLIC HEALTH REP, V100, P622; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NUTTER RD, 1990, SOC SCI MED, V30, P83, DOI 10.1016/0277-9536(90)90331-L; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; WELLS JA, 1990, 6TH INT C AIDS SAN F; 1988, JAMA-J AM MED ASSOC, V259, P2817; 1990, RCS DDRAM11471148 PU; 1977, DICT OCCUPATIONAL TI	25	19	20	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2826	2830		10.1001/jama.265.21.2826	http://dx.doi.org/10.1001/jama.265.21.2826			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN855	2033739				2022-12-28	WOS:A1991FN85500031
J	CROSS, FR; TINKELENBERG, AH				CROSS, FR; TINKELENBERG, AH			A POTENTIAL POSITIVE FEEDBACK LOOP CONTROLLING CLN1 AND CLN2 GENE-EXPRESSION AT THE START OF THE YEAST-CELL CYCLE	CELL			English	Article							MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; NUCLEOTIDE-SEQUENCE; MATING-PHEROMONE; FISSION YEAST; DIVISION; CONJUGATION; MITOSIS; ARREST	The CLN1, CLN2, and CLN3 genes of S. cerevisiae form a redundant family essential for the G1-to-S phase transition. CLN1 and CLN2 mRNAs were previously shown to be negatively regulated by mating pheromone and by cell cycle progression out of G1, whereas CLN3 mRNA is not. The CLN3-2 (DAF1-1) allele prevents both cell cycle arrest and the turnoff of CLN1 and CLN2 mRNAs in response to mating pheromone, but only in the presence of an active CDC28 gene. An internally deleted nonfunctional cln2 gene was used as a reporter gene to demonstrate that in the absence of mating pheromone, efficient expression of cln2 mRNA requires both an active CDC28 gene and at least one functional CLN gene. mRNA from a nonfunctional cln1 gene was regulated similarly. Thus, CLN function and CDC28 activity jointly stimulate CLN1 and CLN2 mRNA levels, potentially forming a positive feedback loop for CLN1 and CLN2 expression.			CROSS, FR (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; CARTER BLA, 1980, GENETICS, V96, P561; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CROSS FR, 1989, J CELL SCI S12, V94, P117; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; HADWIGER JA, 1990, NUCLEIC ACIDS RES, V18, P4025, DOI 10.1093/nar/18.13.4025; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHULTZ LD, 1983, J BACTERIOL, V155, P8, DOI 10.1128/JB.155.1.8-14.1983; SHERMAN F, 1989, METHODS YEAST GENETI; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	37	297	299	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					875	883		10.1016/0092-8674(91)90394-E	http://dx.doi.org/10.1016/0092-8674(91)90394-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040016				2022-12-28	WOS:A1991FP51600017
J	MAHADEVAN, LC; WILLIS, AC; BARRATT, MJ				MAHADEVAN, LC; WILLIS, AC; BARRATT, MJ			RAPID HISTONE H3 PHOSPHORYLATION IN RESPONSE TO GROWTH-FACTORS, PHORBOL ESTERS, OKADAIC ACID, AND PROTEIN-SYNTHESIS INHIBITORS	CELL			English	Article							SWISS 3T3 CELLS; C-FOS; KINASE-C; CHROMATIN STRUCTURE; MOUSE FIBROBLASTS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME STRUCTURE; CELLULAR-REGULATION; REVERSIBLE CHANGES	When quiescent cells are stimulated with growth factors, phorbol esters, okadaic acid, or protein synthesis inhibitors, the early-response genes, which include c-fos and c-jun, are rapidly induced. The earliest growth factor- and phorbol ester-stimulated nuclear signaling events concomitant with proto-oncogene induction are the rapid phosphorylation of two chromatin-associated proteins, pp33 and pp15. We show here that the tumor promoter okadaic acid, which inhibits protein phosphatases 1 and 2A, and the protein synthesis inhibitors anisomycin and cycloheximide also stimulate pp33 and pp15 phosphorylation. Using transcriptional inhibitors, we show that this response is not a consequence of early gene induction. By peptide mapping and microsequencing, chromatin-associated pp15 is identified as histone H3. Upon stimulation, histone H3 is rapidly phosphorylated on serine residues within its highly charged, basic N-terminal domain. Thus, these diverse agents elicit a common early nuclear signal modulating nucleosomal structure or function, potentially contributing to conformational regulation of proto-oncogene induction.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	University of Oxford								ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL HA, 1990, IN PRESS CELLULAR RE; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAVO R, 1986, ONCOGENES GROWTH CON, P253; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Dixon G. H., 1975, CIBA F S, V28, P229; FALK MM, 1990, J VIROL, V64, P748, DOI 10.1128/JVI.64.2.748-756.1990; FENG JL, 1990, MOL CELL BIOL, V10, P1126, DOI 10.1128/MCB.10.3.1126; GLOTOV BO, 1978, FEBS LETT, V91, P149, DOI 10.1016/0014-5793(78)80037-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HARDISON RC, 1977, CELL, V12, P417, DOI 10.1016/0092-8674(77)90118-0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; JONES SD, 1988, COLD SPRING HARB SYM, V53, P531, DOI 10.1101/SQB.1988.053.01.061; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLUG A, 1980, NATURE, V287, P509, DOI 10.1038/287509a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIM RW, 1987, ONCOGENE, V1, P263; MAHADEVAN LC, 1987, EMBO J, V6, P921, DOI 10.1002/j.1460-2075.1987.tb04839.x; MAHADEVAN LC, 1989, ONCOGENE, V4, P699; MAHADEVAN LC, 1988, ONCOGENE, V2, P249; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MAHADEVAN LC, 1990, RECEPTOR EFFECTOR CO, P181; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MAZEN A, 1987, J MOL BIOL, V194, P741, DOI 10.1016/0022-2836(87)90251-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAPINSKI BR, 1986, NATURE, V321, P81; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PYRWES R, 1988, P NATL ACAD SCI USA, V85, P7206; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1988, COLD SPRING HARB SYM, V53, P935; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; TAYLOR SS, 1982, J BIOL CHEM, V257, P6056; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VACQUIER VD, 1989, DEV BIOL, V133, P111, DOI 10.1016/0012-1606(89)90302-3; VAZQUEZ D, 1979, MOL BIOL BIOCH BIOPH, V130, P513; WELLS D, 1989, NUCLEIC ACIDS RES, V17, pR311, DOI 10.1093/nar/17.suppl.r311; WHITLOCK JP, 1983, J BIOL CHEM, V258, P1299; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	60	388	402	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					775	783		10.1016/0092-8674(91)90385-C	http://dx.doi.org/10.1016/0092-8674(91)90385-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040014				2022-12-28	WOS:A1991FP51600008
J	KIRKMANLIFF, BL				KIRKMANLIFF, BL			HEALTH-INSURANCE VALUES AND IMPLEMENTATION IN THE NETHERLANDS AND THE FEDERAL-REPUBLIC-OF-GERMANY - AN ALTERNATIVE PATH TO UNIVERSAL COVERAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN PAYMENT; COST-CONTAINMENT; PROMOTE QUALITY; MEDICAL-CARE; SYSTEM; STRATEGIES; PROPOSAL; PROGRAM; POOR; END	The health care systems in the Netherlands and the Federal Republic of Germany are based on a set of values that involve mutual obligations between private parties. These obligations are realized through systems incorporating private practice physicians, community and church- and municipality-affiliated hospitals, and nonprofit and for-profit insurers. The underlying values and implementation approaches in these systems provide an alternative to the adoption of a Canadian-style health insurance system. A discussion that focuses on "obligations" rather than "rights" may be a more useful approach for the design of reforms of the American health system in the 1990s. Such a discussion would focus on the mutual responsibility of all parties to create and maintain a universal private health care system.	ERASMUS UNIV,COLL MED,DEPT HLTH CARE POLICY & MANAGEMENT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	KIRKMANLIFF, BL (corresponding author), ARIZONA STATE UNIV,SCH HLTH ADM & POLICY,COLL BUSINESS,TEMPE,AZ 85287, USA.							ALTENSTETTER C, 1987, J HEALTH POLIT POLIC, V12, P505, DOI 10.1215/03616878-12-3-505; BATTISTELLA RM, 1989, HOSP HEALTH SERV ADM, V34, P139; BROWN ER, 1988, MILBANK Q, V66, P573, DOI 10.2307/3349932; CAPER P, 1988, NEW ENGL J MED, V318, P1535, DOI 10.1056/NEJM198806093182310; Cyphert S T, 1988, J Public Health Policy, V9, P456, DOI 10.2307/3342574; DAVIS JE, 1988, JAMA-J AM MED ASSOC, V259, P3171; DAVIS K, 1989, AM ECON REV, V79, P349; DICKMAN RL, 1987, NEW ENGL J MED, V317, P1086, DOI 10.1056/NEJM198710223171709; EICHHORN S, 1984, COMP HLTH SYSTEMS DE, P286; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; GINZBERG E, 1988, JAMA-J AM MED ASSOC, V259, P3309; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; IDDENS HA, 1984, COMP HLTH SYSTEMS DE, P371; KINZER DM, 1990, NEW ENGL J MED, V322, P467, DOI 10.1056/NEJM199002153220711; Kirkman-Liff B L, 1988, Int J Health Plann Manage, V3, P89, DOI 10.1002/hpm.4740030204; KIRKMANLIFF BL, 1989, INQUIRY-J HEALTH CAR, V26, P468; KIRKMANLIFF BL, 1990, J HEALTH POLIT POLIC, V15, P69, DOI 10.1215/03616878-15-1-69; KIRKMANLIFF BL, 1989, HEALTH POLICY, V13, P35, DOI 10.1016/0168-8510(89)90109-7; LAPRE RM, 1988, HEALTH POLICY, V10, P21, DOI 10.1016/0168-8510(88)90084-X; LIGHT DW, 1986, POLITICAL VALUES HLT; MCCARTHY CM, 1988, JAMA-J AM MED ASSOC, V259, P75, DOI 10.1001/jama.259.1.75; REGULA R, 1987, INQUIRY-J HEALTH CAR, V24, P48; RELMAN AS, 1989, NEW ENGL J MED, V320, P117, DOI 10.1056/NEJM198901123200208; RUTTEN FFH, 1987, HEALTH POLICY, V7, P135, DOI 10.1016/0168-8510(87)90027-3; SHORTELL SM, 1990, NEW ENGL J MED, V322, P463, DOI 10.1056/NEJM199002153220710; STONE D, 1987, J HLTH POLIT POLICY, V12, P32; TALLON JR, 1989, JAMA-J AM MED ASSOC, V261, P1044; THORPE KE, 1989, JAMA-J AM MED ASSOC, V262, P2114; THORPE KE, 1989, JAMA-J AM MED ASSOC, V261, P1003, DOI 10.1001/jama.261.7.1003; TODD JS, 1989, NEW ENGL J MED, V321, P46, DOI 10.1056/NEJM198907063210109; TUPPER CJ, 1990, JAMA-J AM MED ASSOC, V264, P1150; VANDEVEN WPM, 1987, HLTH POLICY, V11, P253; VANDEVEN WPMM, 1987, HEALTH POLICY, V7, P253, DOI 10.1016/0168-8510(87)90036-4; WOOLHANDLER S, 1989, JAMA-J AM MED ASSOC, V262, P2136; 1989, HLTH NATION; 1989, HLTH CARE FINANCIN S, P111; 1988, CHANGING HLTH CARE N	38	13	13	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2496	2502						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK903	2020065				2022-12-28	WOS:A1991FK90300020
J	KAMAL, GD; PFALLER, MA; REMPE, LE; JEBSON, PJR				KAMAL, GD; PFALLER, MA; REMPE, LE; JEBSON, PJR			REDUCED INTRAVASCULAR CATHETER INFECTION BY ANTIBIOTIC BONDING - A PROSPECTIVE, RANDOMIZED, CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERITONEAL-DIALYSIS CATHETERS; PREVENTION; BACTERIA; CUFF	We report a prospective, randomized, controlled clinical trial to evaluate the efficacy of antibiotic-bonded catheters in reducing theincidence of intravascular catheter-related infections. Ninety-three central venous catheters and 85 arterial catheters were studied in the surgical intensive care unit. Study catheters were pretreated with the cationic surfactant tridodecylmethylammonium chloride. The anionic antibiotic, cefazolin, was bonded before insertion of the catheters by immersing them in a 50-mg/mL solution. Fourteen percent of the 81 catheters in the control group were infected, compared with 2% of the 97 antibiotic-bonded catheters. Staphylococcus epidermidis was the most common organism obtained. There was no significant difference in the number of colonized or clinically inflamed catheter insertion sites. None of the 100 antibiotic immersion solutions yielded anything on microbiologic culture. We conclude that antibiotic bonding is an efficient, safe, and cost-effective method of reducing intravascular catheter infection in patients who are in intensive care units.	UNIV IOWA,COLL MED,DEPT ANESTHESIA,DIV CRIT CARE MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PATHOL,IOWA CITY,IA 52242	University of Iowa; University of Iowa	KAMAL, GD (corresponding author), USN HOSP,DEPT ANESTHESIA,BLDG 215,PORTSMOUTH,VA 23708, USA.							BERNARD RW, 1971, ANN SURG, V173, P191, DOI 10.1097/00000658-197102000-00003; BOZZETI F, 1982, SURGERY, V91, P97; DAVENPORT DS, 1986, J INFECT DIS, V153, P332, DOI 10.1093/infdis/153.2.332; EYKYN SJ, 1984, J ANTIMICROB CHEMOTH, V14, P203, DOI 10.1093/jac/14.3.203; FLOWERS RH, 1989, JAMA-J AM MED ASSOC, V261, P878, DOI 10.1001/jama.261.6.878; GRECO RS, 1985, ARCH SURG-CHICAGO, V120, P71; GRECO RS, 1982, ANN SURG, V195, P168, DOI 10.1097/00000658-198202000-00008; HARVEY RA, 1984, AM J SURG, V147, P205, DOI 10.1016/0002-9610(84)90089-8; LARSSON N, 1989, ACTA ANAESTH SCAND, V33, P223, DOI 10.1111/j.1399-6576.1989.tb02895.x; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; Maki DG, 1982, CURRENT TOPICS CLIN, P309; MARRIE TJ, 1983, J CLIN MICROBIOL, V18, P1388, DOI 10.1128/JCM.18.6.1388-1398.1983; Parsa MH, 1989, TXB CRITICAL CARE, P122; PLIT ML, 1988, INTENS CARE MED, V14, P503, DOI 10.1007/BF00263521; SHETH NK, 1983, J SURG RES, V34, P213, DOI 10.1016/0022-4804(83)90062-8; TROOSKIN SZ, 1985, SURGERY, V97, P547; TROOSKIN SZ, 1987, NEPHRON, V46, P263, DOI 10.1159/000184366; TROOSKIN SZ, 1986, FRONTIERS PERITONEAL; ZIMMERLI W, 1982, J INFECT DIS, V146, P487, DOI 10.1093/infdis/146.4.487; 1985, SAS USERS GUIDE STAT; 1989, EGRET REFERENCE MANU	23	223	238	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2364	2368		10.1001/jama.265.18.2364	http://dx.doi.org/10.1001/jama.265.18.2364			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016833				2022-12-28	WOS:A1991FJ95500031
J	LUESCHER, IF; ROMERO, P; CEROTTINI, JC; MARYANSKI, JL				LUESCHER, IF; ROMERO, P; CEROTTINI, JC; MARYANSKI, JL			SPECIFIC BINDING OF ANTIGENIC PEPTIDES TO CELL-ASSOCIATED MHC CLASS-I MOLECULES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CYTOLYTIC T-CELLS; IMMUNOGENIC PEPTIDES; RECOGNITION; HLA; CAPACITY; GENE	T LYMPHOCYTES recognize antigen in the form of peptides that associate with specific alleles of class I or class II major histocompatibility (MHC) molecules 1,2. By contrast with the clear MHC allele-specific binding of peptides to purified class II molecules 3-6 purified solubilized class I molecules either bind relatively poorly 7 or show degenerate specificity 8-11. Using photoaffinity labelling, we demonstrate here the specific interaction of peptides with cell-associated MHC class I molecules and show that this involves metabolically active processes.			LUESCHER, IF (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.		Maryanski, Janet/G-3161-2013					BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BAYLEY H, 1984, AZIDES NITRENES REAC, P434; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUESCHER IF, 1990, J BIOL CHEM, V265, P11177; LUESCHER IF, 1988, P NATL ACAD SCI USA, V85, P871, DOI 10.1073/pnas.85.3.871; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MARYANSKI JL, 1987, NATURE, V330, P660, DOI 10.1038/330660a0; MARYANSKI JL, 1986, J IMMUNOL, V136, P4340; MARYANSKI JL, 1988, J EXP MED, V167, P1391, DOI 10.1084/jem.167.4.1391; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; PALA P, 1988, J IMMUNOL, V141, P2289; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHAEFFER EB, 1989, P NATL ACAD SCI USA, V86, P4649, DOI 10.1073/pnas.86.12.4649; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; Schwartz R H, 1986, Adv Immunol, V38, P31, DOI 10.1016/S0065-2776(08)60006-1; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213	32	60	75	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					72	74		10.1038/351072a0	http://dx.doi.org/10.1038/351072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027386				2022-12-28	WOS:A1991FK19300063
J	CUMMINS, D; HEUSCHKEL, R; DAVIES, SC				CUMMINS, D; HEUSCHKEL, R; DAVIES, SC			PENICILLIN PROPHYLAXIS IN CHILDREN WITH SICKLE-CELL DISEASE IN BRENT	BRITISH MEDICAL JOURNAL			English	Article							ORAL PENICILLIN; ANEMIA; INFECTION	Objective-To assess compliance with oral penicillin prophylaxis in children with sickle cell disease and identify possible reasons for poor compliance. Design-Closed questionnaires given to parents of children with sickle cell disease and general practitioners in Brent. Urine samples from 23 children were tested for penicillin. Setting-Paediatric haematology clinic, Central Middlesex Hospital, and general practices in Brent. Subjects-50 children (aged less-than-or-equal-to 16) attending clinic with sickle cell disease over six months (33 HbSS, 12 HbSC, five HbS beta-thalassaemia). 30 general practitioners: 15 with the greatest number of patients with sickle cell disease on the Brent register; 15 selected randomly from family practitioner committee's list. Main outcome measures-Reported compliance with and awareness of importance of penicillin prophylaxis. Results of urine tests for penicillin. Results-31 parents claimed that their children received penicillin every day and 19 that they received it most days (greater-than-or-equal-to 5 days a week). Penicillin was detected in only 10 of 23 urine samples tested. Parents and doctors seemed not to appreciate the importance of treatment: only eight parents were aware of the risk of death if penicillin were discontinued, and 16 doctors were unaware that regular penicillin prophylaxis prevents pneumococcal septicaemia and death in these children. Conclusions-Education for families with children with sickle cell disease must be improved. Specialised information and training are needed for doctors working in areas with a high prevalence of the disorder.	CENT MIDDLESEX HOSP,DEPT HAEMATOL,LONDON NW10 7NS,ENGLAND	Imperial College London								BARRETTCONNOR E, 1971, MEDICINE, V50, P97, DOI 10.1097/00005792-197103000-00002; BROWN AK, 1989, PEDIATRICS, V83, P897; BROZOVIC M, 1984, J CLIN PATHOL, V37, P1321, DOI 10.1136/jcp.37.12.1321; BUCHANAN GR, 1982, PEDIATRICS, V70, P926; FRANKLIN IM, 1988, BRIT MED J, V296, P592, DOI 10.1136/bmj.296.6622.592; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GORDIS L, 1969, J PEDIATR-US, V75, P957, DOI 10.1016/S0022-3476(69)80332-X; GORDIS L, 1969, PEDIATRICS, V43, P173; Grove D.C., 1955, ASSAY METHODS ANTIBI, P14; JOHN AB, 1984, BRIT MED J, V288, P1567, DOI 10.1136/bmj.288.6430.1567; MILNE RIG, 1990, BRIT MED J, V300, P371, DOI 10.1136/bmj.300.6721.371; POWARS D, 1987, AM J DIS CHILD, V141, P250, DOI 10.1001/archpedi.1987.04460030028017; Prashar Usha, 1985, SICKLE CELL ANAEMIA; ROBINSON MG, 1966, NEW ENGL J MED, V274, P1006, DOI 10.1056/NEJM196605052741806; ROWLEY PT, 1978, NEW YORK STATE J MED, V78, P42; 1986, LANCET, V2, P1432	16	35	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					989	990		10.1136/bmj.302.6783.989	http://dx.doi.org/10.1136/bmj.302.6783.989			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039895	Bronze, Green Published			2022-12-28	WOS:A1991FJ50800016
J	WISEMAN, PA; MALONELEE, J; RAI, GS				WISEMAN, PA; MALONELEE, J; RAI, GS			TERODILINE WITH BLADDER RETRAINING FOR TREATING DETRUSOR INSTABILITY IN ELDERLY PEOPLE	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare terodiline with bladder retraining against placebo with bladder retraining in the treatment of detrusor instability in frail elderly patients. Design-Randomised, double blind, parallel group study. Treatment lasted for six weeks. Frequency of micturition and episodes of incontinence recorded on diary chart by patients. Setting-Incontinence clinic and a geriatric day hospital at two teaching hospitals. Patients-37 frail but ambulant patients, mean (range) age 80.4 (70-89) years with urinary frequency and urge incontinence, due to detrusor instability. Two patients withdrew before the first assessment (one in each group) and one could not complete the diary chart (placebo group). Interventions-19 patients received bladder retraining and terodiline 25 mg daily and 18 bladder retraining and placebo. Main outcome measures-Change in urinary frequency and number of episodes of incontinence after six weeks' treatment. Patient's subjective evaluation of symptoms. Results-Little difference was found in the results of treatment with terodiline and placebo. The change in episodes of incontinence per 24 hours was no different in the two groups (95% confidence interval -0.6 to 1.2; p = 0.75) and the difference between treatments in the change in frequency of micturition per 24 hours (-0.2) was not significant (-1.1 to 1.2; p = 0.76). Ten patients taking terodiline thought they had improved compared with seven receiving placebo; this difference was not significant. Conclusions-Although the number of patients in each group was small and may have been insufficient to detect a drug effect, the possible benefit of terodiline is likely to be small.	UNIV COLL & MIDDLESEX SCH MED, UNIV COLL HOSP, DEPT GERIATR MED, LONDON, ENGLAND; WHITTINGTON HOSP, LONDON N19 5NF, ENGLAND	University of London; University College London; University of London; University College London								ABRAMS P, 1983, URODYNAMICS, P110; FISCHERRASMUSSEN W, 1984, SCAND J UROL NEPHROL, P35; FREWEN WK, 1982, BRIT J UROL, V54, P372, DOI 10.1111/j.1464-410X.1982.tb08947.x; HALLEN B, 1988, EUR J CLIN PHARMACOL, V34, P291, DOI 10.1007/BF00540958; MACFARLANE JR, 1984, SCAND J UROL NEPHROL, P51; MALONELEE JG, 1988, MED APPLICATIONS MIC, P87; Peters D, 1984, Scand J Urol Nephrol Suppl, V87, P21; RUD T, 1980, ACTA PHARMACOL TOX, V46, P31; ULMSTEN U, 1980, ACTA PHARM TOXICOL S, V46, P7; 1989, MINITAB RELEASE 7	10	28	28	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 27	1991	302	6783					994	996		10.1136/bmj.302.6783.994	http://dx.doi.org/10.1136/bmj.302.6783.994			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039897	Green Published, Bronze			2022-12-28	WOS:A1991FJ50800018
J	ZAHLER, AM; WILLIAMSON, JR; CECH, TR; PRESCOTT, DM				ZAHLER, AM; WILLIAMSON, JR; CECH, TR; PRESCOTT, DM			INHIBITION OF TELOMERASE BY G-QUARTET DNA STRUCTURES	NATURE			English	Article							TERMINAL TRANSFERASE-ACTIVITY; TETRAHYMENA; RIBONUCLEOPROTEIN; OXYTRICHA; REPEATS; ENZYME; MODEL	THE ends or telomeres of the linear chromosomes of eukaryotes are composed of tandem repeats of short DNA sequences, one strand being rich in guanine (G strand) and the complementary strand in cytosine 1,2. Telomere synthesis involves the addition of telomeric repeats to the G strand by telomere terminal transferase (telomerase) 3-6. Telomeric G-strand DNAs from a variety of organisms adopt compact structures 7, the most stable of which is explained by the formation of G-quartets 8,9. Here we investigate the capacity of the different folded forms of telomeric DNA to serve as primers for the Oxytricha nova telomerase in vitro. Formation of the K+-stabilized G-quartet structure in a primer inhibits its use by telomerase. Furthermore, the octanucleotide T4G4, which does not fold, is a better primer than (T4G4)2, which can form a foldback structure 7-10. We conclude that telomerase does not require any folding of its DNA primer. Folding of telomeric DNA into G-quartet structures seems to influence the extent of telomere elongation in vitro and might therefore act as a negative regulator of elongation in vivo.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder			Williamson, James/AAL-2104-2021; Williamson, James R/B-2891-2009	Williamson, James/0000-0002-8772-468X; Williamson, James R/0000-0002-8772-468X; Zahler, Alan/0000-0003-0027-1647				BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; FERSHT A, 1985, ENZYME STRUCTURE MEC, P112; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; Klobutcher L.A., 1986, P111; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAHLER AM, 1990, THESIS U COLORADO; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	21	1001	1049	6	145	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					718	720		10.1038/350718a0	http://dx.doi.org/10.1038/350718a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023635				2022-12-28	WOS:A1991FJ13000064
J	CERVERA, R; RAMIREZ, G; FERNANDEZSOLA, J; DCRUZ, D; CASADEMONT, J; GRAU, JM; ASHERSON, RA; KHAMASHTA, MA; URBANOMARQUEZ, A; HUGHES, GRV				CERVERA, R; RAMIREZ, G; FERNANDEZSOLA, J; DCRUZ, D; CASADEMONT, J; GRAU, JM; ASHERSON, RA; KHAMASHTA, MA; URBANOMARQUEZ, A; HUGHES, GRV			ANTIBODIES TO ENDOTHELIAL-CELLS IN DERMATOMYOSITIS - ASSOCIATION WITH INTERSTITIAL LUNG-DISEASE	BRITISH MEDICAL JOURNAL			English	Article									ST THOMAS HOSP,RAYNE INST,LUPUS ARTHRIT RES UNIT,LONDON SE1 7EH,ENGLAND; HOSP CLIN BARCELONA,DEPT INTERNAL MED,MUSCLE RES UNIT,BARCELONA,SPAIN	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Barcelona; Hospital Clinic de Barcelona			Casademont, Jordi/A-6828-2010; SOLA, JOAQUIM FERNANDEZ/K-3991-2019; Casademont, Jordi/GPK-8669-2022	Casademont, Jordi/0000-0002-8100-1827; SOLA, JOAQUIM FERNANDEZ/0000-0002-3218-0582; Casademont, Jordi/0000-0002-8100-1827				ARSURA EL, 1988, SEMIN ARTHRITIS RHEU, V18, P29, DOI 10.1016/0049-0172(88)90032-7; EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KISSEL JT, 1986, NEW ENGL J MED, V314, P329, DOI 10.1056/NEJM198602063140601; ROSENBAUM J, 1988, CLIN EXP IMMUNOL, V72, P450	5	49	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					880	881		10.1136/bmj.302.6781.880-a	http://dx.doi.org/10.1136/bmj.302.6781.880-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025728	Bronze, Green Published			2022-12-28	WOS:A1991FG42100023
J	SMITH, R				SMITH, R			MEDICAL-RESEARCH IN AUSTRALIA - SCIENCE IN AUSTRALIA - ALIVE, WELL, KICKING, AND GROWING	BRITISH MEDICAL JOURNAL			English	Editorial Material																		HAWKE R, 1989, SCI TECHNOLOGY AUSTR; 1989, PROFILE AUSTR SCI; 1990, COOPERATIVE RES CTR	3	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					840	842		10.1136/bmj.302.6780.840	http://dx.doi.org/10.1136/bmj.302.6780.840			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025710	Bronze, Green Published			2022-12-28	WOS:A1991FF37700031
J	BAIN, J				BAIN, J			BUDGET HOLDING - A STEP INTO THE UNKNOWN	BRITISH MEDICAL JOURNAL			English	Editorial Material									ALDERMOOR HLTH CTR,SOUTHAMPTON SO1 6ST,ENGLAND										0	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					771	773		10.1136/bmj.302.6779.771	http://dx.doi.org/10.1136/bmj.302.6779.771			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021769	Bronze, Green Published			2022-12-28	WOS:A1991FF22900029
J	GREGORY, PB				GREGORY, PB			PROPHYLACTIC SCLEROTHERAPY FOR ESOPHAGEAL-VARICES IN MEN WITH ALCOHOLIC LIVER-DISEASE - A RANDOMIZED, SINGLE-BLIND, MULTICENTER CLINICAL-TRIAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INJECTION SCLEROTHERAPY; HEMORRHAGE; SURVIVAL; SCLEROSIS	Background. Sclerotherapy is an effective treatment for bleeding esophageal varices in patients with alcoholic liver disease. It has also been suggested that sclerotherapy might be effective in preventing initial episodes of bleeding and improving survival among such patients. Methods. We conducted a prospective, randomized trial comparing prophylactic sclerotherapy and sham therapy in 281 men with alcoholic liver disease who had at least three variceal channels and no history of variceal bleeding. All the patients underwent endoscopy; 143 received sclerotherapy, and 138 received sham therapy. Results. The two patient groups were well matched at entry with respect to the extent of liver disease and other clinical indexes, except that other medical illnesses were significantly more common in the sclerotherapy group. The study's data-monitoring board terminated the trial 22.5 months after it began because the rate of mortality from all causes was significantly higher in the sclerotherapy group (32.2 percent) than in the sham-therapy group (17.4 percent, P = 0.004), despite the fact that the men who received sclerotherapy had significantly fewer episodes of esophageal variceal bleeding. The causes of death varied, and there is no obvious explanation for the excess mortality in the sclerotherapy group. After the termination of treatment, the excess mortality rate in the sclerotherapy group promptly declined. There were 53 episodes of upper gastrointestinal bleeding (including 10 from esophageal varices and 9 from esophageal ulcers) in the sclerotherapy group and 40 episodes (including 19 from esophageal varices) in the sham-therapy group. Complications of sclerotherapy were frequent but seldom life-threatening. Conclusions. For unknown reasons, prophylactic sclerotherapy is associated with increased mortality among men with moderate-to-severe alcoholic liver disease and esophageal varices. Sclerotherapy should not be performed until after an initial episode of bleeding from esophageal varices has occurred.			GREGORY, PB (corresponding author), STANFORD UNIV,MED CTR,SCH MED,OFF VICE PRESIDENT,RM M-121,STANFORD,CA 94305, USA.							CONN HO, 1972, MEDICINE, V51, P27, DOI 10.1097/00005792-197201000-00002; COX DR, 1972, J R STAT SOC B, V34, P187; GIBBERT V, 1982, GASTROINTEST ENDOSC, V28, P147; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JENSEN DM, 1986, ENDOSCOPY, V18, P18, DOI 10.1055/s-2007-1018421; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOCH H, 1986, ENDOSCOPY, V18, P40, DOI 10.1055/s-2007-1018322; KORULA J, 1985, HEPATOLOGY, V5, P584, DOI 10.1002/hep.1840050410; LARSON AW, 1986, JAMA-J AM MED ASSOC, V255, P497, DOI 10.1001/jama.255.4.497; PAQUET KJ, 1982, ENDOSCOPY, V14, P4, DOI 10.1055/s-2007-1021560; PAQUET KJ, 1985, HEPATOLOGY, V5, P580, DOI 10.1002/hep.1840050409; PIAI G, 1988, HEPATOLOGY, V8, P1495, DOI 10.1002/hep.1840080605; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SANTANGELO WC, 1988, NEW ENGL J MED, V318, P814, DOI 10.1056/NEJM198803313181304; SAUERBRUCH T, 1988, NEW ENGL J MED, V319, P8, DOI 10.1056/NEJM198807073190102; TARONE RE, 1977, BIOMETRIKA, V64, P156, DOI 10.1093/biomet/64.1.156; TERBLANCHE J, 1983, LANCET, V2, P1328; TERBLANCHE J, 1979, SURG GYNECOL OBSTET, V148, P323; WESTABY D, 1985, HEPATOLOGY, V5, P827, DOI 10.1002/hep.1840050520; WESTABY D, 1989, HEPATOLOGY, V9, P274, DOI 10.1002/hep.1840090219; WITZEL L, 1985, LANCET, V1, P773; 1984, NEW ENGL J MED, V311, P1594	22	149	151	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1779	1784						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	2038367				2022-12-28	WOS:A1991FR68100005
J	ENGLER, P; HAASCH, D; PINKERT, CA; DOGLIO, L; GLYMOUR, M; BRINSTER, R; STORB, U				ENGLER, P; HAASCH, D; PINKERT, CA; DOGLIO, L; GLYMOUR, M; BRINSTER, R; STORB, U			A STRAIN-SPECIFIC MODIFIER ON MOUSE CHROMOSOME-4 CONTROLS THE METHYLATION OF INDEPENDENT TRANSGENE LOCI	CELL			English	Article								A transgene, pHRD, is highly methylated in 12 independent mouse lines when in a C57BL/6 strain background, but becomes progressively less methylated when bred into a DBA/2 background. Transgenes inherited from the mother are generally more methylated; however, this parental effect disappears following continued breeding into the nonmethylating strain. Mapping experiments using BXD recombinant inbred mice as well as other inbred strains indicate that a single strain-specific modifier (Ssm-1) linked to, but distinct from, Fv-1 is responsible for the strain effect. In addition to the methylated and unmethylated transgenic phenotypes, certain mice exhibit a partial methylation pattern that is a consequence of an unusual cellular mosaicism. The pHRD transgene, containing target sequences for the V(D)J recombinase, undergoes site-specific recombination only in lymphoid tissues. This V-J joining is restricted primarily to unmethylated transgene copies.	UNIV PENN, SCH VET MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	ENGLER, P (corresponding author), UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA.			Brinster, Ralph/0000-0003-1408-7656; Pinkert, Carl/0000-0001-7460-3881	NIAID NIH HHS [AI24780] Funding Source: Medline; NICHD NIH HHS [HD23089, HD07136] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024780, R01AI024780] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; DYNAN WS, 1989, TRENDS GENET, V5, P35, DOI 10.1016/0168-9525(89)90016-4; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; ENGLER P, 1991, J IMMUNOL, V146, P2826; ENGLER P, 1987, P NATL ACAD SCI USA, V84, P4949, DOI 10.1073/pnas.84.14.4949; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HOGAN B, 1986, MANIPULATING MOUSE E; Jolicoeur P, 1979, Curr Top Microbiol Immunol, V86, P67; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; Lyon ML, 1989, GENETIC VARIANTS STR, P773; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SAPIENZA C, 1989, PROG NUCLEIC ACID RE, V36, P145; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SOLTER D, 1988, ANNU REV GENET, V22, P127; SPOFFORD JB, 1976, GENET BIOL DROSOPHIL, V1, P953; SPRADLING AC, 1990, GENETICS, V126, P779; STORB U, 1989, MOL CELL BIOL, V9, P711, DOI 10.1128/MCB.9.2.711; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TABAK HF, 1978, NUCLEIC ACIDS RES, V5, P2321, DOI 10.1093/nar/5.7.2321; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YANCOPOULOS GD, 1988, J EXP MED, V168, P417, DOI 10.1084/jem.168.1.417	37	193	196	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					939	947		10.1016/0092-8674(91)90546-B	http://dx.doi.org/10.1016/0092-8674(91)90546-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044153				2022-12-28	WOS:A1991FR04700005
J	MUSSMAN, MG; ZAWISTOWICH, L; WEISMAN, CS; MALITZ, FE; MORLOCK, LL				MUSSMAN, MG; ZAWISTOWICH, L; WEISMAN, CS; MALITZ, FE; MORLOCK, LL			MEDICAL MALPRACTICE CLAIMS FILED BY MEDICAID AND NON-MEDICAID RECIPIENTS IN MARYLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ACCESS	Several databases available in Maryland are used to investigate whether Medicaid recipients are more likely than other persons to engage in medical malpractice litigation. All malpractice claims filed during 1985 and 1986 (N = 1037) were updated for outcomes through 1989 and described with regard to the payer status of claimants. The proportion of claims filed by persons enrolled in Medicaid before and/or during the alleged malpractice incident was lower than the proportion of state residents enrolled in Medicaid. In addition, the proportion of obstetric claims filed by Medicaid recipients was identical to their proportion of hospital discharges for obstetric services during the period in which the incidents occurred.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,624 N BROADWAY,BALTIMORE,MD 21205; HLTH CARE FINANCING ADM,OFF MEDICAID POLICY,BALTIMORE,MD; MARYLAND DEPT HLTH & MENTAL HYG,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR HLTH SERV RES & DEV,BALTIMORE,MD 21205	Johns Hopkins University; Maryland Department of Health & Mental Hygiene; Johns Hopkins University								LEWISIDEMA D, 1988, INCREASING PROVIDER; MITCHELL JB, 1984, MED CARE, V22, P1026, DOI 10.1097/00005650-198411000-00005; ROSENBLATT RA, 1990, OBSTET GYNECOL, V76, P1105; THORPE KE, 1989, JAMA-J AM MED ASSOC, V261, P1003, DOI 10.1001/jama.261.7.1003; WEISMAN CS, 1989, MED CARE, V27, P16, DOI 10.1097/00005650-198901000-00002; 1980, MALPRACTICE CLAIMS M; 1987, MED MALPRACTICE CHAR; 1988, SURVEY PROFESSIONAL; 1989, MED PROFESSIONAL LIA; 1988, HOSPITAL SURVEY OBST; 1988, MEDICAID SOURCEBOOK	11	15	15	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2992	2994		10.1001/jama.265.22.2992	http://dx.doi.org/10.1001/jama.265.22.2992			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP635	2033772				2022-12-28	WOS:A1991FP63500038
J	LISSNER, L; ODELL, PM; DAGOSTINO, RB; STOKES, J; KREGER, BE; BELANGER, AJ; BROWNELL, KD				LISSNER, L; ODELL, PM; DAGOSTINO, RB; STOKES, J; KREGER, BE; BELANGER, AJ; BROWNELL, KD			VARIABILITY OF BODY-WEIGHT AND HEALTH OUTCOMES IN THE FRAMINGHAM POPULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK; MEN	Background. Fluctuation in body weight is a common phenomenon, due in part to the high prevalence of dieting. In this study we examined the associations between variability in body weight and health end points in subjects participating in the Framingham Heart Study, which involves follow-up examinations every two years after entry. Methods. The degree of variability of body weight was expressed as the coefficient of variation of each subject's measured body-mass-index values at the first eight biennial examinations during the study and on their recalled weight at 25 years of age. Using the 32-year follow-up data, we analyzed total mortality, mortality from coronary heart disease, and morbidity due to coronary heart disease and cancer in relation to intraindividual variation in body weight, including only end points that occurred after the 10th biennial examination. We used age-adjusted proportional-hazards regression for the data analysis. Results. Subjects with highly variable body weights had increased total mortality (P = 0.005 for men, P = 0.01 for women), mortality from coronary heart disease (P = 0.009 for men, P = 0.009 for women), and morbidity due to coronary heart disease (P = 0.0009 for men, P = 0.006 for women). Using a multivariate analysis that also controlled for obesity, trends in weight over time, and five indicators of cardiovascular risk, we found that the positive associations between fluctuations in body weight and end points related to mortality and coronary heart disease could not be attributed to these potential confounding factors. The relative risks of these end points in subjects whose weight varied substantially, as compared with those whose weight was relatively stable, ranged from 1.27 to 1.93. Conclusions. Fluctuations in body weight may have negative health consequences, independent of obesity and the trend of body weight over time.	YALE UNIV, DEPT PSYCHOL, 2 HILLHOUSE AVE, BOX 11A, NEW HAVEN, CT 06520 USA; BRYANT COLL, DEPT MATH, SMITHFIELD, RI 02917 USA; BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; DEPT PRIMARY HLTH CARE, GOTHENBURG, SWEDEN; BOSTON UNIV, MED CTR, DEPT PREVENT MED & EPIDEMIOL, BOSTON, MA 02215 USA	Yale University; Bryant University; Boston University; Boston University				Kreger, Bernard/0000-0002-8593-3795	NCI NIH HHS [S-232-CA09430] Funding Source: Medline; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NIMH NIH HHS [MH00319] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009430] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1976, INT CLASSIFICATION D; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; BROWNELL KD, 1986, AM PSYCHOL, V41, P765, DOI 10.1037/0003-066X.41.7.765; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; LISSNER L, 1990, INT J OBESITY, V14, P373; Marlatt GA., 1985, RELAPSE PREVENTION; PERCY C, 1984, CANCER-AM CANCER SOC, V54, P1435, DOI 10.1002/1097-0142(19841001)54:7<1435::AID-CNCR2820540734>3.0.CO;2-O; STEVENS J, 1990, INT J OBESITY, V14, P385; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; 1986, STATISTICAL ANAL SYS; 1985, ADV DATA VITAL HLTH, V113, P2	15	534	543	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1839	1844		10.1056/NEJM199106273242602	http://dx.doi.org/10.1056/NEJM199106273242602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	2041550				2022-12-28	WOS:A1991FT58000002
J	THOMAS, GA				THOMAS, GA			CONNECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3237	3237						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	2046102				2022-12-28	WOS:A1991FR83500012
J	TUTTLE, KR; BRUTON, JL; PERUSEK, MC; LANCASTER, JL; KOPP, DT; DEFRONZO, RA				TUTTLE, KR; BRUTON, JL; PERUSEK, MC; LANCASTER, JL; KOPP, DT; DEFRONZO, RA			EFFECT OF STRICT GLYCEMIC CONTROL ON RENAL HEMODYNAMIC-RESPONSE TO AMINO-ACIDS AND RENAL ENLARGEMENT IN INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR-FILTRATION-RATE; DIETARY-PROTEIN RESTRICTION; INCREASED KIDNEY SIZE; NEPHROPATHY; TRANSPLANTATION; INFUSION; DISEASE; SURFACE; PATHOGENESIS; AMELIORATION	Background. Many patients with insulin-dependent diabetes mellitushave an increase in the glomerular filtration rate and renal enlargement early in the course of their disease. Both these changes may be risk factors for the later development of diabetic nephropathy. Their cause is not known, but they could be due to augmented renal responses to the increase in plasma amino acid concentrations that occurs when dietary protein intake is high, a factor known to increase glomerular filtration and renal blood flow in normal subjects. Methods. We measured the glomerular filtration rate and renal plasma flow after an overnight fast and during an infusion of amino acids in 12 patients with insulin-dependent diabetes mellitus and 9 normal subjects. The diabetic patients were studied when they were hyperglycemic, when they were euglycemic after an insulin infusion for 36 hours, and after intensive insulin therapy for 3 weeks. Kidney volume was measured by ultrasonography before and after the period of intensive insulin therapy. Results. The glomerular filtration rate and renal plasma flow were normal after fasting when the patients were hyperglycemic (mean [+/- SE] fasting plasma glucose level, 11.5 +/- 0.7 mmol per liter). After the amino acid infusion, these values increased more in the patients (glomerular filtration rate, 2.65 +/- 0.07 ml per second per 1.73 m2 of body-surface area; renal plasma flow, 13.30 +/- 0.68 ml per second per 1.73 m2; P < 0.05 for both) than in the normal subjects (2.25 +/- 0.08 and 11.20 +/- 0.65 ml per second per 1.73 m2, respectively). The 36-hour infusion of insulin in the diabetic patients did not alter the glomerular filtration rate or renal plasma flow either before or during the amino acid infusion. After three weeks of intensive insulin therapy (fasting plasma glucose level, 5.3 +/- 0.2 mmol per liter), the glomerular filtration rate and renal plasma flow after the amino acid infusion (2.33 +/- 0.03 and 11.30 +/- 0.43 ml per second per 1.73 m2, respectively) were similar to those in the normal subjects. The kidney volumes in the normal subjects and the patients with diabetes were 219 +/- 14 and 312 +/- 14 ml per 1.73 m2, respectively (P < 0.01); the volume decreased to 267 +/- 22 ml per 1.73 m2 (P < 0.001) in the diabetic patients after three weeks of intensive insulin therapy, which was not significantly different from the volume in the normal subjects (P = 0.1). Conclusions. Conventionally treated diabetic patients who have normal renal function while fasting have augmented renal hemodynamic responses to increased plasma amino acid concentrations. The concomitant decrease in these hemodynamic responses and in kidney size with strict glycemic control suggests that these phenomena are related and influenced by the metabolic state.	UNIV TEXAS,HLTH SCI CTR,DEPT RADIOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV DIABET,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	TUTTLE, KR (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV NEPHROL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.		Lancaster, Jack L/F-2994-2010	Tuttle, Katherine/0000-0002-2235-0103	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001346] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR01346] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABOUNA GM, 1983, LANCET, V2, P1274; BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; BOSCH JP, 1986, AM J MED, V81, P809, DOI 10.1016/0002-9343(86)90350-5; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BROUHARD BH, 1986, AM J DIS CHILD, V140, P473, DOI 10.1001/archpedi.1986.02140190083032; CASTELLINO P, 1986, AM J PHYSIOL, V251, pF132, DOI 10.1152/ajprenal.1986.251.1.F132; CHRISTIANSEN JS, 1981, DIABETOLOGIA, V20, P451; CIAVARELLA A, 1987, DIABETES CARE, V10, P407, DOI 10.2337/diacare.10.4.407; DEFRONZO RA, 1982, DIABETES, V31, P795, DOI 10.2337/diab.31.9.795; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; ELLIS EN, 1986, KIDNEY INT, V29, P889, DOI 10.1038/ki.1986.82; EVANOFF G, 1989, ARCH INTERN MED, V149, P1129, DOI 10.1001/archinte.149.5.1129; FELDTRASMUSSEN B, 1986, NEW ENGL J MED, V314, P665, DOI 10.1056/NEJM198603133141101; HIROSE K, 1980, LAB INVEST, V43, P434; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; JONES TB, 1983, J ULTRAS MED, V2, P151; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KUPIN WL, 1987, DIABETES, V36, P73, DOI 10.2337/diabetes.36.1.73; LEE CS, 1974, J EXP MED, V139, P793, DOI 10.1084/jem.139.4.793; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MOGENSEN CE, 1976, DIABETES, V25, P872; MOGENSEN CE, 1973, DIABETES, V22, P706, DOI 10.2337/diab.22.9.706; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; NOSADINI R, 1989, DIABETES, V38, P75, DOI 10.2337/diabetes.38.1.75; PARVING HH, 1980, DIABETOLOGIA, V19, P350, DOI 10.1007/BF00280519; PETERSEN J, 1988, DIABETES, V37, P1346, DOI 10.2337/diabetes.37.10.1346; Pitts RF, 1944, AM J PHYSIOL, V142, P0355, DOI 10.1152/ajplegacy.1944.142.3.355; PULLMAN TN, 1954, J LAB CLIN MED, V44, P320; SCHWIEGER J, 1990, SEMIN NEPHROL, V10, P242; SLOMOWITZ LA, 1988, AM J PHYSIOL, V255, pF755, DOI 10.1152/ajprenal.1988.255.4.F755; SMITH HW, 1945, J CLIN INVEST, V24, P388, DOI 10.1172/JCI101618; STACKHOUSE S, 1990, DIABETES, V39, P989, DOI 10.2337/diabetes.39.8.989; STALDER G, 1959, ANN PAEDIATR-BASEL, V193, P129; STEFFES MW, 1980, DIABETES, V29, P509, DOI 10.2337/diab.29.7.509; TANK GW, 1954, AM J PHYSIOL, V178, P165, DOI 10.1152/ajplegacy.1954.178.1.165; VIBERTI GC, 1988, DIABETES METAB REV, V4, P147, DOI 10.1002/dmr.5610040205; WALKER JD, 1989, LANCET, V2, P1411; WALSER M, 1955, J CLIN INVEST, V34, P1520, DOI 10.1172/JCI103204; WISEMAN M, 1983, DIABETOLOGIA, V25, P530; WISEMAN MJ, 1985, NEW ENGL J MED, V312, P617, DOI 10.1056/NEJM198503073121004; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; ZATZ R, 1985, P NATL ACAD SCI USA, V82, P5963, DOI 10.1073/pnas.82.17.5963; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	43	154	156	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1626	1632		10.1056/NEJM199106063242304	http://dx.doi.org/10.1056/NEJM199106063242304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	2030719				2022-12-28	WOS:A1991FP30700004
J	ODIO, CM; FAINGEZICHT, I; PARIS, M; NASSAR, M; BALTODANO, A; ROGERS, J; SAEZLLORENS, X; OLSEN, KD; MCCRACKEN, GH				ODIO, CM; FAINGEZICHT, I; PARIS, M; NASSAR, M; BALTODANO, A; ROGERS, J; SAEZLLORENS, X; OLSEN, KD; MCCRACKEN, GH			THE BENEFICIAL-EFFECTS OF EARLY DEXAMETHASONE ADMINISTRATION IN INFANTS AND CHILDREN WITH BACTERIAL-MENINGITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; TUMOR-NECROSIS-FACTOR; CEREBROSPINAL-FLUID; INFLUENZAE MENINGITIS; B MENINGITIS; INTERLEUKIN-1-BETA; INFLAMMATION; CACHECTIN; PRESSURE; THERAPY	Background. In experimental models of meningitis and in children with meningitis, dexamethasone has been shown to reduce meningeal inflammation and to improve the outcome of disease. Methods. We conducted a placebo-controlled, double-blind trial of dexamethasone therapy in 101 infants and children admitted to the National Children's Hospital, San Jose, Costa Rica, who had culture-proved bacterial meningitis or clinical signs of meningitis and findings characteristic of bacterial infection on examination of the cerebrospinal fluid. The patients were randomly assigned to receive either dexamethasone and cefotaxime (n = 52) or cefotaxime plus placebo (n = 49). Dexamethasone (0.15 mg per kilogram of body weight) was given 15 to 20 minutes before the first dose of cefotaxime and was continued every 6 hours thereafter for four days. Results. The demographic, clinical, and laboratory profiles were similar for the patients in the two treatment groups. By 12 hours after the beginning of therapy, the mean opening cerebrospinal pressure and the estimated cerebral perfusion pressure had improved significantly in the dexamethasone-treated children but worsened in the children treated only with cefotaxime (controls). At 12 hours meningeal inflammation and the concentrations of two cytokines (tumor necrosis factor-alpha and platelet-activating factor) in the cerebrospinal fluid had decreased in the dexamethasone-treated children, whereas in the controls the inflammatory response in the cerebrospinal fluid had increased. At 24 hours the clinical condition and mean prognostic score were significantly better among those treated with dexamethasone than among the controls. At follow-up examination after a mean of 15 months, 7 of the surviving 51 dexamethasone-treated children (14 percent) and 18 of 48 surviving controls (38 percent) had one or more neurologic or audiologic sequelae (P = 0.007); the relative risk of sequelae for a child receiving placebo as compared with a child receiving dexamethasone was 3.8 (95 percent confidence interval, 1.3 to 11.5). Conclusions. The results of this study, in which dexamethasone administration began before the initiation of cefotaxime therapy, provide additional evidence of a beneficial effect of dexamethasone therapy in infants and children with bacterial meningitis.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,ELECTROPHYSIOL LABS,DALLAS,TX 75235; NATL CHILDRENS HOSP,SAN JOSE,COSTA RICA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				SAEZ LLORENS, XAVIER/0000-0002-1149-5905				ARDITI M, 1989, J INFECT DIS, V160, P1005, DOI 10.1093/infdis/160.6.1005; FISCHER H, 1984, J BACTERIOL, V157, P507, DOI 10.1128/JB.157.2.507-513.1984; GOITEIN KJ, 1983, AM J DIS CHILD, V137, P777, DOI 10.1001/archpedi.1983.02140340057016; HERSON VC, 1977, PEDIATRICS, V59, P35; JAMES HE, 1986, PEDIATR ANN, V15, P16, DOI 10.3928/0090-4481-19860101-05; JENNETT B, 1977, LANCET, V1, P878; KADURUGAMUWA JL, 1989, J INFECT DIS, V159, P26, DOI 10.1093/infdis/159.1.26; MCALLISTER CK, 1975, J INFECT DIS, V132, P355, DOI 10.1093/infdis/132.4.355; MCCRACKEN GH, 1989, AM J DIS CHILD, V143, P287, DOI 10.1001/archpedi.1989.02150150041013; MCMENAMIN JB, 1984, NEUROLOGY, V34, P500, DOI 10.1212/WNL.34.4.500; MINS RA, 1989, ARCH DIS CHILD, V64, P814; MUSTAFA MM, 1989, J PEDIATR-US, V115, P208, DOI 10.1016/S0022-3476(89)80067-8; MUSTAFA MM, 1989, J INFECT DIS, V160, P818, DOI 10.1093/infdis/160.5.818; MUSTAFA MM, 1990, AM J DIS CHILD, V144, P883, DOI 10.1001/archpedi.1990.02150320047024; ODIO CM, 1986, PEDIATR INFECT DIS J, V5, P402, DOI 10.1097/00006454-198607000-00005; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; SCHAAD UB, 1990, NEW ENGL J MED, V322, P141, DOI 10.1056/NEJM199001183220301; SYROGIANNOPOULOS GA, 1987, J INFECT DIS, V155, P213, DOI 10.1093/infdis/155.2.213; TAUBER MG, 1987, J INFECT DIS, V156, P456, DOI 10.1093/infdis/156.3.456; TAUBER MG, 1985, J INFECT DIS, V151, P528, DOI 10.1093/infdis/151.3.528; TUNKEL AR, 1990, ANN INTERN MED, V112, P610, DOI 10.7326/0003-4819-112-8-610	23	396	402	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1991	324	22					1525	1531		10.1056/NEJM199105303242201	http://dx.doi.org/10.1056/NEJM199105303242201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN051	2027357				2022-12-28	WOS:A1991FN05100001
J	REYNOLDS, GA; CHITNIS, JG; ROLAND, MO				REYNOLDS, GA; CHITNIS, JG; ROLAND, MO			GENERAL-PRACTITIONER OUTPATIENT REFERRALS - DO GOOD DOCTORS REFER MORE PATIENTS TO HOSPITAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RATES	Objective - To investigate the relation between general practitioners' referral rates to individual specialties and the individual areas of expertise of the referring doctors. Design - Data collected on referral patterns in one group practice over nine months. Setting - General practice in suburban Birmingham consisting of five partners and a trainee. Results - In 395 referrals there were large differences in referral patterns among partners for otorhinolaryngology, ophthalmology, general surgery, and dermatology. The doctors with particular expertise in otorhinolaryngology and ophthalmology had high referral rates to those specialties, and these differences persisted after allowing for case mix. Conclusion - A high referral rate does not necessarily imply a high level of inappropriate referral.	POPLARS SURG, BIRMINGHAM B36 0HH, ENGLAND; UNIV CAMBRIDGE, ADDENBROOKES HOSP, SCH CLIN MED, CAMBRIDGE CB2 2QQ, ENGLAND	Addenbrooke's Hospital; University of Cambridge								COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; COULTER A, 1989, BMJ-BRIT MED J, V299, P304, DOI 10.1136/bmj.299.6694.304; Evans E O, 1968, J R Coll Gen Pract, V16, P294; KNOTTNERUS JA, 1990, BRIT J GEN PRACT, V40, P178; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; Morrell D C, 1971, J R Coll Gen Pract, V21, P77; ROLAND MO, 1990, BRIT MED J, V301, P98, DOI 10.1136/bmj.301.6743.98; WILKIN D, 1987, FAM PRACT, V4, P160, DOI 10.1093/fampra/4.3.160	8	80	80	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1991	302	6787					1250	1252		10.1136/bmj.302.6787.1250	http://dx.doi.org/10.1136/bmj.302.6787.1250			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043851	Green Published, Bronze			2022-12-28	WOS:A1991FP27200027
J	BUTLER, SM				BUTLER, SM			A TAX-REFORM STRATEGY TO DEAL WITH THE UNINSURED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNIVERSAL HEALTH-INSURANCE; PROMOTE QUALITY; ECONOMY; 1990S; PLAN	The high level of uninsurance in the United States is due in large measure to the tax treatment of health care, which is based on the tax exclusion for company-provided plans. Correcting the perverse incentives for providers and patients resulting from this tax treatment is the crucial step to creating a national health care system that is affordable and efficient. The Heritage Foundation proposal calls for the elimination of the current tax exclusion and its replacement with a system of refundable tax credits for the purchase of health insurance and medical services.			BUTLER, SM (corresponding author), HERITAGE FDN,214 MASSACHUSETTS AVE NE,WASHINGTON,DC 20002, USA.							BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; BUTLER S, 1989, NATIONAL HLTH SYSTEM; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; GLOBERMAN S, 1990, WAITING YOUR TURN HO; GOODMAN J, 1988, FREEDMON CHOICE HLTH; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; SHORT P, 1990, J HLTH CARE POOR UND, V1, P15; WALKER M, 19 HER F INT BRIEF; WASLEY T, 1989, NATIONAL HLTH SYSTEM, P91; 1990, FINANCING HLTH LONG, P88; 1987, NATIONAL HLTH CARE E; 1990, REDUCING DEFICIT S 2, P143	13	21	21	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2541	2544		10.1001/jama.265.19.2541	http://dx.doi.org/10.1001/jama.265.19.2541			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK903	2020073				2022-12-28	WOS:A1991FK90300029
J	ELLISON, DH				ELLISON, DH			THE PHYSIOLOGICAL-BASIS OF DIURETIC SYNERGISM - ITS ROLE IN TREATING DIURETIC RESISTANCE	ANNALS OF INTERNAL MEDICINE			English	Review							CONGESTIVE HEART-FAILURE; BASOLATERAL MEMBRANE-VESICLES; CORTICAL COLLECTING DUCT; THICK ASCENDING LIMB; INDOMETHACIN-FUROSEMIDE INTERACTION; NATRIURETIC EFFECT ADDITION; DISTAL CONVOLUTED TUBULE; PERMUTATION TRIAL TESTS; OUTPUT CARDIAC-FAILURE; DRUG-PROTEIN-BINDING	Diuretic drugs usually improve edema when used judiciously. Some patients, however, become resistant to their effects. Diuretic resistance may result from dietary indiscretion, poor compliance, impaired bioavailability, impaired diuretic secretion into the lumen of the renal tubule, or because other drugs interfere with diuretic activity. When easily treatable causes of diuretic resistance have been excluded, resistance often reflects the intensity of the stimuli to sodium retention. Recent experimental work has indicated ways in which the kidney adapts to chronic diuretic treatment and has indicated how these adaptations may limit diuretic effectiveness. First, nephron segments downstream from the site of diuretic action increase sodium-chloride (NaCl) reabsorption because the delivered NaCl load increases. Second, diuretic-induced contraction of the extracellular fluid volume stimulates kidney tubules to retain NaCl until the next dose of diuretic is administered. Third, kidney tubules themselves may become hypertrophic because they are chronically stimulated by diuretic-induced increases in NaCl delivery. These adaptations all increases the rate of NaCl reabsorption and blunt the effectiveness of diuretic therapy. When diuretic resistance is present, using a second diuretic drug that acts in a different nephron segment is often effective. Recent experimental results suggest that a second class of drug may act synergistically with the first by blocking the adaptive processes that limit diuretic effectiveness. On the basis of an understanding of the mechanisms of diuretic adaptation and resistance, treatment regimens can be designed to block specific adaptive mechanisms and to improve diuretic therapy.	VET AFFAIRS MED CTR, NEW HAVEN, CT USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	ELLISON, DH (corresponding author), YALE UNIV, SCH MED, DIV NEPHROL 2074 LMP, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.		, David/X-5730-2019	Ellison, David/0000-0003-2915-265X				AJLSTROM NG, 1990, KIDNEY INT, V37, P270; ANDREASEN F, 1984, BRIT J CLIN PHARMACO, V18, P65, DOI 10.1111/j.1365-2125.1984.tb05023.x; ARONSON PS, 1981, AM J PHYSIOL, V240, pF1, DOI 10.1152/ajprenal.1981.240.1.F1; BEAUMONT K, 1988, P NATL ACAD SCI USA, V85, P2311, DOI 10.1073/pnas.85.7.2311; BENNETT WM, 1975, ARCH INTERN MED, V135, P964, DOI 10.1001/archinte.135.7.964; BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BIAGI BA, 1986, AM J PHYSIOL, V250, pF267, DOI 10.1152/ajprenal.1986.250.2.F267; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; BOSCH JP, 1977, AM J PHYSIOL, V232, pF397, DOI 10.1152/ajprenal.1977.232.5.F397; BOYER TD, 1983, GASTROENTEROLOGY, V84, P1051; BRATER DC, 1985, J PHARMACOL EXP THER, V233, P70; BRATER DC, 1983, ANNU REV PHARMACOL, V23, P45, DOI 10.1146/annurev.pa.23.040183.000401; BRATER DC, 1985, DRUGS, V30, P427, DOI 10.2165/00003495-198530050-00003; BRATER DC, 1983, J PHARMACOL EXP THER, V227, P92; BRATER DC, 1984, KIDNEY INT, V26, P183, DOI 10.1038/ki.1984.153; Brater DC, 1986, PHYSL BASIS DIURETIC, P27; BURCKHARDT BC, 1984, PFLUG ARCH EUR J PHY, V401, P34, DOI 10.1007/BF00581530; CHENNAVASIN P, 1980, J PHARMACOL EXP THER, V215, P77; COOPERMAN LB, 1973, AM HEART J, V85, P831, DOI 10.1016/0002-8703(73)90434-1; DAVISON AM, 1974, BRIT MED J, V1, P481, DOI 10.1136/bmj.1.5906.481; DEWEER P, 1985, KIDNEY PHYSL PATHOPH, P31; DUARTE CG, 1971, AM J PHYSIOL, V221, P632, DOI 10.1152/ajplegacy.1971.221.2.632; EARLEY LE, 1961, J CLIN INVEST, V40, P857, DOI 10.1172/JCI104320; EARLEY LE, 1970, CIRCULATION, V42, P323, DOI 10.1161/01.CIR.42.2.323; ELLISON DH, 1990, KIDNEY INT, V37, P562; ELLISON DH, 1989, J CLIN INVEST, V83, P113, DOI 10.1172/JCI113847; ELLISON DH, 1987, MINER ELECTROL METAB, V13, P422; ELLISON DH, 1987, AM J PHYSIOL, V253, pF546, DOI 10.1152/ajprenal.1987.253.3.F546; EPSTEIN M, 1977, CURR THER RES CLIN E, V21, P656; FREHLAND E, 1983, BIOCHIM BIOPHYS ACTA, V732, P636, DOI 10.1016/0005-2736(83)90241-9; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; GARG LC, 1987, KIDNEY INT, V31, P918, DOI 10.1038/ki.1987.86; GECK P, 1989, KIDNEY INT, V36, P334, DOI 10.1038/ki.1989.201; GERBER JG, 1983, FED PROC, V42, P1707; GERLAG PGG, 1988, ARCH INTERN MED, V148, P286, DOI 10.1001/archinte.148.2.286; GOOD DW, 1979, AM J PHYSIOL, V236, pF192, DOI 10.1152/ajprenal.1979.236.2.F192; GOOD DW, 1984, AM J PHYSIOL, V246, pF609, DOI 10.1152/ajprenal.1984.246.5.F609; GRANTHAM JJ, 1978, SODIUM WATER HOMEOST, P178; GREEN TP, 1981, J PHARMACOL EXP THER, V218, P122; GREEN TP, 1980, LIFE SCI, V26, P623, DOI 10.1016/0024-3205(80)90238-6; GREGER R, 1983, PFLUG ARCH EUR J PHY, V396, P315, DOI 10.1007/BF01063937; GREGER R, 1983, KLIN WOCHENSCHR, V61, P1019, DOI 10.1007/BF01537500; GROSS P, 1989, KLIN WOCHENSCHR, V67, P790, DOI 10.1007/BF01745352; GUNSTONE RF, 1971, POSTGRAD MED J, V47, P789, DOI 10.1136/pgmj.47.554.789; HOOK JB, 1966, J PHARMACOL EXP THER, V154, P667; HROPOT M, 1985, KIDNEY INT, V28, P477, DOI 10.1038/ki.1985.154; KAISSLING B, 1982, AM J PHYSIOL, V243, pF211, DOI 10.1152/ajprenal.1982.243.3.F211; KAISSLING B, 1985, AM J PHYSIOL, V248, pF374, DOI 10.1152/ajprenal.1985.248.3.F374; KAISSLING B, 1982, CELL TISSUE RES, V224, P469, DOI 10.1007/BF00213746; KAISSLING B, 1988, AM J PHYSIOL, V255, pF1256, DOI 10.1152/ajprenal.1988.255.6.F1256; KAISSLING B, 1985, FED PROC, V44, P2710; KELLY RA, 1983, KIDNEY INT, V24, P233, DOI 10.1038/ki.1983.149; KHURI RN, 1975, AM J PHYSIOL, V228, P1262, DOI 10.1152/ajplegacy.1975.228.4.1262; KINSELLA JL, 1981, AM J PHYSIOL, V241, pF374, DOI 10.1152/ajprenal.1981.241.4.F374; KIRCHNER KA, 1989, J PHARMACOL EXP THER, V249, P757; KIRCHNER KA, 1986, AM J PHYSIOL, V250, pF980, DOI 10.1152/ajprenal.1986.250.6.F980; KIRCHNER KA, 1990, J PHARMACOL EXP THER, V252, P1097; KIRCHNER KA, 1987, KIDNEY INT, V31, P1097, DOI 10.1038/ki.1987.114; KIRCHNER KA, 1985, AM J PHYSIOL, V248, pF698, DOI 10.1152/ajprenal.1985.248.5.F698; KOEPPEN BM, 1983, AM J PHYSIOL, V244, pF35, DOI 10.1152/ajprenal.1983.244.1.F35; LEHIR M, 1982, CELL TISSUE RES, V224, P493, DOI 10.1007/BF00213747; LIGHT DB, 1989, J CLIN INVEST, V84, P352, DOI 10.1172/JCI114162; LIGHT DB, 1989, SCIENCE, V243, P383, DOI 10.1126/science.2463673; LOHMEIER TE, 1977, AM J PHYSIOL, V233, pF388, DOI 10.1152/ajprenal.1977.233.5.F388; LOON NR, 1989, KIDNEY INT, V36, P682, DOI 10.1038/ki.1989.246; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MORSING P, 1991, IN PRESS AM J PHYSL; NIES AS, 1983, J PHARMACOL EXP THER, V226, P27; ODLIND BG, 1980, BRIT MED J, V280, P1577, DOI 10.1136/bmj.280.6231.1577; OKUSA MD, 1989, AM J PHYSIOL, V257, pF137, DOI 10.1152/ajprenal.1989.257.1.F137; OLESEN KH, 1970, ACTA MED SCAND, V187, P33; OSTER JR, 1983, ANN INTERN MED, V99, P405, DOI 10.7326/0003-4819-99-3-405; PACKER M, 1986, NEW ENGL J MED, V315, P847, DOI 10.1056/NEJM198610023151402; PEREZAYUSO RM, 1983, GASTROENTEROLOGY, V84, P961; PERSSON AEG, 1982, ACTA PHYSIOL SCAND, V114, P1, DOI 10.1111/j.1748-1716.1982.tb06945.x; QUAMME GA, 1986, DIURETICS PHYSL PHAR, P86; REIHMAN DH, 1985, AM J MED, V78, P87, DOI 10.1016/0002-9343(85)90467-X; ROBSON AO, 1964, LANCET, V2, P1085; ROSE BD, 1987, BODY FLUID HOMEOSTAS, P439; ROSE HJ, 1976, J PHARMACOL EXP THER, V196, P238; RUDY D, 1990, CLIN PHARMACOL THER, V47, P144; RUDY DW, 1990, CLIN PHARMACOL THER, V47, P144; SANSOM SC, 1986, AM J PHYSIOL, V251, pF743, DOI 10.1152/ajprenal.1986.251.4.F743; SCHLATTER E, 1983, PFLUG ARCH EUR J PHY, V396, P210, DOI 10.1007/BF00587857; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1127, DOI 10.1056/NEJM198810273191705; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1065, DOI 10.1056/NEJM198810203191606; SIGURD B, 1975, AM HEART J, V89, P163, DOI 10.1016/0002-8703(75)90041-1; SIGURD B, 1977, AM HEART J, V94, P168, DOI 10.1016/S0002-8703(77)80276-7; SMITH DE, 1981, CLIN PHARMACOL THER, V30, P105, DOI 10.1038/clpt.1981.134; SOLEIMANI M, 1989, J BIOL CHEM, V264, P18302; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; SOLEIMANI M, 1989, J CLIN INVEST, V83, P945, DOI 10.1172/JCI113980; SOMOGYI AA, 1989, DRUG METAB DISPOS, V17, P190; STANTON BA, 1989, AM J PHYSIOL, V257, pF1, DOI 10.1152/ajprenal.1989.257.1.F1; STANTON BA, 1988, AM J PHYSIOL, V255, pF1269, DOI 10.1152/ajprenal.1988.255.6.F1269; STEINMULLER SR, 1972, KIDNEY INT, V1, P169, DOI 10.1038/ki.1972.24; STOKES JB, 1984, J CLIN INVEST, V74, P7, DOI 10.1172/JCI111420; STOKES JB, 1981, AM J PHYSIOL, V241, pF395, DOI 10.1152/ajprenal.1981.241.4.F395; STOKES JB, 1982, KIDNEY INT, V22, P473, DOI 10.1038/ki.1982.200; TERADA Y, 1990, AM J PHYSIOL, V259, pF519, DOI 10.1152/ajprenal.1990.259.3.F519; TOUSSAINT C, 1989, KLIN WOCHENSCHR, V67, P1138, DOI 10.1007/BF01726115; VASKO MR, 1985, ANN INTERN MED, V102, P314, DOI 10.7326/0003-4819-102-3-314; VELAZQUEZ H, 1987, AM J PHYSIOL, V253, pF555, DOI 10.1152/ajprenal.1987.253.3.F555; VELAZQUEZ H, 1986, AM J PHYSIOL, V250, P1013, DOI 10.1152/ajprenal.1986.250.6.F1013; VELAZQUEZ H, 1984, AM J PHYSIOL, V247, pF904, DOI 10.1152/ajprenal.1984.247.6.F904; VOELKER JR, 1989, J PHARMACOL EXP THER, V250, P772; VOELKER JR, 1987, KIDNEY INT, V32, P572, DOI 10.1038/ki.1987.246; WALTER SJ, 1986, CLIN SCI, V70, P379, DOI 10.1042/cs0700379; WARNOCK DG, 1982, AM J PHYSIOL, V242, pF561, DOI 10.1152/ajprenal.1982.242.6.F561; WIGAND ME, 1971, POSTGRAD MED J, V47, P54; WILCOX CS, 1983, J LAB CLIN MED, V102, P450; WILCOX CS, 1987, KIDNEY INT, V31, P135, DOI 10.1038/ki.1987.20; WILSON DR, 1988, CAN J PHYSIOL PHARM, V66, P648, DOI 10.1139/y88-101; WILSON DR, 1983, AM J PHYSIOL, V244, pF666, DOI 10.1152/ajprenal.1983.244.6.F666; WILSON DR, 1983, KIDNEY INT, V23, P711, DOI 10.1038/ki.1983.83; WOLLAM GL, 1982, AM J MED, V72, P929, DOI 10.1016/0002-9343(82)90854-3; ZEIDEL ML, 1988, J CLIN INVEST, V82, P1067, DOI 10.1172/JCI113663	117	177	181	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					886	894		10.7326/0003-4819-114-10-886	http://dx.doi.org/10.7326/0003-4819-114-10-886			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014951				2022-12-28	WOS:A1991FL65000010
J	GOODMAN, RA; SOLOMON, SL				GOODMAN, RA; SOLOMON, SL			TRANSMISSION OF INFECTIOUS-DISEASES IN OUTPATIENT HEALTH-CARE SETTINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATITIS-B; EPIDEMIC KERATOCONJUNCTIVITIS; LARGE OUTBREAK; AIRBORNE TRANSMISSION; MEDICAL SETTINGS; DENTAL PRACTICE; ORAL SURGEON; OFFICE; MEASLES; PREVENTION	Increased provision of health care in outpatient settings and concerns about occupational transmission of infections have focused attention on the risk of transmission of infectious diseases in ambulatory health care settings. In contrast to inpatient nosocomial infections, infections transmitted in outpatient settings are neither systematically monitored nor likely to be detected by routine qi surveillance. To better define the spectrum of such events, we reviewed the literature to identify cases and clusters of infections associated with outpatient health care. In this review, we identified and epidemiologically characterized 53 such reports that occurred from 1961 through 1990. Transmission occurred in general medical offices, clinics, and emergency departments (23); ophthalmologists' offices and clinics (11); dental offices (13); and alternative-care settings (six). Our findings suggest that inpatient infection-control practices should be extended to outpatient health care settings by assigning specific responsibility for infection control and by adapting surveillance methods and prevention measures.	CTR DIS CONTROL,CTR INFECT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	GOODMAN, RA (corresponding author), CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333, USA.							AHTONE J, 1983, J AM DENT ASSOC, V106, P219, DOI 10.14219/jada.archive.1983.0416; BEECHAM HJ, 1979, JAMA-J AM MED ASSOC, V241, P1013, DOI 10.1001/jama.241.10.1013; BLOCH AB, 1985, PEDIATRICS, V75, P676; BORGHANS JG, 1973, AM REV RESPIR DIS, V107, P1; BUEHLER JW, 1984, INFECT CONT HOSP EP, V5, P390, DOI 10.1017/S0195941700062238; CANTER J, 1990, ARCH INTERN MED, V150, P1923; DANGELO LJ, 1981, AM J EPIDEMIOL, V113, P44, DOI 10.1093/oxfordjournals.aje.a113064; DAROUGAR S, 1985, BR J OPHTHALMOL, V67, P1; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P1295, DOI 10.1001/jama.255.10.1295; EDELL TA, 1979, 28TH ANN EP INT SERV; FORD E, 1987, EPIDEMIOL REV, V9, P244, DOI 10.1093/oxfordjournals.epirev.a036304; GINSBURG CM, 1976, AM J EPIDEMIOL, V104, P571, DOI 10.1093/oxfordjournals.aje.a112332; GOODMAN RA, 1982, ANN INTERN MED, V96, P119, DOI 10.7326/0003-4819-96-1-119_1; GOODMAN RA, 1990, PUBLIC HLTH REP, V105, P599; GOODWIN D, 1976, CALIF MORBID    0416; GREAVES WL, 1982, JAMA-J AM MED ASSOC, V248, P861, DOI 10.1001/jama.248.7.861; GREAVES WL, 1982, PEDIATR INFECT DIS J, V1, P388, DOI 10.1097/00006454-198211000-00005; HADLER SC, 1981, ANN INTERN MED, V95, P133, DOI 10.7326/0003-4819-95-2-133; HADLER SC, 1974, ANN INTERN MED, V228, P1139; HALEY RW, 1980, AM J EPIDEMIOL, V111, P472, DOI 10.1093/oxfordjournals.aje.a112928; INMAN PM, 1969, ARCH DERMATOL, V100, P141, DOI 10.1001/archderm.100.2.141; ISTRE GR, 1987, PEDIATRICS, V79, P356; ISTRE GR, 1982, NEW ENGL J MED, V307, P339, DOI 10.1056/NEJM198208053070603; KEENLYSIDE RA, 1983, J INFECT DIS, V147, P191, DOI 10.1093/infdis/147.2.191; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; KOBLER E, 1979, SCHWEIZ MED WSCHR, V109, P1828; KOO D, 1989, INFECT CONT HOSP EP, V10, P547; Kothari T, 1977, Can Med Assoc J, V116, P1235; LEVIN ML, 1974, JAMA-J AM MED ASSOC, V228, P1139, DOI 10.1001/jama.228.9.1139; LOBOVITS AM, 1985, NEW ENGL J MED, V313, P425, DOI 10.1056/NEJM198508153130706; LOWRY PW, 1988, NEW ENGL J MED, V319, P978, DOI 10.1056/NEJM198810133191504; MANZELLA JP, 1984, JAMA-J AM MED ASSOC, V252, P2019, DOI 10.1001/jama.252.15.2019; MARTIN WV, 1987, BR DENT J, V183, P152; MURRAH WF, 1988, ANN OPHTHALMOL, V20, P36; NAGINGTON J, 1983, BRIT J OPHTHALMOL, V67, P674, DOI 10.1136/bjo.67.10.674; NAKASHIMA AK, 1987, J CLIN MICROBIOL, V25, P1014, DOI 10.1128/JCM.25.6.1014-1018.1987; NEWMAN PE, 1984, AM J OPHTHALMOL, V97, P344, DOI 10.1016/0002-9394(84)90634-2; OWEN M, 1963, SOUTHERN MED J, V56, P949, DOI 10.1097/00007611-196309000-00004; PATTERSON CH, 1989, AM J INFECT CONTROL, V17, P231, DOI 10.1016/0196-6553(89)90168-5; REINGOLD AL, 1982, J INFECT DIS, V145, P262, DOI 10.1093/infdis/145.2.262; REMINGTON PL, 1985, JAMA-J AM MED ASSOC, V253, P1574, DOI 10.1001/jama.253.11.1574; RICHMOND S, 1984, J HYG CAMB, P285; RIMLAND D, 1977, NEW ENGL J MED, V296, P953, DOI 10.1056/NEJM197704282961701; SHAW FE, 1986, JAMA-J AM MED ASSOC, V255, P3260, DOI 10.1001/jama.255.23.3260; SMITH WHR, 1982, LANCET, V1, P842; STETLER HC, 1985, PEDIATRICS, V75, P299; STRYKER WS, 1986, J FAM PRACTICE, V22, P155; VASTINE DW, 1976, T AM ACAD OPHTHALMOL, V81, P826; WARREN D, 1989, J INFECT DIS, V160, P938, DOI 10.1093/infdis/160.6.938; WEGMAN DH, 1970, AM J PUBLIC HEALTH N, V60, P1230, DOI 10.2105/AJPH.60.7.1230; WENGER JD, 1990, JAMA-J AM MED ASSOC, V264, P373, DOI 10.1001/jama.264.3.373; 1989, MMWR, V38, pS6; 1991, MMWR, V40, P33; 1989, MMWR, V38, P256; 1990, ABSCESSES ALLERGY PR; 1989, MMWR, V38, P263; 1990, HLTH US 1989, P195; 1990, MMWR, V39, P718; 1990, MMWR, V39, P473; 1981, CALIF MORBID    0403; 1987, MMWR, V36, P132; 1987, MMWR S2S, V36, pS3; 1984, MMWR, V33, P471; 1991, MMWR, V40, P21	64	60	60	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2377	2381		10.1001/jama.265.18.2377	http://dx.doi.org/10.1001/jama.265.18.2377			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016835				2022-12-28	WOS:A1991FJ95500034
J	OSTLERE, LS; LANGTRY, JAA				OSTLERE, LS; LANGTRY, JAA			ALLERGY TO SPIRAMYCIN DURING PROPHYLACTIC TREATMENT OF FETAL TOXOPLASMOSIS	BRITISH MEDICAL JOURNAL			English	Letter											OSTLERE, LS (corresponding author), WESTMINSTER MED SCH & HOSP,LONDON SW1P 2AP,ENGLAND.							DAFFOS F, 1988, NEW ENGL J MED, V318, P281; DESCOTERS J, 1988, J ANTIMICROBIAL C SB, P207; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; GALLAND MC, 1987, THERAPIE, V42, P227; HOHFELD P, 1989, J PEDIATR, V115, P765; 1990, LANCET, V336, P346	6	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					970	970		10.1136/bmj.302.6782.970	http://dx.doi.org/10.1136/bmj.302.6782.970			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032060	Bronze, Green Published			2022-12-28	WOS:A1991FH48700071
J	PETITOU, M; LORMEAU, JC; CHOAY, J				PETITOU, M; LORMEAU, JC; CHOAY, J			CHEMICAL SYNTHESIS OF GLYCOSAMINOGLYCANS - NEW APPROACHES TO ANTITHROMBOTIC DRUGS	NATURE			English	Article							HEPARIN PENTASACCHARIDE FRAGMENT; MOLECULAR-WEIGHT HEPARIN; HIGH-AFFINITY; BINDING SEQUENCE; CHROMATOGRAPHY; SEPARATION; THROMBOSIS; MECHANISM	Sanofi, Elf Aquitaine's pharmaceutical subsidiary is a world leader in antithrombotic drugs. This article traces the development of Heparin-based antithrombotic drugs and describes the company's progress in producing synthetic substitutes.			PETITOU, M (corresponding author), SANOFI RECH,9 RUE PRESIDENT SALVADOR ALLENDE,F-94256 GENTILLY,FRANCE.							ABILDGAARD U, 1968, SCAND J CLIN LAB INV, V21, P89, DOI 10.3109/00365516809076981; ANDERSSON LO, 1976, THROMB RES, V9, P575, DOI 10.1016/0049-3848(76)90105-5; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BOSSENNEC V, 1990, BIOCHEM J, V267, P625, DOI 10.1042/bj2670625; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Choay J, 1981, Ann N Y Acad Sci, V370, P644, DOI 10.1111/j.1749-6632.1981.tb29770.x; DUCHAUSSOY P, IN PRESS J BIO M CHE; FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; HOOK M, 1976, FEBS LETT, V66, P90, DOI 10.1016/0014-5793(76)80592-3; ICHIKAWA Y, 1986, TETRAHEDRON LETT, V27, P611, DOI 10.1016/S0040-4039(00)84054-X; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KAKKAR VV, 1982, BRIT MED J, V284, P375, DOI 10.1136/bmj.284.6313.375; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LANE DA, 1989, ANN NY ACAD SCI, V556; LANE DA, 1989, HEPARIN; LINHARDT RJ, 1988, BIOCHEM J, V254, P781, DOI 10.1042/bj2540781; LORMEAU JC, 1978, Patent No. 7831357; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; PETITOU M, 1986, CARBOHYD RES, V147, P221, DOI 10.1016/S0008-6215(00)90633-5; PETITOU M, 1988, CARBOHYD RES, V179, P163, DOI 10.1016/0008-6215(88)84116-8; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; PETITOU M, 1988, EUR J BIOCHEM, V176, P637, DOI 10.1111/j.1432-1033.1988.tb14324.x; PETITOU M, 1983, GLYCOCONJUGATES, P379; PETITOU M, 1989, HEPARIN CHEM BIOL PR, P65; PETITOU M, IN PRESS BIO M CHEM; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SINAY P, 1984, CARBOHYD RES, V132, pC5, DOI 10.1016/0008-6215(84)85236-2; TEIEN AN, 1977, THROMB RES, V10, P399, DOI 10.1016/0049-3848(77)90150-5; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; VANBOECKEL CAA, 1988, TETRAHEDRON LETT, V29, P803, DOI 10.1016/S0040-4039(00)80214-2; VANBOECKEL CAA, 1985, J CARBOHYD CHEM, V4, P293, DOI 10.1080/07328308508070182; WALENGA JM, 1987, THROMB RES, V46, P187, DOI 10.1016/0049-3848(87)90280-5; WESSLER S, 1974, THROMB DIATH HAEMOST, V32, P71, DOI 10.1055/s-0038-1647674	40	54	55	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319		S			30	33						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH681	2017262				2022-12-28	WOS:A1991FH68100011
J	ANDERSON, DC; BLOWER, AL; PACKER, JMV; GANGULI, LA				ANDERSON, DC; BLOWER, AL; PACKER, JMV; GANGULI, LA			PREVENTING NEEDLESTICK INJURIES	BRITISH MEDICAL JOURNAL			English	Article							HIV INFECTION; SEROCONVERSION; DEVICE; NURSE; RISK		HOPE HOSP,DEPT SURG,SALFORD M6 8HD,LANCS,ENGLAND; HOPE HOSP,DEPT MED MICROBIOL,SALFORD M6 8HD,LANCS,ENGLAND; SALFORD AREA HLTH AUTHOR,DEPT PUBL HLTH MED,ECCLES M3O 0NJ,ENGLAND		ANDERSON, DC (corresponding author), HOPE HOSP,DEPT MED,SALFORD M6 8HD,LANCS,ENGLAND.							BESSENT RG, 1987, BRIT MED J, V295, P307, DOI 10.1136/bmj.295.6593.307; Centers for Disease Control reports include, 1988, MMWR, V37, P229; EDMOND M, 1988, INFECT CONT HOSP EP, V9, P114, DOI 10.1086/645806; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; GIOANNINI P, 1988, EUR J EPIDEMIOL, V4, P119, DOI 10.1007/BF00152703; GOLDWTER PN, 1987, INFECT CONT HOSP EP, V10, P21; GREEN ST, 1986, LANCET, V1, P1096; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; KENNEDY DA, 1988, J HOSP INFECT, V12, P315, DOI 10.1016/0195-6701(88)90074-6; KRASINSKI K, 1987, INFECT CONT HOSP EP, V8, P59, DOI 10.1017/S0195941700067084; MARCUS R, 1988, NEW ENGL J MED, V319, P1117; NEISSONVERNANT C, 1986, LANCET, V2, P814; NIXON AD, 1986, LANCET, V1, P888; OKSENHENDLER E, 1986, NEW ENGL J MED, V315, P582; RAMSEY KM, 1988, CLIN RES, V36, pA1; RIBNER BS, 1987, INFECT CONT HOSP EP, V8, P63, DOI 10.1017/S0195941700067096; STRICOF RL, 1986, NEW ENGL J MED, V314, P1115; 1984, LANCET, V2, P1376; 1983, MMWR, V32, P450; 1987, MMWR, V36, P285; 1990, GUIDANCE CLIN HLTH C; 1990, HIV CAUSATIVE AGENTS; 1987, MMWR, V36, P4; 1990, CODE PRACTICE SAFE U; 1990, BMJ, V300, P766; 1986, LAVHTLV 3 CAUSATIVE, P6	26	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					769	770		10.1136/bmj.302.6779.769	http://dx.doi.org/10.1136/bmj.302.6779.769			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2043216	Green Published, Bronze			2022-12-28	WOS:A1991FF22900028
J	CURRAN, WJ				CURRAN, WJ			BEYOND THE BEST INTERESTS OF A CHILD - BONE-MARROW TRANSPLANTATION AMONG HALF-SIBLINGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Curran William J., 1959, NEW YORK U LAW REV, V34, P891; CURRAN WJ, 1969, J AMER MED ASSOC, V210, P77, DOI 10.1001/jama.210.1.77; GOLDSTEIN J, 1980, BEST INTERESTS CHILD; LEVINE MD, 1975, J PEDIATR-US, V86, P145, DOI 10.1016/S0022-3476(75)80728-1	4	7	7	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1818	1819		10.1056/NEJM199106203242519	http://dx.doi.org/10.1056/NEJM199106203242519			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR681	2038375				2022-12-28	WOS:A1991FR68100028
J	FURIE, B; MILLER, KB				FURIE, B; MILLER, KB			HEMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; POLYMERASE CHAIN-REACTION; FACTOR-VIII GENE; ANTIHEMOPHILIC-FACTOR; HEMOPHILIA; DIAGNOSIS; SEQUENCES; LEUKEMIA; INVITRO; DISEASE		TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts University	FURIE, B (corresponding author), NEW ENGLAND MED CTR HOSP,BOSTON,MA 02111, USA.							ANTONARAKIS SE, 1989, NEW ENGL J MED, V320, P153, DOI 10.1056/NEJM198901193200305; EISENSTEIN BI, 1990, NEW ENGL J MED, V322, P178; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FISCHL M, 1990, NEW ENGL J MED, V322, P1488, DOI 10.1056/NEJM199005243222103; FURIE B, 1990, SEMIN HEMATOL, V27, P270; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; HANSENHAGGE TE, 1989, BLOOD, V74, P1762; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; WHITE GC, 1989, NEW ENGL J MED, V320, P166, DOI 10.1056/NEJM198901193200307; WHITE GC, 1989, BLOOD, V73, P1	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3128	3130						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041124				2022-12-28	WOS:A1991FQ77000022
J	THRALL, JH				THRALL, JH			NUCLEAR-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PULMONARY-EMBOLISM; METAIODOBENZYLGUANIDINE; INFECTION				THRALL, JH (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.							GORDON I, 1990, J NUCL MED, V31, P129; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; LEE ME, 1985, RADIOLOGY, V156, P497, DOI 10.1148/radiology.156.2.4011914; LIND P, 1990, J NUCL MED, V31, P417; MCAFEE JG, 1990, J NUCL MED, V31, P413; PALESTRO CJ, 1990, J NUCL MED, V31, P319; RICHALET JP, 1990, J NUCL MED, V31, P34; ROBIN ED, 1977, ANN INTERN MED, V87, P775, DOI 10.7326/0003-4819-87-6-775; RUBIN RH, 1989, NEW ENGL J MED, V321, P935, DOI 10.1056/NEJM198910053211404; SHAPIRO B, 1985, J NUCL MED, V26, P576; SISSON JC, 1987, J NUCL MED, V28, P1620; TOBES MC, 1985, J NUCL MED, V26, P897; 1990, JAMA-J AM MED ASSOC, V263, P2753	13	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3137	3139						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041129				2022-12-28	WOS:A1991FQ77000027
J	BLUMBERG, MS				BLUMBERG, MS			BIASED ESTIMATES OF EXPECTED ACUTE MYOCARDIAL-INFARCTION MORTALITY USING MEDISGROUPS ADMISSION SEVERITY GROUPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVIVAL; SYSTEM	This study examines whether the MedisGroups admission severity groups give unbiased estimates of 30-day mortality in 3037 Medicare-aged patients who were hospitalized in 1985 through 1986 with acute myocardial infarction. The average observed death rate for all acute myocardial infarction patients in the study who were in a given admission severity group was used to estimate the expected death probability for each case in a given group. (This is the same method used by the Pennsylvania Health Care Cost Containment Council for risk adjusting hospital mortality by diagnosis related groups in that state.) When compared with observed deaths, estimates of expected mortality were significantly biased for many patient attributes (eg, age, location of acute myocardial infarction, history of congestive heart failure, serum potassium level, serum urea nitrogen level, pulse rate, and blood pressure). These results are consistent with a conclusion that the MedisGroups scoring algorithm omits some important risk variables, inappropriately includes some other variables reflecting postadmission status, and gives the wrong weights to some appropriate risk variables. To the extent that these findings are also applicable to current MedisGroups scoring algorithms and to other conditions and procedures, MedisGroups admission severity groups cannot fairly adjust for interhospital case mix differences in outcome studies.			BLUMBERG, MS (corresponding author), KAISER FDN HLTH PLAN INC,ONE KAISER PLAZA,OAKLAND,CA 94612, USA.		Blumberg, Mark/K-3221-2019					ALEMI F, 1990, MED CARE, V28, P762, DOI 10.1097/00005650-199009000-00006; [Anonymous], 1986, MED THINKING PSYCHOL; Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; BLUMBERG MS, 1991, STAT MED, V10, P637, DOI 10.1002/sim.4780100414; BLUMBERG MS, 1989, RISK ADJUSTED 30 DAY; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; IEZZONI LI, 1991, AM J PUBLIC HEALTH, V81, P74, DOI 10.2105/AJPH.81.1.74; Iezzoni LI, 1988, ABILITY MEDISGROUPS; IEZZONI LI, 1987, MEDISGROUP CLIN ANAL; IEZZONI LI, 1989, ADMISSION MIDSTAY ME; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1987, ICU COST BENEFIT ANA; Mosteller F., 1968, HDB SOC PSYCHOL, V2, P80; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V147, P1181; SACHS L, 1984, APPLIED STATISTICS H, P66; 1990, HE189 PENNS HLTH CAR, pB4; 1990, HE5488 PENNS HLTH CA, P3	19	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2965	2970						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033767				2022-12-28	WOS:A1991FP63500033
J	LEVIN, BW; DRISCOLL, JM; FLEISCHMAN, AR				LEVIN, BW; DRISCOLL, JM; FLEISCHMAN, AR			TREATMENT CHOICE FOR INFANTS IN THE NEONATAL-INTENSIVE-CARE-UNIT AT RISK FOR AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; INFECTION; TYPE-1; WOMEN; BORN	Many infants admitted to neonatal intensive care units are the children of women infected with the human immunodeficiency virus (HIV); they have approximately a 30% risk of infection. To investigate attitudes surrounding treatment for such newborns, we conducted a survey of professionals at six neonatal intensive care units in New York City. A significant proportion of the 247 respondents recommended less aggressive treatment for non-HIV-related conditions for infants at risk for HIV compared with those not at risk. For example, 97% of respondents recommended open heart surgery for an infant with no known HIV risk but only 77% recommended surgery for an infant whose mother had acquired immunodeficiency syndrome; if certain the infant was infected, 42% of respondents recommended surgery. We conclude that perceived HIV status may influence decision making about treatment for non-HIV-related conditions for critically ill patients, including infants not actually infected. Ethical issues concerning the relevance of HIV status need to be examined.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,DIV NEONATOL,BRONX,NY 10461; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,DIV PERINATAL MED,NEW YORK,NY 10032; MONTEFIORE MED CTR,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine; Columbia University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	LEVIN, BW (corresponding author), CUNY BROOKLYN COLL,DEPT HLTH & NUTR,BROOKLYN,NY 11210, USA.		Levin, Betty Wolder/L-3479-2019	Levin, Betty Wolder/0000-0002-4288-6052				BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; CONDIT D, 1989, ANN THORAC SURG, V47, P182, DOI 10.1016/0003-4975(89)90266-X; CRANE D, 1975, SANCTITY SOCIAL LIFE; Guillemin J, 1986, MIXED BLESSINGS INTE; KATZ BZ, 1989, SEMIN PERINATOL, V13, P27; LEVIN BW, 1988, CHILDBIRTH AM ANTHR; LEVIN BW, 1985, WHICH BABIES LIVE ME; NICHOLAS SW, 1989, PEDIATRICS, V83, P293; OLESKE JM, 1988, PEDIATR ANN, V17, P332, DOI 10.3928/0090-4481-19880501-07; PIZZO PA, 1989, JAMA-J AM MED ASSOC, V262, P1989, DOI 10.1001/jama.262.14.1989; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SEPTIMUS A, 1989, SEMIN PERINATOL, V13, P49; SHEARER W, 1990, SEMIN PEDIATR INFECT, V1, P1; STEVENS A, 1990, BRIT MED J, V300, P447, DOI 10.1136/bmj.300.6722.447; Weir Robert F., 1984, SELECTIVE NONTREATME; 1987, HASTINGS CTR REP, V17, P5	17	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2976	2981		10.1001/jama.265.22.2976	http://dx.doi.org/10.1001/jama.265.22.2976			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033769				2022-12-28	WOS:A1991FP63500035
J	LACROIX, AZ; LANG, J; SCHERR, P; WALLACE, RB; CORNONIHUNTLEY, J; BERKMAN, L; CURB, JD; EVANS, D; HENNEKENS, CH				LACROIX, AZ; LANG, J; SCHERR, P; WALLACE, RB; CORNONIHUNTLEY, J; BERKMAN, L; CURB, JD; EVANS, D; HENNEKENS, CH			SMOKING AND MORTALITY AMONG OLDER MEN AND WOMEN IN 3 COMMUNITIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; CIGARETTE-SMOKING; ARTERY DISEASE; FOLLOW-UP; AGE; OSTEOPOROSIS; PREDICTORS; EVENTS; HEALTH	Background. Although cigarette smoking is the leading avoidable cause of premature death in middle age, some have claimed that no association is present among older persons. Methods. We prospectively examined the relation of cigarette-smoking habits with mortality from all causes, cardiovascular causes, and cancer among 7178 persons 65 years of age or older without a history of myocardial infarction, stroke, or cancer who lived in one of three communities: East Boston, Massachusetts; Iowa and Washington counties, Iowa; and New Haven, Connecticut. At the time of the initial interview, prevalence rates of smoking in the three communities ranged from 5.2 to 17.8 percent among women and from 14.2 to 25.8 percent among men. During five years of follow-up there were 1442 deaths, 729 due to cardiovascular disease and 316 due to cancer. Results. In both sexes, rates of total mortality among current smokers were twice what they were among participants who had never smoked. Relative risks, as adjusted for age and community, were 2.1 among the men (95 percent confidence interval, 1.7 to 2.7) and 1.8 among the women (95 percent confidence interval, 1.4 to 2.4). Current smokers had higher rates of cardiovascular mortality than those who had never smoked (as adjusted for age and community, the relative risk was 2.0 [95 percent confidence interval, 1.4 to 2.9] among the men and 1.6 [95 percent confidence interval, 1.1 to 2.3] among the women), as well as increased rates of cancer mortality (relative risk, 2.4 [95 percent confidence interval, 1.4 to 4.1] among the men and 2.4 [95 percent confidence interval, 1.4 to 3.9] among the women). In both sexes, former smokers had rates of cardiovascular mortality similar to those of the participants who had never smoked, regardless of age at cessation, whereas the rates for all cancers, as well as smoking-related cancers, remained elevated among men who had once smoked. Conclusions. Our prospective findings indicate that the mortality hazards of smoking extend well into later life, and suggest that cessation will continue to improve life expectancy in older people.	NIA, DEMOG & BIOMETRY, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV IOWA, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL, NEW HAVEN, CT 06510 USA; HARVARD UNIV, SCH MED, DEPT PREVENT MED, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Iowa; Yale University; Harvard University; Harvard Medical School					NATIONAL INSTITUTE ON AGING [N01AG002106, N01AG002107, N01AG002105] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-0-2106, N01-AG-0-2105, N01-AG-0-2107] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAMSON JH, 1977, AM J MED SCI, V274, P35, DOI 10.1097/00000441-197707000-00005; AGNER E, 1985, ACTA MED SCAND, V218, P311; ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P903, DOI 10.1016/0021-9681(84)90066-3; BENFANTE RJ, 1989, J CLIN EPIDEMIOL, V42, P95, DOI 10.1016/0895-4356(89)90082-6; BEST EW, 1966, CANADIAN STUDY SMOKI; BUSH TL, 1983, AM J EPIDEMIOL, V118, P480, DOI 10.1093/oxfordjournals.aje.a113653; COLSHER PL, 1990, AM J PREV MED, V6, P61, DOI 10.1016/S0749-3797(18)31026-2; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; CUPPLES LA, 1987, NIH872703 PUBL; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; GURALNIK JM, 1989, AM J PUBLIC HEALTH, V79, P703, DOI 10.2105/AJPH.79.6.703; HAMMOND E C, 1958, J Am Med Assoc, V166, P1159; HAMMOND E. CUYLER, 1966, NAT CANCER INST MONOGR, V19, P127; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HENNEKENS CH, 1979, JAMA-J AM MED ASSOC, V242, P1973, DOI 10.1001/jama.242.18.1973; HENNEKENS CH, 1984, SMOKING AGING, P95; HENNEKENS CH, 1984, SMOKING AGING, P117; HERMANSON B, 1988, NEW ENGL J MED, V319, P1365, DOI 10.1056/NEJM198811243192101; JAJICH CL, 1984, JAMA-J AM MED ASSOC, V252, P2831, DOI 10.1001/jama.252.20.2831; KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P818; KASL SV, 1981, AGING BIOL BEHAVIOR, P345; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; Lapidus L, 1986, Scand J Prim Health Care, V4, P219, DOI 10.3109/02813438609014835; MELLSTROM D, 1982, AGE AGEING, V11, P45, DOI 10.1093/ageing/11.1.45; Mellstrom D, 1987, Compr Gerontol A, V1, P34; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P272; ROGOT E, 1974, J CHRON DIS, V27, P189, DOI 10.1016/0021-9681(74)90045-9; ROGOT E, 1974, DHEW NIH74544 PUBL; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SELTZER CC, 1989, J CLIN EPIDEMIOL, V42, P743, DOI 10.1016/0895-4356(89)90070-X; SIEGEL D, 1987, AM J EPIDEMIOL, V126, P385, DOI 10.1093/oxfordjournals.aje.a114670; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WINGARD DL, 1984, ANNU REV PUBL HEALTH, V5, P433, DOI 10.1146/annurev.pu.05.050184.002245; 1982, DHHS PHS8250179 PUBL; 1983, DHHS PHS8450204 PUBL; 1980, SUDOC HE202SM75 DEP; 1978, J CHRON DIS, V31, P651; 1989, DHHS CDC898411 PUBL; 1989, DHHS PHS891120 PUBL, V38	42	289	294	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1619	1625		10.1056/NEJM199106063242303	http://dx.doi.org/10.1056/NEJM199106063242303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	2030718	Green Published, Bronze			2022-12-28	WOS:A1991FP30700003
J	EISEN, HN				EISEN, HN			ORIGINS OF MIT INQUIRY	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					343	344		10.1038/351343a0	http://dx.doi.org/10.1038/351343a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034281				2022-12-28	WOS:A1991FN85600018
J	PAVLETICH, NP; PABO, CO				PAVLETICH, NP; PABO, CO			ZINC FINGER DNA RECOGNITION - CRYSTAL-STRUCTURE OF A ZIF268-DNA COMPLEX AT 2.1-A	SCIENCE			English	Article							TRANSCRIPTION FACTOR-IIIA; FUNCTIONAL REGIONS; BINDING DOMAINS; 5S-RNA GENE; PROTEIN; RESOLUTION; REPRESSOR; GROWTH; OPERATOR; KRUPPEL	The zinc finger DNA-binding motif occurs in many proteins that regulate eukaryotic gene expression. The crystal structure of a complex containing the three zinc fingers from Zif268 (a mouse immediate early protein) and a consensus DNA-binding site has been determined at 2.1 angstroms resolution and refined to a crystallographic R factor of 18.2 percent. In this complex, the zinc fingers bind in the major groove of B-DNA and wrap partway around the double helix. Each finger has a similar relation to the DNA and makes its primary contacts in a three-base pair subsite. Residues from the amino-terminal portion of an alpha-helix contact the bases, and most of the contacts are made with the guanine-rich strand of the DNA. This structure provides a framework for understanding how zinc fingers recognize DNA and suggests that this motif may provide a useful basis for the design of novel DNA-binding proteins.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	PAVLETICH, NP (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.		Wilson, Matthew H/K-3193-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31471] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS TH, 1988, CELL, V54, P353, DOI 10.1016/0092-8674(88)90198-5; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BEMIS LT, 1988, MOL CELL BIOL, V8, P2125, DOI 10.1128/MCB.8.5.2125; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR V21 MANUAL; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHRISTIANSON DW, 1989, J AM CHEM SOC, V111, P6412, DOI 10.1021/ja00198a065; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; JACOBS G, 1990, New Biologist, V2, P583; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; ONEIL KT, 1990, CELL, V249, P774; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, UNPUB; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WANG JC, 1990, J BIOL CHEM, V265, P6513; 1979, SERC4 DAR LAB COLL C	45	1764	1921	3	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1991	252	5007					809	817		10.1126/science.2028256	http://dx.doi.org/10.1126/science.2028256			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	2028256				2022-12-28	WOS:A1991FL12300038
J	BAILEY, CS; BUCKLEY, RJ				BAILEY, CS; BUCKLEY, RJ			EVERYDAY AIDS AND APPLIANCES - OCULAR PROSTHESES AND CONTACT-LENSES .2. CONTACT-LENSES	BRITISH MEDICAL JOURNAL			English	Article							ULCERATIVE KERATITIS; DAILY-WEAR; USERS				BAILEY, CS (corresponding author), MOORFIELDS EYE HOSP,OPHTHALMOL,LONDON EC1V 2PD,ENGLAND.							DART JKG, 1988, LANCET, V1, P1437; EFRON N, 1987, CONTAX          0705; Fick AE, 1888, ARCH OPHTHALMOL-CHIC, V17, P215; Fick AE, 1888, ARCH AUGENHEILKD, V18, P279; FRANKS WA, 1988, BRIT MED J, V297, P524, DOI 10.1136/bmj.297.6647.524; HOLDEN B A, 1988, CLAO Journal, V14, P220; PEARSON RM, 1989, SURV OPHTHALMOL, V34, P133, DOI 10.1016/0039-6257(89)90041-6; POGGIO EC, 1989, NEW ENGL J MED, V321, P779, DOI 10.1056/NEJM198909213211202; SCHEIN OD, 1989, NEW ENGL J MED, V321, P773, DOI 10.1056/NEJM198909213211201; STAPLETON F, 1989, Investigative Ophthalmology and Visual Science, V30, P166; STAPLETON F, 1990, BRIT CONTACT LENS AS	11	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1066	1069		10.1136/bmj.302.6784.1066	http://dx.doi.org/10.1136/bmj.302.6784.1066			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	2036505	Green Published, Bronze			2022-12-28	WOS:A1991FK56300028
J	MOORE, RD; KESSLER, H; RICHMAN, DD; FLEXNER, C; CHAISSON, RE				MOORE, RD; KESSLER, H; RICHMAN, DD; FLEXNER, C; CHAISSON, RE			NON-HODGKINS-LYMPHOMA IN PATIENTS WITH ADVANCED HIV-INFECTION TREATED WITH ZIDOVUDINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPSTEIN-BARR VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; KAPOSIS SARCOMA; INSITU HYBRIDIZATION; SAN-FRANCISCO; AIDS; MALIGNANCIES; TRENDS; MEN	We wished to determine the incidence of human immunodeficiency virus-related high-grade non-Hodgkin's lymphoma (NHL) and identify factors associated with the development of NHL in patients receiving zidovudine. Data are from a 2-year prospective, observational, multisite study of 1030 patients with the acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex who received zidovudine. Non-Hodgkin's lymphoma developed in 24 (2.3%) of 1030 patients who received zidovudine during 1463 person-years of follow-up (rate, 1.6 per 100 person-years of therapy). The relative hazard for development of NHL was stable throughout 2 years of therapy, with the risk of developing NHL 0.8% for each additional 6 months of therapy. Factors associated with development of NHL were a prior diagnosis of Kaposi's sarcoma, herpes simplex virus infection, or lower mean neutrophil count. Less strongly associated was a prior diagnosis of oral hairy leukoplakia or homosexual transmission of HIV. By Cox proportional hazards analysis, a prior diagnosis of Kaposi's sarcoma, cytomegalovirus disease, or oral hairy leukoplakia was most strongly associated with development of NHL. Our study demonstrates a relatively high incidence of NHL in patients with advanced human immunodeficiency virus disease who are undergoing antiretroviral therapy and suggests possible risk factors for development of NHL.	UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103; VET ADM MED CTR,SAN DIEGO,CA 92161; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT MED,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT IMMUNOL MICROBIOL,CHICAGO,IL 60612	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Johns Hopkins University; Rush University; Rush University								BASHIR RM, 1989, NEUROLOGY, V39, P813, DOI 10.1212/WNL.39.6.813; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERNSTEIN L, 1989, CANCER RES, V49, P466; DREW WL, 1988, LANCET, V1, P66; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; HARNLY ME, 1988, AM J EPIDEMIOL, V128, P261, DOI 10.1093/oxfordjournals.aje.a114966; HOLMBERG SD, 1988, LANCET, V2, P746; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; KRUEGER GRF, 1989, ANTICANCER RES, V9, P1457; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MOORE RD, IN PRESS ARCH INTERN; MURRAY RS, 1987, ANN NEUROL, V22, P155; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; RABKIN CS, 1990, LANCET, V336, P248, DOI 10.1016/0140-6736(90)91775-6; RUTHERFORD GW, 1989, J INFECT DIS, V159, P569, DOI 10.1093/infdis/159.3.569; SAFAI B, 1980, CANCER, V45, P1472, DOI 10.1002/1097-0142(19800315)45:6<1472::AID-CNCR2820450629>3.0.CO;2-A; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904; 1990, COMPREHENSIVE INFORM, P48; 1991, PHYSICIANS DESK REFE, P790; 1985, MMWR, V34, P373	22	82	82	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2208	2211		10.1001/jama.265.17.2208	http://dx.doi.org/10.1001/jama.265.17.2208			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013953				2022-12-28	WOS:A1991FH87700032
J	RAUB, WF				RAUB, WF			LONG-TERM PROPHYLAXIS EFFECTIVE AGAINST RECURRENT URINARY-TRACT INFECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, WF (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, REV INFECT DIS, V13, P77	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2173	2173		10.1001/jama.265.17.2173	http://dx.doi.org/10.1001/jama.265.17.2173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013940				2022-12-28	WOS:A1991FH87700006
J	BAILEY, CS; BUCKLEY, RJ				BAILEY, CS; BUCKLEY, RJ			EVERYDAY AIDS AND APPLIANCES - OCULAR PROSTHESES AND CONTACT-LENSES .1. COSMETIC DEVICES	BRITISH MEDICAL JOURNAL			English	Article											BAILEY, CS (corresponding author), MOORFIELDS EYE HOSP,OPHTHALMOL,LONDON EC1V 2PD,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					1010	1012		10.1136/bmj.302.6783.1010	http://dx.doi.org/10.1136/bmj.302.6783.1010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039879	Green Published, Bronze			2022-12-28	WOS:A1991FJ50800024
J	NISBET, A; KINNEAR, W; WARD, MJ				NISBET, A; KINNEAR, W; WARD, MJ			LESSON OF THE WEEK - BILATERAL DIAPHRAGMATIC PARALYSIS PRESENTING WITH ORTHOPNOEA AND APPARENT RADIOLOGICAL EVIDENCE OF PULMONARY-EMBOLISM	BRITISH MEDICAL JOURNAL			English	Article							WEAKNESS		KINGS MILL HOSP,DEPT MED,SUTTON ASHFIELD NG17 4JL,NOTTS,ENGLAND; CITY HOSP,DEPT THORAC MED,NOTTINGHAM NG5 1PB,ENGLAND	University of Nottingham								Alexander C, 1966, Clin Radiol, V17, P79, DOI 10.1016/S0009-9260(66)80128-9; COMROE JH, 1951, AM J MED, V10, P786, DOI 10.1016/0002-9343(51)90397-X; DAVIS JN, 1976, Q J MED, V45, P87; GIBSON GJ, 1989, THORAX, V44, P960, DOI 10.1136/thx.44.11.960; GRAHAM AN, 1985, THORAX, V40, P635, DOI 10.1136/thx.40.8.635; LAROCHE CM, 1988, AM REV RESPIR DIS, V138, P862, DOI 10.1164/ajrccm/138.4.862; LAROCHE CM, 1988, AM REV RESPIR DIS, V138, P472, DOI 10.1164/ajrccm/138.2.472; SPITZER SA, 1973, CHEST, V64, P355, DOI 10.1378/chest.64.3.355; STRADLING JR, 1988, THORAX, V43, P75, DOI 10.1136/thx.43.1.75; THOMAS NE, 1984, AM REV RESPIR DIS, V129, P507	10	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					954	955		10.1136/bmj.302.6782.954	http://dx.doi.org/10.1136/bmj.302.6782.954			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032039	Bronze, Green Published			2022-12-28	WOS:A1991FH48700026
J	JACOBS, MG; BROOK, MG; WEIR, WRC; BANNISTER, BA				JACOBS, MG; BROOK, MG; WEIR, WRC; BANNISTER, BA			DENGUE HEMORRHAGIC-FEVER - A RISK OF RETURNING HOME	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP,DEPT INFECT & TROP DIS,COPPETTS WOOD UNIT,LONDON N10,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								HALSTEAD SB, 1969, AM J TROP MED HYG, V18, P984, DOI 10.4269/ajtmh.1969.18.984; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; RISDALL RJ, 1979, CANCER, V44, P993, DOI 10.1002/1097-0142(197909)44:3<993::AID-CNCR2820440329>3.0.CO;2-5; SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30; 1986, DENGUE HAEMORRHAGIC	5	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					828	829		10.1136/bmj.302.6780.828	http://dx.doi.org/10.1136/bmj.302.6780.828			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025706	Green Published, Bronze			2022-12-28	WOS:A1991FF37700026
J	DAVIES, MJ; WILSON, RG; KESTON, M; NIXON, SJ				DAVIES, MJ; WILSON, RG; KESTON, M; NIXON, SJ			AN IMPLANTABLE DEVICE FOR LONG-TERM VENOUS ACCESS IN CHRONIC LUNG CONDITIONS	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,SURG UNIT,D BLOCK,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh								BALL ABS, 1989, RESP MED, V83, P429, DOI 10.1016/S0954-6111(89)80076-9; CASSEY J, 1988, CLIN PEDIATR, V27, P91, DOI 10.1177/000992288802700206; GEBARSKI SS, 1984, CANCER, V54, P38, DOI 10.1002/1097-0142(19840701)54:1<38::AID-CNCR2820540110>3.0.CO;2-9; THOMPSON AM, 1989, INTENSIVE THERAP MAY, P142	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					570	571		10.1136/bmj.302.6776.570	http://dx.doi.org/10.1136/bmj.302.6776.570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021722	Green Published, Bronze			2022-12-28	WOS:A1991FB93600021
J	KEMP, JS; THACH, BT				KEMP, JS; THACH, BT			SUDDEN-DEATH IN INFANTS SLEEPING ON POLYSTYRENE-FILLED CUSHIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COT DEATH; HONG-KONG; AROUSAL; RESPONSES; MECHANISM; POSITION; SIDS	Background. Infants are at risk for both the sudden infant death syndrome (SIDS) and accidental suffocation. On postmortem examination, however, it is difficult to distinguish one from the other without information from the scene of death. Healthy infants are assumed to be able to turn their heads and, if not otherwise restrained, to obtain fresh air. We assessed this assumption in an investigation of infant deaths that occurred during sleep on cushions filled with polystyrene beads. Methods. We obtained data on 25 deaths from the U.S. Consumer Product Safety Commission. We also used mechanical and animal models to study physiologic aspects of ventilation relevant to these results, by simulating the effects on an infant of breathing into a cushion. We measured the effects of softness, malleability (molding of the cushion about an infant's head), airflow resistance, and rebreathing of expired gases. Results. All 25 study infants were prone when found dead, and at least 88 percent were face down with nose and mouth obstructed by the cushion. SIDS was the diagnosis in 19 of the 23 infants who underwent autopsy. Our findings show, however, that the cushion would have limited movement of the infant's head to obtain fresh air, and the amount of rebreathing we estimated to have occurred in the infants was lethal in a rabbit model. Conclusions. Accidental suffocation by rebreathing was the most likely cause of death in most of the 25 infants studied. Consequently, there is a need to reassess the cause of death in the 28 to 52 percent of the victims of SIDS who are found with their faces straight down. Safety regulations setting standards for softness, malleability, and the potential for rebreathing are needed for infant bedding.	WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, DIV PULM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, DIV NEWBORN MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NICHD NIH HHS [HD-10993] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD010993, R01HD010993] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADELSON L, 1956, PEDIATRICS, V17, P663; BASS M, 1986, NEW ENGL J MED, V315, P100, DOI 10.1056/NEJM198607103150206; Batchelor G.K., 1967, INTRO FLUID DYNAMICS, P233; BECKWITH JB, 1988, ANN NY ACAD SCI, V533, P37, DOI 10.1111/j.1749-6632.1988.tb37232.x; BECKWITH JB, 1967, HOSP PRACT, V2, P44; BECKWITH JB, 1988, SUDDEN INFANT DEATH, P48; BOWDEN K, 1950, Med J Aust, V1, P65; CAMPS FE, 1970, SUDDEN UNEXPECTED DE, P1; DAVIES DP, 1985, LANCET, V2, P1346; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; EMERY JL, 1970, SUDDEN UNEXPECTED DE, P124; FEWELL JE, 1989, J DEV PHYSIOL, V11, P77; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GESELL A, 1934, INFANT BEHAV, P61; GOLIN M, 1959, JAMA-J AM MED ASSOC, V169, P2021; GORDON I, 1982, FORENSIC MED GUIDE P, P31; GUGGER M, 1989, AM REV RESPIR DIS, V140, P1301, DOI 10.1164/ajrccm/140.5.1301; GUNTHEROTH WG, 1989, CRIB DEATH SUDDEN IN, P21; HATCH DJ, 1982, ARCH DIS CHILD, V57, P443, DOI 10.1136/adc.57.6.443; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; HUNT CE, 1981, J APPL PHYSIOL, V50, P1313, DOI 10.1152/jappl.1981.50.6.1313; ILLINGWORTH RS, 1980, DEV INFANT YOUNG CHI, P117; Jones A M, 1976, J Forensic Sci, V21, P833; KEMP J, 1990, PEDIATR RES, V27, pA358; KRAUS JF, 1985, PUBLIC HEALTH REP, V100, P231; KROUS HF, 1988, SUDDEN INFANT DEATH, P18; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; MCGLASHAN ND, 1988, LANCET, V2, P106; MOUNTCASTLE VB, 1980, MED PHYSL, P1369; NELSON EAS, 1989, AUST PAEDIATR J, V25, P202; PETERSON DR, 1988, ANN NY ACAD SCI, V533, P6, DOI 10.1111/j.1749-6632.1988.tb37229.x; PHILLIPSON EA, 1978, AM REV RESPIR DIS, V118, P807; POLSON CJ, 1985, ESSENTIALS FORENSIC, P583; SMIALEK J E, 1988, Pediatrician, V15, P191; Sturner W Q, 1976, J Forensic Sci, V21, P483; STURNER WQ, 1977, FORENSIC MED, V2, P1015; SULLIVAN CE, 1979, J APPL PHYSIOL, V47, P1304, DOI 10.1152/jappl.1979.47.6.1304; TAN S, 1989, PEDIATR RES, V25, pA328; THACH BT, 1988, ANN NY ACAD SCI, V533, P314, DOI 10.1111/j.1749-6632.1988.tb37261.x; VALDESDAPENA MA, 1967, PEDIATRICS, V39, P123; WINN K, 1986, Pediatric Pathology, V5, P325; WOOLLEY PV, 1945, J PEDIATR-US, V26, P572, DOI 10.1016/S0022-3476(45)80085-9; 1990, FED REGISTER, V55, P42202; 1970, BS4578 BRIT STAND I	44	132	137	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1858	1864		10.1056/NEJM199106273242605	http://dx.doi.org/10.1056/NEJM199106273242605			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	2041551				2022-12-28	WOS:A1991FT58000005
J	MCGEE, S				MCGEE, S			RESTLESS LEGS SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DOUBLE-BLIND; PERIODIC MOVEMENTS; SLEEP				MCGEE, S (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195, USA.							AKPINAR S, 1987, CLIN NEUROPHARMACOL, V10, P69; BRODEUR C, 1988, NEUROLOGY, V38, P1845, DOI 10.1212/WNL.38.12.1845; CLOUGH C, 1987, BRIT MED J, V294, P262, DOI 10.1136/bmj.294.6567.262; EKBOM KA, 1970, HDB CLIN NEUROLOGY, V8, P311; GIBB WRG, 1986, POSTGRAD MED J, V62, P329, DOI 10.1136/pgmj.62.727.329; KRUEGER BR, 1990, MAYO CLIN PROC, V65, P999, DOI 10.1016/S0025-6196(12)65163-5; MONTAGNA P, 1984, ACTA NEUROL SCAND, V69, P428, DOI 10.1111/j.1600-0404.1984.tb07826.x; TELSTAD W, 1984, BRIT MED J, V288, P444, DOI 10.1136/bmj.288.6415.444; VONSCHEELE C, 1986, LANCET, V2, P426; WALTERS AS, 1988, ANN NEUROL, V24, P455, DOI 10.1002/ana.410240318	10	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					3014	3014		10.1001/jama.265.22.3014	http://dx.doi.org/10.1001/jama.265.22.3014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033777				2022-12-28	WOS:A1991FP63500044
J	DAVANZO, J; PARNELL, AM; FOEGE, WH				DAVANZO, J; PARNELL, AM; FOEGE, WH			HEALTH CONSEQUENCES OF CONTRACEPTIVE USE AND REPRODUCTIVE PATTERNS - SUMMARY OF A REPORT FROM THE UNITED-STATES NATIONAL-RESEARCH-COUNCIL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY		RAND CORP,SANTA MONICA,CA 90406; DUKE UNIV,DEPT SOCIOL,DURHAM,NC 27706; EMORY UNIV,CARTER CTR,ATLANTA,GA 30322; NATL RES COUNCIL,COMM POPULAT,WASHINGTON,DC 20418	RAND Corporation; Duke University; Emory University; National Academies of Sciences, Engineering & Medicine								HAAGA J, 1989, CONTRACEPTION REPROD, V2; HOBCRAFT J, 1987, OCT INT C BETT HLTH; KWAST BE, 1986, STUD FAMILY PLANN, V17, P288, DOI 10.2307/1966906; SCRIMSHAW SCM, 1978, POPUL DEV REV, V4, P383, DOI 10.2307/1972856; 1989, CONTRACEPTION REPROD	6	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2692	2696						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL989	2023350				2022-12-28	WOS:A1991FL98900034
J	KINMONTH, AL; LAZOVSKIS, J				KINMONTH, AL; LAZOVSKIS, J			LETTER FROM LATVIA - SURVIVING SURVEILLANCE	BRITISH MEDICAL JOURNAL			English	Article									POLYCLIN CESVAINE,CESVAINE,LATVIA,USSR		KINMONTH, AL (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,SOUTHAMPTON SO1 6ST,ENGLAND.							HARTDAVIS R, 1976, AUTOBIOGRAPHY A RANS; RYAN M, 1984, BRIT MED J, V288, P381, DOI 10.1136/bmj.288.6414.381; VANDERPOST L, 1964, JOURNEY RUSSIA	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1192	1194		10.1136/bmj.302.6786.1192	http://dx.doi.org/10.1136/bmj.302.6786.1192			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043818	Bronze, Green Published			2022-12-28	WOS:A1991FN04500026
J	KESTLER, HW; RINGLER, DJ; MORI, K; PANICALI, DL; SEHGAL, PK; DANIEL, MD; DESROSIERS, RC				KESTLER, HW; RINGLER, DJ; MORI, K; PANICALI, DL; SEHGAL, PK; DANIEL, MD; DESROSIERS, RC			IMPORTANCE OF THE NEF GENE FOR MAINTENANCE OF HIGH VIRUS LOADS AND FOR DEVELOPMENT OF AIDS	CELL			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; OPEN READING FRAME; RHESUS-MONKEYS; PERSISTENT INFECTION; MUTATIONAL ANALYSIS; MACAQUE MONKEYS; HTLV-III; SOR GENE; TYPE-1; PROTEIN	When rhesus monkeys were infected with a form of cloned SIVmac239 having a premature stop signal at the 93rd codon of nef, revertants with a coding codon at this position quickly and universally came to predominate in the infected animals. This suggests that there are strong selective forces for open functional forms of nef in vivo. Although deletion of nef sequences had no detectable effect on virus replication in cultured cells, deletion of nef sequences dramatically altered the properties of virus in infected rhesus monkeys. Our results indicate that nef is required for maintaining high virus loads during the course of persistent infection in vivo and for full pathologic potential. Thus, nef should become a target for antiviral drug development. Furthermore, the properties of virus with a deletion in nef suggest a means for making live-attenuated strains of virus for experimental vaccine testing.	APPLIED BIOTECHNOL,CAMBRIDGE,MA 02142		KESTLER, HW (corresponding author), HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,SOUTHBOROUGH,MA 01772, USA.			Mori, Kazuyasu/0000-0002-1841-6376	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025328, R37AI025328] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00168] Funding Source: Medline; NIAID NIH HHS [AI25328] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; ALLAN JS, 1985, SCIENCE, V230, P810, DOI 10.1126/science.2997921; ARMSTRONG JA, 1984, LANCET, V2, P370; BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; CHALIFOUX LV, 1987, AM J PATHOL, V128, P104; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; COHEN EA, 1988, NATURE, V334, P532, DOI 10.1038/334532a0; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; CULLEN BR, 1990, VIROLOGY, V178, P1, DOI 10.1016/0042-6822(90)90373-Y; DANIEL MD, 1987, J GEN VIROL, V68, P3183, DOI 10.1099/0022-1317-68-12-3183; DANIEL MD, 1988, J VIROL, V62, P4123, DOI 10.1128/JVI.62.11.4123-4128.1988; DESROSIERS RC, 1981, J GEN VIROL, V56, P119, DOI 10.1099/0022-1317-56-1-119; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; GUYADER M, 1989, EMBO J, V8, P1169, DOI 10.1002/j.1460-2075.1989.tb03488.x; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KAMINCHIK J, 1990, J VIROL, V64, P3447, DOI 10.1128/JVI.64.7.3447-3454.1990; KAMINCHIK J, 1991, J VIROL, V65, P583, DOI 10.1128/JVI.65.2.583-588.1991; KANNAGI M, 1985, P NATL ACAD SCI USA, V82, P7053, DOI 10.1073/pnas.82.20.7053; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1988, NATURE, V331, P619, DOI 10.1038/331619a0; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; MALIM MH, 1989, P NATL ACAD SCI USA, V86, P8222, DOI 10.1073/pnas.86.21.8222; MILMAN G, 1981, SOMAT CELL GENET, V7, P161; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P8219, DOI 10.1093/nar/13.22.8219; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; RINGLER DJ, 1989, AM J PATHOL, V134, P373; SAKAI H, 1990, J VIROL, V64, P2202, DOI 10.1128/JVI.64.5.2202-2207.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TERWILLIGER E, 1986, J VIROL, V60, P754, DOI 10.1128/JVI.60.2.754-760.1986; VIGLIANTI GA, 1990, J VIROL, V64, P4207, DOI 10.1128/JVI.64.9.4207-4216.1990; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329; ZWEIG M, 1990, VIROLOGY, V179, P504, DOI 10.1016/0042-6822(90)90325-L	49	1496	1524	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					651	662		10.1016/0092-8674(91)90097-I	http://dx.doi.org/10.1016/0092-8674(91)90097-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032289				2022-12-28	WOS:A1991FM03700015
J	PHILPOTT, A; LENO, GH; LASKEY, RA				PHILPOTT, A; LENO, GH; LASKEY, RA			SPERM DECONDENSATION IN XENOPUS EGG CYTOPLASM IS MEDIATED BY NUCLEOPLASMIN	CELL			English	Article							NUCLEOSOME ASSEMBLY INVITRO; HEN ERYTHROCYTE NUCLEI; CELL-FREE PREPARATIONS; PRONUCLEAR FORMATION; RABBIT SPERMATOZOA; HISTONE COMPLEXES; DNA-REPLICATION; LAEVIS OOCYTES; ACIDIC PROTEIN; SOMATIC CELLS	At fertilization, sperm chromatin decondenses in two stages, which can be mimicked in extracts of Xenopus eggs. Rapid, limited decondensation is followed by slower, membrane-dependent decondensation and swelling. Nucleoplasmin, an acidic nuclear protein, occurs at high concentration in Xenopus eggs and has a histone-binding role in nucleosome assembly. Immunodepleting nucleoplasmin from egg extracts inhibits the initial rapid stage of sperm decondensation, and also the decondensation of myeloma nuclei, relative to controls of mock depletion and TFIIIA depletion. Readdition of purified nucleoplasmin recues depleted extracts. A physiological concentration of purified nucleoplasmin alone decondenses both sperm and myeloma nuclei. We conclude that nucleoplasmin is both necessary and sufficient for the first stage of sperm decondensation in Xenopus eggs.	UNIV CAMBRIDGE, DEPT ZOOL, CANC RES CAMPAIGN, MOLEC EMBRYOL GRP, CAMBRIDGE CB2 3EJ, ENGLAND	CRUK Cambridge Institute; University of Cambridge				Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRY JM, 1972, EXP CELL RES, V71, P90, DOI 10.1016/0014-4827(72)90267-4; BEDFORD JM, 1974, J EXP ZOOL, V188, P137, DOI 10.1002/jez.1401880203; BERRIOS M, 1990, EXP CELL RES, V191, P64, DOI 10.1016/0014-4827(90)90036-A; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Calvin H. I, 1971, Journal Reprod Fertil, VNo. 13, P65; COTTEN M, 1987, EMBO J, V6, P3945, DOI 10.1002/j.1460-2075.1987.tb02736.x; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; GLEDHILL BL, 1972, EXP CELL RES, V73, P33, DOI 10.1016/0014-4827(72)90098-5; GRAHAM CF, 1966, DEV BIOL, V14, P349, DOI 10.1016/0012-1606(66)90020-0; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1968, J EMBRYOL EXP MORPH, V20, P401; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNTER RHF, 1967, J EXP ZOOL, V165, P451, DOI 10.1002/jez.1401650313; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; JOHNSON RT, 1970, J CELL PHYSIOL, V76, P151, DOI 10.1002/jcp.1040760204; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; LAMBERT SF, 1986, EUR J BIOCHEM, V160, P191, DOI 10.1111/j.1432-1033.1986.tb09957.x; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1983, PHILOS T ROY SOC B, V302, P143, DOI 10.1098/rstb.1983.0047; LEAKE RE, 1972, EXP CELL RES, V71, P17, DOI 10.1016/0014-4827(72)90257-1; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; LOHKA MJ, 1983, EXP CELL RES, V148, P481, DOI 10.1016/0014-4827(83)90169-6; Longo F.J., 1978, Current Topics in Developmental Biology, V12, P149, DOI 10.1016/S0070-2153(08)60596-7; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; POGANY GC, 1981, EXP CELL RES, V136, P127, DOI 10.1016/0014-4827(81)90044-6; SAWICKI W, 1971, EXP CELL RES, V66, P145, DOI 10.1016/S0014-4827(71)80022-8; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; THANDANI VM, 1979, J EXP ZOOL, V210, P161; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULITZUR N, 1989, FEBS LETT, V259, P113, DOI 10.1016/0014-5793(89)81507-8; WOLFFE AP, 1989, NUCLEIC ACIDS RES, V17, P767, DOI 10.1093/nar/17.2.767; ZELENIN AV, 1974, CELL DIFFER DEV, V3, P95, DOI 10.1016/0045-6039(74)90031-1	43	248	256	1	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					569	578		10.1016/0092-8674(91)90089-H	http://dx.doi.org/10.1016/0092-8674(91)90089-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032284				2022-12-28	WOS:A1991FM03700007
J	STEENLAND, K; STAYNER, L; GREIFE, A; HALPERIN, W; HAYES, R; HORNUNG, R; NOWLIN, S				STEENLAND, K; STAYNER, L; GREIFE, A; HALPERIN, W; HAYES, R; HORNUNG, R; NOWLIN, S			MORTALITY AMONG WORKERS EXPOSED TO ETHYLENE-OXIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SISTER-CHROMATID EXCHANGES; COHORT; CANCER	Background. Ethylene oxide is a sterilant gas that causes leukemia and other cancers in animals. Studies in Sweden have shown an excess of leukemia and stomach cancer in humans exposed to ethylene oxide, but other studies have generally failed to confirm these findings. Methods. We conducted a study of mortality in 18,254 U.S. workers exposed to ethylene oxide at 14 plants producing sterilized medical supplies and spices. The subjects averaged 4.9 years of exposure to the gas and 16 years of follow-up. The exposure levels in recent years averaged 4.3 ppm (eight-hour time-weighted adjusted exposure) for sterilizer operators and 2.0 ppm for other workers. The levels in earlier years are likely to have been several times higher. Mortality in this cohort was compared with that in the general U.S. population. Results. Overall there was no significant increase in mortality from any cause in the study cohort. The standardized mortality ratios (SMRs) were 0.97 for leukemia (95 percent confidence interval, 0.52 to 1.67; 13 deaths observed), 1.06 for all hematopoietic cancers (95 percent confidence interval, 0.75 to 1.47; 36 deaths), and 0.94 for stomach cancer (95 percent confidence interval, 0.45 to 1.70; 11 deaths). Analyses according to job category and according to the duration of exposure showed no excess in cancers, as compared with the rate in the general population, but there was a significant trend toward increased mortality with increasing lengths of time since the first exposure for all hematopoietic cancers. The rate of death from hematopoietic cancer (especially non-Hodgkin's lymphoma) was significantly increased among men (SMR, 1.55; 27 deaths). Mortality from leukemia in recent years (1985 through 1987) was significantly increased among men (SMR, 3.45; 5 deaths). Conclusions. For the entire cohort, there was no increase in mortality from hematopoietic cancer. There was a slight but significant increase among men, however. Among men and women combined, there was a trend toward an increased risk of death from hematopoietic cancer with increasing lengths of time since the first exposure to ethylene oxide.	NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	STEENLAND, K (corresponding author), NIOSH,R-13,4676 COLUMBIA PKWY,CINCINNATI,OH 45226, USA.							AXELSON O, 1988, AM J IND MED, V13, P105, DOI 10.1002/ajim.4700130107; BRESLOW NE, 1983, J AM STAT ASSOC, V78, P1, DOI 10.2307/2287093; CHECKOWAY H, 1990, ARCH ENVIRON HEALTH, V45, P95, DOI 10.1080/00039896.1990.9935932; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; GALLOWAY SM, 1986, MUTAT RES, V170, P55, DOI 10.1016/0165-1218(86)90082-0; GARDNER MJ, 1989, BRIT J IND MED, V46, P860; GARRY VF, 1979, ENVIRON MUTAGEN, V1, P375, DOI 10.1002/em.2860010410; GREENBERG HL, 1990, BRIT J IND MED, V47, P221; HOGSTEDT C, 1986, JAMA-J AM MED ASSOC, V255, P1575, DOI 10.1001/jama.255.12.1575; HOGSTEDT C, 1979, JAMA-J AM MED ASSOC, V241, P1132, DOI 10.1001/jama.241.11.1132; HOGSTEDT C, 1979, BRIT J IND MED, V36, P276; HOGSTEDT C, 1988, INT AGENCY RES CANCE, V89, P265; KIESSELBACH N, 1990, BRIT J IND MED, V47, P182; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; LAURENT C, 1984, INT ARCH OCC ENV HEA, V54, P33, DOI 10.1007/BF00378726; LYNCH DW, 1984, TOXICOL APPL PHARM, V76, P69, DOI 10.1016/0041-008X(84)90030-9; MORGAN RW, 1981, J OCCUP ENVIRON MED, V23, P767, DOI 10.1097/00043764-198111000-00011; PATTERSON BH, 1986, J NATL CANCER I, V77, P877; RICHMOND GW, 1985, ARCH ENVIRON HEALTH, V40, P20, DOI 10.1080/00039896.1985.10545884; ROTHMAN KJ, 1979, NIH791649 PUBL; SARTO F, 1984, MUTAT RES, V138, P185, DOI 10.1016/0165-1218(84)90043-0; SNELLINGS WM, 1984, TOXICOL APPL PHARM, V75, P105, DOI 10.1016/0041-008X(84)90081-4; STEENLAND K, 1990, J OCCUP ENVIRON MED, V32, P1091, DOI 10.1097/00043764-199011000-00008; STEENLAND K, 1987, AM J IND MED, V12, P419, DOI 10.1002/ajim.4700120407; STOLLEY PD, 1984, MUTAT RES, V129, P89, DOI 10.1016/0027-5107(84)90127-1; THIESS A, 1982, OCCUPATIONAL SAFETY, V46, P249; YAGER JW, 1983, SCIENCE, V219, P1221, DOI 10.1126/science.6828851; 1985, NIH TECHNICAL REPORT, V275; 1987, NIH882582 NAT TOX PR; 1985, IARC MONOGRAPHS S7, V1; 1988, ETHYLENE OXIDE; 1990, DHHS NIOSH89102 NAT	32	94	95	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1402	1407		10.1056/NEJM199105163242004	http://dx.doi.org/10.1056/NEJM199105163242004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020295				2022-12-28	WOS:A1991FL12500004
J	GRISSO, JA; KELSEY, JL; STROM, BL; CHIU, GY; MAISLIN, G; OBRIEN, LA; HOFFMAN, S; KAPLAN, F				GRISSO, JA; KELSEY, JL; STROM, BL; CHIU, GY; MAISLIN, G; OBRIEN, LA; HOFFMAN, S; KAPLAN, F			RISK-FACTORS FOR FALLS AS A CAUSE OF HIP FRACTURE IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POST-MENOPAUSAL WOMEN; ELDERLY WOMEN; NHANES-I; OSTEOPOROSIS; WEIGHT; FEMUR; ESTROGENS	Background. Although even in the elderly most falls are not associated with fractures, over 90 percent of hip fractures are the result of a fall. Few studies have assessed whether the risk factors for falls are also important risk factors for hip fracture. Methods. To examine the importance of risk factors for falls in the epidemiology of hip fracture, we performed a case-control study of 174 women (median age, 80 years) admitted with a first hip fracture to 1 of 30 hospitals in New York and Philadelphia. Controls, matched to the case patients according to age and hospital, were selected from general surgical and orthopedic surgical hospital services. Information was obtained by direct interview. Results. As measured by the odds ratio, increased risks for hip fracture were associated with lower-limb dysfunction (odds ratio = 1.7; 95 percent confidence interval, 1.1 to 2.8), visual impairment (odds ratio = 5.1; 95 percent confidence interval, 1.9 to 13.9), previous stroke (odds ratio = 2.0; 95 percent confidence interval, 1.0 to 4.0), Parkinson's disease (odds ratio = 9.4; 95 percent confidence interval, 1.2 to 76.1), and use of long-acting barbiturates (odds ratio = 5.2; 95 percent confidence interval, 0.6 to 45.0). Of the controls, 44 (25 percent) had had a recent fall. The case patients were more likely than these controls to have fallen from a standing height or higher (odds ratio = 2.4; 95 percent confidence interval, 1.0 to 5.7). Of those with hip fracture the younger patients (< 75 years old) were more likely than the older ones (greater-than-or-equal-to 75 years old) to have fallen on a hard surface (odds ratio = 1.9; 95 percent confidence interval, 1.04 to 3.7). Conclusions. A number of factors that have been identified as risk factors for falls are also associated with hip fracture, including lower-limb dysfunction, neurologic conditions, barbiturate use, and visual impairment. Given the prevalence of these problems among the elderly, who are at highest risk, programs to prevent hip fracture should include measures to prevent falls in addition to measures to slow bone loss.	COLUMBIA UNIV,DIV EPIDEMIOL,NEW YORK,NY 10027; HOSP UNIV PENN,DEPT ORTHOPED,PHILADELPHIA,PA 19104	Columbia University; University of Pennsylvania; Pennsylvania Medicine	GRISSO, JA (corresponding author), UNIV PENN,SCH MED,CLIN EPIDEMIOL UNIT,GEN INTERNAL MED SECT,317R NURSING EDUC BLDG,420 SERV DR,PHILADELPHIA,PA 19104, USA.		Maislin, Greg/S-5322-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035409] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR35409] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALFFRAM PER-AXEL, 1964, ACTA ORTHOPAED SCAND SUPPL, V65, P1; BASTOW MD, 1983, LANCET, V1, P143; BRESLOW NE, 1980, IARC SCI PUBL, V32, P373; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492; CLARK ANG, 1968, GERONTOL CLIN, V10, P257, DOI 10.1159/000245191; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; FARMER ME, 1989, J AM GERIATR SOC, V37, P9, DOI 10.1111/j.1532-5415.1989.tb01562.x; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x; FLOREY CDV, 1970, J CHRON DIS, V23, P93; HERZOG AR, 1988, J GERONTOL, V43, pS200, DOI 10.1093/geronj/43.6.S200; HUTCHINSON TA, 1979, LANCET, V2, P705; KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326; KAYE JM, 1990, GERONTOLOGIST, V30, P100, DOI 10.1093/geront/30.1.100; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KOLLER WC, 1989, CLIN NEUROPHARMACOL, V12, P98; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LOTZ JC, 1990, J BONE JOINT SURG AM, V72A, P689, DOI 10.2106/00004623-199072050-00008; MELTON LJ, 1987, OSTEOPOROTIC SYNDROM, P45; MICOZZI MS, 1986, AM J CLIN NUTR, V44, P725, DOI 10.1093/ajcn/44.6.725; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RESNICK NM, 1989, JAMA-J AM MED ASSOC, V261, P1025, DOI 10.1001/jama.261.7.1025; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; Schlesselman JJ, 1982, CASE CONTROL STUDIES; TAGGART HM, 1988, J AM GERIATR SOC, V36, P1006, DOI 10.1111/j.1532-5415.1988.tb04367.x; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; WALLACE RB, 1987, PHS881214 DEP HLTH H, P423; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695; WOOTTON R, 1979, CLIN SCI, V57, P93, DOI 10.1042/cs0570093; Wootton R, 1982, Age Ageing, V11, P160, DOI 10.1093/ageing/11.3.160; WYSHAK G, 1981, J GERONTOL, V36, P424, DOI 10.1093/geronj/36.4.424; [No title captured]	41	644	665	1	42	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1326	1331		10.1056/NEJM199105093241905	http://dx.doi.org/10.1056/NEJM199105093241905			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK186	2017229				2022-12-28	WOS:A1991FK18600005
J	TRUNKEY, D				TRUNKEY, D			CURRENT CONCEPTS - INITIAL TREATMENT OF PATIENTS WITH EXTENSIVE TRAUMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BLUNT ABDOMINAL-TRAUMA; PERITONEAL LAVAGE; AIR-EMBOLISM; EMERGENCY; CARE				TRUNKEY, D (corresponding author), OREGON HLTH SCI UNIV,SCH MED,DEPT SURG,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.							BAKER CC, 1980, J TRAUMA, V20, P848, DOI 10.1097/00005373-198010000-00005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BIVINS BA, 1978, AM SURGEON, V44, P637; GERE M, 1990, RESOURCES OPTIMAL CA, P15; GILDENBERG PL, 1985, TRAUMA CENTRAL NERVO, P79; JACOBS LM, 1983, JAMA-J AM MED ASSOC, V250, P2175, DOI 10.1001/jama.250.16.2175; LOONG ED, 1981, ANAESTH INTENS CARE, V9, P371, DOI 10.1177/0310057X8100900409; OLSEN WR, 1971, J TRAUM, V11, P824, DOI 10.1097/00005373-197110000-00002; SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003; SHAPIRO M, 1976, S AFR MED J, V50, P105; TARYLE DA, 1979, CHEST, V75, P541, DOI 10.1378/chest.75.5.541; THOMAS AN, 1974, J TRAUMA, V14, P633, DOI 10.1097/00005373-197408000-00001; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28; WEST JG, 1988, TRAUMA, P79; YEE ES, 1983, J THORAC CARDIOV SUR, V85, P661; 1989, ADV TRAUMA LIFE SUPP; 1980, ABBREVIATED INJURY S	17	56	59	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1259	1263						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	2014038				2022-12-28	WOS:A1991FJ82300006
J	VANARSDEL, PP				VANARSDEL, PP			ALLERGY TO CEPHALOSPORINS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											VANARSDEL, PP (corresponding author), UNIV WASHINGTON,MED CTR,SEATTLE,WA 98195, USA.							FISHER AA, 1986, CONTACT DERMATITIS, P240; PETZ LD, 1978, J INFECT DIS, V137, pS74, DOI 10.1093/infdis/137.Supplement.S74; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SOGN D D, 1990, Journal of Allergy and Clinical Immunology, V85, P191; VANARSDEL P P JR, 1990, Journal of Allergy and Clinical Immunology, V85, P188; VANARSDEL PP, 1986, WESTERN J MED, V144, P311	6	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2254	2254		10.1001/jama.265.17.2254	http://dx.doi.org/10.1001/jama.265.17.2254			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013960				2022-12-28	WOS:A1991FH87700043
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - CHECKING FOR FETAL WELLBEING .1.	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.							WESTERGAARD JG, 1985, BRIT J OBSTET GYNAEC, V92, P77, DOI 10.1111/j.1471-0528.1985.tb01052.x	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					837	839		10.1136/bmj.302.6780.837	http://dx.doi.org/10.1136/bmj.302.6780.837			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025709	Bronze, Green Published			2022-12-28	WOS:A1991FF37700030
J	HENNIGAN, TW; FRANKS, PJ; HOCKEN, DB; ALLENMERSH, TG				HENNIGAN, TW; FRANKS, PJ; HOCKEN, DB; ALLENMERSH, TG			INFLUENCE OF UNDERGRADUATE TEACHING ON MEDICAL-STUDENTS ATTITUDES TO RECTAL EXAMINATION	BRITISH MEDICAL JOURNAL			English	Article											HENNIGAN, TW (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON W6 8RF,ENGLAND.		Franks, Peter J/G-3592-2013	Franks, Peter J/0000-0002-9782-0181				HENNIGAN TW, 1990, BRIT MED J, V301, P478, DOI 10.1136/bmj.301.6750.478; [No title captured]	2	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					829	829		10.1136/bmj.302.6780.829	http://dx.doi.org/10.1136/bmj.302.6780.829			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FF377	2025707	Green Published, Bronze			2022-12-28	WOS:A1991FF37700027
J	NEWMAN, A; NORMAN, C				NEWMAN, A; NORMAN, C			MUTATIONS IN YEAST U5 SNRNA ALTER THE SPECIFICITY OF 5' SPLICE-SITE CLEAVAGE	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER RNA; U1 SNRNA; HOST STRAINS; TACTAAC BOX; PROTEIN; DNA; IDENTIFICATION; REQUIREMENTS; RECOGNITION	Recognition of 5' splice sites in pre-mRNA splicing is achieved in part by base pairing with U1 snRNA. We have used interactive suppression in the yeast Saccharomyces cerevisiae to look for other factors involved in 5' splice-site recognition. This approach identified an extragenic suppressor that activates a cryptic 5' splice site. The suppressor is a gene for U5 snRNA (snR7) with a single base mutation in a strictly conserved 9 base sequence. This suggests that U5 snRNA can play a part in determining the position of 5' splice-site cleavage. Consistent with this, we have been able to isolate other mutations in the 9 base element in U5 snRNA that specifically activate a second cryptic 5' splice site nearby.			NEWMAN, A (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; Green MR, 1989, CURR OPIN CELL BIOL, V1, P519, DOI 10.1016/0955-0674(89)90014-8; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUTENBERGER JA, 1987, GENE ANAL TECH, V4, P87, DOI 10.1016/0735-0651(87)90001-X; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; Miller J.H., 1972, EXPT MOL GENETICS; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PERELMAN D, 1990, MOL CELL BIOL, V10, P3284, DOI 10.1128/MCB.10.6.3284; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; VIJAYRAGHAVAN U, 1989, NUCLEIC ACIDS MOL BI, V3, P197; WHITTAKER E, 1990, P NATL ACAD SCI USA, V87, P2216, DOI 10.1073/pnas.87.6.2216; WINKELMANN G, 1989, EMBO J, V8, P3105, DOI 10.1002/j.1460-2075.1989.tb08462.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	47	188	208	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					115	123		10.1016/0092-8674(91)90413-S	http://dx.doi.org/10.1016/0092-8674(91)90413-S			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013092	Bronze			2022-12-28	WOS:A1991FF77300014
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - THE CHANGING BODY IN PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.							HYTTEN F, CLIN PHYSL OBSTETRIC; RIGG LA, 1977, AM J OBSTET GYNECOL, V129, P454, DOI 10.1016/0002-9378(77)90594-4	2	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					719	722		10.1136/bmj.302.6778.719	http://dx.doi.org/10.1136/bmj.302.6778.719			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	2021747	Bronze, Green Published			2022-12-28	WOS:A1991FE33300032
J	URQUHART, JD; BLACK, RJ; MUIRHEAD, MJ; SHARP, L; MAXWELL, M; EDEN, OB; JONES, DA				URQUHART, JD; BLACK, RJ; MUIRHEAD, MJ; SHARP, L; MAXWELL, M; EDEN, OB; JONES, DA			CASE-CONTROL STUDY OF LEUKEMIA AND NON-HODGKINS-LYMPHOMA IN CHILDREN IN CAITHNESS NEAR THE DOUNREAY NUCLEAR INSTALLATION	BRITISH MEDICAL JOURNAL			English	Article							MAGNETIC-FIELDS; LEUKEMIA; EXPOSURE; CANCER	Objective-To examine whether the observed excess of childhood leukaemia and non-Hodgkin's lymphoma in the area around the Dounreay nuclear installation is associated with established risk factors, or with factors related to the plant, or with parental occupation in the nuclear industry. Design-Case-control study. Setting-Caithness local government district. Subjects-14 cases of leukaemia and non-Hodgkin's lymphoma occurring in children aged under 15 years diagnosed in the area between 1970 and 1986 and 55 controls matched for sex, date of birth, and area of residence within Caithness at time of birth. Main outcome measures-Antenatal abdominal x ray examination; drugs taken and viral infections during pregnancy; father's occupation; father's employment at Dounreay and radiation dose; distance of usual residence from the path of microwave beams, preconceptional exposure to non-ionising radiation in the father; and other lifestyle factors. Results-No raised relative risks were found for prenatal exposure to x rays, social class of parents, employment at Dounreay before conception or diagnosis, father's dose of ionising radiation before conception, or child's residence within 50 m of the path of microwave transmission beams. Results also proved negative for all lifestyle factors except an apparent association with use of beaches within 25 km of Dounreay. However, this result was based on small numbers, arose in the context of multiple hypothesis testing, and is certainly vulnerable to possible systematic bias. Conclusion-The raised incidence of childhood leukaemia and non-Hodgkin's lymphoma around Dounreay cannot be explained by paternal occupation at Dounreay or by paternal exposure to external ionising radiation before conception. The observation of an apparent association between the use of beaches around Dounreay and the development of childhood leukaemia and non-Hodgkin's lymphoma might be an artefact of multiple testing and influenced by recall bias.	ROYAL HOSP SICK CHILDREN,DEPT PAEDIAT HAEMATOL,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND		URQUHART, JD (corresponding author), SCOTTISH HLTH SERV,COMMON SERV AGCY,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,SCOTLAND.			Maxwell, Margaret/0000-0003-3318-9500				BLACK D, 1984, INVESTIGATION POSSIB; Breslow N, 1980, STATISTICAL METHODS, V32; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HEASMAN M A, 1987, Health Bulletin (Edinburgh), V45, P147; HEASMAN MA, 1986, LANCET, V1, P266; HEASMAN MA, 1986, LANCET, V1, P385; MCWHIRTER WR, 1982, BRIT J CANCER, V46, P640, DOI 10.1038/bjc.1982.249; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SEVERSON RK, 1988, AM J EPIDEMIOL, V128, P10, DOI 10.1093/oxfordjournals.aje.a114932; STEWART A, 1958, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.5086.1495; 1988, 2ND COMM MED ASP RAD; 1989, EGRET	13	102	102	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					687	692		10.1136/bmj.302.6778.687	http://dx.doi.org/10.1136/bmj.302.6778.687			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	2021742	Green Published, Bronze			2022-12-28	WOS:A1991FE33300021
J	GUZE, BH; FREEDMAN, DX				GUZE, BH; FREEDMAN, DX			PSYCHIATRY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY CARE; RECURRENT DEPRESSION; OUTCOMES; DISORDER				GUZE, BH (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024, USA.							BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100; BLACKER CVR, 1987, BRIT J PSYCHIAT, V150, P737, DOI 10.1192/bjp.150.6.737; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; DAMLUJI NF, 1988, J CLIN PSYCHOPHARM, V8, P347; DELGADO PL, 1990, ARCH GEN PSYCHIAT, V47, P411; FRANK E, 1989, ARCH GEN PSYCHIAT, V46, P397; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; GLASS RM, 1989, JAMA-J AM MED ASSOC, V263, P2883; KLERMAN GL, 1990, ARCH GEN PSYCHIAT, V47, P1158; KUPFER DJ, 1989, ARCH GEN PSYCHIAT, V46, P771; SOLOFF PH, 1986, AM J PSYCHIAT, V143, P1603; VONKORFF M, 1987, ARCH GEN PSYCHIAT, V44, P152; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914	13	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3164	3165		10.1001/jama.265.23.3164	http://dx.doi.org/10.1001/jama.265.23.3164			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ770	2041138				2022-12-28	WOS:A1991FQ77000038
J	GORR, T; KLEINSCHMIDT, T; FRICKE, H				GORR, T; KLEINSCHMIDT, T; FRICKE, H			CLOSE TETRAPOD RELATIONSHIPS OF THE COELACANTH LATIMERIA INDICATED BY HEMOGLOBIN SEQUENCES	NATURE			English	Article							HEMOGLOBIN; AFFINITIES; PARSIMONY; PROTEINS	THE origin of tetrapods has been debated for many years. In traditional systematics, the extinct lobe-finned bony fish (Rhipidistia) are regarded as the closest relatives of tetrapods 1. Among living fish, the coelacanth Latimeria chalumnae (Actinistia) 2-4, which is the only recent representative of the Crossopterygii (Actinistia and Rhipidistia), the lungfish (Dipnoi) 5-8 and ray-finned fish (Actinopterygii) 9, 10, have each been considered as sister-groups of the tetrapods. We have now determined the sequence of the alpha and beta-globin chains of coelacanth haemoglobin and compared them with all known haemoglobins of bony and cartilaginous fish as well as those of tadpoles and adult amphibians. Haemoglobins of bony fish match more closely those of larval than adult amphibians. The beta-chains of Latimeria match those of tadpoles more closely (54%) than do those of any other fish, whereas the alpha-chains of Latimeria (45.4%), and especially of teleosts (49.2%), are closer to those of larval amphibians than are those of lungfish (39.8%). If only synapomorphous sequence matches (those at derived positions shared by one bony fish and tadpoles but not by any other bony fish) are considered, both Latimeria globin chains have distinctly more identities with phase of tadpoles than do those of any bony fish. Thus the primary structure of Latimeria haemoglobin indicates that the coelacanth is the closest living relative of tetrapods.	MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; MAX PLANCK INST VERHALTENSPHYSIOL, W-8131 SEEWIESEN, GERMANY	Max Planck Society; Max Planck Society				Gorr, Thomas/0000-0002-6023-4234				Ax P, 1984, PHYLOGENETISCHE SYST; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; DOBZHANSKY T, 1977, EVOLUTION, P262; FELSENSTEIN J, 1983, ANNU REV ECOL SYST, V14, P313, DOI 10.1146/annurev.es.14.110183.001525; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FELSENSTEIN J, 1989, PHYLIP 32 MANUAL; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; FRITZSCH B, 1987, NATURE, V327, P153, DOI 10.1038/327153a0; Goodman M., 1982, P115; GOODMAN M, 1975, NATURE, V253, P603, DOI 10.1038/253603a0; GOODMAN M M, 1987, P141; HENNIG W, 1999, PHYLOGENETIC SYSTEMA; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILLIS DM, 1989, INT CONGR SER, V824, P355; HOSBACH HA, 1983, CELL, V32, P45, DOI 10.1016/0092-8674(83)90495-6; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; Long J.A., 1989, Journal of Vertebrate Paleontology, V9, P1; MULLER AH, 1985, LEHRBUCH PALAOZOOLOG, V3, P194; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Nelson J.S., 1984, FISHES WORLD, V2nd, P523; PANCHEN AL, 1987, BIOL REV, V62, P341, DOI 10.1111/j.1469-185X.1987.tb01635.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROMER AS, 1976, VERGLEICHENDE ANATOM, P37; ROSEN D E, 1981, Bulletin of the American Museum of Natural History, V167, P159; SCHULTZE HP, 1987, J MORPH S, V1, P39; VONWAHLERT G, 1968, LATIMERIA GESCH WIRB; WAEHNELDT TV, 1989, J NEUROCHEM, V52, P1941, DOI 10.1111/j.1471-4159.1989.tb07281.x; WATT KWK, 1975, J BIOL CHEM, V250, P5934; [No title captured]	30	73	77	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					394	397		10.1038/351394a0	http://dx.doi.org/10.1038/351394a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034288				2022-12-28	WOS:A1991FN85600054
J	BROCKDORFF, N; ASHWORTH, A; KAY, GF; COOPER, P; SMITH, S; MCCABE, VM; NORRIS, DP; PENNY, GD; PATEL, D; RASTAN, S				BROCKDORFF, N; ASHWORTH, A; KAY, GF; COOPER, P; SMITH, S; MCCABE, VM; NORRIS, DP; PENNY, GD; PATEL, D; RASTAN, S			CONSERVATION OF POSITION AND EXCLUSIVE EXPRESSION OF MOUSE XIST FROM THE INACTIVE X-CHROMOSOME	NATURE			English	Article							CONTROLLING ELEMENTS; CONSTRUCTION	X-CHROMOSOME inactivation in mammals is a regulatory phenomenon whereby one of the two X chromosomes in female cells is genetically inactivated, resulting in dosage compensation for X-linked genes between males and females 1. In both man and mouse, X-chromosome inactivation is thought to proceed from a single cis-acting switch region or inactivation centre (XIC/Xic) 2-5. In the human, XIC has been mapped to band Xq13 (ref. 6) and in the mouse to band XD (ref. 7), and comparative mapping has shown that the XIC regions in the two species are syntenic 8. The recently described human XIST gene maps to the XIC region 6 and seems to be expressed only from the inactive X chromosome 9. We report here that the mouse Xist gene maps to the Xic region of the mouse X chromosome and, using an interspecific Mus spretus/Mus musculus domesticus F1 hybrid mouse carrying the T(X; 16)16H translocation, show that Xist is exclusively expressed from the inactive X chromosome. Conservation between man and mouse of chromosomal position and unique expression exclusively from the inactive X chromosome lends support to the hypothesis that XIST and its mouse homologue are involved in X-chromosome inactivation.	MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Medical Research Council Clinical Trials Unit; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				ASHWORTH A, IN PRESS NATURE; BROCKDORFF N, 1990, GENOMICS, V7, P573, DOI 10.1016/0888-7543(90)90201-5; BROCKDORFF N, 1991, GENOMICS, V10, P17, DOI 10.1016/0888-7543(91)90478-W; BROCKDORFF N, IN PRESS MAMMALIAN G; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; CATTANACH BM, 1975, ANNU REV GENET, V9, P1, DOI 10.1146/annurev.ge.09.120175.000245; CATTANACH BM, 1989, MOUSE NEWS LETT, V83, P16; CATTANACH BM, IN PRESS CYTOGENET C; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; JOHNSTON PG, 1981, GENET RES, V37, P151, DOI 10.1017/S0016672300020127; KEER JT, 1990, GENOMICS, V7, P566, DOI 10.1016/0888-7543(90)90200-E; LYON MF, 1964, CYTOGENETICS, V3, P306, DOI 10.1159/000129820; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MATTEI MG, 1981, HUM GENET, V56, P401, DOI 10.1007/BF00274702; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; Sambrook J, 1989, MOL CLONING LABORATO; THERMAN E, 1974, CHROMOSOMA, V44, P361	22	529	542	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					329	331		10.1038/351329a0	http://dx.doi.org/10.1038/351329a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034279				2022-12-28	WOS:A1991FM97600065
J	HAMMOND, J; RONA, RJ				HAMMOND, J; RONA, RJ			CONSENSUS ON CHOLESTEROL	BRITISH MEDICAL JOURNAL			English	Letter											HAMMOND, J (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND.		Rona, Roberto J/C-2348-2011					BLANK DW, 1986, JAMA-J AM MED ASSOC, V256, P2867, DOI 10.1001/jama.256.20.2867; BROUGHTON PMG, 1989, BRIT MED J, V298, P297, DOI 10.1136/bmj.298.6669.297; BURKE JJ, 1988, JAMA-J AM MED ASSOC, V259, P3444, DOI 10.1001/jama.259.23.3444; DELAMOTHE T, 1991, BRIT MED J, V302, P806; ROBERTS L, 1987, SCIENCE, V267, P482	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1209	1209		10.1136/bmj.302.6786.1209-a	http://dx.doi.org/10.1136/bmj.302.6786.1209-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043832	Green Published			2022-12-28	WOS:A1991FN04500052
J	REISER, SJ				REISER, SJ			THE CLINICAL RECORD IN MEDICINE .1. LEARNING FROM CASES	ANNALS OF INTERNAL MEDICINE			English	Article								Case histories of illness have been important agents of both preserving and changing concepts and practices in medicine. These cases, which constitute the collective medical memory, have been used by innovators to recast diagnosis, therapy, and education. They have done this by both extracting insight from the content of the cases and reshaping the form of the document containing them-the clinical record. How the evidence in this record should be ordered, stored, retrieved, and accessed has been a major source of controversy in medicine. The evolution of the clinical case and its written record is examined. The essay appears in two parts. Part I deals with the several uses of cases in medical practice and learning. Part II, which focuses mainly on the development of the clinical record, will appear in the 1 June 1991 issue.			REISER, SJ (corresponding author), UNIV TEXAS, HLTH SCI CTR, POB 20708, HOUSTON, TX 77225 USA.							Cannon WB, 1900, BOSTON MED SURG J, V142, P31, DOI 10.1056/NEJM190001111420202; LAENNEC RT, 1962, TREATISE DISEASES CH, P398; LOUIS PC, 1836, RES EFFECTS BLOODLET, P64; MORGAGNI GB, 1960, SEATS CAUSES DISEASE, V2, P127; PAINTER FM, 1918, MOD HOSP, V2, P356; RODIN AE, 1984, MED CASEBOOK AC DOYL, P199; SYDENHAM T, 1966, T SYDENHAM 1624 1689, V60, P127; WASHBURN FA, 1939, MASSACHUSETTS GENERA, P117; 1983, HIPPOCRATES, V1, P279; 1923, HIPPOCRATES, V2, P193	10	47	47	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					902	907		10.7326/0003-4819-114-10-902	http://dx.doi.org/10.7326/0003-4819-114-10-902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014953				2022-12-28	WOS:A1991FL65000012
J	ROBERTSON, CF; HEYCOCK, E; BISHOP, J; NOLAN, T; OLINSKY, A; PHELAN, PD				ROBERTSON, CF; HEYCOCK, E; BISHOP, J; NOLAN, T; OLINSKY, A; PHELAN, PD			PREVALENCE OF ASTHMA IN MELBOURNE SCHOOLCHILDREN - CHANGES OVER 26 YEARS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; CHILDHOOD ASTHMA; UNITED-KINGDOM; NEW-ZEALAND; TRENDS; CHILDREN; HEALTH; ATOPY	Objectives - To determine the prevalence of asthma in the past 12 months in Melbourne schoolchildren aged 7, 12, and 15 years and to compare the prevalence of a history of asthma with that of 26 years ago. Design - A questionnaire on respiratory symptoms was distributed to children for completion by parents and return to the school. Subjects were selected by a stratified cluster design. Setting - Government and non-government schools in the greater Melbourne area, Australia. Subjects - 10 981 children. Parents completed questionnaires for 3324 children aged 7, 2899 aged 12, and 2968 aged 15. The overall response rate was 90%. Main outcome measures - History of wheeze or asthma in the past 12 months and in lifetime. Results - The prevalences of wheeze in the past 12 months were 23.1%, 21.7%, and 18.6% for 7, 12, and 15 years olds respectively. A history of wheeze was more common in boys than in girls at age 7 (443/1711 v 324/1614) and 12 (418/1767 v 322/1718) but not at age 15. Overall, 78% (1548) of those reporting wheeze also reported a history of asthma and 83% (1611) had used a bronchodilator. The prevalence of a history of asthma among 7 year olds was 46% compared with 19.1% in the 1964 survey, an increase of 141%. Conclusions - The current prevalence of asthma in Melbourne schoolchildren is high and has risen substantially over the past 26 years.	UNIV MELBOURNE, ROYAL CHILDRENS HOSP, DEPT PAEDIAT, MELBOURNE 3054, AUSTRALIA; UNIV MELBOURNE, CLIN EPIDEMIOL & BIOSTAT UNIT, PARKVILLE, VIC 3052, AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne	ROBERTSON, CF (corresponding author), ROYAL CHILDRENS HOSP, DEPT THORAC MED, MELBOURNE 3054, AUSTRALIA.		Nolan, Terry/A-2236-2008	Nolan, Terry/0000-0001-6018-3863				ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; ASHER MI, 1988, AM REV RESPIR DIS, V138, P524, DOI 10.1164/ajrccm/138.3.524; BAUMAN A, 1990, AUSTR MED RES J, V20, P105; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1133, DOI 10.1136/adc.64.8.1133; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HURRY VM, 1988, AUST NZ J MED, V18, P745, DOI 10.1111/j.1445-5994.1988.tb00173.x; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; Kish L, 1965, SURVEY SAMPLING; MITCHELL EA, 1990, THORAX, V45, P176, DOI 10.1136/thx.45.3.176; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	20	321	327	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 11	1991	302	6785					1116	1118		10.1136/bmj.302.6785.1116	http://dx.doi.org/10.1136/bmj.302.6785.1116			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	2043782	Bronze, Green Published			2022-12-28	WOS:A1991FL43900017
J	SLEVIN, ML; GRAY, R				SLEVIN, ML; GRAY, R			ADJUVANT THERAPY FOR CANCER OF THE COLON	BRITISH MEDICAL JOURNAL			English	Editorial Material							COLORECTAL-CANCER; FLUOROURACIL; LEVAMISOLE; CARCINOMA; TRIAL		RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC STUDIES UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	SLEVIN, ML (corresponding author), ST BARTHOLOMEWS & HOMERTON HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND.							BANCEWICZ J, 1980, J ROY SOC MED, V73, P197, DOI 10.1177/014107688007300308; BEART RW, 1990, ARCH SURG-CHICAGO, V125, P897; BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; GRAY BN, 1987, ADJUVANT THERAPY CAN, P357; GRAY R, IN PRESS BR J CANCER; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; MAYER RJ, 1990, NEW ENGL J MED, V322, P399, DOI 10.1056/NEJM199002083220610; METZGER U, 1987, WORLD J SURG, V11, P452, DOI 10.1007/BF01655809; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; TAYLOR I, 1985, BRIT J SURG, V72, P359, DOI 10.1002/bjs.1800720509; VANCHIERI C, 1990, J NATL CANCER I, V82, P898, DOI 10.1093/jnci/82.11.898; WERELDSMA JCJ, 1990, CANCER, V65, P425, DOI 10.1002/1097-0142(19900201)65:3<425::AID-CNCR2820650309>3.0.CO;2-M; WILLS J, 1990, ANN ONCOL, V1, P329; WINDLE R, 1987, BRIT J SURG, V74, P569, DOI 10.1002/bjs.1800740707; WOLMARK N, 1990, J CLIN ONCOL, V8, P1466, DOI 10.1200/JCO.1990.8.9.1466; 1990, ANN ONCOLOGY, V1, P239; 1988, NEW ENGL J MED, V319, P1681; 1990, JAMA-J AM MED ASSOC, V264, P1444	20	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1100	1101		10.1136/bmj.302.6785.1100	http://dx.doi.org/10.1136/bmj.302.6785.1100			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	2043778	Bronze, Green Published			2022-12-28	WOS:A1991FL43900002
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - WORK IN PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.							BLACKWELL R, 1988, BR J OBSTET GYNAECOL, V94, P446	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1070	1073		10.1136/bmj.302.6784.1070	http://dx.doi.org/10.1136/bmj.302.6784.1070			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	2036506	Green Published, Bronze			2022-12-28	WOS:A1991FK56300029
J	MANN, SJ; JAMES, GD; WANG, RS; PICKERING, TG				MANN, SJ; JAMES, GD; WANG, RS; PICKERING, TG			ELEVATION OF AMBULATORY SYSTOLIC BLOOD-PRESSURE IN HYPERTENSIVE SMOKERS - A CASE-CONTROL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CIGARETTE-SMOKING; EXERCISE	Although smoking raises blood pressure, the office blood pressure measurements of smokers are the same as, or lower than, those of nonsmokers. To resolve this paradox, we compared the office and 24-hour ambulatory blood pressures of 59 untreated hypertensive smokers with 118 nonsmoking hypertensives matched for age, sex, and race. The office blood pressures of the smoking and nonsmoking groups were 141/93 and 142/93 mm Hg, respectively. The awake ambulatory systolic blood pressure was significantly higher in the smokers (145 vs 140 mm Hg). This difference was greater among patients over the age of 50 years (153 vs 142 mm Hg), and absent among patients under 50 years (140 vs 139 mm Hg). Blood pressures during sleep did not differ between the two groups (121/76 vs 123/77 mm Hg). We conclude that, among white hypertensives above the age of 50 years, smokers maintain a higher daytime ambulatory systolic blood pressure than nonsmokers even though blood pressure measured in the office is similar.	CORNELL UNIV,MED CTR,NEW YORK HOSP,CTR CARDIOVASC & HYPERTENS,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital			Mann, Samuel J./AAI-5510-2020					BENOWITZ NL, 1984, CLIN PHARMACOL THER, V36, P74, DOI 10.1038/clpt.1984.142; BERGLUND G, 1975, ACTA MED SCAND, V198, P291; BERLIN I, 1990, EUR J CLIN PHARMACOL, V38, P57, DOI 10.1007/BF00314804; CELLINA GU, 1975, AM HEART J, V89, P18, DOI 10.1016/0002-8703(75)90004-6; DEVEREUX RB, 1988, AM HEART J, V116, P1124, DOI 10.1016/0002-8703(88)90176-7; FREESTONE S, 1982, AM J MED, V73, P348, DOI 10.1016/0002-9343(82)90725-2; GOFIN R, 1982, ISRAEL J MED SCI, V18, P1217; GOLDBOURT U, 1977, AM J EPIDEMIOL, V105, P75, DOI 10.1093/oxfordjournals.aje.a112358; GORDON T, 1975, AM HEART J, V90, P322, DOI 10.1016/0002-8703(75)90320-8; GREEN MS, 1986, AM HEART J, V111, P932, DOI 10.1016/0002-8703(86)90645-9; GREENE SB, 1977, J CHRON DIS, V30, P401, DOI 10.1016/0021-9681(77)90034-0; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; HIGGINS MW, 1967, AM J EPIDEMIOL, V86, P60, DOI 10.1093/oxfordjournals.aje.a120734; JAMES GD, 1988, HYPERTENSION, V11, P545, DOI 10.1161/01.HYP.11.6.545; JENKINS CD, 1968, CIRCULATION, V38, P1140, DOI 10.1161/01.CIR.38.6.1140; LEVENSON J, 1987, ARTERIOSCLEROSIS, V7, P572, DOI 10.1161/01.ATV.7.6.572; LORENTSEN E, 1972, CIRCULATION, V46, P257, DOI 10.1161/01.CIR.46.2.257; MANN SJ, 1989, AM J MED, V86, P79, DOI 10.1016/0002-9343(89)90137-X; OROURKE M, 1990, HYPERTENSION, V15, P339, DOI 10.1161/01.HYP.15.4.339; PICKERING TG, 1982, JAMA-J AM MED ASSOC, V247, P992, DOI 10.1001/jama.247.7.992; SPOHR U, 1979, ATHEROSCLEROSIS, V33, P271, DOI 10.1016/0021-9150(79)90179-5; THOMAS CB, 1956, ANN INTERN MED, V44, P874, DOI 10.7326/0003-4819-44-5-874; THULESIUS O, 1978, ANGIOLOGY, V29, P374, DOI 10.1177/000331977802900504; 1964, PUBLICATION US PHS, V1130	24	198	207	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2226	2228		10.1001/jama.265.17.2226	http://dx.doi.org/10.1001/jama.265.17.2226			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013955				2022-12-28	WOS:A1991FH87700035
J	FRANKLIN, RCG; SPIEGELHALTER, DJ; MACARTNEY, FJ; BULL, K				FRANKLIN, RCG; SPIEGELHALTER, DJ; MACARTNEY, FJ; BULL, K			EVALUATION OF A DIAGNOSTIC ALGORITHM FOR HEART-DISEASE IN NEONATES	BRITISH MEDICAL JOURNAL			English	Article							EXPERT SYSTEMS; CHEST PAIN; EMERGENCY; PROTOCOL; INFANTS	Objective-To develop, test, and validate an algorithm for diagnosing disease in neonates during an over the telephone referral to a specialist cardiac centre. Design-A draft algorithm requiring only data available to a referring paediatrician was generated. This was modified in the light of a retrospective review of case records. A questionnaire to elicit all the data required by the algorithm was then generated. There followed a prospective three phase evaluation during consecutive over the telephone referrals. This consisted of (a) a conventional phase with unstructured referral consultations, (b) a phase with referrals structured around the questionnaire but independent of the algorithm, and (c) a validation phase with the algorithm (and its previous errors) available during the referral consultation. Setting-59 paediatric centres in south east England and a central specialist paediatric cardiology unit. Patients-Consecutive neonates (aged < 31 days) referred with suspected heart disease. The retrospective review was of records of 174 neonates from 1979. In the prospective evaluation (1987-90) the conventional phase comprised 71 neonates (over 5.5 months), the structured phase 203 neonates (over 14 months), and the validation phase 195 neonates (over 12 months). Main outcome measures-Diagnostic accuracy (assigning patients to the correct diagnostic category (out of 27)), of the referring paediatrician, the specialist after the referral consultation, and the algorithm as compared with the definitive diagnosis by echocardiography at the specialist centre, and score for the appropriateness of management in transit. Results-Simply structuring the consultation by questionnaire (that is, proceeding from the conventional phase to the structured phase) improved the diagnostic accuracy of both paediatricians (from 34% (24/71 cases) to 48% (97/203) correct) and specialists (from 54% (38/71 cases) to 64% (130/203) correct). The algorithm (structured phase) would have been even more accurate (78% (158/203 cases); p < 0.01). Management scores in the structured phase were also better than in the conventional phase (80% (162/203 cases) upsilon-58% (41/71) appropriate; p < 0.01). Management scores would have improved to 91% appropriate (185/203; p < 0.001) had the algorithmic diagnoses dictated management. The superiority of the algorithm was maintained but not bettered in the validation phase. Conclusions-Applying the algorithm should reduce the morbidity and mortality of neonates with critical heart disease by aiding clinicians in therapeutic decisions for in transit care.	HOSP SICK CHILDREN,PAEDIAT CARDIOL,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; MRC Biostatistics Unit								ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; BOVE EL, 1983, ARCH DIS CHILD, V58, P137, DOI 10.1136/adc.58.2.137; Breiman L., 1984, CLASSIFICATION REGRE; COOK DH, 1978, CAN J PUBLIC HEALTH, V69, P297; DANFORD DA, 1986, J AM COLL CARDIOL, V8, P1125, DOI 10.1016/S0735-1097(86)80391-6; FRANKLIN RCG, 1989, INT J CLIN MONIT COM, V6, P157, DOI 10.1007/BF01721028; FRANKLIN RCG, IN PRESS J THORAC CA; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; LAURITZEN SL, 1988, J ROY STAT SOC B MET, V50, P157; LEWIS AB, 1981, CIRCULATION, V64, P893, DOI 10.1161/01.CIR.64.5.893; REALE A, 1908, COMPUT BIOMED RES, V1, P533; ROETHLINGSBURGE.FJ, 1939, MANAGEMENT WORKER; RUBAY J, 1988, CIRCULATION, V78, P1; SCHWARTZ WB, 1987, NEW ENGL J MED, V316, P685, DOI 10.1056/NEJM198703123161109; TEACH RL, 1981, COMPUT BIOMED RES, V14, P542, DOI 10.1016/0010-4809(81)90012-4; WARBURTON D, 1981, ARCH DIS CHILD, V56, P94, DOI 10.1136/adc.56.2.94; WARNER HR, 1961, JAMA-J AM MED ASSOC, V177, P177, DOI 10.1001/jama.1961.03040290005002; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	19	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					935	939		10.1136/bmj.302.6782.935	http://dx.doi.org/10.1136/bmj.302.6782.935			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032035	Green Published, Bronze			2022-12-28	WOS:A1991FH48700017
J	KEMP, AM; SIBERT, JR				KEMP, AM; SIBERT, JR			OUTCOME IN CHILDREN WHO NEARLY DROWN - A BRITISH-ISLES STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the outcome in nearly drowned children in the British Isles and identify factors that might predict a poor prognosis. Design-Study of drowned and of nearly drowned children aged less-than-or-equal-to 14. Information on nearly drowned children admitted to hospital obtained from consultant paediatricians returning monthly notification cards through the British Paediatric Surveillance Unit. Information on drowned children obtained from Office of Population Censuses and Surveys and other national epidemiological offices. Setting-British Isles, 1988 and 1989. Subjects-330 children who had confirmed submersion incidents. 142 died before admission to hospital and 188 children were admitted after nearly drowning. Main outcome measures-Death, full recovery, or degree of handicap after near drowning and signs on admission to hospital. Results-All of the children who were conscious on admission fully recovered. Of the 64 children unconscious on admission, 31 had normally reactive pupils and all but three (all of whom had severe pre-existing neurological disease) recovered fully. Of the 33 children with fixed dilated pupils on admission, 10 fully recovered, 13 died, and 10 had severe neurological deficit. Spontaneous respiratory effect on admission was associated with normal survival. Pupils that remained dilated six hours after admission and fits continuing 24 hours after admission predicted a poor outcome. Conclusion-Children can survive normally after near drowning in the British Isles, particularly if they have been hypothermic. Resuscitation should not be abandoned in nearly drowned children until they have been rewarmed.	UNIV COLL CARDIFF,LLANDOUGH HOSP,COLL MED,DEPT CHILD HLTH,CARDIFF CF6 1XX,S GLAM,WALES	Cardiff University								CONN AW, 1984, CAN ANAESTH SOC J, V31, pS38, DOI 10.1007/BF03007034; FRATES RC, 1981, AM J DIS CHILD, V135, P1006, DOI 10.1001/archpedi.1981.02130350010004; FREWEN TC, 1985, J PEDIATR-US, V106, P615, DOI 10.1016/S0022-3476(85)80085-8; GOLDEN F, 1980, BR J HOSP MED, V23, P373; HARRIES M, 1986, BMJ, V293, P123; MODELL JH, 1976, CHEST, V70, P231, DOI 10.1378/chest.70.2.231; MODELL JH, 1981, CRIT CARE MED, V9, P351; OCARROLL PW, 1988, JAMA-J AM MED ASSOC, V260, P380, DOI 10.1001/jama.260.3.380; ORLOWSKI JP, 1988, JAMA-J AM MED ASSOC, V26, P390; PEARN J, 1977, LANCET, V1, P7; PEARN J, 1985, BRIT MED J, V291, P1447, DOI 10.1136/bmj.291.6507.1447; PEARN JH, 1979, MED J AUSTRALIA, V1, P463, DOI 10.5694/j.1326-5377.1979.tb127044.x; PEARN JH, 1979, PEDIATRICS, V64, P187; PETERSON B, 1977, PEDIATRICS, V59, P364; RAMEY CA, 1987, J APPL PHYSIOL, V63, P665, DOI 10.1152/jappl.1987.63.2.665; 1989, DEATHS CAUSE 1988 RE	16	44	44	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					931	933		10.1136/bmj.302.6782.931	http://dx.doi.org/10.1136/bmj.302.6782.931			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032033	Green Published, Bronze			2022-12-28	WOS:A1991FH48700015
J	JOHNSEN, R; BERNERSEN, B; STRAUME, B; FORDE, OH; BOSTAD, L; BURHOL, PG				JOHNSEN, R; BERNERSEN, B; STRAUME, B; FORDE, OH; BOSTAD, L; BURHOL, PG			PREVALENCES OF ENDOSCOPIC AND HISTOLOGICAL-FINDINGS IN SUBJECTS WITH AND WITHOUT DYSPEPSIA	BRITISH MEDICAL JOURNAL			English	Article							PEPTIC-ULCER DISEASE; CHRONIC GASTRITIS; DUODENAL-ULCER; BIOPSY SPECIMENS; WORKING PARTY; DIAGNOSIS; SYMPTOMS; GASTRODUODENITIS; VOLUNTEERS; MANAGEMENT	Objective-To examine the association between dyspeptic symptoms and endoscopic and histological diagnoses. Design-Cross sectional study of people with dyspepsia and controls matched for age and sex identified by questionnaire survey of all inhabitants aged 20 to 69. Endoscopy and histological examination was performed with the examiner blind to whether or not the patient had dyspepsia. Setting-Population based survey in Sorreisa, Norway. Subjects-All people with dyspepsia and age and sex matched people without dyspepsia were offered endoscopy. A total of 309 people with dyspepsia and 310 without dyspepsia underwent endoscopy, giving 273 matched pairs. Main outcome measures-Prevalences of endoscopic and histological diagnoses made according to internationally accepted standards. Results-In all, 1802 of 2027 (88.9%) people returned the questionnaire. Of the 163 subjects who refused endoscopy, 114 were controls. Of five endoscopic and four histological diagnoses only peptic ulcer disease, endoscopic duodenitis, and active chronic gastritis were diagnosed significantly more often in people with dyspepsia. In all, 30% to 50% of the diagnoses of mucosal inflammation and peptic ulcer disease were made among subjects without dyspepsia, and only 10% of both those with and those without dyspepsia had normal endoscopic findings. Conclusions-The diagnostic findings, with possible exceptions of peptic ulcer disease and endoscopic duodenitis, showed no association of clinical value with dyspeptic symptoms. The small number of "normal" endoscopic findings in both those with and those without dyspepsia challenge well accepted endoscopic and histological diagnostic criteria with relation to the upper gastrointestinal tract.			JOHNSEN, R (corresponding author), UNIV TROMSO,GEN PRACTICE,N-9000 TROMSO,NORWAY.							AKDAMAR K, 1986, GASTROINTEST ENDOSC, V32, P78, DOI 10.1016/S0016-5107(86)71760-4; BARBARA L, 1989, DIGEST DIS SCI, V34, P1272, DOI 10.1007/BF01537277; BERNERSEN B, 1990, GUT, V31, P989, DOI 10.1136/gut.31.9.989; CHELI R, 1982, SCAND J GASTROENTERO, V17, P84; CHELI R, 1986, ENDOSCOPY, V18, P125, DOI 10.1055/s-2007-1018350; CHELI R, 1983, HEPATO-GASTROENTEROL, V30, P21; COLINJONES DG, 1988, LANCET, V1, P576; DANIELSSON A, 1980, ANN CLIN RES, V12, P4; DELUCA VA, 1981, J CLIN GASTROENTEROL, V3, P17; EARLAM RJ, 1985, GUT, V26, P95, DOI 10.1136/gut.26.1.95; GREENLAW R, 1980, DIGEST DIS SCI, V25, P660, DOI 10.1007/BF01308325; GUSLANDI M, 1986, Digestive Diseases, V4, P231, DOI 10.1159/000171153; JOFFE SN, 1982, SCAND J GASTROENTERO, V17, P62; JOFFE SN, 1982, SCAND J GASTROENTERO, V17, P88; JOHNSSON F, 1987, SCAND J GASTROENTERO, V22, P714, DOI 10.3109/00365528709011148; JORDE R, 1986, LANCET, V1, P119; KREUNING J, 1978, J CLIN PATHOL, V31, P69, DOI 10.1136/jcp.31.1.69; MACKINNON M, 1982, DIGEST DIS SCI, V27, P217, DOI 10.1007/BF01296918; MYREN J, 1974, SCAND J GASTROENTERO, V9, P457; NIE NH, 1975, STATISTICAL PACKAGE; OWEN DA, 1979, PATHOL ANNU, V1, P247; SAVARY M, 1977, LEHRBUCH ENDOSKOPISC; SIRCUS W, 1985, Q J MED, V56, P593; Siurala M, 1980, Front Gastrointest Res, V6, P148; Snedecor G. W., 1967, STATISTICAL METHODS, P432; SPIRO HM, 1974, NEW ENGL J MED, V291, P567, DOI 10.1056/NEJM197409122911107; TALLEY NJ, 1988, ANN INTERN MED, V108, P865, DOI 10.7326/0003-4819-108-6-865; THOMSON WO, 1977, LANCET, V1, P1197; TOUKAN AU, 1985, DIGEST DIS SCI, V30, P313, DOI 10.1007/BF01403839; VENABLES CW, 1985, SCAND J GASTROENTERO, V20, P91, DOI 10.3109/00365528509103941; VILLAKO K, 1984, ANN CLIN RES, V16, P192; VILLAKO K, 1976, SCAND J GASTROENTERO, V2, P817; WHITEHEAD R, 1972, J CLIN PATHOL, V25, P1, DOI 10.1136/jcp.25.1.1; WHITEHEAD R, 1975, DIGESTION, V13, P129, DOI 10.1159/000197701; 1985, LANCET, V2, P1222	35	200	204	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					749	752		10.1136/bmj.302.6779.749	http://dx.doi.org/10.1136/bmj.302.6779.749			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021764	Bronze, Green Published			2022-12-28	WOS:A1991FF22900019
